PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, JY; Levy-Wilson, B; Goodart, S; Cooper, AD				Chen, JY; Levy-Wilson, B; Goodart, S; Cooper, AD			Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; 7 ALPHA-HYDROXYLASE; NUCLEAR RECEPTOR; 7-ALPHA-HYDROXYLASE GENE; FEEDBACK-REGULATION; METABOLISM; SECRETION; LXR; IDENTIFICATION; DISRUPTION	Cholesterol 7alpha-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the pathway responsible for the formation of the majority of bile acids. Transcription of the gene is regulated by the size of the bile acid pool and dietary and hormonal factors. The farnesoid X receptor and the liver X receptor (LXR) are responsible for regulation by bile acids and cholesterol, respectively. To study the effects of dietary cholesterol and fat upon expression of the human CYP7A1 gene, mice were generated by crossing transgenic mice carrying the human CYP7A1 gene with mice that were homozygous knockouts (CYP7A1(-/-)). The mice (mCYP7A1(-/-)/hCYP7A1) expressed the human gene at much higher levels than did the transgenics bred in the wild-type background. A diet containing 1% cholic acid reduced the expression of the human gene in mCYP7A1(-/-)/hCYP7A1 mice to undetectable levels. Cholestyramine (5%) increased the level of expression of the human gene and the mouse gene. Thus, farnesoid X receptor-mediated regulation was preserved. A diet containing 2% cholesterol increased expression of the mouse gene in wild-type mice, but it did not affect expression of the human gene in mCYP7A1(-/-)[hCYP7A1 mice. None of the diets altered the serum cholesterol or triglyceride levels in these mice; 1% cholic acid caused a redistribution of cholesterol from the high density lipoprotein to the low density lipoprotein density in the humanized mice but not in wild-type mice. A diet containing 30% saturated fat and 2% cholesterol caused a decrease in CYP7A1 levels in mCYP7A1(-/-)[hCYP7A1 mice. The serum cholesterol levels rose in all mice fed this diet. The increase was greater in the mCYP7A1(-/-)/hCYP7A1 mice. Together, these data suggest that the lack of an LXR element in the region from -56 to -49 of the human CYP7A1 promoter may account for some of the differences in response to diets between humans and rodents.	Palo Alto Med Res Fdn, Res Inst, Palo Alto, CA 94301 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA	Palo Alto Medical Foundation Research Institute; Stanford University	Cooper, AD (corresponding author), Palo Alto Med Res Fdn, Res Inst, Ames Bldg,795 El Camino Real, Palo Alto, CA 94301 USA.	adc@stanford.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318, P30DK056339] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54775] Funding Source: Medline; NIDDK NIH HHS [DK56339, DK38318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; Cooper AD, 2001, CIRCULATION, V104, P14; Cooper AD, 1997, GASTROENTEROLOGY, V113, P2005; COOPER AD, 1994, HEPATOLOGY, V20, P1522, DOI 10.1002/hep.1840200623; Costet P, 2000, J BIOL CHEM, V275, P28240; EINARSSON K, 1985, NEW ENGL J MED, V313, P277, DOI 10.1056/NEJM198508013130501; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; Erickson SK, 1999, HEPATOLOGY, V30, p319A; Fruchart JC, 2001, PHARMACOL RES, V44, P345, DOI 10.1006/phrs.2001.0871; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Goodart SA, 1999, BIOCHEM BIOPH RES CO, V266, P454, DOI 10.1006/bbrc.1999.1799; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Miyake JH, 2001, J BIOL CHEM, V276, P23304, DOI 10.1074/jbc.M101853200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwarz M, 2001, J LIPID RES, V42, P1594; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Xu GR, 1997, GASTROENTEROLOGY, V113, P1958, DOI 10.1016/S0016-5085(97)70016-7; XU GR, 1995, J CLIN INVEST, V95, P1497, DOI 10.1172/JCI117821; Xu GR, 1998, J LIPID RES, V39, P1608; YU SM, 1995, AM J CLIN NUTR, V61, P1129, DOI 10.1093/ajcn/61.5.1129	42	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42588	42595		10.1074/jbc.M205117200	http://dx.doi.org/10.1074/jbc.M205117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202481	hybrid			2022-12-25	WOS:000179081200022
J	Natalizio, BJ; Muniz, LC; Arhin, GK; Wilusz, J; Lutz, CS				Natalizio, BJ; Muniz, LC; Arhin, GK; Wilusz, J; Lutz, CS			Upstream elements present in the 3'-Untranslated region of collagen genes influence the processing efficiency of overlapping polyadenylation signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-CHAIN-REACTION; POLY(A) SITE SELECTION; PRE-MESSENGER-RNA; SNRNP-A PROTEIN; II COLLAGEN; DOWNSTREAM ELEMENTS; ARTICULAR-CARTILAGE; 3' END; SEQUENCE; TRANSCRIPTION	3'-Untranslated regions (UTRs) of genes often contain key regulatory elements involved in gene expression control. A high degree of evolutionary conservation in regions of the 3'-UTR suggests important, conserved elements. In particular, we are interested in those elements involved in regulation of 3' end formation. In addition to canonical sequence elements, auxiliary sequences likely play an important role in determining the polyadenylation efficiency of mammalian pre-mRNAs. We identified highly conserved sequence elements upstream of the AAUAAA in three human collagen genes, COL1A1, COL1A2, and COL2A1, and demonstrate that these upstream sequence elements (USEs) influence polyadenylation efficiency. Mutation of the USEs decreases polyadenylation efficiency both in vitro and in vivo, and inclusion of competitor oligoribonucleotides representing the USEs specifically inhibit polyadenylation. We have also shown that insertion of a USE into a weak polyadenylation signal can enhance 3' end formation. Close inspection of the COL1A2 3'-UTR reveals an unusual feature of two closely spaced, competing polyadenylation signals. Taken together, these data demonstrate that USEs are important auxiliary polyadenylation elements in mammalian genes.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lutz, CS (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, MSB E671,185 S Orange Ave, Newark, NJ 07103 USA.	lutzcsC@umdnj.edu						AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Arhin GK, 2002, NUCLEIC ACIDS RES, V30, P1842, DOI 10.1093/nar/30.8.1842; Brackenridge S, 1997, NUCLEIC ACIDS RES, V25, P2326, DOI 10.1093/nar/25.12.2326; BROWN PH, 1991, J VIROL, V65, P3340, DOI 10.1128/JVI.65.6.3340-3343.1991; Chao LC, 1999, MOL CELL BIOL, V19, P5588; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Chen F, 1998, NUCLEIC ACIDS RES, V26, P2891, DOI 10.1093/nar/26.12.2891; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; DENOME RM, 1988, MOL CELL BIOL, V8, P4829, DOI 10.1128/MCB.8.11.4829; DEWET W, 1987, J BIOL CHEM, V262, P16032; DEZAZZO JD, 1991, MOL CELL BIOL, V11, P1624, DOI 10.1128/MCB.11.3.1624; DEZAZZO JD, 1989, MOL CELL BIOL, V9, P4951, DOI 10.1128/MCB.9.11.4951; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; ELIMA K, 1987, NUCLEIC ACIDS RES, V15, P9499, DOI 10.1093/nar/15.22.9499; Fehr JE, 2000, AM J VET RES, V61, P900, DOI 10.2460/ajvr.2000.61.900; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GILMARTIN GM, 1992, EMBO J, V11, P4419, DOI 10.1002/j.1460-2075.1992.tb05542.x; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Le Graverand MPH, 2002, J ORTHOP RES, V20, P535, DOI 10.1016/S0736-0266(01)00126-7; Lewis JD, 1995, J CELL SCI, P13; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Lutz CS, 1998, RNA, V4, P1493, DOI 10.1017/S1355838298981183; MAATTA A, 1991, FEBS LETT, V279, P9, DOI 10.1016/0014-5793(91)80237-W; Martin I, 2001, OSTEOARTHR CARTILAGE, V9, P112, DOI 10.1053/joca.2000.0366; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MOORE CL, 1990, METHOD ENZYMOL, V181, P49; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; MYERS JC, 1983, J BIOL CHEM, V258, P128; NINOMIYA Y, 1984, BIOCHEMISTRY-US, V23, P617, DOI 10.1021/bi00299a005; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Persikov AV, 2002, P NATL ACAD SCI USA, V99, P1101, DOI 10.1073/pnas.042707899; PRESCOTT J, 1994, MOL CELL BIOL, V14, P4682, DOI 10.1128/MCB.14.7.4682; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SANDELL LJ, 1984, J BIOL CHEM, V259, P7826; SANFACON H, 1991, GENE DEV, V5, P141, DOI 10.1101/gad.5.1.141; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2815, DOI 10.1093/nar/13.8.2815; SCHEK N, 1992, MOL CELL BIOL, V12, P5386, DOI 10.1128/MCB.12.12.5386; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tasanen K, 1998, BRIT J DERMATOL, V139, P23; UPHOLT WB, 1985, ANN NY ACAD SCI, V460, P130, DOI 10.1111/j.1749-6632.1985.tb51161.x; VALSAMAKIS A, 1991, P NATL ACAD SCI USA, V88, P2108, DOI 10.1073/pnas.88.6.2108; VALSAMAKIS A, 1992, MOL CELL BIOL, V12, P3699, DOI 10.1128/MCB.12.9.3699; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	59	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42733	42740		10.1074/jbc.M208070200	http://dx.doi.org/10.1074/jbc.M208070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200454	hybrid			2022-12-25	WOS:000179081200041
J	Guo, YJ; Pakneshan, P; Gladu, J; Slack, A; Szyf, M; Rabbani, SA				Guo, YJ; Pakneshan, P; Gladu, J; Slack, A; Szyf, M; Rabbani, SA			Regulation of DNA methylation in human breast cancer - Effect on the urokinase-type plasminogen activator gene production and tumor invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; TRANSCRIPTIONAL REGULATION; IN-VIVO; HA-RAS; EXPRESSION; CELLS; UPA; METASTASIS; GROWTH; DEMETHYLATION	Urokinase-type plasminogen activator (uPA) is a member of the serine protease family and can break down various components of the extracellular matrix to promote growth, invasion, and metastasis of several malignancies including breast cancer. In the current study we examined the role that the DNA methylation machinery might be playing in regulating differential uPA gene expression in breast cancer cell lines. uPA mRNA is expressed in the highly invasive, hormone-insensitive human breast cancer cell line MDA-MB-231 but not in hormone-responsive cell line MCF-7. Using methylation-sensitive PCR, we show that 90% of CpG dinucleotides in the uPA promoter are methylated in MCF-7 cells, whereas fully demethylated CpGs were detected in MDA-MB-231 cells. uPA promoter activity, which is directly regulated by the Ets-1 transcription factor, is inhibited by methylation as determined by uPA promoter-luciferase reporter assays. We then tested whether the state of expression and methylation of the uPA promoter correlates with the global level of DNA methyltransferase and demethylase activities in these cell lines. We show that maintenance DNA methyltransferase activity is significantly higher in MCF-7 cells than in MDA-MB-231 cells, whereas demethylase activity is higher in MDA-MB-231 cells. We suggest that the combination of increased DNA methyltransferase activity with reduced demethylase activity contributes to the methylation and silencing of uPA expression in MCF-7 cells. The converse is true in MDA-MB-231 cells, which represents a late stage highly invasive breast cancer. The histone deacetylase inhibitor, Trichostatin A, induces the expression of the uPA gene in MDA-MB-231 cells but not in MCF-7 cells. This supports the hypothesis that DNA methylation is the dominant mechanism involved in the silencing of uPA gene expression. Taken together, these results provide insight into the mechanism regulating the transcription of the uPA gene in the complex multistep process of breast cancer progression.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Rm H4-67, Montreal, PQ H3A 1A1, Canada.	srabbani@med.mcgill.ca		rabbani, shafaat/0000-0001-5594-3899				Altschmied J, 1997, BIOL CHEM, V378, P1457, DOI 10.1515/bchm.1997.378.12.1457; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Frandsen TL, 2001, CANCER RES, V61, P532; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F; Ignar DM, 1998, CLIN EXP METASTAS, V16, P9; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kost TA, 1997, GENE, V190, P139, DOI 10.1016/S0378-1119(97)00019-X; LIU DF, 1995, PROSTATE, V27, P269, DOI 10.1002/pros.2990270506; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Mueller BM, 1996, CURR TOP MICROBIOL, V213, P65; Naito S, 2000, PATHOL RES PRACT, V196, P103, DOI 10.1016/S0344-0338(00)80041-2; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Rabbani SA, 2002, CANCER RES, V62, P2390; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; Rha SY, 2000, CANCER LETT, V150, P137, DOI 10.1016/S0304-3835(99)00376-6; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; SIMILE MM, 1994, CANCER LETT, V79, P9, DOI 10.1016/0304-3835(94)90056-6; Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; SZYF M, 2002, METHODS MOL BIOL EXT; SZYF M, 2002, METHODS MOL BIOL MEA; Van Zee KJ, 1998, ONCOGENE, V16, P2723; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y; Xing RH, 1999, INT J CANCER, V81, P443, DOI 10.1002/(SICI)1097-0215(19990505)81:3<443::AID-IJC19>3.0.CO;2-T; Xing RH, 1997, CANCER RES, V57, P3585; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115	45	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41571	41579		10.1074/jbc.M201864200	http://dx.doi.org/10.1074/jbc.M201864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198113	hybrid			2022-12-25	WOS:000178985300036
J	Higashi, Y; Asanuma, M; Miyazaki, I; Haque, ME; Fujita, N; Tanaka, K; Ogawa, N				Higashi, Y; Asanuma, M; Miyazaki, I; Haque, ME; Fujita, N; Tanaka, K; Ogawa, N			The p53-activated gene, PAG608, requires a zinc finger domain for nuclear localization and oxidative stress-induced	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; 6-HYDROXYDOPAMINE-INDUCED APOPTOSIS; BRAIN MITOCHONDRIA; PC12 CELLS; P53; BAX; PERMEABILITY; EXPRESSION; VIABILITY; NEURONS	The p53-activated gene PAG608, which encodes a nuclear zinc finger protein, is a p53-inducible gene that contributes to p53-mediated apoptosis. However, the mechanisms by which PAG608 is involved in the apoptosis of neuronal cells are still obscure. In this study, we demonstrated that expression of p53 was induced by 100 muM 6-hydroxydopamine (6-OHDA), accompanied by increased PAG608 expression in PC12 cells. On the other hand, transient or permanent transfection of antisense PAG608 cDNA into PC12 cells significantly prevented apoptotic cell death induced by 100 muM 6-OHDA or 200 muM hydrogen peroxide but not by 250 muM 1-methyl-4phenylpyridinium ion. The 6-OHDA-induced activation of caspase-3, DNA fragmentation, loss of mitochondria membrane potential, and induction of p53 and Bax were also prevented in PC12 cells that stably expressed antisense PAG608 cDNA. These results suggest that PAG608 is associated with the apoptotic pathway induced by these oxidative stress-generating reagents, upstream of the collapse in the mitochondrial membrane potential in PC12 cells. Interestingly, transient transfection with PAG608 cDNA increased p53 expression in both PC12 cells and B65 cells, indicating that PAG608 induced by p53 is able to induce p53 expression in these cells inversely. Furthermore, transient transfection of a truncated mutant PAG608 cDNA, lacking the first zinc finger domain, inhibited 6-OHDA-induced cell death and altered the nuclear and nucleolar localization of wild-type PAG608 in PC12 cells. These results suggest that PAG608 may induce or regulate p53 expression and translocate to the nucleus and nucleolus using its first zinc finger domain during oxidative stress-induced apoptosis of catecholamine-containing cells.	Okayama Univ, Sch Med & Dent, Dept Brain Sci, Okayama 7008558, Japan	Okayama University	Higashi, Y (corresponding author), Okayama Univ, Sch Med & Dent, Dept Brain Sci, 2-5-1 Shikatacho, Okayama 7008558, Japan.	ogawakun@cc.okayama-u.acjp						ASANUMA M, 1995, MOL BRAIN RES, V33, P29, DOI 10.1016/0169-328X(95)00102-X; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; Blum D, 2000, NEUROSCI LETT, V283, P193, DOI 10.1016/S0304-3940(00)00948-4; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarkson ED, 1999, P SOC EXP BIOL MED, V222, P157, DOI 10.1046/j.1525-1373.1999.d01-126.x; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; Gillardon F, 1999, MOL BRAIN RES, V73, P138, DOI 10.1016/S0169-328X(99)00251-X; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; He Y, 2000, BRAIN RES, V858, P163, DOI 10.1016/S0006-8993(99)02459-2; Hellborg F, 2001, ONCOGENE, V20, P5466, DOI 10.1038/sj.onc.1204722; Hermann DM, 2001, NEUROSCIENCE, V102, P779, DOI 10.1016/S0306-4522(00)00522-4; Higashi Y, 2000, J NEUROCHEM, V75, P1771, DOI 10.1046/j.1471-4159.2000.0751771.x; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Jiang DM, 2001, J NEUROCHEM, V76, P1745, DOI 10.1046/j.1471-4159.2001.00151.x; Kim DH, 2001, EUR J NEUROSCI, V13, P1861, DOI 10.1046/j.0953-816x.2001.01563.x; Lee CS, 2002, NEUROCHEM INT, V40, P361, DOI 10.1016/S0197-0186(01)00069-9; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lotharius J, 1999, J NEUROSCI, V19, P1284; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L; Soldner F, 1999, EXP CELL RES, V250, P75, DOI 10.1006/excr.1999.4504; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Tomasevic G, 1999, MOL BRAIN RES, V70, P304, DOI 10.1016/S0169-328X(99)00146-1; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woodgate A, 1999, MOL BRAIN RES, V69, P84, DOI 10.1016/S0169-328X(99)00103-5; Wu W, 2001, J Tradit Chin Med, V21, P136; Yamakawa H, 2000, NEUROL RES, V22, P556; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zuch CL, 2000, J COMP NEUROL, V427, P440, DOI 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7	45	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42224	42232		10.1074/jbc.M203594200	http://dx.doi.org/10.1074/jbc.M203594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196512	Green Submitted, hybrid			2022-12-25	WOS:000178985300117
J	Kuksa, V; Franz, B; Maeda, T; Jang, GF; Ritter, E; Heck, M; Van Hooser, JP; Liang, Y; Filipek, S; Gelb, MH; Hofmann, KP; Palczewski, K				Kuksa, V; Franz, B; Maeda, T; Jang, GF; Ritter, E; Heck, M; Van Hooser, JP; Liang, Y; Filipek, S; Gelb, MH; Hofmann, KP; Palczewski, K			Biochemical and physiological properties of rhodopsin regenerated with 11-cis-6-ring- and 7-ring-retinals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; LEBER CONGENITAL AMAUROSIS; LIGHT-STABLE RHODOPSIN; METARHODOPSIN-II; BINDING PROTEIN; VISUAL PIGMENT; MOUSE MODEL; CHILDHOOD BLINDNESS; VERTEBRATE RETINA; CRYSTAL-STRUCTURE	Phototransduction is initiated by the photoisomerization of rhodopsin (Rho) chromophore 11-cis-retinylidene to all-trans-retinylidene. Here, using Rho regenerated with retinal analogs with different ring sizes, which prevent isomerization around the C-11=C-12 double bond, the activation mechanism of this G-protein-coupled receptor was investigated. We demonstrate that 11-cis-7-ring-Rho, does not activate G-protein in vivo and in vitro, and that it does not isomerize along other double bonds, suggesting that it fits tightly into the binding site of opsin. In contrast, bleaching 11-cis-6-ring-Rho modestly activates phototransduction in vivo and at low pH in vitro. These results reveal that partial activation is caused by isomerization along other double bonds in more rigid 6-locked retinal isomers and protonation of key residues by lowering pH in 11-cis-6-ring-Rhos. Full activation is not achieved, because isomerization does not induce a complete set of conformational rearrangements of Rho. These results with 6- and 7-ring-constrained retinoids provide new insights into Rho activation and suggest a potential use of locked retinals, particularly 11-cis-7-ring-retinal, to inactivate opsin in some retinal degeneration diseases.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Warsaw, Int Inst Mol & Cell Bio, PL-02109 Warsaw, Poland; Univ Warsaw, Dept Chem, PL-02109 Warsaw, Poland; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858; gelb, michael/0000-0001-7000-5219	NATIONAL EYE INSTITUTE [R01EY009339, R01EY013385] Funding Source: NIH RePORTER; NEI NIH HHS [EY09339, R01 EY009339, R01 EY013385, EY13385] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; AKITA A, 1980, J AM CHEM SOC, V102, P6372; AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; ALBECK A, 1989, BIOPHYS J, V55, P233, DOI 10.1016/S0006-3495(89)82798-5; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BAUMANN C, 1972, J PHYSIOL-LONDON, V222, P643, DOI 10.1113/jphysiol.1972.sp009819; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL CG, 1993, J ORG CHEM, V58, P3533, DOI 10.1021/jo00065a014; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Choo DW, 1998, FEBS LETT, V440, P195, DOI 10.1016/S0014-5793(98)01459-8; Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169; CROUCH R, 1981, PHOTOCHEM PHOTOBIOL, V33, P91, DOI 10.1111/j.1751-1097.1981.tb04302.x; CROUCH R, 1984, INVEST OPHTH VIS SCI, V25, P419; DEFOE DM, 1983, INVEST OPHTH VIS SCI, V24, P1211; Fujimoto Y, 2002, CHIRALITY, V14, P340, DOI 10.1002/chir.10076; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Heck M, 2000, METHOD ENZYMOL, V315, P329; Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071; Hofmann K P, 1999, Novartis Found Symp, V224, P158; HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; KANDORI H, 1989, BIOCHEMISTRY-US, V28, P6460, DOI 10.1021/bi00441a045; Kefalov VJ, 2001, NEURON, V29, P749, DOI 10.1016/S0896-6273(01)00249-5; KROLL AJ, 1964, ARCH OPHTHALMOL-CHIC, V71, P683; LEBER T, 1869, A VONGRAEFES ARCH OP, V15, P1, DOI DOI 10.1007/BF02721213; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; Ripps H, 2002, EXP EYE RES, V74, P327, DOI 10.1006/exer.2002.1155; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SCHAPPERTKIMMIJ.J, 1949, OPHTHALMOLOGICA, V137, P420; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230	63	35	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42315	42324		10.1074/jbc.M206014200	http://dx.doi.org/10.1074/jbc.M206014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176994	Green Accepted, hybrid			2022-12-25	WOS:000178985300127
J	Menges, M; Hennig, L; Gruissem, W; Murray, JAH				Menges, M; Hennig, L; Gruissem, W; Murray, JAH			Cell cycle-regulated gene expression in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROARRAY ANALYSIS; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PLANT-CELLS; S-PHASE; A-TYPE; TRANSCRIPTIONAL REGULATION; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; HORMONAL-CONTROL	Regulated gene expression is an important mechanism for controlling cell cycle progression in yeast and mammals, and genes involved in cell division-related processes often show transcriptional regulation dependent on cell cycle position. Analysis of cell cycle processes in plants has been hampered by the lack of synchronizable cell suspensions for Arabidopsis, and few cell cycle-regulated genes are known. Using a recently described synchrony system, we have analyzed RNA from sequential samples of Arabidopsis cells progressing through the cell cycle using Affymetrix Gene-arrays. We identify nearly 500 genes that robustly display significant fluctuation in expression, representing the first genomic analysis of cell cycle-regulated gene expression in any plant. In addition to the limited number of genes previously identified as cell cycle-regulated in plants, we also find specific patterns of regulation for genes known or suspected to be involved in signal transduction, transcriptional regulation, and hormonal regulation, including key genes of cytokinin response. Genes identified represent pathways that are cell cycle-regulated in other organisms and those involved in plant-specific processes. The range and number of cell cycle-regulated genes show the close integration of the plant cell cycle into a variety of cellular control and response pathways.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich	Murray, JAH (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.	j.murray@biotech.cam.ac.uk	Murray, James AH/D-3399-2009; Gruissem, Wilhelm/H-1752-2013; Hennig, Lars/G-2081-2011	Murray, James AH/0000-0002-2282-3839; Gruissem, Wilhelm/0000-0002-1872-2998; Hennig, Lars/0000-0002-6645-1862				Beemster GTS, 2002, PLANT PHYSIOL, V129, P854, DOI 10.1104/pp.002923; Boudolf V, 2001, J EXP BOT, V52, P1381, DOI 10.1093/jexbot/52.359.1381; Breyne P, 2001, CURR OPIN PLANT BIOL, V4, P136, DOI 10.1016/S1369-5266(00)00149-7; Callard D, 1997, PLANT PHYSIOL, V115, P1385, DOI 10.1104/pp.115.4.1385; Castellano MM, 2001, PLANT CELL, V13, P2671, DOI 10.1105/tpc.13.12.2671; Chaboute ME, 1998, PLANT MOL BIOL, V38, P797, DOI 10.1023/A:1006083318906; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chaubet N, 1996, PLANT J, V10, P425, DOI 10.1046/j.1365-313X.1996.10030425.x; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cockcroft CE, 2000, NATURE, V405, P575, DOI 10.1038/35014621; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COOKE R, 1981, PLANTA, V152, P1, DOI 10.1007/BF00384976; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; De Veylder L, 1999, PLANTA, V208, P453, DOI 10.1007/s004250050582; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; Durfee T, 2000, PLANT MOL BIOL, V43, P635, DOI 10.1023/A:1006426808185; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FERREIRA P, 1994, P NATL ACAD SCI USA, V91, P11313, DOI 10.1073/pnas.91.24.11313; FERREIRA PCG, 1991, PLANT CELL, V3, P531, DOI 10.1105/tpc.3.5.531; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; Fuerst RAUA, 1996, PLANT PHYSIOL, V112, P1023, DOI 10.1104/pp.112.3.1023; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; HESLOPHARRISON JS, 1994, ARABIDOPSIS, P63; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; Holt CL, 1996, GENETICS, V142, P777; HOWARD A, 1953, HEREDITY S, V6, P216; Hu YX, 2000, PLANT J, V24, P693, DOI 10.1046/j.1365-313x.2000.00915.x; Huntley RP, 1999, CURR OPIN PLANT BIOL, V2, P440, DOI 10.1016/S1369-5266(99)00027-8; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito M, 2000, PLANT MOL BIOL, V43, P677, DOI 10.1023/A:1006336005587; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; Joubes J, 2000, PLANT MOL BIOL, V43, P607, DOI 10.1023/A:1006470301554; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; Kong LJ, 2000, EMBO J, V19, P3485, DOI 10.1093/emboj/19.13.3485; Kovar DR, 2000, PLANT J, V24, P625, DOI 10.1046/j.1365-313x.2000.00907.x; Li Y, 2002, PLANT PHYSIOL, V128, P854, DOI 10.1104/pp.010658; Lui H, 2000, PLANT J, V21, P379, DOI 10.1046/j.1365-313x.2000.00688.x; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; Menand B, 1998, P NATL ACAD SCI USA, V95, P11014, DOI 10.1073/pnas.95.18.11014; Menges M, 2002, PLANT J, V30, P203, DOI 10.1046/j.1365-313X.2002.01274.x; Mews M, 2000, PROTOPLASMA, V212, P236, DOI 10.1007/BF01282924; MEYER Y, 1979, PLANTA, V147, P181, DOI 10.1007/BF00388735; Mironov V, 1999, PLANT CELL, V11, P509; Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakaya M, 2002, PLANT CELL PHYSIOL, V43, P239, DOI 10.1093/pcp/pcf024; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Oakenfull EA, 2002, PHILOS T R SOC B, V357, P749, DOI 10.1098/rstb.2002.1085; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Ouellet F, 2001, PLANT CELL, V13, P829, DOI 10.1105/tpc.13.4.829; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; Reichheld JP, 1996, P NATL ACAD SCI USA, V93, P13819, DOI 10.1073/pnas.93.24.13819; Reichheld JP, 1998, NUCLEIC ACIDS RES, V26, P3255, DOI 10.1093/nar/26.13.3255; Renaudin JP, 1996, PLANT MOL BIOL, V32, P1003, DOI 10.1007/BF00041384; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Richmond T, 2000, CURR OPIN PLANT BIOL, V3, P108, DOI 10.1016/S1369-5266(99)00049-7; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; SALA F, 1980, FEBS LETT, V117, P93, DOI 10.1016/0014-5793(80)80920-3; Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113; Schenk PM, 2000, P NATL ACAD SCI USA, V97, P11655, DOI 10.1073/pnas.97.21.11655; Segers G, 1996, PLANT J, V10, P601, DOI 10.1046/j.1365-313X.1996.10040601.x; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; Shaul O, 1996, P NATL ACAD SCI USA, V93, P4868, DOI 10.1073/pnas.93.10.4868; Shedden K, 2002, NUCLEIC ACIDS RES, V30, P2920, DOI 10.1093/nar/gkf414; Shedden K, 2002, P NATL ACAD SCI USA, V99, P4379, DOI 10.1073/pnas.062569899; Sheen J, 2002, SCIENCE, V296, P1650, DOI 10.1126/science.1071883; Shen B, 2002, PLANT J, V29, P371, DOI 10.1046/j.1365-313X.2002.01221.x; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stals H, 1997, FEBS LETT, V418, P229, DOI 10.1016/S0014-5793(97)01368-9; Stals H, 2001, TRENDS PLANT SCI, V6, P359, DOI 10.1016/S1360-1385(01)02016-7; Sweere U, 2001, SCIENCE, V294, P1108, DOI 10.1126/science.1065022; Swiatek A, 2002, PLANT PHYSIOL, V128, P201, DOI 10.1104/pp.010592; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Urao T, 1998, FEBS LETT, V427, P175, DOI 10.1016/S0014-5793(98)00418-9; van der Meijden CMJ, 2002, CANCER RES, V62, P3233; VANTHOF J, 1974, CELL CYCLE CONTROLS, P77; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Wang H, 1998, PLANT J, V15, P501, DOI 10.1046/j.1365-313X.1998.00231.x; Wang HY, 2002, PLANT PHYSIOL, V129, P638, DOI 10.1104/pp.002675; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zelenaya-Troitskaya O, 1998, GENETICS, V148, P1763; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	100	174	200	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41987	42002		10.1074/jbc.M207570200	http://dx.doi.org/10.1074/jbc.M207570200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12169696	hybrid			2022-12-25	WOS:000178985300088
J	Opazo, C; Huang, XD; Cherny, RA; Moir, RD; Roher, AE; White, AR; Cappai, R; Masters, CL; Tanzi, RE; Inestrosa, NC; Bush, AI				Opazo, C; Huang, XD; Cherny, RA; Moir, RD; Roher, AE; White, AR; Cappai, R; Masters, CL; Tanzi, RE; Inestrosa, NC; Bush, AI			Metalloenzyme-like activity of Alzheimer's disease beta-amyloid - Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; OXIDATIVE STRESS; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; SUPEROXIDE-DISMUTASE; SENILE PLAQUES; ZINC; PROTEIN; NEURONS; COPPER	beta-Amyloid (Abeta) 1-42, implicated in the pathogenesis of Alzheimer's disease, forms an oligomeric complex that binds copper at a CuZn superoxide dismutase-like binding site. Abeta.Cu complexes generate neurotoxic H2O2 from O-2 through Cu2+ reduction, but the reaction mechanism has been unclear. We now report that Abeta1-42, when binding up to 2 eq of Cu2+, generates the H2O2 catalytically by recruiting biological reducing agents as substrates under conditions where the Cu2+ or reducing agents will not form H2O2 themselves. Cholesterol is an important substrate for this activity, as are vitamin C, L-DOPA, and dopamine (V-max for dopamine = 34.5 nM/min, K-m = 8.9 muM). The activity was inhibited by anti-Abeta antibodies, Cu2+ chelators, and Zn2+. Toxicity of Abeta in neuronal culture was consistent with catalytic H2O2 production. All was not toxic in cell cultures in the absence of Cu2+, and dopamine (5 pm) markedly exaggerated the neurotoxicity of 200 rim Abeta1-42.Cu. Therefore, microregional catalytic H2O2 production, combined with the exhaustion of reducing agents, may mediate the neurotoxicity of Abeta in Alzheimer's disease, and inhibitors of this novel activity may be of therapeutic value.	Sun Hlth Res Inst, Haldeman Lab Alzheimer Dis Res, Sun City, AZ 85351 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Univ Melbourne, Mental Hlth Res Inst, Oxidat Disorders Lab, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lab Oxidat Biol, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Regulac Celular & Patol, Santiago 114D, Chile	Banner Research; Banner Health; Banner Sun Health Research Institute; Harvard University; Massachusetts General Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Pontificia Universidad Catolica de Chile	Bush, AI (corresponding author), Massachusetts Gen Hosp, Lab Oxidat Biol, Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019; White, Anthony/P-5596-2016; Cappai, Roberto/B-3347-2010	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; White, Anthony/0000-0003-1802-9891; Opazo, Carlos/0000-0003-3473-7548; Cappai, Roberto/0000-0002-9505-8496	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH002001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012685] Funding Source: NIH RePORTER; NIA NIH HHS [2R01 AG 12685] Funding Source: Medline; NIMH NIH HHS [1K01 MH 02001] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aksenov MY, 1998, J MOL NEUROSCI, V11, P151, DOI 10.1385/JMN:11:2:151; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BUSH AI, 1994, J BIOL CHEM, V269, P12152; Bush AI, 2002, P NATL ACAD SCI USA, V99, P7317, DOI 10.1073/pnas.122249699; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 2002, 7 INT GEN SPRINGF AL; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Mori T, 2001, J NEUROPATH EXP NEUR, V60, P778, DOI 10.1093/jnen/60.8.778; Nunomura A, 1999, J NEUROSCI, V19, P1959; POWERS RE, 1988, NEUROSCIENCE, V25, P401, DOI 10.1016/0306-4522(88)90248-5; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Russell RL, 1999, ARCH BIOCHEM BIOPHYS, V370, P236, DOI 10.1006/abbi.1999.1404; Sagara Y, 1996, J NEUROSCI, V16, P497; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tamagno E, 2000, NEUROREPORT, V11, P1865, DOI 10.1097/00001756-200006260-00013; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; White AR, 2001, J NEUROCHEM, V76, P1509, DOI 10.1046/j.1471-4159.2001.00178.x; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	47	496	535	2	78	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40302	40308		10.1074/jbc.M206428200	http://dx.doi.org/10.1074/jbc.M206428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192006	hybrid			2022-12-25	WOS:000178791400021
J	Vachette, P; Dainese, E; Vasyliev, VB; Di Muro, P; Beltramini, M; Svergun, DI; De Filippis, V; Salvato, B				Vachette, P; Dainese, E; Vasyliev, VB; Di Muro, P; Beltramini, M; Svergun, DI; De Filippis, V; Salvato, B			A key structural role for active site type 3 copper ions in human ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; AMINO-ACID-SEQUENCE; ASPARTATE-TRANSCARBAMYLASE; BIOLOGICAL MACROMOLECULES; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; MOLTEN GLOBULE; RESOLUTION; SERUM; IRON	Human ceruloplasmin is a copper containing serum glycoprotein with multiple functions. The crystal structure shows that its six domains are arranged in three pairs with a pseudo-ternary axis. Both the holo and apo forms of human ceruloplasmin were studied by size exclusion chromatography and small angle x-ray scattering in solution. The experimental curve of the holo form displays conspicuous differences with the scattering pattern calculated from the crystal structure. Once the carbohydrate chains and flexible loops not visible in the crystal are accounted for, remaining discrepancies suggest that the central pair of domains may move as a whole with respect to the rest of the molecule. The quasi-symmetrical crystal structure therefore appears to be stabilized by crystal packing forces. Upon copper removal, the scattering pattern of human ceruloplasmin exhibits very large differences with that of the holoprotein, which are interpreted in terms of essentially preserved domains freely moving in solution around flexible linkers and exploring an ensemble of open conformations. This model, which is supported by the analysis of domain interfaces, provides a structural explanation for the differences in copper reincorporation into the apoprotein and activity recovery between human ceruloplasmin and two other multicopper oxidases, ascorbate oxidase and laccase. Our results demonstrate that, beyond catalytic activity, the three-copper cluster at the N-terminal-C-terminal interface plays a crucial role in the structural stability of human ceruloplasmin.	Univ Paris 11, LURE, F-91898 Orsay, France; Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Inst Expt Med, St Petersburg 197376, Russia; Univ Padua, Dept Biol, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Biomed Technol, I-35100 Padua, Italy; EMBL, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Univ Padua, CRIBI Biotechnol Ctr, Padua, Italy	UDICE-French Research Universities; Universite Paris Saclay; University of Teramo; Institute of Experimental Medicine; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Padua	Vachette, P (corresponding author), Univ Paris 11, LURE, Bat 209d,BP 34, F-91898 Orsay, France.			Svergun, Dmitri/0000-0003-0830-5696; Dainese, Enrico/0000-0001-7163-9344				ANDO K, 1970, J BIOCHEM-TOKYO, V68, P501, DOI 10.1093/oxfordjournals.jbchem.a129380; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Cha MK, 1999, BIOCHEMISTRY-US, V38, P12104, DOI 10.1021/bi990444b; DeFilippis V, 1996, BBA-PROTEIN STRUCT M, V1297, P119, DOI 10.1016/S0167-4838(96)00139-2; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FETLER L, 1995, J MOL BIOL, V251, P243, DOI 10.1006/jmbi.1995.0432; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GITLIN D, 1960, NATURE, V185, P693, DOI 10.1038/185693a0; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; Guinier A., 1955, SMALL ANGLE SCATTERI; GUTTERIDGE JMC, 1980, FEBS LETT, V112, P269, DOI 10.1016/0014-5793(80)80195-5; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KACHURIN AM, 1989, BIOCHEMISTRY-MOSCOW+, V54, P26; KASPER CB, 1963, J BIOL CHEM, V238, P2325; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; MALMSTROM BG, 1978, NEW TRENDS BIOINORGA, P59; MATSUDA I, 1974, PEDIATR RES, V8, P821, DOI 10.1203/00006450-197410000-00001; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MORPURGO L, 1981, ISRAEL J CHEM, V21, P26, DOI 10.1002/ijch.198100007; MORRIS MC, 1983, BIOCHIM BIOPHYS ACTA, V743, P389, DOI 10.1016/0167-4838(83)90397-7; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PROZOROVSKI VN, 1982, INT J PEPT PROT RES, V19, P40; PTITSYN OB, 1995, PROTEIN FOLDING, P243; Roussel A., 1989, SILICON GRAPHICS GEO; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SATO M, 1991, J BIOL CHEM, V266, P5128; SAVINI I, 1990, EUR J BIOCHEM, V190, P491, DOI 10.1111/j.1432-1033.1990.tb15600.x; SAVINI I, 1985, BIOCHEM BIOPH RES CO, V131, P25; Segel DJ, 1999, BIOCHEMISTRY-US, V38, P15352, DOI 10.1021/bi991337k; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; Takahashi Y, 1996, HUM MOL GENET, V5, P81, DOI 10.1093/hmg/5.1.81; TUROVEROV KK, 1982, BIOORG KHIM+, V8, P1165; VACHETTE P, 2000, BIOMOLECULAR STRUCTU, V4, P199; Varghese JN, 1998, STRUCT FOLD DES, V6, P735, DOI 10.1016/S0969-2126(98)00075-6; Vassiliev VB, 1997, J INORG BIOCHEM, V65, P167, DOI 10.1016/S0162-0134(96)00119-5; VASSILIEV VB, 1988, BIOCHEMISTRY-US, V53, P1756; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZAKHAROVA E T, 1983, Biokhimiya, V48, P1709	56	41	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40823	40831		10.1074/jbc.M207188200	http://dx.doi.org/10.1074/jbc.M207188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177070	Green Published, hybrid			2022-12-25	WOS:000178791400086
J	Washington, K; Ammosova, T; Beullens, M; Jerebtsova, M; Kumar, A; Bollen, M; Nekhai, S				Washington, K; Ammosova, T; Beullens, M; Jerebtsova, M; Kumar, A; Bollen, M; Nekhai, S			Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; TRANSCRIPTION; KINASE; PURIFICATION; ACTIVATION; SUBUNIT; PEPTIDE; CDK2; CTD	Transcription by RNA polymerase-II (RNAPII) is controlled by multisite phosphorylation of the heptapeptide repeats in the C-terminal domain (CTD) of the largest subunit. Phosphorylation of CTD is mediated by the cyclin-dependent protein kinases Cdk7 and Cdk9, whereas protein serine/threonine phosphatase FCP1 dephosphorylates CTD. We have recently reported that human immunodeficiency virus-1 (HIV-1) transcription is positively regulated by protein phosphatase-1 (PP1) and that PP1 dephosphorylates recombinant CTD. Here, we provide further evidence that PP1 can dephosphorylate RNAPII CTD. In vitro, PP1 dephosphorylated recombinant CTD as well as purified RNAPII CTD. HeLa nuclear extracts were found to contain a species of PP1 that dephosphorylates both serine 2 and serine 5 of the heptapeptide repeats. In nuclear extracts, PP1 and FCP1 contributed roughly equally to the dephosphorylation of serine 2. PP1 co-purified with RNAPII by gel filtration and associated with RNAPII on immunoaffinity columns prepared with anti-CTD antibodies. In cultured cells treated with CTD kinase inhibitors, the dephosphorylation of RNAPII on serine 2 was inhibited by 45% by preincubation with okadaic acid, which inhibits phosphatases of PPP family, including PP1 but not FCP1. Our data demonstrate that RNAPII CTD is dephosphorylated by PP1 in vitro and by PPP-type phosphatase, distinct from FCP1, in vivo.	Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Howard Univ, Genet Program, Washington, DC 20059 USA; Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; Childrens Natl Med Ctr, Washington, DC 20010 USA; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Howard University; Howard University; Howard University; Universite Catholique Louvain; Children's National Health System; George Washington University	Nekhai, S (corresponding author), Howard Univ, Ctr Sickle Cell Dis, 2121 Georgia Ave,NW, Washington, DC 20059 USA.	snekhai@howard.edu	, nekhai/AFO-2652-2022; , nekhai/AAW-3105-2021		NHLBI NIH HHS [UH1 HL 03679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; Bensaude O, 1999, BIOCHEM CELL BIOL, V77, P249, DOI 10.1139/bcb-77-4-249; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 1998, METH MOL B, V93, P145; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bharucha DC, 2002, VIROLOGY, V296, P6, DOI 10.1006/viro.2002.1438; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Morris MC, 2002, J BIOL CHEM, V277, P23847, DOI 10.1074/jbc.M107890200; Nekhai S, 2000, PEPTIDES, V21, P1449, DOI 10.1016/S0196-9781(00)00297-7; Nekhai S, 2000, VIROLOGY, V266, P246, DOI 10.1006/viro.1999.0035; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Okamoto H, 2000, VIROLOGY, V270, P337, DOI 10.1006/viro.2000.0311; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7	32	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40442	40448		10.1074/jbc.M205687200	http://dx.doi.org/10.1074/jbc.M205687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185079	hybrid			2022-12-25	WOS:000178791400038
J	Shi, WX; Sarver, AE; Wang, CC; Tanaka, KSE; Almo, SC; Schramm, VL				Shi, WX; Sarver, AE; Wang, CC; Tanaka, KSE; Almo, SC; Schramm, VL			Closed site complexes of adenine phosphoribosyltransferase from Giardia lamblia reveal a mechanism of ribosyl migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE STRUCTURE; 2.0 ANGSTROM STRUCTURE; CRYSTAL-STRUCTURES; ANALOG INHIBITOR; ATOMIC MOTION; CATALYSIS; PURINE	The adenine phosphoribosyltransferase (APRTase) from Giardia lamblia was co-crystallized with 9-deazaadenine and sulfate or with 9-deazaadenine and Mg-phosphoribosylpyrophosphate. The complexes were solved and refined to 1.85 and 1.95 Angstrom resolution. Giardia APRTase is a symmetric homodimer with the monomers built around Rossman fold cores, an element common to all known purine phosphoribosyltransferases. The catalytic sites are capped with a small hood domain that is unique to the APRTases. These structures reveal several features relevant to the catalytic function of APRTase: 1) a non-proline cis peptide bond (Glu(61)-Ser(62)) is required to form the pyrophosphate binding site in the APRTase.9dA.MgPRPP complex but is a trans peptide bond in the absence of pyrophosphate group, as observed in the APRTase.9dA.SO4 complex; 2) a catalytic site loop is closed and fully ordered in both complexes, with Glu(100) from the catalytic loop acting as the acid/base for protonation/deprotonation of N-7 of the adenine ring, 3) the pyrophosphoryl charge is neutralized by a single Mg2+ ion and Arg(63), in contrast to the hypoxanthine-guanine phosphoribosyltransferases, which use two Mg2+ ions; and 4) the nearest structural neighbors to APRTases are the orotate phosphoribosyltransferases, suggesting different paths of evolution for adenine relative to other purine PRTases. An overlap comparison of AMP and 9-deazaadenine plus Mg-PRPP at the catalytic sites of APRTases indicated that reaction coordinate motion involves a 2.1-Angstrom excursion of the ribosyl anomeric carbon, whereas the adenine ring and the 5-phosphoryl group remained fixed. G. lamblia APRTase therefore provides another example of nucleophilic displacement by electrophile migration.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA	Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco	Almo, SC (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	almo@aecom.yu.edu; vern@aecom.yu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041916, R37GM041916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19391] Funding Source: Medline; NIGMS NIH HHS [GM41916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashor C, 2002, BIOCHEMISTRY-US, V41, P4020, DOI 10.1021/bi0158730; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DESPOMMIER DD, 1994, PARASITIC DIS, P144; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; FLAKS JG, 1957, J BIOL CHEM, V228, P201; Focia PJ, 1998, BIOCHEMISTRY-US, V37, P17120, DOI 10.1021/bi9821465; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Heroux A, 2000, STRUCTURE, V8, P1309, DOI 10.1016/S0969-2126(00)00546-3; HORI M, 1966, J BIOL CHEM, V241, P3404; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367; MYERS RW, 1989, J BIOL CHEM, V264, P10547; *NAT I ALL INF DIS, 1998, GIARD FACT SHEET; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; PANNEERSELVAM K, 2002, IN PRESS BIOCHEMISTR; Phillips CL, 1999, EMBO J, V18, P3533, DOI 10.1093/emboj/18.13.3533; SAHITA AS, 2001, METABOLIC MOL BASES, P2571; Sarver AE, 2002, J BIOL CHEM, V277, P39973, DOI 10.1074/jbc.M205595200; Schramm VL, 2001, CURR OPIN STRUC BIOL, V11, P657, DOI 10.1016/S0959-440X(01)00269-X; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; Shi WX, 2001, BIOCHEMISTRY-US, V40, P10800, DOI 10.1021/bi010465h; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; Xu YM, 1998, BIOCHEMISTRY-US, V37, P4114, DOI 10.1021/bi972519m	36	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39981	39988		10.1074/jbc.M205596200	http://dx.doi.org/10.1074/jbc.M205596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171925	hybrid			2022-12-25	WOS:000178662500117
J	Tokumura, A; Majima, E; Kariya, Y; Tominaga, K; Kogure, K; Yasuda, K; Fukuzawa, K				Tokumura, A; Majima, E; Kariya, Y; Tominaga, K; Kogure, K; Yasuda, K; Fukuzawa, K			Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE-CELLS; MOLECULAR-CLONING; IN-VITRO; SERUM; PYROPHOSPHATASE; EXPRESSION; LOCALIZATION; INVOLVEMENT; INHIBITION	We purified human plasma lysophospholipase D that produces physiologically active lysophosphatidic acid and showed that it is a soluble form of autotaxin, an ecto-nucleotide pyrophosphatase/phosphodiesterase, originally found as a tumor cell motility-stimulating factor. Its lower K-m value for a lysophosphatidylcholine than that for a synthetic substrate of nucleotide suggests that lysophosphatidylcholine is a more likely physiological substrate for autotaxin and that its predicted physiological and pathophysiological functions could be mediated by its activity to produce lysophosphate acid, an intercellular mediator. Recombinant autotaxin was found to have lysophospholipase D activity; its substrate specificity and metal ion requirement were the same as those of the purified plasma enzyme. The activity of lysophospholipase, D for exogenous lysophosphatidylcholine in human serum was found to increase in normal pregnant women at the third trimester of pregnancy and to a higher extent in patients in threatened preterm delivery, suggesting its roles in induction of parturition.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima, Japan; APRO Life Sci Inst, Naruto 7720001, Japan; Kansai Med Univ, Dept Obstet & Gynecol, Moriguchi, Osaka 5708507, Japan	Tokushima University; Kansai Medical University	Tokumura, A (corresponding author), 1-78 Shomachi, Tokushima 7708505, Japan.	tokumura@ph.tokushima-u.ac.jp						Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fuss B, 1997, J NEUROSCI, V17, P9095; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hinokio K, 2002, LIFE SCI, V70, P759, DOI 10.1016/S0024-3205(01)01448-5; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LUTHJE J, 1988, CLIN CHIM ACTA, V177, P131, DOI 10.1016/0009-8981(88)90134-9; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nakane S, 2001, LIPIDS, V36, P413, DOI 10.1007/s11745-001-0737-1; Nam SW, 2001, CANCER RES, V61, P6938; NARITA M, 1994, J BIOL CHEM, V269, P28235; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Park W, 1996, J RHEUMATOL, V23, P1233; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; SATOUCHI K, 1994, BBA-LIPID LIPID MET, V1214, P303; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 1999, BBA-MOL CELL BIOL L, V1437, P235, DOI 10.1016/S1388-1981(99)00011-6; Tokumura A, 1999, BIOL REPROD, V61, P195, DOI 10.1095/biolreprod61.1.195; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; Tokumura A, 2002, J LIPID RES, V43, P307; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Tokumura A, 2000, ANN NY ACAD SCI, V905, P347; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; ZAITSU K, 1980, ANAL BIOCHEM, V109, P109, DOI 10.1016/0003-2697(80)90017-2; Zimmermann H, 1999, PROG BRAIN RES, V120, P371	42	591	615	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39436	39442		10.1074/jbc.M205623200	http://dx.doi.org/10.1074/jbc.M205623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176993	hybrid			2022-12-25	WOS:000178662500049
J	Sun, JM; Chen, HY; Moniwa, M; Litchfield, DW; Seto, E; Davie, JR				Sun, JM; Chen, HY; Moniwa, M; Litchfield, DW; Seto, E; Davie, JR			The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; NUCLEAR MATRIX; MAMMARY-GLAND; ACTIVATION; ACETYLATION; FAMILY; TUMORIGENESIS; MECHANISM; CELLS; GENES	Spl and Sp3 are ubiquitously expressed mammalian transcription factors that function as activators or repressors. Although both transcription factors share a common domain involved in forming multimers, we demonstrate that Sp1 and Sp3 form separate complexes in estrogen-dependent human breast cancer cells. Sp1 and Sp3 complexes associate with histone deacetylases (HDACs) 1 and 2. Although most HDAC2 is not phosphorylated in the breast cancer cells, HDAC2 bound to Sp1 and Sp3 and cross-linked to chromatin in situ is highly enriched in a phosphorylated form . that has a reduced mobility in SDS-polyacrylamide gels. We show that protein kinase CK2 is associated with and phosphorylates HDAC2. Alkaline phosphatase treatment of HDAC2 and Sp1 and Sp3 complexes reduced the associated HDAC activity. Protein kinase CK2 is up-regulated in several cancers including breast cancer, and Sp1 and Sp3 have key roles in estrogen-induced proliferation and gene expression in estrogen-dependent breast cancer cells. CK2 phosphorylation of HDAC2 recruited by Sp1 or SP3 could regulate HDAC activity and alter the balance of histone deacetylase and histone acetyltransferase activities and dynamic chromatin remodeling of estrogen-regulated genes.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	Western University (University of Western Ontario); H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; Davie, James/0000-0002-0420-6888				Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Davie JR, 2000, CRIT REV EUKAR GENE, V10, P303; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DUBIK D, 1992, ONCOGENE, V7, P1587; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Landesman-Bollag E, 2001, MOL CELL BIOCHEM, V227, P153, DOI 10.1023/A:1013108822847; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Samuel SK, 1998, CANCER RES, V58, P3004; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer VA, 2001, J BIOL CHEM, V276, P34810, DOI 10.1074/jbc.M104886200; Spencer VA, 2002, PROTEIN PROTOCOLS HD, P753; SPENCER VA, 2002, PROTEIN PROTOCOLS HD, P747; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; Sun JM, 1996, J CELL BIOCHEM, V62, P454, DOI 10.1002/(SICI)1097-4644(19960915)62:4<454::AID-JCB3>3.0.CO;2-L; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhao H, 2002, J CELL BIOCHEM, V86, P365, DOI 10.1002/jcb.10215	34	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35783	35786		10.1074/jbc.C200378200	http://dx.doi.org/10.1074/jbc.C200378200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12176973	hybrid			2022-12-25	WOS:000178275100002
J	Schimmel, M; Bauer, G				Schimmel, M; Bauer, G			Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts	ONCOGENE			English	Article						transformed; reactive oxygen species; apoptosis; catalase	INTERCELLULAR INDUCTION; HYDROGEN-PEROXIDE; APOPTOSIS-INDUCTION; RADICAL GENERATION; HYDROXYL RADICALS; SUPEROXIDE ANION; OXIDATIVE STRESS; NADH OXIDASE; NITRIC-OXIDE; CELLS	Oncogenic transformed fibroblasts are characterized by extracellular superoxide anion generation through a membrane-associated NADPH oxidase. After cellular glutathione depletion, extracellular reactive oxygen species (ROS) generated by transformed fibroblasts exhibit a strong apoptosis-inducing potential. As apoptosis induction under glutathione depletion is inhibited by catalase, the NADPH oxidase inhibitor apocynin, superoxide dismutase, the hydroxyl radical scavenger terephthalate and the iron chelator deferoxamine, the metal-catalysed Haber-Weiss reaction seems to be the responsible signaling mechanism. In contrast to extracellular ROS, intracellular ROS play no role for apoptosis induction in glutathione-depleted transformed fibroblasts initially, since a high level of intracellular catalase scavenges intracellular hydrogen peroxide. Intracellular catalase seems to be induced by extracellular hydrogen peroxide, as pretreatment of transformed fibroblasts with exogenous catalase downmodulates endogenous catalase and renders glutathione-depleted transformed cells susceptible for the effect of endogenous hydrogen peroxide. In contrast to transformed fibroblasts, nontransformed glutathione-depleted fibroblasts do not generate substantial extracellular ROS, but apoptosis is efficiently induced in these cells by intracellular ROS. Our data show that extracellular ROS of transformed fibroblasts exhibit redox-related signaling and at the same time represent a potential apoptosis-inducing hazard through the metal-catalysed Haber-Weiss reaction.	Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, D-79104 Freiburg, Germany	University of Freiburg	Bauer, G (corresponding author), Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	tgfb@ukl.uni-freiburg.de						Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; ARUOMA OI, 1988, BIOCHEM J, V256, P251, DOI 10.1042/bj2560251; Barnes AC, 1999, MICROB PATHOGENESIS, V26, P149, DOI 10.1006/mpat.1998.0260; Bauer G, 2000, HANDB EXP PHARM, V142, P275; Bauer G, 2000, ANTICANCER RES, V20, P4115; Beck E, 1997, EXP CELL RES, V234, P47, DOI 10.1006/excr.1997.3587; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Bittinger F, 1998, MELANOMA RES, V8, P381, DOI 10.1097/00008390-199810000-00001; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.3.CO;2-H; Engelmann I, 2000, REDOX REP, V5, P207, DOI 10.1179/135100000101535762; Enoiu M, 2000, FREE RADICAL BIO MED, V29, P825, DOI 10.1016/S0891-5849(00)00370-1; Faure H, 1996, FREE RADICAL BIO MED, V20, P979, DOI 10.1016/0891-5849(95)02187-6; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Girotti AW, 1998, J LIPID RES, V39, P1529; GORCZYCA W, 1993, CANCER RES, V53, P1945; Haufel T, 2001, ANTICANCER RES, V21, P2617; HEIGOLD S, 2002, J LEUKOCYTE BIOL, V23, P939; HEIGOLD S, 2002, IN PRESS CARCINOGENE; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; Herdener M, 2000, FREE RADICAL BIO MED, V29, P1260, DOI 10.1016/S0891-5849(00)00422-6; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lai CC, 1996, J MOL CELL CARDIOL, V28, P1157, DOI 10.1006/jmcc.1996.0106; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li PF, 1997, CIRCULATION, V96, P3602; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Morre DJ, 1997, J BIOENERG BIOMEMBR, V29, P281, DOI 10.1023/A:1022466212083; Mylonas C, 1999, IN VIVO, V13, P295; Nappi AJ, 1998, BBA-GEN SUBJECTS, V1380, P55, DOI 10.1016/S0304-4165(97)00125-6; Oettl K, 1999, BIOCHEM BIOPH RES CO, V264, P262, DOI 10.1006/bbrc.1999.1520; Oyama Y, 1999, EUR J PHARMACOL, V384, P47, DOI 10.1016/S0014-2999(99)00649-4; Paul K, 2001, ANTICANCER RES, V21, P3237; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rohrdanz E, 1998, FREE RADICAL BIO MED, V24, P27, DOI 10.1016/S0891-5849(97)00159-7; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROSEN H, 1979, J CLIN INVEST, V64, P1725, DOI 10.1172/JCI109637; SARAN M, 1994, CHEM-BIOL INTERACT, V90, P35, DOI 10.1016/0009-2797(94)90109-0; Saran M, 1999, FREE RADICAL RES, V31, P429, DOI 10.1080/10715769900300991; Schimmel M, 2001, INT J ONCOL, V19, P299; Schwieger A, 2001, CARCINOGENESIS, V22, P1385, DOI 10.1093/carcin/22.9.1385; SHI XL, 1992, ARCH BIOCHEM BIOPHYS, V292, P323, DOI 10.1016/0003-9861(92)90085-B; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THART BA, 1990, FREE RADICAL BIO MED, V9, P127, DOI 10.1016/0891-5849(90)90115-Y; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; Zucker B, 1997, CELL DEATH DIFFER, V4, P388, DOI 10.1038/sj.cdd.4400258	61	66	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5886	5896		10.1038/sj.onc.1205740	http://dx.doi.org/10.1038/sj.onc.1205740			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185588				2022-12-25	WOS:000177520900008
J	Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S				Sekine, S; Shibata, T; Sakamoto, M; Hirohashi, S			Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype	ONCOGENE			English	Article						colorectal carcinoma; beta-catenin; mutation; gene targeting; TCF/LEF-dependent transcription	COLORECTAL-CANCER; METALLOPROTEINASE MATRILYSIN; INTESTINAL POLYPOSIS; GROWTH; TRANSACTIVATION; SUPPRESSION; PATHWAY; TUMORIGENESIS; EXPRESSION; MUTATIONS	Most colorectal carcinomas harbor genetic alterations that result in stabilization of beta-catenin. A colorectal carcinoma cell line, HCT116, which has both mutated and wild-type beta-catenin genes, was engineered by homologous recombination to investigate the significance of beta-catenin gene mutation. As expected, the mutant allele-targeted clones showed decreased beta-catenin expression and down-regulation of T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription. Morphologically, targeted clones were only minimally altered under usual culture conditions, but under low serum conditions, mutant allele-targeted clones still grew in plane, in contrast to parental cell line and wild allele-targeted clones, which formed spheroids. The mutant allele-targeted clones showed no significant changes in growth rate and anchorage-independent growth in vitro, and displayed rather increased growth in vivo. Although beta-catenin stabilization affects some biological characteristics including adhesive properties, it may not have growth-promoting effects at least in some colorectal carcinomas.	Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo, Japan	National Cancer Center - Japan	Hirohashi, S (corresponding author), Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan.		Sakamoto, Michiie/N-2917-2015					Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mariadason JM, 2001, CANCER RES, V61, P3465; Nagasawa Y, 1999, CANCER RES, V59, P3539; Naishiro Y, 2001, CANCER RES, V61, P2751; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 2000, GENE DEV, V14, P1837; Roh H, 2001, CANCER RES, V61, P6563; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Sekine S, 2002, VIRCHOWS ARCH, V440, P381, DOI 10.1007/s004280100527; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sparks AB, 1998, CANCER RES, V58, P1130; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wagenaar RA, 2001, CANCER RES, V61, P2097; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yamada T, 2000, CANCER RES, V60, P4761	22	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5906	5911		10.1038/sj.onc.1205756	http://dx.doi.org/10.1038/sj.onc.1205756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185590	Green Submitted			2022-12-25	WOS:000177520900010
J	Cozier, GE; Carlton, J; McGregor, AH; Gleeson, PA; Teasdale, BD; Mellor, H; Cullen, PJ				Cozier, GE; Carlton, J; McGregor, AH; Gleeson, PA; Teasdale, BD; Mellor, H; Cullen, PJ			The Phox Homology (PX) domain-dependent, 3-phosphoinositide-mediated association of sorting nexin-1 with an early sorting endosomal compartment is required for its ability to regulate epidermal growth factor receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; INOSITOL LIPIDS; MAMMALIAN-CELLS; BINDING; KINASE; FAB1P; TRANSLOCATION; LOCALIZATION	Recent studies have shown that phox homology (PX) domains act as phosphoinositide-binding motifs. The majority of PX domains studied show binding to phosphatidylinositol 3-monophosphate (Ptdlns(3)P), an association that allows the host protein to localize to membranes of the endocytic pathway. One issue, however, is whether PX domains may have alternative phosphoinositide binding specificities that could target their host protein to distinct subcellular compartments or allow their allosteric regulation by phosphoinositides other than PtdIns(3)P. It has been reported that the PX domain of sorting nexin 1 (SNX1) specifically binds phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) (Zhong, Q., Lazar, C. S., Tronchere, H., Sato, T., Meerloo, T., Yeo, M., Songyang, Z., Emr, S. D., and Gill, G. N. (2002) Proc. Natl. Acad. Sci. U. S. A. 99,6767-6772). In the present study, we have shown that whereas SNX1 binds PtdIns(3,4,5)P-3 in protein:lipid overlay assays, in liposomes-based assays, binding is observed to PtdIns(3)P and phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P-2) but not to PtdIns(3,4,5)P-3. To address the significance of PtdIns(3,4,5)P-3 binding, we examined the subcellular localization of SNX1 under conditions in which plasma membrane PtdIns(3,4,5)P-3 levels were significantly elevated. Under these conditions, we failed to observe association of SNX1 with this membrane. However, consistent with the binding to PtdIns(3)P and PtdIns(3,5)P-2 being of more physiological significance was the observation that the association of SNX1 with an early endosomal compartment was dependent on a 3-phosphoinositide-binding PX domain and the presence of PtdIns(3)P on this compartment. Finally, we somal association of SNX1 is important for its ability to regulate the targeting of internalized epidermal growth factor receptor for lysosomal degradation.	Univ Bristol, Sch Med Sci, Dept Biochem, Inositide Grp,Henry Wellcome Integrated Signallin, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Bristol; University of Bristol; University of Melbourne; University of Queensland	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Inositide Grp,Henry Wellcome Integrated Signallin, Bristol BS8 1TD, Avon, England.		Cozier, Gyles/A-5891-2009; Carlton, Jeremy/X-2918-2019; Carlton, Jeremy/C-7702-2014; Teasdale, Rohan D/B-2538-2009; Teasdale, Rohan/AAD-6698-2019	Carlton, Jeremy/0000-0002-7255-1894; Teasdale, Rohan D/0000-0001-7455-5269; Teasdale, Rohan/0000-0001-7455-5269; Cullen, Peter/0000-0002-9070-8349; Gleeson, Paul/0000-0002-5336-6503; Mellor, Harry/0000-0003-3894-0623; Cozier, Gyles/0000-0003-2851-0902				Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jun X, 2001, J CELL BIOL, V154, P699; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; SHRISSA D, 1999, J BIOL CHEM, V274, P21589; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	55	130	136	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48730	48736		10.1074/jbc.M206986200	http://dx.doi.org/10.1074/jbc.M206986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12198132	hybrid			2022-12-25	WOS:000179789600099
J	Tu, X; Batta, P; Innocent, N; Prisco, M; Casaburi, I; Belletti, B; Baserga, R				Tu, X; Batta, P; Innocent, N; Prisco, M; Casaburi, I; Belletti, B; Baserga, R			Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I - Effect on ribosomal RNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PHOSPHOTYROSINE-BINDING DOMAINS; LARGE TUMOR-ANTIGEN; PLECKSTRIN HOMOLOGY; POSTNATAL-GROWTH; S6 KINASE; PROTEIN; CELL; TRANSFORMATION; TRANSCRIPTION	The insulin receptor substrate-1 (IRS-1) is one of the major substrates of both the insulin and IGF-1 receptors and is generally localized in the cytosol/membrane fraction of the cell. We show here that a substantial fraction of IRS-1 is translocated to the nucleus in mouse embryo fibroblasts (MEF) expressing the simian virus 40 T antigen. Nuclear translocation of IRS-1 occurs also in MEF stimulated with IGF-1 or in MEF expressing the oncogene v-src. Nuclear translocation of IRS-1 can be demonstrated by confocal microscopy, immunohistochemistry, or subcellular fractionation. An antibody to IRS-1 immunoprecipitates from nuclear fractions (but not from cytosolic fractions) the upstream binding factor, which is a key regulator of RNA polymerase I activity and ribosomal RNA (rRNA) synthesis. In agreement with this finding, in 32D murine hemopoietic cells, nuclear translocation of IRS-1 correlates with a markedly increased rRNA synthesis. Our experiments suggest that nuclear IRS-1 may play a specialized role in rRNA synthesis and/or processing.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	R_Baserga@jci.tju.edu	Belletti, Barbara/J-2028-2018	Belletti, Barbara/0000-0003-2249-0285	NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 089640] Funding Source: Medline; NIA NIH HHS [AG 20956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga R, 1985, BIOL CELL REPROD; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; COHEN LS, 1967, J CELL PHYSIOL, V69, P331, DOI 10.1002/jcp.1040690309; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FUKUDA M, 1953, J BIOCHEM, V40, P95, DOI 10.1093/oxfordjournals.jbchem.a126356; Gil D, 2001, J BIOL CHEM, V276, P11174, DOI 10.1074/jbc.M010114200; Ginisty H, 1999, J CELL SCI, V112, P761; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Ringertz Nils R., 1976, CELL HYBRIDS; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SANTOS M, 1982, J CELL BIOCHEM, V19, P127, DOI 10.1002/jcb.240190204; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	54	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44357	44365		10.1074/jbc.M208001200	http://dx.doi.org/10.1074/jbc.M208001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12202493	hybrid			2022-12-25	WOS:000179272000107
J	Goldschmidt, V; Rigourd, M; Ehresmann, C; Le Grice, SFJ; Ehresmann, B; Marquet, R				Goldschmidt, V; Rigourd, M; Ehresmann, C; Le Grice, SFJ; Ehresmann, B; Marquet, R			Direct and indirect contributions of RNA secondary structure elements to the initiation of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER-BINDING-SITE; DEPENDENT DNA-POLYMERASE; YEAST TY1 RETROTRANSPOSON; EFFICIENT INITIATION; TYPE-1 RNA; ANTISENSE OLIGONUCLEOTIDES; MUTATIONAL ANALYSIS; GENETIC-ANALYSIS; TEMPLATE-PRIMER	Initiation of human immunodeficiency virus type 1 (HIV-1) reverse transcription requires specific recognition between the viral RNA (vRNA), tRNA(3)(Lys), which acts as primer, and reverse transcriptase (RT). The specificity of this ternary complex is mediated by intricate interactions between the HIV-1 RNA and tRNA(3)(Lys). Here, we compared the relative importance of the secondary structure elements of this complex in the initiation process. To this aim, we used the previously published three-dimensional model of the initiation complex to rationally introduce a series of deletions and substitutions in the vRNA. When necessary, we used chemical probing to check the structure of the tRNA(3)(Lys)-mutant vRNA complexes. For each of them, we measured the binding affinity of RT and the kinetics of initial extension of tRNA(3)(Lys) and of synthesis of the (-) strand strong stop DNA. Our results were overall in keeping with the three-dimensional model of the initiation complex. Surprisingly, we found that disruption of the intermolecular template-primer interactions, which are not directly recognized by RT, more severely affected reverse transcription than deletions or disruption of one of the intramolecular helices to which RT directly binds. Perturbations of the highly constrained junction between the intermolecular helix formed by the primer binding site and the 3' end of tRNA(3)(Lys) and the helix immediately upstream also had dramatic effects on the initiation of reverse transcription. Taken together, our results demonstrate the overwhelming importance of the overall three-dimensional structure of the initiation complex and identify structural elements that constitute promising targets for anti-initiation-specific drugs.	Univ Strasbourg 1, Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; NCI, Resistance Mech Lab, NIH, Frederick, MD 21702 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Marquet, R (corresponding author), Univ Strasbourg 1, Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.			Marquet, Roland/0000-0002-4209-3976				AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383; Boulme F, 2000, EUR J BIOCHEM, V267, P2803, DOI 10.1046/j.1432-1327.2000.01310.x; Brule F, 2002, RNA, V8, P8, DOI 10.1017/S1355838202010981; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Freund F, 2001, NUCLEIC ACIDS RES, V29, P2757, DOI 10.1093/nar/29.13.2757; Friant S, 1998, MOL CELL BIOL, V18, P799, DOI 10.1128/MCB.18.2.799; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Friant S, 1997, YEAST, V13, P639, DOI 10.1002/(SICI)1097-0061(19970615)13:7<639::AID-YEA143>3.0.CO;2-Y; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; Harrich D, 2000, J VIROL, V74, P5639, DOI 10.1128/JVI.74.12.5639-5646.2000; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; Kang SM, 1999, J VIROL, V73, P1818, DOI 10.1128/JVI.73.3.1818-1827.1999; Kang SM, 1999, VIROLOGY, V257, P95, DOI 10.1006/viro.1999.9615; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kaushik N, 2001, NUCLEIC ACIDS RES, V29, P5099, DOI 10.1093/nar/29.24.5099; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; Miller JT, 2001, J BIOL CHEM, V276, P27721, DOI 10.1074/jbc.M100513200; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Rong LW, 2001, J BIOL CHEM, V276, P47725, DOI 10.1074/jbc.M105124200; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Vaccaro JA, 1999, BIOCHEMISTRY-US, V38, P15978, DOI 10.1021/bi990945x; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Wei X, 2000, NUCLEIC ACIDS RES, V28, P3065, DOI 10.1093/nar/28.16.3065; WILHELM M, 1994, NUCLEIC ACIDS RES, V22, P4560, DOI 10.1093/nar/22.22.4560; Zhang ZJ, 1998, J VIROL, V72, P5464, DOI 10.1128/JVI.72.7.5464-5471.1998; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658	65	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43233	43242		10.1074/jbc.M205295200	http://dx.doi.org/10.1074/jbc.M205295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12194974	hybrid			2022-12-25	WOS:000179081200105
J	Isshiki, M; Ying, YS; Fujita, T; Anderson, RGW				Isshiki, M; Ying, YS; Fujita, T; Anderson, RGW			A molecular sensor detects signal transduction from caveolae in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; SMOOTH-MUSCLE; RECEPTOR; CALCIUM; TRANSPORT; INTERNALIZATION; LOCALIZATION; CHOLESTEROL; ACTIVATION	Biochemical and cell fractionation studies suggest caveolae contain functionally organized sets of signaling molecules that are capable of transmitting specific signals to the cell. It is not known, however, whether any signals actually originate from caveolae in living cells. To address this question, we have engineered the calcium sensor yellow cameleon so that it is targeted either to the plasma membrane, caveolae, or the cytoplasm of endothelial cells. Quantitative measurements of the three Ca2+ pools detected by these probes indicate that caveolae are preferred sites of Ca2+ entry when Ca2+ stores in the endoplasmic reticulum are depleted. These results suggest that the signaling machinery in control of Ca2+ entry is functionally organized in the caveolae of living cells.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Tokyo, Dept Nephrol & Endocrinol, Tokyo 1138688, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	richard.anderson@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SUGI H, 1982, CAN J PHYSIOL PHARM, V60, P576, DOI 10.1139/y82-077; SUZUKI S, 1989, CELL TISSUE RES, V257, P237, DOI 10.1007/BF00261826; TORIHASHI S, 2002, J BIOL CHEM; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	46	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43389	43398		10.1074/jbc.M205411200	http://dx.doi.org/10.1074/jbc.M205411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12177060	hybrid			2022-12-25	WOS:000179081200123
J	Narendra, U; Zhu, LY; Li, BR; Wilken, J; Weiss, MA				Narendra, U; Zhu, LY; Li, BR; Wilken, J; Weiss, MA			Sex-specific gene regulation - The doublesex DM motif is a bipartite DNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YOLK-PROTEIN GENES; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TESTIS DIFFERENTIATION; DOSAGE COMPENSATION; GONADAL-DYSGENESIS; MOLECULAR ANALYSIS; DETERMINING REGION	Sex-specific gene expression in Drosophila melanogaster is regulated in part by the Doublesex (DSX) transcription factor. Male- and female-specific splicing isoforms share a novel DNA-binding domain, designated the DM motif. This domain is conserved among a newly recognized family of vertebrate transcription factors involved in developmental patterning and sex determination. The DM motif consists of an N-terminal zinc module and a disordered C-terminal tail, hypothesized to fold on specific DNA binding as a recognition alpha-helix. Truncation of the tail does not perturb the structure of the zinc module but impairs DNA binding and DNA-dependent dimerization. Chemical protein synthesis and alanine scanning mutagenesis are employed to test the contributions of 13 side chains to specific DNA binding. Selected arginine or lysine residues in the zinc module were substituted by norleucine, an isostere that maintains the aliphatic portion of the side chain but lacks a positive charge. Arginine or glutamine residues in the tail were substituted by alanine. Evidence is obtained that both the zinc module and C-terminal tail contribute to a bipartite DNA-binding surface. Conserved arginine and glutamine residues in the tail are required for high affinity DNA recognition, consistent with its proposed role as a nascent recognition alpha-helix.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	weiss@biochemistry.cwru.edu		Li, Biaoru/0000-0002-5626-9557				Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; AN WQ, 1995, EMBO J, V14, P1221, DOI 10.1002/j.1460-2075.1995.tb07105.x; An WQ, 1996, MOL CELL BIOL, V16, P3106; AN WQ, 1995, GENE DEV, V9, P256, DOI 10.1101/gad.9.2.256; BAKER BS, 1988, GENE DEV, V2, P477, DOI 10.1101/gad.2.4.477; BENNETT CP, 1993, J MED GENET, V30, P518, DOI 10.1136/jmg.30.6.518; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; BOWNES M, 1983, J EMBRYOL EXP MORPH, V75, P241; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P847; Cho S, 1997, J BIOL CHEM, V272, P3185, DOI 10.1074/jbc.272.6.3185; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; CROCKER M, 1988, CLIN GENET, V34, P70; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; Flejter WL, 1998, AM J HUM GENET, V63, P794, DOI 10.1086/302016; FRYNS JP, 1986, ANN GENET-PARIS, V29, P49; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Guioli S, 1998, AM J HUM GENET, V63, P905, DOI 10.1086/302017; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HILDRETH PE, 1965, GENETICS, V51, P659; HINCK AP, 1993, PROTEIN ENG, V6, P221, DOI 10.1093/protein/6.2.221; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HODGKIN J, 1983, GENETICS, V103, P43; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOLDIN B, 1995, NUCLEIC ACIDS RES, V23, P4162, DOI 10.1093/nar/23.20.4162; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Li H, 1998, DEVELOPMENT, V125, P2641; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Magenis RE, 1990, AM J HUM GENET S, V47, pA33; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; McDonald MT, 1997, AM J MED GENET, V73, P321; Meng AM, 1999, DEVELOPMENT, V126, P1259; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Murphy FV, 2000, STRUCT FOLD DES, V8, pR83, DOI 10.1016/S0969-2126(00)00126-X; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; Raymond CS, 2000, GENE DEV, V14, P2587, DOI 10.1101/gad.834100; Raymond CS, 1999, DEV BIOL, V215, P208, DOI 10.1006/dbio.1999.9461; Raymond CS, 1999, HUM MOL GENET, V8, P989, DOI 10.1093/hmg/8.6.989; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Skolnick J, 2000, NAT BIOTECHNOL, V18, P283, DOI 10.1038/73723; VANHOUTE L, 1993, J BIOL CHEM, V268, P18083; Veitia RA, 1998, AM J HUM GENET, V63, P901, DOI 10.1086/302023; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WYMAN J, 1964, ADVANCES PROTEIN CHE, V19, P224; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; Xu B, 2002, PROTEIN SCI, V11, P104, DOI 10.1110/ps.ps.32102; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Yi WS, 1999, DEVELOPMENT, V126, P873; Zarkower D, 2001, NAT REV GENET, V2, P175, DOI 10.1038/35056032; Zhu LY, 2000, GENE DEV, V14, P1750	77	23	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43463	43473		10.1074/jbc.M204616200	http://dx.doi.org/10.1074/jbc.M204616200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12198117	hybrid			2022-12-25	WOS:000179081200131
J	Riobo, NA; Melani, M; Sanjuan, N; Fiszman, ML; Gravielle, MC; Carreras, MC; Cadenas, E; Poderoso, JJ				Riobo, NA; Melani, M; Sanjuan, N; Fiszman, ML; Gravielle, MC; Carreras, MC; Cadenas, E; Poderoso, JJ			The modulation of mitochondrial nitric-oxide synthase activity in rat brain development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; HEART-MITOCHONDRIA; RADICAL PRODUCTION; OXYGEN; GLUTAMATE; NEURONS; DEPOLARIZATION; PEROXYNITRITE; ACTIVATION; APOPTOSIS	Different mitochondrial nitric-oxide synthase (mtNOS) isoforms have been described in rat and mouse tissues, such as liver, thymus, skeletal muscle, and more recently, heart and brain. The modulation of these variants by thyroid status, hypoxia, or gene deficiency opens a broad spectrum of mtNOS-dependent tissue-specific functions. In this study, a new NOS variant is described in rat brain with an M-r of 144 kDa and mainly localized in the inner mitochondrial membrane. During rat brain maturation, the expression and activity of mtNOS were maximal at the late embryonic stages and early postnatal days followed by a decreased expression in the adult stage (100 +/- 9 versus 19 +/- 2 pmol of [H-3]citrulline/min/mg of protein, respectively). This temporal pattern was opposite to that of the cytosolic 157 kDa nNOS protein. Mitochondrial redox changes followed the variations in mtNOS activity: mtNOS-dependent production of hydrogen peroxide was maximal in newborns and decreased markedly in the adult stage, thus reflecting the production and utilization of mitochondrial matrix nitric oxide. Moreover, the activity of brain Mn-superoxide dismutase followed a developmental pattern similar to that of mtNOS. Cerebellar granular cells isolated from newborn rats and with high mtNOS activity exhibited maximal proliferation rates, which were decreased by modifying the levels of either hydrogen peroxide or nitric oxide. Altogether, these findings support the notion that a coordinated modulation of mtNOS and Mn-superoxide dismutase contributes to establish the rat brain redox status and participate in the normal physiology of brain development.	Univ Hosp Buenos Aires, Lab Oxygen Metab, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Sch Med, Dept Microbiol, Lab Expt Pathol, RA-1121 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Inst Invest Farmacol, RA-1113 Buenos Aires, DF, Argentina; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	University of Buenos Aires; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Southern California	Poderoso, JJ (corresponding author), Univ Hosp Buenos Aires, Lab Oxygen Metab, Av Cordoba 2351, RA-1120 Buenos Aires, DF, Argentina.	jpoderos@fmed.uba.ar	Galdo, Natalia Riobo-Del/AAP-2938-2020; Melani, Mariana/GLR-0418-2022	Galdo, Natalia Riobo-Del/0000-0002-8942-7873; Melani, Mariana/0000-0002-9491-932X; Gravielle, Maria/0000-0003-4353-5526	NATIONAL INSTITUTE ON AGING [R01AG016718] Funding Source: NIH RePORTER; NIA NIH HHS [1 R01 AG 16718] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; Borodinsky LN, 1998, DEV BRAIN RES, V107, P43, DOI 10.1016/S0165-3806(97)00217-4; BOVERIS A, 2000, NITRIC OXIDE BIOL PA, P355; BOVERIS A, 1997, OXYGEN GENE EXPRESSI, P3; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Bustamante J, 2002, NITRIC OXIDE-BIOL CH, V6, P333, DOI 10.1006/niox.2001.0420; Carreras MC, 2001, AM J PHYSIOL-HEART C, V281, pH2282, DOI 10.1152/ajpheart.2001.281.6.H2282; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; French S, 2001, AM J PHYSIOL-HEART C, V280, pH2863, DOI 10.1152/ajpheart.2001.280.6.H2863; Ghafourifar P, 2001, BIOL SIGNAL RECEPT, V10, P57; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Inglis FM, 1998, J NEUROSCI, V18, P10493; Ishikawa Y, 1999, BRAIN RES, V824, P71, DOI 10.1016/S0006-8993(99)01108-7; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Knowles RG, 1998, METH MOL B, V100, P67; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LICHTMAN JW, 1999, FUNDAMENTAL NEUROSCI, P547; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; Wharton DC., 1967, METHOD ENZYMOL, P245; White RJ, 1996, J NEUROSCI, V16, P5688; Yermolaieva O, 2000, P NATL ACAD SCI USA, V97, P448, DOI 10.1073/pnas.97.1.448	39	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42447	42455		10.1074/jbc.M204580200	http://dx.doi.org/10.1074/jbc.M204580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202479	hybrid			2022-12-25	WOS:000179081200005
J	Vales, LD; Friedl, EM				Vales, LD; Friedl, EM			Binding of C/EBP and RBP (CBF1) to overlapping sites regulates interleukin-6 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BARR-VIRUS EBNA2; TRANSCRIPTION FACTOR; IN-VITRO; PROMOTER; BETA; ACTIVATION; NOTCH; RECEPTOR; NF-IL6	The ILRE (interleukin response element) contained within the promoter of the interleukin-6 (IL-6) gene is defined as the site recognized by the p65 NF-kappaB transcriptional activator and is crucial for activation of the IL-6 gene. The region of the promoter containing the ILRE is complex containing a CCAAT enhancer-binding protein (C/EBP) site immediately upstream of the ILRE, which is required for optimal activation of the IL-6 gene. Additionally, the ILRE overlaps a site that is recognized by the mammalian transcriptional repressor RBP (CBF-1), and RBP binding within the ILRE region represses activated IL-6 expression. In this study, the complexity of this region is further revealed by the identification of a second nested C/EBP site, which overlaps that of RBP and therefore also the ILRE. Optimal activation requires both the upstream and newly identified C/EBP sites in conjunction with the p65 NF-kappaB binding site. We previously reported that RBP represses IL-6 activation but does not target p65. We extend these analyses here to show that RBP binding does not occlude p65 from binding but instead directly overlaps the newly identified downstream C/EBP site, thereby impeding p65-C/ EBP-mediated co-activation. This result suggests a role for RBP in the repression of other genes containing a C/EBP site that exhibits sequence overlap with the RBP site.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Vales, LD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.			vales, lynne/0000-0003-0117-3440	NIGMS NIH HHS [GM59473] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059473] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Calkhoven CF, 2000, GENE DEV, V14, P1920; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; Elberg G, 2000, J BIOL CHEM, V275, P27815; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu HM, 1998, J IMMUNOL, V160, P2334; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merola M, 1996, J INTERF CYTOK RES, V16, P783, DOI 10.1089/jir.1996.16.783; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; Morel V, 2000, GENE DEV, V14, P377; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Stein B, 1998, DRUG DISCOV TODAY, V3, P202, DOI 10.1016/S1359-6446(97)01164-1; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	40	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42438	42446		10.1074/jbc.M207363200	http://dx.doi.org/10.1074/jbc.M207363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200447	hybrid			2022-12-25	WOS:000179081200004
J	Berggard, T; Szczepankiewicz, O; Thulin, E; Linse, S				Berggard, T; Szczepankiewicz, O; Thulin, E; Linse, S			Myo-inositol monophosphatase is an activated target of calbindin D-28k	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RAT HIPPOCAMPUS; MESSENGER-RNA; CA2+-BINDING PROTEIN; PUTATIVE TARGET; PARVALBUMIN; EXPRESSION; NEURONS; D28K; SECRETAGOGIN	Calbindin D-28k (calbindin) is a member of the calmodulin superfamily of Ca2+-binding proteins. An intracellular target of calbindin was discovered using bacteriophage display. Human recombinant calbindin was immobilized on magnetic beads and used in affinity purification of phage-displayed peptides from a random 12-mer peptide library. One sequence, SYSSLAKYPSHS, was strongly selected both in the presence of Mg2+ and in the presence of Ca2+. Homology search against the protein sequence data base identified a closely similar sequence, ISSIKEKYPSHS, at residues 55-66 in myo-inositol-1(or 4)-monophosphatase (IMPase, EC 3.1.3.25), which constitute a strongly conserved and exposed region in the three-dimensional structure. IMPase is a key enzyme in the regulation of the activity of the phosphatidylinositol-signaling pathway. It catalyzes the hydrolysis of myo-inositol-1(or 4)-monophosphate to form free myo-inositol, maintaining a supply that represents the precursor for inositol phospholipid second messenger signaling systems. Fluorescence spectroscopy showed that isolated calbindin and IMPase interact with an apparent equilibrium dissociation constant, K-D, of 0.9 mum. Both apo and Ca2+-bound calbindin was found to activate IMPase up to 250-fold, depending on the pH and substrate concentration. The activation is most pronounced at conditions that otherwise lead to a very low activity of IMPase, i.e. at reduced pH and at low substrate concentration.	Lund Univ, Dept Biophys Chem, Ctr Chem, S-22100 Lund, Sweden	Lund University	Linse, S (corresponding author), Lund Univ, Dept Biophys Chem, Ctr Chem, POB 124, S-22100 Lund, Sweden.			Linse, Sara/0000-0001-9629-7109				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; ATACK JR, 1995, TRENDS NEUROSCI, V18, P343, DOI 10.1016/0166-2236(95)93926-O; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Berggard T, 2000, BIOCHEMISTRY-US, V39, P6864, DOI 10.1021/bi992394g; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; Fortin M, 1997, J CHEM NEUROANAT, V14, P51, DOI 10.1016/S0891-0618(97)10012-6; Gartner W, 2001, CEREB CORTEX, V11, P1161, DOI 10.1093/cercor/11.12.1161; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee S, 1997, MOL BRAIN RES, V47, P183, DOI 10.1016/S0169-328X(97)00043-0; LOWENSTEIN DH, 1991, NEURON, V6, P627, DOI 10.1016/0896-6273(91)90065-8; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Mikkonen M, 1997, J COMP NEUROL, V388, P64; MORGAN DW, 1986, BIOCHEM BIOPH RES CO, V138, P547, DOI 10.1016/S0006-291X(86)80531-9; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; ROBERTS WM, 1994, J NEUROSCI, V14, P3246; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; Thulin E, 1999, PROTEIN EXPRES PURIF, V15, P265, DOI 10.1006/prep.1999.1028; Wagner L, 2000, J BIOL CHEM, V275, P24740, DOI 10.1074/jbc.M001974200; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WINSKY L, 1995, J NEUROCHEM, V65, P381	29	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41954	41959		10.1074/jbc.M203492200	http://dx.doi.org/10.1074/jbc.M203492200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176979	hybrid			2022-12-25	WOS:000178985300084
J	Kondoh, O; Takasuka, T; Arisawa, M; Aoki, Y; Watanabe, T				Kondoh, O; Takasuka, T; Arisawa, M; Aoki, Y; Watanabe, T			Differential sensitivity between Fks1p and Fks2p against a novel beta-1,3-glucan synthase inhibitor, aerothricin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIDENTIFIED FUNGUS NO.11243; 1,3-BETA-D-GLUCAN SYNTHASE; SACCHAROMYCES-CEREVISIAE; ANTIFUNGAL ACTIVITIES; OVERLAP EXTENSION; MEMBRANE-PROTEIN; CANDIDA-ALBICANS; GENE ENCODES; IN-VITRO; YEAST	Fks1p and Fks2p are catalytic subunits of beta-1,3-glucan synthase, which synthesize beta-1,3-glucan, a main component of the cell wall in Saccharomyces cerevisiae. Although Fks1p and Fks2p are highly homologous, sharing 88.1% identity, it has been shown that Fks2p is more sensitive than Fks1p to one of echinocandin derivatives, which inhibits beta-1,3-glucan synthase activity. Here we show a similar differential sensitivity between Fks1p and Fks2p to a novel beta-1,3-glucan synthase inhibitor, aerothricin1. To investigate the molecular mechanism of this differential sensitivity, we constructed a series of chimeric genes of FKSs and examined their sensitivity to aerothricin1. As a result, it was shown that a region around the fourth extracellular domain of Fks2p, containing 10 different amino acid residues from those of Fks1p, provided Fks1p aerothricin1 sensitivity when the region was replaced with a corresponding region of Fks1p. In order to identify essential amino acid residues responsible for the sensitivity, each of the 10 non-conserved amino acids of Fks1p was substituted into the corresponding amino acid of Fks2p by site-directed mutagenesis. Surprisingly, only one amino acid substitution of Fks1p, (K1336I) conferred Fks1p hypersensitivity to aerothricin1. On the other hand, reverse substitution of the corresponding amino acid of Fks2p (I1355K) resulted in loss of hypersensitivity to aerothricin1. These results suggest that the 1355th isoleucine of Fks2p plays a key role in aerothricin1 sensitivity.	Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 2478530, Japan	Roche Holding	Kondoh, O (corresponding author), Nippon Roche Res Ctr, Dept Oncol, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	osamu.kondoh@roche.com	Arisawa, Mitsuhiro/D-9098-2012					AOKI M, 2001, Patent No. 0005251; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Balkovec J.M., 1994, EXPERT OPIN INV DRUG, V3, P65, DOI [10.1517/13543784.3.2.65, DOI 10.1517/13543784.3.2.65]; CASTRO C, 1995, J BACTERIOL, V177, P5732, DOI 10.1128/jb.177.20.5732-5739.1995; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; Fujie A, 2000, J ANTIBIOT, V53, P920, DOI 10.7164/antibiotics.53.920; FUJIE A, 1998, P 38 INT C ANT AG CH; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Kelly R, 1996, J BACTERIOL, V178, P4381, DOI 10.1128/jb.178.15.4381-4391.1996; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Kondoh O, 1997, J BACTERIOL, V179, P7734, DOI 10.1128/jb.179.24.7734-7741.1997; Kurtz MB, 1997, J MED VET MYCOL, V35, P79; Kurtz MB, 1998, ASM NEWS, V64, P31; Maertens JA, 2000, CURR PHARM DESIGN, V6, P225, DOI 10.2174/1381612003401299; Masubuchi K, 2001, BIOORG MED CHEM LETT, V11, P1273, DOI 10.1016/S0960-894X(01)00178-0; Masubuchi K, 2001, BIOORG MED CHEM LETT, V11, P395, DOI 10.1016/S0960-894X(00)00678-8; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mio T, 1997, J BACTERIOL, V179, P4096, DOI 10.1128/jb.179.13.4096-4105.1997; Pereira M, 2000, YEAST, V16, P451, DOI 10.1002/(SICI)1097-0061(20000330)16:5&lt;451::AID-YEA540&gt;3.0.CO;2-O; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SUDOH M, 1991, AGR BIOL CHEM TOKYO, V55, P2901, DOI 10.1080/00021369.1991.10857906; Thompson JR, 1999, J BACTERIOL, V181, P444, DOI 10.1128/JB.181.2.444-453.1999; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9	29	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41744	41749		10.1074/jbc.M206734200	http://dx.doi.org/10.1074/jbc.M206734200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202487	hybrid			2022-12-25	WOS:000178985300057
J	Takemori, H; Katoh, Y; Horike, N; Doi, J; Okamoto, M				Takemori, H; Katoh, Y; Horike, N; Doi, J; Okamoto, M			ACTH-induced nucleocytoplasmic translocation of salt-inducible kinase - Implication in the protein kinase A-activated gene transcription in mouse adrenocortical tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; HORMONE-SENSITIVE LIPASE; EPIDERMAL GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; RAT-ADRENAL-CORTEX; STAR GENE; CYCLIC-AMP; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; CHOLESTEROL TRANSFER; TYROSINE-PHOSPHATASE	Salt-inducible kinase (SIK), da serine/threonine protein kinase expressed at an early stage of adrenocorticotropic hormone (ACTH) stimulation in Y1 mouse adrenocortical tumor cells, repressed the cAMP-responsive element (CRE)-dependent gene transcription by acting on the basic leucine zipper domain of the CRE-binding protein (Doi, J., Takemori, H., Lin, X.-z., Horike, N., Katoh, Y., and Okamoto, M. (2002) J. Biol. Chem. 277, 15629-15637). The mechanism of SIK-mediated gene regulation has been further explored. Here we show that SIK changes its subcellular location after the addition of ACTH. The immunocytochemical and fluorocytochemical analyses showed that SIK was present both in the nuclear and cytoplasmic compartments of resting cell when the cells were stimulated with ACTH the nuclear SIK moved into the cytoplasm within 15 min; the level of SIK in the nuclear compartment gradually returned to the initial level after 12 h. SIK translocation was blocked by pretreatment with leptomycin B. A mutant SIK whose Ser-577, the cAMP-dependent protein kinase (PKA)-dependent phosphorylation site, was replaced with Ala could not move out of the nucleus under stimulation by ACTH. As expected, the degree of repression exerted by SIK on CRE reporter activity was weak as long as SIK was present in the cytoplasmic compartment. The same was true for the SIK-mediated repression of a steroidogenic acute regulatory (StAR) protein-gene promoter, which contained a CRE-like sequence at -95 to -85 bp. These results suggest that in the ACTH-stimulated Y1 cells the nuclear SIK was PKA-dependently phosphorylated, and the phosphorylated SIK was then translocated out of the nuclei. This intracellular translocation of SIK, a CRE-repressor, may account or the time-dependent change in the level of ACTH-activated expression of the StAR protein gene.	Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Biomol Networks, Suita, Osaka 5650871, Japan; Kinran Coll, Dept Life Sci, Suita, Osaka 5650873, Japan	Osaka University; Osaka University	Okamoto, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol, H-1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; BEINS DM, 1982, BIOCHEM J, V202, P631, DOI 10.1042/bj2020631; Bird IM, 1996, J CLIN ENDOCR METAB, V81, P2171, DOI 10.1210/jc.81.6.2171; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, ARCH MED RES, V32, P576, DOI 10.1016/S0188-4409(01)00338-1; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Clark BJ, 2001, MOL CELL ENDOCRINOL, V173, P183, DOI 10.1016/S0303-7207(00)00410-X; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; Doi J, 2002, J BIOL CHEM, V277, P15629, DOI 10.1074/jbc.M109365200; Doi J, 2001, J ENDOCRINOL, V168, P87, DOI 10.1677/joe.0.1680087; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallo-Payet N, 1999, J STEROID BIOCHEM, V69, P335, DOI 10.1016/S0960-0760(99)00079-5; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; Gyles SL, 2001, J BIOL CHEM, V276, P34888, DOI 10.1074/jbc.M102063200; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; Hong SH, 2001, J BIOL CHEM, V276, P28098, DOI 10.1074/jbc.M010912200; Ikeda Y, 2000, J BIOL CHEM, V275, P31695, DOI 10.1074/jbc.M004892200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jones PM, 2000, J MOL ENDOCRINOL, V24, P233, DOI 10.1677/jme.0.0240233; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; KRAMER RE, 1984, J BIOL CHEM, V259, P707; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Le Roy C, 2000, ENDOCRINOLOGY, V141, P1599, DOI 10.1210/en.141.5.1599; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; Manna PR, 2002, MOL ENDOCRINOL, V16, P184, DOI 10.1210/me.16.1.184; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paz C, 2000, ENDOCR RES, V26, P609, DOI 10.3109/07435800009048579; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; Reyland ME, 2000, J BIOL CHEM, V275, P36637, DOI 10.1074/jbc.M006456200; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1769, DOI 10.1210/en.143.5.1769; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stocco DM, 2000, NAT STRUCT BIOL, V7, P445, DOI 10.1038/75834; Stocco DM, 2001, MOL CELL ENDOCRINOL, V177, P55, DOI 10.1016/S0303-7207(01)00423-3; Stocco DM, 2001, MOL ENDOCRINOL, V15, P1245, DOI 10.1210/me.15.8.1245; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; TRZECIAK WH, 1973, EUR J BIOCHEM, V37, P327, DOI 10.1111/j.1432-1033.1973.tb02991.x; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wang XJ, 2000, J BIOL CHEM, V275, P20204, DOI 10.1074/jbc.M003113200; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; Whitehouse BJ, 2002, J ENDOCRINOL, V172, P583, DOI 10.1677/joe.0.1720583; WONG M, 1992, MOL ENDOCRINOL, V6, P1614, DOI 10.1210/me.6.10.1614; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	71	63	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42334	42343		10.1074/jbc.M204602200	http://dx.doi.org/10.1074/jbc.M204602200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200423	hybrid			2022-12-25	WOS:000178985300129
J	Courselaud, B; Pigeon, C; Inoue, Y; Inoue, J; Gonzalez, FJ; Leroyer, P; Gilot, D; Boudjema, K; Guguen-Guillouzo, C; Brissott, P; Loreal, O; Ilyin, G				Courselaud, B; Pigeon, C; Inoue, Y; Inoue, J; Gonzalez, FJ; Leroyer, P; Gilot, D; Boudjema, K; Guguen-Guillouzo, C; Brissott, P; Loreal, O; Ilyin, G			C/EBP alpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LIVER-SPECIFIC GENE; HEREDITARY HEMOCHROMATOSIS; INNATE IMMUNITY; KNOCKOUT MICE; MOUSE LIVER; EXPRESSION; TISSUE; BETA; DIFFERENTIATION	Originally identified as a gene up-regulated by iron overload in mouse liver, the HEPC gene encodes hepcidin, the first mammalian liver-specific antimicrobial peptide and potential key regulator of iron metabolism. Here we demonstrate that during rat liver development, amounts of HEPC transcripts were very low in fetal liver, strongly and transiently increased shortly after birth, and reappeared in adult liver. To gain insight into mechanisms that regulate hepatic expression of hepcidin, 5'-flanking regions of human and mouse HEPC genes were isolated and analyzed by functional and DNA binding assays. Human and mouse HEPC promoter-luciferase reporter vectors exhibited strong basal activity in hepatoma HuH-7 and mouse hepatocytes, respectively, but not in non-hepatic U-2OS cells. We found that CCAAT/enhancer-binding protein alpha (C/EBPalpha) and C/EBPbeta were respectively very potent and weak activators of both human and mouse promoters. In contrast, co-expression of hepatocyte nuclear factor 4alpha (HNF4alpha) failed to induce HEPC promoter activity. By electrophoretic mobility shift assay we demonstrated that one putative C/EBP element found in the human HEPC promoter (-250/-230) predominantly bound C/EBPalpha from rat liver nuclear extracts. Hepatic deletion of the C/EBPalpha gene resulted in reduced expression of HEPC transcripts in mouse liver. In contrast, amounts of HEPC transcripts increased in liver-specific HNF4alpha-null mice. Decrease of hepcidin mRNA in mice lacking hepatic C/EBPalpha was accompanied by iron accumulation in periportal hepatocytes. Finally, iron overload led to a significant increase of C/EBPalpha protein and HEPC transcripts in mouse liver. Taken together, these data demonstrate that C/EBPalpha is likely to be a key regulator of HEPC gene transcription and provide a novel mechanism for cross-talk between the C/EBP pathway and iron metabolism.	CHRU Pontchaillou, INSERM U522, F-35033 Rennes, France; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; CHRU Pontchaillou, Serv Malad Foie, F-35033 Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CHU Rennes	Ilyin, G (corresponding author), CHRU Pontchaillou, INSERM U522, F-35033 Rennes, France.		Inoue, Yusuke/O-6207-2018; Loreal, Olivier/G-3366-2013	Inoue, Yusuke/0000-0002-9710-7482; Loreal, Olivier/0000-0002-7428-3766; Boudjema, Karim/0000-0002-3894-8767				Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Elizondo G, 2000, J BIOL CHEM, V275, P39747, DOI 10.1074/jbc.M004987200; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Gilot D, 2002, J GENE MED, V4, P415, DOI 10.1002/jgm.279; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Li JX, 2000, GENE DEV, V14, P464; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Ohtake T, 1999, BRIT J CANCER, V81, P393, DOI 10.1038/sj.bjc.6690707; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Pigeon C, 1999, J HEPATOL, V30, P926, DOI 10.1016/S0168-8278(99)80149-4; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Schroder JM, 1999, CELL MOL LIFE SCI, V56, P32, DOI 10.1007/s000180050004; Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x; SONDERGAARD L, 1993, TRENDS GENET, V9, P193, DOI 10.1016/0168-9525(93)90113-V; Wakabayashi H, 1999, BIOSCI BIOTECH BIOCH, V63, P955, DOI 10.1271/bbb.63.955; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	39	205	217	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41163	41170		10.1074/jbc.M202653200	http://dx.doi.org/10.1074/jbc.M202653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183449	hybrid			2022-12-25	WOS:000178791400127
J	Nassar, T; Haj-Yehia, A; Akkawi, S; Kuo, A; Bdeir, K; Mazar, A; Cines, DB; Higazi, A				Nassar, T; Haj-Yehia, A; Akkawi, S; Kuo, A; Bdeir, K; Mazar, A; Cines, DB; Higazi, A			Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANGIOTENSIN-CONVERTING ENZYME; SINGLE-CHAIN UROKINASE; PROTEIN LRP; ENDOCYTIC RECEPTOR; HYPERTENSION; COMPLEX; RATS; FIBRINOLYSIS; INTERNALIZES	Urokinase plasminogen activator (uPA) is a multifunctional protein that has been implicated in several physiological and pathological processes involving cell adhesion and migration in addition to fibrinolysis. In a previous study we found that two-chain urokinase plasminogen activator (tcuPA) stimulates phenylephrine-induced vasoconstriction of isolated rat aortic rings. In the present paper we report that uPA(-/-) mice have a significantly lower mean arterial blood pressure than do wild type mice and that aortic rings from uPA(-/-) mice show an attenuated contractile response to phenylephrine. In contrast, the blood pressure of urokinase receptor knockout (uPAR(-/-)) mice and the response of their isolated aortic rings to phenylephrine were normal, indicating that the effect of uPA on vascular contraction is independent of uPAR. Addition of mouse and human uPA almost completely reversed both the impaired vascular contractility and the lower arterial blood pressure in vivo. The in vitro and in vivo effects of infused uPA on aortic contractility and the restoration of normal blood pressure in uPA(-/-) mice were prevented by antibody to low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP). A modified form of uPA that lacks the kringle failed to restore the blood pressure in uPA(-/-) mice, notwithstanding having a longer half-life in the circulation. Ligands that regulate the interaction of uPA with LRP, such as PAI-1 or the PAI-1-derived peptide (EEIIMD), abolished the vasoactivity of tcuPA in vitro and in vivo. These studies identify a novel signal transducing cellular receptor pathway involved in the regulation of vascular contractility.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Ateenuon LLC, Dept Pathol & Lab Med, San Diego, CA 92121 USA; Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Sch Pharm, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, IL-91120 Jerusalem, Israel	University of Pennsylvania; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Higazi, A (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				FOGARTY INTERNATIONAL CENTER [R03TW001468] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067381, R01HL060169] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 01468] Funding Source: Medline; NHLBI NIH HHS [HL 60169, HL 58107, HL 67381] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; Brown NJ, 1999, HYPERTENSION, V34, P285, DOI 10.1161/01.HYP.34.2.285; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; Erdem Y, 1999, AM J HYPERTENS, V12, P1071, DOI 10.1016/S0895-7061(99)00145-4; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KYONG SK, 1992, BRIT J PHARMACOL, V107, P983; Levi M, 2001, CIRCULATION, V103, P2014; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Mitsui T, 1999, BIOL PHARM BULL, V22, P863; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OYAMA Y, 1986, EUR J PHARMACOL, V132, P75, DOI 10.1016/0014-2999(86)90013-0; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; QUAX PHA, 1991, CELL REGUL, V2, P713; Sakata K, 1999, AM HEART J, V137, P1094, DOI 10.1016/S0002-8703(99)70368-6; Sisson TH, 1999, HUM GENE THER, V10, P2315, DOI 10.1089/10430349950016960; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; vanderKaaden ME, 1997, THROMB HAEMOSTASIS, V77, P710; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YOHTARO O, 1987, EUR J PHARMACOL, V131, P75; Zhang LT, 1997, J BIOL CHEM, V272, P27053, DOI 10.1074/jbc.272.43.27053	32	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40499	40504		10.1074/jbc.M207172200	http://dx.doi.org/10.1074/jbc.M207172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171938	hybrid			2022-12-25	WOS:000178791400045
J	Xiong, LW; Newman, RA; Rodney, GG; Thomas, O; Zhang, JZ; Persechini, A; Shea, MA; Hamilton, SL				Xiong, LW; Newman, RA; Rodney, GG; Thomas, O; Zhang, JZ; Persechini, A; Shea, MA; Hamilton, SL			Lobe-dependent regulation of ryanodine receptor type 1 by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; RABBIT SKELETAL-MUSCLE; CALCIUM-BINDING; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ACTIVATION; SITES; RYR1; APOCALMODULIN; PURIFICATION	Calmodulin activates the skeletal muscle Ca2+ release channel RYR1 at nM Ca2+ concentrations and inhibits the channel at mum Ca2+ concentrations. Using a deletion mutant of calmodulin, we demonstrate that amino acids 2-8 are required for high affinity binding of calmodulin to RYR1 at both nM and muM Ca2+ concentrations and are required for maximum inhibition of the channel at Im Ca2+ concentrations. In contrast, the addition of three amino acids to the N terminus of calmodulin increased the affinity for RYR1 at both nM and gm Ca2+ concentrations, but destroyed its functional effects on RYR1 at nM Ca2+. Using both full-length RYR1 and synthetic peptides, we demonstrate that the calmodulin-binding site on RYR1 is likely to be noncontiguous, with the C-terminal lobe of both apocalmodulin and Ca2+-calmodulin binding to amino acids between positions 3614 and 3643 and the N-terminal lobe binding at sites that are not proximal in the primary sequence. Ca2+ binding to the C-terminal lobe of calmodulin converted it from an activator to an inhibitor, but an interaction with the N-terminal lobe was required for a maximum effect on RYR1. This interaction apparently depends on the native sequence or structure of the first few amino acids at the N terminus of calmodulin.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Missouri, Div Mol Biol & Biochem, Sch Biol Sci, Kansas City, MO 64110 USA	Baylor College of Medicine; University of Iowa; University of Missouri System; University of Missouri Kansas City	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.		Shea, Madeline A/F-5798-2010	Hamilton, Susan/0000-0003-0241-9369; Shea, Madeline/0000-0003-0814-7069	NIAMS NIH HHS [AR 41729, AR 44802] Funding Source: Medline; NIDDK NIH HHS [DK 53863] Funding Source: Medline; NIGMS NIH HHS [GM 57001] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044802, R55AR041729, R01AR041729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057001] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1996, CIRCULAR DICHROISM C; Black DJ, 2000, BIOCHEMISTRY-US, V39, P13831, DOI 10.1021/bi001106+; CHU A, 1990, MOL PHARMACOL, V37, P735; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Krueger JK, 2001, J BIOL CHEM, V276, P4535, DOI 10.1074/jbc.C000857200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XY, 1994, J BIOL CHEM, V269, P6511; Lydan M A, 1994, Methods Mol Biol, V31, P389; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P1179, DOI 10.1021/bi00004a011; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Sencer S, 2001, J BIOL CHEM, V276, P38237; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; Sorensen BR, 1998, BIOCHEMISTRY-US, V37, P4244, DOI 10.1021/bi9718200; Sorensen BR, 2002, BIOCHEMISTRY-US, V41, P15, DOI 10.1021/bi011718+; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang JJ, 1999, BRIT J PHARMACOL, V126, P1066, DOI 10.1038/sj.bjp.0702400	35	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40862	40870		10.1074/jbc.M206763200	http://dx.doi.org/10.1074/jbc.M206763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185083	hybrid			2022-12-25	WOS:000178791400091
J	Zheng, MZ; McKeown-Longo, PJ				Zheng, MZ; McKeown-Longo, PJ			Regulation of HEF1 expression and phosphorylation by TGF-beta 1 and cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; EXTRACELLULAR-MATRIX; INTEGRIN; FIBRONECTIN; P130(CAS); KINASE; GROWTH; CYTOSKELETON; BINDING	Transforming growth factor-beta1 (TGF-beta1) is a multipotential cytokine, which regulates remodeling of tissue extracellular matrix during early tumorigenesis and wound healing. Human enhancer of filamentation-1 (HEF1), a multifunctional docking protein, is involved in integrin-based signaling, which affects cell motility, growth, and apoptosis. Our studies reveal that TGF-beta1 is a potent inducer of HEF1 gene transcription in human dermal fibroblasts. TGF-beta1 promoted HEF1 expression in a dose-dependent manner and resulted in a 16-fold increase in HEF1 protein level. TGF-beta1 had no effect on the stability of either HEF1 protein or mRNA. The TGF-beta1-induced HEF1 expression was independent of cell adhesion and resistant to cytoskeleton disruption. TGF-beta1 increased levels of both p105 and p115 HEF1 in adherent fibroblasts. Digestion with specific phosphatases indicated that the p115HEF1 resulted from serine/threonine phosphorylation of p105HEF1. The appearance of the p115HEF1 as well as tyrosine phosphorylation of p105HEF1 required cell adhesion and/or an organized cytoskeleton. An in vitro kinase assay indicated that p105HEF1 was a substrate for Src. PP1, a specific Src kinase inhibitor, was able to block adhesion-dependent tyrosine phosphorylation of p105HEF1. These findings suggest that TGF-beta1 regulates HEF1 gene expression and that HEF1 phosphorylation is dependent on cell adhesion and Src kinase activity.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Zheng, MZ (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA.	zhengm@mail.amc.edu; Mckeowp@mail.amc.edu			NCI NIH HHS [CA-69612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Berking C, 2001, CANCER RES, V61, P8306; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; D'Ovidio MC, 1998, EUR J CANCER, V34, P1081, DOI 10.1016/S0959-8049(98)00041-0; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Fashena SJ, 2002, J CELL SCI, V115, P99; FEDER D, 1990, J BIOL CHEM, V265, P8205; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Kanda H, 1999, IMMUNOLOGY, V97, P56; Kutz SM, 2001, J CELL SCI, V114, P3905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Olumi AF, 1999, CANCER RES, V59, P5002; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; SPORN MB, 1993, J CLIN INVEST, V92, P2565, DOI 10.1172/JCI116868; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	45	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39599	39608		10.1074/jbc.M202263200	http://dx.doi.org/10.1074/jbc.M202263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12189134	hybrid			2022-12-25	WOS:000178662500071
J	Janz, C; Wiesmuller, L				Janz, C; Wiesmuller, L			Wild-type p53 inhibits replication-associated homologous recombination	ONCOGENE			English	Article						aphidicolin; DNA synthesis; gene conversion; SV40 chromosomes; tumor suppressor	SIMIAN-VIRUS 40; DNA-REPLICATION; MAMMALIAN-CELLS; IN-VITRO; MIMOSINE; PROTEIN; REPAIR; PHOSPHORYLATION; DISSOCIATION; CHECKPOINT	In mammalian cells homologous recombination is stimulated, when the replication fork stalls at DNA breaks or unrepaired lesions. The tumor suppressor p53 downregulates homologous recombination independently of its transcriptional transactivation function and has been linked to enzymes of DNA recombination and replication. To study recombination with respect to replication, we utilized a SV40 virus based assay, to follow the synchronous events after primate cell infection. gamma-ray treatment at different times after viral entry unveiled an increase of interchromosomal exchange frequencies, when the damage was introduced during DNA synthesis. Elevated recombination frequencies were fully suppressed by p53. With respect to the downregulation of spontaneous recombination, we noticed a requirement for active p53 molecules, when replication started. After a transient treatment with replication inhibitors, we observed inhibition of the drug induced recombination by p53, particularly for the elongation inhibitor aphidicolin. Consequently, we propose that p53 is a surveillance factor of homologous recombination at replication forks, when they stall as a consequence of endogenous or of exogenously introduced damage.	Univ Frauenklin & Poliklin, D-89075 Ulm, Germany; Heinrich Pette Inst, Hamburg, Germany	Ulm University; Heinrich Pette Institute	Wiesmuller, L (corresponding author), Univ Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							AKYUZ N, 2002, IN PRESS MOL CELL BI; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fernandez JL, 2001, EXP CELL RES, V270, P102, DOI 10.1006/excr.2001.5328; Gersten KM, 1997, NAT GENET, V17, P378, DOI 10.1038/ng1297-378; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SARASIN AR, 1978, P NATL ACAD SCI USA, V75, P346, DOI 10.1073/pnas.75.1.346; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tooze J, 1980, DNA TUMOR VIRUSES; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	43	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5929	5933		10.1038/sj.onc.1205757	http://dx.doi.org/10.1038/sj.onc.1205757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185593				2022-12-25	WOS:000177520900013
J	Cataldi, M; Perez-Reyes, E; Tsien, RW				Cataldi, M; Perez-Reyes, E; Tsien, RW			Differences in apparent pore sizes of low and high voltage-activated Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SENSORY NEURONS; SENSITIVE CALCIUM-CHANNEL; MONO-VALENT CATIONS; SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; SELECTIVITY FILTER; STRUCTURAL BASIS; SKELETAL-MUSCLE; ORGANIC CATIONS; ION PERMEATION	Pore size is of considerable interest in voltage-gated Ca2+ channels because they exemplify a fundamental ability of certain ion channels: to display large pore diameter, but also great selectivity for their ion of choice. We determined the pore size of several voltage-dependent Ca2+ channels of known molecular composition with large organic cations as probes. T-type channels supported by the Ca(V)3.1, Ca(V)3.2, and Ca(V)3.3 subunits; L-type channels encoded by the Ca(V)1.2,beta(1), and alpha(2)delta(1) subunits; and R-type channels encoded by the Ca(V)2.3 and beta(3) subunits were each studied using a Xenopus oocyte expression system. The weak permeabilities to organic cations were resolved by looking at inward tails generated upon repolarization after a large depolarizing pulse. Large inward NH4+ currents and sizable methylammonium. and dimethylammonium currents were observed in all of the channels tested, whereas trimethylammonium permeated only through L- and R-type channels, and tetramethylammonium currents were observed only in L-type channels. Thus, our experiments revealed an unexpected heterogeneity in pore size among different Ca2+ channels, with L-type channels having the largest pore (effective diameter = 6.2 Angstrom), T-type channels having the tiniest pore (effective diameter = 5.1 Angstrom), and R-type channels having a pore size intermediate between these extremes. These findings ran counter to first-order expectations for these channels based simply on their degree of selectivity among inorganic cations or on the bulkiness of their acidic side chains at the locus of selectivity.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Beckman Ctr, Stanford, CA 94305 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Stanford University; University of Virginia	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Beckman Ctr, Rm B105, Stanford, CA 94305 USA.	rwtsien@stanford.edu	Cataldi, Mauro/AAB-3642-2019	Cataldi, Mauro/0000-0001-7787-3406	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067, R01NS038691] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24067, NS38691] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAIKE N, 1989, J PHYSIOL-LONDON, V412, P181, DOI 10.1113/jphysiol.1989.sp017610; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BOSSU JL, 1985, PFLUG ARCH EUR J PHY, V403, P360, DOI 10.1007/BF00589247; Bourinet E, 1996, J NEUROSCI, V16, P4983; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P571, DOI 10.1113/jphysiol.1987.sp016552; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Cibulsky SM, 2000, J GEN PHYSIOL, V116, P349, DOI 10.1085/jgp.116.3.349; Cloues RK, 2000, J PHYSIOL-LONDON, V524, P19, DOI 10.1111/j.1469-7793.2000.00019.x; CORONADO R, 1987, BIOPHYS J, V51, P497, DOI 10.1016/S0006-3495(87)83371-4; Corry B, 2001, BIOPHYS J, V80, P195, DOI 10.1016/S0006-3495(01)76007-9; Corry B, 2000, BBA-BIOMEMBRANES, V1509, P1, DOI 10.1016/S0005-2736(00)00330-8; Cougnon M, 1996, PFLUG ARCH EUR J PHY, V431, P658, DOI 10.1007/BF02191917; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FUKUSHIMA Y, 1985, J PHYSIOL-LONDON, V358, P255, DOI 10.1113/jphysiol.1985.sp015550; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1971, J GEN PHYSIOL, V58, P599, DOI 10.1085/jgp.58.6.599; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; KOSTYUK PG, 1988, PFLUG ARCH EUR J PHY, V411, P661, DOI 10.1007/BF00580863; Lee JH, 1999, J NEUROSCI, V19, P1912; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; LOIRAND G, 1986, PFLUG ARCH EUR J PHY, V407, P566, DOI 10.1007/BF00657519; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; McCleskey EW, 1999, J GEN PHYSIOL, V113, P765, DOI 10.1085/jgp.113.6.765; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Miller C, 1999, J GEN PHYSIOL, V113, P783, DOI 10.1085/jgp.113.6.783; MITRA R, 1986, P NATL ACAD SCI USA, V83, P5340, DOI 10.1073/pnas.83.14.5340; MULLINS LJ, 1959, J GEN PHYSIOL, V42, P817, DOI 10.1085/jgp.42.4.817; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Nonner W, 2000, BIOPHYS J, V79, P1976, DOI 10.1016/S0006-3495(00)76446-0; Nonner W, 1999, J GEN PHYSIOL, V113, P773, DOI 10.1085/jgp.113.6.773; Nonner W, 1998, BIOPHYS J, V75, P1287, DOI 10.1016/S0006-3495(98)74048-2; Nonner W, 1998, BIOPHYS J, V74, P2327, DOI 10.1016/S0006-3495(98)77942-1; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; Perez-Reyes E, 1999, CELL MOL LIFE SCI, V56, P660, DOI 10.1007/s000180050460; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Piedras-Renteria ES, 1998, P NATL ACAD SCI USA, V95, P7760, DOI 10.1073/pnas.95.13.7760; ROSENBERG RL, 1988, CURR TOP MEMBR TRANS, V33, P393; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Sun YM, 1997, J GEN PHYSIOL, V110, P693, DOI 10.1085/jgp.110.6.693; Talavera K, 2001, J BIOL CHEM, V276, P45628, DOI 10.1074/jbc.M103047200; Tottene A, 2000, J NEUROSCI, V20, P171, DOI 10.1523/JNEUROSCI.20-01-00171.2000; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSIEN RW, 1996, LOW VOLTAGE ACTIVATE; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Varadi G, 1999, CRIT REV BIOCHEM MOL, V34, P181, DOI 10.1080/10409239991209264; VYKLICKY L, 1988, NEUROSCI LETT, V89, P313, DOI 10.1016/0304-3940(88)90545-9; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200; Yang N, 1999, BIOPHYS J, V76, pA259; ZAREI MM, 1995, J NEUROSCI, V15, P1446	69	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45969	45976		10.1074/jbc.M203922200	http://dx.doi.org/10.1074/jbc.M203922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12198115	hybrid			2022-12-25	WOS:000179529300036
J	Ratnam, S; Maclean, KN; Jacobs, RL; Brosnan, ME; Kraus, JP; Brosnan, JT				Ratnam, S; Maclean, KN; Jacobs, RL; Brosnan, ME; Kraus, JP; Brosnan, JT			Hormonal regulation of cystathionine beta-synthase expression in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HOMOCYSTEINE METABOLISM; ENDOTHELIAL DYSFUNCTION; PLASMA HOMOCYSTEINE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; TRANSCRIPTIONAL REGULATION; DIABETES-MELLITUS; RAT HEPATOCYTES; GENE-EXPRESSION; INSULIN	Homocysteine metabolism is altered in diabetic patients. Cystathionine beta-synthase (CBS), a key enzyme involved in the transsulfuration pathway, which irreversibly converts homocysteine to cysteine, catalyzes the condensation of serine and homocysteine to cystathionine. Studies in streptozotocin-induced diabetic rats have shown that CBS enzyme activity is elevated in the liver but not in the kidney, and this effect is reversed by insulin treatment. To determine whether these effects resulted from alterations at the level of gene transcription, CBS mRNA was measured in diabetic and insulin-treated diabetic rats. CBS mRNA levels were found to be markedly higher in streptozotocin-induced diabetic rat livers; these were reduced by insulin administration. In H4IIE cells, a rat hepatoma cell culture model, glucocorticoids increased the cellular levels of CBS enzyme protein and CBS mRNA, insulin inhibited this stimulatory effect. Treatment with insulin also decreased CBS levels in HepG2 cells, a human hepatoma cell line. Nuclear run-on experiments in the rat cells confirmed that stimulation of CBS gene expression by glucocorticoids and the inhibition by insulin occurred at the transcriptional level. Transient transfections of HepG2 cells with a CBS-1b promoter luciferase reporter construct showed that the promoter activity was decreased by 70% after insulin treatment. These results show that insulin has a direct role in regulating homocysteine metabolism. Altered insulin levels in diseases such as diabetes may influence homocysteine metabolism by regulating the hepatic transsulfuration pathway.	Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	Memorial University Newfoundland; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Brosnan, JT (corresponding author), Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada.	jbrosnan@mun.ca		Jacobs, Rene/0000-0002-5525-1355				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGMEYER HU, 1981, METHOD ENZYMAT AN, V3, P1196; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BROSNAN JT, 1983, AM J PHYSIOL, V244, pE151, DOI 10.1152/ajpendo.1983.244.2.E151; CHADEFAUX B, 1988, LANCET, V2, P741; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Freshney RI., 2010, CULTURE ANIMAL CELLS, VSixth; Fukuda H, 2001, BIOCHEM BIOPH RES CO, V280, P1274, DOI 10.1006/bbrc.2001.4260; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; GOSS SJ, 1986, J CELL SCI, V82, P309; GREENBERG ME, 1997, CURRENT PROTOCOLS MO; Hofmann MA, 1997, DIABETES CARE, V20, P1880, DOI 10.2337/diacare.20.12.1880; Hoogeveen EK, 1998, ARTERIOSCL THROM VAS, V18, P133, DOI 10.1161/01.ATV.18.1.133; House JD, 1997, BIOCHEM J, V328, P287; HULTBERG B, 1991, SCAND J CLIN LAB INV, V51, P277, DOI 10.3109/00365519109091615; Jacobs RL, 1998, DIABETES, V47, P1967, DOI 10.2337/diabetes.47.12.1967; Jacobs RL, 2001, J BIOL CHEM, V276, P43740, DOI 10.1074/jbc.M107553200; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KRAUS JP, 1987, METHOD ENZYMOL, V143, P388; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; KREBS HA, 1986, BIOCHEM J, V158, P341; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Lentz SR, 2000, AM J PHYSIOL-HEART C, V279, pH970, DOI 10.1152/ajpheart.2000.279.3.H970; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; MACLEAN KN, 2001, 3 INT C HOM MET SORR, P54; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; MUNKE M, 1988, AM J HUM GENET, V42, P550; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Pogribna M, 2001, AM J HUM GENET, V69, P88, DOI 10.1086/321262; ROBILLON JF, 1994, DIABETES METAB, V20, P494; Roper MD, 1996, MAMM GENOME, V7, P754, DOI 10.1007/s003359900226; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWAROOP M, 1992, J BIOL CHEM, V267, P11455; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; UNGER RH, 1976, DIABETES, V25, P136, DOI 10.2337/diab.25.2.136; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; WILSON DE, 1983, ANN INTERN MED, V98, P219, DOI 10.7326/0003-4819-98-2-219; YAMAMOTO N, 1995, J NUTR SCI VITAMINOL, V41, P197, DOI 10.3177/jnsv.41.197; Yeromenko Y, 2001, NUTR METAB CARDIOVAS, V11, P108	56	117	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42912	42918		10.1074/jbc.M206588200	http://dx.doi.org/10.1074/jbc.M206588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12198128	hybrid			2022-12-25	WOS:000179081200064
J	Folli, C; Calderone, V; Ramazzina, I; Zanotti, G; Berni, R				Folli, C; Calderone, V; Ramazzina, I; Zanotti, G; Berni, R			Ligand binding and structural analysis of a human putative cellular retinol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; FATTY-ACID; APO; PURIFICATION; FAMILY; HOLO; ESTERIFICATION; IDENTIFICATION; MICROSOMES; ALIGNMENT	Three cellular retinol-binding protein (CRBP) types (CRBP I, II, and III) with distinct tissue distributions and retinoid binding properties have been structurally characterized thus far. A human binding protein, whose mRNA is expressed primarily in kidney, heart, and transverse colon, is shown here to be a CRBP family member (human CRBP IV), according to amino acid sequence, phylogenetic analysis, gene structure organization, and x-ray structural analysis. Retinol binding to CRBP IV leads to an absorption spectrum distinct from a typical holo-CRBP spectrum and is characterized by an affinity (K-d = similar to200 nm) lower than those for CRBP I, II, and III, as established in direct and competitive binding assays. As revealed by mutagenic analysis, the presence in CRBP IV of His(108) in place of Gln(108) is not responsible for the unusual holo-CRBP IV spectrum. The 2-Angstrom resolution crystal structure of human apo-CRBP IV is very similar to those of other structurally characterized CRBPs. The side chain of Tyr(60) is present within the binding cavity of the apoprotein and might affect the interaction with the retinol molecule. These results indicate that human CRBP IV belongs to a clearly distinct CRBP subfamily and suggest a relatively different mode of retinol binding for this binding protein.	Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Italian Natl Res Council, Biopolymer Res Ctr, I-35131 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Veneto Institute Molecular Medicine	Zanotti, G (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.	giuseppe.zanotti@unipd.it; rodolfo.berni@unipr.it	Calderone, Vito/A-2917-2014	Calderone, Vito/0000-0002-7963-6241; Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501; Ramazzina, Ileana/0000-0003-1009-2917				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderone V, 2002, J MOL BIOL, V321, P527, DOI 10.1016/S0022-2836(02)00628-9; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; Franzoni L, 2002, J BIOL CHEM, V277, P21983, DOI 10.1074/jbc.M201994200; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; Lu JY, 1999, J MOL BIOL, V286, P1179, DOI 10.1006/jmbi.1999.2544; Lu JY, 2000, J MOL BIOL, V300, P619, DOI 10.1006/jmbi.2000.3883; MALPELI G, 1995, EUR J BIOCHEM, V229, P486, DOI 10.1111/j.1432-1033.1995.0486k.x; Malpeli G, 1998, METH MOL B, V89, P111; Mansfield SG, 1998, P NATL ACAD SCI USA, V95, P6825, DOI 10.1073/pnas.95.12.6825; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Ong David E., 1994, P283; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1993, J BIOL CHEM, V268, P27133; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROEN G, 1994, BIOCHEM J, V300, P793, DOI 10.1042/bj3000793; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Werten PJL, 2000, P NATL ACAD SCI USA, V97, P3282, DOI 10.1073/pnas.050500597; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; YOST RW, 1988, J BIOL CHEM, V263, P18693	42	53	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41970	41977		10.1074/jbc.M207124200	http://dx.doi.org/10.1074/jbc.M207124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177003	hybrid			2022-12-25	WOS:000178985300086
J	Lew, CM; Gralla, JD				Lew, CM; Gralla, JD			New roles for conserved regions within a sigma(54)-dependent enhancer-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING ATP HYDROLYSIS; ESCHERICHIA-COLI; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATOR; SIGMA-FACTOR; IN-VIVO; NTRC; DOMAIN; DNA; OLIGOMERIZATION	23 amino acid substitutions were made in the C7 and C3 regions of pspFDeltaHTH, a protein required to convert sigma(54) closed promoter complexes to open complexes. These mutants were assayed for transcriptional competence, for the ability to hydrolyze ATP, for their multimerization state, and for their ability to interact with sigma(54) and its holoenzyme. C7 region mutants caused the protein to assume a compact form. This property could be mimicked by the addition of ATP, implying that compaction via C7 and ATP is part of the activation process. A number of C3 mutants were important for energy coupling, as indicated previously for several members of this activator family (1, 2). However, a patch within C3 influenced oligomerization. The C3 region was especially important in interacting with sigma(54) during the transition state but not important in inducing sigma(54) holoenzyme to engage the nontemplate strand of the promoter. It is proposed that both regions contain deterrent functions that prevent premature activation. Overall, the results imply unexpected roles for the C7 and C3 regions of this protein family during promoter activation.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; FOSTERHARTNETT D, 1992, MOL MICROBIOL, V6, P1049, DOI 10.1111/j.1365-2958.1992.tb02170.x; Gonzalez V, 1998, MOL MICROBIOL, V28, P55, DOI 10.1046/j.1365-2958.1998.00772.x; Gralla JD, 2000, NAT STRUCT BIOL, V7, P530, DOI 10.1038/76732; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Neuwald AF, 1999, GENOME RES, V9, P27; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; O'Neill E, 2001, EMBO J, V20, P819, DOI 10.1093/emboj/20.4.819; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x; Traviglia SL, 1999, BIOCHEMISTRY-US, V38, P15774, DOI 10.1021/bi9917232; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Walker John M., 1996, P51, DOI 10.1007/978-1-60327-259-9_10; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang YK, 1997, MOL MICROBIOL, V26, P373, DOI 10.1046/j.1365-2958.1997.5851955.x; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41517	41524		10.1074/jbc.M206912200	http://dx.doi.org/10.1074/jbc.M206912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186874	hybrid			2022-12-25	WOS:000178985300029
J	Mueller, E; Drori, S; Aiyer, A; Yie, J; Sarraf, P; Chen, H; Hauser, S; Rosen, ED; Ge, K; Roeder, RG; Spiegelman, BM				Mueller, E; Drori, S; Aiyer, A; Yie, J; Sarraf, P; Chen, H; Hauser, S; Rosen, ED; Ge, K; Roeder, RG; Spiegelman, BM			Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; NUCLEAR RECEPTORS; C/EBP-ALPHA; DIFFERENTIATION; EXPRESSION; COACTIVATOR; INTERACTS; PROTEIN; COMPLEX; LIGAND	dPeroxisome proliferator-activated receptor (PPAR) gamma is a nuclear receptor that is a key regulator of adipogenesis and is present in two isoforms generated by alternative splicing, PPARgamma1 and PPARgamma2. Studies of the ability of each isoform to stimulate fat differentiation have yielded ambiguous results, in part because PPARgamma stimulates its own expression. We have thus undertaken a formal genetic analysis using PPARgamma-null fibroblast cell lines to assess the specific role of each individual isoform in adipogenesis. We show here that both PPARgamma1 and PPARgamma2 have the intrinsic ability to stimulate robust adipogenesis. Adipose cells stimulated by either PPARgamma1 or PPARgamma2 express a similar gene profile and show similar responses to insulin. However, in response to low ligand concentrations, PPARgamma2 shows a quantitatively greater ability to induce adipogenesis. Analyses involving coactivator binding and transcriptional assays indicate that PPARgamma2 has an enhanced ability to bind components of the DRIP/TRAP complex, coactivators required for fat differentiation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Millenium Pharmaceut Inc, Cambridge, MA 02139 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Rockefeller University	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 1 Jimmy Fund Way, Boston, MA 02115 USA.		Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138	NIDDK NIH HHS [2R37DK31405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Brown KK, 1999, DIABETES, V48, P1415, DOI 10.2337/diabetes.48.7.1415; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	26	197	210	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41925	41930		10.1074/jbc.M206950200	http://dx.doi.org/10.1074/jbc.M206950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200443	hybrid			2022-12-25	WOS:000178985300080
J	See, RH; Caday-Malcolm, RA; Singaraja, RR; Zhou, S; Silverston, A; Huber, MT; Moran, J; James, ER; Janoo, R; Savill, JM; Rigot, V; Zhang, LH; Wang, MH; Chimini, G; Wellington, CL; Tafuri, SR; Hayden, MR				See, RH; Caday-Malcolm, RA; Singaraja, RR; Zhou, S; Silverston, A; Huber, MT; Moran, J; James, ER; Janoo, R; Savill, JM; Rigot, V; Zhang, LH; Wang, MH; Chimini, G; Wellington, CL; Tafuri, SR; Hayden, MR			Protein kinase a site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE CHOLESTEROL TRANSPORT; KAPPA B ALPHA; TANGIER-DISEASE; CELLULAR CHOLESTEROL; MEDIATED PHOSPHORYLATION; APOPTOTIC CELLS; P-GLYCOPROTEIN; MESSENGER-RNA; ABCA1; IDENTIFICATION	ATP-binding cassette A1 (ABCA1) is a key mediator of cholesterol and phospholipid efflux to apolipoprotein particles. We show that ABCA1 is a constitutively phosphorylated protein in both RAW macrophages and in a human embryonic kidney cell line expressing ABCA1. Furthermore, we demonstrate that phosphorylation of ABCA1 is mediated by protein kinase A (PKA) or a PKA-like kinase in vivo. Through site-directed mutagenesis studies of consensus PKA phosphorylation sites and in vitro PKA kinase assays, we show that Ser-1042 and Ser-2054, located in the nucleotide binding domains of ABCA1, are major phosphorylation sites for PKA. ApoA-I-dependent phospholipid efflux was decreased significantly by mutation of Ser-2054 alone and Ser-1042/Ser2054 but was not significantly impaired with Ser-1042 alone. The mechanism by which ABCA1 phosphorylation affected ApoA-I-dependent phospholipid efflux did not involve either alterations in ApoA-I binding or changes in ABCA1 protein stability. These studies demonstrate a novel serine (Ser-2054) on the ABCA1 protein crucial for PKA phosphorylation and for regulation of ABCA1 transporter activity.	Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Womens & Childrens Hosp, Vancouver, BC V5Z 4H4, Canada; Xenon Genet Inc, Burnaby, BC V5G 4W8, Canada; CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille, France; Pfizer Global Res & Dev, Cardiovasc Mol Sci & Technol, Ann Arbor, MI 48105 USA	University of British Columbia; University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Pfizer	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	James, Erick R/D-4725-2012; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867				Attie AD, 2001, J LIPID RES, V42, P1717; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Clee SM, 2001, CIRCULATION, V103, P1198; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Costet P, 2000, J BIOL CHEM, V275, P28240; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gadsby DC, 1999, ADV SEC MESS PHOSPH, V33, P79; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; Haidar B, 2001, J LIPID RES, V42, P249; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Huang W, 2001, BBA-MOL BASIS DIS, V1537, P71, DOI 10.1016/S0925-4439(01)00058-8; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; OHTAKI S, 1983, ATHEROSCLEROSIS, V49, P79, DOI 10.1016/0021-9150(83)90009-6; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; ORR GA, 1993, J BIOL CHEM, V268, P25054; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421	49	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41835	41842		10.1074/jbc.M204923200	http://dx.doi.org/10.1074/jbc.M204923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196520	hybrid			2022-12-25	WOS:000178985300069
J	Haggie, PM; Verkman, AS				Haggie, PM; Verkman, AS			Diffusion of tricarboxylic acid cycle enzymes in the mitochondrial matrix in vivo - Evidence for restricted mobility of a multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CITRATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; MALATE-DEHYDROGENASE; FUSION PROTEIN; TCA CYCLE; YEAST; ORGANIZATION; METABOLON; CELLS	It has been proposed that enzymes in many metabolic pathways, including the tricarboxylic acid cycle in the mitochondrial matrix, are physically associated to facilitate substrate channeling and overcome diffusive barriers. We have used fluorescence recovery after photobleaching to measure the diffusional mobilities of chimeras consisting of green fluorescent protein (GFP) fused to the C terminus of four tricarboxylic acid cycle enzymes: malate dehydrogenase, citrate synthase, isocitrate dehydrogenase, and succinyl-CoA synthetase. The GFP-enzyme chimeras were localized selectively in the mitochondrial matrix in transfected Chinese hamster ovary (CHO) and COS7 cells. Laser photobleaching using a 0.7-mum diameter spot demonstrated restricted diffusion of the GFP-enzyme chimeras. Interestingly, all four chimeras had similar diffusional characteristics, similar to45% of each chimera was mobile and had a diffusion coefficient of 4 x 10(-8) cm(2)/s. In contrast, unconjugated GFP in the mitochondrial matrix (targeted using COX8 leader sequence) diffused freely (nearly 100% mobility) with a greater diffusion coefficient of 20 x 10(-8) cm(2)/s. The mobility of the GFP-enzyme chimeras was insensitive to substrate source, ATP depletion, or inhibition of the adenine nucleotide translocase. These results indicate similar mobility characteristics of unrelated tricarboxylic acid cycle enzymes having different sizes and physical properties, providing biophysical evidence for a diffusible multienzyme complex in the mitochondrial matrix.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Haggie, PM (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci East Tower, San Francisco, CA 94143 USA.				NEI NIH HHS [EY 13574] Funding Source: Medline; NHLBI NIH HHS [HL 60288, HL 59198] Funding Source: Medline; NIBIB NIH HHS [EB 00415] Funding Source: Medline; NIDDK NIH HHS [DK 35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KS, 1999, METHOD ENZYMOL, V308, P111; BARNES SJ, 1986, FEBS LETT, V201, P267, DOI 10.1016/0014-5793(86)80621-4; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Elcock AH, 1996, BIOCHEMISTRY-US, V35, P12652, DOI 10.1021/bi9614747; FEDER TJ, 1996, BIOPHYS J, V70, P2367; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haggie PM, 1999, J BIOL CHEM, V274, P3941, DOI 10.1074/jbc.274.7.3941; Haggie PM, 2002, J BIOL CHEM, V277, P16419, DOI 10.1074/jbc.M112361200; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; Hom EFY, 2002, BIOPHYS J, V83, P533, DOI 10.1016/S0006-3495(02)75189-8; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kawasaki K, 2001, BIOCHEM J, V354, P9, DOI 10.1042/0264-6021:3540009; KISPAL G, 1989, J BIOL CHEM, V264, P11204; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11684, DOI 10.1021/bi00205a003; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; Mitchell CG, 1996, BIOCHEM J, V313, P769, DOI 10.1042/bj3130769; Olveczky BP, 1998, BIOPHYS J, V74, P2722, DOI 10.1016/S0006-3495(98)77978-0; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Shatalin K, 1999, BIOCHEMISTRY-US, V38, P881, DOI 10.1021/bi982195h; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; SRERE PA, 1985, TRENDS BIOCHEM SCI, V10, P109, DOI 10.1016/0968-0004(85)90266-X; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Srere PA, 1997, CHANNELING INTERMEDI, P201; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SUMEGI B, 1993, BIOCHEMISTRY-US, V32, P12725, DOI 10.1021/bi00210a022; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Velot C, 1999, BIOCHEMISTRY-US, V38, P16195, DOI 10.1021/bi991695n; Velot C, 1997, BIOCHEMISTRY-US, V36, P14271, DOI 10.1021/bi972011j; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; VERKMAN AS, 2001, METHODS CELLULAR IMA, P112; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WESTERHOFF HV, 1992, CURR TOP CELL REGUL, V33, P361; Wu YK, 1996, BIOPHYS J, V71, P91, DOI 10.1016/S0006-3495(96)79243-3	42	49	50	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40782	40788		10.1074/jbc.M207456200	http://dx.doi.org/10.1074/jbc.M207456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12198136	hybrid			2022-12-25	WOS:000178791400081
J	Zigrino, P; Kamiguti, AS; Eble, J; Drescher, C; Nischt, R; Fox, JW; Mauch, C				Zigrino, P; Kamiguti, AS; Eble, J; Drescher, C; Nischt, R; Fox, JW; Mauch, C			The reprolysin jararhagin, a snake venom metalloproteinase, functions as a fibrillar collagen agonist involved in fibroblast cell adhesion and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; INTEGRIN ALPHA-2-BETA-1; PLATELET-AGGREGATION; TISSUE INHIBITOR; BINDING-SITE; I-DOMAIN; ALPHA(2)BETA(1); CONTRACTION; DISINTEGRIN	The integrins alpha(2)beta(1) and alpha(1)beta(1) have been shown to modulate cellular activities of fibroblasts on contact with fibrillar collagen. Previously it has been shown that collagen binding to alpha(2)beta(1) regulates matrix metalloproteinase MMP-1 and membrane-type MT1-MMP expression. Jararhagin is a snake venom metalloproteinase of the Reprolysin family of zinc metalloproteinases, containing a metalloproteinase domain followed by disintegrin-like and cysteine-rich domains. Jararhagin blocks type I collagen-induced platelet aggregation by binding to the alpha(2)beta(1) integrin and inhibiting collagen-mediated intracellular signaling events. Here we present evidence that, in contrast to the observations in platelets, jararhagin binding to the integrin receptor alpha(2)beta(1) in fibroblasts produces collagen-like cell signaling events such as up-regulation of MMP-1 and MT1-MMP. Inactivation of the metalloproteinase domain had no effect on these properties of jararhagin. Thus, in fibroblasts the snake venom metalloproteinase jararhagin functions as a collagen-mimetic substrate that binds to and activates integrins. Given the homology between the metalloproteinase, disintegrin-like and cysteine-rich domains of jararhagin and those of the members of the ADAMs (a disintegrin-like and metalloproteinase) family of proteins, this work demonstrates the potential of the disintegrin-like/cysteine-rich domains in the ADAMs as cellular signaling agents to elicit responses relevant to the biological function of these proteins.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Virginia, Biomol Res Facil, Charlottesville, VA 22903 USA; Univ Liverpool, Dept Hematol, Liverpool L69 3BX, Merseyside, England; Univ Munster, Dept Physiol Chem, D-48149 Munster, Germany	University of Cologne; University of Virginia; University of Liverpool; University of Munster	Mauch, C (corresponding author), Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany.			Zigrino, Paola/0000-0002-7470-0064				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; EYANS JP, 2001, BIOESSAYS, V23, P628; FOX JW, 1998, SNAKE VENOM ENZYMES, P151; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Hati R, 1999, CRIT REV TOXICOL, V29, P1, DOI 10.1080/10408449991349168; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1985, J BIOL CHEM, V260, P1524; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HUGHES AL, 1992, MOL BIOL EVOL, V9, P216; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; Kamiguti AS, 1998, BRAZ J MED BIOL RES, V31, P853, DOI 10.1590/S0100-879X1998000700001; Kamiguti AS, 2000, ARCH BIOCHEM BIOPHYS, V374, P356, DOI 10.1006/abbi.1999.1627; Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MAUCH C, 1989, FEBS LETT, V250, P301, DOI 10.1016/0014-5793(89)80743-4; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Zigrino P, 1996, BIOCHEM BIOPH RES CO, V221, P51, DOI 10.1006/bbrc.1996.0543; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134	45	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40528	40535		10.1074/jbc.M202049200	http://dx.doi.org/10.1074/jbc.M202049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186858	hybrid			2022-12-25	WOS:000178791400049
J	Dasgupta, S; Jana, M; Liu, XJ; Pahan, K				Dasgupta, S; Jana, M; Liu, XJ; Pahan, K			Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells - Implications for multiple sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PRIMARY ASTROCYTES; NF-KAPPA-B; INTERFERON-BETA; GLIAL-CELLS; IN-VITRO; EXPRESSION; ACTIVATION; INHIBITION; BRAIN; DISEASES	The presence of autoreactive T cells recognizing self myelin antigens is necessary for the development of central nervous system autoimmune diseases such as multiple sclerosis (MS). The present study was undertaken to investigate the role of myelin basic protein (AMP)primed T cells in the expression of inducible nitric oxide synthase (iNOS) in microglial cells. AMP-primed T cells alone markedly induced the production of NO and the expression of iNOS protein and mRNA in mouse BV-2 microglial cells. Similarly, AMP-primed T cells also induced the production of NO in mouse primary microglia. This induction of NO production was primarily dependent on the contact between AMP-primed T cells and microglia. The expression of very late antigen-4 (VLA-4) on the surface of MIBP-primed T cells and inhibition of AMP-primed T cell-induced microglial NO production by functional blocking of antibodies to the alpha(4) chain of VLA-4 (CD49d) suggest that VLA-4 integrin on MBP-primed T cells plays an important role in contact-mediated induction of iNOS. Since IFN-beta has been used to treat MS patients, we examined the effect of IFN-beta on AMP-primed T cell-induced the production of NO. Surprisingly, IFN-beta alone induced the production of NO in microglial cells. However, the pretreatment of MBP-primed T cells with IFN-beta inhibited the expression of VLA-4 integrin on the surface of AMP-primed T cells and thereby inhibited the ability of those T cells to induce the production of NO in microglial cells. This study illustrates a novel role of neuroantigen-primed T cells in inducing contact-mediated expression of iNOS in microglial cells that may participate in the pathogenesis of MS.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039940, R01 NS039940-02, NS39940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1997, J IMMUNOL, V158, P2940; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Calabresi PA, 1997, NEUROLOGY, V49, P1111, DOI 10.1212/WNL.49.4.1111; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chabot S, 2000, NEUROLOGY, V55, P1497, DOI 10.1212/WNL.55.10.1497; Chabot S, 1997, J CLIN INVEST, V100, P604, DOI 10.1172/JCI119571; CONNELLY JF, 1994, ANN PHARMACOTHER, V28, P610, DOI 10.1177/106002809402800511; Ding MZ, 1998, J IMMUNOL, V160, P2560; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hurst RD, 2001, BRAIN RES, V894, P181, DOI 10.1016/S0006-8993(01)01992-8; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; JOHNSON AW, 1995, J NEUROL NEUROSUR PS, V58, P107, DOI 10.1136/jnnp.58.1.107; KOLB H, 1992, IMMUNOL TODAY, V13, P157, DOI 10.1016/0167-5699(92)90118-Q; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NORONHA A, 1993, J NEUROIMMUNOL, V46, P145, DOI 10.1016/0165-5728(93)90244-S; NORONHA A, 1995, ANN NEUROL, V37, P7; OGORMAN MRG, 1987, CLIN EXP IMMUNOL, V67, P66; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; RUDICK RA, 1993, NEUROLOGY, V43, P2080, DOI 10.1212/WNL.43.10.2080; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; UTZ U, 1994, J NEUROPATH EXP NEUR, V53, P351, DOI 10.1097/00005072-199407000-00005; WHITAKER JN, 1994, ANN NEUROL, V36, pS103, DOI 10.1002/ana.410360724; XIE QW, 1994, J BIOL CHEM, V269, P4705; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Yong VW, 1998, NEUROLOGY, V51, P682; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	56	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39327	39333		10.1074/jbc.M111841200	http://dx.doi.org/10.1074/jbc.M111841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176974	Green Accepted, hybrid			2022-12-25	WOS:000178662500036
J	Li, J; Barnard, DC; Patton, JG				Li, J; Barnard, DC; Patton, JG			A unique glutamic acid-lysine (EK) domain acts as a splicing inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PROTEIN-PROTEIN INTERACTIONS; SR PROTEINS; PREMESSENGER RNA; RECOGNITION MOTIFS; POLYPYRIMIDINE TRACT; FUNCTIONAL-ANALYSIS; FACTORS ASF/SF2; SITE SELECTION; FACTOR SF2/ASF	SRrp86 is a unique member of the SR protein superfamily of splicing factors containing one RNA recognition motif and two serine-arginine (SR)-rich domains separated by an unusual glutamic acid-lysine (EK) rich region. Previously, we showed that SRrp86 could regulate alternative splicing by both positively and negatively modulating the activity of other SR proteins as long as the entire region encompassing the RS-EK-RS domains was intact. To further investigate the function and domains of SRrp86, we generated a series of chimeric proteins by swapping the RNA recognition motif and RS domains between SRrp86 and two canonical members of the SR superfamily, ASF/SF2 and SRp75. Although domain swaps between SRrp86 and ASF/SF2 showed that the RRMs primarily determined splicing activity, swaps between SRrp86 and SRp75 demonstrated that the RS domains could also determine activity. Because SRp75 also has two RS domains but lacks the EK domain, we further investigated the role of the EK domain and found that it acts to repress splicing and splice-site selection, both in vitro and in vivo. Incubation of extracts with peptides encompassing the EK-rich region inactivated splicing and insertion of the EK region into SRp75 abolished its ability to activate splicing. Thus, the unique EK domain of SRrp86 plays a modulatory role controlling RS domain function.	Vanderbilt Univ, Dept Sci Biol, Nashville, TN 37235 USA	Vanderbilt University	Patton, JG (corresponding author), Vanderbilt Univ, Dept Sci Biol, Box 1820 Stn B, Nashville, TN 37235 USA.	James.G.Patton@Vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; Barnard DC, 2000, MOL CELL BIOL, V20, P3049, DOI 10.1128/MCB.20.9.3049-3057.2000; Barnard DC, 2002, RNA, V8, P526, DOI 10.1017/S1355838202029928; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Jumaa H, 2000, BBA-GENE STRUCT EXPR, V1494, P137, DOI 10.1016/S0167-4781(00)00233-5; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kennedy CF, 1998, MOL CELL BIOL, V18, P5425, DOI 10.1128/MCB.18.9.5425; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nikolakaki E, 2001, J BIOL CHEM, V276, P40175, DOI 10.1074/jbc.M104755200; PATTON JG, 2001, ENCY MOL MED; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; van Oordt WVH, 2000, NUCLEIC ACIDS RES, V28, P4822, DOI 10.1093/nar/28.24.4822; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhang WJ, 1996, MOL CELL BIOL, V16, P5400; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	63	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39485	39492		10.1074/jbc.M201784200	http://dx.doi.org/10.1074/jbc.M201784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183448	hybrid			2022-12-25	WOS:000178662500056
J	Lopato, S; Forstner, C; Kalyna, M; Hilscher, J; Langhammer, U; Indrapichate, K; Lorkovic, ZJ; Barta, A				Lopato, S; Forstner, C; Kalyna, M; Hilscher, J; Langhammer, U; Indrapichate, K; Lorkovic, ZJ; Barta, A			Network of interactions of a novel plant-specific Arg/Ser-rich protein, atRSZ33, with atSC35-like splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SR PROTEINS; FACTOR U2AF(35); MEDIATED TRANSFORMATION; ARABIDOPSIS-THALIANA; SITE SELECTION; RECOGNITION; TRANSCRIPTION; SC35; PHOSPHORYLATION	Arg/Ser-rich (RS) proteins play a crucial role in splicing and are implicated in splice site selection in metazoa. In plants, intron recognition seems to differ from the one in animals due to specific factor requirements. Here we describe a new plant-specific RS-rich protein, atRSZ33, with a unique domain structure consisting of an RNA recognition motif (RRM), two zinc knuckles embedded in a basic RS region, and an acidic C-terminal domain. atRSZ33 was found to be a phosphoprotein that concentrates in nuclear speckles and is predominantly present in roots and flowers. In a yeast two-hybrid screen, atRSZ33 interacted with splicing factors atSRp34/SR1, an Arabidopsis ortholog of human SF2/ASF; atRSZp21 and atRSZp22, which are similar to the human 9G8; and three novel SC35-like splicing factors termed atSCL28, atSCL30, and atSCL33/SR33. Two further members of the SCL family, namely SCL30a and the ortholog of mammalian SC35, atSC35, were also found to interact with atRSZ33. These interactions were verified by in vitro binding assays; furthermore, the transcriptional activity of atRSZ33 was found to overlap with the ones of its interacting partners. These specific interactions coupled with the many similarities of atRSZ33 to SR proteins suggest that its main activity is in spliceosome assembly. Mapping of regions necessary for protein-protein interaction between atRSZ33 and atSCL33/SR33 revealed that both zinc knuckles together with a small part of the RS and the RRM domain are required for efficient binding. However, the interacting domain is relatively small, allowing binding of additional proteins, a feature that is consistent with the proposed role of atRSZ33 in spliceosome assembly.	Univ Vienna, Vienna Bioctr, Inst Med Biochem, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Barta, A (corresponding author), Univ Vienna, Vienna Bioctr, Inst Med Biochem, Dr Bohrgasse 9-3, A-1030 Vienna, Austria.	Andrea@bch.univie.ac.at	Kalyna, Maria/N-7051-2017	Kalyna, Maria/0000-0003-4702-7625; Hilscher, Julia/0000-0001-5942-8931; Lorkovic, Zdravko/0000-0002-3074-7258; Barta, Andrea/0000-0002-8851-406X				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BARTA A, 1986, PLANT MOL BIOL, V6, P347, DOI 10.1007/BF00034942; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bhalerao RP, 1999, P NATL ACAD SCI USA, V96, P5322, DOI 10.1073/pnas.96.9.5322; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Brown JWS, 1998, ANNU REV PLANT PHYS, V49, P77, DOI 10.1146/annurev.arplant.49.1.77; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Domon C, 1998, J BIOL CHEM, V273, P34603, DOI 10.1074/jbc.273.51.34603; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gniadkowski M, 1996, NUCLEIC ACIDS RES, V24, P619, DOI 10.1093/nar/24.4.619; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; Golovkin M, 1999, J BIOL CHEM, V274, P36428, DOI 10.1074/jbc.274.51.36428; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guth S, 1999, MOL CELL BIOL, V19, P8263; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lambermon MHL, 2000, EMBO J, V19, P1638, DOI 10.1093/emboj/19.7.1638; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; LAZAR G, 1995, P NATL ACAD SCI USA, V92, P7672, DOI 10.1073/pnas.92.17.7672; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Lopato S, 1999, PLANT MOL BIOL, V39, P761, DOI 10.1023/A:1006129615846; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lopato S, 1996, PLANT CELL, V8, P2255, DOI 10.1105/tpc.8.12.2255; Lorkovic ZJ, 2000, RNA, V6, P1610, DOI 10.1017/S1355838200001163; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Lorkovic ZJ, 2002, NUCLEIC ACIDS RES, V30, P623, DOI 10.1093/nar/30.3.623; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; REED R, 1997, SPLICEOSOME ASSEMBLY, P103; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wang HY, 2001, MOL CELL, V7, P331, DOI 10.1016/S1097-2765(01)00181-2; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; XIAO SH, 1997, P NATL ACAD SCI USA, V94, P1148; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	65	67	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39989	39998		10.1074/jbc.M206455200	http://dx.doi.org/10.1074/jbc.M206455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176998	hybrid			2022-12-25	WOS:000178662500118
J	Nyalwidhe, J; Baumeister, S; Hibbs, AR; Tawill, S; Papakrivos, J; Volker, U; Lingelbach, K				Nyalwidhe, J; Baumeister, S; Hibbs, AR; Tawill, S; Papakrivos, J; Volker, U; Lingelbach, K			A nonpermeant biotin derivative gains access to the parasitophorous vacuole in Plasmodium falciparum-infected erythrocytes permeabilized with streptolysin O	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; MEMBRANE; LOCALIZATION; TRANSPORT; PROTEIN; TRAFFICKING; TOXOPLASMA; ANTIGEN; CELLS	In its host erythrocyte, the malaria parasite Plasmodium falciparum resides within a parasitophorous vacuole, the membrane of which forms a barrier between the host cell cytosol and the parasite surface. The vacuole is a unique compartment because it contains specific proteins that are believed to be involved in cell biological functions essential for parasite survival. As a prerequisite for the characterization of the vacuolar proteome, we have developed an experimental approach that allows the selective biotinylation of soluble vacuolar proteins. This approach utilizes nonpermeant biotin derivatives that can be introduced into infected erythrocytes after selective permeabilization of the erythrocyte membrane with the pore-forming protein streptolysin O. The derivatives gain access to the vacuolar lumen but not to the parasite cytosol, thus providing supportive evidence for the existence of nonselective pores within the vacuolar membrane that have been postulated based on electrophysiological studies. Soluble vacuolar proteins that are biotin-labeled can be isolated by affinity chromatography using streptavidin-agarose.	Univ Marburg, FB Biol, D-35032 Marburg, Germany; BIOCON, Ringwood E, Vic 3135, Australia	Philipps University Marburg	Lingelbach, K (corresponding author), Univ Marburg, FB Biol, D-35032 Marburg, Germany.	lingelba@mailer.uni-marburg.de		Volker, Uwe/0000-0002-5689-3448; Baumeister, Stefan/0000-0002-7784-3474				ANSORGE I, 1995, BIOCHEM J, V308, P335, DOI 10.1042/bj3080335; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; Burghaus PA, 2001, J BIOL CHEM, V276, P26838, DOI 10.1074/jbc.M100111200; Cheresh P, 2002, J BIOL CHEM, V277, P16265, DOI 10.1074/jbc.M109331200; Cooke BM, 2000, PARASITOL TODAY, V16, P416, DOI 10.1016/S0169-4758(00)01753-1; CULVENOR JG, 1990, J PROTOZOOL, V37, P59, DOI 10.1111/j.1550-7408.1990.tb01117.x; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; DLUZEWSKI AR, 1992, J CELL SCI, V102, P527; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; Krishna S, 2001, INT J PARASITOL, V31, P1331, DOI 10.1016/S0020-7519(01)00254-5; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; Lingelbach K, 1998, J CELL SCI, V111, P1467; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; Saliba KJ, 2001, INT J PARASITOL, V31, P1321, DOI 10.1016/S0020-7519(01)00258-2; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WARD GE, 1993, J CELL SCI, V106, P237; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335	26	27	28	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40005	40011		10.1074/jbc.M207077200	http://dx.doi.org/10.1074/jbc.M207077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12186876	hybrid			2022-12-25	WOS:000178662500120
J	Tang, YJ; Zaitseva, F; Lamb, RA; Pinto, LH				Tang, YJ; Zaitseva, F; Lamb, RA; Pinto, LH			The gate of the influenza virus M-2 proton channel is formed by a single tryptophan residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M(2) ION-CHANNEL; SHAKER POTASSIUM CHANNEL; INFECTED-CELL SURFACE; A VIRUS; M2 PROTEIN; K+ CHANNEL; TRANSMEMBRANE DOMAIN; NUCLEAR TRANSPORT; LIPID BILAYERS	The influenza virus M-2 proton-selective ion channel is known to be essential for acidifying the interior of virions during virus uncoating in the lumen of endosomes. The M-2 protein is a homotetramer that contains four 19-residue transmembrane (TM) domains. These TM domains are multifunctional, because they contain the channel pore and also anchor the protein in membranes. The M-2 protein is gated by pH, and thus we have measured pH-gated currents, the accessibility of the pore to Cu2+, and the effect of a protein-modifying reagent for a series of TM domain mutant M-2 proteins. The results indicate that gating of the M-2 ion channel is governed by a single side chain at residue 41 of the TM domain and that this property is mediated by an indole moiety. Unlike many ion channels where the gate is formed by a whole segment of a protein, our data suggest a model of striking simplicity for the M-2 ion channel protein, with the side chain of Trp(41) blocking the pore of the M-2 channel when pH(out) is high and with this side chain leaving the pore when pH(out) is low. Thus, the Trp(41) side chain acts as the gate that opens and closes the pore.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-31882, R37 AI-20201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CIAMPOR F, 1992, VIRUS RES, V22, P247, DOI 10.1016/0168-1702(92)90056-F; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; DUFF KC, 1994, VIROLOGY, V202, P287, DOI 10.1006/viro.1994.1345; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GRAMBAS S, 1992, VIROLOGY, V191, P541, DOI 10.1016/0042-6822(92)90229-I; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Lamb R.A., 2001, FIELDS VIROLOGY, P1487; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P746, DOI 10.1016/0042-6822(81)90319-6; LAMB RA, 1981, VIROLOGY, V112, P729, DOI 10.1016/0042-6822(81)90317-2; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; OHUCHI M, 1994, J VIROL, V68, P920, DOI 10.1128/JVI.68.2.920-926.1994; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHROEDER C, 1994, J GEN VIROL, V75, P3477, DOI 10.1099/0022-1317-75-12-3477; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; SKEHEL JJ, 1978, J GEN VIROL, V38, P97, DOI 10.1099/0022-1317-38-1-97; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; Tobler K, 1999, J VIROL, V73, P9695, DOI 10.1128/JVI.73.12.9695-9701.1999; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; Yi BA, 2000, NEURON, V27, P423, DOI 10.1016/S0896-6273(00)00052-0; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; Zhang J, 1996, VIROLOGY, V225, P255, DOI 10.1006/viro.1996.0599; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	70	197	200	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39880	39886		10.1074/jbc.M206582200	http://dx.doi.org/10.1074/jbc.M206582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183461	hybrid			2022-12-25	WOS:000178662500105
J	Woodside, DG; Obergfell, A; Talapatra, A; Calderwood, DA; Shattil, SJ; Ginsberg, MH				Woodside, DG; Obergfell, A; Talapatra, A; Calderwood, DA; Shattil, SJ; Ginsberg, MH			The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SEVERE COMBINED IMMUNODEFICIENCY; HIGH-AFFINITY RECEPTOR; CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; CRYSTAL-STRUCTURE; CALPAIN CLEAVAGE; FAMILY KINASES; ACTIVATION	Syk and ZAP-70 form a subfamily of nonreceptor tyrosine kinases that contain tandem SH2 domains at their N termini. Engagement of these SH2 domains by tyrosine-phosphorylated immunoreceptor tyrosine-based activation motifs leads to kinase activation and downstream signaling. These kinases are also regulated by beta(3) integrin-dependent cell adhesion via a phosphorylation-independent interaction with the beta(3) integrin cytoplasmic domain. Here, we report that the interaction of integrins with Syk and ZAP-70 depends on the N-terminal SH2 domain and the interdomain A region of the kinase. The N-terminal SH2 domain alone is sufficient for weak binding, and this interaction is independent of tyrosine phosphorylation of the integrin tail. Indeed, phosphorylation of tyrosines within the two conserved NXXY motifs in the integrin beta(3) cytoplasmic domain blocks Syk binding. The tandem SH2 domains of these kinases bind to multiple integrin 13 cytoplasmic domains with varying affinities (beta(3), (K-d = 24 n(M)) > beta(2) (K-d = 38 n(M)) > beta(1) (K-d = 71 n(M))) as judged by both affinity chromatography and surface plasmon resonance. Thus, the binding of Syk and ZAP-70 to integrin beta cytoplasmic domains represents a novel phosphotyrosine-independent interaction mediated by their N-terminal SH2 domains.	Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NHLBI NIH HHS [HL 48728, HL 31950, HL 59007] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fernandez R, 1998, J IMMUNOL, V160, P5154; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GRABER M, 1991, J IMMUNOL, V146, P2935; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hwang PM, 2002, EMBO J, V21, P314, DOI 10.1093/emboj/21.3.314; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yan SR, 1997, J IMMUNOL, V158, P1902	47	94	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39401	39408		10.1074/jbc.M207657200	http://dx.doi.org/10.1074/jbc.M207657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171941	hybrid			2022-12-25	WOS:000178662500045
J	Detich, N; Theberge, J; Szyf, M				Detich, N; Theberge, J; Szyf, M			Promoter-specific activation and demethylation by MBD2/demethylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; CPG-BINDING PROTEIN; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; GENE PROMOTER; FAMILY; DOMAIN; MECP2; MBD2; SP1	MBD2 is the only member of a family of methyl-CpG-binding proteins that has been reported to be both a transcriptional repressor and a DNA demethylase (dMTase). To understand the apparently contradictory function of MBD2/dMTase, we studied the effects of dMTase overexpression on the activity of various in vitro methylated promoters transiently transfected into HEK293 cells. We found that forced expression of a MBD2/dMTase expression vector (His-dMTase) differentially activated two methylated reporters, pSV40-CAT (the SV40 enhancerless promoter adjacent to the chloramphenicol acetyltransferase (CAT) reporter gene) and pGL2T+I4xTBRE (a region of the p21 promoter next to the luciferase reporter gene), in a time- and dose-dependent manner. His-dMTase increased pSV40-CAT expression by 3-10-fold after 96 h, while pGL2T+I4xTBRE expression was increased by 2-3-fold after only 48 h and did not further increase at 96 h. Gene activation was not universal because no effect was seen with the p19-ARF promoter. We then assessed whether activation might be due to demethylation within the promoter region. Using bisulfite mapping, we found that exogenous expression of His-dMTase induced demethylation at 8 of the 10 CpG sites within the SV40 promoter. The observation that His-dMTase increases the demethylase activity in the cells was also confirmed using an in vitro CpG demethylase assay with a mC32pG oligonucleotide, substrate and purified Q-Sepharose fractions from HEK293 cells transfected with His-dMTase or empty pcDNA3.1His vector. We propose that a single protein possessing both repressor and demethylase functions has evolved to coordinate a program that requires suppression of some methylated genes and activation of others.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Feng Q, 2001, GENE DEV, V15, P827; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Marhold J, 2002, CHROMOSOMA, V111, P13, DOI 10.1007/s00412-002-0188-2; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Plumb JA, 2000, CANCER RES, V60, P6039; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; Szyf Moshe, 2002, Methods Mol Biol, V200, P163; Szyf Moshe, 2002, Methods Mol Biol, V200, P155; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	144	157	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35791	35794		10.1074/jbc.C200408200	http://dx.doi.org/10.1074/jbc.C200408200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12177048	hybrid			2022-12-25	WOS:000178275100004
J	Kishimoto, M; Okimura, Y; Yagita, K; Iguchi, G; Fumoto, M; Iida, K; Kaji, H; Okamura, H; Chihara, K				Kishimoto, M; Okimura, Y; Yagita, K; Iguchi, G; Fumoto, M; Iida, K; Kaji, H; Okamura, H; Chihara, K			Novel function of the transactivation domain of a pituitary-specific transcription factor, Pit-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBINSTEIN-TAYBI-SYNDROME; HORMONE GENE-EXPRESSION; CREB-BINDING-PROTEIN; GROWTH-HORMONE; POU-DOMAIN; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; PROLACTIN GENE; RECEPTOR GENE; MESSENGER-RNA; CELL-GROWTH	Pit-1 stimulates the expression of growth hormone, prolactin, and thyrotropin J3 subunit genes. Consequently, abnormality of the Pit-1 gene results in combined pituitary hormone deficiency (CPHD). In this study, we analyzed the function of Pit-1 with a mutation (proline to leucine at codon 24) in the transactivation domain, P24L, which has a normal POU domain important for binding to DNA, because this mutation had been reported in a patient with CPHD. We found that codon 24 proline in the transactivation domain as well as the POU domain of Pit-1 was crucial to recruit coactivator CREB-binding protein (CBP) in the cultured cells. P24L completely lost the responsiveness to cAMP to stimulate the expression of the Pit-l-targeted genes. Furthermore, CBP and Pit-1, but not P24L, markedly enhanced the expression of the Pit-l-targeted gene to cAMP, and adenovirus E1a that binds to CBP and abrogates its function blocked the induction by cAMP of Pit-1-stimulated gene transcription in the pituitary-derived GH3 cells. These results suggest that CBP and proline at codon 24 in the transactivation domain of Pit-1 are important for the cAMP-induced activation of Pit-1-targeted genes. However, P24L maintained basal transcriptional activity, suggesting that CBP is unlikely to be an essential coactivator for Pit-1.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Sch Med,Suma Ku, Kobe, Hyogo 6540142, Japan; Kobe Univ, Sch Med, Dept Basic Allied Med,Suma Ku, Div Endocrinol Metab Neurol & Hematol Oncol, Kobe, Hyogo 6540142, Japan; Kobe Univ, Sch Med, Grad Sch Med, Dept Basic Allied Med,Suma Ku, Kobe, Hyogo 6540142, Japan; Kobe Univ, Sch Med, Grad Sch Med, Dept Brain Sci,Suma Ku, Kobe, Hyogo 6540142, Japan	Kobe University; Kobe University; Kobe University; Kobe University	Okimura, Y (corresponding author), Kobe Univ, Sch Med, Dept Basic Allied Med,Suma Ku, Div Endocrinol Metab Neurol & Hematol Oncol, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.	okimura@ams.kobe-u.ac.jp	Iida, Keiji/ABB-5126-2021	Iida, Keiji/0000-0002-1516-7757				Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Blankenstein O, 2001, HORM RES, V56, P81, DOI 10.1159/000048096; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Brown MR, 1998, HORM RES, V49, P98, DOI 10.1159/000023134; Cohen LE, 1999, J CLIN INVEST, V104, P1123, DOI 10.1172/JCI7308; Cohen LE, 1999, MOL ENDOCRINOL, V13, P476, DOI 10.1210/me.13.3.476; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fofanova OV, 1998, AM J MED GENET, V77, P360, DOI 10.1002/(SICI)1096-8628(19980605)77:5<360::AID-AJMG4>3.0.CO;2-R; Gat-Yablonski G, 2002, J PEDIATR ENDOCR MET, V15, P325; Goodman RH, 2000, GENE DEV, V14, P1553; Hendriks-Stegeman BI, 2001, J CLIN ENDOCR METAB, V86, P1545, DOI 10.1210/jc.86.4.1545; Iguchi G, 1999, J BIOL CHEM, V274, P12108, DOI 10.1074/jbc.274.17.12108; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IRIE Y, 1995, ENDOCR J, V42, P351, DOI 10.1507/endocrj.42.351; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIANG J, 1995, J BIOL CHEM, V270, P25520, DOI 10.1074/jbc.270.43.25520; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; OHTA K, 1992, BIOCHEM BIOPH RES CO, V189, P851, DOI 10.1016/0006-291X(92)92281-2; Oike Y, 1999, BLOOD, V93, P2771; OKAMOTO N, 1994, HUM MOL GENET, V3, P1565, DOI 10.1093/hmg/3.9.1565; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; Olson DP, 1997, J CLIN ENDOCR METAB, V82, P3264, DOI 10.1210/jc.82.10.3264; PARKS JS, 1993, HORM RES, V40, P54, DOI 10.1159/000183768; PEERS B, 1991, J BIOL CHEM, V266, P18127; PellegriniBouiller I, 1996, J CLIN ENDOCR METAB, V81, P2790, DOI 10.1210/jc.81.8.2790; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pernasetti F, 1998, J CLIN ENDOCR METAB, V83, P2079, DOI 10.1210/jc.83.6.2079; Petersenn S, 1998, MOL ENDOCRINOL, V12, P233, DOI 10.1210/me.12.2.233; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pfaffle R, 1996, HORM RES, V45, P25, DOI 10.1159/000184824; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RUBINSTEIN JH, 1990, AM J MED GENET, P3; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Tatsumi K, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1016/S1096-6374(99)80076-8; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45141	45148		10.1074/jbc.M202991200	http://dx.doi.org/10.1074/jbc.M202991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12200420	hybrid			2022-12-25	WOS:000179404800071
J	Flannery, CR; Zeng, WL; Corcoran, C; Collins-Racie, LA; Chockalingam, PS; Hebert, T; Mackie, SA; McDonagh, T; Crawford, TK; Tomkinson, KN; LaVallie, ER; Morris, EA				Flannery, CR; Zeng, WL; Corcoran, C; Collins-Racie, LA; Chockalingam, PS; Hebert, T; Mackie, SA; McDonagh, T; Crawford, TK; Tomkinson, KN; LaVallie, ER; Morris, EA			Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; CARTILAGE PROTEOGLYCAN; INTERGLOBULAR DOMAIN; IDENTIFICATION; EXPRESSION; PROTEINS; CLONING; HYALURONAN; CATABOLISM; MEMBER	ADAMTS-4, also referred to as aggrecanase-1, is a glutamyl endopeptidase capable of generating catabolic fragments of aggrecan analogous to those released from articular cartilage during degenerative joint diseases such as osteoarthritis. Efficient aggrecanase activity requires the presence of sulfated glycosaminoglycans (GAGs) attached to the aggrecan core protein, implying the contribution of substrate recognition/binding site(s) to ADAMTS-4 activity. In the present study, we demonstrate that full-length ADAMTS-4 (M-r similar to68,000) undergoes autocatalytic C-terminal truncation to generate two discrete isoforms (M-r similar to53,000 and M-r similar to40,000), which exhibit a marked reduction in affinity of binding to sulfated GAGs. C-terminal sequencing and mass analyses revealed that the GAGbinding thrombospondin type I motif was retained following autocatalysis, indicating that sites present in the C-terminal cysteine (cys)-rich and/or spacer domains also effect binding of full-length ADAMTS-4 to sulfated GAGs. Binding-competition experiments conducted using native and deglycosylated aggrecan provided direct evidence for interaction of the ADAMTS-4 cysteine-rich/spacer domains with aggrecan GAGs. Furthermore, synthetic peptides mimicking putative (consensus) GAG-binding sequences located within the ADAMTS-4 cysteine-rich and spacer domains competitively blocked binding of sulfated GAGs to full-length ADAMTS-4, thereby identifying multiple GAG-binding sites, which may contribute to the regulation of ADAMTS-4 function.	Wyeth Res, Cambridge, MA 02140 USA	Pfizer	Flannery, CR (corresponding author), Wyeth Res, Cambridge, MA 02140 USA.	cflannery@wyeth.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; BOYD VL, 1992, ANAL BIOCHEM, V206, P344, DOI 10.1016/0003-2697(92)90376-I; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Flannery CR, 1999, BIOCHEM BIOPH RES CO, V260, P318, DOI 10.1006/bbrc.1999.0909; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Larsen MR, 2000, FRESEN J ANAL CHEM, V366, P677, DOI 10.1007/s002160051562; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Melrose J, 1996, ELECTROPHORESIS, V17, P205, DOI 10.1002/elps.1150170134; NAGASE H, 2001, CONNECT TISSUE, V33, P27; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181; Roberts S, 2000, SPINE, V25, P3005, DOI 10.1097/00007632-200012010-00007; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wei P, 2002, BIOCHEM BIOPH RES CO, V293, P478, DOI 10.1016/S0006-291X(02)00255-3; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	42	121	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42775	42780		10.1074/jbc.M205309200	http://dx.doi.org/10.1074/jbc.M205309200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202483	hybrid			2022-12-25	WOS:000179081200047
J	Ma, KY; Temiakov, D; Jiang, ML; Anikin, M; McAllister, WT				Ma, KY; Temiakov, D; Jiang, ML; Anikin, M; McAllister, WT			Major conformational changes occur during the transition from an initiation complex to an elongation complex by T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; STRUCTURAL BASIS; TERMINATION SIGNAL; BACTERIOPHAGE-T7; PROMOTER; MECHANISM; MODEL; BINDING; BUBBLE; SITE	To examine changes that occur during the transition from an initiation complex (IC) to an elongation complex (EC) in T7 RNA polymerase (RNAP), we used nucleic acid-protein cross-linking methods to probe interactions of the RNAP with RNA and DNA in a halted EC. As the RNA is displaced from the RNA-DNA hybrid similar to9 hp upstream from the active site (at -9) it interacts with a region within the specificity loop (residues 744-750) and is directed toward a positively charged surface that surrounds residues Lys-302 and Lys-303. Surprisingly, the template and non-template strands of the DNA at the upstream edge of the hybrid (near the site where the RNA is displaced) interact with a region in the N-terininal domain of the RNAP (residues 172-191) that is far away from the specificity loop before isomerization (in the IC). To bring these two regions of the RNAP into proximity, major conformational changes must occur during the transition from an IC to an EC. The observed nucleic acid-protein interactions help to explain the behavior of a number of mutant RNAPs that are affected at various stages in the initiation process and in termination.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	McAllister, WT (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	pogo51@aol.com	Hu, Ruogu/B-2203-2008		NIGMS NIH HHS [R01 GM038147, GM38147, R01 GM038147-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; He B, 1998, J BIOL CHEM, V273, P18802, DOI 10.1074/jbc.273.30.18802; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2002, J MOL BIOL, V319, P37, DOI 10.1016/S0022-2836(02)00261-9; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Kwon YS, 1999, J BIOL CHEM, V274, P29149, DOI 10.1074/jbc.274.41.29149; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; Sambrook J., 1989, MOL CLONING, pA1; Shen HH, 2001, J BIOL CHEM, V276, P4080, DOI 10.1074/jbc.M008616200; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; Sousa R, 2001, Uirusu, V51, P81; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Temiakov D, 2000, PRACT APPROACH SER, P351; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TUNITSKAYA VL, 1990, EUR J BIOCHEM, V191, P99, DOI 10.1111/j.1432-1033.1990.tb19098.x	46	28	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43206	43215		10.1074/jbc.M206658200	http://dx.doi.org/10.1074/jbc.M206658200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12186873	hybrid			2022-12-25	WOS:000179081200102
J	Peoc'h, K; Serres, C; Frobert, Y; Martin, C; Lehmann, S; Chasseigneaux, S; Sazdovitch, V; Grassi, J; Jouannet, P; Launay, JM; Laplanche, JL				Peoc'h, K; Serres, C; Frobert, Y; Martin, C; Lehmann, S; Chasseigneaux, S; Sazdovitch, V; Grassi, J; Jouannet, P; Launay, JM; Laplanche, JL			The human "prion-like" protein doppel is expressed in both sertoli cells and spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP-LIKE PROTEIN; GENE; MICE; BRAIN; IDENTIFICATION; DEGENERATION; DEFICIENT; DISEASES; CLEAVAGE; SEQUENCE	The prion-like Doppel protein (Dpl) has many biochemical and structural properties in common with the cellular prion protein (PrPc), and the physiological role of neither protein is known. Experimental data suggest either direct or indirect interaction between the two proteins. In this study, we investigated the expression pattern and biochemical characteristics of Dpl in human tissues and in Chinese hamster ovary cells transfected with wild-type or variant human Dpl gene constructs. Human Dpl appears to be a glycosylphosphatidylinositol-anchored glycoprotein with N- and O-linked sugars. It was found on Sertoli cells in the testis, on the flagella of epididymal and mature spermatozoa, and in seminal plasma. Dpl coexists only with N-terminally truncated isoforms of PrPc on mature spermatozoa. The localization of human Dpl on both Sertoli cells (somatic cells) and spermatozoa (germinal cells) strongly suggests that this protein may play a major role in human male fertility. Finally, our data indicate that spermatozoa are thus an interesting model for studies of the potential interaction between Dpl and PrPc.	Hop Lariboisiere, Serv Biochim & Biol Mol, F-75475 Paris 10, France; Fac Sci Pharmaceut & Biol Paris, EA 3621, IFR 71, F-75006 Paris, France; CHU Cochin, GREFH, Lab Histol & Embryol Biol Reprod, F-75014 Paris, France; Commissariat Energie Atom, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; CNRS, UPR 1142, IGH, F-34396 Montpellier 5, France; INSERM, U360, Grp Hosp Pitie Salpetriere, Lab Neuropathol R Escourolle, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Peoc'h, K (corresponding author), Hop Lariboisiere, Serv Biochim & Biol Mol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	katell.peoch@lrb.ap-hop-paris.fr	Peoc'h, Katell/V-1604-2017; Lehmann, Sylvain/P-1301-2017; Chasseigneaux, Stephanie/A-4291-2017; LAPLANCHE, Jean-Louis/S-8707-2016; Peoc'h, Katell/D-5261-2014; SCHMITT, Caroline/P-2859-2017	Peoc'h, Katell/0000-0002-8203-1243; Lehmann, Sylvain/0000-0001-6117-562X; Chasseigneaux, Stephanie/0000-0003-2859-371X; SCHMITT, Caroline/0000-0001-5145-7260; LAPLANCHE, Jean-Louis/0000-0003-2836-2903				Behrens A, 2002, EMBO J, V21, P3652, DOI 10.1093/emboj/cdf386; Behrens A, 2001, EMBO REP, V2, P347, DOI 10.1093/embo-reports/kve088; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Blobel CP, 2000, REV REPROD, V5, P75, DOI 10.1530/revreprod/5.2.75; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CARR SA, 1993, PROTEIN SCI, V2, P183; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DACHEUX JL, 1987, ANN NY ACAD SCI, V513, P560, DOI 10.1111/j.1749-6632.1987.tb25107.x; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Fortna RR, 1999, BIOL REPROD, V61, P1042, DOI 10.1095/biolreprod61.4.1042; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Li AM, 2000, CELL MOL NEUROBIOL, V20, P553, DOI 10.1023/A:1007059827541; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Lu K, 2000, BIOCHEMISTRY-US, V39, P13575, DOI 10.1021/bi001523m; Mead S, 2000, NEUROSCI LETT, V290, P117, DOI 10.1016/S0304-3940(00)01319-7; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nishida N, 1999, LAB INVEST, V79, P689; Peoc'h K, 2000, NEUROSCI LETT, V286, P144, DOI 10.1016/S0304-3940(00)01100-9; Rooney IA, 1996, J CLIN INVEST, V97, P1675, DOI 10.1172/JCI118594; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Schroter S, 1999, J BIOL CHEM, V274, P29862, DOI 10.1074/jbc.274.42.29862; Shaked Y, 1999, J BIOL CHEM, V274, P32153, DOI 10.1074/jbc.274.45.32153; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Tranulis MA, 2001, MAMM GENOME, V12, P376, DOI 10.1007/s003350010285; Tuzi NL, 2002, J GEN VIROL, V83, P705, DOI 10.1099/0022-1317-83-3-705; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; World Health Organization, 1992, WHO LAB MAN EX HUM S	38	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43071	43078		10.1074/jbc.M206357200	http://dx.doi.org/10.1074/jbc.M206357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200435	hybrid			2022-12-25	WOS:000179081200085
J	Benarafa, C; Cooley, J; Zeng, WL; Bird, PI; Remold-O'Donnell, E				Benarafa, C; Cooley, J; Zeng, WL; Bird, PI; Remold-O'Donnell, E			Characterization of four murine homologs of the human ov-serpin monocyte neutrophil elastase inhibitor MNEI (SERPINB1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ENDOGENOUS RETROVIRUS; CHROMOSOMAL LOCALIZATION; PROTEINASE COMPLEX; CYSTIC-FIBROSIS; GENE; SEQUENCE; FAMILY; SUPERFAMILY; EXPRESSION	The human ov-serpin monocyte neutrophil elastase inhibitor (MNEI) is encoded by a single gene SERPINB1. It is a highly efficient inhibitor of neutrophil granule proteases. Four murine genes with high sequence identity with MNEI were identified and fully sequenced, and these were named EIA, EIB, EIC, and EID. EIA, EIB and EIC showed the same seven-exon gene structure as SERPINB1. However, EIC included an additional, alternatively spliced, exon due to the insertion of an endogenous retrovirus-like sequence. EID lacked several exons and is a pseudogene. Reverse transcriptase-PCR showed that EIA, like MNEI, is expressed at high levels in many tissues. EIB is mainly expressed in brain, and EIC was only expressed as splicing variants unlikely to encode a functional serpin. Upon incubation with serine proteases, EIA formed inhibitory covalent complexes with pancreatic and neutrophil elastases, cathepsin G, proteinase-3, and chymotrypsin, as previously shown for MNEI, whereas EIB was only able to do so with cathepsin G. According to the new serpin nomenclature, the genes encoding EIIA, EIB, EIC, and EID will be called Serpinb1, Serpinb1b, Serpinb1c, and Serpinb1-ps1. These data demonstrate that the four murine homologs of MNEI have met different evolutionary fates, and that EIA is the mouse ortholog of MNEI.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Monash University	Benarafa, C (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.			Bird, Phillip/0000-0002-6695-606X; Benarafa, Charaf/0000-0002-2049-7769	NHLBI NIH HHS [HL66548-02, R01 HL066548] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066548] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abts HF, 2001, DNA CELL BIOL, V20, P123, DOI 10.1089/104454901300068924; Atchley WR, 2001, MOL BIOL EVOL, V18, P1502, DOI 10.1093/oxfordjournals.molbev.a003936; Bartuski AJ, 1998, GENOMICS, V54, P297, DOI 10.1006/geno.1998.5586; Benit L, 1997, J VIROL, V71, P5652; Benit L, 1999, J VIROL, V73, P3301; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BIRRER P, 1995, RESPIRATION, V62, P25; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; EVANS E, 1995, GENOMICS, V28, P235, DOI 10.1006/geno.1995.1136; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Hughes DC, 2001, J MOL EVOL, V53, P77, DOI 10.1007/s002390010195; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Kaiserman D, 2002, GENOMICS, V79, P349, DOI 10.1006/geno.2002.6716; Kapitonov VV, 1999, J MOL EVOL, V48, P248, DOI 10.1007/PL00013153; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ragg H, 2001, MOL BIOL EVOL, V18, P577, DOI 10.1093/oxfordjournals.molbev.a003838; Rees DD, 1999, AM J RESP CELL MOL, V20, P69, DOI 10.1165/ajrcmb.20.1.3306; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1989, J EXP MED, V169, P1071, DOI 10.1084/jem.169.3.1071; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Scott FL, 1996, J BIOL CHEM, V271, P1605, DOI 10.1074/jbc.271.3.1605; Scott FL, 1999, BLOOD, V93, P2089, DOI 10.1182/blood.V93.6.2089.406k10_2089_2097; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; SUGIMORI T, 1995, AM J RESP CELL MOL, V13, P314, DOI 10.1165/ajrcmb.13.3.7654387; Suminami Y, 2001, BBA-GENE STRUCT EXPR, V1519, P122, DOI 10.1016/S0167-4781(01)00208-1; Sun J, 1998, CYTOGENET CELL GENET, V82, P273, DOI 10.1159/000015118; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Xia ZN, 1998, BIOCHEM BIOPH RES CO, V243, P384, DOI 10.1006/bbrc.1998.8102; Zeng WL, 1998, GENE, V213, P179, DOI 10.1016/S0378-1119(98)00189-9; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	40	48	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42028	42033		10.1074/jbc.M207080200	http://dx.doi.org/10.1074/jbc.M207080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12189154	hybrid			2022-12-25	WOS:000178985300092
J	Cao, ZY; Said, N; Amin, S; Wu, HK; Bruce, A; Garate, M; Hsu, DK; Kuwabara, I; Liu, FT; Panjwani, N				Cao, ZY; Said, N; Amin, S; Wu, HK; Bruce, A; Garate, M; Hsu, DK; Kuwabara, I; Liu, FT; Panjwani, N			Galectins-3 and-7, but not galectin-1, play a role in re-epithelialization of wounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; BINDING-PROTEIN; CELL-ADHESION; MIGRATION; LECTIN; FAMILY; OVEREXPRESSION; PROLIFERATION; EXPRESSION; LAMININ	Disorders of wound healing characterized by impaired or delayed re-epithelialization are a serious medical problem. These conditions affect many tissues, are painful, and are difficult to treat. In this study, using cornea as a model, we demonstrate for the first time the importance of carbohydrate-binding proteins galectins-3 and -7 in re-epithelialization of wounds. In two different models of corneal wound healing, re-epithelialization of wounds was significantly slower in galectin-3-deficient (gal3(-/-)) mice compared with wild-type (gal3(+/+)) mice. In contrast, there was no difference in corneal epithelial wound closure rates between galectin-1-deficient and wild-type mice. Quantitation of the bromodeoxyuridine-labeled cells in gal3(+/+) and gal3(-/-) corneas revealed that corneal epithelial cell proliferation rate is not perturbed in gal3(-/-) corneas. Exogenous galectin-3 accelerated re-epithelialization of wounds in gal3(+/+) mice but, surprisingly, not in the gal3(-/-) mice. Gene expression analysis using cDNA microarrays revealed that healing corneas of gal3(-/-) mice contain markedly reduced levels of galectin-7 compared with those of gal3(+/+) mice. More importantly, unlike galectin-3, galectin-7 accelerated re-epithelialization of wounds in both gal3(-/-) and gal3(+/+) mice. In corresponding experiments, recombinant galectin-1 did not stimulate the corneal epithelial wound closure rate. The extent of acceleration of re-epithelialization of wounds with both galectin-3 and galectin-7 was greater than that observed in most of the published studies using growth factors. These findings have broad implications for developing novel therapeutic strategies for treating nonhealing wounds.	Tufts Univ, Sch Med, Dept Ophthalmol, Ctr Vis Res, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA	Tufts University; Tufts University; Tufts University; University of California System; University of California Davis	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Dept Ophthalmol, Ctr Vis Res, 136 Harrison Ave, Boston, MA 02111 USA.	Noorjahan.Panjwani@tufts.edu	Said, Neveen/K-1563-2019; Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	NATIONAL EYE INSTITUTE [P30EY013078, R01EY009349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958] Funding Source: NIH RePORTER; NEI NIH HHS [EYP30 13078, EY07088, EY09349] Funding Source: Medline; NIAID NIH HHS [AI20958] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bresalier RS, 1996, CANCER RES, V56, P4354; BUMBINER BM, 1996, CELL, V84, P354; Cao ZY, 2001, J BIOL CHEM, V276, P21714, DOI 10.1074/jbc.M009672200; Chung EH, 1999, INVEST OPHTH VIS SCI, V40, P1952; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dudas SP, 2000, GASTROENTEROLOGY, V118, pA273, DOI 10.1016/S0016-5085(00)83173-X; Eaglstein WH, 1997, SURG CLIN N AM, V77, P689, DOI 10.1016/S0039-6109(05)70575-2; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; HO MK, 1982, J IMMUNOL, V128, P1221; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; KANDARAKIS AS, 1984, AM J OPHTHALMOL, V98, P411, DOI 10.1016/0002-9394(84)90121-1; KLIMAN GH, 1999, REFRACTIVE SURG, P469; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; LAIBSON PR, OPHTHALMOLOGY ANN, P65; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Macaluso DC, 1997, CORNEA, V1, P199; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; PANJWANI N, 1995, J BIOL CHEM, V270, P14015, DOI 10.1074/jbc.270.23.14015; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; POIRIER F, 1993, DEVELOPMENT, V119, P1229; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHULTZ G, 1994, EYE, V8, P184, DOI 10.1038/eye.1994.43; SEILER WO, 1989, AM J CLIN PATHOL, V92, P430, DOI 10.1093/ajcp/92.4.430; SINGH G, 1989, CORNEA, V8, P45; SINGH G, 1987, AM J OPHTHALMOL, V103, P802, DOI 10.1016/S0002-9394(14)74397-1; Timmons PM, 1999, INT J DEV BIOL, V43, P229; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Warfield PR, 1997, INVAS METAST, V17, P101; WATANABE K, 1987, INVEST OPHTH VIS SCI, V28, P205; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Woodley DT, 1996, MOL CELLULAR BIOL WO, P339; Zagon IS, 2000, BRAIN RES, V882, P169, DOI 10.1016/S0006-8993(00)02864-X; Zieske JD, 2000, PRINCIPLES PRACTICE, P364	44	154	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42299	42305		10.1074/jbc.M200981200	http://dx.doi.org/10.1074/jbc.M200981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194966	hybrid			2022-12-25	WOS:000178985300125
J	Donovan, JCH; Rothenstein, JM; Slingerland, JM				Donovan, JCH; Rothenstein, JM; Slingerland, JM			Non-malignant and tumor-derived cells differ in their requirement for p27(Kip1) in transforming growth factor-beta-mediated G(1) arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-CANCER; TGF-BETA; CYCLE ARREST; DEPENDENT KINASE; C-MYC; NEGATIVE REGULATORS; DOWN-REGULATION; CDK INHIBITORS; MICE LACKING	Transforming growth factor beta (TGF-beta) induces G(1) arrest in susceptible cells by multiple mechanisms that inhibit the G(1) cyclin-dependent kinases (Cdks), including Cdk2, Cdk4, and Cdk6. TGF-beta treatment of early passage finite lifespan human mammary epithelial cells (HMECs) led to an accumulation of p271(Kipl) in cyclin E1-Cdk2 complexes and kinase inhibition. The requirement for p27 in the G(1) arrest by TGF-beta was assessed by transfection of antisense p27 (ASp27) oligonucleotides into TGF-beta-treated HMECs. Despite a reduction in total and cyclin E-Cdk2 bound p27 after ASp27 transfection, HMECs remained arrested in the G(1) phase. Maintenance of the G(1) arrest was accompanied by increased association of the Cdk inhibitor p21(WAF-1/Cip-1) and the retinoblastoma family member p130(Rb2) in cyclin E1-Cdk2 complexes along with kinase inhibition. In contrast to the findings in HMECs, p27 was essential for G(1) arrest by TGF-beta in two tumor-derived lines. ASp27 transfection into two TGF-beta-responsive, cancer-derived lines was not associated with increased compensatory binding of p21 and p130 to cyclin E1-Cdk2, and these cell lines failed to maintain G(1) arrest despite the continued presence of TGF-beta. Progressive cell cycle deregulation leading to impaired checkpoint controls during malignant tumor progression may alter the role of p27 from a redundant to an essential inhibitor of G(1)-to-S phase progression.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cell Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, JM (corresponding author), UM Sylvester Comprehens Canc Ctr, D8-4,1475 NW 12th Ave, Miami, FL 33136 USA.							Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Florenes VA, 1996, ONCOGENE, V13, P2447; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HERZINGER T, 1995, ONCOGENE, V10, P2079; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; Iavarone A, 1997, NATURE, V387, P417; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Petrocelli T, 1996, ONCOGENE, V12, P1387; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; TAIT L, 1990, CANCER RES, V50, P6087; Tanaka N, 2001, CANCER, V92, P2117, DOI 10.1002/1097-0142(20011015)92:8<2117::AID-CNCR1553>3.0.CO;2-O; Warner BJ, 1999, MOL CELL BIOL, V19, P5913	45	19	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41686	41692		10.1074/jbc.M204307200	http://dx.doi.org/10.1074/jbc.M204307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202478	hybrid			2022-12-25	WOS:000178985300050
J	Jimenez, C; Hernandez, C; Pimental, B; Carrera, AC				Jimenez, C; Hernandez, C; Pimental, B; Carrera, AC			The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PI 3-KINASE; SH2 DOMAINS; CATALYTIC SUBUNIT; TYROSINE KINASE; RECEPTOR; BINDING; AKT; PHOSPHORYLATION	Class IA phosphoinositide 3-kinase (PI3K) is a heterodimer composed of a p85 regulatory and a p110 catalytic subunit that regulates a variety of cell responses, including cell division and survival. PI3K is activated following Tyr kinase stimulation and by Ras. We found that the C-terminal region of p85, including the C-Src homology 2 (C-SH2) domain and part of the inter-SH2 region, protects the p110 catalytic subunit from Ras-induced activation. Although the p110 activity associated with a C-terminal p85 deletion mutant increased significantly in the presence of an active form of Ras, purified wild type p85-p110 was only slightly stimulated by active Ras. Nonetheless, incubation of purified p85-p110 with Tyr-phosphorylated peptides, which mimic the activated platelet-derived growth factor receptor, restored Ras-induced p85-p110 activation. In conclusion, p85 inhibits p110 activation by Ras; this blockage is released by Tyr kinase stimulation, showing that the classical mechanism of class IA, PI3K stimulation mediated by Tyr kinases also regulates Ras-induced PI3K activation.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Carrera, AC (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Carretera Colmenar Km 15, E-28049 Madrid, Spain.	acarrera@cnb.uam.es	Pimentel, Belén/AAI-7986-2020; Pimentel, Belén/I-8339-2016	Pimentel, Belén/0000-0003-4194-9231; Pimentel, Belén/0000-0003-4194-9231; Jimenez, Maria Concepcion/0000-0002-7011-9328; Carrera, Ana/0000-0002-3999-5434				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Borlado LR, 2000, FASEB J, V14, P895; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cipres A, 2001, FEBS LETT, V500, P99, DOI 10.1016/S0014-5793(01)02594-7; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Philp AJ, 2001, CANCER RES, V61, P7426; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; YU FX, 1992, J BIOL CHEM, V267, P14616; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	49	98	125	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41556	41562		10.1074/jbc.M205893200	http://dx.doi.org/10.1074/jbc.M205893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196526	hybrid			2022-12-25	WOS:000178985300034
J	Nguyen, TB; Manova, K; Capodieci, P; Lindon, C; Bottega, S; Wang, XY; Refik-Rogers, J; Pines, J; Wolgemuth, DJ; Koff, A				Nguyen, TB; Manova, K; Capodieci, P; Lindon, C; Bottega, S; Wang, XY; Refik-Rogers, J; Pines, J; Wolgemuth, DJ; Koff, A			Characterization and expression of mammalian cyclin B3, a prepachytene meiotic cyclin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; CELL-CYCLE; DEPENDENT KINASE-5; XENOPUS OOCYTES; MESSENGER-RNA; MEIOSIS-I; A-TYPE; MOUSE; LOCALIZATION; COMPLEX	We report the identification and expression pattern of a full-length human cDNA and a partial mouse cDNA encoding cyclin B3. Cyclin B3 (CCNB3) is conserved from Caenorhabditis elegans to Homo sapiens and has an undefined meiotic function in female, but not male Drosophila melanogaster. We show that H. sapiens cyclin B3 interacts with cdk2, is localized to the nucleus, and is degraded during anaphase entry after the degradation of cyclin B1. Degradation is dependent on sequences conserved in a destruction box motif. Overexpression of nondegradable cyclin B3 blocks the mitotic cell cycle in late anaphase, and at higher doses it can interfere with progression through G, and entry into S phase. H. sapiens cyclin B3 mRNA and protein are detected readily in developing germ cells in the human testis and not in any other tissue. The mouse cDNA has allowed us to further localize cyclin B3 mRNA to leptotene and zygotene spermatocytes. The expression pattern of mammalian cyclin B3 suggests that it may be important for events occurring in early meiotic prophase I.	Mem Sloan Kettering Canc Ctr, Dept Biol Mol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Expt Pathol, New York, NY 10021 USA; Wellcome Trust Canc Res UK, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research UK; Columbia University	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Biol Mol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.	a-koff@ski.mskcc.org		Pines, Jonathon/0000-0002-5227-6004; Koff, Andrew/0000-0003-3271-3067; Lindon, Catherine/0000-0003-3554-2574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052597, R55GM052597] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52597] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Ashley T, 2001, J CELL SCI, V114, P685; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Beumer TL, 2000, BIOL REPROD, V63, P1893, DOI 10.1095/biolreprod63.6.1893; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; CHAPMAN DL, 1994, DEV BIOL, V165, P500, DOI 10.1006/dbio.1994.1270; CLERMONT Y, 1993, SERTOLI CELL, P305; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; Handel M. A., 1998, MEIOSIS GAMETOGENESI; HARTUNG M, 1977, CYTOGENET CELL GENET, V18, P309, DOI 10.1159/000130777; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lozano JC, 2002, BIOCHEM BIOPH RES CO, V291, P406, DOI 10.1006/bbrc.2002.6458; LUCIANI JM, 1977, J EMBRYOL EXP MORPH, V38, P175; Manova K, 1998, DEV DYNAM, V213, P293, DOI 10.1002/(SICI)1097-0177(199811)213:3<293::AID-AJA6>3.0.CO;2-D; MANOVA K, 1990, DEVELOPMENT, V110, P1057; Miller ME, 2000, MOL CELL BIOL, V20, P542, DOI 10.1128/MCB.20.2.542-555.2000; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; TACHIBANA K, 1990, DEV BIOL, V140, P241, DOI 10.1016/0012-1606(90)90074-S; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WILLARD HF, 1989, HUM GENET, V81, P234; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	48	102	109	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41960	41969		10.1074/jbc.M203951200	http://dx.doi.org/10.1074/jbc.M203951200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12185076	hybrid			2022-12-25	WOS:000178985300085
J	van Balkom, BWM; Savelkoul, PJM; Markovich, D; Hofman, E; Nielsen, S; van der Sluijs, P; Deen, PMT				van Balkom, BWM; Savelkoul, PJM; Markovich, D; Hofman, E; Nielsen, S; van der Sluijs, P; Deen, PMT			The role of putative phosphorylation sites in the targeting and shuttling of the aquaporin-2 water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY COLLECTING DUCT; NEPHROGENIC DIABETES-INSIPIDUS; PROTEIN-KINASE-C; VASOPRESSIN-MEDIATED TRANSLOCATION; RENAL PRINCIPAL CELLS; PERMEABILITY RESPONSE; EPITHELIAL-CELLS; RECEPTOR; LOCALIZATION; CYTOSKELETON	In renal collecting ducts, a vasopressin-induced cAMP increase results in the phosphorylation of aquaporin-2 (AQP2) water channels at Ser-256 and its redistribution from intracellular vesicles to the apical membrane. Hormones that activate protein kinase C (PKC) proteins counteract this process. To determine the role of the putative kinase sites in the trafficking and hormonal regulation of human AQP2, three putative casein kinase II (Ser-148, Ser-229, Thr-244), one PKC (Ser-231), and one protein kinase A (Ser-256) site were altered to mimic a constitutively non-phosphorylated/phosphorylated state and were expressed in Madin-Darby canine kidney cells. Except for Ser-256 mutants, seven correctly folded AQP2 kinase mutants trafficked as wild-type AQP2 to the apical membrane via forskolin-sensitive intracellular vesicles. With or without forskolin, AQP2-Ser-256A was localized in intracellular vesicles, whereas AQP2-S256D was localized in the apical membrane. Phorbol 12-myristate 13-acetate-induced PKC activation following forskolin treatment resulted in vesicular distribution of all AQP2 kinase mutants, while all were still phosphorylated at Ser-256. Our data indicate that in collecting duct cells, AQP2 trafficking to vasopressin-sensitive vesicles is phosphorylation-independent, that phosphorylation of Ser-256 is necessary and sufficient for expression of AQP2 in the apical membrane, and that PMA-induced PKC-mediated endocytosis of AQP2 is independent of the AQP2 phosphorylation state.	Nijmegen Ctr Mol Life Sci, Dept Cell Physiol, NL-6500 HB Nijmegen, Netherlands; Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Aarhus Univ, Water & Salt Res Ctr, DK-8000 Aarhus, Denmark; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Radboud University Nijmegen; University of Queensland; Aarhus University; Utrecht University	Deen, PMT (corresponding author), UMC St Radboud, Dept Cell Physiol 160, Res Tower,7th Floor,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Deen, Peter MT/B-9854-2013; Deen, P.M.T./H-8023-2014; Markovich, Daniel/F-7884-2012	Deen, Peter MT/0000-0002-7868-4655; Deen, P.M.T./0000-0002-7868-4655; 				Berl T, 1997, KIDNEY INT, pS2; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Breton S, 1998, J AM SOC NEPHROL, V9, P155; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; Christensen BM, 2000, AM J PHYSIOL-RENAL, V278, pF29, DOI 10.1152/ajprenal.2000.278.1.F29; Deen PMT, 1996, J AM SOC NEPHROL, V7, P836; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Deen PMT, 2002, AM J PHYSIOL-RENAL, V282, pF330, DOI 10.1152/ajprenal.0168.2001; Deen PMT, 1998, CURR OPIN NEPHROL HY, V7, P37; Deen PMT, 1997, PFLUG ARCH EUR J PHY, V433, P780, DOI 10.1007/s004240050345; DEEN PMT, 2001, TRAFFICKING NATIVE M, P235; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Fujioka T, 2001, EUR J BIOCHEM, V268, P25, DOI 10.1046/j.1432-1327.2001.01831.x; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAN JS, 1994, AM J PHYSIOL, V266, pF139, DOI 10.1152/ajprenal.1994.266.1.F139; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Kishore BK, 1995, AM J PHYSIOL-RENAL, V269, pF863, DOI 10.1152/ajprenal.1995.269.6.F863; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MAEDA Y, 1992, AM J PHYSIOL, V263, pF319, DOI 10.1152/ajprenal.1992.263.2.F319; Marr N, 2002, HUM MOL GENET, V11, P779, DOI 10.1093/hmg/11.7.779; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; NADLER SP, 1992, AM J PHYSIOL, V262, pF229, DOI 10.1152/ajprenal.1992.262.2.F229; NADLER SP, 1992, J CLIN INVEST, V90, P1458, DOI 10.1172/JCI116013; Nielsen S, 1998, CURR OPIN NEPHROL HY, V7, P509, DOI 10.1097/00041552-199809000-00005; Nishimoto G, 1999, AM J PHYSIOL-RENAL, V276, pF254, DOI 10.1152/ajprenal.1999.276.2.F254; PEARL M, 1985, BIOL CELL, V55, P163, DOI 10.1111/j.1768-322X.1985.tb00421.x; PHILLIPS ME, 1989, J PHYSIOL-LONDON, V411, P529, DOI 10.1113/jphysiol.1989.sp017588; PHILLIPS ME, 1992, J PHYSIOL-LONDON, V456, P591, DOI 10.1113/jphysiol.1992.sp019355; PRICNO G, 1999, J AM SOC NEPHROL, V10, P23; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; SIMON H, 1993, AM J PHYSIOL, V265, pC757, DOI 10.1152/ajpcell.1993.265.3.C757; Straussman R, 2001, J CELL SCI, V114, P3047; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Vaaraniemi J, 1999, J CELL PHYSIOL, V181, P83, DOI 10.1002/(SICI)1097-4652(199910)181:1<83::AID-JCP9>3.0.CO;2-G; van Tiel CM, 2002, J BIOL CHEM, V277, P22447, DOI 10.1074/jbc.M201532200; WALL SM, 1992, AM J PHYSIOL, V262, pF989, DOI 10.1152/ajprenal.1992.262.6.F989; Zelenina M, 2000, AM J PHYSIOL-RENAL, V278, pF388, DOI 10.1152/ajprenal.2000.278.3.F388; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	50	190	192	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41473	41479		10.1074/jbc.M207525200	http://dx.doi.org/10.1074/jbc.M207525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194985	Green Published, hybrid			2022-12-25	WOS:000178985300024
J	Xu, MG; Chen, JF; Martin, F; Zhao, MW; Eriani, G; Wang, ED				Xu, MG; Chen, JF; Martin, F; Zhao, MW; Eriani, G; Wang, ED			Leucyl-tRNA synthetase consisting of two subunits from hyperthermophilic bacteria Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; EVOLUTIONARY RELATIONSHIPS; BINDING DOMAIN; PURIFICATION; PROTEIN; DISCRIMINATION; RECOGNITION; MECHANISM; COMPLEX	In a hyperthermophilic bacterium, Aquifex aeolicus, leucyl-tRNA synthetase (LeuRS) consists of two nonidentical polypeptide subunits (alpha and beta), different from the canonical LeuRS, which has a single polypeptide chain. By PCR, using genome DNA of A. aeolicus as a template, genes encoding the alpha and beta subunits were amplified and cloned in Escherichia coli. The alpha subunit could not be expressed stably in vivo, whereas the beta subunit was overproduced and purified by a simple procedure. The beta subunit was inactive in catalysis but was able to bind tRNA(Leu). Interestingly, the heterodimer alphabeta-LeuRS could be overproduced in E. coli cells containing both genes and was purified to 95% homogeneity as a hybrid dimer. The kinetics of A. aeolicus LeuRS in pre-steady and steady states and cross-recognition of LeuRS and tRNA(Leu) from A. aeolicus and E. coli were studied. Magnesium concentration, pH value, and temperature aminoacylation optima were determined to be 12 mm, 7.8, and 70 degreesC, respectively. Under optimal conditions, A. aeolicus alphabeta-LeuRS is stable up to 65 degreesC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; CNRS, Inst Biol Mol & Cellulaire, UPR9002, F-67084 Strasbourg, France	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wang, ED (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	wed@server.shcnc.ac.cn	MARTIN, Franck/D-9042-2015	MARTIN, Franck/0000-0001-9724-4025; Eriani, Gilbert/0000-0002-8518-4675				BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Delagoutte B, 2000, EMBO J, V19, P5599, DOI 10.1093/emboj/19.21.5599; DELARUE M, 1995, CURR OPIN STRUC BIOL, V5, P48, DOI 10.1016/0959-440X(95)80008-O; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Geslain R, 2000, RNA, V6, P434, DOI 10.1017/S1355838200992331; Gouda M, 2002, FEBS LETT, V518, P139, DOI 10.1016/S0014-5793(02)02675-3; GRANDA S, 1979, MOL CELL BIOCHEM, V24, P175; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Houman F, 2000, P NATL ACAD SCI USA, V97, P13743, DOI 10.1073/pnas.240465597; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; Li T, 1999, BIOCHEMISTRY-US, V38, P13063, DOI 10.1021/bi990384+; Li T, 1999, BIOCHEMISTRY-US, V38, P9084, DOI 10.1021/bi9901984; LI T, 1995, ACTA BIOCH BIOPH SIN, V27, P279; Li Y, 1999, PROTEIN EXPRES PURIF, V16, P355, DOI 10.1006/prep.1999.1083; Li Y, 1998, SCI CHINA SER C, V41, P225, DOI 10.1007/BF02895095; MEHLER AH, 1967, J BIOL CHEM, V242, P5495; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; PAPAS TS, 1972, BIOCHEMISTRY-US, V11, P4602, DOI 10.1021/bi00774a029; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Schmitt E, 1997, EUR J BIOCHEM, V246, P539, DOI 10.1111/j.1432-1033.1997.00539.x; SHI JP, 1988, ACTA BIOCH BIOPH SIN, V20, P76; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHIBA K, 1992, J BIOL CHEM, V267, P22703; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Tardif KD, 2001, BIOCHEMISTRY-US, V40, P8118, DOI 10.1021/bi0103213; VELTEROP JS, 1995, GENE, V153, P63, DOI 10.1016/0378-1119(94)00790-Y; Wu JF, 1999, ACTA BIOCH BIOPH SIN, V31, P226; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41590	41596		10.1074/jbc.M205126200	http://dx.doi.org/10.1074/jbc.M205126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196521	hybrid			2022-12-25	WOS:000178985300038
J	Lin, KD; Wang, DX; Sadee, WG				Lin, KD; Wang, DX; Sadee, WG			Serum response factor activation by muscarinic receptors via RhoA - Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; CHOLINERGIC-RECEPTOR; SIGNAL-TRANSDUCTION; MAP KINASE; C-FOS; TYROSINE KINASE; ANGIOTENSIN-II; EXPRESSION; BINDING	The muscarinic cholinergic receptor (mAChR) subtypes share high sequence similarity except in their third intracellular loop and COOH terminus, domains thought to be involved in signal transduction. Subtypes M1, M3, and M5 couple mainly through Galpha(i/o). and M2 and M4 couple mainly through Galpha(i/o)., Whether subtypes within each of these two groups differ in their signaling pathways remains to be resolved. This study focused on nuclear signaling pathways leading to activation of the transcription factor, serum response factor (SRF). Genes encoding M1, M2, and M3 were co-expressed in Jurkat T lymphocytes with a reporter gene driven by a mutant serum response element, SRE.L, which responds to SRF activation. We show that only M1 mAChR activated SRF through a pathway involving the small GTPase RhoA, with no response observed for M2 and M3. Transfection of GTPase-deficient Got subunits (GalphaQL; constitutively active form) demonstrated that SRF was activated by Galpha(13)QL but only marginally by Galpha(q)QL and Galpha(12)QL in Jurkat cells. Yet transfection of regulator of G protein-signaling protein, RGS2 and RGS4, which inhibit Galpha(q/11), activity, indicated that Galpha(q/11) and Ca2+ mobilization were required for SRF activation by M1. Calmodulin inhibitors suppressed the M1 and the Galpha(13)QL pathways, acting both upstream and downstream of RhoA. However, calcineurin inhibitors and the tyrosine kinase inhibitor genistein selectively suppressed SRF activation by M1, but not by GaIAL, indicating the presence of separate pathways. The calmodulin-dependent tyrosine kinase Pyk2 was also activated by M1 but not M3, and Pyk2 appears also to play a role in M1-SRF activation, as judged by experiments with two dominant-negative Pyk2 mutants. These results reveal a novel calmodulin-dependent RhoA-SRF signaling pathway unique to the M1 mAChR subtype.	Ohio State Univ, Coll Med & Publ Hlth, Program Pharmacogenom, Dept Pharmacol, Columbus, OH 43210 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University System of Ohio; Ohio State University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sadee, WG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Program Pharmacogenom, Dept Pharmacol, 5072 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	sadee.l@osu.edu	Wang, Danxin/I-5810-2019	Wang, Danxin/0000-0002-7134-3065	NIDA NIH HHS [DA 04166] Funding Source: Medline; NIGMS NIH HHS [GM 43102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brown JH, 1997, LIFE SCI, V60, P1077; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burford NT, 2000, BIOCHEM J, V348, P531, DOI 10.1042/0264-6021:3480531; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CHOU H, 1992, J NEURAL TRANSM-GEN, V90, P171, DOI 10.1007/BF01250959; Cohen RI, 1996, MOL BRAIN RES, V43, P193, DOI 10.1016/S0169-328X(96)00176-3; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ding WQ, 1998, J NEUROCHEM, V70, P1722; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Fisher A, 1998, J NEUROCHEM, V70, P1991; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Gutkind JS, 1997, LIFE SCI, V60, P999; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hamilton SE, 2001, J BIOL CHEM, V276, P15850, DOI 10.1074/jbc.M011563200; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LARSSON C, 1994, EUR J PHARM-MOLEC PH, V268, P19; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MORO O, 1993, J BIOL CHEM, V268, P6862; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSIOKAS L, 1995, MOL PHARMACOL, V47, P272; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang DX, 2000, J NEUROCHEM, V74, P1418, DOI 10.1046/j.1471-4159.2000.0741418.x; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	57	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40789	40798		10.1074/jbc.M202745200	http://dx.doi.org/10.1074/jbc.M202745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12200418	hybrid			2022-12-25	WOS:000178791400082
J	Romanelli, A; Dreisbach, VC; Blenis, J				Romanelli, A; Dreisbach, VC; Blenis, J			Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; C-ZETA; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; DOCKING SITE; ACTIVATION; PDK1; P70(S6K); IDENTIFICATION; DISRUPTION	Phosphorylation of the highly conserved hydrophobic motif site in AGC kinases is necessary for phosphotransferase activity. Phosphorylation of this motif (FLGFT389Y) in p70 S6 kinase (S6K1) is both rapamycin-and wortmannin-sensitive, suggesting a role for both mammalian target of rapamycin- and phosphatidylinositol 3-kinase-dependent pathways. We report here that co-expression of phosphoinositide-dependent kinase-1 (PDK1) and the phosphatidylinositol 3-kinase-regulated atypical protein kinase Q cooperate to increase both phosphorylation of the hydrophobic motif site Thr(389), as well as the activation loop site Thr(229). Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Q required S6K1 activity. Furthermore, Akt, another phosphatidylinositol 3-kinase effector and regulator of S6K1, also increased Thr(389) phosphorylation in a S6K1 activity-dependent manner. Consistent with this, epidermal growth factor-induced Thr(389) phosphorylation in wild type S6K1 persisted for up to 120 min, whereas kinase-inactive mutants of S6K1 displayed only a reduced and transient increase in Thr(389) phosphorylation. We conclude that S6K1 activity is required for maximal Thr(389) phosphorylation by mitogens and by multiple phosphatidylinositol 3-kinase-dependent inputs including PDK1, PKCzeta, and Akt, and we propose that autophosphorylation is an important regulatory mechanism for phosphorylation of the hydrophobic motif Thr(389) site in S6K1.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM 51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; BLENIS J, 1986, P NATL ACAD SCI USA, V82, P1733; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	48	66	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40281	40289		10.1074/jbc.M205168200	http://dx.doi.org/10.1074/jbc.M205168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183455	hybrid			2022-12-25	WOS:000178791400018
J	Wang, DX; Esselman, WJ; Cole, PA				Wang, DX; Esselman, WJ; Cole, PA			Substrate conformational restriction and CD45-catalyzed dephosphorylation of tail tyrosine-phosphorylated Src protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-ACTIVATION; RECIPROCAL REGULATION; KINASE HCK; MECHANISM; CD45; PHOSPHATASES; SPECIFICITY; INSIGHTS; DOMAINS; CSK	Hydrolysis of the tail phosphotyrosine in Src family members is catalyzed by the protein-tyrosine phosphatase CD45, activating Src family-related signaling pathways. Using purified recombinant phospho-Src (P-Src) (amino acid residues 83-533) and purified recombinant CD45 catalytic (cytoplasmic) domain (amino acid residues 565-1268), we have analyzed the kinetic behavior of dephosphorylation. A time course of phosphatase activity showed the presence of a burst phase. By varying the concentration of P-Src, it was shown that the amplitude of this burst phase increased linearly with respect to P-Src concentration. Approximately 2% of P-Src was shown to be rapidly dephosphorylated followed by a slower linear phase. A P-Src protein substrate containing a functional point mutation in the Src homology domain 2 (SH2) led to more rapid dephosphorylation catalyzed by CD45, and this reaction showed only a single linear kinetic phase. These results were interpreted in terms of a model in which P-Src exists in a relatively slow dynamic equilibrium between "closed" and "open" conformational forms. Combined mutations in the SH2 and SH3 domain or the addition of an SH3 domain ligand peptide enhanced the accessibility of P-Src to CD45 by biasing P-Src to a more open form. Consistent with this model, a phosphotyrosine peptide that behaved as an SH2 domain binding ligand showed similar to100-fold greater affinity for unphosphorylated Src versus P-Src. Surprisingly, P-Src possessing combined SH3 and SH2 functional inactivating point mutations was dephosphorylated by CD45 more slowly compared with P-Src completely lacking SH3 and SH2 domains. Additional data suggest that the SH3 and SH2 domains can inhibit accessibility of the P-Src tail to CD45 by interactions other than direct phosphotyrosine binding by the SH2 domain. Taken together, these results suggest how activation of Src family member signaling pathways by CD45 may be influenced by the presence or absence of ligand interactions remote from the tail.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Johns Hopkins University; Michigan State University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	pcole@jhmi.edu			NCI NIH HHS [CA 74305] Funding Source: Medline; NIAID NIH HHS [AI 42794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074305, R01CA074305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GHOSE C, 1985, BIOCHEMISTRY-US, V24, P5894, DOI 10.1021/bi00342a031; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang YL, 2001, J BIOL CHEM, V276, P42347, DOI 10.1074/jbc.M106594200; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; THOMAS ML, 1994, CURR OPIN CELL BIOL, V6, P247, DOI 10.1016/0955-0674(94)90143-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wang DX, 2001, J AM CHEM SOC, V123, P8883, DOI 10.1021/ja010540b; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200	33	20	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40428	40433		10.1074/jbc.M206467200	http://dx.doi.org/10.1074/jbc.M206467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181320	hybrid			2022-12-25	WOS:000178791400036
J	Yu, ZB; Fotouhi-Ardakani, N; Wu, LT; Maoui, M; Wang, SL; Banville, D; Shen, SH				Yu, ZB; Fotouhi-Ardakani, N; Wu, LT; Maoui, M; Wang, SL; Banville, D; Shen, SH			PTEN associates with the vault particles in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR PTEN; RESISTANCE-RELATED PROTEIN; GERMLINE MUTATIONS; COWDEN-DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE; RIBONUCLEOPROTEIN-PARTICLES; SIGNALING PATHWAYS; BREAST-CANCER; PDZ DOMAIN	PTEN is a tumor suppressor that primarily dephosphorylates phosphatidylinositol 3,4,5-trisphosphate to down-regulate the phosphoinositide 3-kinase/Akt signaling pathway. Although the cellular functions of PTEN as a tumor suppressor have been well characterized, the mechanism by which PTEN activity is modulated by other signal molecules in vivo remains poorly understood. In searching for potential PTEN modulators through protein-protein interaction, we identified the major vault protein (MVP) as a dominant PTEN-binding protein in a yeast two-hybrid screen. MVP is the major structural component of vault, the largest intracellular ribonucleoprotein particle. Co-immunoprecipitation confirmed the interaction between PTEN and MVP in transfected mammalian cells. More importantly, we found that a significant portion of endogenous PTEN associates with vault particles in human HeLa cells. Deletion mutation analysis demonstrated that MVP binds to the C2 domain of PTEN and that PTEN interacts with MVP through its EF hand-like motif. Furthermore, the in vitro binding experiments revealed that the interaction of PTEN with MVP is Ca2+-dependent.	Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; Adey NB, 2000, CANCER RES, V60, P35; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; CHUGANI DC, 1993, J CELL SCI, V106, P23; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; Keegan K, 1996, ONCOGENE, V12, P1537; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; VANZON, 2002, BIOCH BIOPHYS RES CO, V291, P535; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wu LT, 2002, MOL CELL BIOL, V22, P2673, DOI 10.1128/MCB.22.8.2673-2686.2002; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	51	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40247	40252		10.1074/jbc.M207608200	http://dx.doi.org/10.1074/jbc.M207608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177006	hybrid			2022-12-25	WOS:000178791400013
J	Cao, GQ; Beyer, TP; Yang, XP; Schmidt, RJ; Zhang, YY; Bensch, WR; Kauffman, RF; Gao, H; Ryan, TP; Liang, Y; Eacho, PI; Jiang, XC				Cao, GQ; Beyer, TP; Yang, XP; Schmidt, RJ; Zhang, YY; Bensch, WR; Kauffman, RF; Gao, H; Ryan, TP; Liang, Y; Eacho, PI; Jiang, XC			Phospholipid transfer protein is regulated by liver X receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; OXYSTEROL RECEPTORS; INTERNAL PROMOTER; TRANSGENIC MICE; TANGIER-DISEASE; LXR-ALPHA; GENE; CHOLESTEROL; EXPRESSION; EFFLUX	Liver X receptors (LXR) belong to the nuclear receptor superfamily that can regulate important lipid metabolic pathways. The plasma phospholipid transfer protein (PLTP) is known to mediate transfer of phospholipids from triglyceride-rich lipoproteins to high density lipoprotein (HDL) and plays a critical role in HDL metabolism. We report here that a specific LXR agonist, T0901317, elevated HDL cholesterol and phospholipid in C57/BL6 mice and generated enlarged HDL particles that were enriched in cholesterol, ApoAI, ApoE, and phospholipid. The appearance of these HDL particles upon oral dosing of T0901317 in C57/BL6 mice was closely correlated with the increased plasma PLTP activity and liver PLTP mRNA levels. Nuclear run-on assay indicated that the effect of LXR agonist on PLTP expression was at the transcriptional level. In mouse peritoneal macrophage cells, PLTP expression was also up-regulated by the LXR/RXR (retinoid X receptor) heterodimer. However, cholesterol efflux in mouse peritoneal macrophage cells from PLTP-deficient mice (PLTP0) was not significantly different from wild type animals. Although in PLTP-deficient mice, the induction of HDL cholesterol as well as HDL particle size increase persisted, the extent of the induction was greatly attenuated. We conclude that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice.	Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, Indianapolis, IN 46285 USA; Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Eli Lilly; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Cao, GQ (corresponding author), Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, Indianapolis, IN 46285 USA.	Guoqing_Cao@lilly.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069817] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69817] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baez JM, 2002, J BIOL CHEM, V277, P6198, DOI 10.1074/jbc.M106799200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bouly M, 2001, J BIOL CHEM, V276, P25841, DOI 10.1074/jbc.M101160200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; Edwards PA, 2002, J LIPID RES, V43, P2; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; Huuskonen J, 1998, J LIPID RES, V39, P2021; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; KIEFT KA, 1991, J LIPID RES, V32, P859; Kirschning CJ, 1997, GENOMICS, V46, P416, DOI 10.1006/geno.1997.5030; KOO C, 1985, J BIOL CHEM, V260, P1934; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2001, EXPERT OPIN INV DRUG, V10, P427, DOI 10.1517/13543784.10.3.427; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Qin SC, 2000, J LIPID RES, V41, P269; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	36	149	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39561	39565		10.1074/jbc.M207187200	http://dx.doi.org/10.1074/jbc.M207187200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177004	hybrid			2022-12-25	WOS:000178662500066
J	Carveth, K; Buck, T; Anthony, V; Skach, WR				Carveth, K; Buck, T; Anthony, V; Skach, WR			Cooperativity and flexibility of cystic fibrosis transmembrane conductance regulator transmembrane segments participate in membrane localization of a charged residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; HUMAN P-GLYCOPROTEIN; PROTEIN TRANSLOCATION; SIGNAL SEQUENCE; POSTTRANSLATIONAL TRANSLOCATION; SPANNING REGIONS; CHLORIDE CHANNEL; ER MEMBRANE; CFTR; BIOGENESIS	Polytopic protein topology is established in the endoplasmic reticulum (ER) by sequence determinants encoded throughout the nascent polypeptide. Here we characterize 12 topogenic determinants in the cystic fibrosis transmembrane conductance regulator, and identify a novel mechanism by which a charged residue is positioned within the plane of the lipid bilayer. During cystic fibrosis transmembrane conductance regulator biogenesis, topology of the C-terminal transmembrane domain (TMs 7-12) is directed by alternating signal (TMs 7,9, and 11) and stop transfer (TMs 8, 10, and 12) sequences. Unlike conventional stop transfer sequences, however, TM8 is unable to independently terminate translocation due to the presence of a single charged residue, Asp 121, within the TM segment. Instead, TM8 stop transfer activity is specifically dependent on TM7, which functions both to initiate translocation and to compensate for the charged residue within TM8. Moreover, even in the presence of TM7, the N terminus of TM8 extends significantly into the ER lumen, suggesting a high degree of flexibility in establishing TM8 transmembrane boundaries. These studies demonstrate that signal sequences can markedly influence stop transfer behavior and indicate that ER translocation machinery simultaneously integrates information from multiple topogenic determinants as they are presented in rapid succession during polytopic protein biogenesis.	Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97201 USA	Oregon Health & Science University	Skach, WR (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97201 USA.	skachw@ohsu.edu		Buck, Teresa/0000-0002-9013-9756	NIDDK NIH HHS [DK 51818] Funding Source: Medline; NIGMS NIH HHS [GM 53457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; Chen MG, 1999, BIOCHEMISTRY-US, V38, P5471, DOI 10.1021/bi982153t; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cotten JF, 1999, J BIOL CHEM, V274, P5429, DOI 10.1074/jbc.274.9.5429; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hammerle MM, 2000, GLYCOCONJUGATE J, V17, P807, DOI 10.1023/A:1010992827511; Hammerle MM, 2001, J BIOL CHEM, V276, P14848, DOI 10.1074/jbc.M011017200; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Mansoura MK, 1998, BIOPHYS J, V74, P1320, DOI 10.1016/S0006-3495(98)77845-2; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Skach WR, 1998, METHOD ENZYMOL, V292, P265; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Tsalkova T, 1998, J MOL BIOL, V278, P713, DOI 10.1006/jmbi.1998.1721; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wigley WC, 2002, NAT STRUCT BIOL, V9, P381, DOI 10.1038/nsb784; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618	61	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39507	39514		10.1074/jbc.M205759200	http://dx.doi.org/10.1074/jbc.M205759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12186867	hybrid			2022-12-25	WOS:000178662500059
J	Li, JH; Park, SW; Loh, HH; Wei, LN				Li, JH; Park, SW; Loh, HH; Wei, LN			Induction of the mouse kappa-opioid receptor gene by retinoic acid in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BOX-BINDING-PROTEINS; HAMSTER OVARY CELLS; SIGNAL-TRANSDUCTION; SP1 PHOSPHORYLATION; DNA-BINDING; C-ZETA; EXPRESSION; CLONING; DIFFERENTIATION	The mouse K-opioid receptor (KOR) gene is expressed in mouse embryonal carcinoma P19 cells and induced by retinoic acid (RA) within 24 h. An RA-responsive cis-acting element is identified within promoter I of the KOR gene. This element contains a GC box, a putative binding site for transcription factor Sp1. Enhanced binding of Sp1 to this GC box correlates with RA induction of KOR gene. Phosphatase inhibitor (sodium pyrophosphate) decreases RA induction of this promoter, whereas hypophosphorylation of Sp1 results in an increase in its DNA binding affinity to this promoter as demonstrated by in vitro gel retardation and in vivo chromatin immunoprecipitation assays. Consistently, the inhibitor of MEK, PD98058, dose-dependently enhances RA induction of this promoter, suggesting that the ERK signaling pathway is negatively involved in the RA induction of mouse KOR gene activities. Collectively, enhanced binding of Sp1 to promoter I of the KOR gene as a result of inhibiting the ERK pathway contributes to RA induction of this gene in P19.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Park, Sung Wook/0000-0002-3393-8826	NIDA NIH HHS [DA00564, DA11190, DA11806] Funding Source: Medline; NIDDK NIH HHS [DK 54733, DK60521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521, R01DK054733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, R56DA000564, P50DA011806, R01DA000564] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALESSI DR, 1995, CURR BIOL, V5, P1275; Alroy I, 1999, MOL CELL BIOL, V19, P1961; ARMSTRONG DL, 1992, TRENDS NEUROSCI, V15, P403, DOI 10.1016/0166-2236(92)90192-B; Bi J, 2001, J NEUROSCI, V21, P1590, DOI 10.1523/JNEUROSCI.21-05-01590.2001; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hu XL, 2001, J BIOL CHEM, V276, P4597, DOI 10.1074/jbc.M005477200; Hu XL, 1999, MOL BRAIN RES, V69, P35, DOI 10.1016/S0169-328X(99)00077-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITCHEN I, 1990, EUR J PHARMACOL, V175, P93, DOI 10.1016/0014-2999(90)90157-2; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li LY, 1996, MOL PHARMACOL, V50, P599; LIU HC, 1995, BIOCHEM BIOPH RES CO, V209, P639, DOI 10.1006/bbrc.1995.1547; Lu SL, 1997, MOL PHARMACOL, V52, P415, DOI 10.1124/mol.52.3.415; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PARK SK, 2001, BIOCHEM BIOPH RES CO, V283, P303; Piros ET, 1996, MOL PHARMACOL, V50, P947; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; ROHLFF C, 1997, J BIOL CHEM, V272, P22199; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; TALLENT M, 1994, NEUROSCIENCE, V63, P1033, DOI 10.1016/0306-4522(94)90570-3; Wei LN, 2000, MOL PHARMACOL, V57, P401; WEI LN, 1996, HDB PSYCHIAT GENETIC, P77; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhu QW, 2000, BIOCHEM BIOPH RES CO, V271, P100, DOI 10.1006/bbrc.2000.2586; Zhu YX, 1998, BIOL REPROD, V59, P925, DOI 10.1095/biolreprod59.4.925; Zhu YX, 1998, J NEUROSCI, V18, P2538	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39967	39972		10.1074/jbc.M200840200	http://dx.doi.org/10.1074/jbc.M200840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171913	hybrid			2022-12-25	WOS:000178662500115
J	Miyata, S; Minami, J; Tamai, E; Matsushita, O; Shimamoto, S; Okabe, A				Miyata, S; Minami, J; Tamai, E; Matsushita, O; Shimamoto, S; Okabe, A			Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; PLASMA-MEMBRANE; ANCHORED PROTEIN; MDCK CELLS; CHOLESTEROL; AEROLYSIN; BINDING; SURFACE; CYCLODEXTRIN; HIPPOCAMPUS	Clostridium perfringens E-toxin, which is responsible for enterotoxaemia in ungulates, forms a heptamer in rat synaptosomal and Madin-Darby canine kidney (MDCK) cell membranes, leading to membrane permealization. Thus, the toxin may target the detergent-resistant membrane domains (DRMs) of these membranes, in analogy to aerolysin, a heptameric pore-forming toxin that associates with DRMs. To test this idea, we examined the distribution of radiolabeled E-toxin in DRM and detergent-soluble membrane fractions of MDCK cells and rat synaptosomal membranes. When MDCK cells and synaptosomal membranes were incubated with the toxin and then fractionated by cold Triton X-100 extraction and flotation on sucrose gradients, the heptameric toxin was detected almost exclusively in DRMs. The results of a toxin overlay assay revealed that the toxin preferentially bound to and heptamerized in the isolated DRMs. Furthermore, cholesterol depletion by methyl-beta-cyclodextrin abrogated their association and lowered the cytotoxicity of the toxin toward MDCK cells. When c-protoxin, an inactive precursor able to bind to but unable to heptamerized in the membrane, was incubated with MDCK cell membranes, it was detected mainly in their DRMs. These results suggest that the toxin is concentrated and induced to heptamerize on binding to a putative receptor located preferentially in DRMs, with all steps from initial binding through pore formation completed within the same DRMs.	Kagawa Med Univ, Fac Med, Dept Microbiol, Kagawa 7610793, Japan; Kagawa Prefectural Coll Hlth Sci, Dept Med Technol, Kagawa 7610123, Japan	Kagawa University	Okabe, A (corresponding author), Kagawa Med Univ, Fac Med, Dept Microbiol, 1750-1 Mik Cho, Kagawa 7610793, Japan.			TAMAI, EIJI/0000-0002-0338-5095				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Borrmann E, 2001, FEMS IMMUNOL MED MIC, V31, P85, DOI 10.1111/j.1574-695X.2001.tb00503.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Finnie JW, 1999, J COMP PATHOL, V120, P415, DOI 10.1053/jcpa.1998.0289; Fivaz M, 2001, TOXICON, V39, P1637, DOI 10.1016/S0041-0101(01)00151-9; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; HABEEB AFSA, 1973, BIOCHIM BIOPHYS ACTA, V322, P245, DOI 10.1016/0005-2795(73)90300-0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Minami J, 1997, MICROBIOL IMMUNOL, V41, P527, DOI 10.1111/j.1348-0421.1997.tb01888.x; Miyamoto O, 1998, INFECT IMMUN, V66, P2501, DOI 10.1128/IAI.66.6.2501-2508.1998; Miyamoto O, 2000, FEMS MICROBIOL LETT, V189, P109, DOI 10.1111/j.1574-6968.2000.tb09215.x; MIYATA S, 1995, MICROBIOL-SGM, V141, P2643, DOI 10.1099/13500872-141-10-2643; Miyata S, 2001, J BIOL CHEM, V276, P13778, DOI 10.1074/jbc.M011527200; NAGAHAMA M, 1992, INFECT IMMUN, V60, P1237, DOI 10.1128/IAI.60.3.1237-1240.1992; NAGAHAMA M, 1991, TOXICON, V29, P211, DOI 10.1016/0041-0101(91)90105-Z; Nelson KL, 2000, J BIOL CHEM, V275, P19839, DOI 10.1074/jbc.M002785200; Nelson KL, 1999, CELL MICROBIOL, V1, P69, DOI 10.1046/j.1462-5822.1999.00009.x; Payne D.W., 1997, CLOSTRIDIA MOL BIOL, P439; Petit L, 1997, J BACTERIOL, V179, P6480, DOI 10.1128/jb.179.20.6480-6487.1997; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shortt SJ, 2000, HUM EXP TOXICOL, V19, P108, DOI 10.1191/096032700678815710; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Zhu C, 2001, EXP NEUROL, V169, P72, DOI 10.1006/exnr.2001.7652; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	39	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39463	39468		10.1074/jbc.M206731200	http://dx.doi.org/10.1074/jbc.M206731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177068	hybrid			2022-12-25	WOS:000178662500053
J	Panagotopulos, SE; Witting, SR; Horace, EM; Hui, DY; Maiorano, JN; Davidson, WS				Panagotopulos, SE; Witting, SR; Horace, EM; Hui, DY; Maiorano, JN; Davidson, WS			The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; CELLULAR CHOLESTEROL; LIPID-FREE; TANGIER-DISEASE; HELICAL PEPTIDES; PLASMA; HDL; REMOVAL; DOMAINS	Recent studies of Tangier disease have shown that the ATP-binding cassette transporter A1 (ABCA1)/apolipoprotein A-I (apoA-I) interaction is critical for high density lipoprotein particle formation, apoA-I integrity, and proper reverse cholesterol transport. However, the specifics of this interaction are unknown. It has been suggested that amphipathic helices of apoA-I bind to a lipid domain created by the ABCA1 transporter. Alternatively, apoA-I may bind directly to ABCA1 itself. To better understand this interaction, we created several truncation mutants of apoA-I and then followed up with more specific point mutants and helix translocation mutants to identify and characterize the locations of apoA-I required for ABCA1-mediated cholesterol efflux. We found that deletion of residues 221-243 (helix 10) abolished ABCA1-mediated cholesterol efflux from cultured RAW mouse macrophages treated with 8-bromo-cAMP. Point mutations in helix 10 that affected the helical charge distribution reduced ABCA1-mediated cholesterol efflux versus the wild type. We noted a strong positive correlation between cholesterol efflux and the lipid binding characteristics of apoA-I when mutations were made in helix 10. However, there was no such correlation for helix translocations in other areas of the protein as long as helix 10 remained intact at the C terminus. From these observations, we propose an alternative model for apolipoprotein-mediated efflux.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NHLBI NIH HHS [R01 HL62542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; CHAMBENOIT O, 2001, J BIOL CHEM, V281; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; FITZGERALD ML, 2002, J BIOL CHEM; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; MCLEAN LR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P289, DOI 10.1016/0005-2760(93)90231-W; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, PROTEIN EXPRES PURIF, V25, P353, DOI 10.1016/S1046-5928(02)00020-7; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SEGREST JP, 1992, J LIPID RES, V33, P141; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	44	103	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39477	39484		10.1074/jbc.M207005200	http://dx.doi.org/10.1074/jbc.M207005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181325	hybrid			2022-12-25	WOS:000178662500055
J	Silverman, JA; Harbury, PB				Silverman, JA; Harbury, PB			Rapid mapping of protein structure, interactions, and ligand binding by misincorporation proton-alkyl exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CYSTEINE; SITE; DNA; MUTAGENESIS; EFFICIENT; RESIDUES; CLEAVAGE; COMPLEX; VILLIN	Understanding protein conformation, interactions, and ligand binding is essential to all biological inquiry. We report a novel biochemical technique, called mis-incorporation proton-alkyl exchange (MPAX), that can be used to footprint protein structure at single amino acid resolution. MPAX exploits translational misincorporation of cysteine residues to generate probes for physical analysis. We apply MPAX to the triosephosphate isomerase (beta/alpha)(8) barrel, accurately determining its substrate-binding site, a protein-protein interaction surface, the solvent-accessible protein surface, and the stability of the barrel. Because MPAX requires only microgram quantities of material and is not limited by protein size, it is ideally suited for proteins not amenable to conventional structural methods, such as membrane proteins, partially folded or insoluble proteins, and large protein complexes.	Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Harbury, PB (corresponding author), Stanford Univ, Dept Biochem, 279 Campus Dr W, Stanford, CA 94305 USA.	harbury@cmgm.stanford.edu						Arnold U, 1999, ANAL BIOCHEM, V271, P197, DOI 10.1006/abio.1999.4149; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, V1, P11; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Bowers PM, 2000, J BIOMOL NMR, V18, P311, DOI 10.1023/A:1026744431105; BRUNGER AT, 1992, X PLOR; CREIGHTON TE, 1993, PROTEINS, P333; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; DOONAN S, 1975, EUR J BIOCHEM, V56, P421, DOI 10.1111/j.1432-1033.1975.tb02248.x; Doring V, 1998, GENETICS, V150, P543; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Ha JH, 1998, NAT STRUCT BIOL, V5, P730, DOI 10.1038/1436; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HARTMAN JC, 1975, BIOCHEMISTRY-US, V14, P5274; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKI FA, 1989, P NATL ACAD SCI USA, V86, P6696, DOI 10.1073/pnas.86.17.6696; Liu XC, 2000, METHODS MOL BIOL, V147, P119; Park HJ, 1998, MOL CELL BIOL, V18, P4418, DOI 10.1128/MCB.18.8.4418; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Silverman JA, 2001, P NATL ACAD SCI USA, V98, P3092, DOI 10.1073/pnas.041613598; STRYER L, 1996, BIOCHEMISTRY-US, P886; Tu BP, 1999, P NATL ACAD SCI USA, V96, P4862, DOI 10.1073/pnas.96.9.4862; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WILTFANG J, 1991, ELECTROPHORESIS, V12, P352, DOI 10.1002/elps.1150120507; Wu J, 1998, ANAL BIOCHEM, V258, P268, DOI 10.1006/abio.1998.2596	30	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30968	30975		10.1074/jbc.M203172200	http://dx.doi.org/10.1074/jbc.M203172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12185208	hybrid			2022-12-25	WOS:000177579800073
J	Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC				Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC			TGF beta inducible early gene enhances TGF beta/Smad-dependent transcriptional responses	ONCOGENE			English	Article						Smad; TGF beta; TIEG; transcription; zinc-finger	GROWTH-FACTOR-BETA; N-TERMINAL KINASE; TUMOR-SUPPRESSOR GENE; PANCREATIC-CANCER; EPITHELIAL-CELLS; FAMILY MEMBERS; DPC4 GENE; SMAD7; PROTEIN; TIEG	TGFbeta inducible early gene (TIEG) encodes a three zinc-finger Kruppel-like transcription factor whose overexpression has been shown to mimic the effects of TGFbeta in human osteosarcoma and pancreatic carcinoma cells. In order to investigate a potential role of TIEG in the TGFbeta signal transduction pathway, we studied its impact on a Smad binding element (SBE) reporter which is known to be regulated by TGFbeta through the R-Smad proteins. We demonstrate that TIEG overexpression enhances TGFbeta induction of SBE reporter activity. TIEG overexpression also enhances induction of the endogenous TGFbeta regulated genes p21 and PAI-1. The ability of TIEG to enhance TGFbeta actions is Smad dependent since TIEG has no effect on SBE transcription in the absence of Smad4 expression or when an inhibitory Smad protein, Smad7, is overexpressed. Furthermore, TIEG overexpression enhances TGFbeta induced Smad2 phosphorylation. Lastly, TIEG appears to function by binding to and thereby repressing a specific element in the proximal promoter of the inhibitory Smad7 gene. In conclusion, these results describe a novel mechanism for the potentiation of TGFbeta/Smad signaling via repression of the inhibitory Smad7 gene by TIEG.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Spelsberg, TC (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Janknecht, Ralf/0000-0003-1741-1562	NIDCR NIH HHS [1R01 DE14036-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOYER PL, 1993, ONCOGENE, V8, P457; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Fautsch MP, 1998, MAMM GENOME, V9, P838, DOI 10.1007/s003359900878; Frey RS, 1997, CANCER RES, V57, P628; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Imai K, 1999, FEBS LETT, V456, P375, DOI 10.1016/S0014-5793(99)00988-6; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SK, 1996, CANCER RES, V56, P2519; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schutte M, 1996, CANCER RES, V56, P2527; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yajima S, 1997, J NEUROSCI, V17, P8657; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	46	115	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5783	5790		10.1038/sj.onc.1205681	http://dx.doi.org/10.1038/sj.onc.1205681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173049				2022-12-25	WOS:000177463400014
J	Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH				Morrison, KB; Tognon, CE; Garnett, MJ; Deal, C; Sorensen, PH			ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation	ONCOGENE			English	Article						ETV6-NTRK3; IGF1 receptor; IRS-1	FACTOR-I RECEPTOR; CONGENITAL MESOBLASTIC NEPHROMA; DOMINANT-NEGATIVE MUTANT; MOUSE EMBRYO FIBROBLASTS; TYPE-1 IGF RECEPTOR; GENE FUSION; PLECKSTRIN HOMOLOGY; TUMOR PROGRESSION; BREAST-CANCER; INHIBITION	Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation. The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6.-NTRK3 (EN). EN transforms N1H3T3 fibroblasts through constitutive activation of both the Ras-mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'kinase (PI3K)-Akt pathway. However, the role of trisomy 11 in CFS and CMN remains unknown. In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors. Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation. EN only very weakly transformed so-called R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFR1), but transformation activity was fully restored in R cells engineered to re-express IGFRI (R + cells). We also observed that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunoprecipitated with EN in either R- or R+ cells expressing the EN oncoprotein. IRS-1 association with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, respectively, was enhanced in both cell types in the presence of EN. However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R- cells compared to EN-transformed R + cells. This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI. Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.	BC Res Inst Childrens & Womens Hlth, Dept Pathol, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; BC Res Inst Childrens & Womens Hlth, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Hop St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada	University of British Columbia; Universite de Montreal	Sorensen, PH (corresponding author), BC Res Inst Childrens & Womens Hlth, Dept Pathol, Room 3082-950,W 28Th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca						BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERNSTEIN R, 1994, CANCER GENET CYTOGEN, V78, P82, DOI 10.1016/0165-4608(94)90051-5; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Dal Cin P, 1998, CANCER GENET CYTOGEN, V103, P68, DOI 10.1016/S0165-4608(97)00350-6; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Downward J, 1996, CANCER SURV, V27, P87; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Fisher C, 1996, EUR J CANCER, V32A, P2094, DOI 10.1016/S0959-8049(96)00287-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; Hongo A, 1996, ONCOGENE, V12, P1231; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KANEKO Y, 1991, CANCER RES, V51, P5937; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Kriauciunas KM, 2000, MOL CELL BIOL, V20, P6849, DOI 10.1128/MCB.20.18.6849-6859.2000; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MASCARELLO JT, 1994, CANCER GENET CYTOGEN, V77, P50, DOI 10.1016/0165-4608(94)90148-1; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2001, J CELL PHYSIOL, V186, P35; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OMalley DP, 1996, ULTRASTRUCT PATHOL, V20, P417, DOI 10.3109/01913129609016344; Pahlman S, 1996, MOL MED TODAY, V2, P432, DOI 10.1016/1357-4310(96)84847-7; Pass HI, 1996, CANCER RES, V56, P4044; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLYCHRONAKOS C, 1995, DEV GENET, V17, P253, DOI 10.1002/dvg.1020170310; Ponten J, 1971, Virol Monogr, V8, P1; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOFIELD DE, 1994, AM J SURG PATHOL, V18, P14, DOI 10.1097/00000478-199401000-00002; SCHOFIELD DE, 1993, AM J PATHOL, V143, P714; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHARIFAH NA, 1995, DIAGN MOL PATHOL, V4, P279, DOI 10.1097/00019606-199512000-00009; Steller MA, 1996, CANCER RES, V56, P5087; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tognon C, 2001, CANCER RES, V61, P8909; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang W, 1998, CANCER RES, V58, P4426; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Werner H, 1998, MOL CELL ENDOCRINOL, V141, P1, DOI 10.1016/S0303-7207(98)00099-9; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	70	61	63	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5684	5695		10.1038/sj.onc.1205669	http://dx.doi.org/10.1038/sj.onc.1205669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173038				2022-12-25	WOS:000177463400003
J	Katsu, R; Onogi, H; Wada, K; Kawaguchi, Y; Hagiwara, M				Katsu, R; Onogi, H; Wada, K; Kawaguchi, Y; Hagiwara, M			Novel SR-rich-related protein clasp specifically interacts with inactivated Clk4 and induces the exon EB inclusion of Clk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTORS; DOA LOCUS; KINASE; LOCALIZATION; DROSOPHILA; SERINE; PHOSPHORYLATION; NUCLEAR; FAMILY; IDENTIFICATION	We identified a novel serine/arginine (SR)-rich-related protein as a binding partner of Clk4 mutant lacking kinase activity (Clk4 K189R) in the two-hybrid screen and designated it Clasp (Clk4-associating SR-related protein). Northern blot analysis revealed that Clasp mRNA was highly expressed in brain, and in situ hybridization of a mouse brain sagittal section hybridized with antisense probes revealed that both Clasp and Clk4 mRNAs were expressed in the hippocampus, the cerebellum, and the olfactory bulb. Two forms of Clasp were produced by a frameshift following alternative splicing. The staining of An HA-tagged short form of Clasp (ClaspS) showed a nucleoplasmic pattern, while the long form of Clasp (ClaspL) was localized as nuclear dots. In vitro protein interaction assay demonstrated that Clk4 K189R was bound to Clasp while wild Clk4 was not. Overexpression of ClaspL, promoted accumulation of Clk4 K189R in the nuclear dots and the exon EB inclusion from CR-1 and CR-2 pre-mRNA of Clk1. These data suggest that Clasp is a binding partner of Clk4 and may be involved in the regulation of the activity of Clk kinase family.	Tokyo Med & Dent Univ, Dept Funct Genom, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Cell Regulat, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Dept Funct Genom, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	m.hagiwara.end@mri.tmc.ac.jp	Wada, Kazuhiro/A-6548-2012	Kawaguchi, Yasushi/0000-0001-8232-6925				BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DENHEZ F, 1994, J BIOL CHEM, V269, P16170; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Menegay HJ, 2000, J CELL SCI, V113, P3241; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; Prasad J, 1999, MOL CELL BIOL, V19, P6991; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; RABINOW L, 1993, GENETICS, V134, P1175; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Sarkissian M, 1996, J BIOL CHEM, V271, P31106, DOI 10.1074/jbc.271.49.31106; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yoshida K, 1998, MOL BRAIN RES, V57, P241, DOI 10.1016/S0169-328X(98)00089-8; Yun B, 2000, GENETICS, V156, P749; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	42	14	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44220	44228		10.1074/jbc.M206504200	http://dx.doi.org/10.1074/jbc.M206504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12169693	hybrid			2022-12-25	WOS:000179272000090
J	Chenal, A; Savarin, P; Nizard, P; Guillain, F; Gillet, D; Forge, V				Chenal, A; Savarin, P; Nizard, P; Guillain, F; Gillet, D; Forge, V			Membrane protein insertion regulated by bringing electrostatic and hydrophobic interactions into play - A case study with the translocation domain of the diphtheria toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM ATPASE; MOLTEN GLOBULE STATE; T-DOMAIN; ANTIMICROBIAL PEPTIDE; LIPID BILAYERS; CA2+ BINDING; ANIONIC PHOSPHOLIPIDS; TRANSMEMBRANE DOMAIN; ALPHA-LACTALBUMIN; MECHANISM	The study of the membrane insertion of the translocation domain of diphtheria toxin deepens our insight into the interactions between proteins and membranes. During cell intoxication, this domain undergoes a change from a soluble and folded state at alkaline pH to a functional membrane-inserted state at acid pH. We found that hydrophobic and electrostatic interactions occur in a sequential manner between the domain and the membrane during the insertion. The first step involves hydrophobic interactions by the C-terminal region. This is because of the pH-induced formation of a molten globule specialized for binding to the membrane. Accumulation of this molten globule follows a precise molecular mechanism adapted to the toxin function. The second step, as the pH decreases, leads to the functional inserted state. It arises from the changes in the balance of electrostatic attractions and repulsions between the N-terminal part and the membrane. Our study shows how the structural changes and the interaction with membranes of the translocation domain are finely tuned by pH changes to take advantage of the cellular uptake system.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; CEA, UMR 5090, Dept Reponse & Dynam Cellulaire, F-38054 Grenoble 9, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA	Gillet, D (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Gillet, Daniel/C-5592-2008; Chenal, Alexandre/C-2240-2009	Gillet, Daniel/0000-0003-0477-3599; Chenal, Alexandre/0000-0002-4959-1003; Nizard, Philippe/0000-0002-7880-7029				ABRUZOVA A, 2002, BIOCHEM J, V362, P1; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BACKLUND BM, 1994, BBA-BIOMEMBRANES, V1190, P337, DOI 10.1016/0005-2736(94)90092-2; BALBACH J, 1995, NAT STRUCT BIOL, V2, P865, DOI 10.1038/nsb1095-865; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; Booth Paula J., 1999, Current Opinion in Structural Biology, V9, P115, DOI 10.1016/S0959-440X(99)80015-3; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; Chenal A, 2002, J TOXICOL-TOXIN REV, V21, P321, DOI 10.1081/TXR-120014408; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; D'Silva PR, 2000, J BIOL CHEM, V275, P11771, DOI 10.1074/jbc.275.16.11771; Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f; DUMOULIN M, 1908, PROTEIN SCI, V11, P500; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Heymann JB, 1996, BIOCHEMISTRY-US, V35, P2717, DOI 10.1021/bi951535l; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Jamin M, 2001, P NATL ACAD SCI USA, V98, P6127, DOI 10.1073/pnas.111157998; Kachel K, 1998, J BIOL CHEM, V273, P22950, DOI 10.1074/jbc.273.36.22950; Kaul P, 1996, PROTEIN SCI, V5, P687; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; Ladokhin AS, 2001, J MOL BIOL, V309, P543, DOI 10.1006/jmbi.2001.4684; LEENHOUTS JM, 1995, FEBS LETT, V370, P189, DOI 10.1016/0014-5793(95)00823-R; Lemichez E, 1997, MOL MICROBIOL, V23, P445, DOI 10.1111/j.1365-2958.1997.tb02669.x; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; Malenbaum SE, 1998, BIOCHEMISTRY-US, V37, P17915, DOI 10.1021/bi981230h; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P8450, DOI 10.1021/bi960342a; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; Mindell JA, 1998, P NATL ACAD SCI USA, V95, P4081, DOI 10.1073/pnas.95.8.4081; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; Nizard P, 1998, FEBS LETT, V433, P83, DOI 10.1016/S0014-5793(98)00890-4; Nizard P, 2001, PROTEIN ENG, V14, P439, DOI 10.1093/protein/14.6.439; Oh KJ, 1999, BIOCHEMISTRY-US, V38, P10336, DOI 10.1021/bi990520a; Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PRATS M, 1986, NATURE, V322, P756, DOI 10.1038/322756a0; Rankin SE, 1998, BIOCHEMISTRY-US, V37, P12588, DOI 10.1021/bi980408x; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Senzel L, 1998, J GEN PHYSIOL, V112, P317, DOI 10.1085/jgp.112.3.317; Senzel L, 2000, J GEN PHYSIOL, V115, P421, DOI 10.1085/jgp.115.4.421; Smith ER, 1999, J BIOL CHEM, V274, P35325, DOI 10.1074/jbc.274.50.35325; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Umata T, 1998, J BIOL CHEM, V273, P8351, DOI 10.1074/jbc.273.14.8351; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Watts A, 1995, BIOCHEM SOC T, V23, P959, DOI 10.1042/bst0230959; WHITE SH, 1994, CURR OPIN STRUC BIOL, V4, P79, DOI 10.1016/S0959-440X(94)90063-9; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200	65	68	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43425	43432		10.1074/jbc.M204148200	http://dx.doi.org/10.1074/jbc.M204148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12193591	hybrid			2022-12-25	WOS:000179081200127
J	Meng, JW; Casey, PJ				Meng, JW; Casey, PJ			Activation of G(z) attenuates Rap1-mediated differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; HETEROTRIMERIC G-PROTEINS; GTP-BINDING PROTEIN; NERVE GROWTH-FACTOR; CYCLIC-AMP; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; MESSENGER-RNA; RGS PROTEINS; MAP KINASE	We previously identified a specific activation-dependent interaction between the a subunit of the heterotrimeric G protein, G(z), and a regulator of Rap1 signaling, Rap1GAP (Meng, J., Glick, J. L., Polakis, P., and Casey, P. J. (1999) J. Biol. Chem 274, 36663-36669). We now demonstrate that activated forms of Galpha(z) are able to recruit Rap1GAP from a cytosolic location to the membrane. Using PC12 cells as a model for neuronal differentiation, the influence of G(z) activation on Rap1-mediated cell differentiation was examined. Introduction of constitutively-activated Galpha(z) into PC12 cells markedly attenuated the differentiation process of these cells induced by a cAMP analogue. Treatment of PC12 cells expressing wild type Galpha(z) with a specific agonist to the alpha(2A)-adrenergic receptor also attenuated cAMP-induced PC12 cell differentiation, demonstrating that receptor-mediated activation of G(z) was also effective in this regard. Furthermore, activation of G(z) decreased the ability of the cAMP analogue to trigger both Rap1 and extracellular-regulated kinase (ERK) activation. Differentiation of PC12 cells induced by nerve growth factor (NGF) is also thought to be a Rap1-mediated process, and G(z) activation was found to attenuate this process as well. Rap1 activation, ERK phosphorylation, and PC12 cell differentation induced by NGF treatment were all significantly attenuated by either transfection of constitutively activated Galpha(z) or receptor-mediated G(z) activation. Based on these findings, a model is proposed in which activation of G(z) results in recruitment of Rap1GAP to the membrane where it can effectively down-regulate Rap1 signaling. The implications of these findings in regard to a possible role for G(z) in neuronal development are discussed.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu	Meng, Jingwei/K-8880-2015	Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM55717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, R55GM055717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker SA, 2001, GENOMICS, V78, P223, DOI 10.1006/geno.2001.6659; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cavalli A, 2000, J BIOL CHEM, V275, P23693, DOI 10.1074/jbc.M910395199; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; HINTON DR, 1990, J NEUROSCI, V10, P2763; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Inoue K, 2001, FEBS LETT, V506, P180, DOI 10.1016/S0014-5793(01)02809-5; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kelleher KL, 1998, DEV BRAIN RES, V107, P247, DOI 10.1016/S0165-3806(98)00020-0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEE V, 1977, P NATL ACAD SCI USA, V74, P5021, DOI 10.1073/pnas.74.11.5021; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NIBUYA M, 1995, J NEUROSCI, V15, P7539; RAO AK, 1988, BLOOD, V71, P494; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vanvooren V, 2001, EUR J ENDOCRINOL, V144, P605, DOI 10.1530/eje.0.1440605; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	42	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43417	43424		10.1074/jbc.M204074200	http://dx.doi.org/10.1074/jbc.M204074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12198116	hybrid			2022-12-25	WOS:000179081200126
J	O'Rourke, L; Gronning, LM; Yeaman, SJ; Shepherd, PR				O'Rourke, L; Gronning, LM; Yeaman, SJ; Shepherd, PR			Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ACYL-COENZYME; FOAM CELLS; ATHEROSCLEROSIS; EXPRESSION; RESISTANCE; DISEASE; DIFFERENTIATION; ACYLTRANSFERASE; ESTERIFICATION	Insulin resistance, obesity, and diabetes are characterized by hyperglycemia, hyperinsulinemia, and hyperleptinemia and are associated with increased risk of atherosclerosis. In an effort to understand how this occurs, we have investigated whether these factors cause disregulation of cholesterol ester metabolism in J774.2 macrophages. Raising glucose levels alone was sufficient to increase uptake of acetylated low density lipoprotein but did not stimulate synthesis of cholesterol esters. In the presence of high glucose, both insulin and leptin increased the rate of cholesterol ester synthesis, although they did not further increase uptake of acetylated low density lipoprotein. However, in the presence of high glucose both insulin and leptin caused a significant increase in the activity of acyl-CoA. cholesterol O-acyltransferase (ACAT) combined with a significant reduction in the level of hormone-sensitive lipase (HSL). Because ACAT is the main enzyme responsible for cholesterol ester synthesis and HSL contributes significantly to neutral cholesterol ester hydrolase activity, this suggests that glucose primes the J774.2 cells so that in the presence of high insulin or leptin they will store cholesterol esters. This contrasts with 3T3-L1 adipocytes, where HSL activity and expression are increased by insulin in high glucose conditions. These findings may provide an explanation for the observation that in conditions characterized by hyperglycemia, hyperleptinemia, and hyperinsulinemia, triglyceride lipolysis in adipocytes is increased while hydrolysis of cholesterol esters in macrophages is decreased, contributing to foam cell formation.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of London; University College London; Newcastle University - UK	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	p.shepherd@biochem.ucl.ac.uk						BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Botion LM, 1999, DIABETES, V48, P1691, DOI 10.2337/diabetes.48.9.1691; Bressler P, 1996, DIABETOLOGIA, V39, P1345, DOI 10.1007/s001250050581; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Escary JL, 1998, ARTERIOSCL THROM VAS, V18, P991, DOI 10.1161/01.ATV.18.6.991; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Heine RJ, 2002, DIABETOLOGIA, V45, P461, DOI 10.1007/s00125-001-0726-0; James RW, 2001, CURR OPIN LIPIDOL, V12, P425, DOI 10.1097/00041433-200108000-00009; Jepson CA, 1996, BIOCHEM J, V318, P173, DOI 10.1042/bj3180173; KANG ES, 1993, DIABETES, V42, P1415, DOI 10.2337/diabetes.42.10.1415; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; KHOO JC, 1976, J BIOL CHEM, V251, P2882; Laakso M, 1999, DIABETES, V48, P937, DOI 10.2337/diabetes.48.5.937; MAZIERE C, 1987, J BIOCHEM BIOPH METH, V14, P267, DOI 10.1016/0165-022X(87)90052-2; Maziere C, 1996, BBA-LIPID LIPID MET, V1300, P30, DOI 10.1016/0005-2760(95)00232-4; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; O'Rourke L, 2001, DIABETES, V50, P955, DOI 10.2337/diabetes.50.5.955; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Okazaki H, 2002, J BIOL CHEM, V277, P31893, DOI 10.1074/jbc.M204016200; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Raines EW, 1996, BIOESSAYS, V18, P271, DOI 10.1002/bies.950180405; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SMITH F, 2002, DIABETES, V51, P293; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang HX, 1996, ARTERIOSCL THROM VAS, V16, P809, DOI 10.1161/01.ATV.16.6.809; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1; Yip J, 1998, J CLIN ENDOCR METAB, V83, P2773, DOI 10.1210/jc.83.8.2773	38	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42557	42562		10.1074/jbc.M202151200	http://dx.doi.org/10.1074/jbc.M202151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200416	hybrid			2022-12-25	WOS:000179081200018
J	Basu, A; Lu, DM; Sun, BH; Moor, AN; Akkaraju, GR; Huang, J				Basu, A; Lu, DM; Sun, BH; Moor, AN; Akkaraju, GR; Huang, J			Proteolytic activation of protein kinase C-is an element of by caspase-mediated processing and transduction of antiapoptotic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; INDUCED APOPTOSIS; INVOLVEMENT; CLEAVAGE; EPSILON; FAMILY; DELTA; SPECIFICITIES; SENSITIVITY	Several novel protein kinase C (PKC) isozymes have been identified as substrates for caspase-3. We have previously shown that novel PKCepsilon is cleaved during apoptosis in MCF-7 cells that lack any functional caspase-3. In the present study, we show that in vitro-translated PKCepsilon is processed by human recombinant caspase-3, -7, and -9. Tumor necrosis factor-alpha (TNF) triggered processing of PKCepsilon to a 43-kDa carboxyl-terminal fragment, and cell-permeable caspase inhibitors prevented TNF-induced processing of PKCe in MCF-7 cells. PKCepsilon was cleaved primarily at the SSPD down arrow G site to generate two fragments with an approximate molecular mass of 43 kDa. It was also cleaved at the DDVD down arrow C site to generate two fragments with molecular masses of 52 and 35 kDa. Treatment of MCF-7 cells with TNF resulted in the activation of PKCepsilon, and mutation at the SSPD down arrow G (D383A) site inhibited proteolytic activation of PKCepsilon. Overexpression of wild-type but not dominant-negative PKCepsilon in MCF-7 cells delayed TNF-induced apoptosis, and mutation at the D383A site prevented antiapoptotic activity of PKCepsilon. These results suggest that cleavage of PKCepsilon by caspase-7 at the SSPD down arrow G site results in the activation of PKCepsilon. Furthermore, activation of PKCepsilon was associated with its antiapoptotic function.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.			Basu, Alakananda/0000-0002-1656-0788; Sun, Baohua/0000-0003-0393-8099	NATIONAL CANCER INSTITUTE [R01CA071727, R01CA085682] Funding Source: NIH RePORTER; NCI NIH HHS [CA71727, CA85682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU A, 1995, INT J CANCER, V63, P597, DOI 10.1002/ijc.2910630422; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Basu A, 1998, MOL PHARMACOL, V53, P105, DOI 10.1124/mol.53.1.105; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Lavie Y, 1998, INT J CANCER, V77, P928, DOI 10.1002/(SICI)1097-0215(19980911)77:6<928::AID-IJC22>3.0.CO;2-W; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907	27	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41850	41856		10.1074/jbc.M205997200	http://dx.doi.org/10.1074/jbc.M205997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198125	hybrid			2022-12-25	WOS:000178985300071
J	Fukuyama, R; Nakayama, A; Nakase, T; Toba, H; Mukainaka, T; Sakaguchi, H; Saiwaki, T; Wada, M; Sakurai, H; Fushiki, S				Fukuyama, R; Nakayama, A; Nakase, T; Toba, H; Mukainaka, T; Sakaguchi, H; Saiwaki, T; Wada, M; Sakurai, H; Fushiki, S			A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals - Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; KEARNS-SAYRE SYNDROME; CYTOCHROME-C-OXIDASE; ALZHEIMERS-DISEASE; MITOCHONDRIAL-DNA; MEDIATED APOPTOSIS; PARKINSONS-DISEASE; FRIEDREICH ATAXIA; LACKING MTDNA; PHOSPHORYLATION	From human neuroblastoma-derived SILA cells we have established a p-0 cell line that is deficient in both respiration and mitochondrial DNA. Lactate dehydrogenase activity, lactate production, and growth in the medium without glucose indicate that these cells shift from aerobic to anaerobic metabolism. Electron microscopic observations revealed abnormal mitochondria with unique cristae structures. Staining with MitoTracker dye showed that the mitochondrial transmembrane potential was reduced by 30-40% from the parent cell levels. These cells were markedly susceptible to H2O2 and died apparently by a necrotic mechanism, a process blocked by deferoxamine in the parent cells but not p-0 cells. Analysis by inductively coupled plasma-mass spectrometry revealed an approximately 3-fold accumulation of iron in the p-0 cells at confluence (n = 4-6, three clones, *p < 0.05). Iron and four other metals were all elevated in the cells of one of the p-0 clones and were similar to control levels in the control cybrid cells, which were replenished with normal mitochondrial DNA. Their sensitivity to H2O2 was also similar to that of the parent cells. These results indicate that a newly established neuronal related p-0 cell line is highly susceptible to active oxygen species and that these toxicity effects appear to be related to an accumulation of transition metals, which probably occurs through the respiratory impairment.	Kyoto Prefectural Univ Med, Dept Pathol & Appl Neurobiol, Res Inst Neurol Dis & Geriatr, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Cent Lab, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Dept Otolaryngol, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Pharmaceut Univ, Dept Analyt & Bioinorgan Chem, Yamashina Ku, Kyoto 6078414, Japan; Kyoto Pharmaceut Univ, Dept Clin Pharmacol, Yamashina Ku, Kyoto 6078414, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto Pharmaceutical University; Kyoto Pharmaceutical University	Fukuyama, R (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Alzheimers Res Lab, E504,10900 Euclid Ave, Cleveland, OH 44106 USA.							Aksenov MY, 1999, NEUROCHEM RES, V24, P767, DOI 10.1023/A:1020783614031; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Asoh S, 1997, BIOCHEM BIOPH RES CO, V237, P659, DOI 10.1006/bbrc.1997.7210; BALOYANNIS K, 2000, NEUROBIOL AGING, V21, pS264; Bartzokis G, 2000, CELL MOL BIOL, V46, P821; Beauchemin D, 1998, ANAL CHEM, V70, P1026, DOI 10.1021/ac970783f; Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Delatycki MB, 1999, ANN NEUROL, V45, P673, DOI 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.3.CO;2-H; DIEBEL MA, 1996, J NEUROL SCI, V143, P137; Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25; Fukuyama R, 1996, BRAIN RES, V713, P290, DOI 10.1016/0006-8993(95)01517-5; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUTTERIDGE JMC, 1994, ANN NY ACAD SCI, V738, P201; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; HUG G, 1970, LAB INVEST, V22, P541; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LOEFFLER DA, 1995, J NEUROCHEM, V65, P710; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marrif H, 1999, J NEUROSCI RES, V57, P255; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; Matsumura T, 1989, Hum Cell, V2, P206; Miller SW, 1996, J NEUROCHEM, V67, P1897; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MORAIS R, 1980, J CELL PHYSIOL, V103, P455, DOI 10.1002/jcp.1041030311; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Nakayama A, 2002, BIOL PHARM BULL, V25, P426, DOI 10.1248/bpb.25.426; OKUSKY J, 1983, ACTA NEUROPATHOL, V61, P116, DOI 10.1007/BF00697390; PORTER JB, 1988, BLOOD, V72, P1497; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; Saiwaki T, 2000, J CLIN PATHOL-MOL PA, V53, P333, DOI 10.1136/mp.53.6.333; SCHWARTZKOPFF B, 1988, J AM COLL CARDIOL, V12, P1522, DOI 10.1016/S0735-1097(88)80020-2; SCHWARTZKOPFF B, 1991, VIRCHOWS ARCH A, V419, P63, DOI 10.1007/BF01600154; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; SOSLAU G, 1971, J CELL BIOL, V51, P514, DOI 10.1083/jcb.51.2.514; STEWART MA, 1965, J NEUROCHEM, V12, P719, DOI 10.1111/j.1471-4159.1965.tb06786.x; Thomas F, 1999, HEALTH CARE FINANC R, V20, P1; Thompson KJ, 2001, BRAIN RES BULL, V55, P155, DOI 10.1016/S0361-9230(01)00510-X; Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333; VAILLANT F, 1991, BIOCHEM INT, V23, P571; VANDOMBURG PHM, 1996, BRAIN, V199, P997; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	53	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41455	41462		10.1074/jbc.M204176200	http://dx.doi.org/10.1074/jbc.M204176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194972	hybrid			2022-12-25	WOS:000178985300022
J	Gengs, CX; Leung, HT; Skingsley, DR; Iovchev, MI; Yin, Z; Semenov, EP; Burg, MG; Hardie, RC; Pak, WL				Gengs, CX; Leung, HT; Skingsley, DR; Iovchev, MI; Yin, Z; Semenov, EP; Burg, MG; Hardie, RC; Pak, WL			The target of Drosophila photoreceptor synaptic transmission is a histamine-gated chloride channel encoded by ort (hclA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; RECEPTOR; MELANOGASTER; MUTATIONS; CLONING; IDENTIFICATION; EXPRESSION; PROTEINS; SEQUENCE; DOMAINS	By screening Drosophila mutants that are potentially defective in synaptic transmission between photoreceptors and their target laminar neurons, L1/L2, (lack of electroretinogram on/off transients), we identified ort as a candidate gene encoding a histamine receptor subunit on Ll/L2. We provide evidence that the ort gene corresponds to CG7411 (referred to as hclA), identified in the Drosophila genome data base, by P-element-mediated germ line rescue of the ort phenotype using cloned hclA cDNA and by showing that several ort mutants exhibit alterations in hclA regulatory or coding sequences and/or allele-dependent reductions in hclA transcript levels. Other workers have shown that hclA, when expressed in Xenopus oocytes, forms histamine-sensitive chloride channels. However, the connection between these chloride channels and photoreceptor synaptic transmission was not established. We show unequivocally that hclA-encoded channels are the channels required in photoreceptor synaptic transmission by 1) establishing the identity between hclA and ort and 2) showing that ort mutants are defective in photoreceptor synaptic transmission. Moreover, the present work shows that this function of the HCLA (ORT) protein is its native function in vivo.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Cambridge, Dept Anat, Cambridge CB2 3EJ, England; Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Cambridge; University of Cambridge; Bulgarian Academy of Sciences	Pak, WL (corresponding author), Purdue Univ, Dept Biol Sci, 1392 Lilly Hall, W Lafayette, IN 47907 USA.			Hardie, Roger/0000-0001-5531-3264; Skingsley, David/0000-0003-1025-7574	NEI NIH HHS [EY00033] Funding Source: Medline; NIMH NIH HHS [MH49727] Funding Source: Medline; NATIONAL EYE INSTITUTE [R56EY000033, R01EY000033, R37EY000033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049727] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; BURG MG, 1993, EMBO J, V12, P911, DOI 10.1002/j.1460-2075.1993.tb05732.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cully DF, 1996, J BIOL CHEM, V271, P20187, DOI 10.1074/jbc.271.33.20187; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13474, DOI 10.1073/pnas.96.23.13474; LINDSLEY DL, 1990, DROSOPHILA INFORMATI, V68, P100; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Nguyen T, 2001, MOL PHARMACOL, V59, P427, DOI 10.1124/mol.59.3.427; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; Pak W.L., 1979, P67; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 2002, IN PRESS RECEPTORS C; PAK WL, 1975, HDB GENETICS, V3, P703; PETROVICH TZ, 1993, GENETICS, V133, P955; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Semenov EP, 1999, J NEUROCHEM, V72, P66, DOI 10.1046/j.1471-4159.1999.0720066.x; SKINGSLEY DR, 1995, J COMP PHYSIOL A, V176, P611, DOI 10.1007/BF01021581; Stuart AE, 1999, NEURON, V22, P431, DOI 10.1016/S0896-6273(00)80699-6; Sved J, 1986, DROSOPH INF SERV, V63, P169; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	33	91	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42113	42120		10.1074/jbc.M207133200	http://dx.doi.org/10.1074/jbc.M207133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196539	hybrid			2022-12-25	WOS:000178985300102
J	Lecat, S; Bucher, B; Mely, Y; Galzi, JL				Lecat, S; Bucher, B; Mely, Y; Galzi, JL			Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE G-PROTEINS; HAMSTER OVARY CELLS; SUBSTANCE-P; BETA(2)-ADRENERGIC RECEPTOR; ACETYLCHOLINE-RECEPTOR; DOPAMINE-RECEPTORS; LIGAND-BINDING; NK-1 RECEPTOR; HIGH-AFFINITY; KINASE-A	By combining real time measurements of agonist binding, by fluorescence resonance energy transfer, and of subsequent responses, we proposed previously that the neurokinin NK2 receptor preexists in equilibrium between three states: inactive, calcium-triggering, and cAMP-producing. Thr(24) and Phe(26) of the NK2 receptor extracellular domain are considered to interact with neuropeptide agonists based on the reduction of affinity when they are substituted by alanine. Using fluorescence resonance energy transfer, we now quantify the binding kinetics of two Texas Red-modified neurokinin A agonists to the fluorescent wild-type (Y-NK2wt) an the mutant (Y-NK2mut) receptor carrying Thr(24) --> Ala and Phe(26) --> Ala mutations. TR1-neurokinin A binds with a fast component and a slow component to the Y-NK2wt receptor and triggers both a calcium and a cAMP response. In contrast, on the mutant receptor, it binds in a single fast step with a lower apparent affinity and activates only the calcium response. Another agonist, TRC4-neurokinin A, binds to both wild-type and mutant receptors in a single fast step, with similar affinities and kinetics and promotes only calcium signaling. Kinetic modeling of ligand binding and receptor interconversions is carried out to analyze phenotypic changes in terms of binding alterations or changes in the transitions between conformational states. We show that the binding and response properties of the Y-NK2mut receptor are best described according to a phenotype where a reduction of the transition between the inactive and the active states occurs.	Ecole Super Biotechnol Strasbourg, CNRS, UPR Recepteurs & Prot Membranaires 9050, F-67400 Illkirch Graffenstaden, France; Univ Louis Pasteur Strasbourg 1, CNRS, UMR Pharmacol & Physicochim Interact Cellulaires, Fac Pharm, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Galzi, JL (corresponding author), Ecole Super Biotechnol Strasbourg, CNRS, UPR Recepteurs & Prot Membranaires 9050, Blvd Sebastien Brandt, F-67400 Illkirch Graffenstaden, France.							ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Bremer AA, 2000, FEBS LETT, V486, P43, DOI 10.1016/S0014-5793(00)02228-6; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; Catalioto RM, 1998, N-S ARCH PHARMACOL, V358, P395, DOI 10.1007/PL00005270; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Ciucci A, 1998, BRIT J PHARMACOL, V125, P393, DOI 10.1038/sj.bjp.0702070; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; Fuchs S, 2001, MOL MED, V7, P115, DOI 10.1007/BF03401945; Galzi JL, 1996, P NATL ACAD SCI USA, V93, P1853, DOI 10.1073/pnas.93.5.1853; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Grammatopoulos DK, 2001, J NEUROCHEM, V76, P509, DOI 10.1046/j.1471-4159.2001.00067.x; Hawes BE, 2000, ENDOCRINOLOGY, V141, P4524, DOI 10.1210/en.141.12.4524; HEIDMANN T, 1980, BIOCHEM BIOPH RES CO, V97, P889, DOI 10.1016/0006-291X(80)91460-6; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; Imamura F, 2000, BIOCHEMISTRY-US, V39, P686, DOI 10.1021/bi991981z; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; KIMURA K, 1995, J NEUROCHEM, V64, P2118; Labrou NE, 1999, PEPTIDES, V20, P795, DOI 10.1016/S0196-9781(99)00064-9; Labrou NE, 2001, J BIOL CHEM, V276, P37944; Lawler OA, 2001, J BIOL CHEM, V276, P33596, DOI 10.1074/jbc.M104434200; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Lorenzen A, 1998, BIOCHEM PHARMACOL, V56, P1287, DOI 10.1016/S0006-2952(98)00207-X; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; Pindon A, 2002, MOL PHARMACOL, V61, P85, DOI 10.1124/mol.61.1.85; Roush ED, 1998, FEBS LETT, V428, P291, DOI 10.1016/S0014-5793(98)00553-5; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; Sidhu A, 1998, MOL NEUROBIOL, V16, P125, DOI 10.1007/BF02740640; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139	40	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42034	42048		10.1074/jbc.M203606200	http://dx.doi.org/10.1074/jbc.M203606200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12185075	hybrid			2022-12-25	WOS:000178985300093
J	Misra, UK; Gonzalez-Gronow, M; Gawdi, G; Hart, JP; Johnson, CE; Pizzo, SV				Misra, UK; Gonzalez-Gronow, M; Gawdi, G; Hart, JP; Johnson, CE; Pizzo, SV			The role of Grp 78 in alpha(2)-macroglobulin-induced signal transduction - Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, Grp 78-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEVATES INTRACELLULAR CALCIUM; METHYL-D-ASPARTATE; RECOGNIZED FORMS; PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR; PARTIAL-PURIFICATION; BINDING; ALPHA-2-MACROGLOBULIN; LIGATION; SOLUBILIZATION; ALPHA(2)M	The low density lipoprotein receptor-related protein (LRP) is a scavenger receptor that binds to many proteins, some of which trigger signal transduction. Receptor-recognized forms of alpha(2)-Macroglobulin (alpha(2)M*) bind to LRP, but the pattern of signal transduction differs significantly from that observed with other LRP ligands. For example, neither Ni2+ nor the receptor-associated protein, which blocks binding of all known ligands to LRP, block alpha(2)M*-induced signal transduction. In the current study, we employed alpha(2)-macroglobulin (alpha(2)M)agarose column chromatography to purify cell surface membrane binding proteins from 1-LN human prostate cancer cells and murine macrophages. The predominant binding protein purified from 1-LN prostate cancer cells was Grp 78 with small amounts of LRP, a fact that is consistent with our previous observations that there is little LRP present on the surface of these cells. The ratio of LRP:Grp 78 is much higher in macrophages. Flow cytometry was employed to demonstrate the presence of Grp 78 on the cell surface of 1-LN cells. Purified Grp 78 binds to alpha(2)M* with high affinity (K-d similar to150 pm). A monoclonal antibody directed against Grp 78 both abolished alpha(2)M*-induced signal transduction and co-precipitated LRP. Ligand blotting with alpha(2)M* showed binding to both Grp 78 and LRP heavy chains in these preparations. Use of RNA interference to silence LRP expression had no effect on alpha(2)M*-mediated signaling. We conclude that Grp 78 is essential for alpha(2)M*-induced signal transduction and that a "co-receptor" relationship exists with LRP like that seen with several other ligands and receptors such as the uPA/uPAR (urinary type plasminogen activator or urokinase/uPA receptor) system.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	pizzo001@mc.duke.edu						Asplin IR, 2000, ARCH BIOCHEM BIOPHYS, V383, P135, DOI 10.1006/abbi.2000.2052; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Berger CL, 1997, INT J CANCER, V71, P1077; Delpino A, 1998, MOL MEMBR BIOL, V15, P21, DOI 10.3109/09687689809027514; DICKSON RB, 1981, FEBS LETT, V126, P265, DOI 10.1016/0014-5793(81)80257-8; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; HANOVER JA, 1983, J BIOL CHEM, V258, P370; HANOVER JA, 1983, ANN NY ACAD SCI, V421, P410, DOI 10.1111/j.1749-6632.1983.tb18135.x; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; JENSEN PEH, 1989, BIOCHEM ARCH, V5, P171; Jorgensen MM, 2000, J BIOL CHEM, V275, P33861, DOI 10.1074/jbc.M004663200; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; Misra UK, 1997, J BIOL CHEM, V272, P497; Misra UK, 1999, J BIOL CHEM, V274, P25785, DOI 10.1074/jbc.274.36.25785; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V372, P238, DOI 10.1006/abbi.1999.1521; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; Misra UK, 2002, J BIOL CHEM, V277, P36509, DOI 10.1074/jbc.M203543200; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V363, P68, DOI 10.1006/abbi.1998.1074; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Odom AR, 1997, BIOCHEMISTRY-US, V36, P12395, DOI 10.1021/bi970806k; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Triantafilou M, 2001, HUM IMMUNOL, V62, P764, DOI 10.1016/S0198-8859(01)00269-5; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WU S, 2001, HEMOSTASIS THROMBOSE, P367; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	38	117	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42082	42087		10.1074/jbc.M206174200	http://dx.doi.org/10.1074/jbc.M206174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194978	hybrid			2022-12-25	WOS:000178985300098
J	Planey, SL; Derfoul, A; Steplewski, A; Robertson, NM; Litwack, G				Planey, SL; Derfoul, A; Steplewski, A; Robertson, NM; Litwack, G			Inhibition of glucocorticoid-induced apoptosis in 697 pre-B lymphocytes by the mineralocorticoid receptor N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 HOMOLOG; CASPASE ACTIVATION; DEATH RECEPTORS; CELL-DEATH; KAPPA-B; MITOCHONDRIA; PROTEIN; HETERODIMERIZATION; TRANSACTIVATION	The glucocorticoid and mineralocorticoid receptors (GR and MR) share considerable structural and functional homology and bind as homodimers to hormone-response elements. We have shown previously that MR and GR can form heterodimers that inhibit transcription from a glucocorticoid (GC)-responsive gene and that this inhibition was mediated by the N-terminal domain (NTD) of MR. In this report, we examined the effect of NTD-MR on GC-induced apoptosis in the GC-sensitive pre-B lymphoma cell line, 697. In GC-treated 697 cells, we demonstrated that stable expression of NTD-MR blocks apoptosis and inhibits proteolytic processing of pro-caspases-3, -8, and -9 and poly(ADP-ribose) polymerase. Importantly, gel shift and immunoprecipitation analyses revealed a direct association between the GR and amino acids 203-603 of NTD-MR. We observed down-regulation of c-Myc and of the anti-apoptotic proteins Bcl-2 and Bfl-1 as well as high levels of the proapoptotic proteins Bax and Bid. Conversely, cells stably expressing NTD-MR exhibited increased expression of Bcl-2 and Bfl-1 and diminished levels of Bid and Bax. These data provide a potential mechanism for the observed inhibition of cytochrome c and Smac release from the mitochondria of NTD-MR cells and resultant resistance to GC-induced apoptosis. Thus, NTD-MR may mediate GC effects through heterodimerization with GR and ensuing inhibition of GC-regulated gene transcription.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University	Litwack, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, 233 S 10th St,BLSB 350, Philadelphia, PA 19107 USA.	Gerry.Litwack@mail.tju.edu	Lobo, Sonia/H-6889-2018	Lobo, Sonia/0000-0002-7406-6956	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/HL 40976] Funding Source: Medline; NIDDK NIH HHS [5T32 DK07705] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida OFX, 2000, FASEB J, V14, P779, DOI 10.1096/fasebj.14.5.779; ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ALNEMRI ES, 1992, CANCER RES, V52, P491; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Derfoul A, 2000, ENDOCRINE, V13, P287, DOI 10.1385/ENDO:13:3:287; Derfoul A, 1998, J BIOL CHEM, V273, P20702, DOI 10.1074/jbc.273.33.20702; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; DSaEipper C, 1996, CANCER RES, V56, P3879; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W; Feinman R, 1999, BLOOD, V93, P3044; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HARBOUR DV, 1990, J STEROID BIOCHEM, V35, P1, DOI 10.1016/0022-4731(90)90137-H; Hassan AHS, 1996, EXP NEUROL, V140, P43, DOI 10.1006/exnr.1996.0113; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU W, 1995, MOL CELL BIOL, V15, P1005; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Robertson NM, 1997, CANCER RES, V57, P43; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THOMPSON EB, 1995, ANN NY ACAD SCI, V761, P261, DOI 10.1111/j.1749-6632.1995.tb31383.x; Trapp T, 1996, TRENDS PHARMACOL SCI, V17, P145, DOI 10.1016/0165-6147(96)81590-2; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; vanSteensel B, 1996, J CELL SCI, V109, P787; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wickert L, 1998, EUR J ENDOCRINOL, V138, P702, DOI 10.1530/eje.0.1380702; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; Zennaro MC, 1997, J CLIN ENDOCR METAB, V82, P1345, DOI 10.1210/jc.82.5.1345; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	69	29	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42188	42196		10.1074/jbc.M205085200	http://dx.doi.org/10.1074/jbc.M205085200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194973	hybrid			2022-12-25	WOS:000178985300112
J	Willcockson, IU; Hong, AL; Whisenant, RP; Edwards, JB; Wang, HJ; Sarkar, HK; Pedersen, SE				Willcockson, IU; Hong, AL; Whisenant, RP; Edwards, JB; Wang, HJ; Sarkar, HK; Pedersen, SE			Orientation of d-tubocurarine in the muscle nicotinic acetylcholine receptor-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONOTOXIN MI; GAMMA-SUBUNIT; DELTA-SUBUNIT; COMPETITIVE ANTAGONISTS; PAIRWISE INTERACTIONS; MOLECULAR DISSECTION; CRYSTAL-STRUCTURE; AMINO-ACIDS; IDENTIFICATION; RESIDUES	Ligand modification and receptor site-directed mutagenesis were used to examine binding of the competitive antagonist, d-tubocurarine (dTC), to the muscle-type nicotinic acetylcholine receptor (AChR). By using various dTC analogs, we measured the interactions of specific dTC functional groups with amino acid positions in the AChR gamma-subunit. Because data for mutations at residue gammaTyr(117) were the most consistent with direct interaction with dTC, we focused on that residue. Double mutant thermodynamic cycle analysis showed apparent interactions of gammaTyr(117) with both the 2-N and the 13'-positions of dTC. Examination of a dTC analog with a negative charge at the 13'-position failed to reveal electrostatic interaction with charged side-chain substitutions at gamma117, but the effects of side-chain substitutions remained consistent with proximity of Tyr(117) to the cationic 2-N of dTC. The apparent interaction of,gammaTyr(117) with the 13'-position of dTC was likely mediated by allosteric changes in either dTC or the receptor. The data also show that cation-pi electron stabilization of the 2-N position is not required for high affinity binding. Molecular modeling of dTC within the binding pocket of the acetylcholine-binding protein places the 2-N in proximity to the residue homologous to gammaTyr(117). This model provides a plausible structural basis for binding of dTC within the acetylcholine-binding site of the AChR family that appears consistent with findings from photoaffinity labeling studies and with site-directed mutagenesis studies of the AChR.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Pedersen, SE (corresponding author), Baylor Coll Med, Dept Mol Physiol, 1 Baylor Plaza, Houston, TX 77030 USA.	pedersen@bcm.tmc.edu		Pedersen, Steen E./0000-0001-8755-8899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035212] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07676] Funding Source: Medline; NINDS NIH HHS [NS35212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CODDING PW, 1972, J CHEM SOC CHEM COMM, P1174, DOI 10.1039/c39720001174; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; Densmore CL, 2000, MOL THER, V1, P180, DOI 10.1006/mthe.1999.0021; DUTCHER JD, 1952, J AM CHEM SOC, V74, P2221, DOI 10.1021/ja01129a021; FILATOV GN, 1993, MOL PHARMACOL, V44, P237; FU DX, 1994, J BIOL CHEM, V269, P26152; KAO PN, 1986, J BIOL CHEM, V261, P8085; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Papineni RVL, 1997, J BIOL CHEM, V272, P24891, DOI 10.1074/jbc.272.40.24891; Papineni RVL, 2001, J BIOL CHEM, V276, P23589, DOI 10.1074/jbc.M102350200; Pedersen S E, 1999, Methods Enzymol, V294, P117; Pedersen SE, 1995, J BIOL CHEM, V270, P31141, DOI 10.1074/jbc.270.52.31141; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1998, J BIOL CHEM, V273, P7843, DOI 10.1074/jbc.273.14.7843; REYNOLDS CD, 1976, ACTA CRYSTALLOGR B, V32, P1431, DOI 10.1107/S0567740876005517; REYNOLDS CD, 1975, BIOCHIM BIOPHYS ACTA, V404, P341, DOI 10.1016/0304-4165(75)90342-6; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SOBELL HM, 1972, P NATL ACAD SCI USA, V69, P2212, DOI 10.1073/pnas.69.8.2212; Wang D, 2000, J BIOL CHEM, V275, P28666, DOI 10.1074/jbc.M005441200; WILSON PT, 1988, MOL PHARMACOL, V34, P643; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZHOROV BS, 1993, J MEMBRANE BIOL, V135, P19	38	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42249	42258		10.1074/jbc.M205383200	http://dx.doi.org/10.1074/jbc.M205383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196523	hybrid			2022-12-25	WOS:000178985300120
J	Zamze, S; Martinez-Pomares, L; Jones, H; Taylor, PR; Stillion, RJ; Gordon, S; Wong, SYC				Zamze, S; Martinez-Pomares, L; Jones, H; Taylor, PR; Stillion, RJ; Gordon, S; Wong, SYC			Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; KLEBSIELLA-PNEUMONIAE; BINDING LECTIN; DENDRITIC CELLS; CONFORMATIONAL-ANALYSIS; NEISSERIA-MENINGITIDIS; POLYACRYLAMIDE GELS; ENDOTHELIAL-CELLS; INNATE IMMUNITY; MARGINAL ZONE	The in vitro binding of the macrophage mannose receptor to a range of different bacterial polysaccharides was investigated. The receptor was shown to bind to purified capsular polysaccharides from Streptococcus pneumoniae and to the lipopolysaccharides, but not capsular polysaccharides, from Klebsiella pneumoniae. Binding was Ca2+-dependent and inhibitable with D-mannose. A fusion protein of the mannose receptor containing carbohydrate recognition domains 4-7 and a full-length soluble form of the mannose receptor containing all domains external to the transmembrane region both displayed very similar binding specificities toward bacterial polysaccharides, suggesting that domains 4-7 are sufficient for recognition of these structures. Surprisingly, no direct correlation could be made between polysaccharide structure and binding to the mannose receptor, suggesting that polysaccharide conformation may play an important role in recognition. The full-length soluble form of the mannose receptor was able to bind simultaneously both polysaccharide via the carbohydrate recognition domains and sulfated oli-gosaccharide via the cysteine-rich domain. The possible involvement of the mannose receptor, either cell surface or soluble, in the innate and adaptive immune responses to bacterial polysaccharides is discussed.	Edward Jenner Inst Vaccine Res, Compton RG20 7NN, Berks, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Zamze, S (corresponding author), Edward Jenner Inst Vaccine Res, Compton RG20 7NN, Berks, England.			Taylor, Philip/0000-0003-0163-1421; Martinez-Pomares, Luisa/0000-0002-2331-127X				Albanyan EA, 2000, INFECT IMMUN, V68, P5794, DOI 10.1128/IAI.68.10.5794-5802.2000; ANDERSEN SR, 1995, MICROB PATHOGENESIS, V19, P159, DOI 10.1006/mpat.1995.0054; ATHAMNA A, 1991, INFECT IMMUN, V59, P1673, DOI 10.1128/IAI.59.5.1673-1682.1991; Berney C, 1999, J EXP MED, V190, P851, DOI 10.1084/jem.190.6.851; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; CESCUTTI P, 1993, EUR J BIOCHEM, V213, P445, DOI 10.1111/j.1432-1033.1993.tb17780.x; CIUFFREDA P, 1992, CARBOHYD RES, V232, P327, DOI 10.1016/0008-6215(92)80064-8; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Devyatyrova-Johnson M, 2000, INFECT IMMUN, V68, P3894, DOI 10.1128/IAI.68.7.3894-3899.2000; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUTTON GGS, 1986, CARBOHYD RES, V149, P411, DOI 10.1016/S0008-6215(00)90061-2; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; Hansen DS, 1999, J CLIN MICROBIOL, V37, P56, DOI 10.1128/JCM.37.1.56-62.1999; Harms G, 1996, INFECT IMMUN, V64, P4220, DOI 10.1128/IAI.64.10.4220-4225.1996; ISAAC DH, 1985, POLYSACCHARIDES TOPI, P141; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JENNINGS HJ, 1996, POLYSACCHARIDES MED, P443; JONES C, 1991, CARBOHYD RES, V221, P95, DOI 10.1016/0008-6215(91)80051-N; Kenne L., 1983, POLYSACCHARIDES, P287; KNUTSON CA, 1968, ANAL BIOCHEM, V24, P470, DOI 10.1016/0003-2697(68)90154-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; Linehan SA, 2001, EUR J IMMUNOL, V31, P1857, DOI 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D; Martinez-Pomares L, 1998, J BIOL CHEM, V273, P23376, DOI 10.1074/jbc.273.36.23376; Martinez-Pomares L, 1999, IMMUNOLOGIST, V7, P119; MartinezPomares L, 1996, J EXP MED, V184, P1927, DOI 10.1084/jem.184.5.1927; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; ORSKOV I, 1984, METHOD MICROBIOL, V14, P143, DOI 10.1016/S0580-9517(08)70449-5; PAROLIS LAS, 1988, CARBOHYD RES, V179, P301, DOI 10.1016/0008-6215(88)84126-0; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAVENSCROFT N, 1987, CARBOHYD RES, V167, P257, DOI 10.1016/0008-6215(87)80283-5; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; RUTHERFORD TJ, 1994, CARBOHYD RES, V265, P79, DOI 10.1016/0008-6215(94)80084-7; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Stenutz R, 1997, CARBOHYD RES, V302, P79, DOI 10.1016/S0008-6215(97)00106-7; STRAUS DC, 1987, INFECT IMMUN, V55, P44, DOI 10.1128/IAI.55.1.44-48.1987; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Thornton BP, 1996, J IMMUNOL, V156, P1235; TOMAS JM, 1991, INFECT IMMUN, V59, P2006; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WESSELS MR, 1989, J EXP MED, V169, P2121, DOI 10.1084/jem.169.6.2121; WESTPHAL O, 1965, METHODS CARB CHEM, V5, P453	60	163	171	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41613	41623		10.1074/jbc.M207057200	http://dx.doi.org/10.1074/jbc.M207057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196537	hybrid			2022-12-25	WOS:000178985300041
J	Dainese, E; Minafra, R; Sabatucci, A; Vachette, P; Melloni, E; Cozzani, I				Dainese, E; Minafra, R; Sabatucci, A; Vachette, P; Melloni, E; Cozzani, I			Conformational changes of calpain from human erythrocytes in the presence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SOLUTION SCATTERING; BIOLOGICAL MACROMOLECULES; CATALYTIC SUBUNIT; ACTIVE-SITE; DOMAIN-VI; EF-HAND; CELL; DISSOCIATION; RESOLUTION	Small angle x-ray scattering has been used to monitor calpain structural transitions during the activation process triggered by Ca2+ binding. The scattering pattern of the unliganded enzyme in solution does not display any significant difference with that calculated from the crystal structure. The addition of Ca2+ promotes the formation of large aggregates, indicating the exposure of hydrophobic patches on the surface of the protease. In contrast, Ca2+ addition in the presence of the thiol proteinase inhibitor E64 or of the inhibitor leupeptin causes a small conformational change with no dissociation of the heterodimer. The resulting conformation appears to be slightly more extended than the unliganded form. From the comparison between ab initio models derived from our data with the crystal structure, the major observable conformational change appears to be localized at level of the L-subunit and in particular seems to confirm the mutual movement already observed by the crystallographic analysis of the dII (dIIb) and the dI (dIIa) domains creating a functional active site. This work not only provides another piece of supporting evidence for the calpain conformational change in the presence of Ca2+, but actually constitutes the first experimental observation of this change for intact heterodimeric calpain in solution.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Univ Paris 11, Utilisat Rayonnement Electromagnet Lab, F-91898 Orsay, France; Univ Genoa, Ctr Excellence Biomed Res, I-16032 Genoa, Italy; Univ Genoa, Dept Expt Med, I-16032 Genoa, Italy	University of Teramo; UDICE-French Research Universities; Universite Paris Saclay; University of Genoa; University of Genoa	Dainese, E (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.	dainese@unite.it	; SABATUCCI, Annalaura/E-9996-2013	Dainese, Enrico/0000-0001-7163-9344; SABATUCCI, Annalaura/0000-0002-8004-2547				Bessiere BA, 1999, BBA-PROTEIN STRUCT M, V1430, P254, DOI 10.1016/S0167-4838(99)00006-0; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; Cygler Miroslaw, 2002, Methods Mol Biol, V172, P243; Dainese E, 1998, EUR J BIOCHEM, V256, P350, DOI 10.1046/j.1432-1327.1998.2560350.x; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Guinier A., 1955, SMALL ANGLE SCATTERI; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Melloni E, 1996, BIOCHEM BIOPH RES CO, V229, P193, DOI 10.1006/bbrc.1996.1779; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nakagawa K, 2001, J BIOCHEM-TOKYO, V130, P605, DOI 10.1093/oxfordjournals.jbchem.a003025; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Pontremoli S, 1999, CALCIUM AS A CELLULAR REGULATOR, P371; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; Santella L, 2000, EXP CELL RES, V259, P117, DOI 10.1006/excr.2000.4969; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suo S, 1999, BIOCHEM BIOPH RES CO, V257, P63, DOI 10.1006/bbrc.1999.0407; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L	44	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40296	40301		10.1074/jbc.M204471200	http://dx.doi.org/10.1074/jbc.M204471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189137	hybrid			2022-12-25	WOS:000178791400020
J	Hill, JJ; Davies, MV; Pearson, AA; Wang, JH; Hewick, RM; Wolfman, NM; Qiu, YC				Hill, JJ; Davies, MV; Pearson, AA; Wang, JH; Hewick, RM; Wolfman, NM; Qiu, YC			The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MOLECULAR-WEIGHT COMPLEX; TRANSCRIPTION ACTIVATION; TRANSGENIC MICE; HUMAN-PLATELETS; MUSCLE GROWTH; PRO DOMAIN; ACTIVIN-A; FACTOR-BETA-1; CELLS	Myostatin, also known as growth and differentiation factor 8, is a member of the transforming growth factor 13 superfamily that negatively regulates skeletal muscle mass (1). Recent experiments have shown that myostatin activity is detected in serum by a reporter gene assay only after activation by acid, suggesting that native myostatin circulates as a latent complex (2). We have used a monoclonal myostatin antibody, JA16, to isolate the native myostatin complex from normal mouse and human serum. Analysis by mass spectrometry and Western blot shows that circulating myostatin is bound to at least two major proteins, the myostatin propeptide and the follistatin-related gene (FLRG). The myostatin propeptide is known to bind and inhibit myostatin in vitro (3). Here we show that this interaction is relevant in vivo, with a majority (>70%) of myostatin in serum bound to its propeptide. Studies with recombinant V5-His-tagged FLRG protein confirm a direct interaction between mature myostatin and FLRG. Functional studies show that FLRG inhibits myostatin activity in a reporter gene assay. These experiments suggest that the myostatin propeptide and FLRG are major negative regulators of myostatin in vivo.	Wyeth Res, Dept Prot Chem & Prote, Cambridge, MA 02140 USA; Wyeth Res, Dept Musculoskeletal Sci, Cambridge, MA 02140 USA	Pfizer; Pfizer	Hill, JJ (corresponding author), Wyeth Res, Dept Prot Chem & Prote, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jhill@wyeth.com						Bartholin L, 2002, ONCOGENE, V21, P2227, DOI 10.1038/sj.onc.1205294; Bartholin L, 2001, ONCOGENE, V20, P5409, DOI 10.1038/sj.onc.1204720; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; KRUMMEN LA, 1993, ENDOCRINOLOGY, V132, P431, DOI 10.1210/en.132.1.431; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lin J, 2002, BIOCHEM BIOPH RES CO, V291, P701, DOI 10.1006/bbrc.2002.6500; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Massague J, 2000, GENE DEV, V14, P627; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Oi V.T., 1980, SELECTED METHODS CEL, P351; Schneyer A, 2001, MOL CELL ENDOCRINOL, V180, P33, DOI 10.1016/S0303-7207(01)00501-9; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SCHNEYER AL, 1992, J CLIN ENDOCR METAB, V74, P1320, DOI 10.1210/jc.74.6.1320; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; SUGINO K, 1993, J BIOL CHEM, V268, P15579; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Tsuchida K, 2001, MOL CELL ENDOCRINOL, V180, P25, DOI 10.1016/S0303-7207(01)00522-6; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	43	352	399	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40735	40741		10.1074/jbc.M206379200	http://dx.doi.org/10.1074/jbc.M206379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12194980	hybrid			2022-12-25	WOS:000178791400075
J	Hou, LM; Kang, I; Marchant, RE; Zagorski, MG				Hou, LM; Kang, I; Marchant, RE; Zagorski, MG			Methionine 35 oxidation reduces fibril assembly of the amyloid A beta-(1-42) peptide of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN FIBRILLOGENESIS; A-BETA; NEUROTOXICITY; BRAIN; MORPHOLOGY; TOXICITY; STRESS; AGGREGATION; INHIBITION; OLIGOMERS	The major component of amyloid plaques in Alzheimer's disease (AD) is Abeta, a small peptide that has high propensity to assemble as aggregated 13-sheet structures. Using three well established techniques for studying amyloid structure, namely circular dichroism, thio-flavin-T fluorescence, and atomic force microscopy, we demonstrate that oxidation of the Met-35 side chain to a methionine sulfoxide (Met-35(ox)) significantly hinders the rate of fibril formation for the 42-residue Abeta-(1-42) at physiological pH. Met-35(ox) also alters the characteristic Abeta fibril morphology and prevents formation of the protofibril, which is a key intermediate in beta-amyloidosis and the associated neurotoxicity. The implications of these results for the biological function and role of Abeta with oxidative stress in AD are discussed.	Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Zagorski, MG (corresponding author), Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040047, R01HL047300, R29HL040047, R01HL070263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 70263-01, HL 40047-12, HL 47300-05] Funding Source: Medline; NIA NIH HHS [AG 14363-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Aliev G, 2002, BRAIN PATHOL, V12, P21; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Head E, 2001, NEUROBIOL DIS, V8, P792, DOI 10.1006/nbdi.2001.0431; Hensley K, 1998, J NEUROSCI, V18, P8126; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kim YH, 2001, PROTEIN ENG, V14, P343, DOI 10.1093/protein/14.5.343; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kontush A, 2001, FREE RADICAL BIO MED, V31, P1120, DOI 10.1016/S0891-5849(01)00688-8; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lorenzo A., 1993, Society for Neuroscience Abstracts, V19, P184; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Riek R, 2001, EUR J BIOCHEM, V268, P5930, DOI 10.1046/j.0014-2956.2001.02537.x; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sayre LM, 2000, CELL MOL BIOL, V46, P731; Schoneich C, 2002, ARCH BIOCHEM BIOPHYS, V397, P370, DOI 10.1006/abbi.2001.2621; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189	48	186	196	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40173	40176		10.1074/jbc.C200338200	http://dx.doi.org/10.1074/jbc.C200338200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12198111	hybrid			2022-12-25	WOS:000178791400002
J	Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB				Iancu, CV; Borza, T; Fromm, HJ; Honzatko, RB			Feedback inhibition and product complexes of recombinant mouse muscle adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; MECHANISM; IMP; HYDANTOCIDIN; PURIFICATION; TARGET; GDP	Adenylosuccinate synthetase governs the committed step of AMP biosynthesis, the generation of 6-phosphoryl-IMP from GTP and IMP followed by the formation of adenylosuccinate from 6-phosphoryl-IMP and L-aspartate. The enzyme is subject to feedback inhibition by AMP and adenylosuccinate, but crystallographic complexes of the mouse muscle synthetase presented here infer mechanisms of inhibition that involve potentially synergistic ligand combinations. AMP alone adopts the productive binding mode of IMP and yet stabilizes the active site in a conformation that favors the binding of Mg2+-IMP to the GTP pocket. On the other hand, AMP, in the presence of GDP, orthophosphate, and Mg2+, adopts the binding mode of adenylosuccinate. Depending on circumstances then, AMP behaves as an analogue of IMP or as an analogue of adenylosuccinate. The complex of adenylosuccinate(.)GDP(.)Mg(2+)-sulfate, the first structure of an adenylosuccinate-bound synthetase, reveals significant geometric distortions and tight non-bonded contacts relevant to the proposed catalytic mechanism. Adenylosuccinate forms from 6-phosphoryl-IMP and L-aspartate by the movement of the purine ring into the alpha-amino group of L-aspartate.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu	Borza, Tudor/A-8510-2012; Borza, Tudor/M-4937-2019	Borza, Tudor/0000-0002-2527-6551; Borza, Tudor/0000-0002-2527-6551	NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASS MB, 1984, J BIOL CHEM, V259, P2330; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; GOODMAN MN, 1977, J BIOL CHEM, V252, P5054; Gorrell A, 2002, J BIOL CHEM, V277, P8817, DOI 10.1074/jbc.M111810200; Hanessian S, 1999, ANGEW CHEM INT EDIT, V38, P3160; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Honzatko RB, 1999, ARCH BIOCHEM BIOPHYS, V370, P1, DOI 10.1006/abbi.1999.1383; Hou ZL, 2002, J BIOL CHEM, V277, P5970, DOI 10.1074/jbc.M109561200; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; Iancu CV, 2002, J BIOL CHEM, V277, P26779, DOI 10.1074/jbc.M203730200; Iancu CV, 2001, J BIOL CHEM, V276, P42146, DOI 10.1074/jbc.M106294200; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARKHAM GD, 1977, ARCH BIOCHEM BIOPHYS, V184, P24, DOI 10.1016/0003-9861(77)90322-8; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; PAO CC, 1981, BIOCHIM BIOPHYS ACTA, V677, P358, DOI 10.1016/0304-4165(81)90247-6; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Walters EW, 1997, PLANT PHYSIOL, V114, P549, DOI 10.1104/pp.114.2.549	32	11	12	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40536	40543		10.1074/jbc.M204952200	http://dx.doi.org/10.1074/jbc.M204952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186864	hybrid			2022-12-25	WOS:000178791400050
J	Mengerink, KJ; Vacquier, VD				Mengerink, KJ; Vacquier, VD			An ATP-binding cassette transporter is a major glycoprotein of sea urchin sperm membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; ACROSOME REACTION; PLASMA-MEMBRANE; LOW-DENSITY; PROTEIN; FRACTION; IDENTIFICATION; SPERMATOZOA; TOPOLOGY; CLEAVAGE	Sperm are terminally differentiated cells that undergo several membrane-altering events before fusion with eggs. One event, the sea urchin sperm acrosome reaction (AR), is blocked by the lectin wheat germ agglutinin (WGA). In an effort to identify proteins involved in the AR induction, the peptide sequence was obtained from a 220-kDa WGA-binding protein. Degenerate PCR and library screening resulted in the full-length deduced amino acid sequence of an ATP-binding cassette transporter, suABCA. The protein of 1,764 residues has two transmembrane regions, two nucleotide-binding domains, and is most closely related to the human ABC subfamily A member 3 transporter (ABCA3). Sequence analysis suggests a large extracellular loop between transmembrane spanning segments 7 and 8, with five N-linked glycosylation sites. An antibody made to the loop region binds to non-permeabilized cells, supporting that this region is extracellular. suABCA is found in sperm membrane vesicles, it can be solubilized with nonionic detergents, and it shifts from 220 to 200 kDa upon protein:N-glycanase F digestion. suABCA localizes to the entire surface of sperm in a punctate pattern, but is not detected in lipid rafts. Based on its relationship to subfamily A, suABCA is most likely involved in phospholipid or cholesterol transport. This is the first investigation of an ABC transporter in animal sperm.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Vacquier, VD (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, 9500 Gilman Dr, La Jolla, CA 92093 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEARER EL, 1990, J ELECTRON MICR TECH, V16, P281, DOI 10.1002/jemt.1060160403; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Dean M, 2001, J LIPID RES, V42, P1007; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Lin GR, 2002, BIOCHEM BIOPH RES CO, V291, P727, DOI 10.1006/bbrc.2002.6505; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mengerink KJ, 2001, GLYCOBIOLOGY, V11, p37R, DOI 10.1093/glycob/11.4.37R; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; Oram JF, 2001, J LIPID RES, V42, P1173; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PODELL SB, 1984, BIOCHIM BIOPHYS ACTA, V778, P25, DOI 10.1016/0005-2736(84)90444-9; PODELL SB, 1985, J BIOL CHEM, V260, P2715; PODELL SB, 1984, J CELL BIOL, V99, P1598, DOI 10.1083/jcb.99.5.1598; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; WARD GE, 1986, J CELL BIOL, V103, P95, DOI 10.1083/jcb.103.1.95; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3	35	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40729	40734		10.1074/jbc.M207184200	http://dx.doi.org/10.1074/jbc.M207184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193601	hybrid			2022-12-25	WOS:000178791400074
J	Miranda, M; Pardo, JP; Allen, KE; Slayman, CW				Miranda, M; Pardo, JP; Allen, KE; Slayman, CW			Stalk segment 5 of the yeast plasma membrane H+-ATPase - Labeling with a fluorescent maleimide reveals a conformational change during glucose activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; SECRETORY VESICLES; CALCIUM-PUMP; IDENTIFICATION; RESOLUTION; S5	Glucose is well known to cause a rapid, reversible activation of the yeast plasma membrane H+-ATPase, very likely mediated by phosphorylation of two or more Ser/Thr residues near the C terminus. Recent mutagenesis studies have shown that glucose-dependent activation can be mimicked constitutively by amino acid substitutions in stalk segment 5 (S5), an alpha-helical stretch connecting the catalytic part of the ATPase with transmembrane segment 5 (Miranda, M., Allen, K. E., Pardo, J. P., and Slayman, C. W. (2001) J. Biol. Chem. 276,2248522490). In the present work, the fluorescent maleimide Alexa-488 has served as a probe for glucose-dependent changes in the conformation of S5. Experiments were carried out in a "3C" version of the ATPase, from which six of nine native cysteines had been removed by site-directed mutagenesis to eliminate background labeling by Alexa-488. In this construct, three of twelve cysteines introduced at various positions along S5 (A668C, S672C, and D676C) reacted with the Alexa dye in a glucose-independent manner, as shown by fluorescent labeling of the 100 kDa Pma1 polypeptide and by isolation and identification of the corresponding tryptic peptides. Especially significant was the fact that three additional cysteines reacted with Alexa-488 more rapidly (Y689C) or only (V665C and L678C) in plasma membranes from glucose-metabolizing cells. The results support a model in which the S5 alpha-helix undergoes a significant change in conformation to expose positions 665, 678, and 689 during glucose-dependent activation of the ATPase.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Miranda, M (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM 15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Chiu I, 1999, P NATL ACAD SCI USA, V96, P13944, DOI 10.1073/pnas.96.24.13944; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; ERASO P, 1994, J BIOL CHEM, V269, P10393; Fiske CH, 1925, J BIOL CHEM, V66, P375; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Miranda M, 2001, J BIOL CHEM, V276, P22485, DOI 10.1074/jbc.M102332200; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Soteropoulos P, 2001, J BIOL CHEM, V276, P16265, DOI 10.1074/jbc.M011115200; Stone Kathryn L., 1996, P427, DOI 10.1007/978-1-60327-259-9_72; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WANG G, 1989, J BIOL CHEM, V271, P25438; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	29	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40981	40988		10.1074/jbc.M206793200	http://dx.doi.org/10.1074/jbc.M206793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12169695	hybrid			2022-12-25	WOS:000178791400106
J	Palmieri, D; Lee, JW; Juliano, RL; Church, FC				Palmieri, D; Lee, JW; Juliano, RL; Church, FC			Plasminogen activator inhibitor-1 and-3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; REACTIVE-SITE MUTANTS; UROKINASE RECEPTOR; SEMINAL PLASMA; MIGRATION; INTEGRIN; INVASION; VITRONECTIN; CHEMOTAXIS; COMPLEXES	Plasminogen activator inhibitor-1 (PAI-1), an inhibitor of urokinase plasminogen activator, is paradoxically associated with a poor prognosis in breast cancer. PAI-1 is linked to several processes in the metastatic cascade. However, the role of PAI-1 in metastatic processes, which may be independent of protease inhibitory activity, is not fully understood. We report herein that PAI-1, when added exogenously to or stably transfected in human MDA-MB-435 breast carcinoma cells, had disparate effects on adhesion to extracellular matrix proteins and motility in vitro. Specifically, exogenously added PAI-1 inhibited cell adhesion to vitronectin but not fibronectin, in agreement with the literature. By contrast, stably transfected PAI-1 stimulated adhesion to both proteins. Wild-type PAI-1 was required for this stimulation, because expression of a non-protease inhibitory P14 (T333R) PAI-1 mutant failed to enhance adhesion. Compared with non-inhibitory PAI-1, wild-type PAI-1 also increased cell motility in chemotaxic assays. Furthermore, stable transfection of a related serine protease inhibitor, plasminogen activator inhibitor-3 (PAI-3, or protein C inhibitor) gave results similar to wild-type PAI-1. The stimulatory activity of PAI-3 was not seen with a non-protease inhibitory P14 PAI-3 mutant (T341R). We show that a downstream effect of endogenous wild-type PAI-1 and PAI-3 overexpression, but not their non-inhibitory counterparts, was the altered expression of alpha(2), alpha(3), alpha(4), alpha(5), and beta(1) integrin subunits. Additionally, blocking antibodies to beta(1) integrin inhibited PAI-1-induced adhesion. Our data provide experimental support for the stimulatory and inhibitory effects of PAI-1 in metastasis and introduce PAI-3 as another serpin potentially important in malignant disease.	Univ N Carolina, Div Hematol Oncol, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Hematol Oncol, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Hematol Oncol, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Church, FC (corresponding author), Univ N Carolina, Div Hematol Oncol, Dept Med, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@email.unc.edu	Palmieri, Diane/B-4258-2015; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200	NATIONAL CANCER INSTITUTE [R01CA074966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007017] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74966] Funding Source: Medline; NHLBI NIH HHS [HL 06350] Funding Source: Medline; NIEHS NIH HHS [5T32 ES 07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; Chazaud B, 2002, AM J PATHOL, V160, P237, DOI 10.1016/S0002-9440(10)64367-2; CHURCH FC, 1997, ADV EXPT MED BIOL, V425; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Degryse B, 2001, FEBS LETT, V505, P249, DOI 10.1016/S0014-5793(01)02797-1; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Elisen MGLM, 1998, FIBRINOLYSIS PROTEOL, V12, P283, DOI 10.1016/S0268-9499(98)80021-0; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jackson TP, 1997, J PROTEIN CHEM, V16, P819, DOI 10.1023/A:1026324102618; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MIHALY J, 2001, INT SOC THROMB HAEM; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; MO Z, 2001, J CELL SCI, V114, P3387; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEESE LL, 1994, BLOOD COAGUL FIBRIN, V5, P737, DOI 10.1097/00001721-199410000-00010; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sliutz G, 1996, BREAST CANCER RES TR, V40, P257, DOI 10.1007/BF01806814; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975	56	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40950	40957		10.1074/jbc.M202333200	http://dx.doi.org/10.1074/jbc.M202333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176977	hybrid			2022-12-25	WOS:000178791400102
J	Ray, AS; Basavapathruni, A; Anderson, KS				Ray, AS; Basavapathruni, A; Anderson, KS			Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POL GENE-MUTATIONS; ANTIVIRAL NUCLEOSIDE ANALOGS; HIGH-LEVEL RESISTANCE; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; COMBINATION THERAPY; DNA-SYNTHESIS; STEADY-STATE; PHYSIOLOGICAL CONCENTRATIONS; NUCLEOTIDE INCORPORATION; PRIMER/TEMPLATE BINDING	Abacavir has been shown to select for multiple resistant mutations in the human immunodeficiency type 1 (HIV-1) pol gene. In an attempt to understand the molecular mechanism of resistance in response to abacavir, and nucleoside analogs in general, a set of reverse transcriptase mutants were studied to evaluate their kinetics of nucleotide incorporation and removal. It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)Q(151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate). However, the magnitude of resistance observed in cell culture to abacavir in previous studies was less than that observed to other compounds. Our mechanistic studies suggest that this may be due to carbovir triphosphate decreasing the overall effect on its efficiency of incorporation by forming strong hydrophobic interactions in the RT active site. Unlike RTAZTR, no increase in the rate of ATP- or PPi-mediated chain terminator removal relative to RTWT could be detected for any of the mutants. However, marked decreases in the steady-state rate may serve as a mechanism for increased removal of a chain-terminating carbovir monophosphate by increasing the time spent at the primer terminus for some of the mutants studied. The triple mutant showed no advantage in selectivity over RTM184V and was severely impaired in its ability to remove a chain terminator, giving no kinetic basis for its increased resistance in a cellular system. Biochemical properties including percentage of active sites, fidelity, and processivity may suggest that the triple mutant's increased resistance to abacavir in cell culture is perhaps due to a fitness advantage, although further cellular studies are needed to verify this hypothesis. These data serve to further the understanding of how mutations in RT confer resistance to nucleoside analogs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.			Ray, Adrian/0000-0002-3508-3008	NIGMS NIH HHS [5T32 GM 07223, GM 49551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; Ford H, 2000, BIOCHEMISTRY-US, V39, P2581, DOI 10.1021/bi992112c; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; GU Z, 1994, LEUKEMIA S1, V8, P166; Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Jonckheere H, 2000, EUR J BIOCHEM, V267, P2658, DOI 10.1046/j.1432-1327.2000.01272.x; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Khanna N, 2000, AIDS, V14, P791, DOI 10.1097/00002030-200005050-00004; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Lennerstrand J, 2001, ANTIMICROB AGENTS CH, V45, P2144, DOI 10.1128/AAC.45.7.2144-2146.2001; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450, DOI 10.1097/00126334-200108150-00005; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MOYLE GJ, 1997, J ANTIMICROB CHEMOTH, V40, P767; Mu L, 2000, BIOCHEMISTRY-US, V39, P11205, DOI 10.1021/bi001090n; Naeger LK, 2001, ANTIVIR THER, V6, P115; PARKER WB, 1994, J NIH RES, V6, P57; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Ray AS, 2002, ANTIMICROB AGENTS CH, V46, P887, DOI 10.1128/AAC.46.3.887-891.2002; Ray AS, 2002, BIOCHEMISTRY-US, V41, P5150, DOI 10.1021/bi0121858; Ray AS, 2001, NUCLEOS NUCLEOT NUCL, V20, P1247, DOI 10.1081/NCN-100002528; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1990, J BIOL CHEM, V265, P20303; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; Sharma PL, 1997, J VIROL, V71, P8846, DOI 10.1128/JVI.71.11.8846-8851.1997; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; Skoog D.A., 1992, PRINCIPLES INSTRUMEN; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; Urban S, 2001, P NATL ACAD SCI USA, V98, P4984, DOI 10.1073/pnas.091324398; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Walter H, 2002, ANTIMICROB AGENTS CH, V46, P89, DOI 10.1128/AAC.46.1.89-94.2002; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057	79	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40479	40490		10.1074/jbc.M205303200	http://dx.doi.org/10.1074/jbc.M205303200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176989	hybrid			2022-12-25	WOS:000178791400043
J	Wen, KK; Yao, XY; Rubenstein, PA				Wen, KK; Yao, XY; Rubenstein, PA			GTP-yeast actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-I RELEASE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; BETA-ACTIN; POLYMERIZATION; CONFORMATION; PROFILIN; PROTEIN; COMPLEX; NUCLEOTIDES	Because of the apparently greater conformational flexibility of yeast versus muscle actin and the ability of other members in the actin protein superfamily to efficiently use both ATP and GTP, we assessed the ability of yeast actin to function with GTP. Etheno-ATP exchange studies showed that the binding of GTP to yeast actin is about 1/9 as tight as that of ATP in contrast to the 1/1,240 ratio for muscle actin. Proteolysis of GTP-bound G-yeast actin suggests that the conformation of subdomain 2 is very much like that of ATP-bound actin, but CD studies show that GTP-bound actin is less thermostable than ATP-bound actin. GTP-actin polymerizes with an apparent critical concentration of 1.5 mum, higher than that of ATP-actin (0.3 mum) although filament structures observed by electron microscopy were similar. Yeast actin hydrolyzes GTP in a polymerization-dependent manner, and GTP-bound F-actin decorates with the myosin S1. Conversion of Phe(306) in the nucleotide binding site to the Tyr found in muscle actin raised the nucleotide discrimination ratio from the 1/9 of wild-type actin to 1/125. This result agrees with modeling that predicts that removal of the Tyr hydroxyl will create a space for the C2 amino group of the GTP guanine.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.			Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45728] Funding Source: Medline; NIGMS NIH HHS [GM 33689] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; BERTAZZON A, 1990, BIOCHEMISTRY-US, V29, P291, DOI 10.1021/bi00453a040; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; CHEN X, 1995, J BIOL CHEM, V270, P11415, DOI 10.1074/jbc.270.19.11415; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COOK RK, 1992, J BIOL CHEM, V267, P9430; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; IYENGAR MR, 1964, BIOCHIM BIOPHYS ACTA, V86, P543, DOI 10.1016/0304-4165(64)90094-7; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; Kinosian HJ, 2000, BIOCHEMISTRY-US, V39, P13176, DOI 10.1021/bi001520+; Klumb LA, 1998, BIOCHEMISTRY-US, V37, P7657, DOI 10.1021/bi9803123; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MARTONOSI A, 1961, J BIOL CHEM, V236, P1345; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; NAGAYAMA F, 1980, BIOCHIM BIOPHYS ACTA, V615, P85, DOI 10.1016/0005-2744(80)90011-X; Nyman T, 2002, J MOL BIOL, V317, P577, DOI 10.1006/jmbi.2002.5436; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Rudoni S, 2001, BBA-MOL CELL RES, V1538, P181, DOI 10.1016/S0167-4889(01)00067-2; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SMITH NH, 1995, MOL BIOL EVOL, V12, P363; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; STRZELECKAGOLASZEWSKA H, 1985, EUR J BIOCHEM, V147, P331, DOI 10.1111/j.1432-1033.1985.tb08754.x; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yao XY, 2002, J BIOL CHEM, V277, P22875, DOI 10.1074/jbc.M201685200; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	40	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41101	41109		10.1074/jbc.M204025200	http://dx.doi.org/10.1074/jbc.M204025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12191996	hybrid			2022-12-25	WOS:000178791400120
J	Eberhardy, SR; Farnham, PJ				Eberhardy, SR; Farnham, PJ			Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; HUMAN C-MYC; HISTONE ACETYLATION; ESSENTIAL COFACTOR; DNA-BINDING; HIV-1 TAT; CELL-GROWTH; IN-VIVO; ELONGATION	The c-Myc protein is up-regulated in many different types of cancer, suggesting that a detailed understanding of Myc function is an important goal. Our previous studies have focused on determining the mechanism by which Myc activates transcription using the target gene cad as an experimental model. Previously, we found that Myc activates cad transcription at a post-RNA polymerase II recruitment step and that the Myc transactivation domain interacts with a number of cdk-cyclin complexes. We now extend these studies to determine the role of these cyclin-cdk complexes in Myc-mediated transactivation. We have found that cyclin T1 binding to Myc localizes to the highly conserved Myc Box I, whereas cdk8 binding localizes to the amino-terminal 41 amino acids of the Myc transactivation domain. We showed that recruitment of cdk8 is sufficient for activation of a synthetic promoter construct. In contrast, the ability of Myc to activate transcription of the cad promoter correlates with binding of cyclin T1. Furthermore, recruitment of cyclin T1 to the cad promoter via a Gal4 fusion protein or through protein-protein interaction with the HIV-1 Tat protein can also activate cad transcription. These results suggest that Myc activates transcription by stimulating elongation and that P-TEFb is a key mediator of this process.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, R01CA045240, R29CA045240] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA45240, CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Giorello L, 1998, CANCER RES, V58, P3654; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lin X, 2002, J BIOL CHEM, V277, P16873, DOI 10.1074/jbc.M200117200; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pescarolo MP, 2001, FASEB J, V15, P31; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; SHOR J, 1995, ONCOGENE, V10, P1587; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	63	184	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40156	40162		10.1074/jbc.M207441200	http://dx.doi.org/10.1074/jbc.M207441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177005	hybrid			2022-12-25	WOS:000178662500139
J	Hermoso, M; Satterwhite, CM; Andrade, YN; Hidalgo, J; Wilson, SM; Horowitz, B; Hume, JR				Hermoso, M; Satterwhite, CM; Andrade, YN; Hidalgo, J; Wilson, SM; Horowitz, B; Hume, JR			ClC-3 is a fundamental molecular component of volume-sensitive outwardly rectifying Cl- channels and volume regulation in HeLa cells and Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CHANNELS; RESISTANCE P-GLYCOPROTEIN; ANION CHANNELS; EPITHELIAL-CELLS; PROTEIN-KINASE; MDCK CELLS; CURRENTS; MECHANISMS; EXPRESSION; DECREASE	Volume-sensitive osmolyte and anion channels (VSOACs) are activated upon cell swelling in most vertebrate cells. Native VSOACs are believed to be a major pathway for regulatory volume decrease (RVD) through efflux of chloride and organic osmolytes. ClC-3 has been proposed to encode native VSOACs in Xenopus laevis oocytes and in some mammalian cells, including cardiac and vascular smooth muscle cells. The relationship between the ClC-3 chloride channel, the native volume-sensitive osmolyte and anion channel (VSOAC) currents, and cell volume regulation in HeLa cells and X. laevis oocytes was investigated using ClC-3 antisense. In situ hybridization in HeLa cells, semiquantitative and real-time PCR, and immunoblot studies in HeLa cells and X. laevis oocytes demonstrated the presence of ClC-3 mRNA and protein, respectively. Exposing both cell types to hypotonic solutions induced cell swelling and activated native VSOACs. Transient transfection of HeLa cells with ClC-3 antisense oligonucleotide or X. laevis oocytes injected with antisense cRNA abolished the native ClC-3 mRNA transcript and protein and significantly reduced the density of native VSOACs activated by hypotonically induced cell swelling. In addition, antisense against native ClC-3 significantly impaired the ability of HeLa cells and X. laevis oocytes to regulate their volume. These results suggest that ClC-3 is an important molecular component underlying VSOACs and the RVD process in HeLa cells and X. laevis oocytes.	Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Pharmacol 318, Reno, NV 89557 USA; Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Physiol & Cell Biol, Reno, NV 89557 USA; Univ Chile, Inst Ciencias Biomed, Fac Med, Santiago 6530499, Chile; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Ciencias Fisiol, Santiago 6530499, Chile	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Universidad de Chile; Pontificia Universidad Catolica de Chile	Hume, JR (corresponding author), Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Pharmacol 318, Reno, NV 89557 USA.	joeh@med.unr.edu	Hermoso, Marcela/L-1500-2014; wilson, sean/D-1206-2017; Hermoso, Marcela A./AAF-6893-2021	wilson, sean/0000-0003-4404-1173; Hermoso, Marcela A./0000-0002-7936-7571	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR15581] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALVAREZLEEFMANS FJ, 1995, METH NEUROSCI, V27, P361; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BERNTSSON K, 1965, J CELL COMPAR PHYSL, V65, P101, DOI 10.1002/jcp.1030650113; Bond TD, 1998, METHOD ENZYMOL, V292, P359; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton FC, 2000, AM J PHYSIOL-HEART C, V279, pH2225, DOI 10.1152/ajpheart.2000.279.5.H2225; CocaPrados M, 1996, J MEMBRANE BIOL, V150, P197, DOI 10.1007/s002329900044; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Duan DY, 2001, J PHYSIOL-LONDON, V531, P437, DOI 10.1111/j.1469-7793.2001.0437i.x; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; Hallows K.R., 1994, Cellular and molecular physiology of cell volume regulation, P3; Hand M, 1997, J MEMBRANE BIOL, V157, P9, DOI 10.1007/s002329900211; Hatton WJ, 2002, BIOPHYS J, V82, p242A; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HIGGINS CF, 1999, CHLORIDE CHANNELS, P35; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; Keller H, 2000, J PHARMACOL EXP THER, V295, P367; KIRK K, 1992, J BIOL CHEM, V267, P23475; Kirk K, 1997, J MEMBRANE BIOL, V158, P1, DOI 10.1007/s002329900239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; LIPECKA J, 1999, J PHYSIOL-LONDON, V517, P69; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Okada Y, 1998, CONTRIB NEPHROL, V123, P21; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; ROY G, 1992, J MEMBRANE BIOL, V130, P83; SASAKI S, 1994, JPN J PHYSIOL, V44, pS3; Satterwhite CM, 1999, BIOPHYS J, V76, pA402; Satterwhite CM, 2000, BIOPHYS J, V78, p469A; Schmid A, 1998, J PHYSIOL-LONDON, V513, P453, DOI 10.1111/j.1469-7793.1998.453bb.x; SHIMADA K, 2000, AM J PHYSIOL, V279, pG286; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Stutzin A, 1999, AM J PHYSIOL-CELL PH, V277, pC392, DOI 10.1152/ajpcell.1999.277.3.C392; Stutzin A, 1998, PFLUG ARCH EUR J PHY, V436, P152, DOI 10.1007/s004240050616; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TIVEY DR, 1985, J MEMBRANE BIOL, V87, P93, DOI 10.1007/BF01870656; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1994, JPN J PHYSIOL, V44, pS55; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; von Weikersthal SF, 1999, J PHYSIOL-LONDON, V516, P75, DOI 10.1111/j.1469-7793.1999.075aa.x; WAGNER RW, 1995, ANTISENSE RES DEV, V5, P113, DOI 10.1089/ard.1995.5.113; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; Waldegger S, 1998, NEPHROL DIAL TRANSPL, V13, P867, DOI 10.1093/ndt/13.4.867; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weiss B, 1997, NEUROCHEM INT, V31, P321, DOI 10.1016/S0197-0186(96)00105-2; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	69	99	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40066	40074		10.1074/jbc.M205132200	http://dx.doi.org/10.1074/jbc.M205132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183454	hybrid			2022-12-25	WOS:000178662500127
J	Kreienkamp, HJ; Larusson, HJ; Witte, I; Roeder, T; Birgul, N; Honck, HH; Harder, S; Ellinghausen, G; Buck, F; Richter, D				Kreienkamp, HJ; Larusson, HJ; Witte, I; Roeder, T; Birgul, N; Honck, HH; Harder, S; Ellinghausen, G; Buck, F; Richter, D			Functional annotation of two orphan G-protein-coupled receptors, Drostar1 and -2, from Drosophila melanogaster and their ligands by reverse pharmacology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOSTATIN RECEPTOR; TRANSMEMBRANE DOMAIN; MANDUCA-SEXTA; ALLATOSTATIN; IDENTIFICATION; NEUROPEPTIDES; EXPRESSION; INSECTS; PEPTIDE; CLONING	By combining a Drosophila genome data base search and reverse transcriptase-PCR-based cDNA isolation, two G-protein-coupled receptors were cloned, which are the closest known invertebrate homologs of the mammalian opioid/somatostatin receptors. However, when functionally expressed in Xenopus oocytes by injection of Drosophila orphan receptor RNAs together with a coexpressed potassium channel, neither receptor was activated by known mammalian agonists. By applying a reverse pharmacological approach, the physiological ligands were isolated from peptide extracts from adult flies and larvae. Edman sequencing and mass spectrometry of the purified ligands revealed two decapentapeptides, which differ only by an N-terminal pyroglutamate/glutamine. The peptides align to a hormone precursor sequence of the Drosophila genome data base and are almost identical to allatostatin C from Manduca sexta. Both receptors were activated by the synthetic peptides irrespective of the N-terminal modification. Site-directed mutagenesis of a residue in transmembrane region 3 and the loop between transmembrane regions 6 and 7 affect ligand binding, as previously described for somatostatin receptors. The two receptor genes each containing three exons and transcribed in opposite directions are separated by 80 kb with no other genes predicted between. Localization of receptor transcripts identifies a role of the new transmitter system in visual information processing as well as endocrine regulation.	Univ Klinikum Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; Univ Hamburg, Inst Zool, D-20146 Hamburg, Germany; Univ Hamburg, Museum Zool, D-20146 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University of Hamburg	Richter, D (corresponding author), Univ Klinikum Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	richter@uke.uni-hamburg.de	Birgül Iyison, Necla/A-7389-2017; Roeder, Thomas/B-9016-2011	Roeder, Thomas/0000-0002-3489-3834; Harder, Sonke/0000-0002-6352-4771				Auerswald L, 2001, BIOCHEM BIOPH RES CO, V282, P904, DOI 10.1006/bbrc.2001.4659; Birgul N, 1999, EMBO J, V18, P5892, DOI 10.1093/emboj/18.21.5892; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; BUCHNER E, 1993, CELL TISSUE RES, V273, P119, DOI 10.1007/BF00304618; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Gade G, 1997, PHYSIOL REV, V77, P963, DOI 10.1152/physrev.1997.77.4.963; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KRAMER SJ, 1991, P NATL ACAD SCI USA, V88, P9458, DOI 10.1073/pnas.88.21.9458; LI XJ, 1992, J BIOL CHEM, V267, P9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MONNIER D, 1992, J BIOL CHEM, V267, P1298; NASSEL DR, 1993, CELL TISSUE RES, V273, P1, DOI 10.1007/BF00304608; NEHRING RB, 1995, DNA CELL BIOL, V14, P939, DOI 10.1089/dna.1995.14.939; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Yoon JG, 1995, J COMP NEUROL, V363, P475, DOI 10.1002/cne.903630310; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063	18	93	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39937	39943		10.1074/jbc.M206931200	http://dx.doi.org/10.1074/jbc.M206931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167655	hybrid			2022-12-25	WOS:000178662500111
J	Spiers, A; Lamb, HK; Cocklin, S; Wheeler, KA; Budworth, J; Dodds, AL; Pallen, MJ; Maskell, DJ; Charles, IG; Hawkins, AR				Spiers, A; Lamb, HK; Cocklin, S; Wheeler, KA; Budworth, J; Dodds, AL; Pallen, MJ; Maskell, DJ; Charles, IG; Hawkins, AR			PDZ domains facilitate binding of high temperature requirement protease A (HtrA) and tail-specific protease (Tsp) to heterologous substrates through recognition of the small stable RNA A (ssrA)-encoded peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI SURVIVAL; 10SA RNA; SERINE-PROTEASE; CELL-ENVELOPE; DEGP; PROTEINS; GENE; DETERMINANTS; DEGRADATION	The Escherichia coli protease HtrA has two PDZ domains, and sequence alignments predict that the E. coli protease Tsp has a single PDZ domain. PDZ domains are composed of short sequences (80-100 amino acids) that have been implicated in a range of protein:protein interactions. The PDZ-like domain of Tsp may be involved in binding to the extreme COOH-terminal sequence of its substrate, whereas the HtrA PDZ domains are involved in subunit assembly and are predicted to be responsible for substrate binding and subsequent translocation into the active site. E. coli has a system of protein quality control surveillance mediated by the ssrA-encoded peptide tagging system. This system tags misfolded proteins or protein fragments with an 11-amino acid peptide that is recognized by a battery of cytoplasmic and periplasmic proteases as a degradation signal. Here we show that both HtrA and Tsp are able to recognize the ssrA-encoded peptide tag with apparent KD values of similar to5 and 390 nm, respectively, and that their PDZ-like domains mediate this recognition. Fusion of the ssrA-encoded peptide tag to the COOH terminus of a heterologous protein (glutathione S-transferase) renders it sensitive to digestion by Tsp but not HtrA. These observations support the prediction that the HtrA PDZ domains facilitate substrate binding and the differential proteolytic responses of HtrA and Tsp to SsrA-tagged glutathione S-transferase are interpreted in terms of the structure of HtrA.	Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Arrow Therapeut Ltd, London SE1 1DA, England; Univ Birmingham, Sch Med, Div Immun & Infect, Microbial Genomics & Pathogenesis Unit, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Clin Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England	Newcastle University - UK; AstraZeneca; University of Birmingham; University of Cambridge	Hawkins, AR (corresponding author), Newcastle Univ, Sch Med, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	a.r.hawkins@ncl.ac.uk	Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P3149, DOI 10.1021/bi992709s; Felden B, 1997, RNA, V3, P89; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; Ponting CP, 1997, PROTEIN SCI, V6, P464; Rawlings ND, 1997, BIOM HLTH R, V13, P13; SEOL JH, 1991, BIOCHEM BIOPH RES CO, V176, P730; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Williams KP, 1996, RNA, V2, P1306	31	40	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39443	39449		10.1074/jbc.M202790200	http://dx.doi.org/10.1074/jbc.M202790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177052	hybrid			2022-12-25	WOS:000178662500050
J	Tanaka, AR; Tanabe, K; Morita, M; Kurisu, M; Kasiwayama, Y; Matsuo, M; Kioka, N; Amachi, T; Imanaka, T; Ueda, K				Tanaka, AR; Tanabe, K; Morita, M; Kurisu, M; Kasiwayama, Y; Matsuo, M; Kioka, N; Amachi, T; Imanaka, T; Ueda, K			ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; TRANSMEMBRANE CONDUCTANCE REGULATOR; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; SULFONYLUREA RECEPTOR; P-GLYCOPROTEIN; GENE-PRODUCT; TRANSPORTER; NUCLEOTIDE; SUR1	The 70-kDa peroxisomal membrane protein (PMP70) and adrenoleukodystrophy protein (ALDP), half-size ATP-binding cassette transporters, are involved in metabolic transport of long and very long chain fatty acids into peroxisomes. We examined the interaction of peroxisomal ATP-binding cassette transporters with ATP using rat liver peroxisomes. PMP70 was photoaffinity-labeled at similar efficiencies with 8-azido-[alpha-P-32]ATP and 8-azido-[gamma-P-32]ATp when peroxisomes were incubated with these nucleotides at 37 degreesC in the absence Mg2+ and exposed to UV light without removing unbound nucleotides. The photoaffinity-labeled PMP70 and ALDP were co-immunoprecipitated together with other peroxisomal proteins, which also showed tight ATP binding properties. Addition of Mg2+ reduced the photoaffinity labeling of PMP70 with 8-azido-[gamma-P-32]ATp by 70%, whereas it reduced photoaffinity labeling with 8-azido-[alpha-P-32]ATP by only 20%. However, two-thirds of nucleotide (probably ADP) was dissociated during removal of unbound nucleotides. These results suggest that ATP binds to PMP70 tightly in the absence of Mg2+, the bound ATP is hydrolyzed to ADP in the presence of Mg2+, and the produced ADP is dissociated from PMP70, which allows ATP hydrolysis turnover. Properties of photoaffinity labeling of ALDP were essentially similar to those of PMP70. Vanadate-induced nucleotide trapping in PMP70 and ALDP was not observed. PMP70 and ALDP were also phosphorylated at a tyrosine residue(s). ATP binding/hydrolysis by and phosphorylation of PMP70 and ALDP are involved in the regulation of fatty acid transport into peroxisomes.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan	Kyoto University; University of Toyama	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Imanaka, Tsuneo/0000-0003-4677-1356; Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Aubourg P, 1999, NEUROCHEM RES, V24, P515, DOI 10.1023/A:1022583813171; Aubourg P, 1996, ANN NY ACAD SCI, V804, P461, DOI 10.1111/j.1749-6632.1996.tb18637.x; Contreras M, 1996, ARCH BIOCHEM BIOPHYS, V334, P369, DOI 10.1006/abbi.1996.0467; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; Imanaka T, 1996, J BIOL CHEM, V271, P3706; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; Kashiwayama Y, 2002, BIOCHEM BIOPH RES CO, V291, P1245, DOI 10.1006/bbrc.2002.6588; KOBAYASHI T, 1994, BIOCHEM BIOPH RES CO, V201, P1029, DOI 10.1006/bbrc.1994.1805; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li YH, 2000, J BIOL CHEM, V275, P24130, DOI 10.1074/jbc.M003617200; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Roerig P, 2001, FEBS LETT, V492, P66, DOI 10.1016/S0014-5793(01)02235-9; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHIMIZU S, 1992, J BIOCHEM-TOKYO, V112, P733, DOI 10.1093/oxfordjournals.jbchem.a123967; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Steinberg SJ, 1999, ANN NEUROL, V46, P409, DOI 10.1002/1531-8249(199909)46:3<409::AID-ANA18>3.0.CO;2-9; Swartzman EE, 1996, J CELL BIOL, V132, P549, DOI 10.1083/jcb.132.4.549; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	44	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40142	40147		10.1074/jbc.M205079200	http://dx.doi.org/10.1074/jbc.M205079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176987	hybrid			2022-12-25	WOS:000178662500137
J	Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO				Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO			Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway	ONCOGENE			English	Article						EMMPRIN; MMP2; phospholipase A(2); 5-lipoxygenase; breast cancer cell; fibroblast	MATRIX-METALLOPROTEINASE INDUCER; PROGELATINASE-A; COLLAGENASE; EXPRESSION; CARCINOMAS; ACTIVATION; RECEPTOR	Metalloproteinases (NIMP) produced by both cancer and normal stromal fibroblast cells play a critical role in the metastatic spread of tumours, however little is known of the regulation of their release. In this report we demonstrate that breast cancer cells in culture release apparently full length soluble EMMPRIN that promotes the release of pro-MMP2 from fibroblasts. The generation of MMP2 is mediated by activation of phospholipase A(2) and 5-lipoxygenase. These results suggest that the production of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therapeutic intervention.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Wakelam, MJO (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	m.j.o.wakelam@bham.ac.uk		Wakelam, Michael/0000-0003-4059-9276				Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; DERRICO A, 1991, MODERN PATHOL, V4, P239; ELLIS SM, 1989, CANCER RES, V49, P3385; Ferry DR, 2000, ANN ONCOL, V11, P1165, DOI 10.1023/A:1008303715515; Guo HM, 1997, J BIOL CHEM, V272, P24; Huang MT, 1997, J CELL BIOCHEM, P26; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Light DB, 1997, J MEMBRANE BIOL, V158, P229, DOI 10.1007/s002329900260; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; NOMURA H, 1995, CANCER RES, V55, P3263; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sun JX, 2001, CANCER RES, V61, P2276; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	24	121	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5765	5772		10.1038/sj.onc.1205702	http://dx.doi.org/10.1038/sj.onc.1205702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173047				2022-12-25	WOS:000177463400012
J	Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A				Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A			Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)	ONCOGENE			English	Article						RNA interference; BCR/ABL rearrangement; apoptosis; STI 571; gene therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; POLYMERASE-CHAIN-REACTION; BCR-ABL; CLINICAL-SIGNIFICANCE; INHIBITOR; RESISTANCE; GROWTH	Short 21-mer double-stranded RNA (dsRNA) molecules have recently been employed for the sequence-specific silencing of endogenous human genes. This mechanism, called RNA interference (RNAi), is extremely potent and requires only a few dsRNA molecules per cell to silence homologous gene mRNA expression. We used dsRNA targeting the M-BCR/ABL fusion site to kill leukemic cells with such a rearrangement. Transfection of dsRNA specific for the M-BCR/ABL fusion mRNA into K562 cells depleted the corresponding mRNA and the M-BCR/ABL oncoprotein. This was demonstrated by real-time quantitative PCR and Western blots. The BCR/ABL knockdown was accompanied by strong induction of apoptotic cell death. Leukemic cells without BCR/ABL rearrangement were not killed by M-BCR/ABL-dsRNA. In addition, to corroborate the extraordinary sequence specificity of RNAi, we designed another RNA oligo matching the M-BCR/ABL fusion site but having two point mutations within its central region. We show that these two point mutations abolished both p210 reduction and induction of apoptosis in K562 cells. Finally, we compared leukemic cell killing by RNAi to that caused by the ABL kinase tyrosine inhibitor, STI 571, Imatinib. For full induction of apoptosis, dsRNA targeting M-BCR/ABL required 24 h more than Imatinib. This may be caused by the relatively long half-life of the BCR/ABL oncoprotein, which is not targeted by the RNAi mechanism, but is affected by STI 571. When we applied ds M-BCR/ABL RNA and STI 571 in combination, we did not observe a further increase in the induction of apoptosis. Nevertheless, these data may open a field for further studies towards gene-therapeutic approaches using RNA interference to kill tumor cells with specific genetic abnormalities.	Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Borkhardt, A (corresponding author), Pediat Hematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany.	Arndt.Borkhardt@paediat.med.uni-giessen.de						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DHUT S, 1990, LEUKEMIA, V4, P745; DOBROVIC A, 1991, LEUKEMIA, V5, P187; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Goldman JM, 2001, NEW ENGL J MED, V344, P1084, DOI 10.1056/NEJM200104053441409; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2001, SCIENCE, V293, P2163; HOOBERMAN AL, 1989, P NATL ACAD SCI USA, V86, P4259, DOI 10.1073/pnas.86.11.4259; LESTINGI TM, 1993, HEMATOL ONCOL CLIN N, V7, P161, DOI 10.1016/S0889-8588(18)30262-4; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; Spiller DG, 1998, BLOOD, V91, P4738, DOI 10.1182/blood.V91.12.4738.412k31_4738_4746; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; WESTBROOK CA, 1992, BLOOD, V80, P2983	36	239	365	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5716	5724		10.1038/sj.onc.1205653	http://dx.doi.org/10.1038/sj.onc.1205653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173041				2022-12-25	WOS:000177463400006
J	Yao, RS; Wang, Y; Lubet, RA; You, M				Yao, RS; Wang, Y; Lubet, RA; You, M			Differentially expressed genes associated with mouse lung tumor progression	ONCOGENE			English	Article						mouse; lung; adenoma; adenocarcinoma; lung tumor progression gene; gene expression	CELL-CYCLE ARREST; CANCER-CELLS; RETINOBLASTOMA PROTEIN; PRENEOPLASTIC LESIONS; CDK INHIBITORS; BETA; ADENOCARCINOMA; ACTIVATION; NEOPLASIA; MUTATIONS	To detect altered gene expression associated with mouse lung tumor progression, we compared the gene expression profile of lung adenocarcinomas with that of lung adenomas and normal lungs. Autoradiographic analysis showed that among the 588 genes surveyed, 152 genes were detected and the remaining 436 genes did not give any signals. A gene-specific semiquantitative reverse transcription polymerase chain reaction method was used to confirm the expression profile. A total of 29 genes was found to be differentially expressed in mouse lung tumors when compared to normal lungs. The pattern of expression, either underexpression or overexpression, was the same for 10 genes between adenocarcinomas and adenomas. Among them, seven genes were over-expressed, two genes were underexpressed and one gene was lost. Interestingly, 19 genes showed differential expression or increased incidence or difference in level of change between lung adenomas and adenocarcinomas, including Stat1, ADAP, IGFBP-6, PDGF-A, TGF-beta2, Int-3, VEGFR2, BAX, BAG-1, c-Jun, FasL, TRAIL, YB-1, CD31, Cdc42, B-raf, Rab-2, Abi-1, and ACE. These,genes can be designated as candidate 'lung tumor progression' (LTP) genes because their expression changes may specifically affect lung tumor progression in mice. Further analyses of these candidate LTP genes may provide new leads for elucidation of lung tumor progression in mice.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005113] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA058554, R01CA078797, R29CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [CA58554, CA78797, CN05113] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1993, CANCER RES, V53, P4817; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIBA I, 1990, ONCOGENE, V5, P1603; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DeRisi J, 1996, NAT GENET, V14, P457; Frank DA, 1999, MOL MED, V5, P432; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Herzog CR, 1997, J CELL BIOCHEM, P49; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin L, 2001, EXP LUNG RES, V27, P217, DOI 10.1080/019021401300053966; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mielnicki LM, 1996, BIOCHEM BIOPH RES CO, V228, P586, DOI 10.1006/bbrc.1996.1702; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OITVAI ZN, 1993, CELL, V74, P609; Palmisano W. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P94; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rhee CH, 1999, ONCOGENE, V18, P2711, DOI 10.1038/sj.onc.1202623; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHISEKI M, 1994, CANCER RES, V54, P5643; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; SOZZI G, 1992, CANCER RES, V52, P6079; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Volm M, 2000, BRIT J CANCER, V82, P1747; XU HJ, 1991, CANCER RES, V51, P2735; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	38	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5814	5821		10.1038/sj.onc.1205422	http://dx.doi.org/10.1038/sj.onc.1205422			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173053				2022-12-25	WOS:000177463400018
J	Baldwin, J; Farajallah, AM; Malmquist, NA; Rathod, PK; Phillips, MA				Baldwin, J; Farajallah, AM; Malmquist, NA; Rathod, PK; Phillips, MA			Malarial dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; PYRIMIDINE BIOSYNTHESIS; SELECTIVE ACTIVITY; PURIFICATION; INHIBITION; BREQUINAR; LEFLUNOMIDE; PURINE; COMBINATION; ATOVAQUONE	The malarial parasite relies on de novo pyrimidine biosynthesis to maintain its pyrimidine pools, and unlike the human host cell it is unable to scavenge preformed pyrimidines. Dihydroorotate dehydrogenase (DHODH) catalyzes the oxidation of dihydroorotate, (DHO) to produce orotate, a key step in pyrimidine biosynthesis. The enzyme is located in the outer membrane of the mitochondria of the malarial parasite. To characterize the biochemical properties of the malarial enzyme, an N-terminally truncated version of P. falciparum DHODH has been expressed as a soluble, active enzyme in E. coli. The recombinant enzyme binds 0.9 molar equivalents of the cofactor FMN and it has a pH maximum of 8.0 (k(cat) 8 s(-1), K-m(aPP) DHO (40-80 mum)). The substrate specificity of the ubiquinone cofactor (CoQ(n)) that is required for the oxidation of FMN in the second step of the reaction was also determined. The isoprenoid (n) length of CoQ(n) was a determinant of reaction efficiency; CoQ(4), CoQ(6) and decylubiquinone (COQ(D)) were efficiently utilized in the reaction, however cofactors lacking an isoprenoid tail (CoQ(0) and vitamin K-3) showed decreased catalytic efficiency resulting from a 4 to 7-fold increase in K-m(app). Five potent inhibitors of mammalian DHODH, Redoxal, dichloroallyl lawsone (DCL), and three analogs of A77 1726 were tested as inhibitors of the malarial enzyme. All five compounds were poor inhibitors of the malarial enzyme, with IC50's ranging from 0.1-1.0 mm. The IC50 values for inhibition of the malarial enzyme are 10(2)-10(4)-fold higher than the values reported for the mammalian enzyme, demonstrating that inhibitor binding to DHODH is species specific. These studies provide direct evidence that the malarial DHODH active site is different from the host enzyme, and that it is an attractive target for the development of new anti-malarial agents.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle; Center for Infectious Disease Research	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Margaret.Phillips@UTSouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432, R01AI040956, R29AI026912, R01AI026912] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40956, R01-AI34432, AI26912] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Baca AM, 2000, INT J PARASITOL, V30, P113, DOI 10.1016/S0020-7519(00)00019-9; Batt DG, 1998, BIOORG MED CHEM LETT, V8, P1745, DOI 10.1016/S0960-894X(98)00308-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breman JG, 2001, AM J TROP MED HYG, V64, P1; CLEAVELAND ES, 1995, BIOCHEM PHARMACOL, V49, P947, DOI 10.1016/0006-2952(95)00009-O; Copeland RA, 2000, J BIOL CHEM, V275, P33373, DOI 10.1074/jbc.M004451200; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Gardner MJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P69; GERO AM, 1990, BLOOD CELLS, V16, P467; Goldenberg MM, 1999, CLIN THER, V21, P1837, DOI 10.1016/S0149-2918(00)86732-6; Grishin NV, 1996, PROTEINS, V24, P272, DOI 10.1002/(SICI)1097-0134(199602)24:2<272::AID-PROT17>3.0.CO;2-K; GUTTERIDGE WE, 1970, J PROTOZOOL, V17, P89, DOI 10.1111/j.1550-7408.1970.tb05163.x; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Herrmann ML, 2000, IMMUNOPHARMACOLOGY, V47, P273, DOI 10.1016/S0162-3109(00)00191-0; HINES V, 1986, J BIOL CHEM, V261, P1386; Jiang L, 2000, ANTIMICROB AGENTS CH, V44, P1047, DOI 10.1128/AAC.44.4.1047-1050.2000; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Knecht W, 2000, FEBS LETT, V467, P27, DOI 10.1016/S0014-5793(00)01117-0; Knecht W, 2000, CHEM-BIOL INTERACT, V124, P61, DOI 10.1016/S0009-2797(99)00144-1; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Kuo EA, 1996, J MED CHEM, V39, P4608, DOI 10.1021/jm9604437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC SB, 1993, MOL BIOCHEM PARASIT, V60, P349, DOI 10.1016/0166-6851(93)90148-Q; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Marcinkeviciene J, 2000, BIOCHEM PHARMACOL, V60, P339, DOI 10.1016/S0006-2952(00)00348-8; McLean JE, 2001, BIOCHEMISTRY-US, V40, P2194, DOI 10.1021/bi001810q; McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7; Miller R W, 1978, Methods Enzymol, V51, P63; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nara T, 2000, GENE, V257, P209, DOI 10.1016/S0378-1119(00)00411-X; Phillips RS, 2001, CLIN MICROBIOL REV, V14, P208, DOI 10.1128/CMR.14.1.208-226.2001; Pitts WJ, 1998, BIOORG MED CHEM LETT, V8, P307, DOI 10.1016/S0960-894X(98)00010-9; RATHOD PK, 1992, ANTIMICROB AGENTS CH, V36, P704, DOI 10.1128/AAC.36.4.704; RATHOD PK, 1994, ANTIMICROB AGENTS CH, V38, P476, DOI 10.1128/AAC.38.3.476; RATHOD PK, 1989, ANTIMICROB AGENTS CH, V33, P1090, DOI 10.1128/AAC.33.7.1090; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Ullrich A, 2001, EUR J BIOCHEM, V268, P1861, DOI 10.1046/j.1432-1033.2001.02061.x; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	45	96	99	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41827	41834		10.1074/jbc.M206854200	http://dx.doi.org/10.1074/jbc.M206854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12189151	hybrid			2022-12-25	WOS:000178985300068
J	Cho, WJ; Yoon, WJ; Moon, CH; Cha, SJ; Song, H; Cho, HR; Jang, SJ; Chung, DK; Jeong, CS; Park, JW				Cho, WJ; Yoon, WJ; Moon, CH; Cha, SJ; Song, H; Cho, HR; Jang, SJ; Chung, DK; Jeong, CS; Park, JW			Molecular cloning of a novel chaperone-like protein induced by rhabdovirus infection with sequence similarity to the bacterial extracellular solute-binding protein family 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HEMATOPOIETIC NECROSIS VIRUS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; IN-VITRO; REVERSE-TRANSCRIPTASE; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE-SEQUENCE; CALNEXIN; GLYCOPROTEIN	Previously we demonstrated that a novel stress protein is induced in fish cells by the infection of a fish rhabdovirus (Cho W. J., Cha, S. J., Do, J. W., Choi, J. Y., Lee, J. Y., Jeong, C. S., Cho, K. J., Choi, W. S., Kang, H. S., Kim, H. D., and Park, J. W. (1997) Biochem. Biophys. Res. Commun. 233, 316-319). In this paper, we present the molecular cloning and characterization of a gene encoding this protein named virus-inducible stress protein (VISP). The VISP was purified partially by immunoprecipitation using a monoclonal antibody against the VISP and further purified by the electroelution from a SDS-PAGE gel. The protein was subjected to internal protein sequencing, and the sequence of three peptides was determined. Degenerate oligonucleotides based on the three peptide sequences were used to screen a cDNA library from rhabdovirus-infected CHSE-214 fish cells, and a cDNA of a 2193-bp open reading frame encoding the VISP with 730 amino acid residues (M-r = 79.84) was identified. Whereas the nucleotide sequence of VISP shows no similarity with other genes in the GenBank(TM), the amino acid sequence of the VISP has similarity with the bacterial extracellular solute-binding protein family 5 (SBP_bac_5) that is proposed to have chaperone activity. Thus, we explored whether the VISP also had chaperone-like activity. Purified recombinant VISP expressed in Escherichia coli promoted the functional folding of alpha-glucosidase after urea denaturation and also prevented thermal aggregation of alcohol dehydrogenase. These results suggest that the VISP has amino acid sequence similarity with SBP-bac-5 and that it has chaperone activity that may play a role in virus infection.	Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Ulsan Univ Hosp, Dept Surg, Coll Med, Ulsan 682060, South Korea; Kyung Hee Univ, Dept Genet Engn, Kyonggi Do 449701, South Korea; Kyung Hee Univ, RNA Inc, Kyonggi Do 449701, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Ulsan University Hospital; Kyung Hee University; Kyung Hee University	Park, JW (corresponding author), Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea.	jwpark@uou.ulsan.ac.kr	chung, dae kyun/AAG-1058-2021					AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Cho WJ, 1997, BIOCHEM BIOPH RES CO, V233, P316, DOI 10.1006/bbrc.1997.6387; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gaudin Y, 1997, J VIROL, V71, P3742, DOI 10.1128/JVI.71.5.3742-3750.1997; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOGG RW, 1991, MOL GEN GENET, V229, P453, DOI 10.1007/BF00267469; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; Ishii T, 1999, J IMMUNOL, V162, P1303; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; Lee JY, 1996, J GEN VIROL, V77, P1731, DOI 10.1099/0022-1317-77-8-1731; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Matsuzaki M, 1998, J BACTERIOL, V180, P2718, DOI 10.1128/JB.180.10.2718-2722.1998; Mirazimi A, 1998, J VIROL, V72, P8705, DOI 10.1128/JVI.72.11.8705-8709.1998; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; PARK MA, 1993, J FISH DIS, V16, P471, DOI 10.1111/j.1365-2761.1993.tb00880.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; Richarme G, 1997, J BIOL CHEM, V272, P15607, DOI 10.1074/jbc.272.25.15607; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SANTOMENNA LD, 1990, J VIROL, V64, P2033, DOI 10.1128/JVI.64.5.2033-2040.1990; Sedger L, 1996, VIROLOGY, V225, P423, DOI 10.1006/viro.1996.0619; SEDGER L, 1994, J VIROL, V68, P4685, DOI 10.1128/JVI.68.7.4685-4689.1994; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TANGUY LGN, 2002, J BIOL CHEM, V277, P5660; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Xu AM, 1998, J VIROL, V72, P9865, DOI 10.1128/JVI.72.12.9865-9872.1998; Yamashita Y, 1996, J VIROL, V70, P2237, DOI 10.1128/JVI.70.4.2237-2246.1996; [No title captured]	49	6	8	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41489	41496		10.1074/jbc.M207104200	http://dx.doi.org/10.1074/jbc.M207104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12183466	hybrid			2022-12-25	WOS:000178985300026
J	Inoue, H; Furukawa, T; Giannakopoulos, S; Zhou, SL; King, DS; Tanese, N				Inoue, H; Furukawa, T; Giannakopoulos, S; Zhou, SL; King, DS; Tanese, N			Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SWI-SNF COMPLEX; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; REGULATE TRANSCRIPTION; HISTONE ACETYLATION; DROSOPHILA-BRAHMA; HUMAN HOMOLOGS; TARGET GENES; FAMILY	The mammalian SWI/SNF-related complexes facilitate gene transcription by remodeling chromatin using the energy of ATP hydrolysis. The recruitment of these complexes to promoters remains poorly understood and may involve histone modifications or direct interactions with site-specific transcription factors or other cofactors. Here we report the isolation of two related but distinct cDNA clones, hOsa1 and hOsa2, that encode the largest subunits of human SWI/SNF. hOsa1 is identical to previously reported BAF250, and hOsa2 shares a high degree of sequence similarity with hOsa1. Mass spectrometric analysis, and immunoblotting with antibodies specific to hOsa1 or hOsa2 demonstrate the presence of both proteins in SWI/SNF-A but not in the related polybromo-BRG1-associated factors complex purified from HeLa cells. Co-precipitation studies indicate that hOsal and hOsa2 associate with BRG1 and hBRM through the C-terminal domain of hOsa. We define multiple domains within hBRM and BRG1 that interact with the hOsa C terminus. In cultured mammalian cells, hOsa1 and hOsa2 stimulate transcription by the glucocorticoid, estrogen, and androgen receptors. The glucocorticoid receptor-mediated activation is not observed with the C-terminal domain or with the hOsa2 polypeptide lacking the ARID DNA binding domain. These results suggest that hOsa1 and hOsa2 participate in promoting transcriptional activation by the steroid hormone receptors.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	New York University; New York University; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Tanese, N (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.			Tanese, Naoko/0000-0002-1946-3211				Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gregory SL, 1996, MOL CELL BIOL, V16, P792; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Hurlstone AFL, 2002, BIOCHEM J, V364, P255, DOI 10.1042/bj3640255; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Kal AJ, 2000, GENE DEV, V14, P1058; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozmik Z, 2001, GENOMICS, V73, P140, DOI 10.1006/geno.2001.6477; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Mangel L, 1998, J BIOL CHEM, V273, P30466, DOI 10.1074/jbc.273.46.30466; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Treisman JE, 1997, GENE DEV, V11, P1949, DOI 10.1101/gad.11.15.1949; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vazquez M, 1999, DEVELOPMENT, V126, P733; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	52	92	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41674	41685		10.1074/jbc.M205961200	http://dx.doi.org/10.1074/jbc.M205961200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200431	hybrid			2022-12-25	WOS:000178985300049
J	Sadlish, H; Williams, FMR; Flintoff, WF				Sadlish, H; Williams, FMR; Flintoff, WF			Functional role of arginine 373 in substrate translocation by the reduced folate carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; METHOTREXATE RESISTANCE; FOLIC-ACID; ANTIFOLATE RESISTANCE; CROSS-LINKING; TRANSPORT; LEUKEMIA; GENE; MEMBRANE; 5,10-DIDEAZATETRAHYDROFOLATE	The reduced folate carrier (RFC) plays a critical role in the cellular uptake of folates. However, little is known regarding the mechanism used to transport substrates or the tertiary structure of the protein. Through the analysis of a Chinese hamster ovary cell line deficient in folate uptake, we have identified a single residue in TM10 (Arg-373) of RFC that appears to play a critical role in the translocation of substrate. Replacement of this position with various amino acids (KHQNA) diminished the rate of translocation by 16-50-fold, although substrate binding, protein stability, and localization were unaffected. Furthermore, the translocation capabilities of an R373C mutant in a cysteine-less form of the reduced folate carrier were enhanced 2.5-fold by the positively charged methanethiosulfonate reagent, confirming the essential role of a positive charge at this position. When considering the membrane-impermeable nature of this reagent, the data further suggest that the Arg-373 residue is located within the substrate translocation pathway of the RFC protein. Moreover, cross-linking analysis of the Arg-373 residue demonstrates that it is within 6 A of residue Glu-394 (TM11), providing the first definitive tertiary structural information for this protein.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Flintoff, WF (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.							BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; CHAN FPH, 1995, CYTOGENET CELL GENET, V71, P148, DOI 10.1159/000134095; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1976, IN VITRO CELL DEV B, V12, P749, DOI 10.1007/BF02835450; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Guo W, 1999, CLIN CANCER RES, V5, P621; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Kim YM, 2001, J BIOL CHEM, V276, P36681, DOI 10.1074/jbc.M106079200; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Ma DQ, 2000, BIOCHEM BIOPH RES CO, V279, P891, DOI 10.1006/bbrc.2000.4019; MURRAY RC, 1997, THESIS U W ONTARIO L; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sadlish H, 2000, BIOCHEM J, V346, P509, DOI 10.1042/0264-6021:3460509; Sadlish H, 2002, BIOCHEM J, V364, P777, DOI 10.1042/BJ20011361; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sharina IG, 2002, BIOCHEM PHARMACOL, V63, P1717, DOI 10.1016/S0006-2952(02)00955-3; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 2000, MOL PHARMACOL, V57, P317	33	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42105	42112		10.1074/jbc.M206459200	http://dx.doi.org/10.1074/jbc.M206459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194981	hybrid			2022-12-25	WOS:000178985300101
J	Yoon, HY; Cho, EH; Kwon, HY; Choi, SY; Cho, SW				Yoon, HY; Cho, EH; Kwon, HY; Choi, SY; Cho, SW			Importance of glutamate 279 for the coenzyme binding of human glutamate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; BOVINE LIVER; ESCHERICHIA-COLI; CLOSTRIDIUM-SYMBIOSUM; SITE; IDENTIFICATION; BRAIN; ISOPROTEINS; DOMAIN; ADP	Although the structure of glutamate dehydrogenase (GDH) has been reported from various sources including mammalian GDH, there are conflicting views regarding the location and mechanism of actions of the coenzyme binding. We have expanded these speculations by photoaffinity labeling and cassette mutagenesis. Photoaffinity labeling with a specific probe, [P-32]nicotinamide 2-azidoadenosine dinucleotide, was used to identify the NAD(+) binding site within human GDH encoded by the synthetic human GDH gene and expressed in Escherichia coli as a soluble protein. Photolabel-containing peptides generated with trypsin were isolated by immobilized boronate affinity chromatography. Photolabeling of these peptides was most effectively prevented by the presence of NAD(+) during photolysis, demonstrating a selectivity of the photoprobe for the NAD(+) binding site. Amino acid sequencing and compositional analysis identified Glu(279) as the site of photoinsertion into human GDH, suggesting that Glu(279) is located at or near the NAD(+) binding site. The importance of the Glu(279) residue in the binding of NAD(+) was further examined by cassette mutagenesis with mutant enzymes containing Arg, Gly, Leu, Met, or Tyr at position 279. The mutagenesis at Glu(279) has no effects on the expression or stability of the different mutants. The K-m values for NAD(+) were 10 -14-fold greater for the mutant GDHs than for wild-type GDH, whereas the V-max values were similar for wild-type and mutant GDHs. The efficiency (k(cat)/ K-m) of the mutant GDH was reduced up to 18-fold. The decreased efficiency of the mutants results from the increase in K-m values for NAD(+). In contrast to the K-m values for NAD(+), wild-type and mutant GDHs show similar K. values for glutamate, indicating that substitution at position 279 had no appreciable effect on the affinity of enzyme for glutamate. There were no differences in sensitivities to ADP activation and GTP inhibition between wild-type and mutant GDH, suggesting that Glu(279) is not directly involved in allosteric regulation. The results with photoaffinity labeling and cassette mutagenesis studies suggest that Glu(279) plays an important role for efficient binding of NAD(+) to human GDH.	Univ Ulsan, Coll Med, Dept Biochem, Songpa Gu, Seoul 138736, South Korea; Chosun Univ, Dept Sci Educ, Coll Educ, Kwangju 501759, South Korea; Hallym Univ, Dept Physiol, Coll Med, Chunchon 200702, South Korea; Hallym Univ, Dept Gen Engn, Div Life Sci, Chunchon 200702, South Korea	University of Ulsan; Chosun University; Hallym University; Hallym University	Cho, SW (corresponding author), Univ Ulsan, Coll Med, Dept Biochem, Songpa Gu, 388-1 Poongnap Dong, Seoul 138736, South Korea.							BAILEY J, 1982, J BIOL CHEM, V257, P5579; BAILEY JM, 1987, J BIOL CHEM, V262, P12620; BANJEREE A, 1987, BIOCHEMISTRY-US, V26, P8443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; Cho SW, 1999, J BIOL CHEM, V274, P13948, DOI 10.1074/jbc.274.20.13948; Cho SW, 1998, J BIOL CHEM, V273, P31125, DOI 10.1074/jbc.273.47.31125; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; Cho SW, 2001, EUR J BIOCHEM, V268, P3205, DOI 10.1046/j.1432-1327.2001.02209.x; Choi SY, 1999, J NEUROCHEM, V72, P2162, DOI 10.1046/j.1471-4159.1999.0722162.x; DALZIEL K, 1972, BIOCHEM J, V126, P975, DOI 10.1042/bj1260975; Dalziel K, 1975, ENZYMES, V11, P1; FANG J, 1905, BIOCHEM J, V363, P81; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; FRIEDEN C, 1963, J BIOL CHEM, V238, P3286; FRIEDEN C, 1959, J BIOL CHEM, V234, P809; GEORGE A, 1980, BIOCHEMISTRY-US, V19, P6057, DOI 10.1021/bi00567a017; Gonzalez R.A., 1983, ANAL BIOCHEM, V135, P69; GUNNERSEN D, 1992, P NATL ACAD SCI USA, V89, P11949, DOI 10.1073/pnas.89.24.11949; HAEFFNERGORMLEY L, 1992, BIOCHEMISTRY-US, V31, P7807, DOI 10.1021/bi00149a010; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; Lee EY, 2001, J BIOL CHEM, V276, P47930, DOI 10.1074/jbc.M108918200; MAK AS, 1978, ANAL BIOCHEM, V84, P432, DOI 10.1016/0003-2697(78)90061-1; Maurizi MR, 2002, ARCH BIOCHEM BIOPHYS, V397, P206, DOI 10.1006/abbi.2001.2703; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; OLCOTT M, 1994, BIOCHEMISTRY-US, V33, P11835; PAL PK, 1979, BIOCHEMISTRY-US, V18, P838, DOI 10.1021/bi00572a016; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Peterson PE, 1997, J STRUCT BIOL, V120, P73, DOI 10.1006/jsbi.1997.3899; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; RICE DW, 1985, J MOL BIOL, V181, P147, DOI 10.1016/0022-2836(85)90334-1; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHMIDT JA, 1984, J BIOL CHEM, V259, P4515; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Shoemaker MT, 1996, BIOCONJUGATE CHEM, V7, P302, DOI 10.1021/bc960014n; SINGH N, 1993, J BIOL CHEM, V268, P21; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; SMITH T, 1982, BIOCHEMISTRY-US, V21, P733, DOI 10.1021/bi00533a023; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; STILLMAN TJ, 1993, J MOL BIOL, V234, P1131, DOI 10.1006/jmbi.1993.1665; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TZIMAGIORGIS G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P250, DOI 10.1016/0167-4781(91)90017-G; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987; VERONESE FM, 1974, J BIOL CHEM, V249, P7922; WOOTTON JC, 1974, NATURE, V252, P542, DOI 10.1038/252542a0; WOOTTON JC, 1974, P NATL ACAD SCI USA, V71, P4361, DOI 10.1073/pnas.71.11.4361; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Yoon HY, 2002, BIOCHEMISTRY-US, V41, P6817, DOI 10.1021/bi0121757	57	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41448	41454		10.1074/jbc.M208208200	http://dx.doi.org/10.1074/jbc.M208208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12193607	hybrid			2022-12-25	WOS:000178985300021
J	Huss, M; Ingenhorst, G; Konig, S; Gassel, M; Drose, S; Zeeck, A; Altendorf, K; Wieczorek, H				Huss, M; Ingenhorst, G; Konig, S; Gassel, M; Drose, S; Zeeck, A; Altendorf, K; Wieczorek, H			Concanamycin a, the specific inhibitor of V-ATPases, binds to the V-o subunit c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM; PLASMA-MEMBRANE; H+-ATPASE; P-TYPE; PROTEINS; BAFILOMYCIN; CELLS; PURIFICATION; CONTAINS; MIDGUT	Vacuolar-type ATPase (V-ATPase) purified from the midgut of the tobacco hornworm Manduca sexta is inhibited 50% by 10 nm of the plecomacrolide concanamycin A, the specific inhibitor of V-ATPases. To determine the binding site(s) of that antibiotic in the enzyme complex, labeling with the semisynthetic 9-O-[p-(trifluoroethyldiazirinyl)-benzoyl]-21,23-dideoxy-23-[I-125]iodo-concanolide A (J-concanolide A) was performed, which still inhibits the V-ATPase 50% at a concentration of 15-20 mum. Upon treatment with UV light, a highly reactive carbene is generated from this concanamycin derivative, resulting in the formation of a covalent bond to the enzyme. In addition, the radioactive tracer 1251 makes the detection of the labeled subunit(s) feasible. Treatment of the V-1/V-o holoenzyme, the V-o complex, and the V-ATPase containing goblet cell apical membranes with concanolide resulted in the labeling of only the proteolipid, subunit c, of the proton translocating V-o complex. Binding of J-concanolide A to subunit c was prevented in a concentration-dependent manner by concanamycin A, indicating that labeling was specific. Binding was also prevented by the plecomacrolides bafilomycin A(1) and B-1 respectively, but not by the benzolactone enamide salicylihalamide, a member of a novel class of V-ATPase inhibitors.	Univ Osnabruck, Fachbereich Biol Chem, Abt Tierphysiol, D-49069 Osnabruck, Germany	University Osnabruck	Wieczorek, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Tierphysiol, D-49069 Osnabruck, Germany.	wieczorek@biologie.uni-osnabrueck.de	König, Simone/B-6504-2008; Dröse, Stefan/E-4903-2010	König, Simone/0000-0003-0672-7246; Dröse, Stefan/0000-0002-9361-9034				ADACHI I, 1990, J BIOL CHEM, V265, P960; AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; BELL RA, 1974, J INSECT PHYSIOL, V20, P669, DOI 10.1016/0022-1910(74)90189-9; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 2001, BIOCHEMISTRY-US, V40, P2816, DOI 10.1021/bi001759q; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GRAF R, 1994, J BIOL CHEM, V269, P3767; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Ingenhorst G, 2001, EUR J ORG CHEM, V2001, P4525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; Merzendorfer H, 1997, FEBS LETT, V411, P239, DOI 10.1016/S0014-5793(97)00699-6; Merzendorfer H, 1999, J BIOL CHEM, V274, P17372, DOI 10.1074/jbc.274.24.17372; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; RATAJCZAK R, 1994, BOT ACTA, V107, P201, DOI 10.1111/j.1438-8677.1994.tb00787.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450; Wieczorek H, 2000, J EXP BIOL, V203, P127; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	34	207	213	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40544	40548		10.1074/jbc.M207345200	http://dx.doi.org/10.1074/jbc.M207345200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186879	hybrid			2022-12-25	WOS:000178791400051
J	Matsuura, H; Nishitoh, H; Takeda, K; Matsuzawa, A; Amagasa, T; Ito, M; Yoshioka, K; Ichijo, H				Matsuura, H; Nishitoh, H; Takeda, K; Matsuzawa, A; Amagasa, T; Ito, M; Yoshioka, K; Ichijo, H			Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN-280; KINASE 1 ASK1; APOPTOSIS; STRESS; TRANSDUCTION; ACTIVATION; INHIBITOR; INDUCTION; COMPLEX; CLONING	JSAP1 (also termed JIP3) is a scaffold protein that interacts with specific components of the JNK signaling pathway. Apoptosis signal-regulating kinase (ASK) 1 is a MAP kinase kinase kinase that activates the JNK and p38 mitogen-activated protein (MAP) kinase cascades in response to environmental stresses such as reactive oxygen species. Here we show that JSAP1 bound ASK1 and enhanced ASK1- and H2O2-induced JNK activity. ASK1 phosphorylated JSAP1 in vitro and in vivo, and the phosphorylation facilitated interactions of JSAP1 with SEK1/MKK4, MKK7 and JNK3. Furthermore, ASK1-dependent phosphorylation was required for JSAP1 to recruit and thereby activate JNK in response to H2O2. We thus conclude that JSAP1 functions not only as a simple scaffold, but it dynamically participates in signal transduction by forming a phosphorylation-dependent signaling complex in the ASK1-JNK signaling module.	Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa 2288555, Japan; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan	Kanazawa University; Kitasato University; Tokyo Medical & Dental University (TMDU)		ichijo@mol.f.u-tokyo.ac.jp	Matsuzawa, Atsushi/GLU-1387-2022	Nishitoh, Hideki/0000-0002-8652-4109; Matsuzawa, Atsushi/0000-0001-8303-3905; Takeda, Kohsuke/0000-0002-8359-8399; Ichijo, Hidenori/0000-0002-5005-6438				Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200	34	82	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40703	40709		10.1074/jbc.M202004200	http://dx.doi.org/10.1074/jbc.M202004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189133	hybrid, Green Submitted			2022-12-25	WOS:000178791400070
J	Ohta, S; Shiomi, Y; Sugimoto, K; Obuse, C; Tsurimoto, T				Ohta, S; Shiomi, Y; Sugimoto, K; Obuse, C; Tsurimoto, T			A proteomics approach to identify proliferating cell nuclear antigen (PCNA)-binding proteins in human cell lysates - Identification of the human CHL12/RFCs2-5 complex as a novel PCNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; SISTER-CHROMATID COHESION; DNA-POLYMERASE-DELTA; SIMIAN VIRUS-40 DNA; RUVB-LIKE PROTEIN; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; PURIFICATION; HOLOENZYME; EXTRACTS	Proliferating cell nuclear antigen (PCNA), a eukaryotic DNA replication factor, functions not only as a processivity factor for DNA polymerase 5 but also as a binding partner for multiple other factors. To understand its broad significance, we have carried out systematic studies of PCNA-binding proteins by a combination of affinity chromatography and mass spectrometric analyses. We detected more than 20 specific protein bands of various intensities in fractions bound to PCNA-fixed resin from human cell lysates and determined their peptide sequences by liquid chromatography and tandem mass spectrometry. A search with human protein data bases identified 12 reported PCNA-binding proteins from both cytoplasmic (S100 lysate) and nuclear extracts with substantial significance and four more solely from the nuclear preparation. CHL12, a factor involved in checkpoint response and chromosome cohesion, was a novel example found in both lysates. Further studies with recombinant proteins demonstrated that CHL12 and small subunits of replication factor C form a complex that interacts with PCNA.	Nara Inst Sci & Technol, Nara 6300101, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4640814, Japan	Nara Institute of Science & Technology; Nagoya University	Tsurimoto, T (corresponding author), Nara Inst Sci & Technol, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hannan RD, 1999, NUCLEIC ACIDS RES, V27, P3720, DOI 10.1093/nar/27.18.3720; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 2002, P NATL ACAD SCI USA, V99, P9133, DOI 10.1073/pnas.142277999; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8	40	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40362	40367		10.1074/jbc.M206194200	http://dx.doi.org/10.1074/jbc.M206194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171929	hybrid			2022-12-25	WOS:000178791400027
J	Torok, M; Milton, S; Kayed, R; Wu, P; McIntire, T; Glabe, CG; Langen, R				Torok, M; Milton, S; Kayed, R; Wu, P; McIntire, T; Glabe, CG; Langen, R			Structural and dynamic features of Alzheimer's A beta peptide in amyloid fibrils studied by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; X-RAY-DIFFRACTION; SOLID-STATE NMR; T4 LYSOZYME; DISEASE; PROTEIN; AGGREGATION; SHEET; MODEL; PARALLEL	Electron paramagnetic resonance spectroscopy analysis of 19 spin-labeled derivatives of the Alzheimer's amyloid beta (Abeta) peptide was used to reveal structural features of amyloid fibril formation. In the fibril, extensive regions of the peptide show an in-register, parallel arrangement. Based on the parallel arrangement and side chain mobility analysis we find the amyloid structure to be mostly ordered and specific, but we also identify more dynamic regions (N and C termini) and likely turn or bend regions (around residues 23-26). Despite their different aggregation properties and roles in disease, the two peptides, Abeta40 and Abeta42, homogeneously co-mix in amyloid fibrils suggesting that they possess the same structural architecture.	Univ Calif Irvine, Dept Biol Mol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ So Calif, Keck Sch Med, Neurogenet Inst, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Southern California; University of Southern California	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Biol Mol, Irvine, CA 92697 USA.	cglabe@uci.edu; langen@usc.edu			NINDS NIH HHS [NS 31230] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Blackley HKL, 1999, EXP NEUROL, V158, P437, DOI 10.1006/exnr.1999.7114; BURDICK D, 1992, J BIOL CHEM, V267, P546; Clements A, 1996, J NEUROCHEM, V66, P740; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Gregory DM, 1998, SOLID STATE NUCL MAG, V13, P149, DOI 10.1016/S0926-2040(98)00086-1; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KIRSCHNER DA, 2002, 23 ACS NAT M POLYM P, P187; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lundberg KM, 1997, CHEM BIOL, V4, P345, DOI 10.1016/S1074-5521(97)90125-3; Lynn DG, 2000, J STRUCT BIOL, V130, P153, DOI 10.1006/jsbi.2000.4287; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; SZENDREI GI, 1994, EUR J BIOCHEM, V226, P917, DOI 10.1111/j.1432-1033.1994.t01-1-00917.x; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	46	325	333	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40810	40815		10.1074/jbc.M205659200	http://dx.doi.org/10.1074/jbc.M205659200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181315	hybrid			2022-12-25	WOS:000178791400084
J	Yoshimura, K; Yabuta, Y; Ishikawa, T; Shigeoka, S				Yoshimura, K; Yabuta, Y; Ishikawa, T; Shigeoka, S			Identification of a cis element for tissue-specific alternative splicing of chloroplast ascorbate peroxidase pre-mRNA in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ARABIDOPSIS-THALIANA; DEFENSE SYSTEM; ISOENZYMES; PROTEINS; STRESS; EXON; EXPRESSION; SEQUENCES; CATALASE	Alternative splicing events in the 3'-terminal region of chloroplast ascorbate peroxidase (ch1APX) pre-mRNA in spinach and tobacco, which produced four types of mRNA variants, one form (tAPX-I) encoding thylakoid-bound APX (tAPX) and three forms (sAPX-I, -II, and -III) encoding stromal APX (sAPX), were regulated in a tissue-specific manner. The ratio of the level of sAPX mRNAs (sAPX-I, -II, and -III) to tAPX-I mRNA was close to 1 in leaf, whereas the ratio in root was greatly elevated due to an increase in sAPX-III and a decrease in tAPX-I resulting from the alternative excision of intron 11 and intron 12, respectively. A putative splicing regulatory cis element, (SRE), which is highly conserved in the sequences of ch1APX genes of higher plants, was identified upstream of the acceptor site in intron 12. The deletion of the SRE sequence diminished the splicing efficiency of intron 12 in tobacco leaf in vivo. Gel-shift analysis showed that SRE interacts strongly with a nuclear protein from leaves but not those from the roots of spinach and tobacco. These results indicate that the tissue-specific alternative splicing of ch1APX pre-mRNA is regulated by the splicing enhancer SRE.	Kinki Univ, Fac Agr, Dept Food & Nutr, Nara 6318505, Japan; Shimane Univ, Fac Life & Environm Sci, Matsue, Shimane 6908504, Japan	Kindai University (Kinki University); Shimane University	Shigeoka, S (corresponding author), Kinki Univ, Fac Agr, Dept Food & Nutr, 3327-204 Nakamachi, Nara 6318505, Japan.	shigeoka@nara.kindai.ac.jp	Yabuta, Yukinori/T-3615-2019	Yabuta, Yukinori/0000-0002-6982-8522				Alba MM, 1998, TRENDS PLANT SCI, V3, P15, DOI 10.1016/S1360-1385(97)01151-5; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Biemelt S, 1998, PLANT PHYSIOL, V116, P651, DOI 10.1104/pp.116.2.651; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Dalton DA, 1998, PLANT PHYSIOL, V116, P37, DOI 10.1104/pp.116.1.37; Gontarek RR, 1996, MOL CELL BIOL, V16, P2325; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; Ishikawa T, 1996, FEBS LETT, V384, P289, DOI 10.1016/0014-5793(96)00332-8; Ishikawa T, 1997, BIOCHEM J, V328, P795, DOI 10.1042/bj3280795; Jespersen HM, 1997, BIOCHEM J, V326, P305, DOI 10.1042/bj3260305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambermon MHL, 2000, EMBO J, V19, P1638, DOI 10.1093/emboj/19.7.1638; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lopato S, 1996, PLANT CELL, V8, P2255, DOI 10.1105/tpc.8.12.2255; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Mano S, 1999, PLANT J, V17, P309, DOI 10.1046/j.1365-313X.1999.00378.x; Mano S, 1997, FEBS LETT, V413, P21, DOI 10.1016/S0014-5793(97)00862-4; Matamoros MA, 1999, PLANT PHYSIOL, V121, P97, DOI 10.1104/pp.121.1.97; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Miyagawa Y, 2000, PLANT CELL PHYSIOL, V41, P311, DOI 10.1093/pcp/41.3.311; Moore M., 1993, RNA WORLD, P303; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; ROBINSON DG, 2001, PLANT CELL BIOL, P295; RUNDLE SJ, 1991, J BIOL CHEM, V266, P14802; Shigeoka S, 2002, J EXP BOT, V53, P1305, DOI 10.1093/jexbot/53.372.1305; Shikanai T, 1998, FEBS LETT, V428, P47, DOI 10.1016/S0014-5793(98)00483-9; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; VALCARCEL J, 1995, PREMRNA PROCESSING, P97; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Yoshimura K, 2000, PLANT PHYSIOL, V123, P223, DOI 10.1104/pp.123.1.223; Yoshimura K, 1999, BIOCHEM J, V338, P41, DOI 10.1042/0264-6021:3380041; Yoshimura K, 2001, BBA-GEN SUBJECTS, V1526, P168, DOI 10.1016/S0304-4165(01)00131-3	36	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40623	40632		10.1074/jbc.M201531200	http://dx.doi.org/10.1074/jbc.M201531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176976	hybrid			2022-12-25	WOS:000178791400061
J	Iwasaki, T; Kounosu, A; Aoshima, M; Ohmori, D; Imai, T; Urushiyama, A; Cosper, NJ; Scott, RA				Iwasaki, T; Kounosu, A; Aoshima, M; Ohmori, D; Imai, T; Urushiyama, A; Cosper, NJ; Scott, RA			Novel [2Fe-2S]-type redox center C in SdhC of archaeal respiratory complex II from Sulfolobus tokodaii strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOACIDOPHILIC ARCHAEON; SUCCINATE-DEHYDROGENASE; FUMARATE REDUCTASE; CRYSTAL-STRUCTURES; PRE-EDGE; FERREDOXIN; RESOLUTION; OXIDASE; SYSTEM; OXIDOREDUCTASE	The SdhC subunit of the archaeal respiratory complex 11 (succinate:quinone oxidoreductase) from Sulfolobus tokodaii strain 7 has a novel cysteine rich motif and is also related to archaeal and bacterial heterodisulfide reductase subunits. We overexpressed the sdhC gene heterologously in Escherichia coli and characterized the gene product in greater detail. Low temperature resonance Raman and x-ray absorption spectroscopic investigation collectively demonstrate the presence of a We-M cluster core with complete cysteinyl ligation (Center C) and an isolated zinc site in the recombinant SdhC. The [2Fe-2S](2+) cluster core is sensitive to dithionite, resulting in irreversible breakdown of the Fe-Fe interaction. EPR analysis confirmed that the novel Center C is an inherent redox center in the archaeal complex II, showing unique EPR signals in the succinate-reduced state. Distinct subunit and cofactor arrangements in the S. tokodaii respiratory complex 11, as compared with those in mitochondrial and some mesophilic bacterial enzymes, indicate modular evolution of this ubiquitous electron entry site in the respiratory chains of aerobic organisms.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan; Juntendo Univ, Dept Chem, Inba, Chiba 2701695, Japan; Rikkyo St Pauls Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Nippon Medical School; University of Tokyo; Juntendo University; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan.	tiwasaki@nms.ac.jp		Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42025] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BERTRAND P, 1985, BIOCHIM BIOPHYS ACTA, V831, P261, DOI 10.1016/0167-4838(85)90044-5; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; ENROTH C, 1999, FLAVINS FLAVOPROTEIN, P783; Gomes CM, 1999, BBA-BIOENERGETICS, V1411, P134, DOI 10.1016/S0005-2728(99)00046-8; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iwasaki T, 2000, J BIOL CHEM, V275, P25391, DOI 10.1074/jbc.M909243199; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; Iwasaki T, 2002, EPR IN THE 21ST CENTURY: BASICS AND APPLICATIONS TO MATERIAL, LIFE AND EARTH SCIENCES, P488, DOI 10.1016/B978-044450973-4/50083-4; Iwasaki T, 2001, METHOD ENZYMOL, V334, P3; Iwasaki T, 1996, FEMS MICROBIOL LETT, V144, P259; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; IWASAKI T, 1999, FLAVINS FLAVOPROTEIN, P779; Janssen S, 1997, J BACTERIOL, V179, P5560, DOI 10.1128/jb.179.17.5560-5569.1997; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lemos RS, 2001, BIOCHEM BIOPH RES CO, V281, P141, DOI 10.1006/bbrc.2001.4317; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Suzuki T, 2002, EXTREMOPHILES, V6, P39, DOI 10.1007/s007920100221; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	39	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39642	39648		10.1074/jbc.M207312200	http://dx.doi.org/10.1074/jbc.M207312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167658	hybrid			2022-12-25	WOS:000178662500076
J	Yellaturu, CR; Bhanoori, M; Neeli, I; Rao, GN				Yellaturu, CR; Bhanoori, M; Neeli, I; Rao, GN			N-ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; HYDROGEN-PEROXIDE; REDOX REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; CELL-SURVIVAL; CYTOCHROME-C; 4E-BINDING PROTEIN-1; IN-VIVO; APOPTOSIS	The redox state plays an important role in gene regulation. Thiols maintain the intracellular redox homeostasis. To understand the role of thiols in redox signaling, we have studied the effect of thiol alkylation on platelet-derived growth factor-BB (PDGF-BB)-induced cell survival events in vascular smooth muscle cells. PDGF-BB stimulated Akt phosphorylation predominantly at Ser-473. N-Ethylmaleimide (NEM), a thiol alkylating agent, blocked PDGF-BB-induced Akt phosphorylation without affecting its upstream phosphatidylinositol 3-kinase (PI3K). On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E. NEM also abrogated the phosphorylation of p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E induced by PDGF-BB, suggesting that thiol alkylation interferes with the PI3K/Akt pathway at the level of Akt. In addition, NEM blocked PDGF-BB-induced phosphorylation of BAD and forkhead transcription factor FKHR-L1, and these events correlated with increased apoptosis. NEM alone and in concert with PDGF-BB increased reactive oxygen species (ROS) production and protein phosphatase 2A (PP2A) activity in VSMC. The inhibition of PDGF-BB-induced Akt phosphorylation by NEM was completely reversed by PP2A inhibitors fostriecin and okadaic acid, ceramide synthase inhibitor fumonisin B1, and ROS scavenger N-acetylcysteine (NAC). NAC also attenuated the apoptosis induced by NEM, alone or in combination with PDGF-BB. Together, these findings demonstrate for the first time that PP2A mediates thiol alkylation-dependent redox regulation of Akt and cell survival.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu	Bhanoori, Manjula/ACH-9333-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Clottes E, 1998, J BIOL CHEM, V273, P19391, DOI 10.1074/jbc.273.31.19391; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dufner A, 1999, MOL CELL BIOL, V19, P4525; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Evans DRH, 2001, FEBS LETT, V498, P110, DOI 10.1016/S0014-5793(01)02448-6; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HOSHI T, 2001, J PHYSL, V15, P1; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	62	110	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40148	40155		10.1074/jbc.M206376200	http://dx.doi.org/10.1074/jbc.M206376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171932	hybrid			2022-12-25	WOS:000178662500138
J	Dugan, KA; Wood, MA; Cole, MD				Dugan, KA; Wood, MA; Cole, MD			TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis	ONCOGENE			English	Article						Myc; E2F; TIP49; TRRAP; apoptosis; proliferation	HISTONE ACETYLASE COMPLEX; CELL-CYCLE PROGRESSION; ESSENTIAL COFACTOR; S-PHASE; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; GROWTH CONTROL; DNA-BINDING; TRANSCRIPTION; PROTEIN	We previously described two nuclear cofactors, TRRAP and TIP49, that have functional roles in Myc-mediated oncogenesis. We have now expanded the analysis of these Myc-associated cofactors to investigate their roles in apoptosis and cell proliferation. Although TRRAP and TIP49 are both essential for transformation, TIP49 modulates c-Myc-mediated apoptosis whereas disruption of TRRAP activity has no apparent effect on apoptosis. We extended our analysis of TIP49 to show that it also binds to the E2F1 transactivation domain and modulates both transforming and apoptotic activities. These results indicate that individual cofactors differentially potentiate c-Myc and E2F1 functions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wood, Marcelo/G-9527-2012					Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V85, P549; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lim CR, 2000, J BIOL CHEM, V275, P22409, DOI 10.1074/jbc.M001031200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mehmet H, 1997, CELL GROWTH DIFFER, V8, P187; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sladek TL, 1997, CELL PROLIFERAT, V30, P97, DOI 10.1111/j.1365-2184.1997.tb00926.x; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANCHINA E, 1998, GENE DEV, V12, P2434; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5835	5843		10.1038/sj.onc.1205763	http://dx.doi.org/10.1038/sj.onc.1205763			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185582				2022-12-25	WOS:000177520900002
J	Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H				Hirano, T; Shino, Y; Saito, T; Komoda, F; Okutomi, Y; Takeda, A; Ishihara, T; Yamaguchi, T; Saisho, H; Shirasawa, H			Dominant negative MEKK1 inhibits survival of pancreatic cancer cells	ONCOGENE			English	Article						MEKK1; ERK; JNK; AP-1; CRE; pancreatic cancer	ACTIVATED PROTEIN-KINASES; LUNG-CARCINOMA CELLS; C-JUN; CONSTITUTIVE ACTIVATION; AP-1 FUNCTION; RAS; TRANSFORMATION; GROWTH; PROLIFERATION; PATHWAY	Human pancreatic cancers harbor mutations in the K-ras gene, and these mutations convert the gene oncogenic and constitutively active forms. However, in pancreatic cancer cells little is known about the activation of the downstream pathways of Ras, MEK - ERK and MEKK1 - JNK, and their roles in cell survival and proliferation. An analysis of nine pancreatic cancer tissues revealed JNK activation in all tumor samples and ERK activation in three tumor samples. Colony formation assays by transfection of dominant negative mutants of Ras, ERK or MEKK1 into pancreatic cancer cell lines (BxPC-3, PANC-1, MIAPa-Ca-2 and AsPC-1) and an amnion-derived cell line (FL) revealed that DN - MEKK strongly inhibits the survival of colonies in pancreatic cancer cells, but not in FL cells. In vitro kinase assays and luciferase assays using the Gal4c-Jun system revealed that in pancreatic cancer cells DN-MEKK fails to inhibit JNK activation. In PANC-1 cells, c-Jun was found to be a major component of protein component binding to AP-1 site and CRE, but not in FL cells. The inhibitory effect of DN-MEKK in PANC-1 cells was thought to be the result of the inhibition of c-Jun DNA-binding. The difference of suppression in pancreatic cancer cells and non-pancreatic cancer cells suggested that the MEKK1 pathway mainly contributes to cell survival in pancreatic cancer cells and may provide an advantage for the gene therapy of pancreatic cancers using DN - MEKK expression vectors.	Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan; Chiba Univ, Dept Med & Clin Oncol K1, Grad Sch Med, Chiba 2608670, Japan	Chiba University; Chiba University	Shirasawa, H (corresponding author), Chiba Univ, Dept Mol Virol E2, Grad Sch Med, Chiba 2608670, Japan.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BRUNET A, 1994, ONCOGENE, V9, P3379; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; SCHNEIDER MTY, 1999, INT J ONCOL, V15, P271; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tessari G, 1999, ANTICANCER RES, V19, P863; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Xiao L, 2000, CANCER RES, V60, P400; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	28	43	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5923	5928		10.1038/sj.onc.1205643	http://dx.doi.org/10.1038/sj.onc.1205643			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185592				2022-12-25	WOS:000177520900012
J	Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T				Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T			DNA damage, death receptor activation and reactive oxygen species contribute to ultraviolet radiation-induced apoptosis in an essential and independent way	ONCOGENE			English	Article						apoptosis; cytochrome c; DNA damage; reactive oxygen species; UV radiation	SUNBURN CELL-FORMATION; CYTOCHROME-C RELEASE; SKIN-CANCER; MITOCHONDRIAL CONTROL; RADICAL REACTIONS; OXIDATIVE STRESS; CD95 FAS/APO-1; REPAIR; LIGHT; CARCINOGENESIS	Nuclear DNA damage and death receptor (CD95) activation by ultraviolet-B radiation (UVB) play a major role in UVB-induced apoptosis. Removal of DNA damage combined with inhibition of death receptor activation resulted in pronounced but not complete suppression of apoptosis, indicating that a third independent pathway is involved. Since reactive oxygen species (ROS) cause apoptosis and are induced by UVB, the radical scavenger pyrrolidene-dithiocarbamate (PDTC) was used. PDTC prevented UVB-induced apoptosis partially, H2O2-induced cell death largely, but not CD95-mediated apoptosis. The same was observed for cytochrome c release from mitochondria, another important event during apoptosis. The proapoptotic protein Bid was cleaved upon exposure to UVB or to agonistic anti-CD95-antibodies, but not to H2O2, indicating that H2O2 uses a different pathway. The fact that PDTC neither inhibited CD95-mediated apoptosis nor affected UV-induced DNA damage indicated that ROS generated during UVB irradiation may directly trigger mitochondrial cytochrome c release, thereby contributing to apoptosis. Accordingly, complete inhibition of apoptosis was observed when in addition to DNA damage removal via photoreactivation and blockade of CD95 signaling by caspase-8 inhibitor zIETD, PDTC was added before UVB exposure. This indicates that DNA damage, death receptor activation and ROS formation contribute to UVB-induced apoptosis in an essential and independent way.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany	University of Munster	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, von Esmarchstr 58, D-48149 Munster, Germany.	schwtho@uni-muenster.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Black HS, 2001, CURR PROBL DERMATOL, V29, P140; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; EKER APM, 1990, J BIOL CHEM, V265, P8009; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Petit-Frere C, 2000, J INVEST DERMATOL, V115, P687, DOI 10.1046/j.1523-1747.2000.00093.x; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; TYRRELL RM, 1995, BIOCH SOC S, V61, P547; Wenk J, 2001, CURR PROBL DERMATOL, V29, P83; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WOODCOCK A, 1976, BRIT J DERMATOL, V95, P459, DOI 10.1111/j.1365-2133.1976.tb00854.x; YAROSH D, 1992, CANCER RES, V52, P4227; YAROSH D, 1994, TRENDS PHOTOCHEM PHO, V3, P175; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	45	197	202	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5844	5851		10.1038/sj.onc.1205743	http://dx.doi.org/10.1038/sj.onc.1205743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185583				2022-12-25	WOS:000177520900003
J	Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM				Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM			Mismatch repair deficiency in hematological malignancies with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hematological malignancy	NUCLEAR EXTRACTS; CELL-LINES; CANCER; GENE; LEUKEMIA; BETA; HETERODIMER; SUPPRESSION; MUTATIONS; EXPRESSION	Mutations in human mismatch repair (MMR) genes are the genetic basis for certain types of solid tumors displaying microsatellite instability (MSI). MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear. Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR. In vitro complementation experiments, using characterized MMR mutant extracts or purified proteins, showed that these hematological cancer cells were defective in either hMutSalpha (a heterodimer of hMSH2 and hMSH6) or hMutLalpha (a heterodimer of hMLH1 and hPMS2). Furthermore, cell lines deficient in hMutSalpha showed large deletions or point mutations in hMSH2, while those deficient in hMutLalpha. exhibited point mutations in hMLH1 or a lack of expression of hPMS2. From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutSalpha or MutLalpha. We also report here, for the first time, that an MSI-positive cell line derived from Burkitt's lymphoma is proficient in MMR.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Gu, LY (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, 800 Rose St, Lexington, KY 40536 USA.	lgu0@uky.edu	Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NCI NIH HHS [CA85377] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DeVita S, 1997, BRIT J HAEMATOL, V97, P463, DOI 10.1046/j.1365-2141.1997.252670.x; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Hayami Y, 1999, LEUKEMIA LYMPHOMA, V32, P345, DOI 10.3109/10428199909167395; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaneko H, 1996, INT J CANCER, V69, P480, DOI 10.1002/(SICI)1097-0215(19961220)69:6<480::AID-IJC11>3.0.CO;2-5; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kodera T, 1999, GENE CHROMOSOME CANC, V26, P267, DOI 10.1002/(SICI)1098-2264(199911)26:3<267::AID-GCC13>3.0.CO;2-V; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Larson RS, 1997, BLOOD, V89, P1114, DOI 10.1182/blood.V89.3.1114; Leung WK, 2000, J BIOL CHEM, V275, P15728, DOI 10.1074/jbc.M908768199; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1999, ONCOL RES, V11, P393; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Molenaar JJ, 1998, BLOOD, V92, P230, DOI 10.1182/blood.V92.1.230.413k17_230_233; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	41	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5758	5764		10.1038/sj.onc.1205695	http://dx.doi.org/10.1038/sj.onc.1205695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173046				2022-12-25	WOS:000177463400011
J	Chou, KC; Cai, YD				Chou, KC; Cai, YD			Using functional domain composition and support vector machines for prediction of protein subcellular location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; STRUCTURAL CLASSES	Proteins are generally classified into the following 12 subcellular locations: 1) chloroplast, 2) cytoplasm, 3) cytoskeleton, 4) endoplasmic reticulum, 5) extracellular, 6) Golgi apparatus, 7) lysosome, 8) mitochondria, 9) nucleus, 10) peroxisome, 11) plasma membrane, and 12) vacuole. Because the function of a protein is closely correlated with its subcellular location, with the rapid increase in new protein sequences entering into databanks, it is vitally important for both basic research and pharmaceutical industry to establish a high throughput tool for predicting protein subcellular location. In this paper, a new concept, the so-called "functional domain composition" is introduced. Based on the novel concept, the representation for a protein can be defined as a vector in a high-dimensional space, where each of the clustered functional domains derived from the protein universe serves as a vector base. With such a novel representation for a protein, the support vector machine (SVM) algorithm is introduced for predicting protein subcellular location. High success rates are obtained by the self-consistency test, jackknife test, and independent dataset test, respectively. The current approach not only can play an important complementary role to the powerful covariant discriminant algorithm based on the pseudo amino acid composition representation (Chou, K. C. (2001) Proteins Struct. Funct. GeneL 43, 246-255; Correction (2001) Proteins Struct. Funct Genet. 44, 60), but also may greatly stimulate the development of this area.	Pharmacia & Upjohn Inc, Upjohn Labs, Kalamazoo, MI 49001 USA; Chinese Acad Sci, Shanghai Res Ctr Biotechnol, Shanghai 200233, Peoples R China	Pfizer; Chinese Academy of Sciences	Cai, YD (corresponding author), Univ Manchester, Biomol Sci Dept, PO Box 88, Manchester M60 1QD, Lancs, England.	y.cai@umist.ac.uk	Chou, Kuo-Chen/A-8340-2009	cai, yudong/0000-0001-5664-7979				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APNIK VN, 1995, NATURE STAT LEARNING; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; Bock JR, 2001, BIOINFORMATICS, V17, P455, DOI 10.1093/bioinformatics/17.5.455; Cai YD, 2002, J CELL BIOCHEM, V84, P343, DOI 10.1002/jcb.10030; Cai YD, 2001, PROTEINS, V43, P336, DOI 10.1002/prot.1045; Cai Yu-Dong, 2000, Molecular Cell Biology Research Communications, V4, P230, DOI 10.1006/mcbr.2001.0285; Cai Yu-Dong, 2000, Molecular Cell Biology Research Communications, V4, P172, DOI 10.1006/mcbr.2001.0269; Cedano J, 1997, J MOL BIOL, V266, P594, DOI 10.1006/jmbi.1996.0804; Chou KC, 1998, BIOCHEM BIOPH RES CO, V252, P63, DOI 10.1006/bbrc.1998.9498; Chou KC, 2000, BIOCHEM BIOPH RES CO, V278, P477, DOI 10.1006/bbrc.2000.3815; Chou KC, 1999, PROTEINS, V34, P137, DOI 10.1002/(SICI)1097-0134(19990101)34:1<137::AID-PROT11>3.3.CO;2-F; Chou KC, 1999, PROTEIN ENG, V12, P107, DOI 10.1093/protein/12.2.107; CHOU KC, 1995, CRIT REV BIOCHEM MOL, V30, P275, DOI 10.3109/10409239509083488; CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406; Chou KC, 1998, PROTEINS, V31, P97, DOI 10.1002/(SICI)1097-0134(19980401)31:1<97::AID-PROT8>3.0.CO;2-E; CHOU KC, 1994, J BIOL CHEM, V269, P22014; Chou KC, 2001, PROTEINS, V43, P246, DOI 10.1002/prot.1035; Chou KC, 1999, BIOCHEM BIOPH RES CO, V264, P216, DOI 10.1006/bbrc.1999.1325; Chou KC, 2000, CURR PROTEIN PEPT SC, V1, P171, DOI 10.2174/1389203003381379; CHOU PY, 1989, PREDICTION PROTEIN S, P549; CHOU PY, 1980, 2 CHEM C N AM CONT L; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Cristianini N., 2000, INTRO SUPPORT VECTOR, DOI [10.1017/CBO9780511801389, DOI 10.1017/CBO9780511801389]; Ding CHQ, 2001, BIOINFORMATICS, V17, P349, DOI 10.1093/bioinformatics/17.4.349; Hua SJ, 2001, J MOL BIOL, V308, P397, DOI 10.1006/jmbi.2001.4580; Joachims T, 1999, ADVANCES IN KERNEL METHODS, P169; Liu WM, 1998, J PROTEIN CHEM, V17, P209, DOI 10.1023/A:1022576400291; Mardia K.V., 1979, MULTIVARIATE ANAL, P322; Murvai J, 2001, NUCLEIC ACIDS RES, V29, P58, DOI 10.1093/nar/29.1.58; NAKASHIMA H, 1994, J MOL BIOL, V238, P54, DOI 10.1006/jmbi.1994.1267; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Vapnik V., 1998, STAT LEARNING THEORY; Wolfe P., 1961, Q APPL MATH, V19, P239, DOI DOI 10.1090/QAM/135625; Zhou GP, 1998, J PROTEIN CHEM, V17, P729, DOI 10.1023/A:1020713915365; Zhou GP, 2001, PROTEINS, V44, P57, DOI 10.1002/prot.1071	37	460	482	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45765	45769		10.1074/jbc.M204161200	http://dx.doi.org/10.1074/jbc.M204161200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12186861	hybrid			2022-12-25	WOS:000179529300008
J	Bidder, M; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Semenkovich, CF; Towler, DA				Bidder, M; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Semenkovich, CF; Towler, DA			Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OSTEOCALCIN PROMOTER; INTERSTITIAL COLLAGENASE PROMOTER; MEDIAL ARTERY CALCIFICATION; INDUCED BONE-RESORPTION; GENE-EXPRESSION; CARDIOVASCULAR RISK; DNA INTERACTIONS; BINDING-PROTEIN; DEFICIENT MICE; FACTOR USF	The expression of the matrix cytokine osteopontin (OPN) is up-regulated in aortic vascular smooth muscle Cells (VSMCs) by diabetes. OPN expression in cultured VSMCs is reciprocally regulated by glucose and 2-deoxy-glucose (2-DG; inhibitor of cellular glucose metabolism). Systematic analyses of OPN promoter-luciferase reporter constructs identify a CCTCATGAC motif at nucleotides -80 to -72 relative to the initiation site that supports OPN transcription in VSMCs. The region -83 to -45 encompassing this motif confers basal and glucose- and 2-DG-dependent transcription on an unresponsive promoter. Competition and gel mobility supershift assays identify upstream stimulatory factor (USF; USF1:USF2) and activator protein-1 (AP1; c-Fos:c-Jun) in complexes binding the composite CCTCATGAC element. Glucose up-regulates both AP1 and USF binding activities 2-fold in A7r5 cells and selectively up-regulates USF1 protein levels. By contrast, USF (but not AP1) binding activity is suppressed by 2-DG and restored by glucose treatment. Expression of either USF or AP1 activates the proximal OPN promoter in A7r5 VSMCs in part via the CCTCATGAC element. Moreover, glucose stimulates the transactivation functions of c-Fos and USF1, but not c-Jun, in one-hybrid assays. Mannitol does not regulate binding, transactivation functions, USF1 protein accumulation, or OPN transcription. Thus, OPN gene transcription is regulated by USF and AP1 in aortic VSMCs, entrained to changes in cellular glucose metabolism.	Washington Univ, Sch Med, Dept Internal Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Med Ctr, Div Bone & Mineral Dis, Barnes Jewish Hosp, N Campus,216 S Kingshighway Blvd, St Louis, MO 63110 USA.	dtowler@im.wustl.edu		Towler, Dwight/0000-0003-2107-7923; Semenkovich, Clay/0000-0003-1163-1871	NHLBI NIH HHS [HL69229] Funding Source: Medline; NIDDK NIH HHS [DK52446] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052446] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bidder M, 2000, BIOCHEMISTRY-US, V39, P8917, DOI 10.1021/bi000343+; Bini A, 1999, ARTERIOSCL THROM VAS, V19, P1852, DOI 10.1161/01.ATV.19.8.1852; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Breen GAM, 2000, BBA-GENE STRUCT EXPR, V1517, P119, DOI 10.1016/S0167-4781(00)00269-4; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Christian RC, 2002, J CLIN ENDOCR METAB, V87, P1062, DOI 10.1210/jc.87.3.1062; Cohn JN, 2001, AM J HYPERTENS, V14, p258S, DOI 10.1016/S0895-7061(01)02154-9; DEMER LL, 1991, CIRCULATION, V83, P2083, DOI 10.1161/01.CIR.83.6.2083; Demer LL, 2001, CIRCULATION, V104, P1881, DOI 10.1161/circ.104.16.1881; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DIGLIO CA, 1989, LAB INVEST, V60, P523; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; HICKLER RB, 1990, CLIN CARDIOL, V13, P317, DOI 10.1002/clc.4960130504; Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Isoda K, 2002, CIRC RES, V91, P77, DOI 10.1161/01.RES.0000025268.10302.0C; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; Lehmann ED, 1998, HYPERTENSION, V32, P565, DOI 10.1161/01.HYP.32.3.565; Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978; Li GH, 2000, CIRCULATION, V101, P2949, DOI 10.1161/01.CIR.101.25.2949; Luo X, 1996, MOL CELL BIOL, V16, P1367; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; MARK MP, 1987, J BONE MINER RES, V2, P337, DOI 10.1002/jbmr.5650020411; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Nicolosi AC, 2002, J SURG RES, V102, P1, DOI 10.1006/jsre.2001.6303; NISKANEN L, 1994, DIABETES CARE, V17, P1252, DOI 10.2337/diacare.17.11.1252; NISKANEN LK, 1990, ATHEROSCLEROSIS, V84, P61, DOI 10.1016/0021-9150(90)90009-8; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Oyama Y, 2002, CIRC RES, V90, P348, DOI 10.1161/hh0302.105098; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Parhami F, 2001, Z Kardiol, V90 Suppl 3, P27; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Takemoto M, 2000, ANN NY ACAD SCI, V902, P357; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; Tintut Y, 2002, CIRCULATION, V105, P650, DOI 10.1161/hc0502.102969; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; Walsh K, 2001, Z Kardiol, V90 Suppl 3, P12; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156	84	104	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44485	44496		10.1074/jbc.M206235200	http://dx.doi.org/10.1074/jbc.M206235200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200434	hybrid			2022-12-25	WOS:000179272000120
J	Chadjichristos, C; Ghayor, C; Herrouin, JF; Ala-Kokko, L; Suske, G; Pujol, JP; Galera, P				Chadjichristos, C; Ghayor, C; Herrouin, JF; Ala-Kokko, L; Suske, G; Pujol, JP; Galera, P			Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; HUMAN COL2A1 GENE; FACTOR-BETA; TGF-BETA; SMAD PROTEINS; TRANSCRIPTIONAL COACTIVATORS; SIGNALING PATHWAYS; ATDC5 CELLS; SP1; RECEPTOR	Although transforming growth factor beta1 (TGF-beta1) is generally considered as a stimulator of type I collagen production in smooth organs, we found that it can inhibit type II collagen biosynthesis in primary rabbit articular chondrocytes (RAC) at transcriptional levels. Constructs of promoter and first intron sequences associated with the luciferase reporter gene were used to delineate the gene sequences involved in TGF-beta1 control of human COL2A1 gene transcription. Cotransfection of these DNA fragments with a TbetaRII/I cDNA hybrid receptor, capable of inducing a TGF-beta1 dominant negative effect, showed that TGF-beta1 inhibits specifically COL2A1 gene transcription in RAC by a 63-bp proximal promoter. Footprint and gel retardation analyses revealed that the TGF-beta1-induced inhibition effect exerted through the 63-bp promoter sequence implies a multimeric complex that binds to the -41/-33 sequence and involves Sp1 and Sp3 transcription factors. Transfection of decoy Sp-binding oligonucleotides corroborated the implication of the proximal promoter in the TGF-beta1-induced inhibition of COL2A1 gene transcription. In addition, TGF-beta1 was found to increase the expression of Sp3 without significant changes to its binding level, but repressed both the biosynthesis and binding activity of Sp1. In functional assays, Sp3 inhibited the 63-bp promoter activity and prevented Sp1 induction of transcription. These findings suggest that TGF-beta1 inhibition of COL2A1 gene transcription in RAC is mediated by an increase of the Sp3/Sp1 ratio and by the repression of Sp1 transactivating effects on that gene.	CHU Niveau, Lab Biochim Tissu Conjonct, Fac Med, F-14032 Caen, France; Div Malad Osseuses, CH-1211 Geneva 14, Switzerland; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Geneva; University of Oulu; University of Oulu; Philipps University Marburg	Galera, P (corresponding author), CHU Niveau, Lab Biochim Tissu Conjonct, Fac Med, 3 Ave Cote Nacre, F-14032 Caen, France.		Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Ghayor, Chafik/0000-0002-3016-3412; Suske, Guntram/0000-0002-4807-0513				ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BRADHAM DM, 1994, J CELL PHYSIOL, V158, P61, DOI 10.1002/jcp.1041580109; BRADHAM DM, 1998, CLIN ORTHOP RELAT R, V2, P39; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Glansbeek HL, 1998, LAB INVEST, V78, P133; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HORTON WE, 1992, DNA CELL BIOL, V11, P193, DOI 10.1089/dna.1992.11.193; HORTON WE, 1988, J CELL PHYSL, V141, P8; HUANG SS, 1988, J BIOL CHEM, V263, P1535; KalffSuske M, 1996, GENOMICS, V37, P410, DOI 10.1006/geno.1996.0582; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazaki Y, 2000, OSTEOARTHR CARTILAGE, V8, P378, DOI 10.1053/joca.1999.0313; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; NIMNI M, 1973, SCIENCE, V181, P751, DOI 10.1126/science.181.4101.751; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; Qi WN, 1998, EXP CELL RES, V241, P142, DOI 10.1006/excr.1998.4032; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; REDINI F, 1991, BIOCHIM BIOPHYS ACTA, V1093, P196, DOI 10.1016/0167-4889(91)90123-F; REDINI F, 1988, FEBS LETT, V234, P172, DOI 10.1016/0014-5793(88)81327-9; Rediske J J, 1994, Osteoarthritis Cartilage, V2, P199, DOI 10.1016/S1063-4584(05)80069-X; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; ROSEN DM, 1988, J CELL PHYSIOL, V134, P337, DOI 10.1002/jcp.1041340304; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takaishi H, 1997, BBA-GENE STRUCT EXPR, V1350, P253, DOI 10.1016/S0167-4781(96)00233-3; TSUKAZAKI T, 1994, EXP CELL RES, V215, P9, DOI 10.1006/excr.1994.1307; van Osch GJVM, 1998, OSTEOARTHR CARTILAGE, V6, P187, DOI 10.1053/joca.1998.0111; VANDERKRAAN PM, 1992, INT J EXP PATHOL, V73, P335; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; VIVIEN D, 1993, EXP CELL RES, V205, P165, DOI 10.1006/excr.1993.1071; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yaeger PC, 1997, EXP CELL RES, V237, P318, DOI 10.1006/excr.1997.3781; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	78	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43903	43917		10.1074/jbc.M206111200	http://dx.doi.org/10.1074/jbc.M206111200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12186868	hybrid			2022-12-25	WOS:000179272000050
J	Cheng, IH; Roberts, LA; Tye, BK				Cheng, IH; Roberts, LA; Tye, BK			Mcm3 is polyubiquitinated during mitosis before establishment of the pre-replication complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; BIND CHROMATIN; S-PHASE; PROTEINS; UBIQUITIN; INITIATION; ORIGINS	To ensure fidelity in genome duplication, eukaryotes restrict DNA synthesis to once every cell division by a cascade of regulated steps. Central to this cascade is the periodic assembly of the hexameric MCM2-7 complex at replication origins. However, in Saccharomyces cerevisiae, only a fraction of each MCM protein is able to assemble into hexamers and associate with replication origins during M phase, suggesting that MCM complex assembly and recruitment may be regulated post-translationally. Here we show that a small fraction of Mcm3p is polyubiquitinated at the onset of MCM complex assembly. Reducing the rate of ubiquitination by uba1-165, a suppressor of mcm3-10, restored the interaction of Mcm3-10p with subunits of the MCM complex and its recruitment to the replication origin. Possible roles for ubiquitinated Mcm3p in the assembly of the MCM complex at replication origins are discussed.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Tye, BK (corresponding author), Cornell Univ, Dept Mol Biol & Genet, 325 Biotechnol Bldg, Ithaca, NY 14853 USA.	bt16@cornell.edu						Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fujita M, 1997, J BIOL CHEM, V272, P10928; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GIBSON SI, 1989, THESIS CORNELL U; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; Haase SB, 1997, METHOD ENZYMOL, V283, P322; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HILT W, 1993, J BIOL CHEM, V268, P3479; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lei M, 2002, J BIOL CHEM, V277, P30824, DOI 10.1074/jbc.M201816200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	59	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41706	41714		10.1074/jbc.M205793200	http://dx.doi.org/10.1074/jbc.M205793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200430	hybrid			2022-12-25	WOS:000178985300053
J	Haimeur, A; Deeley, RG; Cole, SPC				Haimeur, A; Deeley, RG; Cole, SPC			Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; SUBSTRATE-SPECIFICITY; TRANSMEMBRANE DOMAINS; DEPENDENT TRANSPORT; MEMBRANE TOPOLOGY; CHLORIDE CHANNEL; DRUG-RESISTANCE; BASIC RESIDUES; MRP; GLUTATHIONE	The multidrug resistance protein, MRP1 (ABCC1), is an ATP-binding cassette transporter that confers resistance to chemotherapeutic agents. MRP1 also mediates transport of organic anions such as leukotriene C-4 (LTC4), 17beta-estradiol 17-(beta-D-glucuronide) (E(2)17betaG), estrone 3-sulfate, methotrexate (MTX), and GSH. We replaced three charged amino acids, Lys(332), His(335), and Asp(336), predicted to be in the sixth transmembrane (TM6) helix of MRP1 with neutral and oppositely charged amino acids and determined the effect on substrate specificity and transport activity. All mutants were expressed in transfected human embryonic kidney cells at levels comparable with wild-type MRP1, and confocal microscopy showed that they were correctly routed to the plasma membrane. Vesicular transport studies revealed that the MRP1-Lys(332) mutants had lost the ability to transport LTC4, and GSH transport was reduced; whereas E(2)17betaG, estrone 3-sulfate, and MTX transport were unaffected. E(2)17betaG transport was not inhibited by LTC4 and could not be photolabeled with [H-3]LTC4, indicating that the MRP1-Lys(332) mutants no longer bound this substrate. Substitutions of MRP1-His(335) also selectively diminished LTC4 transport and photolabeling but to a lesser extent. Kinetic analyses showed that V-max (LTC4) of these mutants was decreased but K-m was unchanged. In contrast to the selective loss of LTC4 transport in the Lys(332) and His(335) mutants, the MRP1-Asp(336) mutants no longer transported LTC4, E(2)17betaG, estrone 3-sulfate, or GSH, and transport of MTX was reduced by >50%. Lys(332), His(335), and Asp(336) of TM6 are predicted to be in the outer leaflet of the membrane and are all capable of forming intrahelical and interhelical ion pairs and hydrogen bonds. The importance of Lys(332) and His(335) in determining substrate specificity and of Asp(336) in overall transport activity suggests that such interactions are critical for the binding and transport of LTC4 and other substrates of MRP1.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall,Rm 328, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Allen JD, 2002, MOL CANCER THER, V1, P427; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; Cui YH, 1999, MOL PHARMACOL, V55, P929; DEELEY RG, 2002, ABC PROTEINS BACTERI, P393; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; Ito K, 2001, MOL PHARMACOL, V59, P1077, DOI 10.1124/mol.59.5.1077; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kim MH, 2000, J BIOL CHEM, V275, P6175, DOI 10.1074/jbc.275.9.6175; Koike K, 1997, CANCER RES, V57, P5475; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Litman T, 2000, J CELL SCI, V113, P2011; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; NUNES V, 1993, HUM MOL GENET, V2, P79, DOI 10.1093/hmg/2.1.79; Partridge AW, 2002, BIOCHEMISTRY-US, V41, P3647, DOI 10.1021/bi0120502; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 1999, CANCER RES, V59, P5964; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	52	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41326	41333		10.1074/jbc.M206228200	http://dx.doi.org/10.1074/jbc.M206228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186871	hybrid			2022-12-25	WOS:000178985300007
J	Michell, BJ; Harris, MB; Chen, ZP; Ju, H; Venema, VJ; Blackstone, MA; Huang, W; Venema, RC; Kemp, BE				Michell, BJ; Harris, MB; Chen, ZP; Ju, H; Venema, VJ; Blackstone, MA; Huang, W; Venema, RC; Kemp, BE			Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASES; ACTIVATION; AKT; 3-KINASE; INHIBITOR; LY294002; ISOFORMS; SUBUNIT; CELLS; ENOS	Endothelial nitric-oxide synthase (eNOS) is regulated by signaling pathways involving multiple sites of phosphorylation. The coordinated phosphorylation of eNOS at Ser(1179) and dephosphorylation at Thr(497) activates the enzyme, whereas inhibition results when Thr(497) is phosphorylated and Ser(1179) is dephosphorylated. We have identified two further phosphorylation sites, at Ser(617) and Ser(635), by phosphopeptide mapping and matrix-assisted laser desorption ionization time of flight mass spectrometry. Purified protein kinase A (PKA) phosphorylates both sites in purified eNOS, whereas purified Akt phosphorylates only Ser(617). In bovine aortic endothelial cells, bradykinin (BK), ATP, and vascular endothelial growth factor stimulate phosphorylation of both sites. BK-stimulated phosphorylation of Ser(617) is Ca2+-dependent and is partially inhibited by LY294002 and wortmannin, phosphatidylinositol 3-kinase inhibitors, suggesting signaling via Akt. BK-stimulated phosphorylation of Ser(635) is Ca2+-independent and is completely abolished by the PKA inhibitor, KT5720, suggesting signaling via PKA. Activation of PKA with isobutylmethyl-xanthine also causes Ser(635), but not Ser(617), phosphorylation. Mimicking phosphorylation at Ser(635) by Ser to Asp mutation results in a greater than 2-fold increase in activity of the purified protein, whereas mimicking phosphorylation at Ser(617) does not alter maximal activity but significantly increases Ca2+-calmodulin sensitivity. These data show that phosphorylation of both Ser(617) and Ser(635) regulates eNOS activity and contributes to the agonist-stimulated eNOS activation process.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	St. Vincent's Institute of Medical Research; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Venema, RC (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Harris, M. Brennan/F-7772-2015; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Harris, M. Brennan/0000-0002-2908-1647; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MARMYCONUS NJ, 1998, J BIOL CHEM, V273, P4776; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	29	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42344	42351		10.1074/jbc.M205144200	http://dx.doi.org/10.1074/jbc.M205144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12171920	hybrid			2022-12-25	WOS:000178985300130
J	Vaca, L; Sampieri, A				Vaca, L; Sampieri, A			Calmodulin modulates the delay period between release of calcium from internal stores and activation of calcium influx via endogenous TRP1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CA2+ ENTRY; I-CRAC; VASCULAR ENDOTHELIUM; TRANSIENT RECEPTOR; TERMINAL DOMAIN; CATION CHANNEL; INSECT CELLS; IP3 RECEPTOR; PROTEIN	In the present study we have explored the role of calmodulin (CaM) and inositol 1,4,5-trisphosphate receptor (IP(3)R) in the communication process activated after the release of calcium from the endoplasmic reticulum. (ER) and the activation of calcium influx via endogenous TRP1 channels from Chinese hamster ovary cells. Experiments using combined rapid confocal calcium and electrophysiology measurements uncovered a consistent delay of around 900 ms between the first detectable calcium released from the ER and the activation of the calcium current. This delay was evident with two different methods used to release calcium from the ER: either the blockade of the microsomal calcium ATPase with thapsigargin or activation of bradykinin receptors linked to the IP(3) cascade. Direct application of IP(3) or a peptide from the NH(2)-terminal region of the IP(3)R activated store operated calcium, reducing the delay period. Introduction of CaM into the cell via the patch pipette increased the delay period from 900 +/- 100 ms to 10 +/- 2.1 s (n = 18). Furthermore, the use of selective CaM antagonists W7 and trifluoperazine maleate resulted in a substantial reduction of the delay period to 200 +/- 100 ms with 5 muM trifluoperazine maleate (n = 16) and 150 +/- 50 ms with 500 nM W7 (n = 22). CaM reduced also the current density activated by thapsigargin or brandykinin to about 60% from control. The CaM antagonists did not affect significantly the current density. The results presented here are consistent with an antagonistic effect of lP(3)R and CaM for the activation of store operated calcium after depletion of the ER. The functional competition between the activating effect of IP(3)R and the inhibiting effect of CaM may modulate the delay period between the release of calcium from the ER and the activation of calcium influx observed in different cells, as well as the amount of current activated a er depletion of the ER.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Vaca, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Ciudad Univ, Mexico City 04510, DF, Mexico.	lvaca@ifisiol.unam.mx	Sampieri, Alicia/L-3896-2019	Vaca, Luis/0000-0003-2266-4847				Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Gailly P, 2001, CELL CALCIUM, V30, P157, DOI 10.1054/ceca.2001.0221; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Huang Y, 1998, J BIOL CHEM, V273, P31815, DOI 10.1074/jbc.273.48.31815; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MAINE EM, 2000, GENOME BIOL, V1, P1; Martinez-Francois JR, 2002, J PHYSIOL-LONDON, V538, P79, DOI 10.1113/jphysiol.2001.013036; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Reyes-Cruz G, 2000, J CELL BIOCHEM, V76, P658, DOI 10.1002/(SICI)1097-4644(20000315)76:4<658::AID-JCB14>3.3.CO;2-Z; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Sinkins WG, 1996, J BIOL CHEM, V271, P2955, DOI 10.1074/jbc.271.6.2955; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	33	46	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42178	42187		10.1074/jbc.M204531200	http://dx.doi.org/10.1074/jbc.M204531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196518	hybrid			2022-12-25	WOS:000178985300111
J	Abbas, T; Olivier, M; Lopez, J; Houser, S; Xiao, G; Kumar, GS; Tomasz, M; Bargonetti, J				Abbas, T; Olivier, M; Lopez, J; Houser, S; Xiao, G; Kumar, GS; Tomasz, M; Bargonetti, J			Differential activation of p53 by the various adducts of mitomycin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; DNA-DAMAGE; IN-VIVO; ALKYLATING-AGENTS; CANCER CELLS; 2,7-DIAMINOMITOSENE; INDUCTION; GADD45; REPAIR; EXPRESSION	Mitomycin C (MC) is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA crosslinks as well as a variety of DNA monoadducts and is known to induce p53. The various DNA adducts formed upon treatment of mouse mammary tumor cells with MC as well as 10-decarbamoyl MC (DMC) and 2,7-diaminomitosene (2,7-DAM), the major MC metabolite, have been elucidated. The cytotoxicity of DMC parallels closely that of MC in a number of rodent cell lines tested, whereas 2,7-DAM is relatively noncytotoxic. In this study, we investigate the ability of MC, DMC, and 2,7-DAM to activate p53 at equidose concentrations by treating tissue culture cell lines with the three mitomycins. Whereas MC and DMC induced p53 protein levels and increased the levels of p21 and Gadd45 mRNA, 2,7-DAM did not. Furthermore, MC and DMC, but not 2,7-DAM, were able to induce apoptosis efficiently in ML-1 cells. Therefore the 2,7-DAM monoadducts were unable to activate the p53 pathway. Interestingly, DMC was able to initiate apoptosis via a p53-independent pathway whereas MC was not. This is the first finding that adducts of a multiadduct type DNA-damaging agent are differentially recognized by DNA damage sensor pathways.	CUNY Hunter Coll, Inst Biomol Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Sci Biol, New York, NY 10021 USA; Grad Sch, New York, NY 10021 USA; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)	Bargonetti, J (corresponding author), CUNY Hunter Coll, Inst Biomol Struct & Funct, New York, NY 10021 USA.	bargonetti@genectr.hunter.cuny.edu	KUMAR, P. SURESH/AAT-8951-2020; Olivier, Magali/G-3728-2010; Kumar, Gopinatha Suresh/W-1461-2019; Kumar, Dr Suresh/HHZ-2615-2022	KUMAR, P. SURESH/0000-0003-3222-2604; Olivier, Magali/0000-0002-8202-342X; Kumar, Dr Suresh/0000-0002-2539-6553; Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA 71961, CA 28681] Funding Source: Medline; NCRR NIH HHS [RR 03037] Funding Source: Medline; NIGMS NIH HHS [1S06 GM 60754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028681, R01CA071961, R37CA028681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIZANEK R, 1993, CANCER RES, V53, P5127; CARRANO AV, 1979, MUTAT RES, V63, P175, DOI 10.1016/0027-5107(79)90114-3; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; CHIRREY L, 1995, CANCER CHEMOTH PHARM, V35, P318, DOI 10.1007/BF00689451; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOBAN PR, 1990, CANCER RES, V50, P4692; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan QA, 1998, MOL CARCINOGEN, V23, P115, DOI 10.1002/(SICI)1098-2744(199810)23:2<115::AID-MC8>3.0.CO;2-R; Kumar GS, 1996, J AM CHEM SOC, V118, P9209; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Palom Y, 2001, BIOCHEM PHARMACOL, V61, P1517, DOI 10.1016/S0006-2952(01)00609-8; Palom Y, 1998, ONCOL RES, V10, P509; Palom Y, 2000, CHEM RES TOXICOL, V13, P479, DOI 10.1021/tx000024j; PAN SS, 1993, MOL PHARMACOL, V43, P870; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; ROCKWELL S, 1995, ONCOL RES, V7, P39; SZYBALSKI W, 1964, FED PROC, V23, P946; TOMASZ M, 1988, J AM CHEM SOC, V110, P5892, DOI 10.1021/ja00225a048; Verweij J., 1990, ANTITUMOR ANTIBIOTIC, P382; Wani MA, 2000, CANCER RES, V60, P2273; Warren AJ, 2001, CLIN CANCER RES, V7, P1033; Warren AJ, 1998, CANCER RES, V58, P453; Xiao G, 2000, CANCER RES, V60, P1711; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhao RB, 2000, GENE DEV, V14, P981	35	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40513	40519		10.1074/jbc.M205495200	http://dx.doi.org/10.1074/jbc.M205495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183457	hybrid			2022-12-25	WOS:000178791400047
J	Chen, HC; Lin, WC; Tsay, YG; Lee, SC; Chang, CJ				Chen, HC; Lin, WC; Tsay, YG; Lee, SC; Chang, CJ			An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA CELL-LINES; VIRUS CORE PROTEIN; MESSENGER-RNA; HNRNP-K; IN-VITRO; BINDING; ASSOCIATION; DOMAIN; GENE; IDENTIFICATION	Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a multifunctional protein known to be involved in the regulation of transcription, translation, nuclear transport, and signal transduction. To systematically obtain insight into mechanisms of hnRNP K activities, we set out to identify protein factors that interact with hnRNP K by using glutathione S-transferase-hnRNP K affinity chromatography followed by liquid chromatography/mass spectrometry/mass spectrometry analysis. Several partner proteins in the K562 cell lysates were identified through this method. One of them is a DEAD box-containing putative RNA helicase, DDX1. In vitro binding and co-immunoprecipitation studies confirmed the protein-protein interaction between hnRNP K with DDX1, and the region spanning amino acids 1-276 of hnRNP K is apparently responsible for its physical interaction with DDX1. Interestingly, their interaction was disrupted by the addition of poly(C), poly(A), and poly(U) RNA substrates. We found that DDX1 was a homopolymeric poly(A) RNA-binding protein. On the other hand, the ATPase activity of the purified recombinant DDX1 protein was stimulated by these homopolymeric RNAs and yeast total RNA but not by DNA. Moreover, the immunoprecipitated DDX1 complex but not purified DDX1 can unwind double-stranded RNA having single-stranded poly(A) overhangs.	Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Chang, CJ (corresponding author), Acad Sinica, Inst Biol Chem, 1 Sec 4 Roosevelt Rd, Taipei 106, Taiwan.		Chang, Ching-Jin/G-4511-2019; Tsay, Yeou-Guang/HGE-2076-2022	Chang, Ching-Jin/0000-0001-7129-8092				Bleoo S, 2001, MOL BIOL CELL, V12, P3046, DOI 10.1091/mbc.12.10.3046; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Chang CJ, 2001, DNA CELL BIOL, V20, P569, DOI 10.1089/104454901317094981; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gururajan R, 1997, BBA-GENE STRUCT EXPR, V1350, P169, DOI 10.1016/S0167-4781(96)00155-8; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LIANG L, 1994, DEVELOPMENT, V120, P1201; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SQUIRE JA, 1995, ONCOGENE, V10, P1417; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Xu DM, 1996, NATURE, V381, P709, DOI 10.1038/381709a0	39	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40403	40409		10.1074/jbc.M206981200	http://dx.doi.org/10.1074/jbc.M206981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183465	hybrid, Green Published			2022-12-25	WOS:000178791400033
J	Leksa, V; Godar, S; Cebecauer, M; Hilgert, I; Breuss, J; Weidle, UH; Horejsi, V; Binder, BR; Stockinger, H				Leksa, V; Godar, S; Cebecauer, M; Hilgert, I; Breuss, J; Weidle, UH; Horejsi, V; Binder, BR; Stockinger, H			The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; FACTOR-II RECEPTOR; LYSOSOMAL-ENZYME; ADHESION; SURFACE; STREPTOKINASE; VITRONECTIN; PROTEIN; EXPRESSION; COMPLEXES	Leukocyte migration to sites of inflammation is a multistep process involving transient adhesion to the endothelium followed by cell surface-controlled proteolysis for transmigration through the vessel wall and chemotactic movement within tissues. One of the key players in this machinery appears to be the urokinase-type plasminogen activator (uPA)/uPA receptor system. The role of uPA and its receptor (CD87) in plasminogen (Plg) activation, cell adhesion, and chemotaxis is well established; however, less is known of how these activities are regulated. Here we provide evidence that the mannose 6-phosphate/insulin-like growth factor 2 receptor (CD222) controls CD87-mediated functions. Expression of human CD222 in CD222-/- mouse fibroblasts down-regulated Plg activation, cell adhesion, and chemotaxis induced by the uPA/CD87 system. In addition, we demonstrate that the N-terminal region of CD222, which is similar to the Plg-binding site of streptokinase, plays a crucial role in binding of CD87 and Plg. A peptide derived from this region in CD222 is able to disrupt the physical interaction of CD222 with CD87 and, furthermore, mimics the inhibitory effects of CD222 on CD87 functions. Taken together, our results indicate a novel role for CD222 in regulation of fibrinolysis, cell adhesion, and migration.	Univ Vienna, Inst Immunol, Vienna Int Res Cooperat Ctr, NFI, A-1235 Vienna, Austria; Roche Diagnost, Div Pharma, D-82372 Penzberg, Germany; Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	Novartis; University of Vienna; Roche Holding; University of Vienna; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Stockinger, H (corresponding author), Univ Vienna, Inst Immunol, Vienna Int Res Cooperat Ctr, NFI, A-1235 Vienna, Austria.		Stockinger, Hannes/E-5173-2011; Cebecauer, Marek/F-5169-2014; Horejsi, Vaclav/G-3113-2014; Leksa, Vladimir/ABE-7876-2020	Stockinger, Hannes/0000-0001-6404-4430; Cebecauer, Marek/0000-0002-4606-1218; Horejsi, Vaclav/0000-0003-4925-0142; breuss, johannes/0000-0003-1312-3387; Leksa, vladimir/0000-0002-5430-2763				BAIER G, 1994, BIOTECHNIQUES, V17, P94; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOYLE MDP, 1987, J IMMUNOL, V139, P169; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; Degryse B, 2001, FEBS LETT, V505, P249, DOI 10.1016/S0014-5793(01)02797-1; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Ellis V, 1999, BIOCHEMISTRY-US, V38, P651, DOI 10.1021/bi981714d; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GODAR S, 2000, PROTEIN REV WEB, V1, P50; Godar S., 2002, LEUKOCYTE TYPING, P482; GONZALEZGRONOW M, 1993, BIOCHIM BIOPHYS ACTA, V1180, P283, DOI 10.1016/0925-4439(93)90051-2; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Kim DM, 2000, THROMB RES, V99, P93, DOI 10.1016/S0049-3848(00)00225-5; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; Kusch A, 2002, BIOL CHEM, V383, P217, DOI 10.1515/BC.2002.022; LEE SW, 1994, J BIOL CHEM, V269, P2411; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PRENCE EM, 1990, J CELL BIOL, V110, P319, DOI 10.1083/jcb.110.2.319; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; SCOTT CD, 1988, BIOCHEM BIOPH RES CO, V151, P815, DOI 10.1016/S0006-291X(88)80354-1; Sendo F, 1999, J LEUKOCYTE BIOL, V66, P369, DOI 10.1002/jlb.66.3.369; Sitrin RG, 2001, J IMMUNOL, V166, P4822, DOI 10.4049/jimmunol.166.8.4822; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SWIFT S, 1999, CURRENT PROTOCOLS IM; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xue W, 1997, CANCER RES, V57, P1682; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhang QM, 1997, J BIOL CHEM, V272, P23703, DOI 10.1074/jbc.272.38.23703	56	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40575	40582		10.1074/jbc.M207979200	http://dx.doi.org/10.1074/jbc.M207979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189157	hybrid			2022-12-25	WOS:000178791400055
J	Mitsiades, CS; Mitsiades, N; Poulaki, V; Schlossman, R; Akiyama, M; Chauhan, D; Hideshima, T; Treon, SP; Munshi, NC; Richardson, PG; Anderson, KC				Mitsiades, CS; Mitsiades, N; Poulaki, V; Schlossman, R; Akiyama, M; Chauhan, D; Hideshima, T; Treon, SP; Munshi, NC; Richardson, PG; Anderson, KC			Activation of NF-kappa B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications	ONCOGENE			English	Article						multiple myeloma; IGF-1; NF-kappa B; IAPs; Apo2L; TRAIL	GROWTH-FACTOR-I; DEXAMETHASONE-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; NUCLEAR TRANSLOCATION; MEDIATED APOPTOSIS; BIOLOGIC SEQUELAE; CANCER CELLS; INDUCTION; EXPRESSION	Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. We have previously shown that Apo2 ligand/TNF-Related apoptosis inducing ligand (Apo2L/TRAIL) induces apoptosis of MM cells, including cells either sensitive or resistant to Dex and cytotoxic drugs, and overcomes the growth and survival effect of IL-6; conversely, NF-kappaB transcriptional activity attenuates their Apo2L/TRAIL-sensitivity. In the current study, we demonstrate that IGF-1 stimulates sustained activation of NF-kappaB and Akt; induces phosphorylation of the FKHRL-1 Forkhead transcription factor; upregulates a series of intracellular anti-apoptotic proteins including FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP; and decreases Apo2L/TRAIL-sensitivity of MM cells. In contrast, IL-6 does not cause sustained NF-kappaB activation, induces less pronounced Akt activation and FKHRL-1 phosphorylation than IGF-1, and increases the expression of only survivin. Forced overexpression of constitutively active Akt in MM-1S cells reduced their sensitivity to Apo2L/TRAIL and to doxorubicin (Doxo). In contrast, the Akt inhibitor IL-6-Hydroxymethylchiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate induced cell death of both Dex- and Doxo-sensitive and -resistant cells; opposed the protective effect of constitutive Akt activity against Apo2L/TRAIL; and abrogated the NF-kappaB activation, increase of anti-apoptotic proteins and protection against Apo2L/TRAIL induced by IGF-1. These findings therefore define an important role of the Akt pathway in modulating tumor cell responsiveness to Apo2L/TRAIL, delineate molecular mechanisms for the survival effects of IGF-1, and characterize differential pathophysiologic sequelae of IGF-1 vs IL-6 on MM cells. Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1.	Harvard Univ, Jerome Lipper Multiple Myeloma Ctr, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Anderson, KC (corresponding author), Harvard Univ, Jerome Lipper Multiple Myeloma Ctr, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021		PHS HHS [P0-1 78378, R0-1 50947] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Feinman R, 1999, BLOOD, V93, P3044; Ge NL, 2000, BLOOD, V96, P2856; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Grundker C, 2000, J CLIN ENDOCR METAB, V85, P3815, DOI 10.1210/jc.85.10.3815; Han YP, 2001, J CELL SCI, V114, P131; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Jelinek DF, 1997, J IMMUNOL, V159, P487; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kolenko V, 1999, J IMMUNOL, V163, P590; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Mitsiades Constantine S., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P348; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades CS, 2000, BLOOD, V96, p756A; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ogawa M, 2000, CANCER RES, V60, P4262; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Poulaki V, 2001, CANCER RES, V61, P4864; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056	44	403	420	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5673	5683		10.1038/sj.onc.1205664	http://dx.doi.org/10.1038/sj.onc.1205664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173037				2022-12-25	WOS:000177463400002
J	Hoque, MT; Ishikawa, F				Hoque, MT; Ishikawa, F			Cohesin defects lead to premature sister chromatid separation, kinetochore dysfunction, and spindle-assembly checkpoint activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ANAPHASE ONSET; YEAST COHESIN; REPLICATION; PROTEIN; PROTEOLYSIS; CENTROMERES; ATTACHMENT; MITOSIS; CELLS	Scc1/Mcd1 is a component of the cohesin complex that plays an essential role in sister chromatid cohesion in eukaryote cells. Knockout experiments of this gene have been described in budding yeast, fission yeast, and chicken cells, but no study has been reported on human Scc1 thus far. In this study, we found that an N-terminally truncated human Scc1 shows a dominant-negative effect, and we examined the phenotypes of human cells defective in Scc1 function. Scc1 defects led to failure of sister chromatid cohesion in both interphase and mitotic cells. Interestingly, four chromatids derived from two homologues occupied four distinct territories in the nucleus in chromosome painting experiments. In mitotic Scc1-defective cells, chromatids were disjoined with normal condensation, and the spindle-assembly checkpoint was activated. We also found that, although the disjoined kinetochore (half-kinetochore) in Scc1-defective cells contains CENP-A, -B, -C, and -E normally, it apparently does not establish the kinetochore-microtubule association. These results indicate that Scc1 is essential for the association of kinetochores with microtubules.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat,Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Ishikawa, F (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat,Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.		Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Maney T, 2000, INT REV CYTOL, V194, P67; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nogami M, 2000, CHROMOSOMA, V108, P514, DOI 10.1007/s004120050403; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Postow L, 1999, BIOESSAYS, V21, P805, DOI 10.1002/(SICI)1521-1878(199910)21:10<805::AID-BIES1>3.0.CO;2-7; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tatebayashi K, 1998, GENETICS, V148, P49; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toyoda Y, 2002, CURR BIOL, V12, P347, DOI 10.1016/S0960-9822(02)00692-9; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5	36	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42306	42314		10.1074/jbc.M206836200	http://dx.doi.org/10.1074/jbc.M206836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200439	hybrid			2022-12-25	WOS:000178985300126
J	Lee, JH; Skalnik, DG				Lee, JH; Skalnik, DG			CpG-binding protein is a nuclear matrix- and euchromatin-associated protein localized to nuclear speckles containing human trithorax - Identification of nuclear matrix targeting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE GENE; HUMAN ACUTE LEUKEMIAS; DROSOPHILA-TRITHORAX; SWI/SNF COMPLEX; AMINO-TERMINUS; MOUSE EMBRYO; CXXC DOMAIN; PHD FINGER; METHYLATION; CHROMATIN	CpG-binding protein (CGBP) binds unmethylated CpG dinucleotides and is essential for mammalian development. CGBP exhibits a punctate nuclear localization correlated with 4,6-diamidino-2-phenylindole light regions and is excluded from metaphase chromosomes. The distribution of CGBP is distinct from the heterochromatin-associated proteins MBD1, methyl-CpG-binding protein 2, and HP1alpha. Some CGBP-containing nuclear speckles co-localize with splicing factor SC-35 and actively transcribed regions of the genome, whereas most CGBP co-localizes with acetylated histones, indicating that CGBP is localized to active chromatin. CGBP contains two nuclear localization signals that are insufficient to direct punctate subnuclear distribution. Instead, localization of CGBP to nuclear speckles requires signals within the acidic, basic, and coiled-coil domains. CGBP associates with the nuclear matrix, and fragments of CGBP that fail to associate with the nuclear matrix fail to localize to nuclear speckles and exhibit reduced transcriptional activation activity. Mutated versions of CGBP that lack DNA binding activity exhibit a normal nuclear distribution, suggesting that CGBP accumulates at nuclear speckles as a result of protein/ protein interactions. Importantly, the subcellular distribution of CGBP is identical to human trithorax, suggesting that these proteins may be components of a multimeric complex analogous to the histone-methylating Set1 complex of Saccharomyces cerevisiae that contains CGBP and trithorax homologues.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat,Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat,Sect Pediat Hematol Oncol, Canc Res Bldg,Rm 472,1044 W Walnut St, Indianapolis, IN 46202 USA.				NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Adler HT, 1999, MOL CELL BIOL, V19, P7050; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; Caslini C, 2000, LEUKEMIA, V14, P1898, DOI 10.1038/sj.leu.2401933; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; CHEN C, 1987, MOL CELL BIOL, V7, P274; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Fujino T, 2000, BIOCHEM BIOPH RES CO, V271, P305, DOI 10.1006/bbrc.2000.2614; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Gordon JA, 2000, J CELL BIOCHEM, V77, P30, DOI 10.1002/(SICI)1097-4644(20000401)77:1<30::AID-JCB4>3.3.CO;2-B; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Katsani KR, 2001, GENE DEV, V15, P2197, DOI 10.1101/gad.201901; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2001, J BIOL CHEM, V276, P44669, DOI 10.1074/jbc.M107179200; Lee JH, 2000, MOL BRAIN RES, V80, P88, DOI 10.1016/S0169-328X(00)00129-7; Leshkowitz D, 1996, ONCOGENE, V13, P2027; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MONK M, 1987, DEVELOPMENT, V99, P371; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schramke V, 2001, GENE DEV, V15, P1845, DOI 10.1101/gad.193901; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; Zhang SS, 1999, J CELL SCI, V112, P2693	58	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42259	42267		10.1074/jbc.M205054200	http://dx.doi.org/10.1074/jbc.M205054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200428	hybrid			2022-12-25	WOS:000178985300121
J	Matuschewski, K; Ross, J; Brown, SM; Kaiser, K; Nussenzweig, V; Kappe, SHI				Matuschewski, K; Ross, J; Brown, SM; Kaiser, K; Nussenzweig, V; Kappe, SHI			Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM PROTEIN; MOSQUITO SALIVARY-GLANDS; ORNITHINE DECARBOXYLASE; PROTECTIVE IMMUNITY; INVASION; BERGHEI; HOST; ANTIBODIES; POLYAMINES; MEROZOITE	Injection of Plasmodium salivary gland sporozoites into the vertebrate host by Anopheles mosquitoes initiates malaria infection. Sporozoites develop within oocysts in the mosquito midgut and then enter and mature in the salivary glands. Although morphologically similar, oocyst sporozoites and salivary gland sporozoites differ strikingly in their infectivity to the mammalian host, ability to elicit protective immune responses, and cell motility. Here, we show that differential gene expression coincides with these dramatic phenotypic differences. Using suppression subtractive cDNA hybridization we identified highly up-regulated mRNAs transcribed from 30 distinct genes in salivary gland sporozoites. Of those genes, 29 are not significantly expressed in the parasite's blood stages. The most frequently recovered transcript encodes a protein kinase. Developmental up-regulation of specific mRNAs in the infectious transmission stage of Plasmodium indicates that their translation products may have unique roles in hepatocyte infection and/or development of liver stages.	Univ Heidelberg, Sch Med, Dept Parasitol, D-69120 Heidelberg, Germany; NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY 10016 USA; NYU, Med Ctr, New York, NY 10016 USA	Ruprecht Karls University Heidelberg; New York University; New York University	Matuschewski, K (corresponding author), Univ Heidelberg, Sch Med, Dept Parasitol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.			Matuschewski, Kai/0000-0001-6147-8591				AIKAWA M, 1981, J IMMUNOL, V126, P2494; Al-Olayan EM, 2002, SCIENCE, V295, P677, DOI 10.1126/science.1067159; Barreau C, 1995, EXP PARASITOL, V81, P332, DOI 10.1006/expr.1995.1124; Brennan JDG, 2000, P NATL ACAD SCI USA, V97, P13859, DOI 10.1073/pnas.250472597; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FOX BA, 1993, MOL BIOCHEM PARASIT, V61, P37, DOI 10.1016/0166-6851(93)90156-R; Francois G, 1997, ANN TROP MED PARASIT, V91, P103, DOI 10.1080/00034983.1997.11813117; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; HOLLINGDALE MR, 1985, EXP PARASITOL, V60, P111, DOI 10.1016/S0014-4894(85)80028-X; HUDSONTAYLOR DE, 1995, MOL MICROBIOL, V15, P463, DOI 10.1111/j.1365-2958.1995.tb02260.x; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; KLOTZ FW, 1989, MOL BIOCHEM PARASIT, V36, P177, DOI 10.1016/0166-6851(89)90190-4; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Matuschewski K, 2001, MOL BIOCHEM PARASIT, V112, P157, DOI 10.1016/S0166-6851(00)00360-1; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; Pinder JC, 1998, J CELL SCI, V111, P1831; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOURAY MG, 1992, J EXP MED, V175, P1607, DOI 10.1084/jem.175.6.1607; Tsuji M, 2001, BIOL CHEM, V382, P553, DOI 10.1515/BC.2001.069; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1972, P HELM SOC WASH, V39, P514	30	155	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41948	41953		10.1074/jbc.M207315200	http://dx.doi.org/10.1074/jbc.M207315200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177071	hybrid			2022-12-25	WOS:000178985300083
J	Takao, M; Kanno, S; Kobayashi, K; Zhang, QM; Yonei, S; van der Horst, GTJ; Yasui, A				Takao, M; Kanno, S; Kobayashi, K; Zhang, QM; Yonei, S; van der Horst, GTJ; Yasui, A			A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA GLYCOSYLASE; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; IDENTIFICATION; 8-OXOGUANINE; DAMAGE; FPG; NUCLEAR; PROTEIN; CLONING	Thymine glycol, a potentially lethal DNA lesion produced by reactive oxygen species, can be removed by DNA glycosylase, Escherichia coli Nth (endonuclease III), or its mammalian homologue NTH1. We have found previously that mice deleted in the Nth homologue still retain at least two residual glycosylase activities for thymine glycol. We report herein that in cell extracts from the mNth1 knock-out mouse there is a third thymine glycol glycosylase activity that is encoded by one of three mammalian proteins with sequence similarity to E. coli Fpg (MutM) and Nei (endonuclease VIII). Tissue expression of this mouse Nei-like (designated as Neil1) gene is ubiquitous but much lower than that of mNth1 except in heart, spleen, and skeletal muscle. Recombinant NEIL1 can remove thymine glycol and 5-hydroxyuracil in double- and single-stranded DNA much more efficiently than 8-oxoguanine and can nick the strand by an associated (beta-delta) apurinic/apyrimidinic lyase activity. In addition, the mouse NEIL1 has a unique DNA glycosylase/lyase activity toward mismatched uracil and thymine, especially in U:C and T:C mismatches. These results suggest that NEIL1 is a back-up glycosylase for NTH1 with unique substrate specificity and tissue-specific expression.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Radiat Biol Lab, Kyoto 6068502, Japan; Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Tohoku University; Kyoto University; Kyoto University; Erasmus University Rotterdam	Takao, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan.	mtakao@idac.tohoku.ac.jp; ayasui@didac.tohoku.ac.jp	van der Horst, Gijsbertus TJ/E-3661-2015; Kanno, Shin-ichiro/AAE-4549-2019; Hoeijmakers, Jan/AAX-6972-2021	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Kobayashi-Nakamura, Kumiko/0000-0001-5579-3464				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; Avrutskaya AV, 2000, METHODS, V22, P127, DOI 10.1006/meth.2000.1053; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Burgess S, 2002, J BIOL CHEM, V277, P2938, DOI 10.1074/jbc.M110499200; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; Garcia-Ortiz MV, 2001, PLANT MOL BIOL, V47, P795, DOI 10.1023/A:1013644026132; Gogos A, 1999, J BIOL CHEM, V274, P30447, DOI 10.1074/jbc.274.43.30447; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2000, J BIOL CHEM, V275, P27762; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Nilsen H, 2001, CARCINOGENESIS, V22, P987, DOI 10.1093/carcin/22.7.987; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Rieger RA, 2000, J AM SOC MASS SPECTR, V11, P505, DOI 10.1016/S1044-0305(00)00117-3; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Zhang QM, 2000, J BIOL CHEM, V275, P35471, DOI 10.1074/jbc.M006125200; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	39	187	192	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42205	42213		10.1074/jbc.M206884200	http://dx.doi.org/10.1074/jbc.M206884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200441	hybrid			2022-12-25	WOS:000178985300114
J	Agirre, A; Barco, A; Carrasco, L; Nieva, JL				Agirre, A; Barco, A; Carrasco, L; Nieva, JL			Viroporin-mediated membrane permeabilization - Pore formation by nonstructural poliovirus 2B protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; VIRUS PROTEIN; BACILLUS-THURINGIENSIS; LIPID-BILAYERS; HELIX 4; PEPTIDE; CHANNEL; FUSION; CHOLESTEROL; MECHANISM	Enterovirus nonstructural 2B protein is involved in cell membrane permeabilization during late viral infection. Here we analyze the pore forming activity of poliovirus 2B and several of its variants. Solubilization of 2B protein was achieved by generating a fusion protein comprised of poliovirus 2B attached to a maltose-binding protein (MEP) as an N-terminal solubilization. partner. MEP-2B was assayed using large unilamellar vesicles as target membranes. This fusion protein was able to assemble into discrete structures that disrupted the permeability barrier of vesicles composed of anionic phospholipids. The transbilayer aqueous connections generated by MBP-2B were stable over time, allowing the passage of solutes of molecular mass under 1,000 Da. Oligomerization was investigated using fluorescence resonance energy transfer. Our data indicate that MBP-2B aggregation occurs at the membrane surface. Moreover, MBP-2B binding to membranes promoted the formation of SDS-resistant tetramers. We conclude that MBP-2B forms oligomers capable of generating a tetrameric aqueous pore in lipid bilayers. These findings are the first evidence of viroporin activity shown by a protein from a naked animal virus.	Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Basque Country, Unidad Biofis, Ctr Super Investigac Cientificas, E-48080 Bilbao, Spain; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Autonomous University of Madrid	Nieva, JL (corresponding author), Univ Basque Country, Dept Bioquim, Aptdo 644, E-48080 Bilbao, Spain.	gbpniesj@lg.ehu.es	Carrasco, Luis/H-3001-2017; Nieva, Jose L/Q-2063-2019; Barco, Angel/ABF-1864-2021; Carrasco, Luis/E-2435-2012; Barco, Angel/C-3062-2008	Carrasco, Luis/0000-0003-3833-8835; Nieva, Jose L/0000-0001-6446-5649; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751				Agirre A, 2000, J LIPID RES, V41, P621; Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Barco A, 1998, J VIROL, V72, P3560, DOI 10.1128/JVI.72.5.3560-3570.1998; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; CARRASCO L, 1993, NATO ADV SCI INST SE, V240, P283; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 2002, PICORNAVIRUSES, P337; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; LAMA J, 1992, J BIOL CHEM, V267, P15932; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Nicol F, 2000, BIOPHYS J, V78, P818, DOI 10.1016/S0006-3495(00)76639-2; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3; ROST B, 1995, PROTEIN SCI, V4, P521; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Ubarretxena-Belandia I, 1999, BIOCHEMISTRY-US, V38, P7398, DOI 10.1021/bi983077x; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; White SH, 1998, METHOD ENZYMOL, V295, P62; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	48	112	117	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40434	40441		10.1074/jbc.M205393200	http://dx.doi.org/10.1074/jbc.M205393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183456	hybrid			2022-12-25	WOS:000178791400037
J	Krem, MM; Prasad, S; Di Cera, E				Krem, MM; Prasad, S; Di Cera, E			Ser(214) is crucial for substrate binding to serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; THROMBIN; SPECIFICITY; SUBSITE; PROTEIN; TRYPSIN; FORM; S2	Highly conserved amino acids that form crucial structural elements of the catalytic apparatus can be used to account for the evolutionary history of serine proteases and the cascades into which they are organized. One such evolutionary marker in chymotrypsin-like proteases is Ser(214), located adjacent to the active site and forming part of the primary specificity pocket. Here we report the mutation of Ser(214) in thrombin to Ala, Thr, Cys, Asp, Glu, and Lys. None of the mutants seriously compromises active site catalytic function as measured by the kinetic parameter k(cat). However, the least conservative mutations result in large increases in K-m because of lower rates of substrate diffusion into the active site. Therefore, the role of Ser(214) is to promote the productive formation of the enzyme-substrate complex. The S214C mutant is catalytically inactive, which suggests that during evolution the TCN-->AGY codon transitions for Ser(214) occurred through Thr intermediates.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu			NHLBI NIH HHS [HL 49413, HL 58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; EPSTEIN DM, 1992, BIOCHEMISTRY-US, V31, P11216, DOI 10.1021/bi00160a036; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; KIM S, 1995, J BIOL CHEM, V270, P24399, DOI 10.1074/jbc.270.41.24399; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; MCGRATH ME, 1992, BIOCHEMISTRY-US, V31, P3059, DOI 10.1021/bi00127a005; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pletnev VZ, 2000, PROTEINS, V41, P8, DOI 10.1002/1097-0134(20001001)41:1<8::AID-PROT30>3.0.CO;2-2; Rezaie AR, 1998, PROTEIN SCI, V7, P349; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Shilton BH, 1997, BIOCHEMISTRY-US, V36, P9002, DOI 10.1021/bi970433n; Siezen RJ, 1997, PROTEIN SCI, V6, P501	21	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40260	40264		10.1074/jbc.M206173200	http://dx.doi.org/10.1074/jbc.M206173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181318	hybrid			2022-12-25	WOS:000178791400015
J	Liou, GG; Chang, HY; Lin, CS; Sue, LC				Liou, GG; Chang, HY; Lin, CS; Sue, LC			Dead box Rh1B RNA helicase physically associates with exoribonuclease PNPase to degrade double-stranded RNA independent of the degradosome-assembling region of RNase E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; RIBOSOMAL-RNA; TERMINAL HALF; E-CLEAVAGE; PROTEIN; BACTERIA; COMPLEX	The Escherichia coli RNA degradosome is a multicomportent ribonucleolytic complex consisting of three major proteins that assemble on a scaffold provided by the C-terminal region of the endonuclease, RNase E. Using an E. coli two-hybrid system, together with BIAcore apparatus, we investigated the ability of three proteins, polynucleotide phosphorylase (PNPase), Rh1B RNA helicase, and enolase, a glycolytic protein, to interact physically and functionally independently of RNase E. Here ;we report that Rh1B can physically bind to PNPase, both in vitro and in vivo, and can also form homodimers with itself. However, binding of Rh1B or PNPase to enolase was not detected under the same conditions. BIAcore analysis revealed real-time, direct binding for bimolecular interactions between Rh1B units and for the Rh1B interaction with PNPase. Furthermore, in the absence of RNase E, purified Rh1B can carry out ATP-dependent unwinding of double-stranded RNA and consequently modulate degradation of double-stranded RNA together with the exonuclease activity of PNPase. These results provide evidence for the first time that both functional and physical interactions of individual degradosome protein components can occur in the absence of RNase E and raise the prospect that the RNase E-independent complexes of Rh1B RNA helicase and PNPase, detected in vivo, may constitute mini-machines that assist in the degradation of duplex RNA in structures physically distinct from multicomponent RNA degradosomes.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 100, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Yang Ming Chiao Tung University	Sue, LC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbsue@ccvax.sinica.edu.tw	Lin-Chao, Sue/AGI-2030-2022; Liou, Gunn‐Guang/AAI-9787-2020; Lin-Chao, Sue/AAZ-8246-2021; Liou, Gan-Guang/E-3976-2010	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Chang, Hsiang-Yu/0000-0001-5369-4016				Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; APIRION D, 1978, GENETICS, V90, P659; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUTCHINSON AM, 1995, MOL BIOTECHNOL, V3, P47, DOI 10.1007/BF02821334; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; KALMAN M, 1991, NEW BIOL, V3, P886; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Kuhnel K, 2001, J MOL BIOL, V313, P583, DOI 10.1006/jmbi.2001.5065; Lee K, 2001, J BIOL CHEM, V276, P23268, DOI 10.1074/jbc.M102408200; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Matson SW, 1995, METHOD ENZYMOL, V262, P389; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller JH., 1972, EXPT MOL GENETICS; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Regnier P, 2000, BIOESSAYS, V22, P235; REGNIER P, 1987, J BIOL CHEM, V262, P63; SPRING TG, 1971, J BIOL CHEM, V246, P6797; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770	45	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41157	41162		10.1074/jbc.M206618200	http://dx.doi.org/10.1074/jbc.M206618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181321	hybrid			2022-12-25	WOS:000178791400126
J	Gao, NG; Lehrman, MA				Gao, NG; Lehrman, MA			Coupling of the dolichol-P-P-oligosaccharide pathway to translation by perturbation-sensitive regulation of the initiating enzyme, GlcNAc-1-P transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ISOPRENYLTRANSFERASE ACTIVITY; LIPID-LINKED OLIGOSACCHARIDES; PHOSPHATE-MANNOSE SYNTHASE; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; PROTEIN-SYNTHESIS; N-GLYCOSYLATION; GENE ENCODES; BIOSYNTHESIS; RESISTANCE	In mammalian cells, inhibition of translation interferes with synthesis of the lipid-linked oligosaccharide (LLO) Glc(3)Man(9)GlcNAc(2)-P-P-dolichol as measured with radioactive sugar precursors. Conflicting hypotheses have been proposed, and the fundamental basis for this regulation has remained elusive. Here, fluorophore-assisted carbohydrate electrophoresis (FACE) was used to measure LLO concentrations directly in cells treated with translation blockers. Further, LLO biosynthetic enzymes were assayed in vitro with endogenous acceptor substrates using either cells gently permeabilized with streptolysin-O (SLO) or microsomes from homogenized cells. In Chinese hamster ovary (CHO)-K1 cells treated with translation blockers, FACE did not detect changes in concentrations of Glc(3)Man(9)GlcNAc(2)-P-P-dolichol or early LLO intermediates. These results do not support earlier proposals for feedback repression of LLO initiation by accumulated Glc(3)Man(9)GlcNAc(2)-P-P-dolichol, or inhibition of a GDP-mannose dependent transferase. With microsomes from cells treated with translation blockers, there was no interference with LLO initiation by GlcNAc-1-P transferase (GPT), mannose-P-dolichol synthase, glucose-P-dolichol synthase, or LLO synthesis in vitro, as reported previously. Surprisingly, inhibition of all of these was detected with the SLO in vitro system. Additional experiments with the SLO system showed that the three transferases shared a limited pool of dolichol-P that was trapped as Glc(3)Man(9)GlcNAc(2)-P-P-dolichol by translation arrest. Overexpression of GPT was unable to reverse the effects of translation arrest on LLO initiation, and experiments with FACE and the SLO system showed that overexpressed GPT was not functional in vivo, although it was highly active in microsomal assays. Thus, the combined use of the SLO in vitro system and FACE showed that LLO biosynthesis depends upon a limited primary pool of dolichol-P. Physical perturbation associated with microsome preparation appears to make available a secondary pool of dolichol-P, masking inhibition by translation arrest, as well as activating a nonfunctional fraction of GPT. The implications of these results for the organization of the LLO pathway are discussed.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mlehrm@mednet.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; CRISCUOLO BA, 1982, J CELL BIOL, V94, P586, DOI 10.1083/jcb.94.3.586; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; DATTA AK, 1993, J BIOL CHEM, V268, P12663; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; GRANT SR, 1983, EUR J BIOCHEM, V134, P575, DOI 10.1111/j.1432-1033.1983.tb07605.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; Kean EL, 1999, J BIOL CHEM, V274, P34072, DOI 10.1074/jbc.274.48.34072; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAG SS, 1977, J BIOL CHEM, V252, P2621; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SCHER MG, 1984, ARCH BIOCHEM BIOPHYS, V231, P293, DOI 10.1016/0003-9861(84)90391-6; SCHMITT JW, 1979, J BIOL CHEM, V254, P2291; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZENG YC, 1990, J BIOL CHEM, V265, P2296; ZHU XY, 1992, J BIOL CHEM, V267, P8895; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	40	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39425	39435		10.1074/jbc.M205195200	http://dx.doi.org/10.1074/jbc.M205195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176988	hybrid			2022-12-25	WOS:000178662500048
J	Jona, G; Livi, LL; Gileadi, O				Jona, G; Livi, LL; Gileadi, O			Mutations in the RING domain of TFB3, a subunit of yeast transcription factor IIH, reveal a role in cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL DOMAIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; FACTOR TFIIH; FISSION YEAST; BUDDING YEAST	The RNA polymerase II general transcription factor TFIIH is composed of 9 known subunits and possesses DNA helicase and protein kinase activities. The kinase subunits of TFIIH in animal cells, Cdk7, cyclin H, and MAT1, were independently isolated as an activity termed CAK (Cdk-activating kinase), which phosphorylates and activates cell cycle kinases. However, CAK activity of TFIIH subunits could not be demonstrated in budding yeast. TFB3, the 38-kDa subunit of yeast TFIIH, is the homolog of mammalian MAT1. By random mutagenesis we have isolated a temperature-sensitive mutation in the conserved RING domain. The mutant Tfb3 protein associates less efficiently with the kinase moiety of TFIIH than the wild type protein. In contrast to lethal mutants in other subunits of TFIIH, this mutation does not impair general transcription. Transcription of CLB2, and possibly other genes, is reduced in the mutant. At the restrictive temperature, the cells display a defect in cell cycle progression, which is manifest at more than one phase of the cycle. To conclude, in the present study we bring another demonstration of the multifunctional nature of TFIIH.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gileadi, O (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	opher@quantomix.com	Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X; Jona, Ghil/0000-0002-4526-6182				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; Buratowski S, 2000, CURR OPIN CELL BIOL, V12, P320, DOI 10.1016/S0955-0674(00)00095-8; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Gervais V, 2001, J BIOL CHEM, V276, P7457, DOI 10.1074/jbc.M007963200; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hermand D, 1998, EMBO J, V17, P7230, DOI 10.1093/emboj/17.24.7230; Hermand D, 2001, EMBO J, V20, P82, DOI 10.1093/emboj/20.1.82; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jona G, 2000, BBA-GENE STRUCT EXPR, V1491, P37, DOI 10.1016/S0167-4781(00)00016-6; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kaiser C., 1994, METHODS YEAST GENETI; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Ostapenko D, 2000, GENE, V245, P109, DOI 10.1016/S0378-1119(00)00029-9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Umeda M, 1998, P NATL ACAD SCI USA, V95, P5021, DOI 10.1073/pnas.95.9.5021; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7	55	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39409	39416		10.1074/jbc.M202733200	http://dx.doi.org/10.1074/jbc.M202733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176978	hybrid			2022-12-25	WOS:000178662500046
J	Ostrovsky, O; Bengal, E; Aronheim, A				Ostrovsky, O; Bengal, E; Aronheim, A			Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; DIAGNOSTIC UTILITY; REGULATORY FACTORS; AP-1 REPRESSOR; KINASE PATHWAY; DNA-BINDING; CYCLIN D1; MYOD; EXPRESSION; ACTIVATION	Muscle cell differentiation is a result of a complex interplay between transcription factors and cell signaling proteins. Proliferating myoblasts must exit from the cell cycle prior to their differentiation. The muscle regulatory factor and myocyte enhancer factor-2 protein families play a major role in promoting muscle cell differentiation. Conversely, members of the AP-1 family of transcription factors that promote cell proliferation antagonize muscle cell differentiation. Here we tested the role of the c-Jun dimerization protein JDP2 in muscle cell differentiation. Endogenous expression of JDP2 was induced in both C2C12 myoblast and rhabdomyosarcoma (RD) cells programmed to differentiate. Ectopic expression of JDP2 in C2C12 myoblast cells inhibited cell cycle progression and induced spontaneous muscle cell differentiation. Likewise, constitutive expression of JDP2 in RD cells reduced their tumorigenic characteristics and restored their ability to differentiate into myotubes. JDP2 potentiated and synergized with 12-O-tetradecanoylphorbol-13-acetate to induce muscle cell differentiation of RD cells. In addition, JDP2 induced p38 activity in both C2 and RD cells programmed to differentiate. This is the first demonstration of a single transcription factor that rescues the myogenic program in an otherwise non-differentiating cancer cell line. Our results indicate that the JDP2 protein plays a major role in promoting skeletal muscle differentiation via its involvement in cell cycle arrest and activation of the myogenic program.	Technion Israel Inst Technol, Fac Med, B Rappaport Inst Res Med Sci, Dept Mol Genet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, B Rappaport Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, B Rappaport Fac Med, Dept Mol Genet, 7 Efron St Bat Galim,POB 9649, IL-31096 Haifa, Israel.			Aronheim, Ami/0000-0002-8575-4092				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DIAS P, 1992, CANCER RES, V52, P6431; DIAS P, 1990, AM J PATHOL, V137, P1283; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Katz S, 2001, FEBS LETT, V506, P196, DOI 10.1016/S0014-5793(01)02907-6; Knudsen ES, 1998, CANCER RES, V58, P2042; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	31	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40043	40054		10.1074/jbc.M205494200	http://dx.doi.org/10.1074/jbc.M205494200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171923	hybrid			2022-12-25	WOS:000178662500125
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PDK1; ACTIVATION; 14-3-3-PROTEINS; IDENTIFICATION; TRANSLOCATION; PHOSPHOSERINE; 3-KINASE; SIGNAL; SITES	3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in activating the protein kinase A, G, and C subfamily. In particular, PDK1 plays an important role in regulating the Akt survival pathway by phosphorylating Akt on Thr-308. PDK1 kinase activity was thought to be constitutively active; however, recent reports suggested that its activity is regulated by binding to other proteins, such as protein kinase G-related kinase-2 (PRK2), p90 ribosomal protein S6 kinase-2 (RSK2), and heat-shock protein 90 (Hsp90). Here we report that PDK1 binds to 14-3-3 proteins in vivo and in vitro through the sequence surrounding Ser-241, a residue that is phosphorylated by itself and is critical for its kinase activity. Mutation of PDK1 to increase its binding to 14-3-3 decreased its kinase activity in vivo. By contrast, mutation of PDK1 to decrease its interaction with 14-3-3 resulted in increased PDK1 kinase activity. Moreover, incubation of wild-type PDK1 with recombinant 14-3-3 in vitro decreased its kinase activity. These data indicate that PDK1 kinase activity is negatively regulated by binding to 14-3-3 through the PDK1 autophosphorylation site Ser-241.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	31	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39360	39367		10.1074/jbc.M205141200	http://dx.doi.org/10.1074/jbc.M205141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177059	hybrid			2022-12-25	WOS:000178662500040
J	Rogers, JT; Randall, JD; Cahill, CM; Eder, PS; Huang, XD; Gunshin, H; Leiter, L; McPhee, J; Sarang, SS; Utsuki, T; Greig, NH; Lahiri, DK; Tanzi, RE; Bush, AI; Giordano, T; Gullans, SR				Rogers, JT; Randall, JD; Cahill, CM; Eder, PS; Huang, XD; Gunshin, H; Leiter, L; McPhee, J; Sarang, SS; Utsuki, T; Greig, NH; Lahiri, DK; Tanzi, RE; Bush, AI; Giordano, T; Gullans, SR			An iron-responsive element type II in the 5 '-untranslated region of the Alzheimer's amyloid precursor protein transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-PROTEIN; REGULATORY PROTEINS; BINDING PROTEIN; FERRITIN; DISEASE; TRANSLATION; GENE; INTERLEUKIN-1; EXPRESSION	Iron-responsive elements (IREs) are the RNA stem loops that control cellular iron homeostasis by regulating ferritin translation and transferrin receptor mRNA stability. We mapped a novel iron-responsive element (IRE-Type II) within the 5'-untranslated region (5'-UTR) of the Alzheimer's amyloid precursor protein (APP) transcript (+51 to +94 from the 5'-cap site). The APP mRNA IRE is located immediately upstream of an interleukin-1 responsive acute box domain (+101 to +146). APP 5'-UTR conferred translation was selectively down-regulated in response to intracellular iron chelation using three separate reporter assays (chloramphenicol acetyltransferase, luciferase, and red fluorescent protein reflecting an inhibition of APP holoprotein translation in response to iron chelation. Iron influx reversed this inhibition. As an internal control to ensure specificity, a viral internal ribosome entry sequence was unresponsive to intracellular iron chelation with desferrioxamine. Using RNA mobility shift assays, the APP 5'-UTRs, encompassing the IRE, bind specifically to recombinant iron-regulatory proteins (IRP) and to IRP from neuroblastoma cell lysates. IRP binding to the APP 5'-UTR is reduced after treatment of cells with desferrioxamine and increased after interleukin-1 stimulation. IRP binding is abrogated when APP cRNA probe is mutated in the core IRE domain (Delta4 bases:Delta83AGAG86). Iron regulation of APP mRNA through the APP 5'-UTR points to a role for iron in the metabolism of APP and confirms that this RNA structure can be a target for the selection of small molecule drugs, such as desferrioxamine We chelator) and clioquinol (Fe, Cu, and Zn chelator), which reduce Abeta peptide burden during Alzheimer's disease.	Massachusetts Gen Hosp, Genet & Aging Res Unit, Dept Psychiat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Diabet Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Charlestown, MA 02129 USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; Message Pharmaceut, Malvern, PA 19355 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Indiana University System; Indiana University-Purdue University Indianapolis	Rogers, JT (corresponding author), Harvard Univ, Sch Med, Genet & Aging Res Unit, Dept Psychiat Neurosci, Mass Gen E,Bldg 114,3850 16th St, Charlestown, MA 02129 USA.		Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007; Lahiri, Debomoy/AAZ-3322-2020; Tanzi, Rudolph/AAE-9622-2019	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Rogers, Jack/0000-0003-1262-8578	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH002001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000311, ZIAAG000311] Funding Source: NIH RePORTER; NIMH NIH HHS [5K01MH02001] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bartzokis G, 2000, ARCH GEN PSYCHIAT, V57, P47, DOI 10.1001/archpsyc.57.1.47; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Ekblom J, 2001, DRUG DISCOV TODAY, V6, P1259, DOI 10.1016/S1359-6446(01)02113-4; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; Komori N, 1997, MOL BRAIN RES, V49, P103, DOI 10.1016/S0169-328X(97)00133-2; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Mbella EGM, 2000, MOL CELL BIOL, V20, P4572, DOI 10.1128/MCB.20.13.4572-4579.2000; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Pinero DJ, 2000, CELL MOL BIOL, V46, P761; ROBINSON SR, 1995, ALZ RES, V1, P191; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Sampietro M, 2001, NEUROBIOL AGING, V22, P563, DOI 10.1016/S0197-4580(01)00219-6; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; TANZI RE, 1991, NATURE, V350, P564, DOI 10.1038/350564a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; ZUBENKO GS, 1992, J NEUROPATH EXP NEUR, V51, P459, DOI 10.1097/00005072-199207000-00008; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	49	420	437	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45518	45528		10.1074/jbc.M207435200	http://dx.doi.org/10.1074/jbc.M207435200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12198135	hybrid			2022-12-25	WOS:000179404800117
J	Fukuda, A; Matsuyama, S; Hara, T; Nakayama, J; Nagasawa, H; Tokuda, H				Fukuda, A; Matsuyama, S; Hara, T; Nakayama, J; Nagasawa, H; Tokuda, H			Aminoacylation of the N-terminal cysteine is essential for Lol-dependent release of lipoproteins from membranes but does not depend on lipoprotein sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPROTEINS; OUTER-MEMBRANE; CYTOPLASMIC MEMBRANE; LOCALIZATION; PROTEIN; TRANSLOCATION; ACYLTRANSFERASE; PEPTIDOGLYCAN; ACCUMULATION; MECHANISM	Lipoproteins are present in a wide variety of bacteria and are anchored to membranes through lipids attached to the N-terminal cysteine. The Lol system of Escherichia coli mediates the membrane-specific localization of lipoproteins. Aspartate at position 2 functions as a Lol avoidance signal and causes the retention of lipoproteins in the inner membrane, whereas lipoproteins having residues other than aspartate at position 2 are released from the inner membrane and localized to the outer membrane by the Lol system. Phospholipid:apolipoprotein transacylase, Lnt, catalyzes the last step of lipoprotein modification, converting apolipoprotein into mature lipoprotein. To reveal the importance of this aminoacylation for the Lol-dependent membrane localization, apolipoproteins were prepared by inhibiting lipoprotein maturation. Lnt was also purified and used to convert apolipoprotein into mature lipoprotein in vitro. The release of these lipoproteins was examined in proteoliposomes. We show here that the aminoacylation is essential for the Lol-dependent release of lipoproteins from membranes. Furthermore, lipoproteins with aspartate at position 2 were found to be aminoacylated both in vivo and in vitro, indicating that the lipoprotein-sorting signal does not affect lipid modification.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHEN R, 1987, EUR J BIOCHEM, V163, P73, DOI 10.1111/j.1432-1033.1987.tb10738.x; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; HIRASHIMA A, 1973, J BIOL CHEM, V248, P5654; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; HUSSAIN M, 1982, J BIOL CHEM, V257, P5177; INUKAI M, 1978, J ANTIBIOT, V31, P410, DOI 10.7164/antibiotics.31.410; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; MIZUSHIMA S, 1987, BACTERIAL OUTER MEMB, P163; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995	29	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43512	43518		10.1074/jbc.M206816200	http://dx.doi.org/10.1074/jbc.M206816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12198129	hybrid			2022-12-25	WOS:000179081200136
J	Klefstrom, J; Verschuren, EW; Evan, G				Klefstrom, J; Verschuren, EW; Evan, G			c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYTOCHROME-C; CELL-DEATH; KINASE RIP; CASPASE FAMILY; TNF; BCL-2; FAS; RELEASE; LIGAND	Activation of c-Myc sensitizes cells to apoptosis induction by ligand-activated death receptors. Such sensitization to death receptors by oncogenes may well be the mechanism underlying tumor cell sensitivity to tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL). The mechanism by which this c-Myc-induced sensitization occurs is unclear but could involve modulation of expression of death receptors or their ligands or potentiation of the sensitivity of mitochondria to release pro-apoptotic effectors such as holocytochrome c. Here, we show that ectopic expression of the death receptor signaling protein RIP (receptor-interactive protein) triggers apoptosis via a FAS-associated death domain protein (FADD) and caspase 8-dependent pathway. Induction of apoptosis by this intracellular activation of the death receptor signaling pathway is significantly augmented by c-Myc expression. Moreover, c-Myc expression strongly promotes the potential of RIP to induce cytochrome c release from mitochondria. This implicates the mitochondrial apoptotic pathway in this synergy, a notion confirmed by the inability of c-Myc to sensitize to RIP killing in cells lacking the obligate mitochondrial apoptotic effectors Bax and Bak. We conclude that the lethality of the RIP-activated cytosolic caspase 8 pathway is augmented by c-Myc priming mitochondria to release cytochrome c. This places the intersection of apoptotic synergy between c-Myc and death receptor signaling downstream of the death receptors.	Univ Calif San Francisco, San Franciso Comprehens Canc Ctr, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Evan, G (corresponding author), Univ Calif San Francisco, San Franciso Comprehens Canc Ctr, 2340 Sutter St, San Francisco, CA 94115 USA.			Verschuren, Emmy/0000-0001-5771-9129				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mitchell KO, 2000, CANCER RES, V60, P6318; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	40	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43224	43232		10.1074/jbc.M206967200	http://dx.doi.org/10.1074/jbc.M206967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202489	hybrid			2022-12-25	WOS:000179081200104
J	Lei, HT; An, P; Song, SM; Liu, XY; He, LW; Wu, J; Meng, L; Liu, MS; Yang, JS; Shou, CC				Lei, HT; An, P; Song, SM; Liu, XY; He, LW; Wu, J; Meng, L; Liu, MS; Yang, JS; Shou, CC			A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANGIOGENESIS; IDENTIFICATION; EXPRESSION; INTEGRIN; CANCER; ALPHA(V)BETA(3); REGRESSION; SUPPRESSES; SELECTION	Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors, plays an essential role in both physiological and pathological angiogenesis. The VEGF receptor KDR/Flk-1 (a kinase domain receptor) mediates various biological activities of VEGF related to proliferation, differentiation, and migration of endothelial cells. Here we present a novel peptide designated K237-(HTMYYHHYQHHL), which was isolated from a phage-displayed peptide library, binding to KDR with high affinity and specificity. By interfering with the VEGF-KDR interaction, the peptide K237 inhibited proliferation of cultured primary human umbilical vein endothelial cells induced by recombinant human VEGF,,, in a dose-dependent and cell type-specific manner. The peptide also exerted an anti-angiogenesis activity in vivo as revealed using the chick embryo chorioallantoic membrane angiogenesis assay. Moreover, the peptide K237 significantly inhibited the growth of solid tumors implanted beneath the breasts and their metastases to lungs in severe combined immunodeficient mice. Taken together, these findings suggest that the peptide K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. As a consequence, this peptide (and its future derivatives) may have use as a potential cancer therapy.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Beijing 100034, Peoples R China; Peking Union Med Coll, Chinese Acad Med Sci, Inst Med Plant, Beijing 100094, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Shou, CC (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, 1 Da Hong Luo Chang St, Beijing 100034, Peoples R China.			Lei, Hetian/0000-0003-4091-1936				ASANO M, 1995, CANCER RES, V55, P5296; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CLIFF WJ, 1963, PHILOS T ROY SOC B, V246, P305, DOI 10.1098/rstb.1963.0008; Cortese R, 1996, CURR OPIN BIOTECH, V7, P616, DOI 10.1016/S0958-1669(96)80072-3; Felici F, 1995, Biotechnol Annu Rev, V1, P149, DOI 10.1016/S1387-2656(08)70051-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Kumar CC, 2001, CANCER RES, V61, P2232; MELINYK O, 1996, CANCER RES, V56, P921; Millauer B, 1996, CANCER RES, V56, P1615; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SCHOEFL GI, 1963, VIRCHOWS ARCH A, V337, P97, DOI 10.1007/BF00963592; SENGER DR, 1986, CANCER RES, V46, P5629; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	28	100	140	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43137	43142		10.1074/jbc.M203103200	http://dx.doi.org/10.1074/jbc.M203103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183450	hybrid			2022-12-25	WOS:000179081200094
J	Messner, KR; Imlay, JA				Messner, KR; Imlay, JA			Mechanism of superoxide and hydrogen peroxide formation by fumarate reductase, succinate dehydrogenase, and aspartate oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; XANTHINE-OXIDASE; RESPIRATORY COMPLEX; OXIDATIVE STRESS; NADPH OXIDASE; BOUND FLAVIN; DNA-DAMAGE; ENZYME; OXYGEN; IDENTIFICATION	Oxidative stress is created in aerobic organisms when molecular oxygen chemically oxidizes redox enzymes, forming superoxide (O-2 and hydrogen peroxide (H2O2) Prior work identified several flavoenzymes from Escherichia coli that tend to autoxidize. Of these, fumarate reductase (Frd) is notable both for its high turnover number and for its production of substantial 07 in addition to H2O2. We have sought to identify characteristics of Frd that predispose it to this behavior. The ability of excess succinate to block autoxidation and the inhibitory effect of lowering the Flavin potential indicate that all detectable autoxidation occurs from its FAD site, rather than from iron-sulfur clusters or bound quinones. The flavin adenine dinucleotide (FAD) moiety of Frd is unusually solvent-exposed, as evidenced by its ability to bind sulfite, and this may make it more likely to react adventitiously with O-2. The autoxidizing species is apparently fully reduced flavin rather than flavosemiquinone, since treatments that more fully reduce the enzyme do not slow its turnover number. They do, however, switch the major product from O-2 to H2O2. A similar effect is achieved by lowering the potential of the proximal [2Fe-2S] cluster. These data suggest that Frd releases O-2 into bulk solution if this cluster is available to sequester the semiquinone electron; otherwise, that electron is rapidly transferred to the nascent superoxide, and H2O2 is the product that leaves the active site. This model is supported by the behavior of "aspartate oxidase" (aspartate:fumarate oxidoreductase), an Frd homologue that lacks Fe-S clusters. Its dihydroflavin also reacts avidly with oxygen, and H2O2 is the predominant product. In contrast, succinate dehydrogenase, with high potential clusters, generates O-2 exclusively. The identities of enzyme autoxidation products are Significant because O-2 and H2O2 damage cells in different ways.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.	jimlay@uiuc.edu	Messner, Kevin/ABC-8801-2020; Messner, Kevin/J-2242-2014	Messner, Kevin/0000-0003-2516-0695	NIGMS NIH HHS [T32 GM07283-20, GM49640, R01 GM049640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049640, R37GM049640, T32GM007283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; BLAUT M, 1989, J BIOL CHEM, V264, P13599; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P3018, DOI 10.1021/bi015939r; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; CONDON C, 1985, J BIOL CHEM, V260, P9427; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Heering HA, 1997, J AM CHEM SOC, V119, P11628, DOI 10.1021/ja9723242; HILLE R, 1981, J BIOL CHEM, V256, P9090; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iverson TM, 2000, CURR OPIN STRUC BIOL, V10, P448, DOI 10.1016/S0959-440X(00)00113-5; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KUO CF, 1987, J BIOL CHEM, V262, P4724; Leger C, 2001, BIOCHEMISTRY-US, V40, P11234, DOI 10.1021/bi010889b; LEMIRE BD, 1986, METHOD ENZYMOL, V126, P377; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; MIKI T, 1992, J BIOL CHEM, V267, P18695; MILLER JH, 1972, EXPT MOL GENETICS, P37; MISRA HP, 1977, ANAL BIOCHEM, V79, P553, DOI 10.1016/0003-2697(77)90429-8; Mortarino M, 1996, EUR J BIOCHEM, V239, P418, DOI 10.1111/j.1432-1033.1996.0418u.x; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; Pan N, 2001, MOL MICROBIOL, V39, P1562, DOI 10.1046/j.1365-2958.2001.02343.x; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; SALACH JI, 1974, J BIOL CHEM, V249, P3765; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SEIFERT J, 1990, BIOL CHEM H-S, V371, P239, DOI 10.1515/bchm3.1990.371.1.239; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; SILVIUS JR, 1980, P NATL ACAD SCI-BIOL, V77, P1255, DOI 10.1073/pnas.77.3.1255; Singer TP, 1971, METHODS ENZYMOL    B, V18, P416; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Tedeschi G, 1996, EUR J BIOCHEM, V239, P427, DOI 10.1111/j.1432-1033.1996.0427u.x; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	58	210	217	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42563	42571		10.1074/jbc.M204958200	http://dx.doi.org/10.1074/jbc.M204958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200425	hybrid			2022-12-25	WOS:000179081200019
J	Michalski, C; Cui, YH; Nies, AT; Nuessler, AK; Neuhaus, P; Zanger, UM; Klein, K; Eichelbaum, M; Keppler, D; Konig, J				Michalski, C; Cui, YH; Nies, AT; Nuessler, AK; Neuhaus, P; Zanger, UM; Klein, K; Eichelbaum, M; Keppler, D; Konig, J			A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; MULTIDRUG-RESISTANCE PROTEIN; DUBIN-JOHNSON-SYNDROME; HUMAN LIVER; CANALICULAR ISOFORM; EUROPEAN-AMERICANS; AFRICAN-AMERICANS; DRUG-RESISTANCE; IDENTIFICATION; EXPRESSION	The organic anion transporter SLC21A6 (also known as OATP2, OATP-C, or LST-1) is involved in the hepatocellular uptake of a variety of endogenous and xenobiotic substances and drugs. We analyzed 81 human liver samples by immunoblotting and found one with a strongly reduced amount of SLC21A6 protein suggesting mutations in the SLC21A6 gene. The SLC21A6 cDNA from this sample contained five base pair changes in one allele; three of the mutations resulted in amino acid substitutions designated SLC21A6-N130D, SLC21A6-P155T, and SLC21A6-L193R. The former two were polymorphisms (SLC21A6*1b and SLC21A6*4), whereas SLC21A6-L193R represents the first naturally occurring mutation identified in one allele of the SLC21A6 gene, which affects protein maturation and organic anion transport. We introduced each of the mutations into the SLC21A6 cDNA and established stably transfected MDCKII cells expressing the respective mutant SLC21A6 protein. Immunofluorescence microscopy and uptake measurements were used to study localization and transport properties of the mutated proteins. Both proteins carrying the polymorphisms were sorted to the lateral membrane like wild-type SLC21A6, but their transport properties for the substrates cholyltaurine and 17beta-glucuronosyl estradiol were altered. Importantly, most of the mutant protein SLC21A6-L193R was retained intracellularly, and this single amino acid exchange abolished transport function.	Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany; Humboldt Univ, Dept Surg, Charite, D-13353 Berlin, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Konig, J (corresponding author), Deutsch Krebsforschungszentrum, Div Tumor Biochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Zanger, Ulrich M./A-9364-2012; Cui, Yunhai/AAP-7670-2021; Michalski, Christoph/U-9167-2019; Nies, Anne T./D-7923-2016; Keppler, Dietrich/A-5528-2013	Zanger, Ulrich M./0000-0002-5276-2002; Cui, Yunhai/0000-0003-4969-072X; Nies, Anne T./0000-0001-6862-0730; Keppler, Dietrich/0000-0003-2964-2333; Koenig, Joerg/0000-0001-7016-5482				Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; Buchler M, 1996, J BIOL CHEM, V271, P15091; Cui Y, 2001, J BIOL CHEM, V276, P9626, DOI 10.1074/jbc.M004968200; Cui YH, 1999, MOL PHARMACOL, V55, P929; Cui YH, 2001, MOL PHARMACOL, V60, P934, DOI 10.1124/mol.60.5.934; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; Ingelman-Sundberg M, 1999, TRENDS PHARMACOL SCI, V20, P342, DOI 10.1016/S0165-6147(99)01363-2; Ito K, 2001, AM J PHYSIOL-GASTR L, V281, pG1034, DOI 10.1152/ajpgi.2001.281.4.G1034; Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008; Itoda M, 2002, DRUG METAB DISPOS, V30, P363, DOI 10.1124/dmd.30.4.363; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; KEPPLER D, 2001, LIVER BIOL PATHOBIOL, P373; Kim RB, 2001, CLIN PHARMACOL THER, V70, P189, DOI 10.1067/mcp.2001.117412; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; Lang T, 2001, PHARMACOGENETICS, V11, P399, DOI 10.1097/00008571-200107000-00004; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Nebert DW, 2000, PHARMACOGENETICS, V10, P279, DOI 10.1097/00008571-200006000-00001; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; Nozawa T, 2002, J PHARMACOL EXP THER, V302, P804, DOI 10.1124/jpet.302.2.804; Rodrigues AD, 2002, CURR DRUG METAB, V3, P289, DOI 10.2174/1389200023337522; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; Stieger B, 1998, CURR OPIN CELL BIOL, V10, P462, DOI 10.1016/S0955-0674(98)80059-8; Suzuki H, 2000, SEMIN LIVER DIS, V20, P251, DOI 10.1055/s-2000-8408; Tamai I, 2000, BIOCHEM BIOPH RES CO, V273, P251, DOI 10.1006/bbrc.2000.2922; Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200	36	105	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43058	43063		10.1074/jbc.M207735200	http://dx.doi.org/10.1074/jbc.M207735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196548	hybrid			2022-12-25	WOS:000179081200083
J	Boesze-Battaglia, K; Dispoto, J; Kahoe, MA				Boesze-Battaglia, K; Dispoto, J; Kahoe, MA			Association of a photoreceptor-specific tetraspanin protein, ROM-1, with Triton X-100-resistant membrane rafts from rod outer segment disk membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ANCHORED PROTEINS; LIPID RAFTS; CHOLESTEROL; PERIPHERIN/RDS; LOCALIZATION; ACID; TRANSDUCIN; RECEPTOR; COMPLEX	This study reports the isolation and characterization of a Triton X-100-resistant membrane fraction from homogenates of rod outer segment (ROS) disk membranes purified free of the surrounding plasma membrane. A portion of the ROS disk membrane was found to be resistant to Triton X-100 extraction at 4 degreesC. This detergent-resistant fraction was isolated as a low buoyant density band on sucrose density gradients and exhibited an increase in light scattering detected at 600 nm. Biochemical analysis of the Triton X-100-resistant fraction showed it to be enriched in cholesterol and sphingomyelin relative to phospholipid and in phospholipid relative to protein compared with the soluble fraction. The Triton X-100-resistant membranes described herein did not arise simply from partial solubilization of the ROS disk membranes because detergent-treated low buoyant density fractions isolated from homogenates with octyl glucopyranoside had cholesterol and sphingomyelin content indistinguishable from that of solubilized ROS disk homogenates. Analysis of proteins associated with the Triton X-100-resistant fraction showed it to be enriched in the rim-specific protein ROM-1 and eaveolin; surprisingly, the fusion protein peripherin/rds (where rds is retinal degeneration slow), also localized to the disk rim, was entirely absent from the membrane raft domain. The lipid profiles of the Triton X-100-resistant membranes were virtually identical in preparations homogenized in either the light or dark. Slightly more ROM-1 was recovered from samples prepared in the light (23%) than from samples prepared in the dark (13%), but peripherin/rds could not be detected in either preparation. When the Triton X-100-resistant membranes were treated with methyl-beta-cyclodextran to deplete membrane cholesterol, the resultant membranes contained slightly lower levels of ROM-1, specifically in the dimeric form. Cholesterol depletion also resulted in the collapse of the large caveolin complex to monomeric caveolae. The results presented herein characterize a pool of ROM-1, a photoreceptor tetraspanin protein, that may play a regulatory role in peripherin/rds-dependent fusion.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08084 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Boesze-Battaglia, K (corresponding author), Univ Penn, Sch Dent Med, Dept Biochem, 4001 Spruce St, Philadelphia, PA 19104 USA.	battagli@biochem.dental.upenn.edu			NCRR NIH HHS [S10 RR026365-01, S10 RR026365] Funding Source: Medline; NEI NIH HHS [R01 EY010420, EY 10420, R01 EY010420-12, R01 EY010420-15, R29 EY010420, R01 EY010420-11, R01 EY010420-10A2, R01 EY010420-13A2, R01 EY010420-16, R01 EY010420-09, R01 EY010420-08, R21 EY018705, R21 EY018705-02, R01 EY010420-07, R29 EY010420-03, R01 EY010420-06, R21 EY018705-01A1, R01 EY010420-14] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026365] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY010420, R29EY010420, R21EY018705] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANDREWS LD, 1983, J CELL BIOL, V97, P749, DOI 10.1083/jcb.97.3.749; ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; Boesze-Battaglia K, 2002, INT REV CYTOL, V217, P183; BOESZEBATTAGLIA K, 1994, EXP EYE RES, V58, P293, DOI 10.1006/exer.1994.1020; BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; BOESZEBATTAGLIA K, 1992, EXP EYE RES, V54, P821, DOI 10.1016/0014-4835(92)90040-Y; BOESZEBATTAGLIA K, 1989, EXP EYE RES, V49, P699, DOI 10.1016/S0014-4835(89)80064-8; BoeszeBattaglia K, 1997, BIOCHEMISTRY-US, V36, P6835, DOI 10.1021/bi9627370; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867; BOESZEBATTAGLIA K, 1999, INVESTIG OPHTHALMOL, V40, P4909; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Christian AE, 1997, J LIPID RES, V38, P2264; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Fliesler SJ, 1997, EXP EYE RES, V64, P279, DOI 10.1006/exer.1996.0201; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRA AM, 1994, J BIOL CHEM, V269, P30745; Ghalayini AJ, 2002, J BIOL CHEM, V277, P1469, DOI 10.1074/jbc.M011432200; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; LITMAN BJ, 1973, BIOCHEMISTRY-US, V12, P2545, DOI 10.1021/bi00737a028; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Liu Y, 2000, J CELL SCI, V113, P2363; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; Martin-Belmonte F, 2001, J BIOL CHEM, V276, P49337, DOI 10.1074/jbc.M106882200; MERRIL CR, 1982, ELECTROPHORESIS, V3, P17, DOI 10.1002/elps.1150030104; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SPRINGER HA, 1996, CURRENT PROTOCOLS IM; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	56	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41843	41849		10.1074/jbc.M207111200	http://dx.doi.org/10.1074/jbc.M207111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196538	Green Submitted, Green Accepted, hybrid, Green Published			2022-12-25	WOS:000178985300070
J	Boulanger, L; Sabatino, DE; Wong, EY; Cline, AP; Garrett, LJ; Garbarz, M; Dhermy, D; Bodine, DM; Gallagher, PG				Boulanger, L; Sabatino, DE; Wong, EY; Cline, AP; Garrett, LJ; Garbarz, M; Dhermy, D; Bodine, DM; Gallagher, PG			Erythroid expression of the human alpha-spectrin gene promoter is mediated by GATA-1-and NF-E2-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; MEMBRANE SKELETAL PROTEINS; DIMER-DIMER ASSOCIATION; LEUCINE ZIPPER PROTEIN; HUMAN ANKYRIN-1 GENE; LOCUS-CONTROL REGION; KRUPPEL-LIKE FACTOR; BETA-SPECTRIN; FACTOR NF-E2	alpha-Spectrin is a highly expressed membrane protein critical for the flexibility and stability of the erythrocyte. Qualitative and quantitative defects of alpha-spectrin are present in the erythrocytes of many patients with abnormalities of red blood cell shape including hereditary spherocytosis and elliptocytosis. We wished to determine the regulatory elements that determine the erythroid-specific expression of the alpha-spectrin gene. We mapped the 5' end of the alpha-spectrin erythroid cDNA and cloned the 5' flanking genomic DNA containing the putative alpha-spectrin gene promoter. Using transfection of promoter/reporter plasmids in human tissue culture cell lines, in vitro DNase I footprinting analyses, and gel mobility shift assays, an alpha-spectrin gene erythroid promoter with binding sites for GATA-1- and NF-E2-related proteins was identified. Both binding sites were required for full promoter activity. In transgenic mice, a reporter gene directed by the alpha-spectrin promoter was expressed in yolk sac, fetal liver, and erythroid cells of bone marrow but not adult reticulocytes. No expression of the reporter gene was detected in nonerythroid tissues. We conclude that this alpha-spectrin gene promoter contains the sequences necessary for low level expression in erythroid progenitor cells.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Univ Paris 07, Assoc Claude Bernard, INSERM, U409, F-75870 Paris 18, France; NHGRI, Genet & Mol Biol Branch, Hematopoiesis Sect, NIH, Bethesda, MD 20892 USA	Yale University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.				NHLBI NIH HHS [HL65448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065448] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000083, Z01HG000083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGRE P, 1982, NEW ENGL J MED, V306, P1155, DOI 10.1056/NEJM198205133061906; AGRE P, 1986, NEW ENGL J MED, V315, P1579, DOI 10.1056/NEJM198612183152504; AGRE P, 1985, NATURE, V314, P380, DOI 10.1038/314380a0; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bieker J J, 1998, Curr Opin Hematol, V5, P145; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COETZER T, 1990, BLOOD, V75, P2235; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ELEOUET JF, 1993, EUR J BIOCHEM, V212, P763, DOI 10.1111/j.1432-1033.1993.tb17716.x; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, BLOOD, V80, P530; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOGAN B, 1986, MANIPULATING MOUSE E; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; LIU SC, 1982, P NATL ACAD SCI-BIOL, V79, P2072, DOI 10.1073/pnas.79.6.2072; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MASON P, 1993, GENE TRANSCRIPTION P, P47; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1997, HDB PHYSIOL 14, P485; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Philipp S, 1998, FEBS LETT, V438, P315, DOI 10.1016/S0014-5793(98)01326-X; PTERES LL, 1992, P NATL ACAD SCI USA, V89, P5749; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sabatino DE, 2000, J BIOL CHEM, V275, P28549, DOI 10.1074/jbc.M004043200; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAHR KE, 1989, J CLIN INVEST, V84, P1243, DOI 10.1172/JCI114291; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; Wandersee N J, 2000, Hematol J, V1, P235, DOI 10.1038/sj.thj.6200030; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	72	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41563	41570		10.1074/jbc.M208184200	http://dx.doi.org/10.1074/jbc.M208184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196550	hybrid			2022-12-25	WOS:000178985300035
J	Chakraborty, S; Massey, V				Chakraborty, S; Massey, V			Reaction of reduced flavins and flavoproteins with diphenyliodonium chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; 2-METHYL-3-HYDROXYPYRIDINE-5-CARBOXYLIC ACID OXYGENASE; OLD YELLOW ENZYME; NEUTROPHIL NADPH OXIDASE; PSEUDOMONAS-FLUORESCENS; PHENOL HYDROXYLASE; CRYSTAL-STRUCTURE; MECHANISM; INHIBITION; BINDING	The reaction of diphenyliodonium chloride with free reduced flavins has been studied by stopped flow spectrophotometry under anaerobic conditions, and second order rate constants were determined as a function of pH. The reactive flavin species was identified as the reduced anion, based on an observed reaction pK of 6.7. The product mixture was independent of the initial concentration of reactant and contained similar to20% oxidized flavin. The results can be modeled quantitatively on a modification of the mechanism proposed by Tew (Tew, D. G. (1993) Biochemistry 32,10209-10215). The composition of the complex reaction mixture has been analyzed, and four flavin-phenyl adducts with distinctive absorbance and fluorescence characteristics have been identified, involving substitution at the flavin C4a, N5, and C8 positions. Inactivation of flavoprotein enzymes by diphenyliodonium has also been studied, and several examples were found where inactivation occurs readily, despite noninvolvement of radical intermediates in their reaction mechanisms. It can be concluded that inactivation by phenyliodonium species is not a valid indicator of catalytic mechanism involving radical intermediates. One of the several factors determining inactivation is maintenance of the enzyme flavin in the reduced form in the steady state of catalysis, the other factors being redox potential and accessibility of the inhibitor to the flavin active site.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chakraborty, S (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine St, Ann Arbor, MI 48109 USA.	sumita@umich.de						BANKS DF, 1966, CHEM REV, V66, P243, DOI 10.1021/cr60241a001; BERINGER FM, 1972, J ORG CHEM, V37, P2486; BRUSTLEIN M, 1971, ANGEW CHEM INT EDIT, V10, P804, DOI 10.1002/anie.197108041; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P8060, DOI 10.1021/bi970089u; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P2612, DOI 10.1021/bi962325r; Chaiyen PC, 1997, P NATL ACAD SCI USA, V94, P7233, DOI 10.1073/pnas.94.14.7233; Coves J, 1999, BIOCHEM J, V342, P465, DOI 10.1042/0264-6021:3420465; DETMER K, 1984, J BIOL CHEM, V259, P1265; DUPLATRE G, 1984, RADIAT PHYS CHEM, V24, P557, DOI 10.1016/0146-5724(84)90193-6; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P1166; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Goez M, 1999, J PHYS CHEM A, V103, P5714, DOI 10.1021/jp990681o; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; Hemmerich P, 1971, FLAVINS FLAVOPROTEIN, P83; Hennig H, 2001, CHEM-EUR J, V7, P2114, DOI 10.1002/1521-3765(20010518)7:10<2114::AID-CHEM2114>3.0.CO;2-D; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; KOMAI H, 1969, J BIOL CHEM, V244, P1692; Kunze A, 1997, J PHOTOCH PHOTOBIO A, V110, P115, DOI 10.1016/S1010-6030(97)00178-0; LAND EJ, 1969, BIOCHEMISTRY-US, V8, P2117, DOI 10.1021/bi00833a050; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V37, P314, DOI 10.1016/0006-3002(60)90239-0; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Massey V., 1973, OXIDASES RELATED RED, P25; MAYHEW SG, 1975, EUR J BIOCHEM, V59, P539, DOI 10.1111/j.1432-1033.1975.tb02480.x; MAYHEW SG, 1984, FLAVINS FLAVOPROTEIN, P261; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007; Moran GR, 1996, BIOCHEMISTRY-US, V35, P9278, DOI 10.1021/bi960360s; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V3, P557; MULLER F, 1987, FLAVINS FLAVOPROTEIN, P261; Mullis K B, 1991, PCR Methods Appl, V1, P1; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; PALFEY BA, 1994, BIOCHEMISTRY-US, V33, P1545, DOI 10.1021/bi00172a035; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; POWLOWSKI JB, 1987, J BIOL CHEM, V262, P69; Press W. H., 1992, ART SCI COMPUTING; SAITO K, 1991, J BIOL CHEM, V266, P20720; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SPECTOR T, 1972, J BIOL CHEM, V247, P7123; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; VANDENBERGHESNOREK S, 1985, J BIOL CHEM, V260, P3373; Xu D, 2001, BIOCHEMISTRY-US, V40, P12369, DOI 10.1021/bi010962y; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	51	47	48	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41507	41516		10.1074/jbc.M205432200	http://dx.doi.org/10.1074/jbc.M205432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186866	hybrid			2022-12-25	WOS:000178985300028
J	Hong, Q; Gutierrez-Aguirre, I; Barlic, A; Malovrh, P; Kristan, K; Podlesek, Z; Macek, P; Turk, D; Gonzalez-Manas, JM; Lakey, JH; Anderluh, G				Hong, Q; Gutierrez-Aguirre, I; Barlic, A; Malovrh, P; Kristan, K; Podlesek, Z; Macek, P; Turk, D; Gonzalez-Manas, JM; Lakey, JH; Anderluh, G			Two-step membrane binding by equinatoxin II, a pore-forming toxin from the sea anemone, involves an exposed aromatic cluster and a flexible helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; ACTINIA-EQUINA; STICHODACTYLA-HELIANTHUS; PERFRINGOLYSIN-O; LIPID-MEMBRANES; CHOLESTEROL-BINDING; CRYSTAL-STRUCTURE; MODEL MEMBRANES; STICHOLYSIN-II; GOLD SURFACES	Equinatoxin 11 (EqtII) belongs to a unique family of 20-kDa pore-forming toxins from sea anemones. These toxins preferentially bind to membranes containing sphingomyelin and create cation-selective pores by oligomerization of 3-4 monomers. In this work we have studied the binding of EqtII to lipid membranes by the use of lipid monolayers and surface plasmon resonance (SPR). The binding is a two-step process, separately mediated by two regions of the molecule. An exposed aromatic cluster involving tryptophans 112 and 116 mediates the initial attachment that is prerequisite for the next step. Steric shielding of the aromatic cluster or mutation of Trp-112 and -116 to phenylalanine significantly reduces the toxin-lipid interaction. The second step is promoted by the N-terminal amphiphilic helix, which translocates into the lipid phase. The two steps were distinguished by the use of a double cysteine mutant having the N-terminal helix fixed to the protein core by a disulfide bond. The kinetics of membrane binding derived from the SPR experiments could be fitted to a two-stage binding model. Finally, by using membrane-embedded quenchers, we showed that EqtII does not insert deeply in the membrane. The first step of the EqtII binding is reminiscent of the binding of the evolutionarily distant cholesterol-dependant cytolysins, which share a similar structural motif in the membrane attachment domain.	Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Basque Country, Unidad Biofis, CSIC, EHU, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Ljubljana, Dept Biol, Biotech Fac, Ljubljana 1000, Slovenia; Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia	Newcastle University - UK; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; University of Ljubljana; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute	Anderluh, G (corresponding author), Newcastle Univ, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	gregor.anderluh@ncl.ac.uk	Maček, Peter/Y-9877-2019; Anderluh, Gregor/C-6905-2014; Maček, Peter/U-4662-2017	Maček, Peter/0000-0001-6470-7759; Anderluh, Gregor/0000-0002-9916-8465; Maček, Peter/0000-0001-6470-7759; Gutierrez Aguirre, Ion/0000-0002-8348-8616; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982				Anderluh G, 1997, PROTEIN ENG, V10, P751, DOI 10.1093/protein/10.7.751; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 1998, BIOCHEM BIOPH RES CO, V242, P187, DOI 10.1006/bbrc.1997.7944; Anderluh G, 1996, BIOCHEM BIOPH RES CO, V220, P437, DOI 10.1006/bbrc.1996.0391; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; BELMONTE G, 1994, BBA-BIOMEMBRANES, V1192, P197, DOI 10.1016/0005-2736(94)90119-8; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; Driscoll PC, 1999, CURR BIOL, V9, pR857, DOI 10.1016/S0960-9822(00)80046-9; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Kem W.R., 1988, P375; Kennedy MW, 2000, CELL MOL LIFE SCI, V57, P1379, DOI 10.1007/PL00000623; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; Ladokhin AS, 2001, J MOL BIOL, V309, P543, DOI 10.1006/jmbi.2001.4684; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MACEK P, 1981, TOXICON, V19, P233, DOI 10.1016/0041-0101(81)90026-X; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; MACEK P, 1988, TOXICON, V26, P441, DOI 10.1016/0041-0101(88)90183-3; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARKER MW, 1996, PROTEIN TOXIN STRUCT; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SekinoSuzuki N, 1996, EUR J BIOCHEM, V241, P941, DOI 10.1111/j.1432-1033.1996.00941.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Terrettaz S, 2002, PROTEIN SCI, V11, P1917, DOI 10.1110/ps.0206102; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; van der Goot G., 2001, PORE FORMING TOXINS; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZOREC R, 1990, J MEMBRANE BIOL, V118, P243, DOI 10.1007/BF01868608	54	177	191	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41916	41924		10.1074/jbc.M204625200	http://dx.doi.org/10.1074/jbc.M204625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198118	hybrid			2022-12-25	WOS:000178985300079
J	Kwon, YH; Jovanovic, A; Serfas, MS; Kiyokawa, H; Tyner, AL				Kwon, YH; Jovanovic, A; Serfas, MS; Kiyokawa, H; Tyner, AL			p21 functions to maintain quiescence of p27-deficient hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; CDK INHIBITORS; DEPENDENT KINASES; P27(KIP1); P21(CIP1); P21(WAF1/CIP1); EXPRESSION; PROLIFERATION; GROWTH; GENE	Hepatocytes rarely proliferate in the healthy adult liver. We explored the roles of the cyclin kinase inhibitors p21 and p27 in maintaining hepatocyte quiescence. p27 is expressed throughout the wild-type liver, but the related protein p21 was not detected. However, p21 was detected in livers of p27-deficient mice. Increased p21 protein levels did not result from an increase in p21 mRNA expression, indicating that p21 expression is regulated post-transcriptionally. p21 protein levels increased in cultured primary hepatocytes treated with the proteasome inhibitor MG132 and cycloheximide, indicating that p21 expression is regulated at the level of protein stability in liver cells. Although increased expression of cyclin-dependent kinase (Cdk) 4, Cdk2, and proliferating cell nuclear antigen was detected in p27-deficient livers, increased hepatocyte proliferation was detected only in livers of mice deficient for both p21 and p27. In p27-deficient livers, p21 was found in complexes with Cdk2 and CdK4 and can compensate for the absence of p27. Our data indicate that cyclin kinase inhibitor activity is important for maintaining hepatocyte quiescence in the adult liver. Significant increases in p21 were detected in multiple tissues of mature p27-deficient mice compared with wild-type mice, suggesting that the ability of p21 to functionally substitute for p27 is not liver-specific.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, MC 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455; Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK56283, R01 DK056283-05, R01 DK056283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hui AM, 1998, CANCER LETT, V132, P67, DOI 10.1016/S0304-3835(98)00164-5; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Karnezis AN, 2001, J CLIN INVEST, V108, P383, DOI 10.1172/JCI11933; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Klibanov SA, 2001, J CELL SCI, V114, P1867; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee LA, 2001, J CLIN INVEST, V108, P367, DOI 10.1172/JCI200113650; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Megyesi J, 1999, P NATL ACAD SCI USA, V96, P10830, DOI 10.1073/pnas.96.19.10830; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Viollet B, 2001, MOL CELL BIOL, V21, P3662, DOI 10.1128/MCB.21.11.3662-3670.2001; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462	57	33	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41417	41422		10.1074/jbc.M203388200	http://dx.doi.org/10.1074/jbc.M203388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202477	hybrid			2022-12-25	WOS:000178985300017
J	Zor, T; Mayr, BM; Dyson, HJ; Montminy, MR; Wright, PE				Zor, T; Mayr, BM; Dyson, HJ; Montminy, MR; Wright, PE			Roles of phosphorylation and helix propensity in the binding of the KIX domain of CREB-binding protein by constitutive (c-Myb) and inducible (CREB) activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; COACTIVATOR COMPLEX; SECONDARY STRUCTURE; GENE ACTIVATION; CHEMICAL-SHIFTS; CELL-GROWTH; PEPTIDES; KINASE; CBP; DIFFERENTIATION	cAMP-response element-binding protein (CREB)binding protein (CBP) is a general transcriptional coactivator that mediates interactions between transcription factors and the basal transcription machinery. To obtain insights into the mechanism by which the KIX domain of CBP can recognize the transactivation domains of many different transcription factors, we have used NMR and biochemical analyses to study the interactions of KIX with the transactivation domain from the constitutive activator c-Myb and with the kinase-inducible transactivation domain (KID) from CREB. NAIR chemical shift mapping shows that both activation domains bind to the same surface of KIX. In the unbound state, both the phosphorylated KID and c-Myb activation domains are only partly structured, and binding to KIX is coupled with folding to form an amphipathic helix. Helix-destabilizing mutations significantly impair binding, whereas mutations that increase the intrinsic secondary structure content of the free phosphorylated KID peptide have only a small influence on binding affinity. Low affinity but specific binding of unphosphorylated KID to KIX was measured by ITC and was also observed in Western blot assays and by a fluorescence resonance energy transfer experiment in living cells. The large increase in the affinity for phosphorylated KID is due to favorable intermolecular interactions involving the phosphate moiety. After induction by phosphorylation, CREB is able to compete effectively with other transcriptional activators for binding to CBP.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Salk Institute	Wright, PE (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wright@scripps.edu	Zor, Tsaffrir/H-1802-2013; Mayr, Bernhard M/F-6936-2012; Dyson, Jane/D-4160-2011	Zor, Tsaffrir/0000-0002-7224-3939; Mayr, Bernhard M/0000-0002-8973-4494; Dyson, Jane/0000-0001-6855-3398; Wright, Peter/0000-0002-1368-0223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bienkiewicz EA, 2002, BIOCHEMISTRY-US, V41, P752, DOI 10.1021/bi015763t; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Goodman RH, 2000, GENE DEV, V14, P1553; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kohno T, 1998, J BIOMOL NMR, V12, P109, DOI 10.1023/A:1008254603368; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Mestas SP, 1999, NAT STRUCT BIOL, V6, P613; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1996, MOL CELL BIOL, V16, P694; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Radhakrishnan I, 1998, FEBS LETT, V430, P317, DOI 10.1016/S0014-5793(98)00680-2; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Rohl CA, 1998, METHOD ENZYMOL, V295, P1; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Wagner BL, 2000, J BIOL CHEM, V275, P8263, DOI 10.1074/jbc.275.12.8263; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; [No title captured]	39	125	132	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42241	42248		10.1074/jbc.M207361200	http://dx.doi.org/10.1074/jbc.M207361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196545	hybrid			2022-12-25	WOS:000178985300119
J	Mann, T; Gaskins, E; Beckers, C				Mann, T; Gaskins, E; Beckers, C			Proteolytic processing of TgIMC1 during maturation of the membrane skeleton Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; REPRODUCTION; CYTOSKELETON; PARASITE; ARTICULINS; FILAMENTS	Membrane skeletons play an important role in the maintenance of cell shape and integrity in many cell types. In the protozoan parasite Toxoplasma gondii this function is performed by the subpellicular network, a resilient structure composed of tightly interwoven 10-nm filaments. We report here that this network is assembled at an early stage in the development of daughter parasites. The networks of immature and mature parasites differ dramatically with respect to their stability. Although in immature parasites the network is completely solubilized by detergent, the network in mature parasites is entirely detergent-resistant. Conversion of the detergent-labile to the detergent-resistant network occurs late in daughter cell development and appears to be coupled to proteolytic processing of the carboxyl terminus of TgIMC1, the major subunit of the network filaments. A single cysteine residue in the TgIMC1 carboxyl terminus was found to be essential for this processing event. The dramatic change in resistance to detergent extraction probably reflects an overall change in structural stability of the subpellicular network that accompanies maturation of daughter parasites and allows a switch from an assembly-competent but loose structure to one that is rigid and offers mechanical strength to the mature parasite.	Univ Alabama Birmingham, Dept Geog Med, Div Geog Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckers, C (corresponding author), Univ Alabama Birmingham, Dept Geog Med, Div Geog Med, 845 19th St S,BBRB 206, Birmingham, AL 35294 USA.	cbeckers@uab.edu						BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; CHOBOTAR WM, 1985, BIOL COCCIDIA, P101; CROSSLEY R, 1983, J CELL SCI, V59, P81; DUBREUIL RR, 1985, J CELL BIOL, V101, P1884, DOI 10.1083/jcb.101.5.1884; GOLDMAN M, 1958, J PARASITOL, V44, P161, DOI 10.2307/3274692; HONTS JE, 1990, J CELL SCI, V96, P293; Hu K, 2002, MOL BIOL CELL, V13, P593, DOI 10.1091/mbc.01-06-0309; Huttenlauch I, 1998, J CELL SCI, V111, P1909; Jackson M. H., 1989, Advances in Parasitology, V28, P55, DOI 10.1016/S0065-308X(08)60331-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHTRECK KF, 1991, J CELL BIOL, V115, P705, DOI 10.1083/jcb.115.3.705; Luft B. J., 1989, Parasitic infections in the compromised host., P179; Mann T, 2001, MOL BIOCHEM PARASIT, V115, P257, DOI 10.1016/S0166-6851(01)00289-4; MARRS JA, 1992, J CELL BIOL, V118, P1465, DOI 10.1083/jcb.118.6.1465; NICHOLS BA, 1987, J PROTOZOOL, V34, P217, DOI 10.1111/j.1550-7408.1987.tb03162.x; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; RUSSELL DG, 1982, INT J PARASITOL, V12, P221, DOI 10.1016/0020-7519(82)90020-0; RUSSELL DG, 1984, J CELL SCI, V65, P193; SHEFFIELD HG, 1968, J PARASITOL, V54, P209, DOI 10.2307/3276925; SINENSKY M, 1994, J CELL SCI, V107, P61; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; VIVIER E, 1969, J CELL BIOL, V43, P329, DOI 10.1083/jcb.43.2.312; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; [No title captured]	27	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41240	41246		10.1074/jbc.M205056200	http://dx.doi.org/10.1074/jbc.M205056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177058	hybrid			2022-12-25	WOS:000178791400135
J	Naughton, P; Foresti, R; Bains, SK; Hoque, M; Green, CJ; Motterlini, R				Naughton, P; Foresti, R; Bains, SK; Hoque, M; Green, CJ; Motterlini, R			Induction of heme oxygenase 1 by nitrosative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; CARBON-MONOXIDE; NITROXYL ANION; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; S-NITROSOTHIOLS; MESSENGER-RNA; INDUCIBLE EXPRESSION; HYDROGEN-PEROXIDE	Nitric oxide and S-nitrosothiols modulate a variety of important physiological activities. In vascular cells, agents that release NO and donate nitrosonium cation (NO+), such as S-nitrosoglutathione, are potent inducers of the antioxidant protein heme oxygenase 1 (HO-1) (Foresti, R., Clark, J. E., Green, C. J., and Motterlini, R. (1997) J. BioL Chem. 272, 18411-18417; Motterlini, R., Foresti, R., Bassi, R., Calabrese, V., Clark, J. E., and Green, C. J. (2000) J. BioL Chem. 275,13613-13620). Here, we report that Angeli's salt (AS) (0.25-2 mm), a compound that releases nitroxyl anion (NO-) at physiological pH, induces HO-1 mRNA and protein expression in a concentration- and time-dependent manner, resulting in increased heme oxygenase activity in rat H9c2 cells. A time course analysis revealed that NO--mediated HO-1 expression is transient and gradually disappears within 24 h, in accordance with the short half-life of AS at 37 degreesC (t(1/2) = 2.3 min). Interestingly, multiple additions of AS at lower concentrations (50 or 100 mum) over a period of time still promoted a significant increase in heme oxygenase activity. Experiments performed using a NO scavenger and the NO electrode confirmed that NO-, not NO, is the species involved in HO-1 induction by AS; however, the effect on heme oxygenase activity can be amplified by accelerating the rate of NO- oxidation. N-Acetylcysteine almost completely abolished AS-mediated induction of HO-1, whereas a glutathione synthesis inhibitor (buthionine sulfoximine) significantly decreased heme oxygenase activation by AS, indicating that sulfydryl groups are crucial targets in the regulation of HO-1 expression by NO-. We conclude that NO-, in analogy with other reactive nitrogen species, is a potent inducer of heme oxygenase activity and HO-1 protein expression. These findings indicate that heme oxygenase can act both as a sensor to and target of redox-based mechanisms involving NO and extend our knowledge on the biological function of HO-1 in response to nitrosative stress.	Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Motterlini, R (corresponding author), Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow HA1 3UJ, Middx, England.		Motterlini, Roberto/Q-1890-2019; Motterlini, Roberto/G-2489-2013	Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Foresti R, 2001, AM J PHYSIOL-HEART C, V281, pH1976, DOI 10.1152/ajpheart.2001.281.5.H1976; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1986, J BIOL CHEM, V261, P411; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Motterlini R, 1998, CIRC RES, V83, P568, DOI 10.1161/01.RES.83.5.568; MOTTERLINI R, 1996, AM J PHYSIOL, V270, P107; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Nelli S, 2000, BRIT J PHARMACOL, V131, P356, DOI 10.1038/sj.bjp.0703550; Paolocci N, 2001, P NATL ACAD SCI USA, V98, P10463, DOI 10.1073/pnas.181191198; Patel RP, 2000, FREE RADICAL BIO MED, V28, P1780, DOI 10.1016/S0891-5849(00)00235-5; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sawle P, 2001, FEBS LETT, V508, P403, DOI 10.1016/S0014-5793(01)03117-9; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shoeman DW, 2000, ALCOHOL, V20, P55, DOI 10.1016/S0741-8329(99)00056-7; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087, DOI 10.1152/ajpcell.1998.275.4.C1087; Wang R, 1998, CAN J PHYSIOL PHARM, V76, P1; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295	63	100	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40666	40674		10.1074/jbc.M203863200	http://dx.doi.org/10.1074/jbc.M203863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12194971	hybrid			2022-12-25	WOS:000178791400066
J	Robin, MA; Anandatheerthavarada, HK; Biswas, G; Sepuri, NBV; Gordon, DM; Pain, D; Avadhani, NG				Robin, MA; Anandatheerthavarada, HK; Biswas, G; Sepuri, NBV; Gordon, DM; Pain, D; Avadhani, NG			Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CYTOCHROME-P450 2E1; PROTEIN IMPORT; RECOGNITION PARTICLE; OXIDATIVE STRESS; TRANSLOCATION; P450; RAT; CHANNEL; IDENTIFICATION	Cytochrome P450 2E1 (CYP2E1) plays an important role in alcohol-induced toxicity and oxidative stress. Recently, we showed that this predominantly microsomal protein is also localized in rat hepatic mitochondria. In this report, we show that the N-terminal 30 amino acids of CYP2E1 contain a chimeric signal for bimodal targeting of the apoprotein to endoplasmic reticulum (ER) and mitochondria. We demonstrate that the cryptic mitochondrial targeting signal at sequence 21-31 of the protein is activated by cAMP-dependent phosphorylation at Ser-129. S129A mutation resulted in lower affinity for binding to cytoplasmic Hsp70, mitochondrial translocases (TOM40 and TIM44) and reduced mitochondrial import. S129A mutation, however, did not affect the extent of binding to the signal recognition particle and association with ER membrane translocator protein Sec61. Addition of saturating levels of signal recognition particle caused only a partial inhibition of CYP2E1 translation under in vitro conditions, and saturating levels of ER resulted only in partial membrane integration. cAMP enhanced the mitochondrial CYP2E1 (referred to as P450MT5) level but did not affect its level in the ER. Our results provide new insights on the mechanism of cAMP-mediated activation of a cryptic mitochondrial targeting signal and regulation of P450MT5 targeting to mitochondria.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Marie Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA; Thomas Jefferson Univ, Sch Med, Dept Biochem & Pharmacol, Philadelphia, PA 19107 USA	University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Sepuri, Naresh/AAF-2704-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057067, R01GM034883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57067, GM 34883, R01 GM057067, R01 GM034883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Banerjee A, 2000, DRUG METAB DISPOS, V28, P118; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; Coon MJ, 1996, FASEB J, V10, P428, DOI 10.1096/fasebj.10.4.8647341; Dupont I, 2000, ALCOHOL ALCOHOLISM, V35, P98, DOI 10.1093/alcalc/35.1.98; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; Gordon DM, 2001, BIOCHEM J, V356, P207, DOI 10.1042/0264-6021:3560207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenfield JJA, 1999, J CELL SCI, V112, P1477; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KOCH JA, 1991, METHOD ENZYMOL, V206, P305; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Oesch-Bartlomowicz B, 1998, EXP CELL RES, V242, P294, DOI 10.1006/excr.1998.4120; PYERIN W, 1989, EMBO J, V8, P3003, DOI 10.1002/j.1460-2075.1989.tb08450.x; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Smith MD, 2001, CELL, V105, P293, DOI 10.1016/S0092-8674(01)00337-3; SONG BJ, 1986, J BIOL CHEM, V261, P6689; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; SZCZESNASKORUPA E, 1991, METHOD ENZYMOL, V206, P64; Tanaka E, 2000, J CLIN PHARM THER, V25, P165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wu DF, 1999, ALCOHOL CLIN EXP RES, V23, P67	47	120	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40583	40593		10.1074/jbc.M203292200	http://dx.doi.org/10.1074/jbc.M203292200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12191992	Green Accepted, hybrid			2022-12-25	WOS:000178791400056
J	Basso, AD; Solit, DB; Chiosis, G; Giri, B; Tsichlis, P; Rosen, N				Basso, AD; Solit, DB; Chiosis, G; Giri, B; Tsichlis, P; Rosen, N			Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; UBIQUITIN-PROTEASOME PATHWAY; GLUCOCORTICOID RECEPTOR; ONCOGENIC TRANSFORMATION; SIGNALING PATHWAY; ANSAMYCINS CAUSES; BINDING-SITE; MUTATED P53; RAF KINASE	Hsp90 is a chaperone required for the conformational maturation of certain signaling proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small molecules that bind to the ATP-binding pocket in the amino-terminal domain of Hsp90 inhibit its function and cause the degradation of these client proteins. Inhibition of Hsp90 function in cells causes down-regulation of an Akt kinase-dependent pathway required for D-cyclin expression and retinoblastoma protein-dependent G, arrest. Intracellular Akt is associated with Hsp90 and Cdc37 in a complex in which Akt kinase is active and regulated by phosphatidylinositol 3-kinase. Functional Hsp90 is required for the stability of Akt in the complex. Occupancy of the ATP-binding pocket by inhibitors is associated with the ubiquitination of Akt and its targeting to the proteasome, where it is degraded. This results in a shortening of the half-life of Akt from 36 to 12 h and an 80% reduction in its expression. Akt and its activating kinase, PDK1, are the only members of the protein kinase A/protein kinase B/protein kinase C-like kinase family that are affected by Hsp90 inhibitors. Thus, transduction of growth factor signaling via the Akt and Raf pathways requires functional Hsp90 and can be coordinately blocked by its inhibition.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Thomas Jefferson Univ, Kimmel Canc, Philadelphia, PA 19107 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Memorial Sloan Kettering Cancer Center; Jefferson University; Cornell University	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 271, New York, NY 10021 USA.		Solit, David B./AAC-5309-2019; Rosen, Neal/ABF-2677-2020; 高, 雨莉/HGU-8187-2022		NCI NIH HHS [P50CA9262901, R01 CA57436, U01CA91178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA091178, P50CA092629, R01CA057436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; An WG, 2000, CELL GROWTH DIFFER, V11, P355; BANSAL GS, 1991, EXP CELL RES, V195, P303, DOI 10.1016/0014-4827(91)90377-7; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; CHIOSIS G, 2002, IN PRESS BIOORG MED; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; DOLLE RE, 1994, J MED CHEM, V37, P3863, DOI 10.1021/jm00049a001; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hostein I, 2001, CANCER RES, V61, P4003; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Moasser MM, 2001, CANCER RES, V61, P7184; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Munster PN, 2001, CANCER RES, V61, P2945; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Page C, 2000, ANTICANCER RES, V20, P407; Page C, 2000, INT J ONCOL, V17, P23; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHIMADA Y, 1995, J ANTIBIOT, V48, P824, DOI 10.7164/antibiotics.48.824; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Webb CP, 2000, CANCER RES, V60, P342; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	62	512	536	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39858	39866		10.1074/jbc.M206322200	http://dx.doi.org/10.1074/jbc.M206322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176997	hybrid			2022-12-25	WOS:000178662500102
J	Inoue, K; Zhuang, L; Maddox, DM; Smith, SB; Ganapathy, V				Inoue, K; Zhuang, L; Maddox, DM; Smith, SB; Ganapathy, V			Structure, function, and expression pattern of a novel sodium-coupled citrate transporter (NaCT) cloned from mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTER; AFFINITY DICARBOXYLATE TRANSPORTER; TISSUE DISTRIBUTION PATTERN; SIGMA-RECEPTOR; CLONING; COTRANSPORTER; PROTEINS; PLACENTA; SEQUENCE; IDENTITY	Citrate plays a pivotal role not only in the generation of metabolic energy but also in the synthesis of fatty acids, isoprenoids, and cholesterol in mammalian cells. Plasma levels of citrate are the highest (similar to 135 muM) among the intermediates of the tricarboxylic acid cycle. Here we report on the cloning and functional characterization of a plasma membrane transporter (NaCT for Na+-coupled citrate transporter) from rat brain that mediates uphill cellular uptake of citrate coupled to an electrochemical Na+ gradient. NaCT consists of 572 amino acids and exhibits structural similarity to the members of the Na+-dicarboxylate cotransporter/Na+-sulfate cotransporter (NaDC/NaSi) gene family including the recently identified Drosophila Indy. In rat, the expression of NaCT is restricted to liver, testis, and brain. When expressed heterologously in mammalian cells, rat NaCT mediates the transport of citrate with high affinity (Michaelis-Menten constant, similar to20 muM) and with a Na+:citrate stoichiometry of 4:1. The transporter does interact with other dicarboxylates and tricarboxylates but with considerably lower affinity. In mouse brain, the expression of NaCT mRNA is evident in the cerebral cortex, cerebellum, hippocampus, and olfactory bulb. NaCT represents the first transporter to be identified in mammalian cells that shows preference for citrate over dicarboxylates. This transporter is likely to play an important role in the cellular utilization of citrate in blood for the synthesis of fatty acids and cholesterol (liver) and for the generation of energy (liver and brain). NaCT thus constitutes a potential therapeutic target for the control of body weight, cholesterol levels, and energy homeostasis.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.							Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BRIDGES CD, 2000, J BIOL CHEM, V275, P20676; Chen XM, 1999, J CLIN INVEST, V103, P1159, DOI 10.1172/JCI5392; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Helfand SL, 2000, RES PRO CEL, V29, P67; HODGKINSON A, 1963, CLIN SCI, V24, P167; Huang W, 2000, J PHARMACOL EXP THER, V295, P392; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KASER H., 1961, CLIN CHIM ACTA, V6, P337, DOI 10.1016/0009-8981(61)90060-2; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; KREBS HA, 1950, ANNU REV BIOCHEM, V19, P409, DOI 10.1146/annurev.bi.19.070150.002205; Nakanishi T, 2001, AM J PHYSIOL-CELL PH, V281, pC1757, DOI 10.1152/ajpcell.2001.281.6.C1757; NORDMANN R, 1965, CLIN CHIM ACTA, V12, P304, DOI 10.1016/0009-8981(65)90050-1; Ola MS, 2001, MOL BRAIN RES, V95, P86; Pajor AM, 2000, AM J PHYSIOL-RENAL, V279, pF482, DOI 10.1152/ajprenal.2000.279.3.F482; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Seth P, 2001, BBA-MOL CELL RES, V1540, P59, DOI 10.1016/S0167-4889(01)00117-3; Seth P, 1998, J NEUROCHEM, V70, P922; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; Wang H, 1998, AM J PHYSIOL-CELL PH, V275, pC967, DOI 10.1152/ajpcell.1998.275.4.C967; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	34	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39469	39476		10.1074/jbc.M207072200	http://dx.doi.org/10.1074/jbc.M207072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177002	hybrid			2022-12-25	WOS:000178662500054
J	Stadler, JA; Schweyen, RJ				Stadler, JA; Schweyen, RJ			The yeast iron regulon is induced upon cobalt stress and crucial for cobalt tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; ERYTHROPOIETIN GENE; OXYGEN SENSOR; HEME PROTEIN; EXPRESSION; TRANSPORTER; ENCODES; IDENTIFICATION; FAMILY	To identify yeast genes involved in cobalt detoxification, we performed RNA expression profiling experiments and followed changes in gene activity upon cobalt stress on a genome-wide scale. We found that cobalt stress specifically results in an immediate and dramatic induction of genes involved in iron uptake. This response is dependent on the Aft1 protein, a transcriptional factor known to regulate a set of genes involved in iron uptake and homeostasis (iron regulon). Like iron starvation, cobalt stress induces accumulation of the Aft1 protein in the nucleus to activate transcription of its target genes. Cells lacking the AFT1 gene (aft1) are hypersensitive to cobalt as well as to other transition metals, whereas expression of the dominant AFT1-1(up) allele, which results in up-regulation of AFT1-controlled genes, confers resistance. Cobalt resistance correlates with an increase in intracellular iron in AFTI-1(up) cells, and sensitivity of aft1 cells is associated with a lack of iron accumulation. Furthermore, elevated iron levels in the growth medium suppress the cobalt sensitivity of the aft1 mutant cells, even though they increase cellular cobalt. Results presented indicate that yeast cells acquire cobalt tolerance by activating the Aft1p-dependent iron regulon and thereby increasing intracellular iron levels.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schweyen, RJ (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.							Agency for Toxic Substances and Disease Registry (ATSDR), 1992, AG TOX SUBST DIS REG; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201, DOI 10.1081/CLT-100102420; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; BEYERSMANN D, 1992, TOXICOL APPL PHARM, V115, P137, DOI 10.1016/0041-008X(92)90377-5; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Bunn HF, 1998, J EXP BIOL, V201, P1197; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graschopf A, 2001, J BIOL CHEM, V276, P16216, DOI 10.1074/jbc.M101504200; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; JENETTE KW, 1981, ENV HLTH PERSPECT, V40, P233; KASPRZAK KS, 1991, CHEM RES TOXICOL, V4, P604, DOI 10.1021/tx00024a002; KAZANTZIS G, 1981, ENVIRON HEALTH PERSP, V40, P143, DOI 10.2307/3429228; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; LAUWERYS R, 1994, SCI TOTAL ENVIRON, V150, P1, DOI 10.1016/0048-9697(94)90125-2; Leonard S, 1998, J INORG BIOCHEM, V70, P239, DOI 10.1016/S0162-0134(98)10022-3; LESFARGUES G, 1994, AM J IND MED, V26, P585; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; Maniatis T., 1982, MOL CLONING LAB MANU; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANG XY, 1993, ARCH BIOCHEM BIOPHYS, V306, P402, DOI 10.1006/abbi.1993.1529; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	44	70	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39649	39654		10.1074/jbc.M203924200	http://dx.doi.org/10.1074/jbc.M203924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176980	hybrid			2022-12-25	WOS:000178662500077
J	Bova, MP; Huang, QL; Ding, LL; Horwitz, J				Bova, MP; Huang, QL; Ding, LL; Horwitz, J			Subunit exchange, conformational stability, and chaperone-like function of the small heat shock protein 16.5 from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; A-CRYSTALLIN; OLIGOMERIC STRUCTURE; QUATERNARY STRUCTURE; MISSENSE MUTATION; CONSERVED DOMAIN; LIGHT-SCATTERING; CELL-DEATH; PHOSPHORYLATION	Hsp16.5, isolated from the hyperthermophilic Archaea Methanococcus jannaschii, is a member of the small heat-shock protein family. Small Hsps have 12- to 42-kDa subunit sizes and have sequences that are conserved among all organisms. The recently determined crystal structure of Hsp16.5 indicates that it consists discretely of 24 identical subunits. Using fluorescence resonance energy transfer, we show that at temperatures above 60degreesC, the subunits of MjHsp16.5 freely and reversibly exchange with a rate constant of exchange at 68 degreesC of 0.067 min(-1). The subunit exchange reactions were strongly temperature-dependent, similar to the exchange reactions of the alpha-crystallins. The exchange reaction was specific to MjHsp16.5 subunits, as other sHsps such as alpha-crystallin were not structurally compatible and could not integrate into the MjHsp16.5 oligomer. In addition, we demonstrate that at temperatures as high as 70 degreesC, MjHsp16.5 retains its multimeric structure and subunit organization. Using insulin and a-lactalbumin as model target proteins, we also show that MjHsp16.5 at 37degreesC is a markedly inefficient chaperone compared with other sHsps with these substrates. The results of this study support the hypothesis that MjHsp16.5 has a dynamic quaternary structure at temperatures that are physiologically relevant to M. jannaschii.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Horwitz, J (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	horwitz@jsei.ucla.edu			NATIONAL EYE INSTITUTE [R37EY003897] Funding Source: NIH RePORTER; NEI NIH HHS [R37-EY3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 2000, PATHOL BIOL, V48, P280; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haugland R., 1996, HDB FLUORESCENT PROB; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, J STRUCT BIOL, V121, P76, DOI 10.1006/jsbi.1998.3969; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; Laksanalamai P, 2001, J BACTERIOL, V183, P5198, DOI 10.1128/JB.183.17.5198-5202.2001; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vanhoudt J, 2000, BIOCHEMISTRY-US, V39, P4483, DOI 10.1021/bi990386u; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	46	114	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38468	38475		10.1074/jbc.M205594200	http://dx.doi.org/10.1074/jbc.M205594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12176992	hybrid			2022-12-25	WOS:000178529600062
J	Christine, KS; MacFarlane, AW; Yang, KS; Stanley, RJ				Christine, KS; MacFarlane, AW; Yang, KS; Stanley, RJ			Cyclobutylpyrimidine dimer base flipping by DNA photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE CYCLOBUTANE DIMER; CIS-SYN; DAMAGE RECOGNITION; CRYSTAL-STRUCTURE; ABASIC SITES; 2-AMINOPURINE; FLUORESCENCE; RECONSTITUTION; MECHANISM; FLAVIN	DNA Photolyase is a flavoprotein that uses light to repair cyclobutylpyrimidine dimers in DNA. From considerations of the crystal structure of the protein, it has been hypothesized that the dimer lesion is flipped out of the DNA double helix into the substrate binding pocket. We have used a fluorescent adenine analog, 2-aminopurine (2-Ap), as a probe of local double helical structure upon binding of the substrate to the protein. Our results show that the local structure around the thymidine lesion changes dramatically upon binding to Photolyase. This is consistent with base flipping of the lesion into the protein binding cavity with concomitant destacking of the opposing complementary 2-Ap nucleotide.	Temple Univ, Dept Chem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stanley, RJ (corresponding author), Temple Univ, Dept Chem, 201 Beury Hall, Philadelphia, PA 19122 USA.	robert.stanley@temple.edu		Stanley, Robert/0000-0003-4140-4311; MacFarlane IV, Alexander/0000-0003-1740-4848				Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BERG BJV, 1998, J BIOL CHEM, V273, P20276; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FISHER GJ, 1976, PHOTOCHEM PHOTOBIOL, V24, P223, DOI 10.1111/j.1751-1097.1976.tb06815.x; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LIPTAY W, 1969, ANGEW CHEM INT EDIT, V8, P177, DOI 10.1002/anie.196901771; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; Rachofsky EL, 1998, ACTA PHYS POL A, V94, P735, DOI 10.12693/APhysPolA.94.735; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1987, J BIOL CHEM, V262, P492; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; WARD DC, 1969, J BIOL CHEM, V244, P1228; XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	37	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38339	38344		10.1074/jbc.M206531200	http://dx.doi.org/10.1074/jbc.M206531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12169694	hybrid			2022-12-25	WOS:000178529600045
J	Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M				Zhang, ZQ; Wang, Y; Herzog, CR; Liu, GJ; Lee, HW; DePinho, RA; You, M			A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression	ONCOGENE			English	Article						Cdkn2a; p16(INK4a); ARF; genetic variants; mouse lung tumors; pulmonary adenoma progression 1; quantitative trait locus	CELL-CYCLE CONTROL; SUPPRESSOR GENE; PLASMACYTOMA SUSCEPTIBILITY; STABILIZES P53; MDM2; P19(ARF); CANCER; P16(INK4A); CDKN2A; MICE	Lung cancer is the leading cause of cancer death among both men and women, accounting for more than 28% of all cancer deaths. In fact, more people die of lung cancer than of colon, breast, and prostate cancers combined. Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in the development of lung cancer. Inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci since genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Papg-1 (pulmonary adenoma progression 1) was previously mapped to a region on mouse chromosome 4. This locus contains a candidate gene, Cdkn2a also referred to as Ink4a/Arf, which dually encodes two established tumor suppressors p16(INK4a) and ARE Cdkn2a became a primary candidate for Papg-1 for two reasons: (1) two haplotypes of mouse Cdkn2a were found to segregate with differential genetic susceptibility to lung tumor progression in mice; and (2) in vitro studies showed that the p16(INK4a) allele from the BALB/cJ mouse had a significantly decreased ability to bind and inhibit CDK6 and to suppress cell growth when compared with the p16(INK4a) allele from the A/J mouse. Here, we report that mice with a heterozygous deficiency for the A/J Cdkn2a allele were significantly more susceptible to lung tumor progression than mice with a heterozygous deficiency for a BALB/cJ Cdkn2a allele, when compared to their respective wild type mice. These results offer strong evidence that naturally occurring variation of p16(INK4a) influences susceptibility to enhance lung tumor progression making it a strong candidate for the lung tumor progression locus, Papg-1.	Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA; Amer Hlth Fdn, Valhalla, NY 10595 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; American Health Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	You, M (corresponding author), Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, 420 W 12th Ave, Columbus, OH 43210 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [R01CA78797, R01CA58554, P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058554, P30CA016058, R01CA078797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERVONT HB, 1938, PUBLIC HLTH REP, V53, P232; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; Herzog CR, 1997, J CELL BIOCHEM, P49; HERZOG CR, 1994, CANCER RES, V54, P4007; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1997, CANCER RES, V57, P4164; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; QUELLE DE, 1995, CELL, V83, P993; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1992, GENET EPIDEMIOL, V9, P261, DOI 10.1002/gepi.1370090405; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIMKIN MB, 1955, ADV CANCER RES, V3, P223, DOI 10.1016/S0065-230X(08)60921-5; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XF, 1997, CANCER, V79, P1527, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1527::AID-CNCR13>3.0.CO;2-#; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	32	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5960	5966		10.1038/sj.onc.1205725	http://dx.doi.org/10.1038/sj.onc.1205725			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185599				2022-12-25	WOS:000177520900019
J	Brown, MT; McBride, KM; Baniecki, ML; Reich, NC; Marriotti, G; Mangel, WF				Brown, MT; McBride, KM; Baniecki, ML; Reich, NC; Marriotti, G; Mangel, WF			Actin can act as a cofactor for a viral proteinase in the cleavage of the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOVIRUS PROTEINASE; CYTOKERATIN NETWORK; CRYSTAL-STRUCTURE; HELA-CELLS; PROTEASE; ACTIVATION; PEPTIDE; BINDING; PURIFICATION; PROFILIN	Cytoskeletal. proteins are exploited by many viruses during infection. We report a novel finding that actin can act as a cofactor for the adenovirus proteinase (AVP) in the degradation of cytoskeletal proteins. Transfection studies in HeLa cells revealed AVP localized with cytokeratin 18, and this was followed by destruction of the cytokeratin network. For AVP to cleave cytokeratin 18, a cellular cofactor was shown to be required, consistent with AVP being synthesized as an inactive proteinase. Actin was considered a cellular cofactor for AVP, because the C terminus of actin is homologous to a viral cofactor for AVP. AVP was shown to bind to the C terminus of actin, and in doing so AVP exhibited full enzymatic activity. In vitro, actin was a cofactor in the cleavage of cytokeratin 18 by AVP. The proteinase alone could not cleave cytokeratin 18, but in the presence of actin, AVP cleaved cytokeratin 18. Indeed, actin itself was shown to be a cofactor and a substrate for its own destruction in that it was cleaved by AVP in vitro. Cleavage of cytoskeletal proteins weakens the structure of the cell, and therefore, actin as a cofactor may play a role in cell lysis and release of nascent virions.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wisconsin System; University of Wisconsin Madison	Mangel, WF (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.	Mangel@BNL.Gov	mcbride, kevin/E-8230-2011	Marriott, Gerard/0000-0003-3197-4839	NCI NIH HHS [R01CA50733, P01CA28146] Funding Source: Medline; NIAID NIH HHS [AI41599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041599, R56AI041599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CW, 1993, PROTEIN EXPRES PURIF, V4, P8, DOI 10.1006/prep.1993.1002; Baniecki ML, 2001, BIOCHEMISTRY-US, V40, P12349, DOI 10.1021/bi0109008; BHATTI AR, 1979, VIROLOGY, V96, P478; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Cabrita G, 1997, J BIOL CHEM, V272, P5635, DOI 10.1074/jbc.272.9.5635; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; Cudmore S, 1997, TRENDS MICROBIOL, V5, P142, DOI 10.1016/S0966-842X(97)01011-1; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Lanier LM, 1996, VIROLOGY, V216, P380, DOI 10.1006/viro.1996.0073; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P14468, DOI 10.1021/bi011562d; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; RANCOURT C, 1995, VIROLOGY, V209, P167, DOI 10.1006/viro.1995.1240; Rey O, 1996, VIROLOGY, V220, P530, DOI 10.1006/viro.1996.0343; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Seipelt J, 2000, J BIOL CHEM, V275, P20084, DOI 10.1074/jbc.275.26.20084; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEBER JM, 1994, METHOD ENZYMOL, V244, P595; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; ZECHEL K, 1993, BIOCHEM J, V290, P411, DOI 10.1042/bj2900411; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	33	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46298	46303		10.1074/jbc.M202988200	http://dx.doi.org/10.1074/jbc.M202988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12191991	hybrid			2022-12-25	WOS:000179529300079
J	Schroder, K; Pulvermuller, A; Hofmann, KP				Schroder, K; Pulvermuller, A; Hofmann, KP			Arrestin and its splice variant Arr(1-370A) (P-44) - Mechanism and biological role of their interaction with rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN COMPLEX; PHOTORECEPTOR-MEMBRANES; CRYSTAL-STRUCTURE; METARHODOPSIN-II; VISUAL ARRESTIN; 48-KDA PROTEIN; BINDING; LIGHT; ACTIVATION; TRANSDUCIN	Deactivation of G-protein-coupled receptors relies on a timely blockade by arrestin. However, under dim light conditions, virtually all arrestin is in the rod inner segment, and the splice variant p(44) (Arr(1-370A)) is the stop protein responsible for receptor deactivation. Using size exclusion chromatography and biophysical assays for membrane-bound protein-protein interaction, membrane binding, and G-protein activation, we have investigated the interactions of Arr(1-370A) and proteolytically truncated Arr(3-367) with rhodopsin. We find that these short arrestins do not only interact with the phosphorylated active receptor but also with inactive phosphorylated rhodopsin or opsin in membranes or solution. Because of the latter interaction they are not soluble (like arrestin) but membrane-bound in the dark. Upon photoexcitation, Arr(3-367) and Arr(1-370A) interact with pre-phosphorylated rhodopsin faster than arrestin and start to quench G(t) activation on a subsecond time scale. The data indicate that in the course of rhodopsin deactivation, Arr(1-370A) is handed over from inactive to active phosphorylated rhodopsin. This mechanism could provide a new aspect of receptor shutoff in the single photon operating range of the rod cell.	Humboldt Univ, Inst Med Phys & Biophys, Klinikum Charite, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pulvermuller, A (corresponding author), HU Berlin, IMPB, Charite, 5-9 Ziegelstr, D-10117 Berlin, Germany.	alexander.pulvermueller@charite.de						ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; Binder BM, 1996, J BIOL CHEM, V271, P19826, DOI 10.1074/jbc.271.33.19826; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOFMANN KP, 1985, BIOCHIM BIOPHYS ACTA, V810, P278, DOI 10.1016/0005-2728(85)90143-4; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KOHL B, 1987, BIOPHYS J, V52, P271, DOI 10.1016/S0006-3495(87)83214-9; KONIG B, 1989, FEBS LETT, V257, P163, DOI 10.1016/0014-5793(89)81811-3; KUHN H, 1982, METHOD ENZYMOL, V81, P556; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; MANGINI NJ, 1988, INVEST OPHTH VIS SCI, V29, P1221; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; MOLDAY RS, 2000, MOL MECH VISUAL TRAN, P143; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1992, BIOCHEMISTRY-US, V31, P3902, DOI 10.1021/bi00131a003; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Sachs K, 2000, METHOD ENZYMOL, V315, P238; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SMITH WC, 1994, J BIOL CHEM, V269, P15407; Sokal I, 2002, METHOD ENZYMOL, V343, P578; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	55	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43987	43996		10.1074/jbc.M206211200	http://dx.doi.org/10.1074/jbc.M206211200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12194979	hybrid			2022-12-25	WOS:000179272000060
J	Erlitzki, R; Long, JC; Theil, EC				Erlitzki, R; Long, JC; Theil, EC			Multiple, conserved iron-responsive elements in the 3 '-untranslated region of transferrin receptor mRNA enhance binding of iron regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; MAMMALIAN-CELLS; MITOCHONDRIAL ACONITASE; DIETARY IRON; HAIRPIN LOOP; INTERNAL LOOP/BULGE; NMR-SPECTROSCOPY; RAT-LIVER; METABOLISM; EXPRESSION	Synthesis of proteins for iron homeostasis is regulated by specific, combinatorial mRNA/protein interactions between RNA stem-loop structures (iron-responsive elements, IREs) and iron-regulatory proteins (IRP1 and IRP2), controlling either mRNA translation or stability. The transferrin receptor W-untranslated region (TfR-3'-UTR) mRNA is unique in having five IREs, linked by AU-rich elements. A C-bulge in the stem of each TfR-IRE folds into an IRE that has low IRP2 binding, whereas a loop/bulge in the stem of the ferritin-IRE allows equivalent IRP1 and IRP2 binding. Effects of multiple IRE interactions with IRP1 and IRP2 were compared between the native TfR-3'-UTR sequence (5xIRE) and RNA with only 3 or 2 IREs. We show 1) equivalent IRP1 and IRP2 binding to multiple TfR-IRE RNAs; 2) increased IRP-dependent nuclease resistance of 5xIRE compared with lower IRE copy-number RNAs; 3) distorted TfR-IRE helix structure within the context of 5xIRE, detected by Cu-(phen)(2) binding/cleavage, that coincides with ferritin-IRE conformation and enhanced IRP2 binding, and 4) variable IRP1 and IRP2 expression in human cells and during development (IRP2-mRNA predominated). Changes in TfR-IRE structure conferred by the full length TfR-3'-UTR mRNA explain in part evolutionary conservation of multiple IRE-RNA, which allows TfR mRNA stabilization and receptor synthesis when IRP activity varies, and ensures iron uptake for cell growth.	Childrens Hosp, Oakland Res Inst, Inst Res, Oakland, CA 94609 USA; Med Ctr Oakland, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Theil, EC (corresponding author), Childrens Hosp, Oakland Res Inst, Inst Res, 5700 Martin Luther King,Jr Way, Oakland, CA 94609 USA.	etheil@chori.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020251, R37DK020251, R56DK020251] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20251] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bouton C, 2002, J BIOL CHEM, V277, P31220, DOI 10.1074/jbc.M203276200; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHAN LNL, 1989, NUCLEIC ACIDS RES, V17, P3763, DOI 10.1093/nar/17.10.3763; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; Chen OS, 1998, J NUTR, V128, P525, DOI 10.1093/jn/128.3.525; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; Henderson ER, 1996, J BIOL CHEM, V271, P4900; HOROWITZ JA, 1992, NEW BIOL, V4, P330; JOHANSSON HE, 2002, MOL CELLULAR IRON TR, P237; Kaldy P, 1999, EMBO J, V18, P6073, DOI 10.1093/emboj/18.21.6073; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Ke YH, 2002, J BIOL CHEM, V277, P2373, DOI 10.1074/jbc.C100614200; Ke YH, 2000, BIOCHEMISTRY-US, V39, P6235, DOI 10.1021/bi9924765; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Leibold EA, 2001, HISTOCHEM CELL BIOL, V115, P195; Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200; Meehan HA, 2001, J BIOL CHEM, V276, P14791, DOI 10.1074/jbc.M010295200; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURAKAWA GJ, 1989, NUCLEIC ACIDS RES, V17, P5361, DOI 10.1093/nar/17.13.5361; PATINO MM, 1992, J BIOL CHEM, V267, P19011; Pinero DJ, 2000, CELL MOL BIOL, V46, P761; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740; Schlegl J, 1997, RNA, V3, P1159; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SIERZPUTOWSKAGRACZ H, 1995, NUCLEIC ACIDS RES, V23, P146, DOI 10.1093/nar/23.1.146; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Zhang L, 2000, BIOCHEM J, V349, P289, DOI 10.1042/0264-6021:3490289	63	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42579	42587		10.1074/jbc.M207918200	http://dx.doi.org/10.1074/jbc.M207918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200453	hybrid			2022-12-25	WOS:000179081200021
J	Heng, JIT; Tan, SS				Heng, JIT; Tan, SS			Cloning and characterization of GRIPE, a novel interacting partner of the transcription factor E12 in developing mouse forebrain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; LOOP-HELIX GENES; DNA-BINDING; NEURONAL PLASTICITY; TUBEROUS SCLEROSIS; E2A PROTEINS; EXPRESSION; DIFFERENTIATION; DIMERIZATION; SPECIFICITY	The helix-loop-helix (HLH) family of transcription factors are key contributors to a wide array of developmental processes, including neurogenesis and hematopoiesis. These factors are thought to exert their regulatory influences by binding to cognate promoter-DNA sequences as dimers. Although studies in mice have convincingly demonstrated that neurogenic HLH proteins such as NeuroD are intimately involved in neuronal fate determination, the role of the ubiquitously expressed HLH protein, E12, in mammalian neurogenesis remains ambiguous. To address this, a yeast two-hybrid interaction screen was employed to identify dimerization partners to E12. Screening of an embryonic day 11.5 forebrain library resulted in the cloning of GRIPE, a novel GAP-related interacting protein to E12. GRIPE binds to the HLH region of E12 and may require E12 for nuclear import. Furthermore, GRIPE may negatively regulate E12-dependent target gene transcription. High levels of GRIPE and E12 mRNA were coincidentally detected during embryogenesis, but only GRIPE mRNA levels remained high in adult brain, particularly in neurons of the cortex and hippocampus. These observations were recapitulated through an in vitro model of neurogenesis. Taken together, these results indicate that GRIPE is a novel protein dimerization of which with E12 has important consequences for cells undergoing neuronal differentiation.	Univ Melbourne, Howard Florey Inst, Brain Dev Grp, Melbourne, Vic 3010, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Tan, SS (corresponding author), Univ Melbourne, Howard Florey Inst, Brain Dev Grp, Melbourne, Vic 3010, Australia.			Heng, Julian Ik-Tsen/0000-0002-0378-7078				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CHIARAMELLO A, 1995, MOL BRAIN RES, V29, P107, DOI 10.1016/0169-328X(94)00236-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Goldfarb AN, 1998, J BIOL CHEM, V273, P2866, DOI 10.1074/jbc.273.5.2866; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; James P, 1996, GENETICS, V144, P1425; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Loveys DA, 1997, GENE, V201, P169, DOI 10.1016/S0378-1119(97)00444-7; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; SOOSAAR A, 1994, MOL BRAIN RES, V25, P176, DOI 10.1016/0169-328X(94)90297-6; VAESSIN H, 1994, DEVELOPMENT, V120, P935; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	34	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43152	43159		10.1074/jbc.M204858200	http://dx.doi.org/10.1074/jbc.M204858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200424	hybrid			2022-12-25	WOS:000179081200096
J	Chakrabarti, D; Da Silva, T; Barger, J; Paquette, S; Patel, H; Patterson, S; Allen, CM				Chakrabarti, D; Da Silva, T; Barger, J; Paquette, S; Patel, H; Patterson, S; Allen, CM			Protein farnesyltransferase and protein prenylation in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; PEPTIDOMIMETIC INHIBITORS; P21(RAS) FARNESYLTRANSFERASE; ISOPRENYLATION; CELLS; BIOSYNTHESIS; TRANSFERASE; FARNESYL; GERANYLGERANYLTRANSFERASE; MEVALONATE	Comparison of the malaria parasite and mammalian protein prenyltransferases and their cellular substrates is important for establishing this enzyme as a target for developing antimalarial agents. Nineteen heptapeptides differing only in their carboxyl-terminal amino acid were tested as alternative substrates of partially purified Plasmodium falciparum protein farnesyltransferase. Only NRSCAIM and NRSCAIQ serve as substrates, with NRSCAIM being the best. Peptidomimetics, FTI-276 and GGTI-287, inhibit the transferase with IC50 values of 1 and 32 nm, respectively. Incubation of P. falciparum-infected erythrocytes with [H-3]farnesol labels 50- and 22-28-kDa proteins, whereas [H-3]geranylgeraniol labels only 22-28-kDa proteins. The 50-kDa protein is shown to be farnesylated, whereas the 22-28-kDa proteins are geranylgeranylated, irrespective of the labeling prenol. Protein labeling is inhibited more than 50% by either 5 mum FTI-277 or GGTI-298. The same concentration of inhibitors also inhibits parasite growth from the ring stage by 50%, decreases expression of prenylated proteins as measured with prenyl-specific antibody, and inhibits parasite differentiation beyond the trophozoite stage. Furthermore, differentiation specific prenylation of P. falciparum proteins is demonstrated. Protein labeling is detected predominantly during the trophozoite to schizont and schizont to ring transitions. These results demonstrate unique properties of protein prenylation in P. falciparum: a limited specificity of the farnesyltransferase for peptide substrates compared with mammalian enzymes, the ability to use farnesol to label both farnesyl and geranylgeranyl moieties on proteins, differentiation specific protein prenylation, and the ability of peptidomimetic prenyltransferase inhibitors to block parasite differentiation.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA	State University System of Florida; University of Florida; State University System of Florida; University of Central Florida	Allen, CM (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	callen@biochem.med.ufl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043679] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43679] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Buckner FS, 2000, J BIOL CHEM, V275, P21870, DOI 10.1074/jbc.M000975200; Buckner FS, 2002, MOL BIOCHEM PARASIT, V122, P181, DOI 10.1016/S0166-6851(02)00099-3; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chakrabarti D, 1998, MOL BIOCHEM PARASIT, V94, P175, DOI 10.1016/S0166-6851(98)00065-6; CHEN GZ, 1993, MOL BIOCHEM PARASIT, V59, P287, DOI 10.1016/0166-6851(93)90226-N; Couto AS, 1999, BIOCHEM J, V341, P629, DOI 10.1042/0264-6021:3410629; Crespo NC, 2001, J BIOL CHEM, V276, P16161, DOI 10.1074/jbc.M006213200; Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; deCastro FA, 1996, MOL BIOCHEM PARASIT, V80, P77, DOI 10.1016/0166-6851(96)02670-9; DUGAN JM, 1995, BIOL REPROD, V53, P958, DOI 10.1095/biolreprod53.4.958; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FLESCH G, 1988, EUR J BIOCHEM, V175, P405, DOI 10.1111/j.1432-1033.1988.tb14210.x; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; Ibrahim M, 2001, INT J PARASITOL, V31, P1489, DOI 10.1016/S0020-7519(01)00268-5; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; LUJAN HD, 1995, MOL BIOCHEM PARASIT, V72, P121, DOI 10.1016/0166-6851(94)00070-4; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MBAYA B, 1990, BIOCHEM BIOPH RES CO, V173, P849, DOI 10.1016/S0006-291X(05)80864-2; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Moura IC, 2001, ANTIMICROB AGENTS CH, V45, P2553, DOI 10.1128/AAC.45.9.2553-2558.2001; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ohkanda J, 2001, BIOORG MED CHEM LETT, V11, P761, DOI 10.1016/S0960-894X(01)00055-5; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SEPPLORENZINO L, 1991, EUR J BIOCHEM, V200, P579, DOI 10.1111/j.1432-1033.1991.tb16221.x; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VIAL HJ, 1984, MOL BIOCHEM PARASIT, V13, P53, DOI 10.1016/0166-6851(84)90101-4; Wallace A, 1996, J BIOL CHEM, V271, P31306, DOI 10.1074/jbc.271.49.31306; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Yokoyama K, 1998, J BIOL CHEM, V273, P26497, DOI 10.1074/jbc.273.41.26497; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X	61	125	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42066	42073		10.1074/jbc.M202860200	http://dx.doi.org/10.1074/jbc.M202860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194969	hybrid			2022-12-25	WOS:000178985300096
J	Funaba, M; Zimmerman, CM; Mathews, LS				Funaba, M; Zimmerman, CM; Mathews, LS			Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; SMAD PROTEINS; MESODERM INDUCTION; SERINE-THREONINE; I RECEPTORS; MAP KINASE; GS DOMAIN; PHOSPHORYLATION; ACTIVIN	Components of the transforming growth factor-beta and mitogen-activated protein kinase pathways interact in controlling cell growth and differentiation. We show that phosphorylation of Smad2, a mediator of the activin/transforming growth factor-beta signal, by activated extracellular signal-regulated kinase 1 (ERK1) increases the amount of Smad2 protein and leads to enhanced transcriptional activity. Epidermal growth factor increased phosphorylation of Smad2 in COS7 cells, and Smad2-dependent transcription in a mink lung epithelial cell line, L17, was enhanced by co-transfection of a constitutively active MEK1. In addition, transfection of Smad2 mutants lacking ERK sites resulted in reduced transcription, whereas mutants that mimicked ERK phosphorylation stimulated transcription. The amount of Smad2 protein was increased by transfection with a constitutively active MEK1 and reduced by co-transfection with the ERK phosphatase, HVH2. The elevation of Smad2 protein levels was because of increased half-life and resulted in increased complex formation with Smad4. A site of ERK-dependent phosphorylation on Smad2 was located to Thr(8), a site that overlaps with the calmodulin binding region. We show that calmodulin inhibits Smad2 phosphorylation by ERK1, and overexpressing calmodulin, or stimulating calmodulin activity with ionomycin, reduces Smad2 levels. These findings suggest that the ERK pathway positively regulates Smad2 signaling by phosphorylating Smad2 and that negative regulation of Smad2 signaling by calmodulin is achieved in part by inhibiting this phosphorylation.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Funaba, M (corresponding author), Azabu Univ, Sch Vet Med, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 2298501, Japan.		Funaba, Masayuki/E-4676-2018	Funaba, Masayuki/0000-0002-4303-6682				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Funaba M, 2000, PROTEIN EXPRES PURIF, V20, P507, DOI 10.1006/prep.2000.1315; Funaba M, 2000, MOL ENDOCRINOL, V14, P1583, DOI 10.1210/me.14.10.1583; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, GENE DEV, V14, P627; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scherer A, 2000, J BIOL CHEM, V275, P41430, DOI 10.1074/jbc.M005727200; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SETH A, 1992, J BIOL CHEM, V267, P24796; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1997, FEBS LETT, V420, P117, DOI 10.1016/S0014-5793(97)01499-3; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Yamanashi Y, 2000, GENE DEV, V14, P11; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677; ZIMMERMAN CM, 2001, INHIBIN ACTIVIN FOLL, P239	55	146	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41361	41368		10.1074/jbc.M204597200	http://dx.doi.org/10.1074/jbc.M204597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12193595	hybrid			2022-12-25	WOS:000178985300011
J	Kirsch, T; Koyama, E; Liu, MF; Golub, EE; Pacifici, M				Kirsch, T; Koyama, E; Liu, MF; Golub, EE; Pacifici, M			Syndecan-3 is a selective regulator of chondrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; FACTOR-I; CELL-PROLIFERATION; CORE PROTEIN; BONE-GROWTH; TENASCIN-C; EXPRESSION; SULFATE	Chondrocyte proliferation is important for skeletal development and growth, but the mechanisms regulating it are not completely clear. Previously, we showed that syndecan-3, a cell surface heparan sulfate proteoglycan, is expressed by proliferating chondrocytes in vivo and that proliferation of cultured chondrocytes in vitro is sensitive to heparitinase treatment. To further establish the link between syndecan-3 and chondrocyte proliferation, additional studies were carried out in vivo and in vitro. We found that the topographical location of proliferating chondrocytes in developing chick long bones changes with increasing embryonic age and that syndecan-3 gene expression changes in a comparable manner. For in vitro analysis, mitotically quiescent chondrocytes were exposed to increasing amounts of fibroblast growth factor-2 (FGF-2). Proliferation was stimulated by as much as 8-10-fold within 24 h; strikingly, this stimulation was significantly prevented when the cells were treated with both fibroblast growth factor-2 (FGF-2) and antibodies against syndecan-3 core protein. This neutralizing effect was dose-dependent and elicited a maximum of 50-60% inhibition. To establish specificity of neutralizing effect, cultured chondrocytes were exposed to FGF-2, insulin-like growth factor-1, or parathyroid hormone, all known mitogens for chondrocytes. The syndecan-3 antibodies interfered only with FGF-2 mitogenic action, but not that of insulin-like growth factor-1 or parathyroid hormone. Protein cross-linking experiments indicated that syndecan-3 is present in monomeric, dimeric, and oligomeric forms on the chondrocyte surface. In addition, molecular modeling indicated that contiguous syndecan-3 molecules might form stable complexes by parallel pairing of beta-sheet segments within the ectodomain of the core protein. In conclusion, the results suggest that syndecan-3 is a direct and selective regulator of the mitotic behavior of chondrocytes and its role may involve formation of dimeric/oligomeric structures on their cell surface.	Univ Maryland, Sch Med, Dept Orthopaed, Baltimore, MD 21201 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland Baltimore; University of Pennsylvania; University of Pennsylvania	Kirsch, T (corresponding author), Univ Maryland, Sch Med, Dept Orthopaed, 22 S Greene St, Baltimore, MD 21201 USA.	tkirsch@psu.edu			NIAMS NIH HHS [AR45302, AR46245] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046245] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Butler AA, 2001, ENDOCRINOLOGY, V142, P1685, DOI 10.1210/en.142.5.1685; Carey DJ, 1997, BIOCHEM J, V327, P1; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; GOULD SE, 1995, DEV BIOL, V168, P438, DOI 10.1006/dbio.1995.1093; HAMERMAN D, 1989, NEW ENGL J MED, V320, P1322; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; Iwamoto M, 1995, J ORTHOPAED RES, V13, P838, DOI 10.1002/jor.1100130606; KATO Y, 1990, J BIOL CHEM, V265, P5903; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; Koyama E, 1996, J ORTHOPAED RES, V14, P403, DOI 10.1002/jor.1100140310; KOYAMA E, 1995, DEV DYNAM, V203, P152, DOI 10.1002/aja.1002030204; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; LOVEYS LS, 1993, J ORTHOPAED RES, V11, P884, DOI 10.1002/jor.1100110615; MANKIN HJ, 2000, ORTHOPAEDIC BASIC SC, P471; MATSUMOTO T, 1994, ANN RHEUM DIS, V53, P128, DOI 10.1136/ard.53.2.128; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Naski MC, 1998, DEVELOPMENT, V125, P4977; Nixon AJ, 1998, J ORTHOPAED RES, V16, P531, DOI 10.1002/jor.1100160503; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; ROSS AM, 1988, NUCLEIC ACIDS RES, V16, P1801; ROSSELOT G, 1994, J BONE MINER RES, V9, P431; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SARKA T, 2000, INT J BIOCHEM CELL B, V32, P269; Saunders S, 1997, DEV BIOL, V190, P78, DOI 10.1006/dbio.1997.8690; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Shimazu A, 1996, EXP CELL RES, V229, P126, DOI 10.1006/excr.1996.0350; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Wilsman NJ, 1996, J ORTHOPAED RES, V14, P562, DOI 10.1002/jor.1100140410	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42171	42177		10.1074/jbc.M207209200	http://dx.doi.org/10.1074/jbc.M207209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194984	hybrid			2022-12-25	WOS:000178985300110
J	Loberg, RD; Vesely, E; Brosius, FC				Loberg, RD; Vesely, E; Brosius, FC			Enhanced glycogen synthase kinase-3 beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL; INHIBITION; ACTIVATION	Hypoxia triggers apoptosis in a number of different cell types largely through a mitochondrial cell death pathway, which can be abrogated for the most part by enhanced glucose metabolism. The purpose of the current study was to identify intracellular signaling mechanisms that mediate hypoxia-induced apoptosis and are regulated by glucose metabolism. Hypoxia-induced apoptosis in vascular smooth muscle cells and COS-7 cells was accompanied by a significant reduction in Akt and glycogen synthase kinase-3 (GSK-3) phosphorylation resulting in increased GSK-3 activity. Morphologic features of apoptosis, as well as caspases 3 and 9 activation, were prevented by GSK-3 inhibition with either LiCl or SB216763. Phosphorylation of Akt and GSK-3 was enhanced by glucose metabolism or overexpression of the glucose transporter, GLUT1, and was prevented by glycolytic inhibition. These findings indicate that GSK-3 is an important mediator of hypoxia-induced apoptosis and that GSK-3-mediated apoptotic effects occur via activation of the mitochondrial death pathway. Moreover, the results suggest that prevention of hypoxia-mediated apoptosis by enhanced glucose transport and metabolism results, in part, from inhibition of GSK-3 activation.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Brosius, FC (corresponding author), Univ Michigan, Dept Internal Med, 1560 MSRB2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	fbrosius@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065567, R01HL060156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65567, R01 HL 60156] Funding Source: Medline; NIGMS NIH HHS [T32 GM008322, T32 GM08322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Ekhterae D, 1999, CIRC RES, V85, pE70; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; WOODGETT JR, 2001, SCI STKE; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200	24	121	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41667	41673		10.1074/jbc.M206405200	http://dx.doi.org/10.1074/jbc.M206405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200436	hybrid			2022-12-25	WOS:000178985300048
J	Overton, MC; Blumer, KJ				Overton, MC; Blumer, KJ			The extracellular N-terminal domain and transmembrane domains 1 and 2 mediate oligomerization of a yeast G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; FUNCTIONAL GABA(B) RECEPTOR; ALPHA-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; SPLICE VARIANT; STE2 GENE; IN-VIVO; DIMERIZATION; TRAFFICKING	G protein-coupled receptors (GPCRs) can form homodimers/oligomers and/or heterodimers/oligomers. The mechanisms used to form specific GPCR oligomers are poorly understood because the domains that mediate such interactions and the step(s) in the secretory pathway where oligomerization occurs have not been well characterized. Here we have used subcellular fractionation and fluorescence resonance energy transfer (FRET) experiments to show that oligomerization of a GPCR (alpha-factor receptor; STE2 gene product) of the yeast Saccharomyces cerevisiae occurs in the endoplasmic reticulum. To identify domains of this receptor that mediate oligomerization, we used FRET and endocytosis assays of oligomerization in vivo to analyze receptor deletion mutants. A mutant lacking the N-terminal extracellular domain and transmembrane (TM) domain 1 was expressed at the cell surface but did not selfassociate. In contrast, a receptor fragment containing only the N-terminal extracellular domain and TM1 could self-associate and heterodimerize with wild type receptors. Analysis of other mutants suggested that oligomerization is facilitated by the N-terminal extracellular domain and TM2. Therefore, the N-terminal extracellular domain, TM1, and TM2 appear to stabilize alpha-factor receptor oligomers. These domains may form an interface in contact or domain-swapped oligomers. Similar domains may mediate dimerization of certain mammalian GPCRs.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228, St Louis, MO 63110 USA.		Blumer, Kendall J/C-5268-2012		NIGMS NIH HHS [GM44596] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Calver AR, 2001, J NEUROSCI, V21, P1203; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Gouldson PR, 1997, BIOCHEM SOC T, V25, P1066, DOI 10.1042/bst0251066; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pagano A, 2001, J NEUROSCI, V21, P1189; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Ray K, 2000, J BIOL CHEM, V275, P34245, DOI 10.1074/jbc.M005581200; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Schwarz DA, 2000, J BIOL CHEM, V275, P32174, DOI 10.1074/jbc.M005333200; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Stefan CJ, 1999, J BIOL CHEM, V274, P1835, DOI 10.1074/jbc.274.3.1835; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; WEINER JL, 1993, J BIOL CHEM, V268, P8070; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	60	102	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41463	41472		10.1074/jbc.M205368200	http://dx.doi.org/10.1074/jbc.M205368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194975	hybrid			2022-12-25	WOS:000178985300023
J	Vandenplas, ML; Carlson, RW; Jeyaretnam, BS; McNeill, B; Barton, MH; Norton, N; Murray, TF; Moore, JN				Vandenplas, ML; Carlson, RW; Jeyaretnam, BS; McNeill, B; Barton, MH; Norton, N; Murray, TF; Moore, JN			Rhizobium Sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; LIPID-A; BINDING-PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; IN-VITRO; CD14; RECOGNITION; ACTIVATION; ENDOTOXIN; INDUCTION	Endotoxin (lipopolysaccharide (LPS)), a component of Gram-negative bacteria, is among the most potent proinflammatory substances known. The lipid-A region of this molecule initiates the production of multiple host-derived inflammatory mediators, including cytokines (e.g. tumor necrosis factor-alpha (TNFalpha)). It has been a continuous effort to identify methods of interfering with the interaction between enteric LPS and inflammatory cells using natural and synthetic LPS analogs. Some of these LPS analogs (e.g. Rhodobacter spheroides LPS/lipid-A derivatives) are antagonists in human cells but act as potent agonists with cells of other species. Data reported here indicate that structurally novel LPS from symbiotic, nitrogen-fixing bacteria found in association with the root nodules of legumes do not stimulate human monocytes to produce TNFa. Furthermore, LPS from one of these symbiotic bacterial species, Rhizobium sp. Sin-1, significantly inhibits the synthesis of TNFa by human cells incubated with Escherichia coli LPS. Rhizobium Sin-1 LPS exerts these effects by competing with E. coli LPS for binding to LPS-binding protein and by directly competing with E. coli LPS for binding to human monocytes. Rhizobial lipid-A differs significantly from previously characterized lipid-A analogs in phosphate content, fatty acid acylation patterns, and carbohydrate backbone. These structural differences define the rhizobial lipid-A compounds as a potentially novel class of LPS antagonists that might well serve as therapeutic agents for the treatment of Gram-negative sepsis.	Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA; Univ Georgia, Coll Vet Med, Dept Physiol & Pharmacol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Vandenplas, ML (corresponding author), Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA.	mvdplas@vet.uga.edu			NIGMS NIH HHS [GM89583, GM61761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON MH, 1994, CIRC SHOCK, V44, P216; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; *CTR DIS CONTR, 1990, MMWR-MORBID MORTAL W, V39, P31; Eperon S, 1996, J IMMUNOL METHODS, V194, P121, DOI 10.1016/0022-1759(96)00073-7; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Henneke P, 2001, NAT IMMUNOL, V2, P828, DOI 10.1038/ni0901-828; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Jeyaretnam B, 2002, J BIOL CHEM, V277, P41802, DOI 10.1074/jbc.M112140200; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; MORRIS D, 1992, AM J VET RES, P1565; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Pedron T, 2000, IMMUNOLOGY, V101, P262, DOI 10.1046/j.1365-2567.2000.00107.x; Pollack M, 1996, CURR TOP MICROBIOL, V216, P275; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; QURESHI N, 1997, ENDOTOXIN SEPSIS MOL, P289; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; ULEVITCH RJ, 1990, J TRAUMA, V30, pS189; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang ZG, 1996, J LEUKOCYTE BIOL, V59, P241, DOI 10.1002/jlb.59.2.241; YORK WS, 1986, METHOD ENZYMOL, V118, P3; YOUNG LS, 1991, INFECTIOUS DISEASE C, V5, P739	39	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41811	41816		10.1074/jbc.M205252200	http://dx.doi.org/10.1074/jbc.M205252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12193596	hybrid			2022-12-25	WOS:000178985300066
J	Chou, DM; Petersen, P; Walter, JC; Walter, G				Chou, DM; Petersen, P; Walter, JC; Walter, G			Protein phosphatase 2A regulates binding of Cdc45 to the prereplication complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; ORIGIN RECOGNITION COMPLEX; XENOPUS EGG EXTRACTS; IN-VITRO PHOSPHORYLATION; CYCLIN-DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; S-PHASE; POLYMERASE-ALPHA; BUDDING YEAST	In eukaryotic cells, an ordered sequence of events leads to the initiation of DNA replication. During the G, phase of the cell cycle, a prereplication complex (pre-RC) consisting of ORC, Cdc6, Cdt1, and MCM2-7 is established at replication origins on the chromatin. At the G(1)/S transition, MCM10 and the protein kinases Cdc7-Dbf4 and Cdk2-cyclin E cooperate to recruit Cdc45 to the pre-RC, followed by origin unwinding, RPA binding, and recruitment of DNA polymerases. Using the soluble DNA replication system derived from Xenopus eggs, we demonstrate that immunodepletion of protein phosphatase 2A (PP2A) from egg extracts and inhibition of PP2A activity by okadaic acid abolish loading of Cdc45 to the pre-RC. Consistent with a defect in Cdc45 loading, origin unwinding and the loading of RPA and DNA polymerase a are also inhibited. Inhibition of PP2A has no effect on MCM10 loading and on Cdc7-Dbf4 or Cdk2 activity. The substrate of PP2A is neither a component of the pre-RC nor Cdc45. Instead, our data suggest that PP2A functions by dephosphorylating and activating a soluble factor that is required to recruit Cdc45 to the pre-RC. Furthermore, PP2A appears to counteract an unknown inhibitory kinase that phosphorylates and inactivates the same factor. Thus, the initiation of eukaryotic DNA replication is regulated at the level of Cdc45 loading by a combination of stimulatory and inhibitory phosphorylation events.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of California System; University of California San Diego; Harvard University; Harvard Medical School	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol 0612, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gwalter@ucsd.edu		Walter, Johannes/0000-0002-4186-7570	NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLLINGSWORTH RE, 1990, P NATL ACAD SCI USA, V87, P6272, DOI 10.1073/pnas.87.16.6272; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; MOIR D, 1982, GENETICS, V100, P547; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; Nakajima R, 2002, MOL BIOL CELL, V13, P1462, DOI 10.1091/mbc.02-01-0006; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	75	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40520	40527		10.1074/jbc.M207226200	http://dx.doi.org/10.1074/jbc.M207226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185086	hybrid			2022-12-25	WOS:000178791400048
J	Donnelly, MA; Steiner, TS				Donnelly, MA; Steiner, TS			Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; SALMONELLA-TYPHI FLAGELLA; BACTERIAL FLAGELLIN; PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA; INTERLEUKIN-8; INFLAMMATION; SENSITIVITY; STIMULATION; INFECTION	Flagellin is the major structural protein of the flagella of Gram-negative bacteria. Recent work has demonstrated that flagellin is a potent trigger of innate immune responses in a number of eukaryotic cells and organisms, including both mammals and plants. In several different human epithelial cell lines, this innate immune response involves toll-like receptor 5 (TLR5). The mechanisms by which flagellin activates TLR5 and the importance of this interaction in other model systems of flagellin-induced inflammation remain unknown. In this work, random and site-directed mutagenesis of the inflammatory flagellin from enteroaggregative Escherichia coli identified two regions in the conserved D1 domain that are required for interleukin-8 release and TLR5 activation. In contrast, large regions of the variable domain could be excised without reducing the inflammatory activity. In addition, regions of the protein analogous to epitopes that trigger innate immune responses in plants are not involved in Caco-2 flagellin responses. These results highlight the complexity of the interaction between bacterial flagellin and its eukaryotic recognition partners and provide the basis for further studies to characterize the innate immune response to flagellin.	Univ Virginia, Hlth Sci Ctr, Div Geog & Int Med, Charlottesville, VA 22908 USA; Univ British Columbia, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada	University of Virginia; University of British Columbia	Steiner, TS (corresponding author), Rm D452,HP,VGH,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.			Steiner, Ted/0000-0002-3136-6668	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001573] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI 01573-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bauer Z, 2001, J BIOL CHEM, V276, P45669, DOI 10.1074/jbc.M102390200; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; IGIMI S, 2000, 100 GEN M AM SOC MIC, P62; IKEDA JS, 2000, 100 GEN M AM SOC MIC, P81; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Meindl T, 2000, PLANT CELL, V12, P1783, DOI 10.1105/tpc.12.9.1783; Mobley HLT, 1996, INFECT IMMUN, V64, P5332, DOI 10.1128/IAI.64.12.5332-5340.1996; OhtaTada U, 1997, SCAND J GASTROENTERO, V32, P455, DOI 10.3109/00365529709025080; Ramphal R, 1996, AM J RESP CRIT CARE, V154, pS170, DOI 10.1164/ajrccm/154.4_Pt_2.S170; Samatey FA, 2000, J STRUCT BIOL, V132, P106, DOI 10.1006/jsbi.2000.4312; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; STEINER T, 2000, J CLIN INVEST, V105; Steiner TS, 1998, J INFECT DIS, V177, P88, DOI 10.1086/513809; VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9; Wyant TL, 1999, INFECT IMMUN, V67, P3619, DOI 10.1128/IAI.67.7.3619-3624.1999; Wyant TL, 1999, INFECT IMMUN, V67, P1338, DOI 10.1128/IAI.67.3.1338-1346.1999	26	112	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40456	40461		10.1074/jbc.M206851200	http://dx.doi.org/10.1074/jbc.M206851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185085	hybrid			2022-12-25	WOS:000178791400040
J	Farzan, M; Chung, S; Li, WH; Vasilieva, N; Wright, PL; Schnitzler, CE; Marchione, RJ; Gerard, C; Gerard, NP; Sodroski, J; Choe, H				Farzan, M; Chung, S; Li, WH; Vasilieva, N; Wright, PL; Schnitzler, CE; Marchione, RJ; Gerard, C; Gerard, NP; Sodroski, J; Choe, H			Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN; GENETIC RESTRICTION; CORECEPTOR ACTIVITY; MOLECULAR-CLONING; N-TERMINUS; INFECTION; BINDING	Entry of most primary human immunodeficiency virus, type 1 (HIV-1) isolates into their target cells requires the cellular receptor CD4 and the G protein-coupled chemokine coreceptor CCR5. An acidic, tyrosine-rich, and tyrosine-sulfated domain of the CCR5 amino terminus plays a critical role in the ability of CCR5 to serve as an HIV-1 coreceptor, and tyrosine-sulfated peptides based on this region physically associate with the HIV-1 envelope glycoprotein gp120 and slow HIV-1 entry into CCR5-expressing cells. Here we show that the same tyrosine-sulfated peptides, but not their unsulfated analogs, can restore the HIV-1 coreceptor activity of a CCR5 variant lacking residues 2-17 of its amino terminus. Additionally, these sulfated peptides restored the ability of this CCR5 variant to mobilize calcium in response to the chemokines macrophage inflammatory factors 1alpha and 1beta. These observations show that a tyrosine-sulfated region of the CCR5 amino terminus can function independently to mediate association of chemokines and the HIV-1 envelope glycoprotein with the remaining domains of CCR5.	Childrens Hosp, Permutter Lab, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Choe, H (corresponding author), Childrens Hosp, Permutter Lab, 300 Longwood Ave, Boston, MA 02115 USA.		Schnitzler, Christine/G-8733-2013	Farzan, Michael/0000-0002-2990-5319; Schnitzler, Christine/0000-0002-5001-6524; Li, Wenhui/0000-0003-1305-7404	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI048425] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI043891, AI 48425, AI 43891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; FARZAN M, 2002, J BIOL CHEM, V28, P28; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; WU L, 1996, NATURE, V184, P179	45	54	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40397	40402		10.1074/jbc.M206784200	http://dx.doi.org/10.1074/jbc.M206784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183462	hybrid			2022-12-25	WOS:000178791400032
J	Sayama, K; Yamasaki, K; Hanakawa, Y; Shirakata, Y; Tokumaru, S; Ijuin, T; Takenawa, T; Hashimoto, K				Sayama, K; Yamasaki, K; Hanakawa, Y; Shirakata, Y; Tokumaru, S; Ijuin, T; Takenawa, T; Hashimoto, K			Phosphatidylinositol 3-kinase is a key regulator of early phase differentiation in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; NF-KAPPA-B; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; CELL-ADHESION; BETA-1-INTEGRIN EXPRESSION; MICE LACKING; ACTIVATION	The survival and growth of epithelial cells depend on adhesion to the extracellular matrix. Because epidermal keratinocytes differentiate as they leave the basement membrane, an adhesion signal may regulate the initiation of differentiation. Phosphatidylinositol 3-kinase (PI3K) is a fundamental signaling molecule that regulates the adhesion signal. Transfection of a dominant negative form of PI3K into keratinocytes using an adenovirus vector resulted in significant morphological changes comparable to differentiation and the induction of differentiation markers, keratin (K) 1 and K10. In turn, transfection with the constitutively active form of PI3K almost completely abolished the induction of K1 and K10 by differentiation in suspension cultures using polyhydroxyethylmethacrylate-coated dishes. PI3K activity was lost in suspension culture, except by cells bearing the constitutively active form of PI3K. These data demonstrate that blockade of PI3K results in differentiation and that activation of PI3K prevents differentiation. Furthermore, expression of the dominant negative form of PI3K significantly inhibited keratinocyte adhesion to the extracellular matrix and reduced the surface expression of alpha(6) and beta(1) integrins in suspension culture. Moreover, expression of the active form of PI3K restored the mRNA levels of adhesion molecules that were reduced in suspension culture, including alpha(3), alpha(6), and beta(1) integrins, BP180, and BP230. In conclusion, loss of PI3K activity results in keratinocytes leaving the basement membrane and the initiation of a "default" differentiation mechanism.	Ehime Univ, Sch Med, Dept Dermatol, Ehime 7910295, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1138657, Japan	Ehime University; University of Tokyo	Sayama, K (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Ehime 7910295, Japan.	sayama@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018; Ijuin, Takeshi/H-7016-2017	Yamasaki, Kenshi/0000-0002-5495-4956; Ijuin, Takeshi/0000-0002-0618-1776				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sokol S, 2000, NAT CELL BIOL, V2, pE124, DOI 10.1038/35017136; Somasiri A, 2001, J CELL SCI, V114, P1125; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wakita N, 1999, J BIOL CHEM, V274, P37285, DOI 10.1074/jbc.274.52.37285; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	51	34	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40390	40396		10.1074/jbc.M112423200	http://dx.doi.org/10.1074/jbc.M112423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183446	hybrid			2022-12-25	WOS:000178791400031
J	Yamazaki, M; Li, N; Bondarenko, VA; Yamazaki, RK; Baehr, W; Yamazaki, A				Yamazaki, M; Li, N; Bondarenko, VA; Yamazaki, RK; Baehr, W; Yamazaki, A			Binding of cGMP to GAF domains in amphibian rod photoreceptor cGMP phosphodiesterase (PDE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; TRANSDUCIN ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; INHIBITORY GAMMA-SUBUNIT; AMINO-ACID SEQUENCE; OUTER SEGMENTS; RETINAL RODS; REGULATORY SUBUNIT; PROTEIN-KINASE; DELTA-SUBUNIT	Retinal cGMP phosphodiesterase (PDE6) is a key enzyme in vertebrate phototransduction. Rod PDE contains two homologous catalytic subunits (Palphabeta) and two identical regulatory subunits (Pgamma). Biochemical studies have shown that amphibian Palphabeta has high affinity, cGMP-specific, non-catalytic binding sites and that Pgamma stimulates cGMP binding to these sites. Here we show by molecular cloning that each catalytic subunit in amphibian PDE, as in its mammalian counterpart, contains two homologous tandem GAF domains in its N-terminal region. In Pgamma-depleted membrane-bound PDE (20-40% Pgamma still present), a single type of cGMP-binding site with a relatively low affinity (K-d similar to 100 nm) was observed, and addition of Pgamma increased both the affinity for cGMP and the level of cGMP binding. We also show that mutations of amino acid residues in four different sites in Pgamma reduced its ability to stimulate cGMP binding. Among these, the site involved in Pgamma phosphorylation by Cdk5 (positions 20-23) had the largest effect on cGMP binding. However, except for the C terminus, these sites were not involved in Pgamma inhibition of the cGMP hydrolytic activity of Palphabeta. In addition, the Pgamma concentration required for 50% stimulation of cGMP binding was much greater than that required for 50% inhibition of cGMP hydrolysis. These results suggest that the Palphabeta heterodimer contains two spatially and functionally distinct types of Pgamma-binding sites: one for inhibition of cGMP hydrolytic activity and the second for activation of cGMP binding to GAF domains. We propose a model for the Palphabeta-Pgamma interaction in which Pgamma, by binding to one of the two sites in Palphabeta, may preferentially act either as an inhibitor of catalytic activity or as an activator of cGMP binding to GAF domains in frog PDE.	Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA	Wayne State University; Wayne State University; Wayne State University; Utah System of Higher Education; University of Utah	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Dept Ophthalmol, 4717 Antoine Blvd, Detroit, MI 48201 USA.	ayamazak@med.wayne.edu	Bondarenko, Vladimir/AFY-8370-2022		NATIONAL EYE INSTITUTE [R01EY008123, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY 09631, EY 08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; Ando S, 1997, J BIOCHEM, V122, P409; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CATTY P, 1992, J BIOL CHEM, V267, P19489; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; Jindrova H, 1998, PHYSIOL RES, V47, P155; Kachi S, 2000, J ELECTRON MICROSC, V49, P699, DOI 10.1093/oxfordjournals.jmicro.a023861; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LIN W, 1998, J BIOL CHEM, V273, P34284; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MIKI N, 1975, J BIOL CHEM, V250, P6320; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Muradov KG, 2002, BIOCHEMISTRY-US, V41, P3884, DOI 10.1021/bi015935m; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PIRIEV NI, 1994, GENE, V151, P297, DOI 10.1016/0378-1119(94)90674-2; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A., 1998, IOVS, V39, pS953; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	82	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40675	40686		10.1074/jbc.M203469200	http://dx.doi.org/10.1074/jbc.M203469200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177054	hybrid			2022-12-25	WOS:000178791400067
J	Yanagi, K; Mizuno, T; You, ZY; Hanaoka, F				Yanagi, K; Mizuno, T; You, ZY; Hanaoka, F			Mouse geminin inhibits not only Cdt1-MCM6 interactions but also a novel intrinsic Cdt1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; HELICASE ACTIVITY; FISSION YEAST; IN-VITRO; S-PHASE; REPLICATION; PROTEIN; INITIATION; MITOSIS; TRANSCRIPTION	DNA replication is controlled by the stepwise assembly of a pre-replicative complex and the replication apparatus. Cdt1 is a novel component of the pre-replicative complex and plays a role in loading the minichromosome maintenance (MCM) 2-7 complex onto chromatin. Cdt1 activity is inhibited by geminin, which is essential for the G2/M transition in metazoan cells. To understand the molecular basis of the Cdt1-geminin regulatory mechanism in mammalian cells, we cloned and expressed the mouse Cdt1 homologue cDNA in bacterial cells and purified mouse Cdt1 to near homogeneity. We found by yeast two-hybrid analysis that mouse Cdt1 associates with geminin, MCM6, and origin recognition complex 2. MCM6 interacts with the Cdt1 carboxyl-terminal region (amino acids 407-477), which is conserved among eukaryotes, whereas geminin associates with the Cdt1 central region (amino acids 177-380), which is conserved only in metazoans. In addition, we found that Cdt1 can bind DNA in a sequence-, strand-, and conformation-independent manner. The Cdt1 DNA binding domain overlaps with the geminin binding domain, and the binding of Cdt1 to DNA is inhibited by geminin. Taken together, we have defined structural domains and novel biochemical properties for mouse Cdt1 that suggest that Cdt1 behaves as an intrinsic DNA binding factor in the pre-replicative complex.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Wako, Saitama 3510198, Japan; RIKEN Inst Phys & Chem Res, Cellular Physiol Lab, Wako, Saitama, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.							Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DEAN FB, 1991, J BIOL CHEM, V266, P5062; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Diffley JFX, 2002, J CELL SCI, V115, P869; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 2001, J CELL SCI, V114, P1447; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mizuno T, 1999, MOL CELL BIOL, V19, P7886; Mizushima T, 2000, GENE DEV, V14, P1631; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Rialland M, 2002, J CELL SCI, V115, P1435; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; You ZY, 1999, MOL CELL BIOL, V19, P8003	42	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40871	40880		10.1074/jbc.M206202200	http://dx.doi.org/10.1074/jbc.M206202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192004	hybrid			2022-12-25	WOS:000178791400092
J	Eggler, AL; Inman, RB; Cox, MM				Eggler, AL; Inman, RB; Cox, MM			The Rad51-dependent pairing of long DNA substrates is stabilized by replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI RECA; YEAST RAD51 PROTEIN; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ATP HYDROLYSIS; PARTIAL DENATURATION; BRANCH MIGRATION; STABLE COMPLEXES; EXCHANGE	Rad51 protein forms nucleoprotein filaments on single-stranded DNA (ssDNA) and then pairs that DNA with the complementary strand of incoming duplex DNA. In apparent contrast with published results, we demonstrate that Rad51 protein promotes an extensive pairing of long homologous DNAs in the absence of replication protein A. This pairing exists only within the Rad51 filament; it was previously undetected because it is lost upon deproteinization. We further demonstrate that RPA has a critical postsynaptic role in DNA strand exchange, stabilizing the DNA pairing initiated by Rad51 protein. Stabilization of the Rad51-generated DNA pairing intermediates can be can occur either by binding the displaced strand with RPA or by degrading the same DNA strand using exonuclease VII. The optimal conditions for Rad51-mediated DNA strand exchange used here minimize the secondary structure in single-stranded DNA, minimizing the established presynaptic role of RPA in facilitating Rad51 filament formation. We verify that RPA has little effect on Rad51 filament formation under these conditions, assigning the dramatic stimulation of strand exchange nevertheless afforded by RPA to its postsynaptic function of removing the displaced DNA strand from Rad51 filaments.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Eggler, Aimee/0000-0002-7286-2107	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711, U01GM032335, R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32335, GM14711-34] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; Gumbs OH, 1998, BIOCHEMISTRY-US, V37, P11692, DOI 10.1021/bi980646s; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Haag ES, 2000, GENETICS, V155, P105; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; INMAN RB, 1987, J MOL BIOL, V193, P377, DOI 10.1016/0022-2836(87)90225-7; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Nishinaka T, 1998, P NATL ACAD SCI USA, V95, P11071, DOI 10.1073/pnas.95.19.11071; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Singleton SF, 2001, BIOPOLYMERS, V61, P145; Smith J, 1999, GENETICS, V151, P447; Soustelle C, 2002, GENETICS, V161, P535; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Umezu K, 1998, GENETICS, V148, P989; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898	40	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39280	39288		10.1074/jbc.M204328200	http://dx.doi.org/10.1074/jbc.M204328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169690	hybrid			2022-12-25	WOS:000178662500030
J	Krejci, L; Song, BW; Bussen, W; Rothstein, R; Mortensen, UH; Sung, P				Krejci, L; Song, BW; Bussen, W; Rothstein, R; Mortensen, UH; Sung, P			Interaction with Rad51 is indispensable for recombination mediator function of Rad52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; ALLELE; REPAIR; MUTATIONS; COMPLEX; RPA; SUPPRESSION	In the yeast Saccharomyces cerevisiae, the RAD52 gene is indispensable for homologous recombination and DNA repair. Rad52 protein binds DNA, anneals complementary ssDNA strands, and self-associates to form multimeric complexes. Moreover, Rad52 physically interacts with the Rad51. recombinase and serves as a mediator in the Rad51-catalyzed DNA strand exchange reaction. Here, we examine the functional significance of the Rad51/Rad52 interaction. Through a series of deletions, we have identified residues 409-420 of Rad52 as being indispensable and likely sufficient for its interaction with Rad51. We have constructed a four-amino acid deletion mutation within this region of Rad52 to ablate its interaction with Rad51. We show that the rad52Delta409-412 mutant protein is defective in the mediator function in vitro even though none of the other Rad52 activities, namely, DNA binding, ssDNA annealing, and protein oligomerization, are affected. We also show that the sensitivity of the rad52Delta409-412 mutant to ionizing radiation can be complemented by overexpression of Rad51. These results thus demonstrate the significance of the Rad51-Rad52 interaction in homologous recombination.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark	University of Texas System; University of Texas Health San Antonio; Columbia University; Technical University of Denmark	Krejci, L (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.		Mortensen, Uffe/AAQ-1150-2021; Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405; Rothstein, Rodney/0000-0002-4107-9654	NATIONAL CANCER INSTITUTE [T32CA086800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM050237] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA86800] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NIGMS NIH HHS [R01 GM50237, R01 GM57814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; Asleson EN, 1999, GENETICS, V153, P681; Bai Y, 1999, GENETICS, V153, P1117; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Fan HY, 1996, GENETICS, V142, P749; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kaytor MD, 1996, CURR GENET, V29, P203; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SHERMAN F, 1991, P3; Sherman F., 1986, METHODS YEAST GENETI; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Smith J, 1999, GENETICS, V151, P447; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	36	87	89	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40132	40141		10.1074/jbc.M206511200	http://dx.doi.org/10.1074/jbc.M206511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171935	hybrid			2022-12-25	WOS:000178662500136
J	Irusta, PM; Luo, Y; Bakht, O; Lai, CC; Smith, SO; DiMaio, D				Irusta, PM; Luo, Y; Bakht, O; Lai, CC; Smith, SO; DiMaio, D			Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; INTERNAL TANDEM DUPLICATION; FAMILY TYROSINE KINASES; C-KIT; CONSTITUTIVE ACTIVATION; PHOSPHORYLATION SITES; AMINO-ACIDS; FLT3 GENE; SRC; PDGF	A variety of tumors contain activating mutations in the cytoplasmic juxtamembrane domain of the type III family of receptor-tyrosine kinases, and some constructed mutations in this domain induce ligand-independent receptor activation. To explore the role of this domain in regulation of receptor activity, we subjected the juxtamembrane domain of the murine platelet-derived growth factor (PDGF) beta receptor to alanine-scanning mutagenesis. The mutant receptors were expressed in Ba/F3 cells and tested for constitutive tyrosine phosphorylation, association with phosphatidylinositol 3'-kinase, and their ability to induce cell survival and proliferation in the absence of interleukin-3. The mutant receptors accumulated to similar levels and appeared to undergo a normal PDGF-induced increase in tyrosine phosphorylation. Alanine substitutions at numerous positions located throughout the juxtamembrane domain caused constitutive receptor activation, as did an alanine insertion in the membrane-proximal segment of the juxtamembrane domain and a six-amino acid deletion in the center of the domain. It is possible to model the PDGF receptor juxtamembrane domain as a short a-helix followed by a three-stranded beta-sheet very similar to the known structures of WW domains. Strikingly, the activating mutations clustered in the central portions of the first and second beta strands and along one face of the beta-sheet, whereas the loops connecting the strands were largely devoid of mutationally sensitive positions. These findings provide strong support for the model that the activating mutations in the juxtamembrane region stimulate receptor activity by disrupting an inhibitory WW-like domain.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA	Yale University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	daniel.dimaio@yale.edu			NCI NIH HHS [CA85757, CA37157] Funding Source: Medline; NIGMS NIH HHS [GM46732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037157, R01CA037157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046732, R55GM046732] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERBST R, 1995, ONCOGENE, V10, P369; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jiang X, 2001, PROTEIN SCI, V10, P1454, DOI 10.1110/ps.640101; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nakao M, 1996, LEUKEMIA, V10, P1911; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tsujimura T, 1996, BLOOD, V87, P273; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38627	38634		10.1074/jbc.M204890200	http://dx.doi.org/10.1074/jbc.M204890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12181311	hybrid			2022-12-25	WOS:000178529600080
J	Chuang, JL; Wynn, RM; Chuang, DT				Chuang, JL; Wynn, RM; Chuang, DT			The C-terminal hinge region of lipoic acid-bearing domain of E2b is essential for domain interaction with branched-chain alpha-keto acid dehydrogenase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BOVINE KIDNEY; DIHYDROLIPOYL ACETYLTRANSFERASE; COMPLEX; PHOSPHORYLATION; PURIFICATION; EXPRESSION; RAT	The branched-chain a-keto acid dehydrogenase (BCKD) kinase (abbreviated as BCK) down-regulates activity of the mammalian mitochondrial. BCKD complex by reversible phosphorylation of the decarboxylase (E1b) component of the complex. The binding of BCK to the holotransacylase (E2b) core of the BCKD complex results in the stimulation of BCK activity. Here we show that the lipoylated lipoic acid-bearing domain (lip-LBD) (residues 1-84) of E2b alone does not interact with BCK. However, lip-LBD constructs containing various lengths of the C-terminal hinge region of LBD are able to bind to BCK as measured by a newly developed solubility-based binding assay. Isothermal titration calorimetry measurements produced a dissociation constant of 8.06 x 10(-6) m and binding enthalpy of -3.68 kcal/mol for the interaction of BCK with a construct containing lip-LBD and the Glu-Glu-Asp-Xaa-Xaa-Glu sequence of the C-terminal hinge region of LBD. These thermodynamic parameters are similar to those obtained for binding of BCK to a lipoylated di-domain construct, which harbors LBD, the entire hinge region, and the downstream subunit-binding domain of E2b. Our data establish that the C-terminal hinge region of LBD containing the above negatively charged residues is essential for the interaction between the lip-LBD construct and BCK.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	David.Chuang@UTSouthwestern.edu		Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Chang CF, 2002, J BIOL CHEM, V277, P15865, DOI 10.1074/jbc.M110952200; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 1997, J CLIN INVEST, V100, P736, DOI 10.1172/JCI119586; COOK KG, 1984, EUR J BIOCHEM, V145, P587, DOI 10.1111/j.1432-1033.1984.tb08597.x; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; Jung HI, 2002, PROTEIN SCI, V11, P1091, DOI 10.1110/ps.4970102; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; Mann WR, 2000, BBA-PROTEIN STRUCT M, V1480, P283, DOI 10.1016/S0167-4838(00)00079-0; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P66, DOI 10.1111/j.1749-6632.1989.tb14987.x; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301	22	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36905	36908		10.1074/jbc.C200430200	http://dx.doi.org/10.1074/jbc.C200430200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12189132	hybrid			2022-12-25	WOS:000178447100001
J	Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R				Miyake, I; Hakomori, Y; Shinohara, A; Gamou, T; Saito, M; Iwamatsu, A; Sakai, R			Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines	ONCOGENE			English	Article						She family proteins; anaplastic lymphoma kinase (ALK); constitutive phosphorylation; neuroblastoma; gene amplification	NON-HODGKINS-LYMPHOMA; PHOSPHOTYROSINE BINDING DOMAIN; RECEPTOR TYROSINE KINASE; HUMAN N-MYC; ADAPTER PROTEIN; MAMMARY TUMORIGENESIS; TRANSFORMING ACTIVITY; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION	She family of docking proteins, ShcA, Shell and ShcC, play roles in cellular signal transduction by binding to phosphotyrosine residues of various activated receptor tyrosine kinases. Both Shell and ShcC proteins are selectively expressed in the neural system of adult mouse tissues. In most of neuroblastoma cells, obvious tyrosine phosphorylation of ShcC was observed, whereas expression of ShcB was considerably low. Phosphoproteins associated with hyperphosphorylated ShcC were purified from neuroblastoma cell lines, and identified by mass-spectrometry. Anaplastic lymphoma kinase (ALK), which turned out to be one of these phosphoproteins, was constitutively activated and associated with the PTB domain of ShcC in three neuroblastoma cells. In vitro kinase assay revealed that ShcC is a potent substrate of the activated ALK kinase. The ALK gene locus was significantly amplified in both of these cell lines, suggesting that gene amplification leads to constitutive activation of the ALK kinase, which results in hyperphosphorylation of ShcC. Constitutive activation of ALK appeared to interfere with signals from other receptor tyrosine kinases. ALK-ShcC signal activation, possibly caused. by co-amplification with the N-myc gene, might give additional effects on malignant tumor progression of neuroblastoma.	Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuo Ku, Tokyo 1040045, Japan; Kirin Brewery Co Ltd, Lab Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Meiji Pharm Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan; Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2288555, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Kirin Brewery Company Limited; Meiji Pharmaceutical University; Kitasato University	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Canc Signal Transduct Project, Chuo Ku, 5-1-1 Tsukuji, Tokyo 1040045, Japan.			Sakai, Ryuichi/0000-0001-6833-1103				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; George RE, 1996, ONCOGENE, V12, P1583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; KUGA N, 1975, GANN, V66, P547; Lai KMV, 2000, GENE DEV, V14, P1132; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LAYFIELD LJ, 1995, J SURG ONCOL, V59, P21, DOI 10.1002/jso.2930590107; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nojiri H, 1999, FEBS LETT, V453, P140, DOI 10.1016/S0014-5793(99)00709-7; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; OLE NJ, 1996, RAPID COMMUN MASS SP, V10, P1371; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, J BIOL CHEM, V269, P32740; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SOUTHERN EM, 1975, J MOL BIOL, V94, P51, DOI 10.1016/0022-2836(75)90404-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGIMOTO T, 1984, J NATL CANCER I, V72, P923; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287	54	91	96	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5823	5834		10.1038/sj.onc.1205735	http://dx.doi.org/10.1038/sj.onc.1205735			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185581				2022-12-25	WOS:000177520900001
J	Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A				Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A			Rare mutations of the DMBT1 gene in human astrocytic gliomas	ONCOGENE			English	Article						DMBT1; mutation; glioblastoma; pilocytic astrocytoma	TUMORS; PTEN; PROGRESSION; EXPRESSION; CANCER	The Deleted in Malignant Brain Tumors I gene (DMBT1) has been proposed as a tumor suppressor gene candidate in human brain tumors, based on the observation of homozygous deletions affecting the DMBT1 region or part of the gene. In order to support this hypothesis, we performed a mutational analysis of the entire coding region of DMBT1, employing SSCP analysis and direct DNA sequencing in a series of 79 astrocytic gliomas. Five somatic mutations were detected. Two mutations, one of which resulted in an amino acid exchange, occurred in glioblastomas. One pilocytic astrocytoma carried two missense mutations and another pilocytic astrocytoma contained a somatic mutation, not affecting the presumed protein. In addition, 21 of the 27 single nucleotide polymorphisms identified in this study have not been recognized previously. The data indicate, that small mutations are not a frequent finding in gliomas.	Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany; Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Charite Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Deimling, A (corresponding author), Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany.		von Deimling, Andreas/F-7774-2013; Mollenhauer, Jan/G-4452-2012	von Deimling, Andreas/0000-0002-5863-540X; Stockhammer, Florian/0000-0002-0525-5956				Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 1999, ONCOGENE, V18, P6233, DOI 10.1038/sj.onc.1203071; Mollenhauer J, 2000, CANCER RES, V60, P1704; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Takeshita H, 1999, JPN J CANCER RES, V90, P903, DOI 10.1111/j.1349-7006.1999.tb00833.x; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wu WG, 1999, CANCER RES, V59, P1846	15	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5956	5959		10.1038/sj.onc.1205733	http://dx.doi.org/10.1038/sj.onc.1205733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185598				2022-12-25	WOS:000177520900018
J	Aziz, QH; Partridge, CJ; Munsey, TS; Sivaprasadarao, A				Aziz, QH; Partridge, CJ; Munsey, TS; Sivaprasadarao, A			Depolarization induces intersubunit cross-linking in a S4 cysteine mutant of the shaker potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNEL; SLOW INACTIVATION; VOLTAGE SENSOR; ION CHANNELS; MOVEMENT; ACTIVATION; SEGMENT; DOMAIN; PORE; CONFORMATIONS	Voltage-gated potassium (K-v) channels are integral membrane proteins, composed of four subunits, each comprising six (S1-S6) transmembrane segments. S1-S4 comprise the voltage-sensing domain, and S5-S6 with the linker P-loop forms the ion conducting pore domain. During activation, S4 undergoes structural rearrangements that lead to the opening of the channel pore and ion conduction. To obtain details of these structural changes we have used the engineered disulfide bridge approach. For this we have introduced the L361C mutation at the extracellular end of S4 of the Shaker K channel and expressed the mutant channel in Xenopus oocytes. When exposed to mild oxidizing conditions (ambient oxygen or copper phenanthroline), Cys-361 formed an intersubunit disulfide bridge as revealed by the appearance of a dimeric band on Western blotting. As a consequence, the mutant channel suffered a significant loss in conductance (measured by two-electrode voltage clamp). Removal of native cysteines failed to prevent the disulfide formation, indicating that Cys-361 forms a disulfide with its counterpart in the neighboring subunit. The effect was voltage-dependent and occurred during channel activation after Cys-361 has been exposed to the extracellular phase. Although the disulfide bridge reduced the maximal conductance, it caused a hyperpolarizing shift in the conductance-voltage relationship and reduced the deactivation kinetics of the channel. The latter two effects suggest stabilization of the open state of the channel. In conclusion, we report that during activation the intersubunit distance between the N-terminal ends of the S4 segments of the L361C mutant Shaker K channel is reduced.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Aziz, Qasim/AAC-4730-2020	Aziz, Qadeer/0000-0002-7636-6813; Sivaprasadarao, Asipu/0000-0002-6755-3502				Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; BOLAND LM, 1994, BIOPHYS J, V66, P694, DOI 10.1016/S0006-3495(94)80843-4; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Elinder F, 2001, BIOPHYS J, V80, P1802, DOI 10.1016/S0006-3495(01)76150-4; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Loots E, 2000, J GEN PHYSIOL, V116, P623, DOI 10.1085/jgp.116.5.623; Loots E, 1998, J GEN PHYSIOL, V112, P377, DOI 10.1085/jgp.112.4.377; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Olcese R, 1997, J GEN PHYSIOL, V110, P579, DOI 10.1085/jgp.110.5.579; Ruegg U T, 1977, Methods Enzymol, V47, P111; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Shammat IM, 1999, NEURON, V23, P809, DOI 10.1016/S0896-6273(01)80038-6; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tu LW, 1999, BIOPHYS J, V76, P2004, DOI 10.1016/S0006-3495(99)77358-3; Wang MH, 1999, J PHYSIOL-LONDON, V521, P315, DOI 10.1111/j.1469-7793.1999.00315.x; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yellen G, 2001, TRENDS PHARMACOL SCI, V22, P439, DOI 10.1016/S0165-6147(00)01798-3; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	40	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42719	42725		10.1074/jbc.M207258200	http://dx.doi.org/10.1074/jbc.M207258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196543	hybrid			2022-12-25	WOS:000179081200039
J	Lutz, C; Nimpf, J; Jenny, M; Boecklinger, K; Enzinger, C; Utermann, G; Baier-Bitterlich, G; Baier, G				Lutz, C; Nimpf, J; Jenny, M; Boecklinger, K; Enzinger, C; Utermann, G; Baier-Bitterlich, G; Baier, G			Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; N-TERMINAL KINASE; APOLIPOPROTEIN-E RECEPTORS; FACTOR-INDUCED ACTIVATION; T-CELL-ACTIVATION; NEURITE OUTGROWTH; TYROSINE PHOSPHORYLATION; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; CYTOSOLIC ADAPTER	Lipoprotein receptors, such as LRP, have been shown to assemble multiprotein complexes containing intracellular signaling molecules; however, in vivo, their signaling function is poorly understood. Using a novel LRP receptor fusion construct, a type I transmembrane protein chimera, termed sIgG-LRP (bearing the intracellular COOH-terminal tail of human LRP as recombinant fusion to a transmembrane region plus the extracellular IgG-F-c domain), we here investigated LRP signal transduction specificity in intact cells. First and similar to activated alpha2-macroglobulin as agonist of endogenous LRP, expression of sIgG-LRP demonstrated significant apoptosis protection. Second and similar to a2-macroglobulin-induced endogenous LRP, sIgG-LRP is sufficient to negatively modulate mitogen-induced Elk-1 and cJun (but not NF-kappaB) transcriptional activity. Third, expression of sIgG-LRP also impaired cJun transactivation mediated by constitutive active mutants of Rac-1 and MEKK-1. Fourth and unexpectedly, sIgG-LRP expression was found to be associated with a marked enhancement of mitogen-induced cJun amino-terminal kinase (JNK) activation. Fifth, confocal microscopic examination and subcellular fractionation demonstrated that sIgG-LRP and JNK co-localize in transfected cells. Therefore, sIgG-LRP expression was found to significantly impair activation-induced translocation of JNK into the nucleus. Taken together, we here demonstrate that sIgG-LRP protein sequesters activated JNK into the plasma membrane compartment in intact cells, inhibiting nuclear activation of the JNK-dependent transcription factors Elk-1 and cJun.	Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Univ Vienna, Inst Med Biochem, A-1030 Vienna, Austria; Bioctr, A-1030 Vienna, Austria	University of Innsbruck; University of Innsbruck; University of Vienna	Baier, G (corresponding author), Univ Innsbruck, Inst Med Biol & Human Genet, Schoepfstr 41, A-6020 Innsbruck, Austria.	Gottfried.Baier@uibk.ac.at	Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325; Nimpf, Johannes/0000-0002-9273-3492				Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Bauer B, 2000, EUR J IMMUNOL, V30, P3645, DOI 10.1002/1521-4141(200012)30:12<3645::AID-IMMU3645>3.0.CO;2-#; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enzinger C, 2002, EUR J CELL BIOL, V81, P197, DOI 10.1078/0171-9335-00236; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hashimoto K, 2001, J NEUROSCI, V21, P9701, DOI 10.1523/JNEUROSCI.21-24-09701.2001; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ho YY, 2001, J BIOL CHEM, V276, P43455, DOI 10.1074/jbc.M105325200; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Inamura N, 2001, BRAIN RES, V904, P270, DOI 10.1016/S0006-8993(01)02472-6; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kerkhoff E, 2001, CURR BIOL, V11, P1963, DOI 10.1016/S0960-9822(01)00602-9; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kobayashi K, 2001, BBA-MOL BASIS DIS, V1537, P79, DOI 10.1016/S0925-4439(01)00059-X; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.3.CO;2-C; Matsuda S, 2001, J NEUROSCI, V21, P6597; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Narita M, 1997, J NEUROCHEM, V68, P587; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Postuma RB, 1998, FEBS LETT, V428, P13, DOI 10.1016/S0014-5793(98)00475-X; ROMEO C, 1992, COLD SPRING HARB SYM, V57, P117, DOI 10.1101/SQB.1992.057.01.015; Roses Allen D., 1994, Current Opinion in Biotechnology, V5, P663, DOI 10.1016/0958-1669(94)90091-4; ROZEMULLER JM, 1992, RES IMMUNOL, V143, P646, DOI 10.1016/0923-2494(92)80050-U; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Villunger A, 1999, EUR J IMMUNOL, V29, P3549, DOI 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhu Y, 1998, ARTERIOSCL THROM VAS, V18, P473, DOI 10.1161/01.ATV.18.3.473; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	65	56	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43143	43151		10.1074/jbc.M204426200	http://dx.doi.org/10.1074/jbc.M204426200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12193592	hybrid			2022-12-25	WOS:000179081200095
J	Torres, J; Di Como, CJ; Herrero, E; de la Torre-Ruiz, MA				Torres, J; Di Como, CJ; Herrero, E; de la Torre-Ruiz, MA			Regulation of the cell integrity pathway by rapamycin-sensitive TOR function in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; PEPTIDYL-PROLYL ISOMERASE; EXCHANGE FACTOR ROM2; SACCHAROMYCES-CEREVISIAE; MAP KINASE; WALL INTEGRITY; ACTIN CYTOSKELETON; SIGNALING PATHWAY; IMMUNOSUPPRESSANT FK506	The TOR (target of rapamycin) pathway controls cell growth in response to nutrient availability in eukaryotic cells. Inactivation of TOR function by rapamycin or nutrient exhaustion is accompanied by triggering various cellular mechanisms aimed at overcoming the nutrient stress. Here we report that in Saccharomyces cerevisiae the protein kinase C (PKC)-mediated mitogen-activated protein kinase pathway is regulated by TOR function because upon specific Tor1 and Tor2 inhibition by rapamycin, Mpk1 is activated rapidly in a process mediated by Sit4 and Tap42. Osmotic stabilization of the plasma membrane prevents both Mpk1 activation by rapamycin and the growth defect that occurs upon the simultaneous absence of Tor1 and Mpk1 function, suggesting that, at least partially, TOR inhibition is sensed by the PKC pathway at the cell envelope. This process involves activation of cell surface sensors, Rom2, and downstream elements of the mitogen-activated protein kinase cascade. Rapamycin also induces depolarization of the actin cytoskeleton through the TOR proteins, Sit4 and Tap42, in an osmotically suppressible manner. Finally, we show that entry into stationary phase, a physiological situation of nutrient depletion, also leads to the activation of the PKC pathway, and we provide further evidence demonstrating that Mpk1 is essential for viability once cells enter G(0).	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Aureon Biosci Corp, Yonkers, NY 10701 USA	Universitat de Lleida	de la Torre-Ruiz, MA (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Rovira Roure 44, Lleida 25198, Spain.		Herrero, Enrique/B-5592-2009; de la Torre, M Angeles/A-7357-2010; Torres-Rosell, Jordi/A-4213-2010	Herrero, Enrique/0000-0002-6763-111X; de la Torre, M Angeles/0000-0002-6111-1359; Torres-Rosell, Jordi/0000-0003-1308-6926; DiComo, Charles/0000-0003-2818-9215				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; Clotet J, 1999, MOL CELL BIOL, V19, P2408; COSTIGAN C, 1994, MOL GEN GENET, V243, P286, DOI 10.1007/BF00301064; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de la Torre-Ruiz MA, 2002, J BIOL CHEM, V277, P33468, DOI 10.1074/jbc.M203515200; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOSEFF AI, 1995, GENETICS, V141, P857; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Karpova TS, 1998, J CELL SCI, V111, P2689; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; Lim YM, 1997, GENETICS, V146, P263; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Manning BD, 1997, MOL BIOL CELL, V8, P1829, DOI 10.1091/mbc.8.10.1829; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanduri J, 2001, MOL CELL, V8, P281, DOI 10.1016/S1097-2765(01)00312-4; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	75	108	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43495	43504		10.1074/jbc.M205408200	http://dx.doi.org/10.1074/jbc.M205408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12171921	hybrid, Green Published			2022-12-25	WOS:000179081200134
J	Abad, MC; Binderup, K; Rios-Steiner, J; Arni, RK; Preiss, J; Geiger, JH				Abad, MC; Binderup, K; Rios-Steiner, J; Arni, RK; Preiss, J; Geiger, JH			The X-ray crystallographic structure of Escherichia coli branching enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ALPHA-AMYLASE; MAIZE ENDOSPERM; CYCLODEXTRIN GLYCOSYLTRANSFERASE; ANGSTROM RESOLUTION; AMYLOLYTIC ENZYMES; MUTAGENESIS; SPECIFICITY; STABILITY; MECHANISM; RESIDUES	Branching enzyme catalyzes the formation of alpha-1,6 branch points in either glycogen or starch. We report the 2.3-Angstrom crystal structure of glycogen branching enzyme from Escherichia coli. The enzyme consists of three major domains, an NH2-terminal seven-stranded beta-sandwich domain, a COOH-terminal domain, and a central alpha/beta-barrel domain containing the enzyme active site. While the central domain is similar to that of all the other amylase family enzymes, branching enzyme shares the structure of all three domains only with isoamylase. Oligosaccharide binding was modeled or branching enzyme using the enzyme-oligosaccharide complex structures of various alpha-amylases and cyclodextrin glucanotransferase and residues were implicated in oligosaccharide binding. While most of the oligosaccharides modeled well in the branching enzyme structure, an approximate 50degrees rotation between two of the glucose units was required to avoid steric clashes with Trp(298) of branching enzyme. A similar rotation was observed in the mammalian alpha-amylase structure caused by an equivalent tryptophan residue in this structure. It appears that there are two binding modes for oligosaccharides in these structures depending on the identity and location of this aromatic residue.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Univ Puerto Rico, Dept Chem, Mayaguez, PR 00681 USA; UNESP, IBILCE, Dept Phys, BR-15054400 Sao Jose Dos Campos, SP, Brazil	Michigan State University; Michigan State University; University of Puerto Rico; University of Puerto Rico Mayaguez; Universidade Estadual Paulista	Geiger, JH (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	preiss@pilot.msu.edu; geiger@cem.msu.edu	Arni, Raghuvir K/N-9338-2018; Arni, Raghuvir K/B-2222-2013	Arni, Raghuvir K/0000-0003-2460-1145; Arni, Raghuvir K/0000-0003-2460-1145; Geiger, James/0000-0002-9443-4488				Abad MC, 2002, ACTA CRYSTALLOGR D, V58, P359, DOI 10.1107/S090744490102073X; BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; Bao Y, 1996, J CLIN INVEST, V97, P941, DOI 10.1172/JCI118517; Binderup K, 1998, BIOCHEMISTRY-US, V37, P9033, DOI 10.1021/bi980199g; Binderup K, 2000, ARCH BIOCHEM BIOPHYS, V377, P366, DOI 10.1006/abbi.2000.1815; Binderup K, 2000, ARCH BIOCHEM BIOPHYS, V374, P73, DOI 10.1006/abbi.1999.1580; Binderup M, 2002, ARCH BIOCHEM BIOPHYS, V397, P279, DOI 10.1006/abbi.2001.2544; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN YT, 1995, METABOLIC MOL BASES, V1, P935; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIMAURO S, 1994, MYOLOGY, V2, P1554; Funane K, 1998, J PROTEIN CHEM, V17, P579, DOI 10.1007/BF02780959; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; Guan HP, 1997, ARCH BIOCHEM BIOPHYS, V342, P92, DOI 10.1006/abbi.1997.0115; Harata K, 1996, ACTA CRYSTALLOGR D, V52, P1136, DOI 10.1107/S0907444996008438; Hong SJ, 2001, ARCH BIOCHEM BIOPHYS, V386, P62, DOI 10.1006/abbi.2000.2179; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; Katsuya Y, 1998, J MOL BIOL, V281, P885, DOI 10.1006/jmbi.1998.1992; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; Kuriki T, 1996, J PROTEIN CHEM, V15, P305, DOI 10.1007/BF01887119; Kuriki T, 1997, J BIOL CHEM, V272, P28999, DOI 10.1074/jbc.272.46.28999; Libessart N, 1998, ARCH BIOCHEM BIOPHYS, V360, P135, DOI 10.1006/abbi.1998.0960; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; Mikkelsen R, 2001, ARCH BIOCHEM BIOPHYS, V385, P372, DOI 10.1006/abbi.2000.2164; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian MX, 2001, BIOCHEMISTRY-US, V40, P7700, DOI 10.1021/bi0102050; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; SCHRODER JM, 1993, ACTA NEUROPATHOL, V85, P419, DOI 10.1007/BF00334454; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x	39	99	104	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42164	42170		10.1074/jbc.M205746200	http://dx.doi.org/10.1074/jbc.M205746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196524	hybrid			2022-12-25	WOS:000178985300109
J	Ranalli, TA; Tom, S; Bambara, RA				Ranalli, TA; Tom, S; Bambara, RA			AP endonuclease 1 coordinates flap endonuclease 1 and DNA ligase I activity in long patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; HUMAN APURINIC ENDONUCLEASE; DEOXYRIBOSE-PHOSPHATE RESIDUES; COLI EXONUCLEASE-III; POLYMERASE-BETA; APYRIMIDINIC ENDONUCLEASE; MAMMALIAN-CELLS; REPLICATION FORK; ABASIC SITES; CDNA	Base loss is common in cellular DNA, resulting from spontaneous degradation and enzymatic removal of damaged bases. Apurinic/apyrimidinic (AP) endonucleases recognize and cleave abasic (AP) sites during base excision repair (BER). APE1 (REF1, HAP1) is the predominant AP endonuclease in mammalian cells. Here we analyzed the influences of APEI on the human BER pathway. Specifically, APE1 enhanced the enzymatic activity of both flap endonuclease1 (FEN1) and DNA ligase I. FEN1 was stimulated on all tested substrates, regardless of flap length. Interestingly, we have found that APE1 can also inhibit the activities of both enzymes on substrates with a tetrahydrofuran (THF) residue on the 5'-downstream primer of a nick, simulating a reduced abasic site. However once the THF residue was displaced at least a single nucleotide, stimulation of FEN1 activity by APE1 resumes. Stimulation of DNA ligase I required the traditional nicked substrate. Furthermore, APE1 was able to enhance overall product formation in reconstitution of BER steps involving FEN1 cleavage followed by ligation. Overall, APE1 both stimulated downstream components of BER and prevented a futile cleavage and ligation cycle, indicating a far-reaching role in BER.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	50	58	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41715	41724		10.1074/jbc.M207207200	http://dx.doi.org/10.1074/jbc.M207207200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200445	hybrid			2022-12-25	WOS:000178985300054
J	Yamaguchi, H; Wang, HG				Yamaguchi, H; Wang, HG			Bcl-XL protects BimEL-induced Bax conformational change and cytochrome c release independent of interacting with Bax or BimEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; DEPENDENT ANION CHANNEL; FAMILY MEMBER BIM; CELL-DEATH; PROMOTES APOPTOSIS; MOLECULAR-CLONING; BH3-ONLY PROTEINS; ENDONUCLEASE-G; BH4 DOMAIN; SURVIVAL	The Bcl-2 homology (BH) 3-only pro-apoptotic Bcl-2 family protein Bim plays an essential role in the mitochondrial pathway of apoptosis through activation of the BH1-3 multidomain protein Bax or Bak. To further understand how the BH3-only protein activates Bax, we provide evidence here that BimEL induces Bax conformational change and apoptosis through a Bcl-XL-suppressible but heterodimerization-independent mechanism. Substitution of the conserved leucine residue in the BH3 domain of BimEL for alanine (M1) inhibits the interaction of BimEL with Bcl-XL but does not abolish the ability of BimEL to induce Bax conformational change and apoptosis. However, removal of the C-terminal hydrophobic region from the M1 mutant (M1DeltaC) abolishes its ability to activate Bax and to induce apoptosis, although deletion of the C-terminal domain (DeltaC) alone has little if any effect on the pro-apoptotic activity of BimEL. Subcellular fractionation experiments show that the Bim mutant M1DeltaC is localized in the cytosol, indicating that both the C-terminal hydrophobic region and the BH3 domain are required for the mitochondrial targeting and pro-apoptotic activity of BimEL. Moreover, the Bcl-XL mutant (mt1), which is unable to interact with Bax and BimEL, blocks Bax conformational change and cytochrome c release induced by BimEL in intact cells and isolated mitochondria. BimEL or BakBH3 peptide induces Bax conformational change in vitro only under the presence of mitochondria, and the outer mitochondrial membrane fraction is sufficient for induction of Bax conformational change. Interestingly, native Bax is attached loosely on the surface of isolated mitochondria, which undergoes conformational change and insertion into mitochondrial membrane upon stimulation by BimEL, Bak-BH3 peptide, or freeze/thaw damage. Taken together, these findings indicate that BimEL may activate Bax by damaging the mitochondrial membrane structure directly, in addition to its binding and antagonizing Bcl-2/Bcl-XL function.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Wang, HG (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu			NCI NIH HHS [CA82197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Lan L, 2000, BIOCHEM J, V349, P611, DOI 10.1042/0264-6021:3490611; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schimmer AD, 2001, CELL DEATH DIFFER, V8, P725, DOI 10.1038/sj.cdd.4400870; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2002, CANCER RES, V62, P466; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	74	81	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41604	41612		10.1074/jbc.M207516200	http://dx.doi.org/10.1074/jbc.M207516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198137	hybrid			2022-12-25	WOS:000178985300040
J	Zambotti, A; Makhluf, H; Shen, JH; Ducy, P				Zambotti, A; Makhluf, H; Shen, JH; Ducy, P			Characterization of an osteoblast-specific enhancer element in the CBFA1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; CARTILAGE MATRIX PROTEIN; TRANSCRIPTION FACTOR; BONE-FORMATION; CHONDROCYTE DIFFERENTIATION; PARATHYROID-HORMONE; POTENTIAL ROLE; EXPRESSION; PROMOTER; MOUSE	Cbfa1 is a critical regulator of cell differentiation expressed only in the osteochondrogenic lineage. To define the molecular basis of this cell-specific expression we analyzed the murine Cbfa1 promoter. Here we show that the first 976 bp of this promoter are specifically active in osteoblastic cells. Within this region DNase I footprinting delineated a 40-bp area (CE1) protected differently by nuclear extracts from osteoblastic cells and from non-osteoblastic cells. When multimerized, CE1 conferred an osteoblast-specific activity to a heterologous promoter in DNA transfection experiments; this enhancing ability was conserved between mouse, rat, and human CE1 present in the respective Cbfa1 promoters. CE1 site-specific mutagenesis determined that it binds NF1- and AP1-like activities. Further analyses revealed that the NF1 site acts as a repressor in non-osteoblastic cells due to the binding of NF1-A, a NF1 isoform not expressed in osteoblastic cells. In contrast, the AP1 site mediates an osteoblast-specific activation caused by the preferential binding of FosB to CE1 in osteoblastic cells. In summary, this study identified an osteoblast-specific enhancer in the Cbfa1 promoter whose activity is achieved by the combination of an inhibitory and an activatory mechanism.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Ducy, P (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,Rm S911, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046487] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR46487] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; AUSUBEL FM, 1995, SONS; Bidder M, 2000, BIOCHEMISTRY-US, V39, P8917, DOI 10.1021/bi000343+; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; KLEEREKOPER M, 1998, METABOLIC BONE DIS; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Osada S, 1997, BIOCHEM BIOPH RES CO, V238, P744, DOI 10.1006/bbrc.1997.7382; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Rajas F, 1998, BIOCHEM J, V333, P77, DOI 10.1042/bj3330077; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303-7207(01)00594-9; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945-053X(96)90153-5	40	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41497	41506		10.1074/jbc.M204271200	http://dx.doi.org/10.1074/jbc.M204271200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186862	hybrid			2022-12-25	WOS:000178985300027
J	da Silva, EF; Mandal, SS; Reha-Krantz, LJ				da Silva, EF; Mandal, SS; Reha-Krantz, LJ			Using 2-aminopurine fluorescence to measure incorporation of incorrect nucleotides by wild type and mutant bacteriophage T4 DNA Polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; REPLICATION FIDELITY; KINETIC MECHANISM; BIOCHEMICAL BASIS; 3'->5'-EXONUCLEASE ACTIVITY; AMINO-ACID; I KLENOW; MUTATOR; ANTIMUTATOR; SELECTION	The ability of wild type and mutant T4 DNA polymerases to discriminate in the utilization of the base analog 2-aminopurine (2AP) and the fluorescence of 2AP were used to determine how DNA polymerases distinguish between correct and incorrect nucleotides. Because T4 DNA polymerase incorporates dTMP opposite 2AP under single-turnover conditions, it was possible to compare directly the kinetic parameters for incorporation of dTMP opposite template 2AP to the parameters for incorporation of dTMP opposite template A without the complication of enzyme dissociation. The most significant difference detected was in the K-d for dTTP, which was 10-fold higher for incorporation of dTMP opposite template 2AP (similar to367 mum) than for incorporation of dTMP opposite template A (similar to31 mum). In contrast, the dTMP incorporation rate was reduced only about 2-fold from about 318 s(-1) with template A to about 165 s(-1) for template 2AP. Discrimination is due to the high selectivity in the initial nucleotide-binding step. T4 DNA polymerase binding to DNA with 2AP in the template position induces formation of a nucleotide binding pocket that is preshaped to bind dTTP and to exclude other nucleotides. If nucleotide binding is hindered, initiation of the proofreading pathway acts as an error avoidance mechanism to prevent incorporation of incorrect nucleotides.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Reha-Krantz, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.		Reha-Krantz, Linda/A-3748-2014	Reha-Krantz, Linda/0000-0003-4497-423X; Mandal, Subhrangsu/0000-0001-8495-9881; Fidalgo da Silva, Elizabeth/0000-0003-3540-9335				Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; GOODMAN M, 1999, Patent No. 5945312; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HOPKINS R, 1979, J MOL BIOL, V135, P1, DOI 10.1016/0022-2836(79)90337-1; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LO KY, 1976, J BIOL CHEM, V251, P2475; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Mandal SS, 2002, BIOCHEMISTRY-US, V41, P4399, DOI 10.1021/bi015723p; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PLESS RC, 1983, BIOCHEMISTRY-US, V22, P4905, DOI 10.1021/bi00290a006; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; REDDY MK, 1992, J BIOL CHEM, V267, P14157; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1981, J MOL BIOL, V145, P677, DOI 10.1016/0022-2836(81)90309-0; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; TSUJIKAWA L, 2000, THESIS U ALBERTA EDM; WARD DC, 1969, J BIOL CHEM, V244, P1228; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; WATANABE SM, 1982, P NATL ACAD SCI-BIOL, V79, P6429, DOI 10.1073/pnas.79.21.6429; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924	45	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40640	40649		10.1074/jbc.M203315200	http://dx.doi.org/10.1074/jbc.M203315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189135	hybrid			2022-12-25	WOS:000178791400063
J	Shalom-Barak, T; Knaus, UG				Shalom-Barak, T; Knaus, UG			A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PHOSPHOGLYCERATE MUTASE; HUMAN NEUTROPHILS; ACTIVATION; PHOSPHORYLATION; PURIFICATION; SERINE-303; GTPASES; RAC-2; CELLS	Chemoattractant-stimulated phagocytes increase their glucose uptake and divert energy production from glycolysis to the pentose phosphate pathway to generate NADPH. NADPH is a required cofactor for the NADPH oxidase to produce reactive oxygen metabolites, an important microbicidal tool in host defense. p21-Activated kinases (Paks) are regulated by the GTPases Rac and Cdc42 and control actin dynamics and phosphorylation of the oxidase component p47(phox). Here we report the interaction of Pak with phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Activated Pak1 inhibits glycolysis by association of its catalytic domain with PGAM-B and subsequent phosphorylation of the enzyme on serine residues 23 and 118, thereby abolishing PGAM activity. Leukocyte activation through chemoattractant receptors leads to Pak activation and transient inhibition of endogenous PGAM-B activity. Consistent with these observations, treatment of neutrophils with phosphoglycolic acid, a competitive PGAM-B inhibitor, increases upstream intermediates, thereby amplifying the respiratory burst. These results demonstrate that Rho GTPases regulate the glycolytic pathway through Pak and suggest a link between chemoattractant signaling and metabolic responses to enhance host defense.	Scripps Res Inst, Dept Immunol IMM28, La Jolla, CA 92037 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Scripps Research Institute; Jackson Laboratory	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol IMM28, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	uknaus@scripps.edu			NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Beutler E., 1984, GLUTATHIONE RED CELL; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURCHILL BR, 1978, J CELL BIOL, V76, P439, DOI 10.1083/jcb.76.2.439; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dharmawardhane S, 1999, J LEUKOCYTE BIOL, V66, P521, DOI 10.1002/jlb.66.3.521; Hagi Akifumi, 2000, Journal of Medical Investigation, V47, P19; Hall A, 1999, BRIT J CANCER, V80, P25; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; King CC, 2000, METHOD ENZYMOL, V325, P155; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Merkulova T, 1997, BIOCHEM J, V323, P791, DOI 10.1042/bj3230791; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; SASAKI R, 1971, BIOCHIM BIOPHYS ACTA, V227, P595, DOI 10.1016/0005-2744(71)90010-6; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; STJERNHOLM RL, 1980, RETICULOENDOTHELIAL, V2, P73; UCHIDA K, 1995, CLIN CHIM ACTA, V237, P43, DOI 10.1016/0009-8981(95)06063-J; VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743; ZATTI M, 1965, BIOCHIM BIOPHYS ACTA, V99, P557, DOI 10.1016/S0926-6593(65)80213-2; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565	29	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40659	40665		10.1074/jbc.M206650200	http://dx.doi.org/10.1074/jbc.M206650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189148	hybrid			2022-12-25	WOS:000178791400065
J	Vogel, R; Fan, GB; Ludeke, S; Siebert, F; Sheves, M				Vogel, R; Fan, GB; Ludeke, S; Siebert, F; Sheves, M			A nonbleachable rhodopsin analogue with a slow photocycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL CHROMOPHORE; BACTERIORHODOPSIN; ISOMERIZATION; ACTIVATION; MECHANISM; PIGMENTS; STATE	Archaeal rhodopsins, e.g. bacteriorhodopsin, all have cyclic photoreactions. Such cycles are achieved by a light-induced isomerization step of their retinal chromophores, which thermally re-isomerize in the dark. Visual pigment rhodopsins, which contain in the dark state an 11-cis retinal Schiff base, do not share such a mechanism, and following light absorption, they experience a bleaching process and a subsequent release of the photo-isomerized all-trans chromophore from the binding pocket. The pigment is eventually regenerated by the rebinding of a new 11-cis retinal. In the artificial visual pigment, Rh-6.10, in which the retinal chromophore is locked in an 11-cis geometry by the introduction of a six-member ring structure, an activated receptor may be formed by light-induced isomerization around other double bonds. We have examined this activation of Rh-6.10 by UV-visible and FTIR spectroscopy and have revealed that Rh-6.10 is a nonbleachable pigment. We could further show that the activated receptor consists of two different subspecies corresponding to 9-trans and 9-cis isomers of the chromophore. Both subspecies relax in the dark via separate pathways back to their respective inactive states by thermal isomerization presumably around the C-13=C-14 double bond. This nonbleachable pigment can be repeatedly photolyzed to undergo identical activation-relaxation cycles. The rate constants of these photocycles are pH-dependent, and the half-times vary between several hours' at acidic pH and about 1.5 min at neutral to alkaline pH, which is several orders of magnitude longer than for bacteriorhodopsin.	Univ Freiburg, Biophys Grp, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	University of Freiburg; Weizmann Institute of Science	Vogel, R (corresponding author), Inst Mol Med & Zellforsch, Arbeitsgrp Biophys, Hermann Herder Str 9, D-79104 Freiburg, Germany.			Ludeke, Steffen/0000-0003-1498-5552				ALBECK A, 1992, J AM CHEM SOC, V114, P2400, DOI 10.1021/ja00033a015; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; Fan GB, 2002, J BIOL CHEM, V277, P40229, DOI 10.1074/jbc.M205033200; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Lanyi JK, 1995, ISR J CHEM, V35, P365; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; SHEVES M, 1984, J AM CHEM SOC, V106, P6840, DOI 10.1021/ja00334a061; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; Varo G, 2000, BBA-BIOENERGETICS, V1460, P220, DOI 10.1016/S0005-2728(00)00141-9; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011	21	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40222	40228		10.1074/jbc.M205032200	http://dx.doi.org/10.1074/jbc.M205032200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177056	hybrid			2022-12-25	WOS:000178791400010
J	Lee, CG				Lee, CG			RH70, a bidirectional RNA helicase, co-purifies with U1snRNP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SPLICING FACTORS; DNA; PROTEINS; SPLICEOSOME; CYCLOPHILIN; HYDROLYSIS; COMPLEX; DUPLEX; SNRNPS	In this report, I describe the co-purification of a novel 70-kDa RNA helicase (RH70) and U1snRNP through six column steps. Peptide sequence analysis by mass spectrometry and Edman degradation revealed that RH70 is the previously reported DDX17. Biochemical characterization of RH70, obtained by partial separation from U1snRNP, yielded the following results. (a) RH70 mediates the unwinding of duplex RNA but not DNA in an ATP-dependent manner. W Both the RNA-dependent ATPase and RNA helicase activities of RH70 are highly specific for ATP, exhibiting an apparent K-m of 0.5 mm. (c) RH70 catalyzes the unwinding of duplex RNA containing single-stranded regions at either the 5'- or W-end. Its association with U1snRNP and ATP specificity suggest a role for RH70 in pre-mRNA splicing, in particular, at the early stages of the splicing reaction involving U1snRNP.	Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Lee, CG (corresponding author), Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.							Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Campodonico E, 2002, GENETICS, V160, P407; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Horowitz DS, 1997, RNA, V3, P1374; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; LEE CG, 1992, J BIOL CHEM, V267, P4338; Liu ZR, 1998, MOL CELL BIOL, V18, P6910, DOI 10.1128/MCB.18.12.6910; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Martin A, 2002, J BIOL CHEM, V277, P17743, DOI 10.1074/jbc.M200762200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; ROSEN F, 1990, MOL CELL BIOL, V10, P1134; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Teigelkamp S, 1998, RNA, V4, P127; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39679	39683		10.1074/jbc.C200337200	http://dx.doi.org/10.1074/jbc.C200337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12193588	hybrid			2022-12-25	WOS:000178662500081
J	Osaki, T; Okino, N; Tokunaga, F; Iwanaga, S; Kawabata, S				Osaki, T; Okino, N; Tokunaga, F; Iwanaga, S; Kawabata, S			Proline-rich cell surface antigens of horseshoe crab hemocytes are substrates for protein cross-linking with a clotting protein coagulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TACHYPLEUS-TRIDENTATUS; CLOTTABLE PROTEIN; MOLECULAR-BASIS; PURIFICATION; COMPONENTS; HOMOLOG; PLASMA	Monoclonal antibodies were raised against hemocytes of the horseshoe crab Tachypleus tridentatus. All of the antibodies obtained reacted with the same protein bands on SDS-PAGE of hemocyte lysate. Flow cytometry and biotinylation of surface substances on the hemocytes indicated that the antigens are major peripheral proteins of hemocytes. The antigens were purified from hemocyte lysate and were good substrates for the horseshoe crab hemocyte transglutaminase (HcTGase). Transglutaminases play an important role during the final stage of blood coagulation in mammals and crustaceans. Although HcTGase did not intermolecularly cross-link a clottable protein coagulogen or its proteolytic product coagulin, HcTGase promoted the cross-linking of coagulin with the surface antigens, resulting in the formation of a stable polymer. We determined the nucleotide sequences for two isoproteins of the antigens. The two proteins containing 271 and 284 residues (66% identity) were composed of tandem repeats of proline-rich segments. We named them proxins-1 and -2 after proline-rich proteins for protein cross-linking. Proxins may form a stable physical barrier against invading pathogens in cooperation with hemolymph coagulation at injured sites.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan	Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021	Tokunaga, Fuminori/0000-0003-3626-9119; Osaki, Tsukasa/0000-0002-9487-3253				Ashida Masaaki, 1998, P135; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DOOLITTLE RF, 1990, BIOCHEM BIOPH RES CO, V167, P16, DOI 10.1016/0006-291X(90)91723-6; DOOLITTLE RF, 1984, PLASMA PROTEINS, V10, P421; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Iwanaga S, 2002, CURR OPIN IMMUNOL, V14, P87, DOI 10.1016/S0952-7915(01)00302-8; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kawasaki H, 2000, J BIOL CHEM, V275, P35297, DOI 10.1074/jbc.M006856200; KOPACEK P, 1993, EUR J BIOCHEM, V213, P591, DOI 10.1111/j.1432-1033.1993.tb17798.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; NAKAMURA S, 1976, J BIOCHEM, V80, P1011, DOI 10.1093/oxfordjournals.jbchem.a131357; NAKAMURA S, 1976, BIOCHEM BIOPH RES CO, V72, P902, DOI 10.1016/S0006-291X(76)80217-3; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; TAKAGI T, 1984, J BIOCHEM-TOKYO, V95, P1445, DOI 10.1093/oxfordjournals.jbchem.a134752; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOKUNAGA F, 1993, J BIOL CHEM, V268, P252; WILSON J, 1992, BIOCHEM BIOPH RES CO, V188, P655, DOI 10.1016/0006-291X(92)91106-Z	29	52	54	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40084	40090		10.1074/jbc.M206773200	http://dx.doi.org/10.1074/jbc.M206773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12189150	hybrid			2022-12-25	WOS:000178662500129
J	Poon, S; Rybchyn, MS; Easterbrook-Smith, SB; Carver, JA; Pankhurst, GJ; Wilson, MR				Poon, S; Rybchyn, MS; Easterbrook-Smith, SB; Carver, JA; Pankhurst, GJ; Wilson, MR			Mildly acidic pH activates the extracellular molecular chaperone clusterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ALPHA-A-CRYSTALLIN; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; CIRCULAR-DICHROISM; BINDING PROPERTIES; PROTEINS; IDENTIFICATION; BISANS; BRAIN; RAT	Many features of the chaperone action of clusterin are similar to those of the intracellular small heat shock proteins (sHSPs) that, like clusterin, exist in solution as heterogeneous aggregates. Increased temperature induces dissociation of some sHSP aggregates and an enhanced chaperone action, suggesting that a dissociated form is the active chaperone species. We recently reported that clusterin aggregates dissociate at mildly acidic pH. To further explore the similarities between clusterin and the sHSPs, we tested the effects of temperature and pH on the structure of clusterin and its chaperone action. Our results demonstrate that increased temperature does not induce dissociation of clusterin aggregates, or other major structural changes, and has little effect on its chaperone action. However, we show that the chaperone action of clusterin is enhanced at mildly acidic pH. Clusterin is the first chaperone shown to be activated by reduced pH. This unique mode of activation appears to result from an increase in regions of solvent-exposed hydrophobicity, which is independent of any major changes in secondary or tertiary structure. We propose a model in which low pH-induced dissociation of clusterin aggregates increases the abundance of the heterodimeric chaperone-active species, which has greater hydrophobicity exposed to solution.	Univ Wollongong, Dept Sci Biol, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Wollongong; University of Wollongong; University of Sydney	Easterbrook-Smith, SB (corresponding author), Univ Wollongong, Dept Sci Biol, Northfields Ave, Wollongong, NSW 2522, Australia.	sbe@mmb.usyd.edu.au; mrw@uow.edu.au	Wilson, Mark R/B-3254-2018; Carver, John Adrian/J-3825-2014	Wilson, Mark R/0000-0002-9551-7445; Carver, John Adrian/0000-0002-2441-8108; Rybchyn, Mark/0000-0002-4336-6227				BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Chakraborty S, 1999, BBA-PROTEIN STRUCT M, V1432, P350, DOI 10.1016/S0167-4838(99)00110-7; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; Epps DE, 1998, J PROTEIN CHEM, V17, P699, DOI 10.1007/BF02780973; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hochgrebe T, 2000, BIOCHEMISTRY-US, V39, P1411, DOI 10.1021/bi991581b; Holtzman DM, 2001, NAT MED, V7, P977, DOI 10.1038/nm0901-977; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; JACOBUS WE, 1977, NATURE, V265, P756, DOI 10.1038/265756a0; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kapron JT, 1997, PROTEIN SCI, V6, P2120; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Pankhurst GJ, 1998, BIOCHEMISTRY-US, V37, P4823, DOI 10.1021/bi972367v; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PUNNIAMOORTHY A, 1987, J ORAL PATHOL MED, V16, P36, DOI 10.1111/j.1600-0714.1987.tb00674.x; Rosenberg ME, 2002, MOL CELL BIOL, V22, P1893, DOI 10.1128/MCB.22.6.1893-1902.2002; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SLINGSBY C, 1990, EXP EYE RES, V51, P21, DOI 10.1016/0014-4835(90)90165-Q; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8552, DOI 10.1021/bi00151a024; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x	35	83	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39532	39540		10.1074/jbc.M204855200	http://dx.doi.org/10.1074/jbc.M204855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176985	hybrid, Green Submitted			2022-12-25	WOS:000178662500062
J	Sarver, AE; Wang, CC				Sarver, AE; Wang, CC			The adenine phosphoribosyltransferase from Giardia lamblia has a unique reaction mechanism and unusual substrate binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-XANTHINE PHOSPHORIBOSYLTRANSFERASE; STATE ANALOG INHIBITOR; 2.0 ANGSTROM STRUCTURE; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; OROTATE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE; SALMONELLA-TYPHIMURIUM; PYRIMIDINE METABOLISM; ESCHERICHIA-COLI	Purine phosphoribosyltransferases catalyze the Mg2+-dependent reaction that transforms a purine base into its corresponding nucleotide. They are present in a wide variety of organisms including plants, mammals, and parasitic protozoa. Giardia lamblia, the causative agent of giardiasis, lacks de novo purine biosynthesis and relies primarily on adenine and guanine phosphoribosyltransferases (APRTase and GPRTase) constituting two independent and essential purine salvage pathways. The APRTase from G. lamblia was cloned and expressed with a 6-His tag at its C terminus and purified to apparent homogeneity. Adenine and alpha-D-5-phosphoribosyl-1-pyrophosphate (PRPP) have K-m values of 4.2 and 143 mum with a k(cat) of 2.8 s(-1) in the forward reaction, whereas AMP and PPi have K-m values of 87 and 450 mum with a k(cat) of 9.5 x 10(-3) s(-1) in the reverse reaction. Product inhibition studies indicated that the forward reaction follows a random Bi Bi mechanism. Results from the kinetics of equilibrium isotope exchange further verified a random Bi Bi mechanism in the forward reaction. In a mutant enzyme, F25W, with kinetic constants similar to those of the wild type and a tryptophan residue at the adenine binding site, the addition of adenine or AMP to the free mutant enzyme resulted, in fluorescence quenching, whereas PRPP caused fluorescence enhancement. The dissociation constants thus estimated are 16.5 mum for adenine, 14.3 mum for AMP, and 83.0 mum for PRPP. PPi exerted no detectable effect on the tryptophan fluorescence at all, suggesting a lack of PPi binding to the free enzyme. An ordered substrate binding in the reverse reaction with AMP bound first followed by PPi is thus postulated.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Box 0446,513 Parnassus Ave, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Aronov AM, 2001, ANTIMICROB AGENTS CH, V45, P2571, DOI 10.1128/AAC.45.9.2571-2576.2001; Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g; Bashor C, 2002, BIOCHEMISTRY-US, V41, P4020, DOI 10.1021/bi0158730; BECK JT, 1993, MOL BIOCHEM PARASIT, V60, P187, DOI 10.1016/0166-6851(93)90130-P; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Focia PJ, 1998, BIOCHEMISTRY-US, V37, P17120, DOI 10.1021/bi9821465; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; Munagala N, 2000, J BIOL CHEM, V275, P37072, DOI 10.1074/jbc.M007239200; Munagala N, 2001, BIOCHEMISTRY-US, V40, P4303, DOI 10.1021/bi0026932; Munagala N, 2002, MOL MICROBIOL, V44, P1073, DOI 10.1046/j.1365-2958.2002.02942.x; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P4045, DOI 10.1021/bi972515h; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; PARSONSON IM, 1974, AUST VET J, V50, P421, DOI 10.1111/j.1751-0813.1974.tb06861.x; Phillips CL, 1999, EMBO J, V18, P3533, DOI 10.1093/emboj/18.13.3533; Purich D L, 1980, Methods Enzymol, V64, P1; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SEGEL IH, 1993, ENZYME KINETICS BEHA, P505; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; Shi WX, 2002, J BIOL CHEM, V277, P39981, DOI 10.1074/jbc.M205596200; Shi WX, 2001, BIOCHEMISTRY-US, V40, P10800, DOI 10.1021/bi010465h; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Simmonds H, 1995, METABOLIC MOL BASES, P1707; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1998, BIOCHEMISTRY-US, V37, P5344, DOI 10.1021/bi973095z; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Vos S, 1998, J MOL BIOL, V282, P875, DOI 10.1006/jmbi.1998.2051; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; WANG CC, 1983, P NATL ACAD SCI-BIOL, V80, P2564, DOI 10.1073/pnas.80.9.2564; WYNGAARDEN JB, 1957, ARCH BIOCHEM BIOPHYS, V70, P150, DOI 10.1016/0003-9861(57)90088-7; Xu YM, 1997, BIOCHEMISTRY-US, V36, P3700, DOI 10.1021/bi9616007; YUAN L, 1992, BIOCHEMISTRY-US, V31, P806, DOI 10.1021/bi00118a024	41	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39973	39980		10.1074/jbc.M205595200	http://dx.doi.org/10.1074/jbc.M205595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171924	hybrid			2022-12-25	WOS:000178662500116
J	Zhu, W; Mustelin, T; David, M				Zhu, W; Mustelin, T; David, M			Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; HISTONE H3; TRANSCRIPTION; INTERFERON; ACTIVATION; INACTIVATION; INHIBITION; LIGANDS; DOMAINS	Transcriptional induction by interferons requires the tyrosine and serine phosphorylation of the STAT1 transcription factor as well as its amino-terminal arginine methylation. Here we show that arginine methylation of STAT1 controls the rate of STAT1 dephosphorylation by modulating its interaction with PIAS1 and the nuclear tyrosine phosphatase TcPTP. Inhibition of STAT1 arginine methylation, or mutation of STAT1 Arg-31, results in a prolonged half-life of STAT1 tyrosine phosphorylation. This effect appears to be mediated by an increased binding of PIAS1 to STAT1 in the absence of STAT1 arginine methylation and a concomitant decrease in the association of STAT1 with TcPTP. Furthermore, inhibitors of arginine methylation require the presence of PIAS1 to exert their negative regulatory effect on the dephosphorylation of STAT1.	Univ Calif San Diego, Div Biol, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Burnham Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	David, M (corresponding author), Univ Calif San Diego, Div Biol, Mol Biol Sect, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.	midavid@ucsd.edu		Mustelin, Tomas/0000-0001-5912-8840	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [CA80105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	26	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35787	35790		10.1074/jbc.C200346200	http://dx.doi.org/10.1074/jbc.C200346200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12171910	hybrid			2022-12-25	WOS:000178275100003
J	Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F				Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F			Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						FGF-binding proteins; FGF-BP; prostate cancer cells; ribozyme-targeting; prostate tumorigenesis; HBp17	FIBROBLAST-GROWTH-FACTOR; GENE-EXPRESSION; STRUCTURAL CHARACTERIZATION; ANGIOGENIC SWITCH; OVER-EXPRESSION; RETINOIC ACID; TUMOR-GROWTH; RECEPTOR; STIMULATION; CARCINOMA	Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male. Since locally advanced or metastatic prostate tumors are essentially incurable, identification of new target molecules and treatment strategies is of critical importance. Fibroblast growth factor-2 (FGF-2) acts as potent mitogen which is upregulated in prostate cancers modulating cancer cell proliferation and development of an invasive phenotype. Normally it is tightly bound to the extracellular matrix that quenches its biological activity. The FGF-binding proteins (FGF-BP, HBp17) is a secreted protein which is able to mobilize and activate FGF-2 from the extracellular matrix. Here we show that FGF-BP is highly expressed in prostate tumor cells. To study the functional role of FGF-BP, we use a ribozymetargeting approach to selectively deplete FGF-BP in prostate cancer cells achieving a more than 50% reduction of FGF-BP mRNA and protein levels in two mass-transfected cell lines. FGF-BP depletion reduces proliferation of the cells in vitro without changes in cell cycle distribution or apoptosis. Using cDNA microarrays, Northern blotting and RT-PCR, we show a complex pattern of changes in the gene expression profiles upon FGF-BP depletion. Most strikingly, ribozyme-mediated reduction of FGF-BP levels completely abolishes the ability of the highly metastatic PC-3 prostate carcinoma cells to grow tumors in an athymic nude mouse in vivo model which is far beyond the effects of FGF-BP ribozyme targeting observed previously in cells from other tumors in the same model. Taken together, our study identifies FGF-BP as a potential rate-limiting factor for prostate cancer growth and, due to its restricted expression pattern in adults, a potentially attractive target for prostate cancer therapy.	Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; JW Goethe Univ, Dept Med 1, Frankfurt, Germany	Philipps University Marburg; Fred Hutchinson Cancer Center; Goethe University Frankfurt	Aigner, A (corresponding author), Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2000, TOXICOLOGY, V144, P221, DOI 10.1016/S0300-483X(99)00210-3; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Aumuller G, 1999, PROSTATE, V38, P261; BEGUN FP, 1995, J UROLOGY, V153, P839, DOI 10.1016/S0022-5347(01)67732-2; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; CHACKALROY M, 1989, J CLIN INVEST, V84, P43, DOI 10.1172/JCI114167; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Giri D, 1999, CLIN CANCER RES, V5, P1063; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; LAROCCA RV, 1991, J UROLOGY, V145, P393, DOI 10.1016/S0022-5347(17)38351-9; Leung HY, 1996, ONCOGENE, V12, P1833; LiaudetCoopman EDE, 1996, BIOCHEM BIOPH RES CO, V229, P930, DOI 10.1006/bbrc.1996.1904; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Lieberman R, 2001, UROLOGY, V57, P4, DOI 10.1016/S0090-4295(00)00931-6; Martin R, 2000, J HISTOCHEM CYTOCHEM, V48, P1121, DOI 10.1177/002215540004800809; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; Middleman MN, 1996, CANCER TREAT REV, V22, P105, DOI 10.1016/S0305-7372(96)90030-4; MORI H, 1990, PROSTATE, V16, P71, DOI 10.1002/pros.2990160108; NAKAMOTO T, 1992, CANCER RES, V52, P571; NISHI N, 1988, PROSTATE, V13, P39, DOI 10.1002/pros.2990130105; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Ropiquet F, 2000, CANCER RES, V60, P4245; Ropiquet F, 1999, J UROLOGY, V162, P595, DOI 10.1016/S0022-5347(05)68632-6; Shain SA, 1996, CELL GROWTH DIFFER, V7, P573; Stoppler H, 2001, ONCOGENE, V20, P7430, DOI 10.1038/sj.onc.1204957; STORY MT, 1989, PROSTATE, V15, P355, DOI 10.1002/pros.2990150408; Thomas R, 2001, INT J CANCER, V93, P47, DOI 10.1002/ijc.1291; van Bokhoven A, 2001, PROSTATE, V47, P36; Webber MM, 1997, PROSTATE, V30, P58; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; Wellstein A, 1996, BREAST CANCER RES TR, V38, P109, DOI 10.1007/BF01803789; WU DQ, 1991, J BIOL CHEM, V266, P16778; YAGODA A, 1993, CANCER-AM CANCER SOC, V71, P1098, DOI 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	49	31	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5733	5742		10.1038/sj.onc.1205560	http://dx.doi.org/10.1038/sj.onc.1205560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173043				2022-12-25	WOS:000177463400008
J	Redeuilh, G; Attia, A; Mester, J; Sabbah, M				Redeuilh, G; Attia, A; Mester, J; Sabbah, M			Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases	ONCOGENE			English	Article						oestrogen receptor; p21(waf1); cell cycle; coactivators; cyclin-dependent kinases	CREB BINDING-PROTEIN; HISTONE ACETYLTRANSFERASE ACTIVITY; ESTROGEN-RECEPTOR; CELL-CYCLE; NUCLEAR RECEPTORS; BIOLOGICAL-ACTIVITY; P300 COACTIVATOR; DISTINCT ROLES; BREAST-CANCER; D1 EXPRESSION	We have investigated the interaction between the expression of p21(WAF1/CIP1/SDI1), a stoichiometric inhibitor of Cdk, and the transcriptional activity of the oestrogen receptor alpha (ERalpha). Transient transfection experiments demonstrated that the expression of p21(WAF1/CIP1/SDI1) amplified the transcriptional activation by ERalpha. A dominant negative mutant of Cdk2 also enhanced the ERa transcriptional activity, indicating that the underlying mechanism relies on the inhibition of Cdk2 activity and cell cycle arrest. In agreement with this conclusion, experiments with p21(WAF1/CIP1/SDI1) mutants demonstrated that the domain involved in the binding of p21(WAF1/CIP1/SDI1) to Cdks was indispensable for the modulation of ERa activity. In addition, we show that expression of p21(WAF1/CIP1/SDI1) alleviates the block on CBP function mediated by Cdk2 and in turn stimulates transcriptional activation by ERalpha in a CBP-histone acetyltransferase (HAT)-dependent manner. These results suggest a novel mechanism by which p21(WAF1/CIP1/SDI1) functions as an enhancer of ERalpha activity through the modulation of CBP function.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Sabbah, M (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	sabbah@st-antoine.inserm.fr		SABBAH, Michele/0000-0001-5368-9022				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Altucci L, 1996, ONCOGENE, V12, P2315; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Auwerx J, 1999, CELL, V97, P161; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XM, 2000, J NATL CANCER I, V92, P1403, DOI 10.1093/jnci/92.17.1403; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GAGNE D, 1994, J BIOLUM CHEMILUM, V9, P201, DOI 10.1002/bio.1170090314; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMAN T, 1995, CANCER RES, V55, P5187; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	69	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5773	5782		10.1038/sj.onc.1205753	http://dx.doi.org/10.1038/sj.onc.1205753			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173048				2022-12-25	WOS:000177463400013
J	Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R				Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R			Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair	ONCOGENE			English	Article						transcription-coupled nucleotide excision repair; DNA mismatch repair; ligation mediated PCR; cyclobutane pyrimidine dieter	COCKAYNE-SYNDROME; TUMOR-CELLS; UV; INVOLVEMENT; SUNLIGHT; LIGHT; MSH2; PHOTOPRODUCTS; DEFICIENCY; POLYMERASE	The transcription-coupled nucleotide excision repair (TONER) pathway maintains genomic stability by rapidly eliminating helix-distorting DNA adducts, such as UV-induced cyclobutane pyrimidine dimers (CPDs), specifically from the transcribed strands of active genes. DNA mismatch repair (MMR) constitutes yet another critical antimutagenic pathway that removes mispaired bases generated during semiconservative replication. It was previously reported that the human colon adenocarcinoma strains HCT11G and LoVo (bearing homozygous mutations in the MMR genes hMLH1 and hMSH2, respectively), besides manifesting hallmark phenotypes associated with defective DNA mismatch correction, are also completely deficient in TONER of UV-induced CPDs. This revealed a direct mechanistic link between MMR and TONER in human cells, although subsequent studies have either supported, or argued against, the validity of this important notion. Here, the ligation-mediated polymerase chain reaction was used to show at nucleotide resolution that MMR-deficient HCT11G and LoVo retain the ability to excise UV-induced CPDs much more rapidly from the transcribed vs the nontranscribed strands of active genes. Moreover, relative to DNA repair-proficient counterparts, MMR-deficient cells were not more sensitive to the cytotoxic effects of UV, and displayed equal ability to recover mRNA synthesis following UV challenge. These results conclusively demonstrate that hMLH1- and hMSH2-deficient human colon adenocarcinoma cells are fully proficient in TONER.	Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada; Univ Quebec, Cent Hosp, Hop St Francois Assise, Unite Rech Genet Humaine & Mol,Res Ctr, Quebec City, PQ G1L 3L5, Canada; Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1Y 4K7, Canada; Hop Maison Neuve Rosemont, Ctr Rech Guy Bernier, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Fac Med, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Laval University; Laval University; University of Quebec; University of Ottawa; Ottawa Hospital Research Institute; Universite de Montreal; Universite de Montreal	Drobetsky, EA (corresponding author), Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada.	regen.drouin@crsfa.ulaval.ca	Rochette, Patrick/HHN-2300-2022; Therrien, Jean-Philippe/AAW-8912-2021; McKay, Bruce C/I-4081-2013	Therrien, Jean-Philippe/0000-0001-5878-6841; McKay, Bruce C/0000-0002-7921-1331; Rochette, Patrick/0000-0002-0678-8869				Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; AFZAL V, 1995, MUTAGENESIS, V10, P457, DOI 10.1093/mutage/10.5.457; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; Angers M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e83; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; Drouin R, 2001, Methods Mol Biol, V148, P175; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fleck O, 1999, NAT GENET, V21, P314, DOI 10.1038/6838; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KOI M, 1994, CANCER RES, V54, P4308; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; Ljungman M, 1996, ONCOGENE, V13, P823; MAYNE LV, 1982, CANCER RES, V42, P1473; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Reitmair AH, 1997, CANCER RES, V57, P3765; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; Sonneveld E, 2001, ONCOGENE, V20, P538, DOI 10.1038/sj.onc.1204125; Sweder KS, 1996, GENETICS, V143, P1127; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Therrien JP, 2001, CANCER RES, V61, P3781; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174	42	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5743	5752		10.1038/sj.onc.1205641	http://dx.doi.org/10.1038/sj.onc.1205641			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173044				2022-12-25	WOS:000177463400009
J	Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S				Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S			Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array	ONCOGENE			English	Article						cDNA array; RT-PCR; adenocarcinoma; lung cancer	CELL LUNG-CANCER; POLO-LIKE KINASE; TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; MALIGNANT MESOTHELIOMA; HYDROCARBON RECEPTOR; ENDOTHELIAL-CELLS; TISSUE INHIBITOR	No clear patterns in molecular changes underlying the malignant processes in lung cancer of different histological types have been found so far. To identify critical genes in lung cancer progression we compared the expression profile of cancer related genes in 14 pulmonary adenocarcinoma patients with normal lung tissue by using the cDNA array technique. Principal component analyses (PCA) and permutation test were used to detect the differentially expressed genes. The expression profiles of 10 genes were confirmed by semiquantitative real-time RT-PCR. In tumour samples, as compared to normal lung tissue, the up-regulated genes included such known tumour markers as CCNB1, PLK, tenascin, KRT8, KRT19 and TOP2A. The down-regulated genes included caveolin 1 and 2, and TIMP3. We also describe, for the first time, down-regulation of the interesting SOCS2 and 3, DOC2 and gravin. We show that silencing of SOCS2 is not caused by methylation of exon 1 of the gene. In conclusion, by using the cDNA array technique we were able to reveal marked differences in the gene expression level between normal lung and tumour tissue and find possible new tumour markers for pulmonary adenocarcinoma.	Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Finnish Inst Occupat Hlth, Dept Occupat Med, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Aalto University; Finnish Institute of Occupational Health	Knuutila, S (corresponding author), Haartman Inst, Dept Med Genet, POB 21, FIN-00014 Helsinki, Finland.			Wikman, Harriet/0000-0001-6862-0888				Aalto Y, 2001, LEUKEMIA, V15, P1721, DOI 10.1038/sj.leu.2402282; Anbazhagan R, 1999, CANCER RES, V59, P5119; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bjorkqvist AM, 1998, BRIT J CANCER, V77, P260, DOI 10.1038/bjc.1998.42; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; Chen JJW, 2001, CANCER RES, V61, P5223; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Cilley RE, 2000, J PEDIATR SURG, V35, P113, DOI 10.1016/S0022-3468(00)80026-3; Diviani D, 2001, J CELL SCI, V114, P1431; Dohmoto K, 2000, LUNG CANCER-J IASLC, V30, P55, DOI 10.1016/S0169-5002(00)00125-2; Dohr O, 1997, MOL PHARMACOL, V51, P703, DOI 10.1124/mol.51.5.703; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; EVERETT AD, 2001, J BIOL CHEM, V31, P31; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Hand D. J., 2001, ADAPTIVE COMPUTATION; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hellmann GM, 2001, TOXICOL SCI, V61, P154, DOI 10.1093/toxsci/61.1.154; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Huang Y, 2001, LAB INVEST, V81, P863, DOI 10.1038/labinvest.3780295; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Karameris A, 1997, AM J RESP CRIT CARE, V156, P1930, DOI 10.1164/ajrccm.156.6.9612046; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Kellner U, 2000, ONKOLOGIE, V23, P424, DOI 10.1159/000027205; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kishimoto T, 2001, NAT GENET, V28, P4, DOI 10.1038/88244; Kojima S, 2000, BLOOD, V95, P1309; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee IH, 1997, MOL CELLS, V7, P589; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; Nhung N V, 1999, Cesk Patol, V35, P80; Nishihira J, 1998, INT J MOL MED, V2, P17; PENDLETON N, 1994, EUR J CANCER, V1, P93; PINES J, 1992, CIBA F SYMP, V170, P187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; RAZANI B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241; Reeves R, 1995, Prog Cell Cycle Res, V1, P339; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Soria JC, 2000, CANCER RES, V60, P4000; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; Thomas P, 2000, J PATHOL, V190, P150; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tuder RM, 2001, EUR RESPIR J, V17, P1065, DOI 10.1183/09031936.01.00202701; Ueki T, 2000, CANCER RES, V60, P1835; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wilson MJ, 2000, IMMUNOL RES, V22, P21, DOI 10.1385/IR:22:1:21; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wolf M, 2000, CANCER GENET CYTOGEN, V123, P128, DOI 10.1016/S0165-4608(00)00319-8; Xia W, 2001, CANCER RES, V61, P5644; Xiao S, 1997, AM J PATHOL, V150, P901; Ylisirnio S, 2001, CLIN CANCER RES, V7, P1633; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	84	148	164	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5804	5813		10.1038/sj.onc.1205726	http://dx.doi.org/10.1038/sj.onc.1205726			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173052				2022-12-25	WOS:000177463400017
J	Sun, HJ; Unoki, H; Wang, XF; Liang, JY; Ichikawa, T; Arai, Y; Shiomi, M; Marcovina, SM; Watanabe, T; Fan, JL				Sun, HJ; Unoki, H; Wang, XF; Liang, JY; Ichikawa, T; Arai, Y; Shiomi, M; Marcovina, SM; Watanabe, T; Fan, JL			Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; LOW-DENSITY LIPOPROTEINS; RISK FACTOR; ARTERIAL CALCIFICATION; LDL RECEPTOR; IN-VITRO; MICE; LESIONS; ASSOCIATION; PLASMA	High lipoprotein(a) (Lp(a)) levels are a major risk factor for the development of atherosclerosis. The risk of elevated Lp(a) concentration is increased significantly in patients who also have high levels of low density lipoprotein (LDL) cholesterol. To test the hypothesis that increased plasma levels of Lp(a) may enhance the development of atherosclerosis in the setting of hypercholesterolemia, we generated Watanabe heritable hyperlipidemic (WHHL) transgenic (Tg) rabbits expressing human apolipoprotein(a) (apo(a)). We report here that Tg WHHL rabbits developed more extensive advanced atherosclerotic lesions than did non-Tg WHHL rabbits. In particular, the advanced atherosclerotic lesions in Tg WHHL rabbits were frequently associated with calcification, which was barely evident in non-Tg WHHL rabbits. To investigate the molecular mechanism of Lp(a)-induced vascular calcification, we examined the effect of human Lp(a) on cultured rabbit aortic smooth muscle cells and found that smooth muscle cells treated with Lp(a) showed increased alkaline phosphatase activity and enhanced calcium accumulation. These results demonstrate for the first time that Lp(a) accelerates advanced atherosclerotic lesion formation and may play an important role in vascular calcification.	Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Lab Cardiovasc Dis, Tsukuba, Ibaraki 3058575, Japan; Kobe Univ, Sch Med, Inst Expt Anim, Kobe, Hyogo 6500017, Japan; Univ Washington, Dept Med, NW Lipid Res Labs, Seattle, WA 98103 USA; Saga Med Sch, Saga 8498501, Japan	University of Tsukuba; Kobe University; University of Washington; University of Washington Seattle; Saga University	Fan, JL (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Lab Cardiovasc Dis, Tsukuba, Ibaraki 3058575, Japan.		Unoki-Kubota, Hiroyuki/H-7268-2019; Liang, Jingyan/F-6630-2014	Unoki-Kubota, Hiroyuki/0000-0003-4827-8805; Fan, Jianglin/0000-0002-1737-6130				ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; Cantin B, 1998, J AM COLL CARDIOL, V31, P519, DOI 10.1016/S0735-1097(97)00528-7; CHIESA G, 1992, J BIOL CHEM, V267, P24369; Dangas G, 1998, J AM COLL CARDIOL, V32, P2035, DOI 10.1016/S0735-1097(98)00469-0; DEMER LL, 1991, CIRCULATION, V83, P2083, DOI 10.1161/01.CIR.83.6.2083; Djurovic S, 1997, CLIN GENET, V52, P281; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Edelstein C, 2001, ANAL BIOCHEM, V288, P201, DOI 10.1006/abio.2000.4904; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; Fan JL, 1999, BIOCHEM BIOPH RES CO, V255, P639, DOI 10.1006/bbrc.1999.0242; Fan JL, 2000, J LIPID RES, V41, P1004; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; Galle J, 1999, KIDNEY INT, V55, P1450, DOI 10.1046/j.1523-1755.1999.00351.x; GUREWICH V, 1994, JAMA-J AM MED ASSOC, V271, P1025, DOI 10.1001/jama.271.13.1025; HANSEN PR, 1994, EUR J CLIN INVEST, V24, P497, DOI 10.1111/j.1365-2362.1994.tb02381.x; Hsu HHT, 2000, ATHEROSCLEROSIS, V153, P337, DOI 10.1016/S0021-9150(00)00425-1; Ichikawa T, 2002, AM J PATHOL, V160, P227, DOI 10.1016/S0002-9440(10)64366-0; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; KROON PA, 1985, ATHEROSCLEROSIS, V56, P323, DOI 10.1016/0021-9150(85)90007-3; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; Lawn RM, 1996, J BIOL CHEM, V271, P31367, DOI 10.1074/jbc.271.49.31367; LIU AC, 1994, J LIPID RES, V35, P2263; MAHER VMG, 1995, CURR OPIN LIPIDOL, V6, P229, DOI 10.1097/00041433-199508000-00007; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; Marcovina SM, 1998, AM J CARDIOL, V82, p57U, DOI 10.1016/S0002-9149(98)00954-0; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Parhami F, 2001, Z Kardiol, V90 Suppl 3, P27; Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Rouy D, 1998, J BIOL CHEM, V273, P1247, DOI 10.1074/jbc.273.2.1247; Sanan DA, 1998, P NATL ACAD SCI USA, V95, P4544, DOI 10.1073/pnas.95.8.4544; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433-200110000-00012; UTERMANN G, 1995, METABOLIC MOL BASES, P1887; Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	43	55	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47486	47492		10.1074/jbc.M205814200	http://dx.doi.org/10.1074/jbc.M205814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12196525	hybrid			2022-12-25	WOS:000179663700085
J	Zhang, JS; Ferreira, C				Zhang, JS; Ferreira, C			Transient state kinetic investigation of 5-aminolevulinate synthase reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE COFACTOR; DELTA-AMINOLEVULINATE SYNTHASE; O-ACETYLSERINE SULFHYDRYLASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 8-AMINO-7-OXONONANOATE SYNTHASE; DIALKYLGLYCINE DECARBOXYLASE; SERINE PALMITOYLTRANSFERASE; ASPARTATE-AMINOTRANSFERASE; CONFORMATIONAL CHANGE	5-Aminolevulinate synthase (ALAS), a pyridoxal 5'-phosphate-dependent enzyme, catalyzes the first, and regulatory, step of the heme biosynthetic pathway in nonplant eukaryotes and some bacteria. 5-Aminolevulinate synthase is a dimeric protein having an ordered kinetic mechanism with glycine binding before succinyl-CoA and with aminolevulinate release after CoA and carbon dioxide. Rapid scanning stopped-flow absorption spectrophotometry in conjunction with multiple turnover chemical quenched-flow kinetic analyses and a newly developed CoA detection method were use to examine the ALAS catalytic reaction and identify the rate-determining step. The reaction of glycine with ALAS follows a three-step kinetic process, ascribed to the formation of the Michaelis complex and the pyridoxal 5'-phosphate-glycine aldimine, followed by the abstraction of the glycine pro-R proton from the external aldimine. Significantly, the rate associated with this third step (k(3) = 0.002 s(-1)) is consistent with the rate determined for the ALAS-catalyzed removal of tritium from [2-H-3(2)]glycine. Succinyl-CoA and acetoacetyl-CoA increased the rate of glycine proton removal similar to250,000 and 10-fold, respectively, supporting our previous proposal that the physiological substrate, succinyl-CoA, promotes a protein conformational change, which accelerates the conversion of the external aldimine into the initial quinonoid intermediate (Hunter, G. A., and Ferreira, G. C. (1999) J. Biol. Chem. 274,12222-12228). Rapid scanning stopped-flow and quenched-flow kinetic analyses of the ALAS reaction under single turnover conditions lend evidence for two quinonoid reaction intermediates and a model of the ALAS kinetic mechanism in which product release is at least the partially rate-limiting step. Finally, the carbonyl and carboxylate groups of 5-aminolevulinate play a major protein-interacting role by inducing a conformational change in ALAS and, thus, possibly modulating product release.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ferreira, C (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.				NIDDK NIH HHS [R01 DK063191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD MM, 1974, J CHEM SOC CHEM COMM, P643, DOI 10.1039/c39740000643; AHKTAR M, 1979, COMPREHENSIVE ORGANI, V5, P1121; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1022; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Cheltsov AV, 2001, J BIOL CHEM, V276, P19141, DOI 10.1074/jbc.M100329200; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; FANICAGA.M, 1973, EUR J BIOCHEM, V40, P19, DOI 10.1111/j.1432-1033.1973.tb03164.x; Farazi TA, 2000, BIOCHEMISTRY-US, V39, P15807, DOI 10.1021/bi002074t; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P151, DOI 10.1007/BF02110030; FERREIRA GC, 1993, J BIOL CHEM, V268, P585; Ferreira GC., 1999, IRON METABOLISM, P15, DOI [10.1002/9783527613700.CH02., DOI 10.1002/9783527613700.CH02]; FERSHT A, 1998, STRUCTURE MECH PROTE, P152; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gong J, 1998, BIOCHEMISTRY-US, V37, P3509, DOI 10.1021/bi9719298; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hayashi H, 1999, BIOCHEMISTRY-US, V38, P15615, DOI 10.1021/bi9909795; HUNTER GA, 1995, ANAL BIOCHEM, V226, P221, DOI 10.1006/abio.1995.1217; Hunter GA, 1999, BIOCHEMISTRY-US, V38, P3711, DOI 10.1021/bi982390w; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; Ikushiro H, 2001, J BIOL CHEM, V276, P18249, DOI 10.1074/jbc.M101550200; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P61; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGHAI A, 1977, BIOCHEM SOC T, V5, P299, DOI 10.1042/bst0050299; LIEN LF, 1982, ENZYME, V28, P120; MATHESON IBC, 1990, COMPUT CHEM, V14, P49, DOI 10.1016/0097-8485(90)80007-O; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MILES EW, 1994, ADV LIF SCI-SERIES, P113; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; NANDI DL, 1978, J BIOL CHEM, V253, P8872; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; Schmidt A, 2001, BIOCHEMISTRY-US, V40, P5151, DOI 10.1021/bi002204y; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Sun SX, 1998, BIOCHEMISTRY-US, V37, P3876, DOI 10.1021/bi972056k; Tan DW, 1996, BIOCHEMISTRY-US, V35, P8934, DOI 10.1021/bi952918m; Tan DW, 1998, BIOCHEMISTRY-US, V37, P1478, DOI 10.1021/bi971928f; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; ZAMAN Z, 1973, BIOCHEM J, V135, P257, DOI 10.1042/bj1350257; Zhou XZ, 2001, BIOCHEMISTRY-US, V40, P1367, DOI 10.1021/bi001237a	47	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44660	44669		10.1074/jbc.M203584200	http://dx.doi.org/10.1074/jbc.M203584200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12191993	Green Accepted, hybrid			2022-12-25	WOS:000179404800010
J	Cramer, J; Strerath, M; Marx, A; Restle, T				Cramer, J; Strerath, M; Marx, A; Restle, T			Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FIDELITY; STERIC HINDRANCE; 3TC RESISTANCE; SUBSTRATE; MECHANISM; SELECTIVITY; INFIDELITY; INHIBITORS; KINETICS; SUGAR	To examine the concept of polymerase active site tightness as a criteria for DNA polymerase fidelity, we performed pre-steady-state single nucleotide incorporation kinetic analyses with sugar modified thymidine 5'- triphosphate (TTP) analogues and human immunodeficiency virus (HIV-1) reverse transcriptase (RT). The employed TTP analogues (TTP) are modified at the 4'-position of the sugar moiety with alkyl groups, gradually expanding their steric demand. Introduction of a methyl group reduces the maximum rate of nucleotide incorporation by about 200-fold for RTWT and about 400-fold for RTM184V. Interestingly, the affinity of RT for the modified nucleotide is only marginally affected. Increasing the size to an ethyl group leads to further reduction of the rate of incorporation and first effects on binding affinities are observed. Finally, substitution for an isopropyl group results not only in a further reduction of I. incorporation rates but also in a dramatic loss of bin,ding affinity for the nucleotide analogue. By increasing the steric demand the effects on RTM184V in comparison with RTWT become progressively more pronounced. Mis-incorporation of either TTP or (TTP)-T-Me opposite a template G causes additional decline in incorporation rates accompanied by a drastic decrease in binding affinities. This results in relative incorporation efficiencies [(k(pol)/K-d)(incorrect)/(k(pol)/K-d)(TTPcorrect)] of of 4.1 X 10(-5) for TTP and 3.4 X 10(-6) for (TTP)-T-Me in case of RTWT and 1.4 X 10(-5) for TTP and 2.9 X 10(-8) for (TTP)-T-Me in case of RTM184V.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Max Planck Society; University of Bonn	Restle, T (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Beard WA, 2001, NAT STRUCT BIOL, V8, P915, DOI 10.1038/nsb1101-915; Creighton S, 1995, METHOD ENZYMOL, V262, P232; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Ellenberger T, 2001, NAT STRUCT BIOL, V8, P827, DOI 10.1038/nsb1001-827; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Marx A, 2002, CHEMBIOCHEM, V3, P405, DOI 10.1002/1439-7633(20020503)3:5<405::AID-CBIC405>3.0.CO;2-4; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Morales JC, 2000, J AM CHEM SOC, V122, P1001, DOI 10.1021/ja993464+; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; MULLER B, 1989, J BIOL CHEM, V264, P13975; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; Patel PH, 2001, NAT STRUCT BIOL, V8, P656, DOI 10.1038/90344; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Souquet M, 1998, BIOCHEMISTRY-US, V37, P12144, DOI 10.1021/bi9731596; Strerath M, 2002, CHEMBIOCHEM, V3, P578, DOI 10.1002/1439-7633(20020603)3:6<578::AID-CBIC578>3.0.CO;2-W; Strerath M, 2002, J AM CHEM SOC, V124, P11230, DOI 10.1021/ja027060k; Summerer D, 2001, ANGEW CHEM INT EDIT, V40, P3693, DOI 10.1002/1521-3773(20011001)40:19<3693::AID-ANIE3693>3.0.CO;2-O; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057	40	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43593	43598		10.1074/jbc.M207854200	http://dx.doi.org/10.1074/jbc.M207854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200452	Green Published, hybrid			2022-12-25	WOS:000179272000009
J	Sivaraman, J; Sauve, V; Matte, A; Cygler, M				Sivaraman, J; Sauve, V; Matte, A; Cygler, M			Crystal structure of Escherichia coli glucose-1-phosphate thymidylyltransferase (RffH) complexed with dTTP and Mg2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; RFB GENE-CLUSTER; CATALYTIC MECHANISM; BIOSYNTHESIS REGION; PATHWAY; PYROPHOSPHORYLASE; MOLSCRIPT; SOFTWARE; LOCATION; GLMU	The enzyme glucose-1-phosphate thymidylyltransferase (RffH), the product of the rffh gene, catalyzes one of the steps in the synthesis of enterobacterial common antigen (ECA), a cell surface glycolipid found in Gram-negative enteric bacteria. In Escherichia coli two gene products, RffH and Rm1A, catalyze the same enzymatic reaction and are homologous in sequence; however, they are part of different operons and function in different pathways. We report the crystal structure of RffH bound to deoxythymidine triphosphate (dTTP), the phosphate donor, and Mg2+, refined at 2.6 Angstrom to an R-factor of 22.3% (R-free = 28.4%). The crystal structure of RffH shows a tetrameric enzyme best described as a dimer of dimers. Each monomer has an overall alpha/beta fold and consists of two domains, a larger nucleotide binding domain (residues 1-115, 222-291) and a smaller sugar-binding domain (116-221), with the active site located at the domain interface. The Mg2+ ion is coordinated by two conserved aspartates and the alpha-phosphate of deoxythymidine triphosphate. Its location corresponds well to that in a structurally similar domain of N-acetylglucosamine-1-phosphate uridylyltransferase (GlmU). Analysis of the RffH, RmIA, and GlmU complexes with substrates and products provides an explanation for their different affinities for Mg2+ and leads to a proposal for the dynamics along the reaction pathway.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; McGill University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Sivaraman, J/H-8028-2012	J, Sivaraman/0000-0001-9781-5326				Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; BERNSTEI.RL, 1965, J BIOL CHEM, V240, P391; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Godfroid F, 2000, RES MICROBIOL, V151, P655, DOI 10.1016/S0923-2508(00)90130-X; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kostrewa D, 2001, J MOL BIOL, V305, P279, DOI 10.1006/jmbi.2000.4296; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; SHEU KFR, 1979, BIOCHEMISTRY-US, V18, P5548, DOI 10.1021/bi00592a004; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; STEVENSON G, 1991, MOL GEN GENET, V227, P173, DOI 10.1007/BF00259668; Tsukioka Y, 1997, J BACTERIOL, V179, P1126, DOI 10.1128/jb.179.4.1126-1134.1997; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	26	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44214	44219		10.1074/jbc.M206932200	http://dx.doi.org/10.1074/jbc.M206932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12171937	hybrid			2022-12-25	WOS:000179272000089
J	Karni, R; Dor, Y; Keshet, E; Meyuhas, O; Levitzki, A				Karni, R; Dor, Y; Keshet, E; Meyuhas, O; Levitzki, A			Activated pp60(c-Src) leads to elevated hypoxia-inducible factor (HIF)-1 alpha expression under normoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; TYROSINE KINASE INHIBITOR; TUMOR-SUPPRESSOR PROTEIN; C-SRC; FACTOR-I; MESSENGER-RNA; CELL-LINE; INDUCTION; HIF-1	Hypoxia-inducible factor (HIF)-1 is a master transcription factor, which up-regulates glycolysis, erythropoiesis, and angiogenesis under hypoxia. HIF-1alpha accumulates in normoxic tumor cells, leading to glycolysis under aerobic conditions. This phenomenon, known as the "Warburg effect," is caused by a yet unknown mechanism. Here we show that transformed cells that express constitutively active pp60(c-Src) (Src) express HIF-1alpha protein under normoxia, which results in the expression of multiple HIF-1alpha target genes. We show that this occurrence is due to an enhanced rate of HIF-1alpha protein synthesis and not due to reduced HIF-1alpha degradation. Furthermore, we show that the Src-induced increase in protein synthesis is due to the global increase in the rate of cap-dependent translation and does not involve inhibition of HIF-1alpha degradation.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biol Mol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.		Dor, Yuval/C-2405-2011; Keshet, Eli/GQR-0445-2022					CARROLL RC, 1978, P NATL ACAD SCI USA, V75, P5015, DOI 10.1073/pnas.75.10.5015; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Feldser D, 1999, CANCER RES, V59, P3915; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gleadle JM, 1997, BLOOD, V89, P503, DOI 10.1182/blood.V89.2.503; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Jiang BH, 1997, CANCER RES, V57, P5328; Krystal GW, 1998, CANCER RES, V58, P4660; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Li SL, 1996, CELL BIOL INT, V20, P723; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Seko Y, 1996, BIOCHEM BIOPH RES CO, V226, P530, DOI 10.1006/bbrc.1996.1389; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830	35	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42919	42925		10.1074/jbc.M206141200	http://dx.doi.org/10.1074/jbc.M206141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200433	hybrid			2022-12-25	WOS:000179081200065
J	Cybulsky, AV; Takano, T; Papillon, J; Khadir, A; Liu, JH; Peng, HW				Cybulsky, AV; Takano, T; Papillon, J; Khadir, A; Liu, JH; Peng, HW			Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PASSIVE HEYMANN NEPHRITIS; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; NUCLEATED CELLS; ACTIVATION; NEPHROPATHY; INJURY; DEATH; RATS	In the passive Heymann nephritis (PHN) model of membranous nephropathy, complement C5b-9 induces glomerular epithelial cell (GEC) injury, proteinuria, and activation of cytosolic phospholipase A(2) (cPLA(2)). This study addresses the role of endoplasmic reticulum (ER) stress proteins (bip, grp94) in GEC injury. GEC that overexpress cPLA(2) (produced by transfection) and "neo" GEC (which expresses cPLA(2) at a lower level) were incubated with complement (40 min), and leakage of constitutively expressed bip and grp94 from ER into cytosol was measured to monitor ER injury. Greater leakage of bip and grp94 occurred in complement-treated GEC that overexpress cPLA(2), as compared with neo, implying that cPLA(2) activation perturbed ER membrane integrity. After chronic incubation (4-24 h), C5b-9 increased bip and grp94 mRNAs and proteins, and the increases were dependent on cPLA(2). Expression of bip-antisense mRNA reduced stimulated bip protein expression and enhanced complement-dependent GEC injury. Glomerular hip and grp94 proteins were up-regulated in proteinuric rats with PHN, as compared with normal control. Pretreatment of rats with tunicamycin or adriamycin, which increase ER stress protein expression, reduced proteinuria in PHN. Thus, C5b-9 injures the ER and enhances ER stress protein expression, in part, via activation of cPLA(2). ER stress protein induction is a novel mechanism of protection from complement attack.	McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Cybulsky, AV (corresponding author), Royal Victoria Hosp, Div Nephrol, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	andrey.cybulsky@mcgill.ca	Cybulsky, Andrey V./AAG-8238-2020	Cybulsky, Andrey V./0000-0003-4348-2348				BAKER PJ, 1989, AM J PATHOL, V135, P185; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CYBULSKY AV, 1986, J CLIN INVEST, V77, P1096, DOI 10.1172/JCI112408; CYBULSKY AV, 1986, J IMMUNOL, V137, P1511; CYBULSKY AV, 1987, AM J PATHOL, V128, P45; Cybulsky AV, 2000, KIDNEY INT, V57, P1052, DOI 10.1046/j.1523-1755.2000.00932.x; CYBULSKY AV, 1995, AM J PHYSIOL-RENAL, V269, pF739, DOI 10.1152/ajprenal.1995.269.5.F739; Cybulsky AV, 1998, KIDNEY INT, V54, P360, DOI 10.1046/j.1523-1755.1998.00013.x; Cybulsky AV, 1999, AM J PATHOL, V155, P1701, DOI 10.1016/S0002-9440(10)65485-5; CYBULSKY AV, 2000, KIDNEY PHYSL PATHOPH, P2645; Dessen A, 2000, BBA-MOL CELL BIOL L, V1488, P40, DOI 10.1016/S1388-1981(00)00108-6; GOLBETZ H, 1989, AM J PHYSIOL, V256, pF44, DOI 10.1152/ajprenal.1989.256.1.F44; GROND J, 1984, LAB INVEST, V51, P277; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; Kilgore KS, 1997, AM J PATHOL, V150, P2019; KIRSCHENBAUM MA, 1985, PROSTAGLANDINS, V30, P295, DOI 10.1016/0090-6980(85)90192-3; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Liu JH, 2001, BIOCHEM J, V353, P79, DOI 10.1042/bj3530079; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; Nagao T, 1996, EUR J PHARMACOL, V316, P73, DOI 10.1016/S0014-2999(96)00662-0; NICHOLSONWELLER A, 1993, IMMUNOL RES, V12, P244, DOI 10.1007/BF02918256; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; Niculescu F, 1997, J IMMUNOL, V158, P4405; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Panesar M, 1997, J IMMUNOL, V159, P3584; PAPADIMITRIOU JC, 1994, CELL CALCIUM, V15, P217, DOI 10.1016/0143-4160(94)90061-2; PAPADIMITRIOU JC, 1991, J IMMUNOL, V147, P212; PAPADIMITRIOU JC, 1994, VIRCHOWS ARCH, V424, P677, DOI 10.1007/BF01069750; PRUCHNO CJ, 1991, AM J PATHOL, V138, P203; QUIGG RJ, 1988, KIDNEY INT, V34, P43, DOI 10.1038/ki.1988.143; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Rus HG, 1996, J IMMUNOL, V156, P4892; SALANT DJ, 1988, METHOD ENZYMOL, V162, P421; Samstein B, 2001, J AM SOC NEPHROL, V12, P182, DOI 10.1681/ASN.V121182; Shankland SJ, 1999, KIDNEY INT, V56, P538, DOI 10.1046/j.1523-1755.1999.00560.x; Takano T, 2000, AM J PATHOL, V156, P2091, DOI 10.1016/S0002-9440(10)65080-8; Tisher CC, 2000, J AM SOC NEPHROL, V11, P183; Topham PS, 1999, KIDNEY INT, V55, P1763, DOI 10.1046/j.1523-1755.1999.00407.x; WEISE WJ, 1993, KIDNEY INT, V43, P359, DOI 10.1038/ki.1993.54; Yedgar S, 2000, BBA-MOL CELL BIOL L, V1488, P182, DOI 10.1016/S1388-1981(00)00120-7; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; ZOJA C, 1987, KIDNEY INT, V31, P1335, DOI 10.1038/ki.1987.147	52	98	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41342	41351		10.1074/jbc.M204694200	http://dx.doi.org/10.1074/jbc.M204694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12191998	hybrid			2022-12-25	WOS:000178985300009
J	Hager, J; Staker, BL; Bugl, H; Jakob, U				Hager, J; Staker, BL; Bugl, H; Jakob, U			Active site in RrmJ, a heat shock-induced methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; MESSENGER-RNA; STIMULATORY ACTIVITIES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; VACCINIA VIRUS; PROTEIN; BINDING	The heat shock protein RrmJ (FtsJ), highly conserved from eubacteria to eukarya, is responsible for the 2'-O-ribose methylation of the universally conserved base U2552 in the A-loop of the 23 S rRNA. Absence of this methylation, which occurs late in the maturation process of the ribosome, appears to cause the destabilization and premature dissociation of the 50 S ribosomal subunit. To understand the mechanism of 2'-O-ribose methyltransfer reactions, we characterized the enzymatic parameters of RrmJ and conducted site-specific mutagenesis of RrmJ. A structure based sequence alignment with VP39, a structurally related 2'-O-methyltransferase from vaccinia virus, guided our mutagenesis studies. We analyzed the function of our RrmJ mutants in vivo and characterized the methyltransfer reaction of the purified proteins in vitro. The active site of RrmJ appears to be formed by a catalytic triad consisting of two lysine residues, Lys-38 and Lys-164, and the negatively charged residue Asp-124. Another highly conserved residue, Glu-199, that is present in the active site of RrmJ and VP39 appears to play only a minor role in the methyltransfer reaction in vivo. Based on these results, a reaction mechanism for the methyltransfer activity of RrmJ is proposed.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Emerald BioStruct Inc, W Bainbridge Isl, WA 98110 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	ujakob@umich.edu		Staker, Bart/0000-0001-9570-5086				Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BJOERK GR, 1996, CELLULAR MOL BIOL, P861; Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6; Bujnicki JM, 2001, GENOME BIOL, V2; Bujnicki JM, 2002, J MOL MICROB BIOTECH, V4, P93; Caldas T, 2000, J BIOL CHEM, V275, P16414, DOI 10.1074/jbc.M001854200; Caldas T, 2000, BIOCHEM BIOPH RES CO, V271, P714, DOI 10.1006/bbrc.2000.2702; DENOYA CD, 1987, J BACTERIOL, V169, P3857, DOI 10.1128/jb.169.8.3857-3860.1987; FERSHT A, 2000, STRUCTURE MECH PROTE, P188; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; Hansen MA, 2002, RNA, V8, P202, DOI 10.1017/S1355838202013365; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HODEL AE, 1999, S ADENOSYLMETHIONINE, P255; Hu GH, 2002, BIOCHEMISTRY-US, V41, P7677, DOI 10.1021/bi0201926; JEFFERY DR, 1987, BIOCHEMISTRY-US, V26, P2955, DOI 10.1021/bi00384a042; Lovgren JM, 2001, J BACTERIOL, V183, P6957, DOI 10.1128/JB.183.23.6957-6960.2001; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Pintard L, 2002, EMBO J, V21, P1139, DOI 10.1093/emboj/21.5.1139; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; Vidgren J., 1999, S ADENOSYLMETHIONINE, P55; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317	28	71	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41978	41986		10.1074/jbc.M205423200	http://dx.doi.org/10.1074/jbc.M205423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12181314	hybrid			2022-12-25	WOS:000178985300087
J	Jensen, ML; Timmermann, DB; Johansen, TH; Schousboe, A; Varming, T; Ahring, PK				Jensen, ML; Timmermann, DB; Johansen, TH; Schousboe, A; Varming, T; Ahring, PK			The beta subunit determines the ion selectivity of the GABA(A) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; A RECEPTORS; CHANNEL; STOICHIOMETRY; SUPERFAMILY; MUTAGENESIS; EXPRESSION; LOCATION; REGION	The gamma-aminobutyric acid, type A (GABA(A)) receptor is a chloride-conducting receptor composed of alpha, beta, and gamma subunits assembled in a pentameric structure forming a central pore. Each subunit has a large extracellular agonist binding domain and four transmembrane domains (M1-M4), with the second transmembrane (M2) domain lining the pore. Mutation of five amino acids in the M1-M2 loop of the beta(3) subunit to the corresponding amino acids of the alpha(7) nicotinic acetylcholine subunit rendered the GABA(A) receptor cation-selective upon co-expression with wild type alpha2 and gamma2 subunits. Similar mutations in the a2 or gamma2 subunits did not lead to such a change in ion selectivity. This suggests a unique role for the beta(3) subunit in determining the ion selectivity of the GABA(A) receptor. The pharmacology of the mutated GABA(A) receptor is similar to that of the wild type receptor, with respect to muscimol binding, Zn2+ and bicuculline sensitivity, flumazenil binding, and potentiation of GABA-evoked currents by diazepam. There was, however, an increase in GABA sensitivity (EC50 = 1.3 mum) compared with the wild type receptor (EC50 = 6.4 mum) and a loss of desensitization to GABA of the mutant receptor.	NeuroSearch AS, DK-2750 Ballerup, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Royal Danish School of Pharmacy	Ahring, PK (corresponding author), NeuroSearch AS, Pederstrupvej 93, DK-2750 Ballerup, Denmark.			Ahring, Joergen Philip Kiaer/0000-0003-1807-3331				Barry PH, 1999, CLIN EXP PHARMACOL P, V26, P935, DOI 10.1046/j.1440-1681.1999.03149.x; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CHANG Y, 1996, J NEUROSCI, V16, P5414; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Dalziel JE, 1999, EUR J PHARMACOL, V370, P345, DOI 10.1016/S0014-2999(99)00138-7; FATIMASHAD K, 1993, P ROY SOC B-BIOL SCI, V253, P69, DOI 10.1098/rspb.1993.0083; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; SLILATY SN, 1990, ANAL BIOCHEM, V185, P194, DOI 10.1016/0003-2697(90)90279-I; Tretter V, 1997, J NEUROSCI, V17, P2728; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YAKEL JL, 1990, BRAIN RES, V533, P46, DOI 10.1016/0006-8993(90)91793-G	27	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41438	41447		10.1074/jbc.M205645200	http://dx.doi.org/10.1074/jbc.M205645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177063	hybrid			2022-12-25	WOS:000178985300020
J	Battaglioli, E; Andres, ME; Rose, DW; Chenoweth, JG; Rosenfeld, MG; Anderson, ME; Mandel, G				Battaglioli, E; Andres, ME; Rose, DW; Chenoweth, JG; Rosenfeld, MG; Anderson, ME; Mandel, G			REST repression of neuronal genes requires components of the hSWI-SNF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; CHROMATIN-REMODELING COMPLEXES; HISTONE DEACETYLASE COMPLEX; TRANSCRIPTIONAL REPRESSION; TARGET GENES; SANT DOMAIN; CELL-CYCLE; SWI-SNF; IN-VIVO; N-COR	A function of the transcription factor REST is to block the expression of neuronal phenotypic traits in non-neuronal cells. Previous studies have shown that REST-mediated repression requires histone deacetylase activity and that recruitment of deacetylases is mediated by two co-repressors, Sin3A and CoREST. In this study, we show that a repressor domain in CoREST interacts with BRG1-associated factor (BAF) 57, a component of the hSWI-SNF complex. In vivo, BAF57 occupies the neuronal sodium channel gene (Nav1.2) promoter, and targeting to this gene requires REST. In addition to BAF57, the ATPase BRG1 and BAF170, other members of the hSWI-SNF complex, are also present in the REST-CoREST repressor complex. Microinjection of specific antibodies against BRG1, BAF57, or BAF170 into Rat1 fibroblasts relieves repression of REI reporter genes. Together, our data suggest that ATP-dependent chromatin remodeling, as well as histone deacetylation, is needed for REST-mediated repression.	SUNY Stony Brook, Howard Hughes Med Inst, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Mandel, G (corresponding author), SUNY Stony Brook, Howard Hughes Med Inst, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.		battaglioli, elena/H-9350-2017	Battaglioli, Elena/0000-0001-9168-7212	NIDDK NIH HHS [DK 54802] Funding Source: Medline; NINDS NIH HHS [NS 22518] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022518] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones FS, 1999, BIOESSAYS, V21, P372, DOI 10.1002/(SICI)1521-1878(199905)21:5<372::AID-BIES3>3.0.CO;2-3; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TRIMMER JS, 1985, CELL, V40, P697, DOI 10.1016/0092-8674(85)90218-1; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; VANDENBERGH DJ, 1989, NEURON, V3, P507, DOI 10.1016/0896-6273(89)90209-2; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	46	149	156	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41038	41045		10.1074/jbc.M205691200	http://dx.doi.org/10.1074/jbc.M205691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192000	hybrid			2022-12-25	WOS:000178791400113
J	Huss, JM; Kopp, RP; Kelly, DP				Huss, JM; Kopp, RP; Kelly, DP			Peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1 alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma - Identification of novel leucine-rich interaction motif within PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; CHAIN ACYL-COENZYME; TRANSCRIPTIONAL COACTIVATOR; GENE PROMOTER; RESPONSE ELEMENTS; PGC-1; BINDING; MODULATION; OXIDATION; MUSCLE	The transcriptional coactivator PPARgamma coactivator-1alpha (PGC-1alpha) has been characterized as a broad regulator of cellular energy metabolism. Although PGC-1alpha functions through many transcription factors, the PGC-1alpha partners identified to date are unlikely to account for all of its biologic actions. The orphan nuclear receptor estrogen-related receptor alpha (ERRalpha) was identified in a yeast two-hybrid screen of a cardiac cDNA library as a novel PGC-1alpha-binding protein. ERRalpha was implicated previously in regulating the gene encoding medium-chain acyl-CoA dehydrogenase (MCAD), which catalyzes the initial step in mitochondrial fatty acid oxidation. The cardiac perinatal expression pattern of ERRalpha paralleled that of PGC-1alpha and MCAD. Adenoviral-mediated ERRalpha overexpression in primary neonatal cardiac mycoytes induced endogenous MCAD expression. Furthermore, PGC-1alpha enhanced the transactivation of reporter plasmids containing an estrogen response element or the MCAD gene promoter by ERRalpha and the related isoform ERRgamma. In vitro binding experiments demonstrated that ERRa interacts with PGC-1alpha via its activation function-2 homology region. Mutagenesis studies revealed that the LXXLL motif at amino acid position 142-146 of PGC-1alpha (L2), necessary for PGC-1alpha interactions with other nuclear receptors, is not required for the PGC1alpha.ERRalpha interaction. Rather, ERRalpha binds PGC-1alpha primarily through a Leu-rich motif at amino acids 209-213 (Leu-3) and utilizes additional LXXLL-containing domains as accessory binding sites. Thus, the PGC1alpha.ERRalpha interaction is distinct from that of other nuclear receptor PGC-1alpha partners, including PPARalpha, hepatocyte nuclear factor-4alpha, and estrogen receptor alpha. These results identify ERRa and ERRgamma as novel PGC-1alpha interacting proteins, implicate ERR isoforms in the regulation of mitochondrial energy metabolism, and suggest a potential mechanism whereby PGC-1alpha selectively binds transcription factor partners.	Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.	dkelly@im.wustl.edu	Kelly, Daniel/ABG-2056-2021	Kopp, Ryan/0000-0003-3478-8564	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493, F32HL010410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P30DK052574, R01DK045416] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL 10410, R01 HL 58493] Funding Source: Medline; NIDDK NIH HHS [P30 DK 52574, P30 DK 56341, R01 DK 45416] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAAR K, 2002, IN PRESS FASEB J; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; Lu DS, 2001, CANCER RES, V61, P6755; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pike ACW, 2000, J STEROID BIOCHEM, V74, P261, DOI 10.1016/S0960-0760(00)00102-3; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	44	386	395	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40265	40274		10.1074/jbc.M206324200	http://dx.doi.org/10.1074/jbc.M206324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181319	hybrid			2022-12-25	WOS:000178791400016
J	Kamal, JKA; Nazeerunnisa, M; Behere, DV				Kamal, JKA; Nazeerunnisa, M; Behere, DV			Thermal unfolding of soybean peroxidase - Appropriate high denaturant concentrations induce cooperativity allowing the correct measurement of thermodynamic parameters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED COAT PEROXIDASE; GUANIDINE-HYDROCHLORIDE; CIRCULAR-DICHROISM; HEAT-CAPACITY; GLYCINE-MAX; STABILITY; PROTEIN; BACTERIORHODOPSIN; FLEXIBILITY; EQUILIBRIUM	We have earlier reported that both guanidine hydrochloride (GdnHCl)-induced and heat-induced unfolding of seed coat soybean peroxidase (SBP), monitored by far UV CD, show single step transition. However, although GdnHCl-induced unfolding follows a two-state pathway, the heat-induced denaturation proceeds through intermediates as indicated by the very low cooperativity of transition. In the former case, analysis of the data based on the two-state model gives true thermodynamic parameters, whereas underestimated values are obtained in the latter case. Available complex equations also cannot be applied for the analysis of the thermal unfolding of SBP due to the absence of separate transitions for the intermediates. In the present study, we report a method to obtain true thermodynamic parameters from thermal transition curves of SBP using the two-state model. When SBP is subjected to thermal unfolding at high GdnHCl concentrations (5.8-6.9 m), cooperative behavior is observed, which allowed the analysis by the two-state model to determine their thermodynamic parameters. We then obtained the thermodynamic parameters in the absence of GdnHCl by extrapolating the graph of linear dependence of DeltaH(m) on T-m to the T-m corresponding to 0 m GdnHCl. Another key point for checking the validity of our method was the fact that the unfolded state of SBP generated by either heat or GdnHCl is the same by which we could cross-check our results with that obtained from GdnHCl unfolding. Having obtained the true thermodynamic parameters, we report a detailed thermodynamic study of SBP. Further we address the effect of heme in the thermal unfolding mechanism of SBP.	Tata Inst Fundamental Res, Dept Chem Engn, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR)	Behere, DV (corresponding author), Tata Inst Fundamental Res, Dept Chem Engn, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.							AGASHE VR, 1995, BIOCHEMISTRY-US, V34, P3286, DOI 10.1021/bi00010a019; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Chiti F, 1998, BIOCHEMISTRY-US, V37, P1447, DOI 10.1021/bi971692f; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Fitter J, 1998, FEBS LETT, V433, P321, DOI 10.1016/S0014-5793(98)00938-7; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; Freire E, 1995, METHOD ENZYMOL, V259, P144; Gershenson A, 2000, BIOCHEMISTRY-US, V39, P4658, DOI 10.1021/bi992473s; Gijzen M, 1997, PLANT J, V12, P991, DOI 10.1046/j.1365-313X.1997.12050991.x; GILLIKIN JW, 1991, PLANT PHYSIOL, V96, P214, DOI 10.1104/pp.96.1.214; HAWKES R, 1984, J MOL BIOL, V175, P195, DOI 10.1016/0022-2836(84)90474-1; Heberle J, 2000, BIOPHYS CHEM, V85, P229, DOI 10.1016/S0301-4622(99)00154-4; Henriksen A, 2001, PROTEIN SCI, V10, P108, DOI 10.1110/ps.37301; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; Kamal JKA, 2002, BIOCHEMISTRY-US, V41, P9034, DOI 10.1021/bi025621e; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; McEldoon JP, 1996, BIOTECHNOL PROGR, V12, P555, DOI 10.1021/bp960010x; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; Otlewski J, 1996, EUR J BIOCHEM, V242, P601, DOI 10.1111/j.1432-1033.1996.0601r.x; Pace C N, 1986, Methods Enzymol, V131, P266; PAPPA HS, 1993, EUR J BIOCHEM, V212, P227, DOI 10.1111/j.1432-1033.1993.tb17654.x; PFEIL W, 1976, BIOPHYS CHEM, V4, P33, DOI 10.1016/0301-4622(76)80004-X; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; Schmitz N, 1997, CAN J BOT, V75, P1336, DOI 10.1139/b97-845; SIEVERS G, 1978, BIOCHIM BIOPHYS ACTA, V536, P212, DOI 10.1016/0005-2795(78)90067-3; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; Vallee B, 1999, EUR J BIOCHEM, V266, P40, DOI 10.1046/j.1432-1327.1999.00812.x; Wittung-Stafshede P, 1998, BIOCHEMISTRY-US, V37, P3172, DOI 10.1021/bi972901z	32	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40717	40721		10.1074/jbc.M208129200	http://dx.doi.org/10.1074/jbc.M208129200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192011	hybrid			2022-12-25	WOS:000178791400072
J	Kickhoefer, VA; Poderycki, MJ; Chan, EKL; Rome, LH				Kickhoefer, VA; Poderycki, MJ; Chan, EKL; Rome, LH			The La RNA-binding protein interacts with the vault RNA and is a vault-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL CYTOPLASMIC RIBONUCLEOPROTEINS; MULTIDRUG-RESISTANT CANCER; POLYMERASE-III; PARTICLES; TEP1; RO; CONTAIN; CELLS; RAT	Vaults are highly conserved ubiquitous ribonucleoprotein particles with an undefined function. Three protein species (p240/TEP1, p193/VPARP, and p100/MVP) and a small RNA comprise the 13-MDa vault particle. The expression of the unique 100-kDa major vault protein is sufficient to form the basic vault structure. Previously, we have shown that stable association of the vault RNA with the vault particle is dependent on its interaction with the p240/TEP1 protein. To identify other proteins that interact with the vault RNA, we used a UV-cross-linking assay. We find that a portion of the vault RNA is complexed with the La autoantigen in a separate smaller ribonucleoprotein particle. La interacts with the vault RNA (both in vivo and in vitro) presumably through binding to 3'-uridylates. Moreover, we also demonstrate that the La autoantigen is the 50-kDa protein that we have previously reported as a protein that co-purifies with vaults.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Scripps Res Inst, Wm Keck Autoimmune Dis Ctr, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Scripps Research Institute	Kickhoefer, VA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 33-131 CHS Mail Code 173717,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	vkick@mednet.ucla.edu	Rome, Leonard H/E-8786-2016; Chan, Edward K. L./B-5671-2009	Rome, Leonard H/0000-0002-1236-2063; Chan, Edward K. L./0000-0003-3938-9503; Kickhoefer, Valerie/0000-0002-0048-0580	NIGMS NIH HHS [GM 38097] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; KEDERSHA NL, 1986, ANAL BIOCHEM, V156, P161, DOI 10.1016/0003-2697(86)90168-5; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, J CELL BIOL, V153, pF13, DOI 10.1083/jcb.153.4.F13; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200; van Zon A, 2001, J BIOL CHEM, V276, P37715, DOI 10.1074/jbc.M106055200; VANVENROOIJ WJ, 1993, MOL BIOL REP, V18, P113, DOI 10.1007/BF00986765; VILALTA A, 1994, J BIOL CHEM, V269, P29752; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; WOLIN SL, 1984, P NATL ACAD SCI-BIOL, V81, P1996, DOI 10.1073/pnas.81.7.1996	26	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41282	41286		10.1074/jbc.M206980200	http://dx.doi.org/10.1074/jbc.M206980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12196535	hybrid			2022-12-25	WOS:000178791400141
J	Osman, H; Murigande, C; Nadakal, A; Capponi, AM				Osman, H; Murigande, C; Nadakal, A; Capponi, AM			Repression of DAX-1 and induction of SF-1 expression - Two mechanisms contributing to the activation of aldosterone biosynthesis in adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; ANGIOTENSIN-II; MINERALOCORTICOID BIOSYNTHESIS; STEROIDOGENIC FACTOR-1; PROMOTER ACTIVITY; RECEPTOR DAX-1; STAR GENE; CALCIUM; TRANSCRIPTION; HORMONE	Angiotensin II (Ang II) and adrenocorticotropic hormone stimulate aldosterone biosynthesis in the zona glomerulosa of the adrenal cortex through induction of the expression of the steroidogenic acute regulatory (StAR) protein, which promotes intramitochondrial cholesterol transfer. To understand the mechanism of this induction of the StAR protein, we have examined the effect of Ang II and forskolin, a mimicker of adrenocorticotropic hormone action, on two transcription factors known to modulate StAR gene expression in opposite ways, DAX-1 and SF-1, in bovine adrenal glomerulosa cells in primary culture. Ang II markedly inhibited DAX-1 protein expression in a time- and concentration-dependent manner (to 38.7 +/- 12.9% of controls at 3 nm after 6 h, p < 0.01), an effect that required de novo protein synthesis and ERK2/1 activation. This effect was associated with a concomitant decrease in DAX-1 mRNA and an increase in mitochondrial StAR protein levels. Similarly, forskolin dramatically repressed DAX-1 protein and mRNA expression (to 19.6 +/- 1.8 and 50.3 +/- 4.7% of controls, respectively, p < 0.01). Neither Ang II nor forskolin affected DAX-1 protein and mRNA stability. The aldosterone response to Ang H was markedly reduced (to 59 +/- 4% of controls, p < 0.01) in transiently transfected cells overexpressing DAX-1. Whereas Ang II was without effect on SF-1 expression, forskolin significantly increased SF-1 protein and mRNA levels in a cycloheximide-sensitive manner (to 167.4 +/- 16.6 and 173.1 +/- 25.1% of controls after 6 h, respectively, p < 0.01). These results demonstrate that the balance between repressor and inducer function of DAX-1 and SF-1 are of critical importance in the regulation of adrenal aldosterone biosynthesis.	Univ Hosp Geneva, Div Endocrinol & Diabetol, CH-111 Geneva 14, Switzerland	University of Geneva	Capponi, AM (corresponding author), Univ Hosp Geneva, Div Endocrinol & Diabetol, 24 Rue Micheli du Crest, CH-111 Geneva 14, Switzerland.	alessandro.capponi@medecine.unige.ch	Osman-Ponchet, Hanan/AAD-3939-2022	Osman-Ponchet, Hanan/0000-0003-4994-5673				AEsoy R, 2002, ENDOCRINOLOGY, V143, P295, DOI 10.1210/en.143.1.295; Babu PS, 2002, ENDOCRINOLOGY, V143, P665, DOI 10.1210/en.143.2.665; Babu PS, 2000, ENDOCR RES, V26, P985, DOI 10.3109/07435800009048628; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; Capponi AM, 1996, CURR OPIN ENDOCRINOL, V3, P248, DOI [10.1097/00060793-199606000-00010, DOI 10.1097/00060793-199606000-00010]; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; Cherradi N, 1998, EUR J ENDOCRINOL, V139, P249, DOI 10.1530/eje.0.1390249; Cherradi N, 1998, TRENDS ENDOCRIN MET, V9, P412, DOI 10.1016/S1043-2760(98)00099-X; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Clark BJ, 1999, ENDOCRINOLOGY, V140, P4390, DOI 10.1210/en.140.10.4390; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; Cote M, 1998, ENDOCR RES, V24, P415, DOI 10.3109/07435809809032625; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; ELLIOTT ME, 1984, BIOCHEM PHARMACOL, V33, P1519, DOI 10.1016/0006-2952(84)90422-2; Gyles SL, 2001, J BIOL CHEM, V276, P34888, DOI 10.1074/jbc.M102063200; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4679, DOI 10.1210/en.139.11.4679; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; Lalli E, 1998, ENDOCRINOLOGY, V139, P4237, DOI 10.1210/en.139.10.4237; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lalli E, 1999, CURR OPIN ENDOCRINOL, V6, P185; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Muller J., 1988, REGULATION ALDOSTERO; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PYTHON CP, 1993, ENDOCRINOLOGY, V132, P1489, DOI 10.1210/en.132.4.1489; Rust W, 1998, J MOL ENDOCRINOL, V21, P189, DOI 10.1677/jme.0.0210189; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Shibata H, 2001, MOL GENET METAB, V74, P206, DOI 10.1006/mgme.2001.3231; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Tai CJ, 2001, ENDOCRINOLOGY, V142, P1554, DOI 10.1210/en.142.4.1554; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; Tian Y, 1998, ENDOCRINOLOGY, V139, P1801, DOI 10.1210/en.139.4.1801; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Yu RN, 1998, TRENDS ENDOCRIN MET, V9, P169, DOI 10.1016/S1043-2760(98)00048-4; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	48	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41259	41267		10.1074/jbc.M206595200	http://dx.doi.org/10.1074/jbc.M206595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186872	hybrid			2022-12-25	WOS:000178791400138
J	Siripurkpong, P; Yuvaniyama, J; Wilairat, P; Goldberg, DE				Siripurkpong, P; Yuvaniyama, J; Wilairat, P; Goldberg, DE			Active site contribution to specificity of the aspartic proteases plasmepsins I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM HEMOGLOBIN DEGRADATION; PARASITE PLASMODIUM-FALCIPARUM; DIGESTIVE VACUOLE; PATHWAY; PROTEINASE; EXPRESSION; INHIBITION; ENZYME	Plasmepsins I and II (PM I and II) are aspartic proteases involved in the initial steps of Plasmodium hemoglobin degradation. They are attractive targets for antimalarial drug development. The two enzymes are 73% identical, yet have different substrate and inhibitor specificities. The x-ray structures of proform and mature PM II have been determined, but models of PM I do not adequately explain the selectivity of the two proteases. To better understand the basis of these recognition differences, we have identified nine residues of PM II that are in proximity to the inhibitor pepstatin in the crystal structure and differ in PM I. We mutated these residues in PM II to the cognate amino acids of PM I. Kinetic parameters for substrate and inhibitors for the PM II-mutant were similar to those of PM II-wild type (WT). Cleavage specificity was assessed using hemoglobin or a random decamer peptide library as substrate. Again, PM II-mutant behaved like PM II-WT rather than PM I-WT. These results indicate that differences in plasmepsin specificity depend more on conformational differences from distant sites than on specific active site variation.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Mahidol University	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA.			Yuvaniyama, Jirundon/0000-0002-6800-8944	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; COPELAND RA, 2000, ENZYMES PRACTICAL IN; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1992, INFECT AGENT DIS, V1, P207; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; Khan AR, 1999, P NATL ACAD SCI USA, V96, P10968, DOI 10.1073/pnas.96.20.10968; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Williams J W, 1979, Methods Enzymol, V63, P437	24	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41009	41013		10.1074/jbc.M204852200	http://dx.doi.org/10.1074/jbc.M204852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189138	hybrid			2022-12-25	WOS:000178791400109
J	Chung, PJ; Chang, YS; Liang, CL; Meng, CL				Chung, PJ; Chang, YS; Liang, CL; Meng, CL			Negative regulation of Epstein-Barr virus latent membrane protein 1-mediated functions by the bone morphogenetic protein receptor IA-binding protein, BRAM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROGRAMMED CELL-DEATH; IKK-BETA SUBUNIT; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE; CYCLIN D1; ACTIVATION; EXPRESSION; MEMBRANE-PROTEIN-1; PHOSPHORYLATION	The latent membrane protein 1 (LMP1) of Epstein-Barr virus causes cellular transformation and activates several intracellular signals, including NF-kappaB and c-Jun N-terminal kinase. Using yeast two-hybrid screening with the LMP1 C-terminal sequence as bait, we demonstrate that BRAM1 (bone morphogenetic protein receptor-associated molecule 1) is an LMP1-interacting protein. BRAM1 associates with LMP1, both in vitro and in vivo, as revealed by confocal microscopy, glutathione S-transferase pull-down, and co-immunoprecipitation assays. This association mainly involves the C-terminal half of BRAM1 comprising the MYND domain and the CTAR2 region of LMP1, which is critical in LMP1-mediated signaling pathways. We show that BRAM1 interferes with LMP1-mediated NF-kappaB activation but not the JNK signaling pathway. Because the CTAR2 region interacts with the tumor necrosis factor TNF-alpha receptor-associated death domain protein, it is interesting to find that BRAM1 also interferes with NF-kappaB activation mediated by TNF-alpha. BRAM1 interferes LMP1-mediated and TNF-alpha-induced NF-kappaB activation by targeting IkappaBalpha molecules. Moreover, BRAM1 inhibits the resistance of LMP1-expressing cells to TNF-alpha-induced cytotoxicity. We therefore propose that the BRAM1 molecule associates with LMP1 and functions as a negative regulator of LMP1-mediated biological functions.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan	National Defense Medical Center; Chang Gung University	Meng, CL (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, POB 90048-517, Taipei 114, Taiwan.							Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUEN DS, 1995, ONCOGENE, V10, P549; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li SN, 1996, ONCOGENE, V12, P2129; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Morita K, 2001, P NATL ACAD SCI USA, V98, P6284, DOI 10.1073/pnas.111409798; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Sandberg ML, 2000, J VIROL, V74, P9755, DOI 10.1128/JVI.74.20.9755-9761.2000; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sugawara K, 2001, GENES CELLS, V6, P599, DOI 10.1046/j.1365-2443.2001.00444.x; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Yeh TS, 1997, DNA CELL BIOL, V16, P1311, DOI 10.1089/dna.1997.16.1311	48	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39850	39857		10.1074/jbc.M206736200	http://dx.doi.org/10.1074/jbc.M206736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181323	hybrid			2022-12-25	WOS:000178662500101
J	Finkielstein, CV; Chen, LG; Maller, JL				Finkielstein, CV; Chen, LG; Maller, JL			A role for G(1)/S cyclin-dependent protein kinases in the apoptotic response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; XENOPUS EGG EXTRACTS; CELL-FREE APOPTOSIS; RETINOBLASTOMA PROTEIN; MIDBLASTULA TRANSITION; MEDIATED ACTIVATION; DEVELOPMENTAL TIMER; DNA FRAGMENTATION; FAMILY PROTEASES; CASPASE FAMILY	In Xenopus development the mid-blastula transition (MBT) marks a dramatic change in response of the embryo to ionizing radiation. Whereas inhibition of cyclin D1-Cdk4 and cyclin A2-Cdk2 by p27(Xic1) has been linked to cell cycle arrest and prevention of apoptosis in embryos irradiated post-MBT, distinct roles for these complexes during apoptosis are evident in embryos irradiated pre-MBT. Cyclin A2 is cleaved by caspases to generate a truncated complex termed DeltaN-cyclin A2-Cdk2, which is kinase active, not inhibited by p27(Xic1), and not sensitive to degradation by the ubiquitin-mediated proteasome pathway. Moreover, AN-cyclin A2-Cdk2 has an expanded substrate specificity and can phosphorylate histone H2B at Ser-32, which may facilitate DNA cleavage. Consistent with a role for cyclin A2 in apoptosis, the addition of AN-cyclin A2-Cdk2, but not full-length cyclin A2-Cdk2, to Xenopus egg extracts triggers apoptotic DNA fragmentation even when caspases are not activated. Similarly, cyclin D1 is targeted by caspases, and the generated product exhibits higher affinity for p27(Xic1), leading to reduced phosphorylation of the retinoblastoma protein (pRB) during apoptosis. These data suggest that caspase cleavage of both cyclin D1-Cdk4 and cyclin A2-Cdk2 promotes specific apoptotic events in embryos undergoing apoptosis in response to ionizing radiation.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, 4200 E 9th Ave,Box C-236, Denver, CO 80262 USA.			finkielstein, carla/0000-0002-8417-4643	NCI NIH HHS [CA 46934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; An B, 1996, CANCER RES, V56, P438; Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; AUSUBEL FM, 1981, COLD SPRING HARB SYM, V45, P487; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Finkielstein CV, 2001, P NATL ACAD SCI USA, V98, P1006, DOI 10.1073/pnas.98.3.1006; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sherr CJ, 2000, CANCER RES, V60, P3689; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Sible JC, 1997, DEV BIOL, V189, P335, DOI 10.1006/dbio.1997.8683; Stack JH, 1997, DEVELOPMENT, V124, P3185; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yao SL, 1996, CANCER RES, V56, P4551; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	62	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38476	38485		10.1074/jbc.M206184200	http://dx.doi.org/10.1074/jbc.M206184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12176996	hybrid			2022-12-25	WOS:000178529600063
J	Gao, HW; Parkin, S; Johnson, PF; Schwartz, RC				Gao, HW; Parkin, S; Johnson, PF; Schwartz, RC			C/EBP gamma has a stimulatory role on the IL-6 and IL-8 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN-2; LYMPHOBLASTIC CELL-LINE; BINDING-PROTEIN; GENE-EXPRESSION; LEUCINE-ZIPPER; TRANSCRIPTIONAL ACTIVATORS; INTERLEUKIN-8 PRODUCTION; MESSENGER-RNA	CCAAT/enhancer-binding protein gamma (C/EBPgamma) is an ubiquitously expressed member of the C/EBP family of transcription factors that has been shown to be an inhibitor of C/EBP transcriptional activators and has been proposed to act as a buffer against C/EBP-mediated activation. We have now unexpectedly found that C/EBPgamma dramatically augments the activity of C/EBPbeta in lipopolysaccharide induction of the interleukin-6 and interleukin-8 promoters in a B lymphoblast cell line. This activating role for C/EBPgamma is promoter-specific, neither being observed in the regulation of a simple C/EBP-dependent promoter nor the TNFalpha promoter. C/EBPgamma activity also shows cell-type specificity with no activity observed in a macrophage cell line. Studies with chimeric C/EBP proteins implicate the formation of a heterodimeric leucine zipper between C/EBPbeta and C/EBPgamma as the critical structural feature required for C/EBPgamma stimulatory activity. These findings suggest a unique role for C/EBPgamma in B cell gene regulation and, along with our previous observation of the ability of C/EBP basic region-leucine zipper domains to confer lipopolysaccharide inducibility of interleukin-6, suggest that the C/EBP leucine zipper domain has a role in C/EBP function beyond allowing dimerization between C/EBP family members.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; NCI, Eukaryot Transcript Regulat Sect, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Michigan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schwartz, RC (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUER SR, 1986, J IMMUNOL, V136, P4695; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COOPER C, 1992, J IMMUNOL, V149, P3225; COOPER CL, 1994, J IMMUNOL, V153, P5049; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GUTMAN GA, 1981, CLIN IMMUNOL IMMUNOP, V18, P230, DOI 10.1016/0090-1229(81)90029-5; HOBBS MV, 1991, CELL IMMUNOL, V132, P442, DOI 10.1016/0008-8749(91)90041-9; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu HM, 1998, J IMMUNOL, V160, P2334; HUANG S, 1992, AM J PATHOL, V141, P981; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kaisho T, 1999, J EXP MED, V190, P1573, DOI 10.1084/jem.190.11.1573; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JR, 1998, EUR J IMMUNOL, V28, P4188, DOI 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Omori SA, 1997, J IMMUNOL, V159, P1800; Pan Q, 2000, EUR J IMMUNOL, V30, P1019, DOI 10.1002/(SICI)1521-4141(200004)30:4<1019::AID-IMMU1019>3.0.CO;2-W; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Shapiro VS, 2001, BLOOD, V98, P187, DOI 10.1182/blood.V98.1.187; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TANABE O, 1988, J IMMUNOL, V141, P3875; Treon S P, 1998, Curr Opin Hematol, V5, P42; Venkataraman C, 1999, IMMUNOL LETT, V69, P233, DOI 10.1016/S0165-2478(99)00068-1; Wall L, 1996, J BIOL CHEM, V271, P16477, DOI 10.1074/jbc.271.28.16477; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wuyts A, 1996, J IMMUNOL, V157, P1736; Zafarana G, 2000, EMBO J, V19, P5856, DOI 10.1093/emboj/19.21.5856; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38827	38837		10.1074/jbc.M206224200	http://dx.doi.org/10.1074/jbc.M206224200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12177065	hybrid			2022-12-25	WOS:000178529600104
J	Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE				Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE			Interplay between cdk9 and NF-kappa B factors determines the level of HIV-1 gene transcription in astrocytic cells	ONCOGENE			English	Article						HIV-1 transcription; NF-kappa B; cdk9	HUMAN-IMMUNODEFICIENCY-VIRUS; TAR-INDEPENDENT TRANSACTIVATION; RNA-POLYMERASE-II; FACTOR P-TEFB; IN-VITRO; CELLULAR PROTEIN; PUR-ALPHA; CYCLIN T1; ACTIVATION; KINASE	Basal transcription of the HIV-1 genome is controlled by a variety of ubiquitous and inducible regulatory factors, some with the ability to associate with the viral DNA sequences within the promoter spanning the long terminal repeat (LTR). In this report we demonstrate that activation of the HIV-1 promoter through the inducible DNA binding NF-kappaB transcription factors can be affected by cdk9 in human astrocytic cells. Our results show that ectopic expression of cdk9, but not its mutant variant which lacks the domain responsible for its kinase activity, augments transcription of the LTR. Moreover, we demonstrate that induction of the NF-kappaB pathway by PMA, or overexpression of its subunits including p50/p65 have a negative effect on the ability of cdk9 to stimulate viral gene transcription in these cells. Results from band-shift experiments demonstrated significant suppression of p50/p65 association to its DNA target motif by cdk9. Further, data from GST pull-down and combined immunoprecipitation/Western blot analysis of the protein extracts from cells expressing cdk9, p50 and p65 have revealed the interaction of cdk9 with both p50 and p65 in the absence of DNA containing the kappaB motif. All of these observations led us to conclude that the interaction of cdk9 with the NF-kappaB factors can determine the ability of NF-kappaB to modulate HIV-1 gene transcription.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Sbarro Inst Canc Res, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12Th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Hiscott J, 1997, J LEUKOCYTE BIOL, V62, P82, DOI 10.1002/jlb.62.1.82; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; LINDHOLM P F, 1990, New Biologist, V2, P1034; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rostasy K, 2000, J NEUROVIROL, V6, P537, DOI 10.3109/13550280009091954; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	27	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5797	5803		10.1038/sj.onc.1205754	http://dx.doi.org/10.1038/sj.onc.1205754			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173051				2022-12-25	WOS:000177463400016
J	Armstrong, AP; Tometsko, ME; Glaccum, M; Sutherland, CL; Cosman, D; Dougall, WC				Armstrong, AP; Tometsko, ME; Glaccum, M; Sutherland, CL; Cosman, D; Dougall, WC			A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; DEFECTIVE INTERLEUKIN-1; BONE-RESORPTION; KEY REGULATOR; MICE LACKING; TRAF FAMILY; C-SRC; RANK	Signaling through receptor activator of nuclear factor-kappaB (RANK) is essential for the differentiation and activation of osteoclasts, the cell principally responsible for bone resorption. Animals genetically deficient in RANK or the cognate RANK ligand are profoundly osteopetrotic because of the lack of bone resorption and remodeling. RANK provokes biochemical signaling via the recruitment of intracellular tumor necrosis factor receptor-associated factors (TRAFs) after ligand binding and receptor oligomerization. To understand the RANK-mediated signal transduction mechanism in osteoclastogenesis, we have designed a system to recapitulate osteoclast differentiation and activation in vitro by transfer of the RANK cDNA into hematopoietic precursors genetically deficient in RANK. Gene transfer of RANK constructs that are selectively incapable of binding different TRAF proteins revealed that TRAF pathways downstream of RANK that affect osteoclast differentiation are functionally redundant. In contrast, the interaction of RANK with TRAF6 is absolutely required for the proper formation of cytoskeletal structures and functional resorptive activity of osteoclasts. Moreover, signaling via the interleukin-1 receptor, which also utilizes TRAF6, rescues the osteoclast activation defects observed in the absence of RANK/TRAF6 interactions. These studies are the first to define the functional domains of the RANK cytoplasmic tail that control specific differentiation and activation pathways in osteoclasts.	Immunex Corp, Dept Mol Biol, Seattle, WA 98101 USA; Immunex Corp, Dept Mol Immunol, Seattle, WA 98101 USA	Immunex Corporation; Immunex Corporation	Dougall, WC (corresponding author), Amgen Inc, Dept Canc Biol, 51 Univ St, Seattle, WA 98101 USA.	dougallw@amgen.com		Dougall, William/0000-0001-9487-251X				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281-200005000-00006; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Riggs BL, 2000, J BONE MINER RES, V15, P2293; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	43	184	206	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44347	44356		10.1074/jbc.M202009200	http://dx.doi.org/10.1074/jbc.M202009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12185073	hybrid			2022-12-25	WOS:000179272000106
J	Hall, JM; Korach, KS				Hall, JM; Korach, KS			Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; RESPONSE ELEMENTS; ER-ALPHA; ANTIESTROGENS; PHYTOESTROGENS; COREGULATORS; CONFORMATION; RECRUITMENT; XENOBIOTICS; CONTEXT	Most of the currently available information on the transcriptional activities of endocrine-disrupting chemicals (xenoestrogens) through estrogen receptors a (ERalpha) and beta (ERbeta) has been derived from transactivation studies on synthetic estrogen-responsive reporters. Thus, the ability of the xenoestrogen-liganded ERs to regulate endogenous estrogen-responsive gene expression has not been well characterized. Here, we have evaluated the activities of xenoestrogens through ERalpha and ERbeta on the vitellogenin A2 estrogen-response element (ERE) and the human pS2, lactoferrin, and complement 3 physiological target gene promoters. Using mammalian cell transient transfection assays, we found that the activities of xenoestrogens were mediated in a promoter-specific manner. For example, when bound to all ligands examined, ERa displayed high levels of transcription on the vitellogenin ERE and the lactoferrin promoter, but substantially lower activity on the complement 3 and pS2 promoters. However, one of the most important observations was that there were significant differences in the relative transcriptional activities of xenoestrogen-bound ERalpha and ERbeta on different promoters, suggesting that ERalpha and ERbeta make unique contributions to xenoestrogen action in target cells. When probing the molecular mechanism of the promoter-specific activities observed, we found that the transcriptional activity of the ERs correlated with the ability of each receptor to assume an active conformation on specific promoters. Taken together, the results indicate that the transcriptional activities of xenoestrogens are mediated in a promoter-specific manner and that estrogen-responsive promoters communicate differently with ERalpha and ERbeta by influencing their structures in a distinct manner that leads to diversity in their transcriptional responses.	NIEHS, Receptor Biol Sect, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hall, JM (corresponding author), NIEHS, Receptor Biol Sect, Bldg 101,Rm E460,MD E4-01,111 TW Alexander Dr,POB, Res Triangle Pk, NC 27709 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Korach, Kenneth/0000-0002-7765-418X				An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; CARSON R, 1994, SILENT SPRING; Colburn Theo, 1996, OUR STOLEN FUTURE; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; Giguere V, 1998, STEROIDS, V63, P335, DOI 10.1016/S0039-128X(98)00024-5; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hall JM, 2000, MOL ENDOCRINOL, V14, P2010, DOI 10.1210/me.14.12.2010; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1991, J BIOL CHEM, V266, P21880; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MCLACHLAN JA, 1993, ENVIRON HEALTH PERSP, V101, P386, DOI 10.2307/3431891; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; Petit F, 1997, J MOL ENDOCRINOL, V19, P321, DOI 10.1677/jme.0.0190321; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114	33	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44455	44461		10.1074/jbc.M200849200	http://dx.doi.org/10.1074/jbc.M200849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200415	hybrid			2022-12-25	WOS:000179272000117
J	Krauss, SW; Heald, R; Lee, G; Nunomura, W; Gimm, JA; Mohandas, N; Chasis, JA				Krauss, SW; Heald, R; Lee, G; Nunomura, W; Gimm, JA; Mohandas, N; Chasis, JA			Two distinct domains of protein 4.1 critical for assembly of functional nuclei in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC APPARATUS PROTEIN; ACTIN BINDING DOMAIN; INTERPHASE NUCLEI; CYCLIN SYNTHESIS; 4.1 FAMILY; NUMA; SPECTRIN; SPINDLE; COMPLEX; EXPRESSION	Protein 4.1R, a multifunctional structural protein, acts as an adaptor in mature red cell membrane skeletons linking spectrin-actin complexes to plasma membrane-associated proteins. In nucleated cells protein 4.1 is not associated exclusively with plasma membrane but is also detected at several important subcellular locations crucial for cell division. To identify 4.1 domains having critical functions in nuclear assembly, 4.1 domain peptides were added to Xenopus egg extract nuclear reconstitution reactions. Morphologically disorganized, replication deficient nuclei assembled when spectrin-actin-binding domain or NuMA-binding C-terminal domain peptides were present. However, control variant spectrin-actin-binding domain peptides incapable of binding actin or mutant C-terminal domain peptides with reduced NuMA binding had no deleterious effects on nuclear reconstitution. To test whether 4.1 is required for proper nuclear assembly, 4.1 isoforms were depleted with spectrin-actin binding or C-terminal domain-specific antibodies. Nuclei assembled in the depleted extracts were deranged. However, nuclear assembly could be rescued by the addition of recombinant 4.1R. Our data establish that protein 4.1 is essential for nuclear assembly and identify two distinct 4.1 domains, initially characterized in cytoskeletal interactions, that have crucial and versatile functions in nuclear assembly.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Dept Subcellular Struct, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA; Tokyo Womens Med Univ, Sch Med, Dept Biochem, Shinju Ku, Tokyo 1628666, Japan	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Tokyo Women's Medical University	Krauss, SW (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Dept Subcellular Struct, 1 Cyclotron Rd,MS 74-157, Berkeley, CA 94720 USA.	sakrauss@lbl.gov		Heald, Rebecca/0000-0001-6671-6528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059079, P01DK032094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59079, DK32094] Funding Source: Medline; NIGMS NIH HHS [GM57839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DISCHER D, 1993, J BIOL CHEM, V268, P7186; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HUANG JP, 1993, J BIOL CHEM, V268, P3758; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 1998, MOL BIOL CELL, V9, p294A; Lallena MJ, 1997, J CELL SCI, V110, P239; Lallena MJ, 1998, J CELL SCI, V111, P1963; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MARCOTTE P, 1990, ABA J, V76, P12; MATTAGAJASINGH S, 1997, BLOOD, V90, P408; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; Mattagajasingh SN, 1998, BLOOD, V92, p300A; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1998, J CELL SCI, V111, P71; MILANKOV K, 1993, EXP CELL RES, V209, P189, DOI 10.1006/excr.1993.1301; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORRIS MB, 1995, BIOCHEMISTRY-US, V34, P4538, DOI 10.1021/bi00014a006; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; PRICE CM, 1986, EXP CELL RES, V166, P295, DOI 10.1016/0014-4827(86)90478-7; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Smrzka OW, 2000, CURR BIOL, V10, P413, DOI 10.1016/S0960-9822(00)00418-8; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; Taimen P, 2000, EXP CELL RES, V256, P140, DOI 10.1006/excr.2000.4799; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Tse WT, 2001, J BIOL CHEM, V276, P23974, DOI 10.1074/jbc.M009307200; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; WINARDI R, 1995, BLOOD, V86, P4315, DOI 10.1182/blood.V86.11.4315.bloodjournal86114315; Woulfe J, 2000, NEUROPATH APPL NEURO, V26, P161, DOI 10.1046/j.1365-2990.2000.026002161.x; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M; ZENG CQ, 1994, P NATL ACAD SCI USA, V91, P1505, DOI 10.1073/pnas.91.4.1505; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; Zhang SS, 2002, J BIOL CHEM, V277, P843, DOI 10.1074/jbc.M109393200; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	77	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44339	44346		10.1074/jbc.M204135200	http://dx.doi.org/10.1074/jbc.M204135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12171917	hybrid			2022-12-25	WOS:000179272000105
J	Jenkins, GM; Cowart, LA; Signorelli, P; Pettus, BJ; Chalfant, CE; Hannun, YA				Jenkins, GM; Cowart, LA; Signorelli, P; Pettus, BJ; Chalfant, CE; Hannun, YA			Acute activation of de novo sphingolipid biosynthesis upon heat shock causes an accumulation of ceramide and subsequent dephosphorylation of SR proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; INDUCED APOPTOSIS; CELL APOPTOSIS; STRESS; GENERATION; DIFFERENTIATION; TRANSCRIPTION; INVOLVEMENT; INHIBITION	Recent studies are beginning to implicate sphingolipids in the heat stress response. In the yeast Saccharomyces cerevisiae, heat stress has been shown to activate de novo biosynthesis of sphingolipids, whereas in mammalian cells the sphingolipid ceramide has been implicated in the heat shock responses. In the current study, we found an increase in the ceramide mass of Molt-4 cells in response to heat shock, corroborating findings in HL-60 cells. Increased ceramide was determined to be from de novo biosynthesis by two major lines of evidence. First, the accumulation of ceramide was dependent upon the activities of both ceramide synthase and serine palmitoyltransferase. Second, pulse labeling studies demonstrated increased production of ceramide through the de novo biosynthetic pathway. Significantly, the de novo sphingolipid biosynthetic pathway was acutely induced upon heat shock, which resulted in a 2-fold increased flux in newly made ceramides within 1-2 min of exposure to 42.5 degreesC. Functionally, heat shock induced the dephosphorylation of the SR proteins, and this effect was demonstrated to be dependent upon the accumulation of de novo-produced ceramides. Thus, these studies disclose an evolutionary conserved activation of the de novo pathway in response to heat shock. Moreover, SR dephosphorylation is emerging as a specific downstream target of accumulation of newly made ceramides in mammalian cells.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Milan, Dept Patol Gen, I-20157 Milan, Italy	Medical University of South Carolina; University of Milan	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Rm 501,Basic Sci Bldg,173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.			signorelli, paola/0000-0003-2368-2393	NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87584] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Dickson RC, 2000, METHOD ENZYMOL, V311, P3; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wang E, 2000, METHOD ENZYMOL, V311, P15; Wang HT, 2001, CANCER RES, V61, P5102; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	28	65	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42572	42578		10.1074/jbc.M207346200	http://dx.doi.org/10.1074/jbc.M207346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200446	hybrid			2022-12-25	WOS:000179081200020
J	Wang, YD; Dziegielewski, J; Chang, AY; Dervan, PB; Beerman, TA				Wang, YD; Dziegielewski, J; Chang, AY; Dervan, PB; Beerman, TA			Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLE-IMIDAZOLE POLYAMIDES; SIMIAN VIRUS-40 DNA; MINOR-GROOVE; SIMIAN-VIRUS-40 DNA; BSC-1 CELLS; MAMMALIAN-CELLS; DRUG ADOZELESIN; GENE-EXPRESSION; SMALL MOLECULES; SV40 DNA	Alkylating agents are generally highly reactive with DNA but demonstrate limited DNA sequence selectivity. In contrast, synthetic pyrrole-imidazole polyamides recognize specific DNA sequences with high affinity but are unable to permanently damage DNA. An eight-ring hairpin polyamide conjugated to the alkylating moiety cyclopropylpyrroloindole, related to the natural product CC-1065, affords a conjugate 1-CBI (polyamide 1-CBI (1-(chloromethyl)-5-hydroxyl-1,2-dihydro-3H-benz[e]indole) conjugate), which binds to specific sequences in the minor groove of DNA and alkylates a single adenine flanking the polyamide binding site. In this study, we show that 1-CBI alkylates DNA in both plasmid and intracellular minichromosomal form and inhibits DNA replication under both cell-free and cellular conditions. In addition, it inhibits cell growth and arrests cells in the G(2)/M phase of the cell cycle.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Roswell Park Cancer Institute; California Institute of Technology	Beerman, TA (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.		Wang, Yong-Dong/K-3563-2013		NCI NIH HHS [CA80939, CA16056] Funding Source: Medline; NIGMS NIH HHS [GM27681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA080939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027681, R37GM027681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arad U, 1998, BIOTECHNIQUES, V24, P760, DOI 10.2144/98245bm14; Belitsky JM, 2002, BIOORGAN MED CHEM, V10, P3313, DOI 10.1016/S0968-0896(02)00204-3; BHUYAN BK, 1983, CANCER RES, V43, P4227; Chang AY, 2000, J AM CHEM SOC, V122, P4856, DOI 10.1021/ja994345x; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; Cobuzzi RJ, 1996, J BIOL CHEM, V271, P19852, DOI 10.1074/jbc.271.33.19852; Dervan PB, 2001, BIOORGAN MED CHEM, V9, P2215, DOI 10.1016/S0968-0896(01)00262-0; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; Dziegielewski J, 2001, BIOCHEMISTRY-US, V40, P704, DOI 10.1021/bi002181n; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Gottesfeld JM, 2000, GENE EXPRESSION, V9, P77; GRIMWADE JE, 1986, MOL PHARMACOL, V30, P358; Herzig MCS, 2002, BIOCHEMISTRY-US, V41, P1545, DOI 10.1021/bi011907s; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; MCHUGH MM, 1994, BIOCHEMISTRY-US, V33, P9158, DOI 10.1021/bi00197a019; MCHUGH MM, 1995, BIOCHEMISTRY-US, V34, P1805, DOI 10.1021/bi00005a038; McHugh MM, 1999, BIOCHEMISTRY-US, V38, P11508, DOI 10.1021/bi990598r; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; REYNOLDS VL, 1985, BIOCHEMISTRY-US, V24, P6228, DOI 10.1021/bi00343a029; SCOTT WA, 1978, CELL, V15, P1511, DOI 10.1016/0092-8674(78)90073-9; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; Wang YZ, 2001, CANCER RES, V61, P3787; WARPEHOSKI MA, 1992, BIOCHEMISTRY-US, V31, P2502, DOI 10.1021/bi00124a009; White S, 1997, J AM CHEM SOC, V119, P8756, DOI 10.1021/ja971569b; White S, 1996, BIOCHEMISTRY-US, V35, P12532, DOI 10.1021/bi960744i; Woynarowski JM, 1999, BBA-GENE STRUCT EXPR, V1444, P201, DOI 10.1016/S0167-4781(99)00002-0; WOYNAROWSKI JM, 1995, BIOCHEMISTRY-US, V34, P13042, DOI 10.1021/bi00040a015; Woynarowski JM, 1997, BBA-GENE STRUCT EXPR, V1353, P50, DOI 10.1016/S0167-4781(97)00046-8; ZSIDO TJ, 1992, BIOCHEM PHARMACOL, V43, P1817, DOI 10.1016/0006-2952(92)90715-U; ZSIDO TJ, 1991, BIOCHEMISTRY-US, V30, P3733, DOI 10.1021/bi00229a021	32	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42431	42437		10.1074/jbc.M207179200	http://dx.doi.org/10.1074/jbc.M207179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196541	hybrid, Green Accepted			2022-12-25	WOS:000179081200003
J	Babini, E; Paukert, M; Geisler, HS; Grunder, S				Babini, E; Paukert, M; Geisler, HS; Grunder, S			Alternative splicing and interaction with di- and polyvalent cations control the dynamic range of acid-sensing ion channel 1 (ASIC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CALCIUM; SODIUM-CHANNEL; POTASSIUM CHANGES; NEURONS; RECEPTOR; ISCHEMIA; POTENTIATION; POLYAMINES; SENSATION; RELEASE	Homomeric acid-sensing ion channel 1 (ASIC1) can be activated by extracellular H+ in the physiological pH range and may, therefore, contribute to neurotransmission and peripheral pain perception. ASIC1a and ASIC1b are alternative splice products of the ASIC1 gene. Here we show that both splice variants show steady-state inactivation when exposed to slightly decreased pH, limiting their operational range. Compared with ASIC1a, steady-state inactivation and pH activation of ASIC1b are shifted to more acidic values by 0.25 and 0.7 pH units, respectively, extending the dynamic range of ASIC1. Shifts of inactivation and activation are intimately linked; only two amino acids in the ectodomain, which are exchanged by alternative splicing, control both properties. Moreover, we show that extracellular, divalent cations like Ca2+ and Mg2+ as well as the polyvalent cation spermine shift the steady-state inactivation of ASIC1a and ASIC1b to more acidic values. This leads to a potentiation of the channel response and is due to a stabilization of the resting state. Our results indicate that ASIC1b is an effective sensor of transient H+ signals during slight acidosis and that, in addition to alternative splicing, interaction with di- and polyvalent cations extends the dynamic range of ASIC H+ sensors.	Res Grp Sensory Physiol, Dept Otolaryngol, D-72076 Tubingen, Germany		Grunder, S (corresponding author), Res Grp Sensory Physiol, Dept Otolaryngol, D-72076 Tubingen, Germany.		Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883				Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; BENNINGER C, 1980, BRAIN RES, V187, P165, DOI 10.1016/0006-8993(80)90502-8; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Cook SP, 1998, J NEUROSCI, V18, P9238; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Grunder S, 2000, NEUROREPORT, V11, P1607; HEBERT SC, 1995, CURR OPIN CELL BIOL, V7, P484, DOI 10.1016/0955-0674(95)80004-2; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; KROIGAARD M, 1992, ACTA PHYSIOL SCAND, V146, P233, DOI 10.1111/j.1748-1716.1992.tb09412.x; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Madeja M, 1995, J NEUROSCI METH, V63, P211, DOI 10.1016/0165-0270(95)00094-1; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; NICHOLSON C, 1977, P NATL ACAD SCI USA, V74, P1287, DOI 10.1073/pnas.74.3.1287; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; PAOLETTI P, 1995, NEURON, V15, P1109, DOI 10.1016/0896-6273(95)90099-3; PASCHEN W, 1992, NEUROSCI LETT, V135, P121, DOI 10.1016/0304-3940(92)90150-6; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; PUMAIN R, 1985, J NEUROPHYSIOL, V53, P1; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	32	167	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41597	41603		10.1074/jbc.M205877200	http://dx.doi.org/10.1074/jbc.M205877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198124	hybrid			2022-12-25	WOS:000178985300039
J	Hartenstine, MJ; Goodman, MF; Petruska, J				Hartenstine, MJ; Goodman, MF; Petruska, J			Weak strand displacement activity enables human DNA polymerase beta to expand CAG/CTG triplet repeats at strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HEREDITARY-DISEASE GENES; IN-VITRO; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; REPLICATION; INSTABILITY; SLIPPAGE; YEAST; RECONSTITUTION	Using synthetic DNA constructs in vitro, we find that human DNA polymerase beta effectively catalyzes CAG/ CTG triplet repeat expansions by slippage initiated at nicks or 1-base gaps within short (14 triplet) repeat tracts in DNA duplexes under physiological conditions. In the same constructs, Escherichia coli DNA polymerase I Klenow Fragment exo(-) is much less effective in expanding repeats, because its much stronger strand displacement activity inhibits slippage by enabling rapid extension through two downstream repeats into flanking non-repeat sequence. Polymerase beta expansions of CAG/CTG repeats, observed over a 32-min period at rates of similar to1 triplet added per min, reveal significant effects of break type (nick versus gap), strand composition (CTG versus CAG), and dNTP substrate concentration, on repeat expansions at strand breaks. At physiological substrate concentrations (1-10 mum of each dNTP), polymerase beta expands triplet repeats with the help of weak strand displacement limited to the two downstream triplet repeats in our constructs. Such weak strand displacement activity in DNA repair at strand breaks may enable short tracts of repeats to be converted into longer, increasingly mutable ones associated with neurological diseases.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, SHS Room 172,Univ Pk, Los Angeles, CA 90089 USA.				NIA NIH HHS [AG17179] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017179] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BERGER SL, 1987, METHOD ENZYMOL, V152, P100; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Canceill D, 1999, J BIOL CHEM, V274, P27481, DOI 10.1074/jbc.274.39.27481; da Silva EF, 2000, J BIOL CHEM, V275, P31528, DOI 10.1074/jbc.M004594200; DARLOW JM, 1995, GENETICS, V141, P825; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GACY AM, 1995, CELL, V81, P533; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Gellibolian R, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P561; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Hartenstine MJ, 2000, J BIOL CHEM, V275, P18382, DOI 10.1074/jbc.275.24.18382; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Intano GW, 2001, NUCLEIC ACIDS RES, V29, P1366, DOI 10.1093/nar/29.6.1366; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kroutil LC, 1999, NUCLEIC ACIDS RES, V27, P3481, DOI 10.1093/nar/27.17.3481; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MITCHELL JB, 1985, MUTAT RES, V146, P295, DOI 10.1016/0167-8817(85)90071-9; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Morel P, 1998, P NATL ACAD SCI USA, V95, P10003, DOI 10.1073/pnas.95.17.10003; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009	40	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41379	41389		10.1074/jbc.M207013200	http://dx.doi.org/10.1074/jbc.M207013200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196536	hybrid			2022-12-25	WOS:000178985300013
J	Li, L; von Bergen, M; Mandelkow, EM; Mandelkow, E				Li, L; von Bergen, M; Mandelkow, EM; Mandelkow, E			Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-BINDING REGION; IN-VITRO POLYMERIZATION; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; FRONTOTEMPORAL DEMENTIA; BETA-STRUCTURE; AMYLOID-BETA; FLUORESCENCE; PEPTIDES; ISOFORMS	By using tryptophan scanning mutagenesis, we observed the kinetics and structure of the polymerization of tau into paired helical filaments (PHFs) independently of exogenous reporter dyes. The fluorescence exhibits pronounced blue shifts due to burial of the residue inside PHFs, depending on Trp position. The effect is greatest near the center of the repeat domain, showing that the packing is tightest near the beta-structure inducing hexapeptide motifs. The tryptophan response allows measurement of PHF stability made by different tau isoforms and mutants. Unexpectedly, the stability of PHFs is quite low (denaturation half-points similar to1.0 M GdnHCl), implying that incipient aggregation should be reversible and that the observed high stability of Alzheimer PHFs is due to other factors. The stability increases with the number of repeats and with tau mutants promoting beta-structure, arguing for a gain of toxic function in frontotemporal dementias. Fluorescence resonance energy transfer (FRET) was used to analyze the distances of Tyr(310) to tryptophans in different positions. The degree of FRET in the soluble protein was position-dependent, with highest signals within the second and third repeats but low or no signals further away. In PHFs most mutants showed FRET, indicating that tight packing results from assembly of tau into PHFs.	Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society	Mandelkow, E (corresponding author), Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.		von Bergen, Martin/D-7960-2011	von Bergen, Martin/0000-0003-2732-2977				Abraha A, 2000, J CELL SCI, V113, P3737; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CHIU HC, 1977, BIOPOLYMERS, V16, P277, DOI 10.1002/bip.1977.360160205; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DeTure MA, 1996, J BIOL CHEM, V271, P32702, DOI 10.1074/jbc.271.51.32702; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Garzon-Rodriguez W, 2000, J BIOL CHEM, V275, P22645, DOI 10.1074/jbc.M000756200; Gasymov OK, 2001, BIOCHEMISTRY-US, V40, P14754, DOI 10.1021/bi0110342; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, PROG BRAIN RES, V117, P287; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Perez M, 1996, J NEUROCHEM, V67, P1183; PERRY G, 1991, J NEUROSCI, V11, P3679; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Ropson IJ, 1997, BIOCHEMISTRY-US, V36, P8594, DOI 10.1021/bi962983b; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; Takano K, 2001, EUR J BIOCHEM, V268, P155, DOI 10.1046/j.1432-1327.2001.01863.x; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; Wilson DM, 1997, AM J PATHOL, V150, P2181; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884	54	65	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41390	41400		10.1074/jbc.M206334200	http://dx.doi.org/10.1074/jbc.M206334200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198126	hybrid			2022-12-25	WOS:000178985300014
J	Opresko, PL; von Kobbe, C; Laine, JP; Harrigan, J; Hickson, ID; Bohr, VA				Opresko, PL; von Kobbe, C; Laine, JP; Harrigan, J; Hickson, ID; Bohr, VA			Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CELLS; DNA HELICASE; SYNDROME FIBROBLASTS; RECQ FAMILY; WRN; REPLICATION; EXONUCLEASE; INTERACTS; REPEATS; REPAIR	Werner syndrome is a human premature aging disorder displaying cellular defects associated with telomere maintenance including genomic instability, premature senescence, and accelerated telomere erosion. The yeast homologue of the Werner protein (WRN), Sgs1, is required for recombination-mediated lengthening of telomeres in telomerase-deficient cells. In human cells, we report that WRN co-localizes and physically interacts with the critical telomere maintenance protein TRF2. This interaction is mediated by the RecQ conserved G terminal region of WRN. In vitro, TRF2 demonstrates high affinity for WRN and for another RecQ family member, the Bloom syndrome protein (BLM). TRF2 interaction with either WRN or BLM results in a notable stimulation of their helicase activities. Furthermore, the WRN and BLM helicases, partnered with replication protein A, actively unwind long telomeric duplex regions that are pre-bound by TRF2. These results suggest that TRF2 functions with WRN, and possibly BLM, in a common pathway at telomeric ends.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cancer Research UK; University of Oxford	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Hickson, Ian/0000-0002-0583-566X; von Kobbe, Cayetano/0000-0003-3895-3790; Opresko, Patricia/0000-0002-6470-2189	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; DADDA DF, 2001, CURR BIOL, V11, P1192; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hisama FM, 2000, CANCER RES, V60, P2372; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Schulz VP, 1996, HUM GENET, V97, P750; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yeager TR, 1999, CANCER RES, V59, P4175; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	51	306	318	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41110	41119		10.1074/jbc.M205396200	http://dx.doi.org/10.1074/jbc.M205396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181313	hybrid			2022-12-25	WOS:000178791400121
J	Vogen, S; Gidalevitz, T; Biswas, C; Simen, BB; Stein, E; Gulmen, F; Argon, Y				Vogen, S; Gidalevitz, T; Biswas, C; Simen, BB; Stein, E; Gulmen, F; Argon, Y			Radicicol-sensitive peptide binding to the N-terminal portion of GRP94	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; IN-VITRO; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; GP96 GRP94; DOMAIN; ANTIGEN; BIP	GRP94 is a molecular chaperone that carries immuno-logically relevant peptides from cell to cell, transferring them to major histocompatibility proteins for presentation to T cells. Here we examine the binding of several peptides to recombinant GRP94 and study the regulation and site of peptide binding. We show that GRP94 contains a peptide-binding site in its N-terminal 355 amino acids. A number of peptides bind to this site with low on- and off-rates and with specificity that is distinct from that of another endoplasmic reticulum chaperone, BiP/GRP78. Binding to the N-terminal fragment is sufficient to account for the peptide binding activity of the entire molecule. Peptide binding is inhibited by radicicol, a known inhibitor of the chaperone activities of HSP90-family proteins. However, the peptide-binding site is distinct from the radicicol-binding pocket, because both can bind to the N-terminal fragment simultaneously. Furthermore, peptide binding does not cause the same conformational change as does binding of radicicol. When the latter binds to the N-terminal domain, it induces a conformational change in the downstream, acidic domain of GRP94, as measured by altered gel mobility and loss of an antibody epitope. These results relate the peptide-binding activity of GRP94 to its other function as a chaperone.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Cell Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Argon, Y (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.		Gidalevitz, Tali/C-9217-2009; Simen, Birgitte/A-3574-2010	Gidalevitz, Tali/0000-0002-9178-6648; Simen, Birgitte/0000-0003-0503-0973	NCI NIH HHS [CA 74182] Funding Source: Medline; NHLBI NIH HHS [HL 07237] Funding Source: Medline; NIDDK NIH HHS [DK 07074] Funding Source: Medline; NIGMS NIH HHS [GM 07183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1995, SEMIN CANCER BIOL, V6, P349, DOI 10.1016/1044-579X(95)90004-7; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Davis DP, 1999, J IMMUNOL, V163, P3842; EDWARDS DP, 1984, BIOCHEMISTRY-US, V23, P4427, DOI 10.1021/bi00314a029; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Linderoth NA, 2001, J BIOL CHEM, V276, P11049, DOI 10.1074/jbc.M010059200; Linderoth NA, 2001, BIOCHEMISTRY-US, V40, P1483, DOI 10.1021/bi0016218; Linderoth NA, 2000, J BIOL CHEM, V275, P5472, DOI 10.1074/jbc.275.8.5472; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MELNICK J, 1995, THESIS DULE U DURHAM; Nair S, 1999, J IMMUNOL, V162, P6426; Nemoto TK, 2001, EUR J BIOCHEM, V268, P5258, DOI 10.1046/j.0014-2956.2001.02457.x; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SARGAN DR, 1986, BIOCHEMISTRY-US, V25, P6252, DOI 10.1021/bi00368a062; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAKEDA S, 1996, COLD SPRING HARB SYM, P289; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Tanaka E, 2001, EUR J BIOCHEM, V268, P5270, DOI 10.1046/j.0014-2956.2001.02458.x; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	52	56	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40742	40750		10.1074/jbc.M205323200	http://dx.doi.org/10.1074/jbc.M205323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189140	hybrid			2022-12-25	WOS:000178791400076
J	Wu, LT; Yu, ZB; Shen, SH				Wu, LT; Yu, ZB; Shen, SH			SKAP55 recruits to lipid rafts and positively mediates the MAPK pathway upon T cell receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; MEMBRANE MICRODOMAINS; LYMPHOCYTE-ACTIVATION; LAT; COMPLEX; CD45	T cell receptor (TCR) engagement triggers a series of events including protein tyrosine kinase activation, tyrosine phosphorylation of adapter proteins, and multiple protein-protein interactions. We observed that adapter protein SKAP55, the Src kinase-associated phosphoprotein, formed homodimers through its SH3 domain and SK region. SKAP55 as a substrate interacted with Fyn kinase in vivo. In Jurkat cells, interaction between SKAP55 and Fyn kinase depended on TCR activation. Stable overexpression of SKAP55 in Jurkat cells caused mitogen-activated protein kinase activation following TCR engagement. Anti-CD3 stimulation also promoted the interaction of SKAP55 with Grb-2 in T cells. Mutational analysis revealed that tyrosine 271 in SKAP55 played a pivotal role for interaction with both Fyn kinase and adapter protein Grb-2, indicating that the Fyn-phosphorylated SKAP55 transiently associates with adapter Grb-2 to mediate mitogen-activated protein kinase activation. Intriguingly, T cell receptor engagement dramatically induced the translocation of endogenous SKAP55 to lipid rafts where SKAP55 was found to interact with Fyn kinase, suggesting that the positive function of SKAP55 via its association with Fyn and other signaling components may have been involved in raft-mediated T cell activation.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	shi.shen@nrc.ca						Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Lin J, 2001, J CELL SCI, V114, P243; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; THOMAS ML, 1994, CURR OPIN CELL BIOL, V6, P247, DOI 10.1016/0955-0674(94)90143-0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Viola A, 2001, TRENDS IMMUNOL, V22, P322, DOI 10.1016/S1471-4906(01)01938-X; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu LT, 2002, MOL CELL BIOL, V22, P2673, DOI 10.1128/MCB.22.8.2673-2686.2002; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40420	40427		10.1074/jbc.M206023200	http://dx.doi.org/10.1074/jbc.M206023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171928	hybrid			2022-12-25	WOS:000178791400035
J	Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J				Lee, D; Kim, JW; Kim, K; Joe, CO; Schreiber, V; Menissier-de Murcia, J; Choe, J			Functional interaction between human papillomavirus type 18 E2 and poly(ADP-ribose) polymerase 1	ONCOGENE			English	Article						PARP; HPV; transcriptional activation	CALCIUM-INDUCED DIFFERENTIATION; HUMAN KERATINOCYTES; ADP-RIBOSYLATION; TRANSCRIPTIONAL REPRESSOR; CELL-DIFFERENTIATION; MAMMALIAN-CELLS; E7 ONCOPROTEIN; E6 ONCOPROTEIN; EARLY PROMOTER; HELA-CELLS	Human papillomavirus E2 protein is a transcription factor of viral gene expression and DNA replication. Here we show that PARP is a positive regulator of the E2 protein of human papillomavirus type 18 (HPV-18). PARP interacted with the COOH terminal region of HPV-18 E2 in vitro. The E2 interaction domain within PARP is located in the NH2-terminal zinc finger motif and the BRCT motif included in the automodification domain. Overexpression of either wild type or the NH2-terminal region of PARP containing zinc finger and BRCT stimulated E2-dependent transcription. Gel retardation assay indicates that PARP augments DNA binding activity of E2 in vitro. We also show that PARP-1 is recruited to E2-dependent promoter in vivo using ChIP assay. These results suggest that PARP serves a transcriptional co-activator in E2-dependent transcription by interacting directly with the HPV E2 protein.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Univ Strasbourg 1, UPR 9003, CNRS,Ecole Super Biotechnol, Lab Convent Commissariat Energie Atom, F-67400 Illkirch Graffenstaden, France	Korea Advanced Institute of Science & Technology (KAIST); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011; Kim, Karam/K-1412-2018; Schreiber, Valérie/M-5007-2016; Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	Lee, Daeyoup/0000-0003-2006-1823; Kim, Karam/0000-0002-1886-5163; Schreiber, Valérie/0000-0003-0507-639X; KIM, JIN WOO/0000-0003-0767-1918				Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; di Fagagna FD, 1999, NAT GENET, V23, P76; FERRO AM, 1984, J BIOL CHEM, V259, P547; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, J BIOL CHEM, V277, P6483, DOI 10.1074/jbc.M105085200; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Masutani M, 2001, MUTAT RES-FUND MOL M, V477, P111, DOI 10.1016/S0027-5107(01)00112-9; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; OHASHI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7132, DOI 10.1073/pnas.81.22.7132; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Pugh B F, 1995, Methods Mol Biol, V37, P349; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sherman L, 1997, VIROLOGY, V237, P296, DOI 10.1006/viro.1997.8778; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5877	5885		10.1038/sj.onc.1205723	http://dx.doi.org/10.1038/sj.onc.1205723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185587				2022-12-25	WOS:000177520900007
J	Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M				Malanchi, I; Caldeira, S; Krutzfeldt, M; Giarre, M; Alunni-Fabbroni, M; Tommasino, M			Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition	ONCOGENE			English	Article						HPV; E6; G1/S transition	CELL-CYCLE REGULATION; RETINOBLASTOMA-PROTEIN; E7 ONCOPROTEIN; INHIBITOR P27(KIP1); GROWTH ARREST; GENE-PRODUCT; S-PHASE; C-MYC; BINDING; PATHWAY	In this study we show that E6 of human papillomavirus has the ability to deregulate the cell cycle G1/S transition. In rodent immortalized fibroblasts (NIH3T3) serum deprivation or over-expression of the cyclin-dependent kinase inhibitors, p16(INK4a) or p27(KIP1), leads to G1 cell cycle arrest. HPV16 E6 overcomes the antiproliferative signals, gaining the ability to drive serum-deprived and p16(INK4a) or p27(KIP1) over-expressing cells into S phase. E6 protein from the benign HPV type 1 displays a similar activity to HPV16 E6 to deregulate the G1/S transition. Thus, this activity appears to be conserved between E6 proteins from non-oncogenic and oncogenic HPV types. Furthermore, we show that HPV16 E6 is not able to circumvent a G1 arrest imposed by pRb mutant in which all CDK phosphorylation sites have been mutated. These data indicate that the viral protein acts upstream of pRb and its mechanism in promoting cell cycle progression is dependent on pRb phosphorylation. In summary, this study describes a novel biological function of HPV E6 and shows that the S phase entry, required for viral DNA replication, is not exclusively controlled by E7, but that E6 also is involved in this event.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alunni-Fabbroni M, 2000, ONCOGENE, V19, P2277, DOI 10.1038/sj.onc.1203570; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; TOMMASINO M, 1997, E7 PROTEIN HUMAN PAP; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zwerschke W, 2000, ADV CANCER RES, V78, P1	30	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5665	5672		10.1038/sj.onc.1205617	http://dx.doi.org/10.1038/sj.onc.1205617			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173036				2022-12-25	WOS:000177463400001
J	Stamos, J; Sliwkowski, MX; Eigenbrot, C				Stamos, J; Sliwkowski, MX; Eigenbrot, C			Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; CRYSTAL-STRUCTURE; EGF RECEPTOR; CANCER; ACTIVATION; SUBSTRATE; ONCOGENE; REVEALS; TARGET; REGION	The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-Angstrom resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva(TM)). The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains. Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor., Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain. Significant intermolecular contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Eigenbrot, C (corresponding author), 1 DNA Way, San Francisco, CA 94080 USA.	eigenbrot.c@gene.com						Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASU M, 1986, J BIOL CHEM, V261, P2879; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bridges AJ, 2001, CHEM REV, V101, P2541, DOI 10.1021/cr000250y; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OSIGO H, 2002, CELL, V110, P775; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Palmer BD, 1997, J MED CHEM, V40, P1519, DOI 10.1021/jm960789h; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REWCASTLE GW, 1995, J MED CHEM, V38, P3482, DOI 10.1021/jm00018a008; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TIMMS JF, 1995, BIOCHEM J, V308, P219, DOI 10.1042/bj3080219; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wissner A, 2000, J MED CHEM, V43, P3244, DOI 10.1021/jm000206a; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	48	967	1014	3	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46265	46272		10.1074/jbc.M207135200	http://dx.doi.org/10.1074/jbc.M207135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12196540	hybrid			2022-12-25	WOS:000179529300075
J	Cabiscol, E; Belli, G; Tamarit, J; Echave, P; Herrero, E; Ros, J				Cabiscol, E; Belli, G; Tamarit, J; Echave, P; Herrero, E; Ros, J			Mitochondrial Hsp60, resistance to oxidative stress, and the labile iron pool are closely connected in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DNA-DAMAGE; STATIONARY-PHASE; CELL-DEATH; IN-VIVO; OXYGEN; CHAPERONE; GROEL; IDENTIFICATION; REQUIREMENT	In the present study, we have analyzed the role of the molecular chaperone Hsp60 in protection of Saccharomyces cerevisiae against oxidative damage. We constructed mutant strains in which the levels of Hsp60 protein, compared with wild-type cells, were four times greater, and the addition of doxycycline gradually reduces them to 20% of wild-type. Under oxidative-stress conditions, the progressive decrease in Hsp60 levels in these mutants resulted in reduced cell viability and an increase in both cell peroxide species and protein carbonyl content. Protection of Fe/S-containing enzymes from oxidative inactivation was found to be dose-dependent with respect to Hsp60 levels. As these enzymes release their iron ions under oxidative-stress conditions, the intracellular labile iron pool, monitored with calcein, was higher in cells with reduced Hsp60 levels. Consistently, the iron chelator deferoxamine protected low Hsp60-expressing cells from both oxidant-induced death and protein oxidation. These results indicate that the role of Hsp60 in oxidative-stress defense is explained by protection of several Fe/S proteins, which prevent the release of iron ions and thereby avert further damage.	Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Lleida 25198, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Av Rovira Roure 44, Lleida 25198, Spain.	joaquim.ros@cmb.udl.es	Bellí, Gemma/AAD-5325-2019; Herrero, Enrique/B-5592-2009; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009; belli, gemma/A-7424-2011; ROS, Joaquim/ABG-7487-2020	Bellí, Gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999; belli, gemma/0000-0002-4161-3204; ROS, Joaquim/0000-0003-0901-8648				Baumann F, 2000, FEBS LETT, V487, P307, DOI 10.1016/S0014-5793(00)02364-4; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; BRIONES P, 1997, J INHERIT METAB DIS, V20, P469; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Davidson JF, 2001, J BACTERIOL, V183, P4580, DOI 10.1128/JB.183.15.4580-4587.2001; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; Dubaquie Y, 1998, EMBO J, V17, P5868, DOI 10.1093/emboj/17.20.5868; Echave P, 2002, P NATL ACAD SCI USA, V99, P4626, DOI 10.1073/pnas.072504199; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GALEY JP, 1997, ANTIOXIDANTS DIS MEC, P147; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gosslau A, 2001, J BIOL CHEM, V276, P1814, DOI 10.1074/jbc.M008280200; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Huang J, 1996, BRAIN RES, V711, P184, DOI 10.1016/0006-8993(95)01376-8; HUCKRIEDE A, 1995, VIRCHOWS ARCH, V427, P159; HUCKRIEDE A, 1994, BBA-MOL BASIS DIS, V1227, P200, DOI 10.1016/0925-4439(94)90096-5; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu HD, 1996, GENE DEV, V10, P592; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PETIT MA, 1994, J BIOL CHEM, V269, P23824; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SLURZ LA, 2001, J BIOL CHEM, V276, P38084; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	82	116	118	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44531	44538		10.1074/jbc.M206525200	http://dx.doi.org/10.1074/jbc.M206525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200437	hybrid, Green Published			2022-12-25	WOS:000179272000125
J	Barnakov, AN; Barnakova, LA; Hazelbauer, GL				Barnakov, AN; Barnakova, LA; Hazelbauer, GL			Allosteric enhancement of adaptational demethylation by a carboxyl-terminal sequence on chemoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-ABUNDANCE CHEMORECEPTOR; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; SENSORY TRANSDUCER; REGULATORY DOMAIN; COVALENT MODIFICATION; METHYLESTERASE CHEB; DOCKING SITE; GENE-PRODUCT	Sensory adaptation in bacterial chemotaxis is mediated by covalent modification of chemoreceptors. Specific glutamyl residues are methylated and demethylated in reactions catalyzed by methyltransferase CheR and methylesterase CheB. In Escherichia coli and Salmonella enterica serovar typhimurium, efficient adaptational modification by either enzyme is dependent on a conserved pentapeptide sequence at the chemoreceptor carboxyl terminus, a position distant from the sites of modification. For CheR-catalyzed methylation, previous work demonstrated that this sequence acts as a high affinity docking site, enhancing methylation by increasing enzyme concentration near methyl-accepting glutamates. We investigated pentapeptide-mediated enhancement of CheB-catalyzed demethylation and found it occurred by a distinctly different mechanism. Assays of binding between CheB and the pentapeptide sequence showed that it was too weak to have a significant effect on local enzyme concentration. Kinetic analyses revealed that interaction of the sequence and the methylesterase enhanced the rate constant of demethylation not the Michaelis constant. This allosteric activation occurred if the sequence was attached to chemoreceptor, but hardly at all if it was present as an isolated peptide. In addition, free peptide inhibited demethylation of the native receptor carrying the pentapeptide sequence at its carboxyl terminus. These observations imply that the allosteric change is transmitted through the protein substrate, not the enzyme.	Washington State Univ, Pullman, WA 99164 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	Washington State University; University of Missouri System; University of Missouri Columbia	Hazelbauer, GL (corresponding author), Washington State Univ, Pullman, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029963, R37GM029963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand GS, 1998, BIOCHEMISTRY-US, V37, P14038, DOI 10.1021/bi980865d; Anand GS, 2002, BIOCHEMISTRY-US, V41, P6752, DOI 10.1021/bi012102n; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; Barnakov AN, 1998, J BACTERIOL, V180, P6713, DOI 10.1128/JB.180.24.6713-6718.1998; Barnakov AN, 1999, P NATL ACAD SCI USA, V96, P10667, DOI 10.1073/pnas.96.19.10667; Barnakov AN, 2001, J BIOL CHEM, V276, P32984, DOI 10.1074/jbc.M105925200; BORCZUK A, 1986, BIOCHEM BIOPH RES CO, V141, P918, DOI 10.1016/S0006-291X(86)80130-9; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; CLARKE S, 1979, J BIOL CHEM, V254, P9695; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Feng XH, 1999, J BACTERIOL, V181, P3164, DOI 10.1128/JB.181.10.3164-3171.1999; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1981, J BACTERIOL, V145, P43, DOI 10.1128/JB.145.1.43-49.1981; HAZELBAUER GL, 1980, NATURE, V283, P98, DOI 10.1038/283098a0; HAZELBAUER GL, 1999, ENCY NEUROSCIENCE, P181; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Levin MD, 2002, BIOPHYS J, V82, P1809, DOI 10.1016/S0006-3495(02)75531-8; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MESIBOV R, 1973, J GEN PHYSIOL, V62, P203, DOI 10.1085/jgp.62.2.203; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; RICE MS, 1991, J BIOL CHEM, V266, P9746; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SHAPIRO MJ, 1995, P NATL ACAD SCI USA, V92, P1053, DOI 10.1073/pnas.92.4.1053; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SORBER HA, 1968, HDB BIOCH; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1981, J BIOL CHEM, V256, P826; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WEST AH, 1995, PROTEINS, V21, P345, DOI 10.1002/prot.340210407; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YAMAMOTO K, 1990, J BACTERIOL, V172, P383, DOI 10.1128/JB.172.1.383-388.1990	50	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42151	42156		10.1074/jbc.M206245200	http://dx.doi.org/10.1074/jbc.M206245200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196531	hybrid			2022-12-25	WOS:000178985300107
J	Lu, H; Xu, TL				Lu, H; Xu, TL			The general anesthetic pentobarbital slows desensitization and deactivation of the glycine receptor in the rat spinal dorsal horn neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG SENSORY NEURONS; GATED ION CHANNELS; GABA(A) RECEPTORS; HIPPOCAMPAL-NEURONS; COMMISSURAL NEURONS; SYNAPTIC TRANSMISSION; IN-VITRO; CORD; ACTIVATION; BRAIN	Although many general anesthetics have been found to produce anesthetic and analgesic effects by augmenting GABA(A) receptor (GABA(A)R) function, the role of the glycine receptor (GlyR) in this process is not fully understood at the neuronal level in the spinal cord. We investigated the effects of a barbiturate general anesthetic, pentobarbital (PB), on the glycinergic miniature inhibitory postsynaptic currents (mIPSCs) and the responses to exogenously applied glycine, or taurine, a low affinity GlyR agonist, by using the whole-cell patch-clamp technique in the rat spinal dorsal horn neurons isolated using a novel mechanical method. Bath application of 30 mum PB significantly prolonged the decay time constant of the spontaneous glycinergic mIPSC without changing its amplitude and frequency. Co-application of 0.3 mm PB reduced the peak amplitude, affected the macroscopic desensitization and deactivation of the response to externally applied Gly in a concentration-dependent manner. In addition, the recovery of Gly response from desensitization was also prolonged by PB. However, PB did not change the desensitization and deactivation kinetics of the taurine-induced response. The GABA(A)R antagonist bicuculline (10 mum) did not affect the effect of PB on the Gly response. Thus, PB prolonged the spinal glycinergic mIPSCs by slowing desensitization and deactivation of GlyR. Two other structurally different intravenous anesthetics, i.e. propofol (10 mum) and etomidate (3 mum), prolonged the duration of the glycinergic mIPSC in the rat spinal dorsal horn neurons. In conclusion, on GlyR-Cl- channel complexes there may exist action site(s) of intravenous general anesthetics. GlyR and glycinergic neurotransmission may play an important role in the modulation of general anesthesia in the mammalian spinal cord.	Univ Sci & Technol China, Det Neurobiol & Biophys, Sch Life Sci, Lab Receptor Pharmacol, Hefei 230027, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Xu, TL (corresponding author), Univ Sci & Technol China, Det Neurobiol & Biophys, Sch Life Sci, Lab Receptor Pharmacol, POB 4, Hefei 230027, Peoples R China.	xutianle@ustc.edu.cn	Lu, Hui/K-2322-2013					AKAIKE N, 1985, J PHYSIOL-LONDON, V360, P367, DOI 10.1113/jphysiol.1985.sp015622; AKAIKE N, 1987, J PHYSIOL-LONDON, V394, P85, DOI 10.1113/jphysiol.1987.sp016861; AKAIKE N, 1990, AM J PHYSIOL, V258, pC452, DOI 10.1152/ajpcell.1990.258.3.C452; Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; Antognini JF, 1997, ANESTHESIOLOGY, V87, pA292, DOI 10.1097/00000542-199709001-00292; Antognini JF, 1998, TOXICOL LETT, V101, P51, DOI 10.1016/S0378-4274(98)00164-7; Bai DL, 1999, J NEUROSCI, V19, P10635, DOI 10.1523/JNEUROSCI.19-24-10635.1999; Beckstead MJ, 2001, J BIOL CHEM, V276, P24959, DOI 10.1074/jbc.M011627200; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Cheng G, 2002, BRIT J PHARMACOL, V136, P673, DOI 10.1038/sj.bjp.0704760; COLLINS JG, 1995, TRENDS NEUROSCI, V18, P549, DOI 10.1016/0166-2236(95)98377-B; Dalziel JE, 1999, EUR J PHARMACOL, V385, P283, DOI 10.1016/S0014-2999(99)00710-4; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Jones MV, 1996, TRENDS NEUROSCI, V19, P96, DOI 10.1016/S0166-2236(96)80037-3; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Jones MV, 1998, J NEUROSCI, V18, P8590; KENDIG JJ, 1993, ANESTHESIOLOGY, V79, P1161; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Lei SB, 2001, J NEUROPHYSIOL, V85, P2030, DOI 10.1152/jn.2001.85.5.2030; Li XS, 2000, J NEUROSCI, V20, P899, DOI 10.1523/JNEUROSCI.20-03-00899.2000; Li Y, 2002, NEUROREPORT, V13, P223, DOI 10.1097/00001756-200202110-00010; Li YX, 1997, DEV BRAIN RES, V102, P261, DOI 10.1016/S0165-3806(97)00102-8; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; ORSER BA, 1994, J NEUROSCI, V14, P7747; Pang ZP, 1998, ACTA PHARMACOL SIN, V19, P327; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; Rho JM, 1996, J PHYSIOL-LONDON, V497, P509, DOI 10.1113/jphysiol.1996.sp021784; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Serafini R, 2000, J PHYSIOL-LONDON, V524, P649, DOI 10.1111/j.1469-7793.2000.00649.x; Shen WX, 2000, J NEUROSCI, V20, P3571, DOI 10.1523/JNEUROSCI.20-10-03571.2000; Wang ZM, 2001, J NEUROSCI, V21, P2983, DOI 10.1523/JNEUROSCI.21-09-02983.2001; WU J, 1994, BRAIN RES, V645, P303, DOI 10.1016/0006-8993(94)91664-0; Wu LJ, 2002, NEUROREPORT, V13, P977, DOI 10.1097/00001756-200205240-00016; Wu LJ, 2001, J NEUROSCI METH, V108, P199, DOI 10.1016/S0165-0270(01)00404-6; Xu TL, 1998, BRIT J PHARMACOL, V124, P779, DOI 10.1038/sj.bjp.0701896; Xu TL, 1999, J AUTONOM NERV SYST, V75, P156, DOI 10.1016/S0165-1838(98)00187-8; Xu TL, 1996, J PHYSIOL-LONDON, V496, P491, DOI 10.1113/jphysiol.1996.sp021701; Zhu WJ, 1997, J NEUROSCI, V17, P4022	44	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41369	41378		10.1074/jbc.M206768200	http://dx.doi.org/10.1074/jbc.M206768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196533	hybrid			2022-12-25	WOS:000178985300012
J	Muroi, M; Ohnishi, T; Tanamoto, K				Muroi, M; Ohnishi, T; Tanamoto, K			Regions of the mouse CD14 molecule required for Toll-like receptor 2-and 4-mediated activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; LIPOPOLYSACCHARIDE LPS; CELLULAR-RESPONSES; BINDING; TLR4; MICE; IDENTIFICATION; ENDOTOXIN; MD-2; RESPONSIVENESS	Regions of mouse CD14 required for Toll-like receptor 2 (TLR2)- and TLR4-mediated activation of NF-kappaB were studied in transiently transfected 293 cells. Wild-type CD14 enhanced lipopolysaccharide (LPS)-induced NF-kappaB-dependent reporter activity in cells expressing TLR4/MD-2, and deletion of amino acid regions 35-44, 144-153, 235-243, and 270-275 impaired the TLR4-mediated activation. Unlike human CD14, mouse CD14 truncated at amino acid 151 lost the activity. Deletion of amino acids 35-44 or 235-243 also abrogated TLR2-mediated activation of NF-kappaB, whereas mutants lacking 144-153 and 270-275 retained the activity. Deletion and alanine substitution experiments revealed that amino acids 151-153 and 273-275 were required for the TLR4-mediated activation. Both deletion mutants lacking amino acids 35-44 and 235-243 and alanine substitution mutants in regions 151-153 and 273-275 were expressed on the cell surface and retained the ability to associate with TLR4. A cross-linking study with photoreactive LPS showed that the labeling intensities to CD14 mutants/TLR4/MD-2 were paralleled by the ability of CD14 mutants to increase TLR4-mediated activation. These results indicate that different regions of mouse CD14 are required for TLR4- and TLR2-mediated activation of NF-kappaB and suggest that amino acids 35- 44, 151-153, 235243, and 273-275 of mouse CD14 play an important role in LPS binding and its transfer to TLR4/MD-2.	Natl Inst Hlth Sci, Div Microbiol, Tokyo 1588501, Japan	National Institute of Health Sciences - Japan	Tanamoto, K (corresponding author), Natl Inst Hlth Sci, Div Microbiol, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	tanamoto@nihs.go.jp						Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Means TK, 1999, J IMMUNOL, V163, P6748; MUROI M, 1995, J ENDOTOXIN RES, V2, P337, DOI 10.1177/096805199500200504; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Ohnishi T, 2001, J IMMUNOL, V167, P3354, DOI 10.4049/jimmunol.167.6.3354; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shapiro RA, 1997, INFECT IMMUN, V65, P293, DOI 10.1128/IAI.65.1.293-297.1997; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stelter F, 1997, EUR J BIOCHEM, V243, P100, DOI 10.1111/j.1432-1033.1997.00100.x; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; ULMER AJ, 1990, ENDOTOXIN HLTH DIS, P463; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; Vogel SN, 1999, J IMMUNOL, V162, P5666; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	41	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42372	42379		10.1074/jbc.M205966200	http://dx.doi.org/10.1074/jbc.M205966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196527	hybrid			2022-12-25	WOS:000178985300134
J	Donovan, N; Becker, EBE; Konishi, Y; Bonni, A				Donovan, N; Becker, EBE; Konishi, Y; Bonni, A			JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; C-JUN; INDUCED APOPTOSIS; BCL-2 FAMILY; NEURONAL APOPTOSIS; PROTEIN-KINASES; SURVIVAL SIGNAL; MAP KINASES; AGONIST BAD; MITOCHONDRIA	The c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in mediating apoptosis in the developing and mature organism. The JNK signaling pathway is thought to induce apoptosis via transcription-dependent and transcription-independent mechanisms that remain to be elucidated. In this study, we report a novel mechanism by which the JNK signaling pathway directly activates a component of the cell death machinery. We have found that JNK catalyzes the phosphorylation of the BH3-only protein BAD at the distinct site of serine 128 in vitro. Activation of the JNK signaling pathway induces the BAD serine 128 phosphorylation in vivo, including in primary granule neurons of the developing rat cerebellum. The JNK-induced BAD serine 128 phosphorylation promotes the apoptotic effect of BAD in primary neurons by antagonizing the ability of growth factors to inhibit BAD-mediated apoptosis. These findings indicate that BAD is a novel substrate of JNK that links the stress-activated signaling pathway to the cell death machinery.	Harvard Univ, Sch Med, Program Biol & Biomed Sci, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Bonni, A (corresponding author), Harvard Univ, Sch Med, Program Biol & Biomed Sci, Dept Pathol, Boston, MA 02115 USA.			Becker, Esther B E/0000-0002-5238-4902	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 41021-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEL PL, 1997, SCIENCE, V278, P687; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LOWENSTEIN DH, 1991, EPILEPSY RES, V10, P49, DOI 10.1016/0920-1211(91)90094-V; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; THOMPSON CB, 1995, SCIENCE, V267; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Watson A, 1998, J NEUROSCI, V18, P751; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	197	199	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40944	40949		10.1074/jbc.M206113200	http://dx.doi.org/10.1074/jbc.M206113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189144	hybrid			2022-12-25	WOS:000178791400101
J	Muscat, GEO; Wagner, BL; Hou, JZ; Tangirala, RK; Bischoff, ED; Rohde, P; Petrowski, M; Li, JL; Shao, G; Macondray, G; Schulman, IG				Muscat, GEO; Wagner, BL; Hou, JZ; Tangirala, RK; Bischoff, ED; Rohde, P; Petrowski, M; Li, JL; Shao, G; Macondray, G; Schulman, IG			Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; GENE-EXPRESSION; DIETARY-CHOLESTEROL; LXR; EFFLUX; ABCA1; ATHEROSCLEROSIS; MUTATIONS; ALPHA; IDENTIFICATION	Recent studies have identified the liver X receptors (LXRalpha and LXRbeta) as important regulators of cholesterol and lipid metabolism. Although originally identified as liver-enriched transcription factors, LXRs are also expressed in skeletal muscle, a tissue that accounts for similar to40% of human total body weight and is the major site of glucose utilization and fatty acid oxidation. Nevertheless, no studies have yet addressed the functional role of LXRs in muscle. In this work we utilize a combination of in vivo and in vitro analysis to demonstrate that LXRs can functionally regulate genes involved in cholesterol metabolism in skeletal muscle. Furthermore we show that treatment of muscle cells in vitro with synthetic agonists of LXR increases the efflux of intracellular cholesterol to extracellular acceptors such as high density lipoprotein, thus identifying this tissue as a potential important regulator of reverse cholesterol transport and high density lipoprotein levels. Additionally we demonstrate that LXRa and a subset of LXR target genes are induced during myogenesis, suggesting a role for LXR-dependent signaling in the differentiation process.	X Ceptor Therapeut Inc, San Diego, CA 92121 USA; Univ Queensland, Ritchie Res Labs, Ctr Cellular & Mol Biol, Inst Mol Biosci, St Lucia, Qld 4072, Australia	University of Queensland	Muscat, GEO (corresponding author), X Ceptor Therapeut Inc, San Diego, CA 92121 USA.	g.muscat@imb.uq.edu.au; ischulman@x-ceptor.com	Muscat, George/A-6401-2017	Muscat, George/0000-0002-5829-5695				Attie AD, 2001, J LIPID RES, V42, P1717; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Costet P, 2000, J BIOL CHEM, V275, P28240; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Edwards PA, 2002, J LIPID RES, V43, P2; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; Hobbs HH, 1999, J CLIN INVEST, V104, P1015, DOI 10.1172/JCI8509; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kohro T, 2000, J Atheroscler Thromb, V7, P145; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Oram JF, 2001, J LIPID RES, V42, P1173; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	38	81	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40722	40728		10.1074/jbc.M206681200	http://dx.doi.org/10.1074/jbc.M206681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193599	hybrid			2022-12-25	WOS:000178791400073
J	Virkki, LV; Franke, C; Somieski, P; Boron, WF				Virkki, LV; Franke, C; Somieski, P; Boron, WF			Cloning and functional characterization of a novel aquaporin from Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NEUTRAL SOLUTE CHANNEL; MOLECULAR CHARACTERIZATION; WATER CHANNEL; TRANSPORT; EXPRESSION; GLYCEROL; LENS; MIP; PERMEABILITY	We have cloned a novel aquaporin (AQP) from Xenopus laevis oocytes, which we have provisionally named AQPxlo. The predicted protein showed highest homology (39-50%) to aquaglyceroporins. Northern blot analysis showed strong hybridization to an similar to1.4-kb transcript in X. laevis fat body and oocytes, whereas a weaker signal was obtained in kidney. We injected in vitro transcribed cRNA encoding AQPxlo into Xenopus oocytes for functional characterization. AQPxlo expression increased osmotic water permeability (P-f), as well as the uptake of glycerol and urea. However, AQPxlo excluded larger polyols and thiourea. An alkaline extracellular pH (pH(o)) increased P-f and to a lesser extent urea uptake but not glycerol uptake. Remarkably, low HgCl2, concentrations (0.3-10 mum) reduced P-f and urea uptake, whereas high concentrations (300-1000 mum) reversed the inhibition. We propose that AQPxlo is a new AQP paralogue unknown in mammals.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Virkki, LV (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,POB 208026, New Haven, CT 06520 USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				Chandy G, 1997, J MEMBRANE BIOL, V159, P29, DOI 10.1007/s002329900266; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; KARNISKI LP, 1992, J BIOL CHEM, V267, P19218; KUSHMERICK C, 1995, EXP EYE RES, V61, P351, DOI 10.1016/S0014-4835(05)80129-0; Kushmerick C, 1998, J MEMBRANE BIOL, V161, P9, DOI 10.1007/s002329900310; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Palacin M, 2001, CURR OPIN GENET DEV, V11, P328, DOI 10.1016/S0959-437X(00)00198-2; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schreiber R, 2000, FEBS LETT, V475, P291, DOI 10.1016/S0014-5793(00)01689-6; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549; Virkki LV, 2002, AM J PHYSIOL-CELL PH, V282, pC1278, DOI 10.1152/ajpcell.00589.2001; Virkki LV, 2001, AM J PHYSIOL-REG I, V281, pR1994, DOI 10.1152/ajpregu.2001.281.6.R1994; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631; ZHANG R, 1990, J BIOL CHEM, V265, P15375	26	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40610	40616		10.1074/jbc.M206157200	http://dx.doi.org/10.1074/jbc.M206157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192003	hybrid			2022-12-25	WOS:000178791400059
J	Borza, DB; Bondar, O; Todd, P; Sundaramoorthy, M; Sado, Y; Ninomiya, Y; Hudson, BG				Borza, DB; Bondar, O; Todd, P; Sundaramoorthy, M; Sado, Y; Ninomiya, Y; Hudson, BG			Quaternary organization of the goodpasture autoantigen, the alpha 3(IV) collagen chain - Sequestration of two cryptic autoepitopes by intraprotomer interactions with the alpha 4 and alpha 5 NC1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; LINKED ALPORT SYNDROME; IV COLLAGEN; DIFFERENTIAL EXPRESSION; NONCOLLAGENOUS DOMAIN; MONOCLONAL-ANTIBODIES; IDENTIFICATION; NETWORK; ANTIGEN; EPITOPE	Goodpasture's (GP) disease is caused by autoantibodies that target the alpha3(IV) collagen chain in the glomerular basement membrane (GBM). Goodpasture autoantibodies bind two conformational epitopes (E-A and E-B) located within the non-collagenous (NC1) domain of this chain, which are sequestered within the NC1 hexamer of the type IV collagen network containing the alpha3(IV), alpha4(IV)l and alpha5(IV) chains. In this study, the quaternary organization of these chains and the molecular basis for the sequestration of the epitopes were investigated. This was accomplished by physicochemical and immunochemical characterization of the NC1 hexamers using chain-specific antibodies. The hexamers were found to have a molecular composition of (alpha3)(2)(alpha4)(2)(alpha5)(2) and to contain cross-linked alpha3-alpha5 heterodimers and alpha4-alpha4 homodimers. Together with association studies of individual NC1 domains, these findings indicate that the alpha3, alpha4, and alpha5 chains occur together in the same triple-helical protomer. In the GBM, this protomer dimerizes through NC1-NC1 domain interactions such that the alpha3, alpha4, and alpha5 chains of one protomer connect with the alpha5, alpha4, and alpha3 chains of the opposite protomer, respectively. The immunodominant Goodpasture autoepitope, located within the E-A region, is sequestered within the alpha3alpha4alpha5 protomer near the triple-helical junction, at the interface between the alpha3NC1 and alpha5NC1 domains, whereas the E-B epitope is sequestered at the interface between the alpha3NC1 and alpha4NC1 domains. The results also reveal the network distribution of the six chains of collagen IV in the renal glomerulus and provide a molecular explanation for the absence of the alpha3, alpha4, alpha5, and alpha6 chains in Alport syndrome.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Shigei Med Res Inst, Div Immunol, Okayama 701, Japan; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan	Vanderbilt University; Okayama University	Borza, DB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 221 Kirkland Hall, Nashville, TN 37232 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [P01 DK53763, R37 DK18381, R01 DK63925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, R37DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; David M, 2001, J BIOL CHEM, V276, P6370, DOI 10.1074/jbc.M008956200; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; GUBLER MC, 1995, KIDNEY INT, V47, P1142, DOI 10.1038/ki.1995.163; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Heidet L, 2000, AM J PATHOL, V156, P1901, DOI 10.1016/S0002-9440(10)65063-8; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kashtan C E, 1996, Contrib Nephrol, V117, P142; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Nakanishi K, 1996, J AM SOC NEPHROL, V7, P938; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; Nomura S, 1998, Am J Kidney Dis, V31, pE4; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; Seki T, 1998, HISTOCHEM CELL BIOL, V110, P359, DOI 10.1007/s004180050296; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WEBER S, 1988, EUR J BIOCHEM, V175, P229, DOI 10.1111/j.1432-1033.1988.tb14188.x; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; WILSON CB, 2002, MOL PATHOLOGY AUTOIM, P981; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	34	64	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40075	40083		10.1074/jbc.M207769200	http://dx.doi.org/10.1074/jbc.M207769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12193605	hybrid			2022-12-25	WOS:000178662500128
J	Fukuda, M; Kanno, E; Saegusa, C; Ogata, Y; Kuroda, TS				Fukuda, M; Kanno, E; Saegusa, C; Ogata, Y; Kuroda, TS			Slp4-a/granuphilin-a regulates dense-core vesicle exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOTAGMIN-IV; MELANOSOME TRANSPORT; NEUROENDOCRINE CELLS; RAB GTPASES; ASHEN MICE; DOMAIN; BINDING; FAMILY; TRANSMEMBRANE; MELANOCYTES	Synaptotagmin-like protein 4-a (Slp4-a)/granuphilin-a was originally identified as a protein specifically associated with insulin-containing vesicles in pancreatic beta-cells (Wang, J., Takeuchi, T., Yokota, H., and Izumi, T. (1999) J. Biol Chem. 274, 28542-28548). Previously, we showed that the N-terminal Slp homology domain of Slp4-a interacts with the GTP-bound form of Rab3A, Rab8, and Rab27A both in vitro and in intact cells (Kuroda, T. S., Fukuda, M., Ariga, H., and Alikoshiba, K. (2002) J. Biol Chem. 277,9212-9218). How Slp4-a-Rab complex controls regulated secretion, and which Rab isoforms dominantly interact with Slp4-a in vivo, however, have remained unknown. In this study, we showed by immunocytochemistry and subcellular fractionation that three Rabs, Rab3A, Rab8, and Rab27A, and Slp4-a are endogenously expressed in neuroendocrine PC12 cells and localized on dense-core vesicles, and we discovered that the Slp4-a.Rab8 and Slp4-a.Rab27A complexes, but not Slp4-a.Rab3A complexes, are formed on dense-core vesicles in PC12 cells, although the majority of Rab8 is present in the cell body and is free of Slp4-a. We further showed that expression of Rab27A, but not of Rab8, promotes high KCl-dependent secretion of neuropeptide Y (NPY) in PC12 cells, whereas expression of Slp4-a, but not of an Slp4-a mutant incapable of Rab27A binding, inhibits NPY secretion in PC12 cells. In contrast, expression of Slp3-a, but not of Slp3-b lacking an N-terminal Rab27A-binding domain, promotes NPY secretion. These findings suggest that the Slp family controls regulated dense-core vesicle exocytosis via binding to Rab27A.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	45	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39673	39678		10.1074/jbc.M205349200	http://dx.doi.org/10.1074/jbc.M205349200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176990	hybrid			2022-12-25	WOS:000178662500080
J	Nieswandt, B; Schulte, V; Zywietz, A; Gratacap, MP; Offermanns, S				Nieswandt, B; Schulte, V; Zywietz, A; Gratacap, MP; Offermanns, S			Costimulation of G(i)- and G(12)/G(13)-mediated signaling pathways induces integrin alpha(IIb)beta(3) activation in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAPE CHANGE; ANTITHROMBOTIC DRUGS; INDUCED AGGREGATION; COUPLED RECEPTORS; P2Y(1) RECEPTOR; GLYCOPROTEIN-VI; G-PROTEIN; COLLAGEN; KINASE; MICE	Platelet activation is a complex process induced by a variety of stimuli, which act in concert to ensure the rapid formation of a platelet plug at places of vascular injury. We show here that fibrillar collagen, which initiates platelet activation at the damaged vessel wall, activates only a small fraction of platelets in suspension directly, whereas the majority of platelets becomes activated by mediators released from collagen-activated platelets. In Galpha(q)-deficient platelets that do not respond with activation of integrin alpha(IIb)beta(3) to a variety of mediators like thromboxane A(2) (TXA(2)), thrombin, or ADP, collagen at high concentrations was able to induce aggregation, an effect that could be blocked by antagonists of the TXA(2) or P2Y(12) receptors. The activation of TXA(2) or P2Y(12) receptors alone, which in Galpha(q)-deficient platelets couple to G(12)/G(13) and G(i), respectively, did not induce platelet integrin activation or aggregation. However, concomitant activation of both receptors resulted in irreversible integrin alpha(IIb)beta(3)-mediated aggregation of Galpha(q)-deficient platelets. Thus, the activation of G(12)/G(13)- and G(i)-mediated signaling pathways is sufficient to induce integrin alpha(IIb)beta(3) activation. Although G(q)-mediated signaling plays an important role in platelet activation, it is not strictly required for the activation of integrin alpha(IIb)beta(3). This indicates that the efficient induction of platelet aggregation through G-protein-coupled receptors is an integrated response mediated by various converging G-protein-mediated signaling pathways involving G(q) and G(i) as well as G(12)/G(13).	Univ Wurzburg, Rudolf Virchow Ctr Exptl Biomed, D-97078 Wurzburg, Germany; Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany	University of Wurzburg; Ruprecht Karls University Heidelberg	Nieswandt, B (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr Exptl Biomed, Versbacher Str 9, D-97078 Wurzburg, Germany.		; Offermanns, Stefan/L-3313-2017	Gratacap, Marie-Pierre/0000-0003-4362-6401; Offermanns, Stefan/0000-0001-8676-6805				Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Gachet C, 2001, THROMB HAEMOSTASIS, V86, P222; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; HEDBERG A, 1988, J PHARMACOL EXP THER, V245, P786; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; LANZA F, 1985, THROMB HAEMOSTASIS, V54, P402; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohkubo S, 1996, BRIT J PHARMACOL, V117, P1095, DOI 10.1111/j.1476-5381.1996.tb16702.x; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; SIMPSON AWM, 1986, FEBS LETT, V201, P301, DOI 10.1016/0014-5793(86)80628-7; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	25	103	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39493	39498		10.1074/jbc.M207256200	http://dx.doi.org/10.1074/jbc.M207256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183468	hybrid			2022-12-25	WOS:000178662500057
J	Rangaraj, P; Ludden, PW				Rangaraj, P; Ludden, PW			Accumulation of (99)Mo-containing iron-molybdenum cofactor precursors of nitrogenase on NifNE, NifH, and NifK of Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO BIOSYNTHESIS; KLEBSIELLA-PNEUMONIAE; GENE-PRODUCT; INVITRO SYNTHESIS; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; PROTEIN; APODINITROGENASE; HOMOCITRATE; MATURATION	The biosynthesis of the iron-molybdenum cofactor (FeMo-co) of nitrogenase was investigated using the purified in vitro FeMo-co synthesis system and (99)Mo. The purified system involves the addition of all components that are known to be required for FeMo-co synthesis in their purified forms. Here, we report the accumulation of a (99)Mo-containing FeMo-co precursor on NifNE. Apart from NifNE, NifH and NifX also accumulate (99)Mo label. We present evidence that suggests NifH may serve as the entry point for molybdenum incorporation into the FeMo-co biosynthetic pathway. We also present evidence suggesting a role for NifX in specifying the organic acid moiety of FeMo-co.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Stuy Nitrogen Fixat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Calif Berkeley, Coll Nat Resources, 101 Giannini Hall,Rm 3100, Berkeley, CA 94720 USA.	pludden@nature.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; COUCOUVANIS D, 1993, ACS SYM SER, V535, P304; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; MCLEAN PA, 1983, BIOCHEM J, V211, P589, DOI 10.1042/bj2110589; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PIENKOS PT, 1981, J BACTERIOL, V145, P743, DOI 10.1128/JB.145.2.743-751.1981; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rangaraj P, 1999, J BIOL CHEM, V274, P29413, DOI 10.1074/jbc.274.41.29413; Rangaraj P, 2001, J BIOL CHEM, V276, P15968, DOI 10.1074/jbc.M100907200; ROBERTS GP, 1980, J BACTERIOL, V144, P210, DOI 10.1128/JB.144.1.210-216.1980; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Rubio LM, 2002, J BIOL CHEM, V277, P14299, DOI 10.1074/jbc.M107289200; Ruttimann-Johnson C, 2001, J BIOL CHEM, V276, P4522, DOI 10.1074/jbc.M007288200; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; Siemann S, 2001, EUR J BIOCHEM, V268, P1940, DOI 10.1046/j.1432-1327.2001.02063.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P175; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	46	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40106	40111		10.1074/jbc.M204581200	http://dx.doi.org/10.1074/jbc.M204581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176981	hybrid			2022-12-25	WOS:000178662500132
J	Singh, K; Batuman, OA; Akman, HO; Kedees, MH; Vakil, V; Hussain, MM				Singh, K; Batuman, OA; Akman, HO; Kedees, MH; Vakil, V; Hussain, MM			Differential, tissue-specific, transcriptional regulation of apolipoprotein B secretion by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; NECROSIS-FACTOR-ALPHA; CACO-2 CELLS; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; TRANSGENIC MICE; SMAD PROTEINS; MESSENGER-RNA; AMINO-ACIDS; GENE	Apolipoprotein B (apoB) is required for the assembly and secretion of triglyceride-rich lipoproteins. ApoB synthesis is constitutive, and post-translational mechanisms modulate its secretion. Transforming growth factor 13 (TGF-beta) increased apoll secretion in both differentiated and nondifferentiated Caco-2 cells and decreased secretion in HepG2 cells without affecting apolipoprotein A-I secretion. TGF-beta altered apoll secretion by changing steady-state mRNA levels and protein synthesis. Expression of SAMD3 and SMAD4 differentially regulated apoB secretion in these cells. Thus, SMADs mediate dissimilar secretion of apoll in both the cell lines by affecting gene transcription. We identified a 485-bp element, 55 kb upstream of the apob gene that contains a SMAD binding motif. This motif increased the expression of chloramphenicol acetyltransferase in Caco-2 ells treated with TGF-beta or transfected with SMADs. Hence, TGF-beta activates SMADs that bind to the 485-bp intestinal enhancer element in the apob gene and increase its transcription and secretion in Caco-2 cells. This is the first example showing differential transcriptional regulation of the apob gene by cytokines and dissimilar regulation of one gene in two different cell lines by TGF-beta. In this regulation, the presence of cytokineresponsive motif in the tissue-specific enhancer element confers cell-specific response.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA.	mahmood.hussain@downstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6731, DOI 10.1021/bi0100743; Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6720, DOI 10.1021/bi010073a; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; Antes TJ, 2000, J BIOL CHEM, V275, P26637, DOI 10.1074/jbc.M003025200; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; Cianflone K, 1996, J BIOL CHEM, V271, P29136, DOI 10.1074/jbc.271.46.29136; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Gillian-Daniel DL, 2002, P NATL ACAD SCI USA, V99, P4337, DOI 10.1073/pnas.072557199; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kim E, 1998, J LIPID RES, V39, P703; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; LUDWIG EH, 1991, DNA CELL BIOL, V10, P329, DOI 10.1089/dna.1991.10.329; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; Mehran M, 1995, AM J PHYSIOL-GASTR L, V269, pG953, DOI 10.1152/ajpgi.1995.269.6.G953; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Murthy S, 1996, AM J PHYSIOL-GASTR L, V270, pG94, DOI 10.1152/ajpgi.1996.270.1.G94; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; Nayak N, 2001, J LIPID RES, V42, P272; Nielsen LB, 1999, J MOL CELL CARDIOL, V31, P695, DOI 10.1006/jmcc.1998.0918; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; van 't Hooft FM, 1999, J LIPID RES, V40, P1686; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Yao ZM, 1997, J LIPID RES, V38, P1937; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; ZHANG ZJ, 1993, J BIOL CHEM, V268, P26920; Zhou ZY, 1998, BBA-LIPID LIPID MET, V1391, P13, DOI 10.1016/S0005-2760(97)00200-2	73	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39515	39524		10.1074/jbc.M205513200	http://dx.doi.org/10.1074/jbc.M205513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177061	hybrid			2022-12-25	WOS:000178662500060
J	Steiner, H; Winkler, E; Edbauer, D; Prokop, S; Basset, G; Yamasaki, A; Kostka, M; Haass, C				Steiner, H; Winkler, E; Edbauer, D; Prokop, S; Basset, G; Yamasaki, A; Kostka, M; Haass, C			PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; AMYLOID PRECURSOR PROTEIN; IN-VIVO; PROTEOLYTIC FRAGMENTS; ENDOPROTEOLYSIS; DEFICIENCY; MUTATION; INHIBITORS; PROTEASES; STATE	The Alzheimer disease-associated presenilin (PS) proteins apparently provide the active site of gamma-secretase, an unusual intramembrane-cleaving aspartyl protease. PSs principally occur as high molecular weight protein complexes that contain nicastrin (Nct) and additional so far unidentified components. Recently, PEN-2 has been implicated in gamma-secretase function. Here we identify PEN-2 as a critical component of PS1/gamma-secretase and PS2/gamma-secretase complexes. Strikingly, in the absence of PS1 and PS1/PS2, PEN-2 levels are strongly reduced. Similarly, PEN-2 levels are reduced upon RNA interference-mediated down-regulation of Nct. On the other side, down-regulation of PEN-2 by RNA interference is associated with reduced PS levels, impaired Nct maturation, and deficient gamma-secretase complex formation. We conclude that PEN-2 is an integral gamma-secretase complex component and that gamma-secretase complex components are expressed in a coordinated manner.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Boehringer Ingelheim Pharma KG, Dept CNS Res, D-88397 Biberach, Germany	University of Munich; Boehringer Ingelheim	Steiner, H (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Prokop, Stefan/Y-1257-2019; Edbauer, Dieter/M-9906-2019	Prokop, Stefan/0000-0002-5633-2149; Edbauer, Dieter/0000-0002-7186-4653				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	34	240	254	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39062	39065		10.1074/jbc.C200469200	http://dx.doi.org/10.1074/jbc.C200469200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12198112	hybrid			2022-12-25	WOS:000178662500002
J	Williams, SJ; Mark, BL; Vocadlo, DJ; James, MNG; Withers, SG				Williams, SJ; Mark, BL; Vocadlo, DJ; James, MNG; Withers, SG			Aspartate 313 in the Streptomyces plicatus hexosaminidase plays a critical role in substrate-assisted catalysis by orienting the 2-acetamido group and stabilizing the transition state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; BETA-N-ACETYLHEXOSAMINIDASE; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; CHITINASE; MECHANISM; CHITOBIASE; SITE; STEREOCHEMISTRY; IDENTIFICATION	SpHex, a retaining family 20 glycosidase from Streptomyces plicatus, catalyzes the hydrolysis of N-acetyl-beta-hexosaminides. Accumulating evidence suggests that the hydrolytic mechanism involves substrate-assisted catalysis wherein the 2-acetamido substituent acts as a nucleophile to form an oxazolinium ion intermediate. The role of a conserved aspartate residue (D313) in the active site of SpHex was investigated through kinetic and structural analyses of two variant enzymes, D313A and D313N. Three-dimensional structures of the wildtype and variant enzymes in product complexes with N-acetyl-D-glucosamine revealed substantial differences. In the D313A variant the 2-acetamido group was found in two conformations of which only one is able to aid in catalysis through anchimeric assistance. The mutation D313N results in a steric clash in the active site between Asn-313 and the 2-acetamido group preventing the 2-acetamido group from providing anchimeric assistance, consistent with the large reduction in catalytic efficiency and the insensitivity of this variant to chemical rescue. By comparison, the D313A mutation results in a shift in a shift in the pH optimum and a modest decrease in activity that can be rescued by using azide as an exogenous nucleophile. These structural and kinetic data provide evidence that Asp-313 stabilizes the transition states flanking the oxazoline intermediate and also assists to correctly orient the 2-acetamido group for catalysis. Based on analogous conserved residues in the family 18 chitinases and family 56 hyaluronidases, the roles played by the Asp-313 residue is likely general for all hexosaminidases using a mechanism involving substrate-assisted catalysis.	Univ British Columbia, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ Alberta, Canadian Inst Hlth Res Prot Struct, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of British Columbia; University of British Columbia; University of Alberta; University of Alberta	Withers, SG (corresponding author), Univ British Columbia, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada.		Withers, Stephen G/I-7229-2019; Williams, Spencer/C-3545-2009; Vocadlo, David J/E-5508-2014	Withers, Stephen G/0000-0002-6722-5701; Williams, Spencer/0000-0001-6341-4364; Vocadlo, David J/0000-0001-6897-5558; Mark, Brian/0000-0002-7344-1355				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen E, 2001, PEST MANAG SCI, V57, P946, DOI 10.1002/ps.363; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Drouillard S, 1997, BIOCHEM J, V328, P945, DOI 10.1042/bj3280945; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hou YM, 2001, BIOCHEMISTRY-US, V40, P2201, DOI 10.1021/bi002018s; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; KNAPP S, 1995, J AM CHEM SOC, V118; Kobayashi S, 2001, J AM CHEM SOC, V123, P11825, DOI 10.1021/ja017104+; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI ECK, 1994, BIOCHEMISTRY-US, V33, P14743, DOI 10.1021/bi00253a012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 2001, GRAFIT 4 0; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; Mark BL, 1998, J BIOL CHEM, V273, P19618, DOI 10.1074/jbc.273.31.19618; Mark BL, 2001, J BIOL CHEM, V276, P42131, DOI 10.1074/jbc.M107154200; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MO F, 1978, ACTA CRYSTALLOGR B, V34, P1562, DOI 10.1107/S0567740878006081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; Prag G, 2000, J MOL BIOL, V300, P611, DOI 10.1006/jmbi.2000.3906; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; VOCALDO DJ, 2002, THESIS U BRIT COLUMB; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Zechel D. L., 1999, COMPREHENSIVE NATURA, V5, P279	42	125	128	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40055	40065		10.1074/jbc.M206481200	http://dx.doi.org/10.1074/jbc.M206481200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171933	hybrid			2022-12-25	WOS:000178662500126
J	Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T				Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T			Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571	ONCOGENE			English	Article						BCR/ABL; PI-3k; STI571; wortmannin; combination therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DNA-BINDING ACTIVITY; BCR-ABL; CELL-LINES; CONSTITUTIVE ACTIVATION; CLINICAL RESISTANCE	BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome (Ph-1)-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL). STI571 (Gleevec), a novel anti-leukemia drug targeting BCR/ABL kinase can induce remissions of the Ph-1-positive leukemias. STI571 was recently combined with the standard cytostatic drugs to achieve better therapeutic results and to overcome emerging drug resistance mechanisms. We decided to search for a more specific partner compound for ST1571. Our previous studies showed that a signaling protein phosphatidylinositol-3 kinase (PI-3k) is essential for the growth of CML cells, but not of normal hematopoietic cells (Blood, 86:726,1995). Therefore the anti-Ph-1-leukemia effect of the combination of BCR/ABL kinase inhibitor ST1571 and PI-3k inhibitor wortmannin (WT) or LY294002 (LY) was tested. We showed that ST1571 + WT exerted a synergistic effect against the Ph-1-positive cell lines, but did not affect the growth of Ph-1-negative cell line. Moreover, the combinations of STI571+WT or STI571+LY were effective in the inhibition of clonogenic growth of CML-chronic phase and CML-blast crisis patient cells, while sparing normal bone marrow cells. Single colony RT-PCR assay showed that colonies arising from the mixture of CML cells and normal bone marrow cells after treatment with STI571+WT were selectively depleted of BCR/ABL-positive cells. Biochemical analysis of the CML cells after the treatment revealed that combination of ST1571 + WT caused a more pronounced activation of caspase-3 and induced massive apoptosis, in comparison to ST1571 and WT alone. In conclusion, combination of ST1571 + WT or ST1571 + LY may represent a novel approach against the Ph-1-positive leukemias.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Bio Life Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.	tskorski@astro.temple.edu	Klejman, Agata/AAC-1844-2021	Klejman, Agata/0000-0001-6083-9957	NCI NIH HHS [CA87300] Funding Source: Medline; NIDDK NIH HHS [K01 DK02896] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chai SK, 1997, J IMMUNOL, V159, P4720; Clift RA, 1996, BONE MARROW TRANSPL, V17, pS1; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DHUT S, 1990, LEUKEMIA, V4, P745; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gordon MY, 1999, LEUKEMIA, V13, pS65, DOI 10.1038/sj.leu.2401281; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gratwohl A, 1996, BONE MARROW TRANSPL, V17, pS7; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nielsen M, 1996, J IMMUNOL, V157, P5350; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Silver RT, 1999, BLOOD, V94, P1517; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; Slupianek A, 2001, CANCER RES, V61, P2194; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; TALPAZ M, 1987, CANCER, V59, P664, DOI 10.1002/1097-0142(19870201)59:3+<664::AID-CNCR2820591316>3.0.CO;2-Y; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; Van Etten RA, 2001, BLOOD CELL MOL DIS, V27, P201, DOI 10.1006/bcmd.2000.0370; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yu CR, 2002, CANCER RES, V62, P188	85	126	132	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5868	5876		10.1038/sj.onc.1205724	http://dx.doi.org/10.1038/sj.onc.1205724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185586				2022-12-25	WOS:000177520900006
J	Kavanagh, KL; Klimacek, M; Nidetzky, B; Wilson, DK				Kavanagh, KL; Klimacek, M; Nidetzky, B; Wilson, DK			Crystal structure of Pseudomonas fluorescens mannitol 2-dehydrogenase binary and ternary complexes - Specificity and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; DEHYDROGENASE GENE; PROTEIN; PURIFICATION; LOCATION; ALCOHOLS; REVEALS; PROGRAM; CLONING; ENZYME	Long-chain mannitol dehydrogenases are secondary alcohol dehydrogenases that are of wide interest because of their involvement in metabolism and potential applications in agriculture, medicine, and industry. They differ from other alcohol and polyol dehydrogenases because they do not contain a conserved tyrosine and are not dependent on Zn2+ or other metal cofactors. The structures of the long-chain mannitol 2-dehydrogenase (54 kDa) from Pseudomonas fluorescens in a binary complex with NAD(+) and ternary complex with NAD(+) and D-mannitol have been determined to resolutions of 1.7 and 1.8 Angstrom and R-factors of 0.171 and 0.176, respectively. These results show an N-terminal domain that includes a typical Rossmann fold. The C-terminal domain is primarily alpha-helical and mediates mannitol binding. The electron lone pair of Lys-295 is steered by hydrogen-bonding interactions with the amide oxygen of Asn-300 and the main-chain carbonyl oxygen of Val-229 to act as the general base. Asn-191 and Asn-300 are involved in a web of hydrogen bonding, which precisely orients the mannitol O2 proton for abstraction. These residues also aid in stabilizing a negative charge in the intermediate state and in preventing the formation of nonproductive complexes with the substrate. The catalytic lysine may be returned to its unprotonated state using a rectifying proton tunnel driven by Glu-292 oscillating among different environments. Despite low sequence homology, the closest structural neighbors are glycerol-3-phosphate dehydrogenase, N-(1-D-carboxylethyl)-L-norvaline dehydrogenase, UDP-glucose dehydrogenase, and 6-phosphogluconate dehydrogenase, indicating a possible evolutionary relationship among these enzymes.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Graz Univ Technol, Inst Biotechnol, A-8010 Graz, Austria	University of California System; University of California Davis; Graz University of Technology	Wilson, DK (corresponding author), Univ Calif Davis, Mol Biol Sect, 1 Shields Ave, Davis, CA 95616 USA.	dave@alanine.ucdavis.edu		Nidetzky, Bernd/0000-0002-5030-2643				ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Britton KL, 1998, NAT STRUCT BIOL, V5, P593, DOI 10.1038/854; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunker P, 1997, BBA-GENE STRUCT EXPR, V1351, P157, DOI 10.1016/S0167-4781(96)00189-3; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; DIAMANDIS EP, 1992, CLIN BIOCHEM, V25, P457, DOI 10.1016/0009-9120(92)90120-H; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Horer S, 2001, J BIOL CHEM, V276, P27555, DOI 10.1074/jbc.M102850200; Jennings DB, 1998, P NATL ACAD SCI USA, V95, P15129, DOI 10.1073/pnas.95.25.15129; JENNINGS DH, 1984, ADV MICROB PHYSIOL, V25, P149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Klimacek M, 2002, BIOCHEMISTRY-US, V41, P10158, DOI 10.1021/bi025517x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEHAUS WG, 1982, J BACTERIOL, V151, P243, DOI 10.1128/JB.151.1.243-250.1982; NOVOTNY MJ, 1984, J BACTERIOL, V159, P986, DOI 10.1128/JB.159.3.986-990.1984; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schmatz DM, 1997, PARASITOLOGY, V114, pS81; SCHNEIDER KH, 1993, J GEN MICROBIOL, V139, P2475, DOI 10.1099/00221287-139-10-2475; Shen B, 1999, PLANT PHYSIOL, V121, P45, DOI 10.1104/pp.121.1.45; Slatner M, 1998, BIOCATAL BIOTRANSFOR, V16, P351, DOI 10.3109/10242429809003628; Slatner M, 1999, BIOCHEMISTRY-US, V38, P10489, DOI 10.1021/bi990327g; STOOP JMH, 1992, ARCH BIOCHEM BIOPHYS, V298, P612, DOI 10.1016/0003-9861(92)90456-7; Suresh S, 2000, STRUCT FOLD DES, V8, P541, DOI 10.1016/S0969-2126(00)00135-0; Suvarna K, 2000, MICROBIOL-SGM, V146, P2705, DOI 10.1099/00221287-146-10-2705; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILLIAMSON JD, 1995, P NATL ACAD SCI USA, V92, P7148, DOI 10.1073/pnas.92.16.7148	36	34	35	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43433	43442		10.1074/jbc.M206914200	http://dx.doi.org/10.1074/jbc.M206914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196534	hybrid			2022-12-25	WOS:000179081200128
J	Miles, LA; Dy, CY; Nielsen, J; Barnham, KJ; Hinds, MG; Olivera, BM; Bulaj, G; Norton, RS				Miles, LA; Dy, CY; Nielsen, J; Barnham, KJ; Hinds, MG; Olivera, BM; Bulaj, G; Norton, RS			Structure of a novel P-superfamily spasmodic conotoxin reveals an inhibitory cystine knot motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; NUCLEAR MAGNETIC-RESONANCE; NMR STRUCTURE CALCULATION; SPIN COUPLING-CONSTANTS; MUSCLE SODIUM-CHANNELS; BIOLOGICAL MACROMOLECULES; GLYCINE RECEPTOR; PEPTIDES; SPECTROSCOPY; PROTEINS	Conotoxin gm9a, a putative 27-residue polypeptide encoded by Conus gloriamaris, was recently identified as a homologue of the "spasmodic peptide", tx9a, isolated from the venom of the mollusk-hunting cone shell Conus textile (Lirazan, M. B., Hooper, D., Corpuz, G. P., Ramilo, C. A., Bandyopadhyay, P., Cruz, L. J., and Olivera, B. M. (2000) Biochemistry 39, 1583-1588). The C. gloriamaris spasmodic peptide has been synthesized, and the refolded polypeptide was shown to be biologically active using a mouse bioassay. The chemically synthesized gm9a elicited the same symptomatology described previously for natively folded tx9a, and gm9a and tx9a were of similar potency, implying that neither the two gamma-carboxyglutamate (Gla) residues found in tx9a (Ser(8) and Ala(13) in gm9a) nor Gly(1) (Ser(1) in gm9a) are crucial for biological activity. We have determined the three-dimensional structure of gm9a in aqueous solution and demonstrated that the molecule adopts the well known inhibitory cystine knot motif constrained by three disulfide bonds involving Cys(2)-Cys(16), Cys(6)-Cys(18) and Cys(12)-Cys(23). Based on the gm9a structure, the sites of Gla substitution in tx9a are in loops located on one surface of the molecule, which is unlikely to be involved directly in receptor binding. Because this is the first structure reported for a member of the newly defined P-superfamily conotoxins, a comparison has been made with structurally related conotoxins. This shows that the structural scaffold that characterizes the P-conotoxins has the greatest potential for exhibiting structural diversity among the robust inhibitory cystine knot-containing conotoxins, a finding that has implications for functional epitope mimicry and protein engineering.	NMR Lab, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Philippines, Inst Marine Sci, Quezon City 1101, Philippines; Cognetix Incorp, Salt Lake City, UT 84108 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia	Walter & Eliza Hall Institute; Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman; University of Melbourne	Norton, RS (corresponding author), NMR Lab, Walter & Eliza Hall Inst Med Res, 381 Royal Parade, Parkville, Vic 3052, Australia.		Dy, Catherine/D-7215-2013; Hinds, Mark Gavin/AAD-3653-2020; Miles, Luke/C-5363-2009	Dy, Catherine/0000-0003-3414-1613; Hinds, Mark Gavin/0000-0002-2856-5375; Miles, Luke Anthony/0000-0003-2412-3171; Norton, Raymond/0000-0001-8893-0584	NIGMS NIH HHS [GM48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balaji RA, 2000, J BIOL CHEM, V275, P39516, DOI 10.1074/jbc.M006354200; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; *BMRB, BIOMAGRESBANK; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 2000, EUR J BIOCHEM, V267, P4649, DOI 10.1046/j.1432-1327.2000.01507.x; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEIM P, 1973, J BIOL CHEM, V248, P7811; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEVITT MH, 1983, ADV MAGN RESON, V11, P47; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mitchell SS, 1998, BIOCHEMISTRY-US, V37, P1215, DOI 10.1021/bi972186t; Mourier G, 2000, PROTEIN ENG, V13, P217, DOI 10.1093/protein/13.3.217; Nielsen KJ, 1996, J MOL BIOL, V263, P297, DOI 10.1006/jmbi.1996.0576; Norton RS, 1999, DRUG DEVELOP RES, V46, P206, DOI 10.1002/(SICI)1098-2299(199903/04)46:3/4<206::AID-DDR6>3.3.CO;2-W; Norton RS, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P159; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; Pallaghy PK, 2000, BIOPOLYMERS, V54, P173, DOI 10.1002/1097-0282(200009)54:3<173::AID-BIP30>3.3.CO;2-1; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Pallaghy PK, 1999, J PEPT RES, V53, P343, DOI 10.1034/j.1399-3011.1999.00040.x; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; SATO K, 1991, J BIOL CHEM, V266, P16989; SAUL B, 1994, FEBS LETT, V350, P71, DOI 10.1016/0014-5793(94)00736-5; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; SHIRE SJ, 1974, BIOCHEMISTRY-US, V13, P2967, DOI 10.1021/bi00711a028; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; TANOKURA M, 1976, BIOPOLYMERS, V15, P393, DOI 10.1002/bip.1976.360150215; Vita C, 1999, P NATL ACAD SCI USA, V96, P13091, DOI 10.1073/pnas.96.23.13091; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777	45	35	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43033	43040		10.1074/jbc.M206690200	http://dx.doi.org/10.1074/jbc.M206690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12193600	hybrid			2022-12-25	WOS:000179081200080
J	Nebl, T; Pestonjamasp, KN; Leszyk, JD; Crowley, JL; Oh, SW; Luna, EJ				Nebl, T; Pestonjamasp, KN; Leszyk, JD; Crowley, JL; Oh, SW; Luna, EJ			Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FC-EPSILON-RI; ACTIN-BINDING PROTEIN; GPI-ANCHORED PROTEINS; LIPID RAFTS; POLYMORPHONUCLEAR LEUKOCYTE; PEPTIDE RECEPTORS; GROWTH-FACTOR; MICRODOMAINS; DOMAINS; LOCALIZATION	Plasma membranes are organized into functional domains both by liquid-ordered packing into "lipid rafts," structures that resist Triton extraction, and by attachments to underlying cytoskeletal proteins in assemblies called "membrane skeletons." Although the actin cytoskeleton is implicated in many lipid raft-mediated signaling processes, little is known about the biochemical basis for actin involvement. We show here that a subset of plasma membrane skeleton proteins from bovine neutrophils co-isolates with cholesterol-rich, detergent-resistant membrane fragments (DRMs) that exhibit a relatively high buoyant density in sucrose (DRM-H; d similar to 1.16 g/ml). By using matrix-assisted laser desorption/ionization time of flight and tandem mass spectrometry, we identified 19 major DRM-H proteins. Membrane skeleton proteins include fodrin (nonerythroid spectrin), myosin-IIA, myosin-IG, alpha-actinin 1, alpha-actinin 4, vimentin and the F-actin-binding protein, supervillin. Other DRM-H components include lipid raft-associated integral membrane proteins (stomatin, flotillin 1, and flotillin 2), extracellular surface-bound and glycophosphatidylinositol-anchored proteins (IgM, membrane-type 6 matrix metalloproteinase), and intracellular dually acylated signaling proteins (Lyn kinase, Galpha(i-2)). Consistent with cytoskeletal association, most DRM-H-associated flotillin 2, Lyn, and Galpha(i)-2 also resist extraction with 0.1 m octyl glucoside. Supervillin, myosin-IG, and myosin-IIA resist extraction with 0.1 m sodium carbonate, a treatment that removes all detectable actin, suggesting that these cytoskeletal proteins are proximal to the DRM-H bilayer. Binding of supervillin to the DRM-H fragments is confirmed by co-immunoaffinity purification. In spreading neutrophils, supervillin localizes with F-actin in cell extensions and in discrete basal puncta that partially overlap with Galpha(i) staining. We suggest that the DRM-H fraction represents a membrane skeleton-associated subset of leukocyte signaling domains.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Proteom Mass Spectrometry Lab, Shrewsbury, MA 01545 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System	Luna, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Biotech 4,Ste 306,377 Plantat St, Worcester, MA 01605 USA.	Elizabeth.Luna@umassmed.edu	Nebl, Thomas/N-1620-2017; Luna, Elizabeth/B-4364-2012	Nebl, Thomas/0000-0003-4003-9340; Pestonjamasp, Kersi/0000-0001-8586-303X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33048, R01 GM033048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Benting J, 1999, FEBS LETT, V462, P47, DOI 10.1016/S0014-5793(99)01501-X; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BICKEL PE, 2001, AM J PHYSIOL, V282, pE1; Bloch RJ, 1997, SOC GEN PHY, V52, P177; BOYLES J, 1979, J CELL BIOL, V82, P347, DOI 10.1083/jcb.82.2.347; BOYLES J, 1981, CELL, V24, P905, DOI 10.1016/0092-8674(81)90116-1; Bremer A, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P277; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CARBONI JM, 1987, AM J PATHOL, V129, P589; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DELLANGELICA E, 2000, CURRENT PROTOCOLS CE, V1; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Dykstra M, 2001, J LEUKOCYTE BIOL, V70, P699; Eberle HB, 2002, J CELL SCI, V115, P827; FEINSTEIN A, 1969, NATURE, V224, P1307, DOI 10.1038/2241307a0; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUJIMOTO T, 1990, J CELL SCI, V96, P477; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Godaly G, 2001, J LEUKOCYTE BIOL, V69, P899; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; GREWAL AS, 1978, INT ARCH ALLER A IMM, V56, P289, DOI 10.1159/000232034; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Holowka D, 2000, J CELL SCI, V113, P1009; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; Jonkman MF, 1999, J DERMATOL SCI, V20, P103, DOI 10.1016/S0923-1811(99)00017-1; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; KLOTZ KN, 1994, BIOESSAYS, V16, P193, DOI 10.1002/bies.950160310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange K, 2002, AM J PHYSIOL-CELL PH, V282, pC1, DOI 10.1152/ajpcell.2002.282.1.C1; LANGLEY RC, 1987, CELL MOTIL CYTOSKEL, V8, P165, DOI 10.1002/cm.970080208; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Luna EJ, 1997, SOC GEN PHY, V52, P3; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; McMillan JR, 2001, J DERMATOL, V28, P291, DOI 10.1111/j.1346-8138.2001.tb00136.x; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morozumi T, 2001, J PERIODONTAL RES, V36, P160, DOI 10.1034/j.1600-0765.2001.360304.x; MOTTOLA C, 1980, EUR J BIOCHEM, V111, P341, DOI 10.1111/j.1432-1033.1980.tb04947.x; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Nabi IR, 1999, J CELL SCI, V112, P1803; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; NAKAMURA T, 1993, J IMMUNOL, V151, P6933; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; OHNO T, 1990, J EXP MED, V172, P1165, DOI 10.1084/jem.172.4.1165; Pappin D J, 1997, Methods Mol Biol, V64, P165; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; PETERSON MD, 1992, J CELL SCI, V102, P581; Pierce RA, 2001, J IMMUNOL, V167, P3223, DOI 10.4049/jimmunol.167.6.3223; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Pope RK, 1998, GENOMICS, V52, P342, DOI 10.1006/geno.1998.5466; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Runembert I, 2002, J CELL SCI, V115, P713; RUPPERT C, 1995, J CELL SCI, V108, P3775; SALGAR SK, 1994, AM J VET RES, V55, P803; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Sarndahl E, 1996, J BIOL CHEM, V271, P15267; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schulte T, 1997, DEVELOPMENT, V124, P577; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; SHEETZ MP, 1979, BIOCHIM BIOPHYS ACTA, V557, P122, DOI 10.1016/0005-2736(79)90095-6; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STEVENSON KB, 1989, BLOOD, V74, P2136; STOSSEL TP, 1994, SCI AM, V271, P54, DOI 10.1038/scientificamerican0994-54; STOSSEL TP, 1985, BLOOD PRINCIPLES PRA, P575; THOMAS JL, 1994, J CELL BIOL, V125, P795, DOI 10.1083/jcb.125.4.795; Valensin S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; von Haller PD, 2001, PROTEOMICS, V1, P1010; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; WILLIAMS MR, 1982, RES VET SCI, V33, P47, DOI 10.1016/S0034-5288(18)32358-0; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; WORKU M, 1994, AM J VET RES, V55, P221; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	102	250	263	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43399	43409		10.1074/jbc.M205386200	http://dx.doi.org/10.1074/jbc.M205386200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202484	hybrid			2022-12-25	WOS:000179081200124
J	Shi, JX; Radic, Z; Taylor, P				Shi, JX; Radic, Z; Taylor, P			Inhibitors of different structure induce distinguishing conformations in the omega loop, Cys(69)-Cys(96), of mouse acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SITE LIGANDS; CRYSTAL-STRUCTURE; BINDING; COMPLEX; FASCICULIN; CHOLINESTERASES; PURIFICATION; SPECIFICITY; EXPRESSION; CHIRALITY	We have shown previously that association of reversible active site ligands induces a conformational change in an omega loop (Omega loop), Cys(69)-Cys(96), of acetylcholinesterase. The fluorophore acrylodan, site-specifically incorporated at positions 76, 81, and 84, on the external portion of the loop not lining the active site gorge, shows changes in its fluorescence spectrum that reflect the fluorescent side chain moving from a hydrophobic environment to become more solvent-exposed. This appears to result from a movement of the Omega loop accompanying ligand binding. We show here that the loop is indeed flexible and responds to conformational changes induced by both active center and peripheral site inhihitors (gallamine and fasciculin). Moreover, phosphorylation and carbamoylation of the active center serine shows distinctive changes in acrylodan fluorescence spectra at the Omega loop sites, depending on the chirality and steric dimensions of the covalently conjugated ligand. Capping of the gorge with fasciculin, although it does not displace the bound ligand, dominates in inducing a conformational change in the loop. Hence, the ligand-induced conformational changes are distinctive and suggest multiple loop conformations accompany conjugation at the active center serine. The fluorescence changes induced by the modified enzyme may prove useful in the detection of organophosphates or exposure to cholinesterase inhibitors.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM07752, GM-R37-18360] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldridge W. N., 1972, ENZYME INHIBITORS SU; Ariel N, 1998, BIOCHEM J, V335, P95, DOI 10.1042/bj3350095; AUGUSTINSSON KB, 1948, ACTA PHYSL SCAND S, V52, P1; Bar-On P, 2002, BIOCHEMISTRY-US, V41, P3555, DOI 10.1021/bi020016x; BELLEAU B, 1970, J AM CHEM SOC, V92, P6320, DOI 10.1021/ja00724a035; BERMAN HA, 1978, BIOCHEMISTRY-US, V17, P1704, DOI 10.1021/bi00602a019; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BERMAN JD, 1971, P NATL ACAD SCI USA, V68, P395, DOI 10.1073/pnas.68.2.395; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BOURNE Y, 2002, 11 INT S CHOL MECH S, P39; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; KOELLE GB, 1994, J APPL TOXICOL, V14, P105, DOI 10.1002/jat.2550140211; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lew J, 1997, J BIOL CHEM, V272, P1507, DOI 10.1074/jbc.272.3.1507; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MILLARD CB, 1995, J NEUROCHEM, V64, P1909, DOI 10.1046/j.1471-4159.1995.64051909.x; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; Morel N, 1999, MOL PHARMACOL, V55, P982, DOI 10.1124/mol.55.6.982; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P93; TAYLOR P, 2001, GOODMAN GILMANS PHAR, P161; Velan B, 1996, FEBS LETT, V395, P22, DOI 10.1016/0014-5793(96)00995-7; Wilson I. B., 1960, ENZYMES, V4, P501; Wong L, 2000, BIOCHEMISTRY-US, V39, P5750, DOI 10.1021/bi992906r	43	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43301	43308		10.1074/jbc.M204391200	http://dx.doi.org/10.1074/jbc.M204391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196517	hybrid			2022-12-25	WOS:000179081200113
J	Kosoy, A; Pagans, S; Espinas, ML; Azorin, F; Bernues, J				Kosoy, A; Pagans, S; Espinas, ML; Azorin, F; Bernues, J			GAGA factor down-regulates its own promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCOMB RESPONSE ELEMENT; GLUTAMINE-RICH DOMAIN; DNA-BINDING; IN-VITRO; TRANSCRIPTION FACTOR; CHROMATIN-STRUCTURE; DROSOPHILA; REQUIRES; MAINTENANCE; ESTABLISHMENT	GAGA factor is involved in many nuclear transactions, notably in transcription as an activator in Drosophila. The genomic region corresponding to the Trl promoter has been obtained, and a minimal version of a fully active Trl promoter has been defined using transient transfection. assays in S2 cells. DNase I footprinting analysis has shown that this region contains multiple GAGA binding sites, suggesting a potential regulatory role of GAGA on its own promoter. The study shows that GAGA down-regulates Trl expression. The repression does not depend on the GAGA isoform, but binding to DNA is absolutely required. A fragment of the Trl promoter can mediate repression to a heterologous promoter only upon GAGA overexpression in transiently transfected S2 cells. Chromatin immunoprecipitation analysis of S2 cells confirmed that GAGA factors are bound to the Trl promoter over a region of 1.4 kbp. Using a double-stranded RNA interference approach, we show that endogenous GAGA factors limit Trl expression in S2 cells. Our results open the possibility of observing similar GAGA repressive effects on other promoters.	CSIC, Inst Mol Biol, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Bernues, J (corresponding author), CSIC, Inst Mol Biol, Dept Mol & Cellular Biol, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	jbmbmc@ibmb.csic.es	Bernues, Jordi/ABE-8360-2021; Pagans, Sara/G-3407-2015; Azorin, Fernando/N-4388-2014	Bernues, Jordi/0000-0001-6218-8254; Pagans, Sara/0000-0003-0772-6982; Azorin, Fernando/0000-0002-8426-7858; Espinas, M Lluisa/0000-0003-3914-2228				Agianian B, 1999, J MOL BIOL, V285, P527, DOI 10.1006/jmbi.1998.2355; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Busturia A, 2001, DEVELOPMENT, V128, P2163; Cavalli G, 1999, PRACT APPROACH SER, P20; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Greenberg AJ, 2001, MOL CELL BIOL, V21, P8565, DOI 10.1128/MCB.21.24.8565-8574.2001; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; JONES KA, 1984, EMBO J, V3, P3247, DOI 10.1002/j.1460-2075.1984.tb02286.x; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Lintermann KG, 1998, DEV GENES EVOL, V208, P447, DOI 10.1007/s004270050202; Mishra RK, 2001, MOL CELL BIOL, V21, P1311, DOI 10.1128/MCB.21.4.1311-1318.2001; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Pile LA, 2000, J BIOL CHEM, V275, P1398, DOI 10.1074/jbc.275.2.1398; Platero JS, 1998, J CELL BIOL, V140, P1297; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Tsukiyama T, 1996, METHOD ENZYMOL, V274, P291; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; Vaquero A, 2000, J BIOL CHEM, V275, P19461, DOI 10.1074/jbc.M000967200; VAQUERO A, 2000, THESIS U BARCELONA; Weber JA, 1997, MOL CELL BIOL, V17, P3799, DOI 10.1128/MCB.17.7.3799; Wilkins RC, 1998, NUCLEIC ACIDS RES, V26, P2672, DOI 10.1093/nar/26.11.2672; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963	42	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42280	42288		10.1074/jbc.M207505200	http://dx.doi.org/10.1074/jbc.M207505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200449	hybrid			2022-12-25	WOS:000178985300123
J	Lin, L; Jeanclos, EM; Treuil, M; Braunewell, KH; Gundelfinger, ED; Anand, R				Lin, L; Jeanclos, EM; Treuil, M; Braunewell, KH; Gundelfinger, ED; Anand, R			The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist sensitivity of the alpha 4 beta 2 nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; CHRONIC EXPOSURE; DRUG-ADDICTION; CA2+ CHANNELS; UP-REGULATION; HUMAN-BRAIN; BINDING; INACTIVATION	The calcium sensor protein visinin-like protein-1 (VILIP-1) was isolated from a brain cDNA yeast two-hybrid library using the large cytoplasmic domain of the alpha4 subunit as a bait. VILIP-1 is a myristoylated calcium sensor protein that contains three functional calcium binding EF-hand motifs. The alpha4 subunit residues 302-339 were found to be essential for the interaction with VILIP-1. VILIP-1 coimmunopurified with detergent-solubilized recombinant alpha4beta2 acetylcholine receptors (AChRs) expressed in tsA201 cells and with native alpha4 AChRs isolated from brain. Coexpression of VILIP-1 with recombinant alpha4beta2 AChRs up-regulated their surface expression levels similar to2-fold and increased their agonist sensitivity to acetylcholine similar to3-fold. The modulation of the recombinant alpha4beta2 AChRs by VILIP-1 was attenuated in VILIP-1 mutants that lacked the ability to be myristoylated or to bind calcium. Collectively, these results suggest that VILIP-1 represents a novel modulator of alpha4beta2 AChRs that increases their surface expression levels and agonist sensitivity in response to changes in the intracellular levels of calcium.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA; Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany; Humboldt Univ, Charite, Neurosci Res Ctr, Signal Transduct Res Grp, D-10117 Berlin, Germany	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Leibniz Institut fur Neurobiologie (LIN); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Anand, R (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, Suite D,2020 Gravier St, New Orleans, LA 70112 USA.			Jeanclos, Elisabeth/0000-0001-5934-5490				Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anand R, 1998, J PHARMACOL EXP THER, V287, P469; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Braunewell KH, 1997, NEUROSCI LETT, V234, P139, DOI 10.1016/S0304-3940(97)00696-4; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DIDIER M, 1995, MOL BRAIN RES, V30, P17, DOI 10.1016/0169-328X(94)00266-H; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fenster CP, 1999, J NEUROSCI, V19, P4804; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hsu YN, 1997, J NEUROCHEM, V69, P2427; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; Kato M, 1998, BIOCHEM J, V331, P871, DOI 10.1042/bj3310871; KOBAYASHI M, 1994, BBA-MOL CELL RES, V1222, P515, DOI 10.1016/0167-4889(94)90062-0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; Lenz SE, 1996, CELL TISSUE RES, V283, P413, DOI 10.1007/s004410050552; Lin L, 2002, BIOCHEM BIOPH RES CO, V296, P827, DOI 10.1016/S0006-291X(02)00943-9; Lindstrom J, 1996, Ion Channels, V4, P377; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Pauly JR, 1996, J PHARMACOL EXP THER, V278, P361; PENG X, 1994, MOL PHARMACOL, V46, P523; POLYMEROPOULOS MH, 1995, GENOMICS, V29, P273, DOI 10.1006/geno.1995.1244; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	40	92	97	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41872	41878		10.1074/jbc.M206857200	http://dx.doi.org/10.1074/jbc.M206857200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202488	hybrid			2022-12-25	WOS:000178985300074
J	Otten, LG; Sio, CF; Vrielink, J; Cool, RH; Quax, WJ				Otten, LG; Sio, CF; Vrielink, J; Cool, RH; Quax, WJ			Altering the substrate specificity of cephalosporin acylase by directed evolution of the beta-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-G ACYLASE; ESCHERICHIA-COLI; ACID ACYLASE; PSEUDOMONAS STRAIN; CRYSTAL-STRUCTURE; CLONING; EXPRESSION; GENES; ENZYMES; AMIDASE	Using directed evolution, we have selected an adipyl acylase enzyme that can be used for a one-step bioconversion of adipyl-7-aminodesacetoxycephalosporanic acid (adipyl-7-ADCA) to 7-ADCA an important compound for the synthesis of semisynthetic cephalosporins. The starting point for the directed evolution was the glutaryl acylase from Pseudomonas SY-77. The gene fragment encoding the beta-subunit was divided into five overlapping parts that were mutagenized separately using error-prone PCR. Mutants were selected in a leucine-deficient host using adipyl-leucine as the sole leucine source. In total, 24 out of 41 plate-selected mutants were found to have a significantly improved ratio of adipyl-7-ADCA versus glutaryl-7-ACA hydrolysis. Several mutations around the substrate-binding site were isolated, especially in two hot spot positions: residues Phe-375 and Asn-266. Five mutants were further characterized by determination of their Michaelis-Menten parameters. Strikingly, mutant SY-77(N266H) shows a nearly 10-fold improved catalytic efficiency (k(cat)/K-m) on adipyl-7-ADCA, resulting from a 50% increase in k(cat) and a 6-fold decrease in K-m, without decreasing the catalytic efficiency on glutaryl-7-ACA. In contrast, the improved adipyl/glutaryl activity ratio of mutant SY-77(F375L) mainly is a consequence of a decreased catalytic efficiency toward glutaryl-7-ACA. These results are discussed in the light of a structural model of SY-77 glutaryl acylase.	Univ Groningen, Univ Ctr Pharm, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands	University of Groningen	Quax, WJ (corresponding author), Univ Groningen, Univ Ctr Pharm, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.		Quax, Wim/K-2802-2012; Quax, Wim/O-2875-2019; Otten, Linda/A-4802-2010	Quax, Wim/0000-0002-5162-9947; Quax, Wim/0000-0002-5162-9947; Cool, Robbert/0000-0002-9845-2202; Sio, Charles/0000-0002-1504-9101				ARAMORI I, 1991, J FERMENT BIOENG, V72, P232, DOI 10.1016/0922-338X(91)90155-A; ARAMORI I, 1991, J BACTERIOL, V173, P7848, DOI 10.1128/jb.173.24.7848-7855.1991; Armisen P, 1999, J CHROMATOGR A, V848, P61, DOI 10.1016/S0021-9673(99)00489-6; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; Bruggink A, 1998, ORG PROCESS RES DEV, V2, P128, DOI 10.1021/op9700643; CADWELL RC, 1994, PCR METH APPL, V3, P136; CRAWFORD L, 1995, BIO-TECHNOL, V13, P58, DOI 10.1038/nbt0195-58; FORNEY LJ, 1989, APPL ENVIRON MICROB, V55, P2556, DOI 10.1128/AEM.55.10.2556-2560.1989; FORNEY LJ, 1989, APPL ENVIRON MICROB, V55, P2550, DOI 10.1128/AEM.55.10.2550-2555.1989; Fritz-Wolf K, 2002, PROTEIN SCI, V11, P92, DOI 10.1110/ps.ps.27502; GARCIA JL, 1986, J BIOTECHNOL, V3, P187, DOI 10.1016/0168-1656(86)90001-5; Griffiths AD, 2000, CURR OPIN BIOTECH, V11, P338, DOI 10.1016/S0958-1669(00)00109-9; ISHII Y, 1994, J FERMENT BIOENG, V77, P591, DOI 10.1016/0922-338X(94)90138-4; ISHIYE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P233, DOI 10.1016/0167-4781(92)90155-S; Kim Y, 2001, CHEM BIOL, V8, P1253, DOI 10.1016/S1074-5521(01)00092-8; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung DW, 1989, TECHNIQUE, V1, P11; Li Y, 1998, PROTEIN EXPRES PURIF, V12, P233, DOI 10.1006/prep.1997.0823; MATSUDA A, 1987, J BACTERIOL, V169, P5815, DOI 10.1128/jb.169.12.5815-5820.1987; McDonough MA, 1999, PROTEIN SCI, V8, P1971, DOI 10.1110/ps.8.10.1971; Monti D, 2000, BIOTECHNOL BIOENG, V70, P239, DOI 10.1002/1097-0290(20001020)70:2<239::AID-BIT13>3.0.CO;2-I; REYES F, 1989, J PHARM PHARMACOL, V41, P136, DOI 10.1111/j.2042-7158.1989.tb06412.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schroen CGPH, 2000, BIOTECHNOL BIOENG, V70, P654, DOI 10.1002/1097-0290(20001220)70:6<654::AID-BIT7>3.0.CO;2-3; SHIBUYA Y, 1981, AGR BIOL CHEM TOKYO, V45, P1561, DOI 10.1080/00021369.1981.10864767; Sio CF, 2002, EUR J BIOCHEM, V269, P4495, DOI 10.1046/j.1432-1033.2002.03143.x; ZHANG QJ, 1993, ARCH MICROBIOL, V159, P392, DOI 10.1007/BF00290923; Zhao HM, 2002, CURR OPIN BIOTECH, V13, P104, DOI 10.1016/S0958-1669(02)00291-4	29	51	57	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42121	42127		10.1074/jbc.M208317200	http://dx.doi.org/10.1074/jbc.M208317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198140	Green Published, hybrid			2022-12-25	WOS:000178985300103
J	Ablonczy, Z; Crouch, RK; Goletz, PW; Redmond, TM; Knapp, DR; Ma, JX; Rohrer, B				Ablonczy, Z; Crouch, RK; Goletz, PW; Redmond, TM; Knapp, DR; Ma, JX; Rohrer, B			11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC ANALYSIS; MULTIPLE PHOSPHORYLATION; RECEPTOR KINASE; VISUAL PIGMENT; RHODOPSIN; LIGHT; MODEL; RPE65; DESENSITIZATION; ACTIVATION	Rpe65(-/-) mice produce minimal amounts of 11-cis-retinal, the ligand necessary for the formation of photosensitive visual pigments. Therefore, the apoprotein opsin in these animals has not been exposed to its normal ligand. The Rpe65(-/-) mice contain less than 0.1% of wild type levels of rhodopsin. Mass spectrometric analysis of opsin from Rpe65(-/-) mice revealed unusually high levels of phosphorylation in dark-adapted mice but no other structural alterations. Single flash and flicker electroretinograms (ERGs) from 1-month-old animals showed trace rod function but no cone response. B-wave kinetics of the single-flash ERG are comparable with those of dark-adapted wild type mice containing a full compliment of rhodopsin. Application (intraperitoneal injection) of 11-cis-retinal to Rpe65(-/-) mice increased the rod ERG signal, increased levels of rhodopsin, and decreased opsin phosphorylation. Therefore, exogenous 11-cis-retinal improves photoreceptor function by regenerating rhodopsin and removes constitutive opsin phosphorylation. Our results indicate that opsin, which has not been exposed to 11-cis-retinal, does not generate the activity generally associated with the bleached apoprotein.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Rohrer, B (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.	rohrer@musc.edu		Redmond, T. Michael/0000-0002-1813-5291	NEI NIH HHS [EY 08239, EY 04939, EY 12231, EY 13520] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008239, R01EY013520, Z01EY000260, R01EY004939, R01EY012231] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2000, MOL VIS, V6, P109; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Ball LE, 1998, PROTEIN SCI, V7, P758; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Bohm SK, 1997, BIOCHEM J, V322, P1; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; Crouch R. K., 2000, P59; Ekesten B, 2001, VISION RES, V41, P2425, DOI 10.1016/S0042-6989(01)00140-7; Greene NM, 1997, J BIOL CHEM, V272, P10341; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; Harris EW, 2001, INT OPHTHALMOL CLIN, V41, P73, DOI 10.1097/00004397-200101000-00008; HOOD DC, 1992, VISUAL NEUROSCI, V8, P107, DOI 10.1017/S0952523800009275; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Jeon CJ, 1998, J NEUROSCI, V18, P8936; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Jones GJ, 1996, J GEN PHYSIOL, V108, P333, DOI 10.1085/jgp.108.4.333; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Liou GI, 1998, J NEUROSCI, V18, P4511; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; NAARENDORP F, 2002, INVEST OPHTHALMOL VI, V43; RATTO GM, 1991, NATURE, V351, P654, DOI 10.1038/351654a0; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Robson JG, 1996, J OPT SOC AM A, V13, P613, DOI 10.1364/JOSAA.13.000613; Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999; Rohrer B, 2001, MOL VIS, V7, P288; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Schneeweis DM, 2000, VISUAL NEUROSCI, V17, P659, DOI 10.1017/S0952523800175017; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; WITKOVSKY P, 1976, J NEUROPHYSIOL, V39, P1272, DOI 10.1152/jn.1976.39.6.1272; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	41	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40491	40498		10.1074/jbc.M205507200	http://dx.doi.org/10.1074/jbc.M205507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176991	hybrid			2022-12-25	WOS:000178791400044
J	Chandra, V; Jasti, J; Kaur, P; Dey, S; Perbandt, M; Srinivasan, A; Betzel, C; Singh, TP				Chandra, V; Jasti, J; Kaur, P; Dey, S; Perbandt, M; Srinivasan, A; Betzel, C; Singh, TP			Crystal structure of a complex formed between a snake venom phospholipase A(2) and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 A resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DABOIA-RUSSELLI-PULCHELLA; TRANSITION-STATE ANALOG; RHEUMATOID-ARTHRITIS; ANGSTROM RESOLUTION; SEPTIC SHOCK; PURIFICATION; CRYSTALLOGRAPHY; ASSOCIATION; MOLSCRIPT; BINDING	Phospholipase A(2) is an important enzyme involved in the production of prostaglandins and their related compounds causing inflammatory disorders. Among the several peptides tested, the peptide Phe-Leu-Ser-Tyr-Lys (FLSYK) showed the highest inhibition. The dissociation constant (K-d) for this peptide was calculated to be 3.57 +/- 0.05 x 10(-9) m. In order to further improve the degree of inhibition of phospholipase A(2), a complex between Russells viper snake venom phospholipase A(2) and a peptide inhibitor FLSYK was crystallized, and its structure was determined by crystallographic methods and refined to an R-factor of 0.205 at 1.8 Angstrom resolution. The structure contains two crystallographically independent molecules of phospholipase A(2) (molecules A and B) and a peptide molecule specifically bound to molecule A only. The two molecules formed an asymmetric dimer. The dimerization caused a modification in the binding site of molecule A. The overall conformations of molecules A and B were found to be generally similar except three regions i.e. the Trp-31-containing loop (residues 25-34), the beta-wing consisting of two antiparallel beta-strands (residues 74-85) and the C-terminal region (residues 119-133). Out of the above three, the most striking difference pertains to the conformation of Trp-31 in the two molecules. The orientation of Trp-31 in molecule A was suitable for the binding of FLSYK, while it disallowed the binding of peptide to molecule B. The structure of the complex clearly shows that the peptide is so placed in the binding site of molecule A that the side chain of its lysine residue interacted extensively with the enzyme and formed several hydrogen bonds in addition to a strong electrostatic interaction with critical Asp-49. The C-terminal carboxylic group of the peptide interacted with the catalytic residue His-48.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India; DESY, UKE, Inst Med Biochem & Mol Biol, D-22603 Hamburg, Germany	All India Institute of Medical Sciences (AIIMS) New Delhi; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hamburg; University Medical Center Hamburg-Eppendorf	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.		Perbandt, Markus/K-7603-2018; Betzel, Christian/G-8105-2018; Hu, Ruogu/B-2203-2008	Betzel, Christian/0000-0002-3879-5019; 				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cha SS, 1996, J MED CHEM, V39, P3878, DOI 10.1021/jm960502g; Chandra V, 2002, J MOL BIOL, V320, P215, DOI 10.1016/S0022-2836(02)00473-4; Chandra V, 1999, ACTA CRYSTALLOGR D, V55, P925, DOI 10.1107/S090744499900058X; Chandra V, 2001, ACTA CRYSTALLOGR D, V57, P1793, DOI 10.1107/S0907444901014524; Chandra V, 2002, BIOCHEMISTRY-US, V41, P10914, DOI 10.1021/bi0258593; Chandra V, 2000, J MOL BIOL, V296, P1117, DOI 10.1006/jmbi.2000.3537; CHANDRA V, 2002, IN PRESS ACTA CRYSTA; Church WB, 2001, J BIOL CHEM, V276, P33156, DOI 10.1074/jbc.M101272200; Cruickshank D.W.J, 1996, P CCP4 STUD WEEK, P11; DAHNEKE BE, 1983, MEASUREMENT SUSPENDE, P199; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Jamal OS, 1998, ANN RHEUM DIS, V57, P550, DOI 10.1136/ard.57.9.550; JAYANTHI GP, 1989, TOXICON, V27, P875, DOI 10.1016/0041-0101(89)90099-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTURI S, 1989, TOXICON, V27, P229, DOI 10.1016/0041-0101(89)90136-0; KINI RM, 1997, VENOM PHOSPHOLIPASES, P146; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LASKOWSKI RA, 1994, P CCP4 STUD WEEK 1 M, P149; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; MAKKER J, 2002, THESIS ALL INDIA I M; MERITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Murshudov G.N., 1997, CCP4 NEWSLETTER, V33, P31; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONO T, 1988, J BIOL CHEM, V263, P5732; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; Perbandt M, 1997, FEBS LETT, V412, P573, DOI 10.1016/S0014-5793(97)00853-3; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHULZE T, 1996, THESIS U HAMBURG HAM; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Sekar K, 1997, BIOCHEMISTRY-US, V36, P14186, DOI 10.1021/bi971370b; SMITH GM, 1992, BRIT J RHEUMATOL, V31, P175; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TOMOO K, 1994, PROTEINS, V19, P330, DOI 10.1002/prot.340190408; Tseng A, 1996, J BIOL CHEM, V271, P23992, DOI 10.1074/jbc.271.39.23992; VADAS P, 1984, J LAB CLIN MED, V104, P873; Waite M, 1987, HDB LIPID RES, V5, P155; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	49	36	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41079	41085		10.1074/jbc.M206130200	http://dx.doi.org/10.1074/jbc.M206130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186870	hybrid			2022-12-25	WOS:000178791400117
J	Lee, J; Petris, MJ; Thiele, DJ				Lee, J; Petris, MJ; Thiele, DJ			Characterization of mouse embryonic cells deficient in the Ctr1 high affinity copper transporter - Identification of a Ctr1-independent copper transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; MOLECULAR CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL EXPRESSION; IRON TRANSPORT; YEAST; GENE; CHAPERONE	The trace metal copper is an essential cofactor for a number of enzymes that have critical roles in biological processes, but it is highly toxic when allowed to accumulate in excess of cellular needs. Consequently, homeostatic copper metabolism is maintained by molecules involved in copper uptake, distribution, excretion, and incorporation into copper-requiring enzymes. Previously, we reported that overexpression of the human or mouse Ctr1 copper transporter stimulates copper uptake in mammalian cells, and deletion of one Ctr1 allele in mice gives rise to tissue-specific defects in copper accumulation and in the activities of copper-dependent enzymes. To investigate the physiological roles for mammalian Ctr1 protein in cellular copper metabolism, we characterized wild type, Ctr1 heterozygous, and Ctr1 homozygous knock-out cells isolated from embryos obtained by the inter-cross of Ctr1 heterozygous mice. Ctr1-deficient mouse embryonic cells are viable but exhibit significant defects in copper uptake and accumulation and in copper-dependent enzyme activities. Interestingly, Ctr1-deficient cells exhibit similar to30% residual copper transport activity that is saturable, with a K-m of similar to10 mum, with biochemical features distinct from that of Ctr1. These observations demonstrate that, although Ctr1 is critical for both cellular copper uptake and embryonic development, mammals possess additional biochemically distinct functional copper transport activities.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Missouri, Dept Nutrit Sci, Columbia, MO 65211 USA	University of Michigan System; University of Michigan; University of Missouri System; University of Missouri Columbia	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu			NCI NIH HHS [1R24 CA 86307] Funding Source: Medline; NIDDK NIH HHS [DK 59893] Funding Source: Medline; NIGMS NIH HHS [GM 62555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Conrad ME, 2000, AM J PHYSIOL-GASTR L, V279, pG767, DOI 10.1152/ajpgi.2000.279.4.G767; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; LEE J, 2002, J BIOL CHEM, V275, P33244; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Linder M, 1991, BIOCH COPPER; Moller LB, 2000, GENE, V257, P13, DOI 10.1016/S0378-1119(00)00394-2; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Prohaska JR, 2001, ARCH BIOCHEM BIOPHYS, V393, P170, DOI 10.1006/abbi.2001.2470; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Riggio M, 2002, BBA-GENE STRUCT EXPR, V1576, P127, DOI 10.1016/S0167-4781(02)00337-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	48	184	186	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40253	40259		10.1074/jbc.M208002200	http://dx.doi.org/10.1074/jbc.M208002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177073	hybrid			2022-12-25	WOS:000178791400014
J	Rochdi, MD; Watier, V; La Madeleine, C; Nakata, H; Kozasa, T; Parent, JL				Rochdi, MD; Watier, V; La Madeleine, C; Nakata, H; Kozasa, T; Parent, JL			Regulation of GTP-binding protein alpha(q) (G alpha(q)) signaling by the ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN-MEDIATED INTERACTION; PHOSPHOLIPASE-C ISOZYMES; COUPLED RECEPTOR KINASE; RECOMBINANT-GQ-ALPHA; BETA-GAMMA-SUBUNITS; PDZ-DOMAIN; NA+/H+ EXCHANGER; THROMBOXANE A(2); NHE-RF	Although ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is a PDZ domain-containing protein known to bind to various channels, receptors, cytoskeletal elements, and cytoplasmic proteins, there is still very little evidence for a role of EBP50 in the regulation of receptor signal transduction. In this report, we show that EBP50 inhibits the phospholipase C (PLC)-beta-mediated inositol phosphate production of a Galpha(q)-coupled receptor as well as PLC-A activation by the constitutively active Galpha(q)-R183C mutant. Coinimunoprecipitation experiments revealed that EBP50 interacts with Galpha(q) and to a greater extent with Galpha(q)-R183C. Agonist stimulation of the thromboxane A(2) receptor (TP receptor) resulted in an increased interaction between EBP50 and Galpha(q), suggesting that EBP50 preferentially interacts with activated Galpha(q). We also demonstrate that EBP50 inhibits Galpha(q) signaling by preventing the interaction between Galpha(q) and the TP receptor and between activated Galpha(q) and PLC-beta1. Investigation of the EBP50 regions involved in Gaq binding indicated that its two PDZ domains are responsible for this interaction. This study constitutes the first demonstration of an interaction between a G protein alpha subunit and another protein through a PDZ domain, with broad implications in the regulation of diverse physiological systems.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, CHUS, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Sherbrooke; University of Sherbrooke; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001 12e Ave Nord, Fleurimont, PQ J1H 5N4, Canada.							Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Ingi T, 1998, J NEUROSCI, V18, P7178; Kinsella BT, 2001, BIOCHEM SOC T, V29, P641, DOI 10.1042/BST0290641; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	36	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40751	40759		10.1074/jbc.M207910200	http://dx.doi.org/10.1074/jbc.M207910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193606	hybrid			2022-12-25	WOS:000178791400077
J	Gallois-Montbrun, S; Schneider, B; Chen, YX; Giacomoni-Fernandes, V; Mulard, L; Morera, S; Janin, J; Deville-Bonne, D; Veron, M				Gallois-Montbrun, S; Schneider, B; Chen, YX; Giacomoni-Fernandes, V; Mulard, L; Morera, S; Janin, J; Deville-Bonne, D; Veron, M			Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; THYMIDINE DIPHOSPHATE; STEADY-STATE; PHOSPHORYLATION; MECHANISM; BINDING; ENZYME	Antiviral nucleoside analog therapies rely on their incorporation by viral DNA polymerases/reverse transcriptase leading to chain termination. The analogs (3'-deoxy-3'-azidothymidine (AZT), 2',3'-didehydro-2',3'dideoxythymidine (d4T), and other dideoxynucleosides) are sequentially converted into triphosphate by cellular kinases of the nucleoside salvage pathway and are often poor substrates of these enzymes. Nucleoside diphosphate (NDP) kinase phosphorylates the diphosphate derivatives of the analogs with an efficiency some 104 lower than for its natural substrates. Kinetic and structural studies of Dictyostelium and human NDP kinases show that the sugar X-OH, absent from all antiviral analogs, is required for catalysis. To improve the catalytic efficiency of NDP kinase on the analogs, we engineered several mutants with a protein OH group replacing the sugar 3'-OH. The substitution of Asn-115 in Ser and Leu-55 in His results in an NDP kinase mutant with an enhanced ability to phosphorylate antiviral derivatives. Transfection of the mutant enzyme in Escherichia coli results in an increased sensitivity to AZT. An x-ray structure at 2.15-Angstrom resolution of the Dictyostelium enzyme bearing the serine substitution in complex with the R-p-alpha-borano-triphosphate derivative of AZT shows that the enhanced activity reflects an improved geometry of binding and a favorable interaction of the X-azido group with the engineered serine.	Inst Pasteur, CNRS, Regulat Enzymat Activ Cellulaires FRE 2364, F-75724 Paris 15, France; CNRS, Lab Enzymol & Biochim Struct, UPR 9063, F-91198 Gif Sur Yvette, France; Inst Pasteur, CNRS, Unite Chim Organ, URA 1228, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deville-Bonne, D (corresponding author), Inst Pasteur, CNRS, Regulat Enzymat Activ Cellulaires FRE 2364, 25 Rue Dr Roux, F-75724 Paris 15, France.	ddeville@pasteur.fr	Janin, Joel/I-2958-2012; Schneider, Benoit/AAF-3850-2019; Gallois-Montbrun, Sarah/L-9843-2017; Chen, Yuxing/P-4156-2014	Schneider, Benoit/0000-0002-1377-2670; Gallois-Montbrun, Sarah/0000-0002-7870-1814; Chen, Yuxing/0000-0002-7560-1922				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; ELWELL LP, 1987, ANTIMICROB AGENTS CH, V31, P274, DOI 10.1128/AAC.31.2.274; Encell LP, 1999, NAT BIOTECHNOL, V17, P143, DOI 10.1038/6142; GALLOISMONTBRUN S, 2002, Patent No. 2382470; GALLOISMONTBRUN S, 2002, Patent No. 10133628; Gonin P, 1999, BIOCHEMISTRY-US, V38, P7265, DOI 10.1021/bi982990v; Guettari N, 1997, VIROLOGY, V235, P398, DOI 10.1006/viro.1997.8706; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; Keller R, 2002, IMMUNOL LETT, V83, P1, DOI 10.1016/S0165-2478(02)00065-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LASCU I, 1993, J BIOL CHEM, V268, P20268; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; Neet KE, 1998, J BIOL CHEM, V273, P25527, DOI 10.1074/jbc.273.40.25527; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARENTEAU NL, 2002, ANN NY ACAD SCI, V951, P27; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; ROUSSEL A, 1991, SILICON GRAPHICS DIR; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Schneider B, 2000, MOL PHARMACOL, V57, P948; Schneider B, 2001, EUR J BIOCHEM, V268, P1964, DOI 10.1046/j.1432-1327.2001.02070.x; Xu YW, 1997, P NATL ACAD SCI USA, V94, P7162, DOI 10.1073/pnas.94.14.7162; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	36	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39953	39959		10.1074/jbc.M206360200	http://dx.doi.org/10.1074/jbc.M206360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171931	hybrid			2022-12-25	WOS:000178662500113
J	Gonzalez, E; Kou, R; Lin, AJ; Golan, DE; Michel, T				Gonzalez, E; Kou, R; Lin, AJ; Golan, DE; Michel, T			Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL ACYLATION; ACTIVATION; AKT; TRANSLOCATION; PALMITOYLATION; DOMAIN; GOLGI; CELLS	The endothelial isoform of nitric-oxide synthase (eNOS) undergoes a complex pattern of covalent modifications, including acylation with the fatty acids myristate and palmitate as well as phosphorylation on multiple sites. eNOS acylation is a key determinant for the reversible subcellular targeting of the enzyme to plasmalemmal caveolae. We transfected a series of hemagglutinin epitope-tagged eNOS mutant cDNAs deficient in palmitoylation (palm(-)) and/or myristoylation (myr(-)) into bovine aortic endothelial cells; after treatment with the eNOS agonists sphingosine 1-phosphate or vascular endothelial growth factor, the recombinant eNOS was immunoprecipitated using an antibody directed against the epitope tag, and patterns of eNOS phosphorylation were analyzed in immunoblots probed with phosphorylation state-specific eNOS antibodies. The wild-type eNOS underwent agonist-induced phosphorylation at serine 1179 (a putative site for phosphorylation by kinase Akt), but phosphorylation of the myr(-) eNOS at this residue was nearly abrogated; the palm- eNOS exhibited an intermediate phenotype. The addition of the CD8 transmembrane domain to the amino terminus of eNOS acylation-deficient mutants rescued the wild-type phenotype of robust agonist-induced serine 1179 phosphorylation. Thus, membrane targeting, but not necessarily acylation, is the critical determinant for agonist-promoted eNOS phosphorylation at serine 1179. In striking contrast to serine 1179, phosphorylation of eNOS at serine 116 was enhanced in the myr- eNOS mutant and was markedly attenuated in the CD8-eNOS membrane-targeted fusion protein. We conclude that eNOS targeting differentially affects eNOS phosphorylation at distinct sites in the protein and suggest that the inter-relationships of eNOS acylation and phosphorylation may modulate eNOS localization and activity and thereby influence NO signaling pathways in the vessel wall.	Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Div Hematol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Biol Chem & Mol Pharmacol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA.	dgolan@hms.harvard.edu; michel@calvin.bwh.harvard.edu	Mordwinkin, Nicholas M/A-4347-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032854, R37HL032854, R01HL046457, R29HL046457, P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32854, HL15157, HL46457] Funding Source: Medline; NIEHS NIH HHS [T32ES07155] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561	39	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39554	39560		10.1074/jbc.M207299200	http://dx.doi.org/10.1074/jbc.M207299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12189156	hybrid			2022-12-25	WOS:000178662500065
J	Zhao, R; Holmgren, A				Zhao, R; Holmgren, A			A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE ORGANOSELENIUM COMPOUND; GLUTATHIONE-PEROXIDASE ACTIVITY; CEREBRAL-ARTERY OCCLUSION; BLIND CLINICAL-TRIAL; SELENOORGANIC COMPOUND; GLUTAREDOXIN SYSTEMS; IMMUNOHISTOCHEMICAL LOCALIZATION; NEUROPROTECTIVE EFFICACY; ISOLATED HEPATOCYTES; PZ-51 EBSELEN	The antioxidant mechanism of ebselen involves recently discovered reductions by mammalian thioredoxin reductase (TrxR) and thioredoxin (Trx) forming ebselen selenol. Here we describe a previously unknown reaction; ebselen reacts with its selenol forming an ebselen diselenide with a rate constant of 372 M(-1)s(-1). The diselenide also was a substrate of TrxR forming the selenol with K-m of 40 mum and k(cat) of 79 min(-1) (k(cat)/K-m of 3.3 x 10(4) m(-1)s(-1)). Trx increased the reduction because of its fast reaction with diselenide (rate constant 1.7 x 10(3) m(-1)s(-1)). Diselenide stimulated the H2O2 reductase activity of TrxR, even more efficiently with Trx present. Because the mechanism of ebselen as an antioxidant has been assumed to involve glutathione peroxidase-like activity, we compared the H2O2 reductase activity of ebselen with the GSH and Trx systems. TrxR at 50 nm, far below the estimated physiological level, gave 8-fold higher activity compared with 1 mm GSH; addition of 5 pm Trx increased this difference to 13-fold. The rate constant of ebselen selenol reacting with H2O2 was estimated to be faster than 350 m(-1)s(-1). We propose novel mechanisms for ebselen antioxidant action involving ebselen selenol and diselenide formation, with the thioredoxin system rather than glutathione as the predominant effector and target.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.							Alam MM, 1998, INT J CHEM KINET, V30, P193, DOI 10.1002/(SICI)1097-4601(1998)30:3<193::AID-KIN4>3.0.CO;2-N; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; COTGREAVE IA, 1987, BIOCHEM PHARMACOL, V36, P2899, DOI 10.1016/0006-2952(87)90200-0; COTGREAVE IA, 1992, CHEM-BIOL INTERACT, V84, P69, DOI 10.1016/0009-2797(92)90121-Z; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; FISCHER H, 1988, XENOBIOTICA, V18, P1347, DOI 10.3109/00498258809042259; FISCHER H, 1987, B SOC CHIM BELG, V96, P757; HAENEN GRMM, 1990, MOL PHARMACOL, V37, P412; HANSSON HA, 1986, CELL TISSUE RES, V245, P189; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAIORINO M, 1988, BIOCHEM PHARMACOL, V37, P2267, DOI 10.1016/0006-2952(88)90591-6; Maulik N, 1998, FREE RADICAL BIO MED, V24, P869, DOI 10.1016/S0891-5849(97)00388-2; MORGENSTERN R, 1992, CHEM-BIOL INTERACT, V84, P77, DOI 10.1016/0009-2797(92)90122-2; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; MULLER A, 1985, BIOCHEM PHARMACOL, V34, P1185, DOI 10.1016/0006-2952(85)90493-9; MULLER A, 1988, BIOCHEM PHARMACOL, V37, P1103, DOI 10.1016/0006-2952(88)90517-5; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Ogawa A, 1999, CEREBROVASC DIS, V9, P112, DOI 10.1159/000015908; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Saito I, 1998, NEUROSURGERY, V42, P269, DOI 10.1097/00006123-199802000-00038; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; SIES H, 1994, METHOD ENZYMOL, V234, P476; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Sies H., 1989, SELENIUM BIOL MED, P153; Takasago T, 1997, BRIT J PHARMACOL, V122, P1251, DOI 10.1038/sj.bjp.0701426; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WENDEL A, 1984, BIOCHEM PHARMACOL, V33, P3241, DOI 10.1016/0006-2952(84)90084-4; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhao R, 1998, J AM CHEM SOC, V120, P2811, DOI 10.1021/ja974136h; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	53	151	157	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39456	39462		10.1074/jbc.M206452200	http://dx.doi.org/10.1074/jbc.M206452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177067	hybrid			2022-12-25	WOS:000178662500052
J	Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A				Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A			pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation	ONCOGENE			English	Article						apoptosis; gamma-radiation; pRb2/p130; glioblastoma; p73; Bcl-2; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN NEUROBLASTOMA-CELLS; GROWTH IN-VIVO; KINASE C-ABL; INDUCED APOPTOSIS; DNA-DAMAGE; TISSUE TRANSGLUTAMINASE; TUMOR-CELLS; PROTEIN; CYCLE	This study shows that in the glioblastoma hamster cell line HJC12 the retinoblastoma family member pRb2/p130 enhances gamma-radiation-induced cell death. In HJC12 cells the tetracycline-regulated expression of pRb2/p130 increased the percentage of gamma-radiation-induced apoptotic cells from 27 to 47%. pRb2/p130 overexpression was associated with the downregulation of the anti-apoptotic factor Bcl-2 and the upregulation of the steady-state protein levels of the pro-apoptotic transcription factor p73. In particular, RT-PCR showed a significant increase in the expression of the p73delta isoform when pRb2/p130 was overexpressed. The ability of pRb2/p130 to modulate apoptosis was not associated with its role in mediating G0/G1 arrest during cell cycle progression. Our data suggest a role for pRb2/p130 in glioblastoma gamma-radiation-induced cell death, indicating that the antitumoral action of pRb2/p130 can regulate both inhibition of cell cycle progression and induction of cell death.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillo Faccial, I-80131 Naples, Italy; Univ Roma Tor Vergata, Dipartimento Med Interna, I-00133 Rome, Italy; Univ Roma Tor Vergata, Biochim Lab, IDI, IRCCS,Dipartimento Med Sperimentale & Sci Biochim, I-00133 Rome, Italy; Temple Univ, Ctr Neuro Virol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; University of Naples Federico II; University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		TERRINONI, Alessandro/J-1533-2012; Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	TERRINONI, Alessandro/0000-0002-7442-2252; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X	NCI NIH HHS [5 T32 CA09137, P01-CA56309, R01 CA60999/01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309, R01CA060999, T32CA009137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 1999, NATURE, V399, P809; An B, 1996, CANCER RES, V56, P438; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Berry DE, 1996, ONCOGENE, V12, P1809; Bowen C, 1998, CANCER RES, V58, P3275; CHOISYROSSI C, 1999, CELL DEATH DIFFER, V5, P1162; Claudio PP, 2000, CANCER RES, V60, P372; CLAUDIO PP, 1994, CANCER RES, V54, P5555; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Debatin KM, 1997, BIOCHEM SOC T, V25, P405, DOI 10.1042/bst0250405; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fan GS, 1996, ONCOGENE, V12, P1909; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong JG, 1999, NATURE, V399, P806; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOST C, 1997, NATURE, V38, P191; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; RAY GV, 1995, INT J ONCOL, V7, P801; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhivotovsky B, 1997, J CELL BIOCHEM, V64, P43, DOI 10.1002/(SICI)1097-4644(199701)64:1<43::AID-JCB7>3.3.CO;2-S	47	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5897	5905		10.1038/sj.onc.1205750	http://dx.doi.org/10.1038/sj.onc.1205750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185589				2022-12-25	WOS:000177520900009
J	Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK				Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK			WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma	ONCOGENE			English	Article						WAVE3; neuroblastoma; actin polymerization	NEURO-BLASTOMA; MOLECULAR CHARACTERIZATION; NEUROBLASTOMA; FAMILY; REGION; RETINOBLASTOMA; BREAKPOINT; MUTATION; DELETION; CANCER	Neuroblastoma (Nb) is a malignancy of the sympathetic nervous system which affects children in their first decade. It is the most common extra-cranial solid tumor in children with an incidence of approximately 1 in 8 - 10 000 live births annually and accounts for approximately 10% of all children's cancers. Ganglioneuroblastoma is a relatively benign form of Nb and consists of a mixture of fibrils, mature and maturing ganglion cells, as well as undifferentiated neuroblasts. During routine cytogenetic analysis of patients with different manifestations of neuroblastoma we have identified one patient with ganglioneuroblastoma that carries an apparently balanced t(1:13)(q21:q12) reciprocal translocation. Positional cloning of the translocation breakpoint on chromosome 13 resulted in the mapping of the breakpoint between coding exon 2 and exon 3 of WAVE3, a member of WASP gene family. Although the breakpoint region on chromosome I was localized to within 2 kb of genomic sequence, no gene was found to be interrupted on this chromosome. The WAVE3 transcript is mainly expressed in the nervous system and, like all the members of the WASP gene family, WAVE3 is a key element in actin polymerization and cytoskeleton organization. WAVE3, therefore, is important for cell differentiation and motility and its expression is lost in a number of low grade and stage 4S tumors. From analysis of its expression pattern and function, WAVE3 is a candidate tumor suppressor gene, at least in some forms of neuroblastoma.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Roswell Park Cancer Institute; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 16056-26] Funding Source: Medline; NINDS NIH HHS [NS35791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson J, 2001, BRIT J CANCER, V85, P493, DOI 10.1054/bjoc.2001.1979; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Castleberry RP, 1999, J PEDIAT HEMATOL ONC, V21, P178, DOI 10.1097/00043426-199905000-00004; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; DANGIO GJ, 1971, LANCET, V1, P1046; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; Fryns JP, 1996, GENET COUNSEL, V7, P73; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; Kitamura E, 2000, ONCOGENE, V19, P5772, DOI 10.1038/sj.onc.1203978; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; LANCIOTTI M, 1992, CELL MOL NEUROBIOL, V12, P225, DOI 10.1007/BF00712928; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; MICHALSKI AJ, 1993, GENOMICS, V18, P141, DOI 10.1006/geno.1993.1439; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MITCHELL CD, 1991, BRIT MED BULL, V47, P136, DOI 10.1093/oxfordjournals.bmb.a072452; MITCHELL CD, 1989, ONCOGENE, V4, P253; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; NAGANO H, 1980, JPN J HUM GENET, V25, P39, DOI 10.1007/BF01876544; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; PONZONI M, 1991, CELL MOL NEUROBIOL, V11, P397, DOI 10.1007/BF00711421; RICCARDI VM, 1978, PEDIATRICS, V61, P604; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Roberts T, 1998, CANCER GENET CYTOGEN, V100, P10, DOI 10.1016/S0165-4608(97)00013-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER WG, 1984, CANCER GENET CYTOGEN, V11, P153, DOI 10.1016/0165-4608(84)90109-2; Sossey-Alaoui K, 1999, GENOMICS, V60, P330, DOI 10.1006/geno.1999.5924; Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takenawa T, 2001, J CELL SCI, V114, P1801; Van Roy N, 1997, EUR J CANCER, V33, P1974, DOI 10.1016/S0959-8049(97)00319-5; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; XU Y, 1994, ISMB, V2, P376; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	42	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5967	5974		10.1038/sj.onc.1205734	http://dx.doi.org/10.1038/sj.onc.1205734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185600				2022-12-25	WOS:000177520900020
J	Srivenugopal, KS; Ali-Osman, F				Srivenugopal, KS; Ali-Osman, F			The DNA repair protein, O-6-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein	ONCOGENE			English	Article						MGMT; DNA repair; ubiquitin; proteasome; alkylating agents	PROTEASOME-MEDIATED DEGRADATION; GLUTATHIONE-S-TRANSFERASE; POSITIVE CANCER-CELLS; HUMAN TUMOR-CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; PROMOTER HYPERMETHYLATION; MOLECULAR-BASIS; BETA-CATENIN; P53 PROTEIN; K-RAS	We have previously shown that O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein that protects tissues against toxic and carcinogenic effects of alkylating agents, is degraded through ubiquitination-dependent proteolysis. Here, we investigated the role of the human papillomavirus (HPV) E6 protein in MGMT degradation. In three pairs of isogenic human tumor cell lines in which a member of each pair expressed the E6 protein through stable transfection (HCT116/HCT116-E6, MCF7/MCF7-E6, and RKO/RKO-E6), we found a consistent 40-55% reduction in the MGMT protein level and its activity in all E6-expressing cells compared with the parent cells (P = <0.05). E6 expression did not, however, alter the levels of MGMT mRNA. Addition of the recombinant MGMT (rMGMT) protein to extracts of HCT116/E6 cells resulted in the binding of E6 to MGMT. Further, the purified E6 protein promoted the degradation of rMGMT in rabbit reticulocyte lysates. Immunoprecipitation assays showed the presence of a ternary protein complex between MGMT, E6, and the cellular ubiquitin-ligase E6-associated protein (E6-AP). Transient transfection of the p53-null H1299 lung tumor cells with an E6 construct also down-regulated the MGMT. The MGMT protein also showed structural features that are compatible for interaction with the E6, and E6-AP components. Collectively, these data suggest that the oncogenic E6 proteins enhance the ubiquitin-dependent proteolysis of MGMT.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Box 64, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NCI NIH HHS [CA-74321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali-Osman F., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P572; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Boyer SN, 1996, CANCER RES, V56, P4620; BRENT T P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P421; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; BUTZ K, 1995, ONCOGENE, V10, P927; Chen C, 1999, CARCINOGENESIS, V20, P699, DOI 10.1093/carcin/20.4.699; CHEN JY, 1993, ONCOGENE, V8, P2159; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dolan ME, 1997, CLIN CANCER RES, V3, P837; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Esteller M, 2000, CANCER RES, V60, P2368; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GERSON SL, 1995, HEMATOL ONCOL CLIN N, V9, P431, DOI 10.1016/S0889-8588(18)30103-5; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris LC, 1996, CANCER RES, V56, P2029; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUSSAIN SP, 1994, ONCOGENE, V9, P13; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; KEISS TD, 1993, P NATL ACAD SCI USA, V90, P3988; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Maki CG, 1996, CANCER RES, V56, P2649; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3; SKHEDY D, 1994, FEBS LETT, V348, P126; Srivenugopal KS, 2002, CANCER LETT, V181, P87, DOI 10.1016/S0304-3835(01)00823-0; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; WAJNBERG EF, 1989, FEBS LETT, V243, P141, DOI 10.1016/0014-5793(89)80116-4; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Wolf P, 2001, CANCER RES, V61, P8113; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhang QW, 2001, J PHARMACOL EXP THER, V298, P141; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	59	66	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5940	5945		10.1038/sj.onc.1205762	http://dx.doi.org/10.1038/sj.onc.1205762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185595				2022-12-25	WOS:000177520900015
J	Netzel-Arnett, S; Mitola, DJ; Yamada, SS; Chrysovergis, K; Holmbeck, K; Birkedal-Hansen, H; Bugge, TH				Netzel-Arnett, S; Mitola, DJ; Yamada, SS; Chrysovergis, K; Holmbeck, K; Birkedal-Hansen, H; Bugge, TH			Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; SMOOTH-MUSCLE-CELLS; INTERSTITIAL COLLAGENASE; DEGRADING PROTEASES; IV COLLAGENASE; GROWTH-FACTOR; IN-VIVO; SYSTEM; INHIBITION; MECHANISM	Matrix metalloproteinase-14 is required for degradation of fibrillar collagen by mesenchymal cells. Here we show that keratinocytes use an alternative plasminogen and matrix metalloproteinase-13-dependent pathway for dissolution of collagen fibrils. Primary keratinocytes displayed an absolute requirement for serum to dissolve collagen. Dissolution of collagen was abolished in plasminogen-depleted serum and could be restored by the exogenous addition of plasminogen. Both plasminogen activator inhibitor-1 and tissue inhibitor of metalloproteinase blocked collagen dissolution, demonstrating the requirement of both plasminogen activation and matrix metalloproteinase activity for degradation. Cell surface plasmin activity was critical for the degradation process as aprotinin, but not alpha(2)-antiplasmin, prevented collagen dissolution. Keratinocytes with single deficiencies in either urokinase or tissue plasminogen activator retained the ability to dissolve collagen. However, collagen fibril dissolution was abolished in keratinocytes with a combined deficiency in both urokinase and tissue plasminogen activator. Combined, but not single, urokinase and tissue plasminogen activator deficiency also completely blocked the activation of the fibrillar collagenase, matrix metalloproteinase-13, by keratinocytes. The activation of matrix metalloproteinase-13 in normal keratinocytes was prevented by plasminogen activator inhibitor-1 and aprotinin but not by tissue inhibitor of metalloproteinase-1 and -2, suggesting that plasmin activates matrix metalloproteinase-13 directly. We propose that plasminogen activation facilitates keratinocyte-mediated collagen breakdown via the direct activation of matrix metalloproteinase-13 and possibly other fibrillar collagenases.	NIDCR, Matrix Metalloprot Unit, NIH, Bethesda, MD 20892 USA; NIDCR, Proteases & Tissue Remodeling Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Birkedal-Hansen, H (corresponding author), NIDCR, Matrix Metalloprot Unit, NIH, Rm 30-132,30 Convent Dr, Bethesda, MD 20892 USA.	netzelars@usa.redcross.org; Henning.Birkedal-Hansen@nih.gov		Holmbeck, Kenn/0000-0002-4472-3257				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAKER MS, 1990, CANCER RES, V50, P4676; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Bezerra JA, 2001, AM J PATHOL, V158, P921, DOI 10.1016/S0002-9440(10)64039-4; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Blavier L, 2001, MOL BIOL CELL, V12, P1457, DOI 10.1091/mbc.12.5.1457; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Davis GE, 2001, J CELL SCI, V114, P917; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; HALL SW, 1991, J BIOL CHEM, V266, P12329; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Hay ED., 1991, CELL BIOL EXTRACELLU, P7; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Luttun A, 2000, Curr Atheroscler Rep, V2, P407, DOI 10.1007/s11883-000-0079-z; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; Moons L, 1998, J CLIN INVEST, V102, P1788, DOI 10.1172/JCI3316; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Romisch J, 1999, HAEMOSTASIS, V29, P292; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SAWAYA R, 1988, J NEUROSURG, V68, P73, DOI 10.3171/jns.1988.68.1.0073; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Segal G, 2001, J CELL SCI, V114, P119; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; Werner F, 1999, J BIOL CHEM, V274, P21555, DOI 10.1074/jbc.274.31.21555; Windsor L. J, 2002, MATRIX METALLOPROTEI, DOI DOI 10.8.6-10.8.7; WOESSNER JF, 1996, MATRIX METALLOPROTEI; YUSPA SH, 1985, METHODS SKIN RES, P213	77	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45154	45161		10.1074/jbc.M206354200	http://dx.doi.org/10.1074/jbc.M206354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12192005	hybrid			2022-12-25	WOS:000179404800073
J	Day, KC; McCabe, MT; Zhao, X; Wang, YH; Davis, JN; Phillips, J; Von Geldern, M; Ried, T; KuKuruga, MA; Cunha, GR; Hayward, SW; Day, ML				Day, KC; McCabe, MT; Zhao, X; Wang, YH; Davis, JN; Phillips, J; Von Geldern, M; Ried, T; KuKuruga, MA; Cunha, GR; Hayward, SW; Day, ML			Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; CELL-CYCLE; MALIGNANT TRANSFORMATION; CHROMOSOMAL-ABERRATIONS; TARGETED DISRUPTION; PROSTATE-CANCER; CARCINOMA-CELLS; VIRAL ONCOGENES; KINASE-ACTIVITY; G(1) CONTROL	The ability to rescue viable prostate precursor tissue from retinoblastoma-deficient (Rb-/-) fetal mice has allowed for the isolation and characterization of the first Rb-/- prostate epithelial cell line. This cell line, designated Rb-/-PrE, was utilized for experiments examining the consequences of Rb loss on an epithelial population. These findings demonstrated that Rb deletion has no discernible effect on prostatic histodifferentiation in Rb-/-PrE cultures. When Rb-/-PrE cells were recombined with embryonic rat urogenital mesenchyme and implanted into athymic male, nude mouse hosts, the recombinants developed into fully differentiated and morphologically normal prostate tissue. The Rb-/-PrE phenotype was characterized by serum independence in culture and immortality in vivo, when compared with wild type controls. Cell cycle analysis revealed elevated S phase DNA content accompanied by increased expression of cyclin El and proliferating cell nuclear antigen. Rb-/-PrE cultures also exhibited a diminished ability to growth arrest under high density culture conditions. We believe that the development of Rb-/- prostate tissue and cell lines has provided a unique experimental platform with which to investigate the consequences of Rb deletion in epithelial cells under various physiological conditions. Additionally, the development of this technology will allow similar studies in other tissues and cell populations rescued from Rb-/- fetuses.	Univ Michigan, Dept Urol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; NCI, Urol Oncol Branch, Genet Sect, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Urol Surg, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Vanderbilt University	Day, ML (corresponding author), Univ Michigan, Dept Urol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.			Wang, Yuzhuo/0000-0002-9749-8591; Hayward, Simon/0000-0002-6059-6550	NATIONAL CANCER INSTITUTE [U01CA096403, P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056137] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568, CA96403] Funding Source: Medline; NIDDK NIH HHS [DK56137] Funding Source: Medline; PHS HHS [F005952, F005192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Blagosklonny MV, 1997, CANCER RES, V57, P320; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; CUNHA GR, 1984, STAIN TECHNOL, V59, P7, DOI 10.3109/10520298409113823; DANIELSEN HE, 1991, CARCINOGENESIS, V12, P1777, DOI 10.1093/carcin/12.10.1777; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DEKLERK DP, 1978, INVEST UROL, V16, P240; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; Hayward SW, 1999, PROSTATE, V39, P205; Hayward SW, 2001, CANCER RES, V61, P8135; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; KRAEMER PM, 1987, CANCER GENET CYTOGEN, V27, P273, DOI 10.1016/0165-4608(87)90010-0; KUBBIES M, 1986, CYTOMETRY, V7, P551, DOI 10.1002/cyto.990070609; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LORKE DE, 1994, ACTA ANAT, V150, P159; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NORMAN JT, 1986, PROSTATE, V8, P209, DOI 10.1002/pros.2990080302; Ozer H L, 2000, Prog Mol Subcell Biol, V24, P121; Phillips JL, 2001, CANCER RES, V61, P8143; Robinson GW, 2001, ONCOGENE, V20, P7115, DOI 10.1038/sj.onc.1204888; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Thompson JB, 2000, PETROLOGY+, V8, P303; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; Wagner M, 2001, DEV DYNAM, V220, P198, DOI 10.1002/1097-0177(20010301)220:3<198::AID-DVDY1103>3.0.CO;2-T; Wan TSK, 1997, CANCER GENET CYTOGEN, V95, P166, DOI 10.1016/S0165-4608(96)00245-2; Wang YH, 2000, CANCER RES, V60, P6008; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Yang F, 2000, CHROMOSOME RES, V8, P219, DOI 10.1023/A:1009200912436; YEE AS, 1998, FRONT BIOSCI, V3, P532; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwerschke W, 2000, ADV CANCER RES, V78, P1	61	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44475	44484		10.1074/jbc.M205361200	http://dx.doi.org/10.1074/jbc.M205361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12191999	hybrid			2022-12-25	WOS:000179272000119
J	Philipps, B; Glockshuber, R				Philipps, B; Glockshuber, R			Randomization of the entire active-site helix alpha 1 of the thiol-disulfide oxidoreductase DsbA from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; FORMATION IN-VIVO; REDOX PROPERTIES; ELECTROSTATIC INTERACTIONS; EFFICIENT CATALYSIS; CYSTEINE RESIDUES; ISOMERASE DSBA; PROTEIN; THIOREDOXIN; SEQUENCE	DsbA from Escherichia coli is the most oxidizing member of the thiol-disulfide oxidoreductase family (E-o' = -122 mV) and is required for efficient disulfide bond formation in the periplasm. The reactivity of the catalytic disulfide bond (Cys(30)-Pro(31)-His(32)-Cys(33)) is primarily due to an extremely low pK(alpha) value (3.4) Of Cys(30), which is stabilized by the partial positive dipole charge of the active-site helix alpha1 (residues 30-37). We have randomized all non-cysteine residues of helix alpha1 (residues 31, 32, and 34-37) and found that two-thirds of the resulting variants complement DsbA deficiency in a dsbA deletion strain. Sequencing of 98 variants revealed a large number of non-conservative replacements in active variants, even at well conserved positions. This indicates that tertiary structure context strongly determines a-helical secondary structure formation of the randomized sequence. A subset of active and inactive variants was further characterized. All these variants were more reducing than wild type DsbA, but the redox potentials of active variants did not drop below -210 mV. All inactive variants had redox potentials lower than -210 mV, although some of the inactive proteins were still re-oxidized by DsbB. This demonstrates that efficient oxidation of substrate polypeptides is the crucial property of DsbA in vivo.	ETH Honggerberg, Inst Molekularbiol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Glockshuber, R (corresponding author), ETH Honggerberg, Inst Molekularbiol & Biophys, CH-8093 Zurich, Switzerland.							Axe DD, 1996, P NATL ACAD SCI USA, V93, P5590, DOI 10.1073/pnas.93.11.5590; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; DeGrado WF, 1999, ANNU REV BIOCHEM, V68, P779, DOI 10.1146/annurev.biochem.68.1.779; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Gustafsson C, 2001, J MOL RECOGNIT, V14, P308, DOI 10.1002/jmr.543; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Jacobi A, 1997, J BIOL CHEM, V272, P21692, DOI 10.1074/jbc.272.35.21692; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mossner E, 2000, FEBS LETT, V477, P21, DOI 10.1016/S0014-5793(00)01738-5; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Riddle DS, 1997, NAT STRUCT BIOL, V4, P805, DOI 10.1038/nsb1097-805; ROST N, 1964, NATURE, V201, P185; Schirra HJ, 1998, BIOCHEMISTRY-US, V37, P6263, DOI 10.1021/bi980136y; Sillen A, 1999, PROTEINS, V37, P253, DOI 10.1002/(SICI)1097-0134(19991101)37:2<253::AID-PROT10>3.0.CO;2-J; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	47	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43050	43057		10.1074/jbc.M207638200	http://dx.doi.org/10.1074/jbc.M207638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12193604	hybrid			2022-12-25	WOS:000179081200082
J	Li, YH; Knisely, JM; Lu, WY; McCormick, LM; Wang, JY; Henkin, J; Schwartz, AL; Bu, GJ				Li, YH; Knisely, JM; Lu, WY; McCormick, LM; Wang, JY; Henkin, J; Schwartz, AL; Bu, GJ			Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; EXPRESSION; FAMILY; COMPLEXES; SYSTEM; GENE; INTERNALIZATION; ASTROCYTOMAS	The low density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a newly identified member of the LDL receptor family and is closely related to LRP. It was discovered as a putative tumor suppressor and is frequently inactivated in lung cancer cells. In the present study, we used an LRP1B minireceptor (mLRP1B4), which mimics the function and trafficking of LRP1B, to explore the roles of LRP1B on the plasminogen activation system. We found that mLRP1B4 and urokinase plasminogen activator receptor (uPAR) form immuno-precipitable complexes on the cell surface in the presence of complexes of uPA and its inhibitor, plasminogen activator inhibitor type-1 (PAI-1). However, compared with cells expressing the analogous LRP minireceptor (mLRP4), cells expressing mLRPIB4 display a substantially slower rate of uPA.PAI-1 complex internalization. Expression of mLRP1B4, or an mLRP4 mutant deficient in endocytosis, leads to an accumulation of uPAR at the cell surface and increased cell-associated uPA and PAI-1 when compared with cells expressing mLRP4. In addition, we found that expression of mLRP1B or the mLRP4 endocytosis mutant impairs the regeneration of unoccupied uPAR on the cell surface and that this correlates with a diminished rate of cell migration. Taken together, these results demonstrate that LRP1B can function as a negative regulator of uPAR regeneration and cell migration.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Abbott Laboratories	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.							Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chazaud B, 2002, AM J PATHOL, V160, P237, DOI 10.1016/S0002-9440(10)64367-2; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; deVries TJ, 1996, CANCER RES, V56, P1432; Fowler B, 1998, THROMB HAEMOSTASIS, V80, P148, DOI 10.1055/s-0037-1615154; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; Huang HT, 2000, CANCER RES, V60, P6868; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; Langbein S, 2002, LAB INVEST, V82, P639, DOI 10.1038/labinvest.3780458; LI Y, 1999, INVAS METAST, V18, P240; Li YH, 2001, MOL NEUROBIOL, V23, P53; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; LOPES MBS, 1994, FEBS LETT, V338, P301, DOI 10.1016/0014-5793(94)80288-2; Maletinska L, 2000, CANCER RES, V60, P2300; MAZAR AP, 1995, FIBRINOLYSIS S1, V6, P49; McGarvey T, 1996, PROSTATE, V28, P311; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Wang JY, 1997, EUR J BIOCHEM, V247, P256, DOI 10.1111/j.1432-1033.1997.00256.x; Yamamoto M, 1997, CANCER RES, V57, P2799; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	37	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42366	42371		10.1074/jbc.M207705200	http://dx.doi.org/10.1074/jbc.M207705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194987	hybrid			2022-12-25	WOS:000178985300133
J	Fong, A; Zhang, MY; Neely, J; Sun, SC				Fong, A; Zhang, MY; Neely, J; Sun, SC			S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappa B2/p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; 26S PROTEASOME; DEATH DOMAIN; IKK-ALPHA; P50; PROTEOLYSIS; INVOLVEMENT; ACTIVATION; PATHWAY; KINASE	Proteasome-mediated processing of the nfkappab2 gene product p100 is a regulated event that generates the NF-kappaB subunit p52. This event can be induced through p100 phosphorylation by a signaling pathway involving the nuclear factor-kappaB-inducing kinase (NIK). The C-terminal region of p100, which contains its phosphorylation site and a death domain, plays a pivotal role in regulating the processing of p100. To understand the biochemical mechanism of p100 processing, we searched for cellular factors interacting with the C-terminal regulatory region of p100 using the yeast two-hybrid system. This led to the identification of S9, a non-ATPase subunit of the 19 S proteasome with no known functions. Interestingly, the S9/p100 interaction could be induced by NIK but not by a catalytically inactive NIK mutant. This inducible molecular interaction required p100 ubiquitination and was dependent on the intact death domain. We further demonstrated that the death domain is essential for NIK-induced post-translational processing of p100, thus providing a functional link between the S9 binding and the processing of p100. Finally, we provide genetic evidence for the essential role of S9 in the inducible processing of p100.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NIAID NIH HHS [1R01 AI 45045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Caplen NJ, 2002, TRENDS BIOTECHNOL, V20, P49, DOI 10.1016/S0167-7799(01)01900-X; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hoffman L, 1997, FEBS LETT, V404, P179, DOI 10.1016/S0014-5793(97)00126-9; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40697	40702		10.1074/jbc.M205330200	http://dx.doi.org/10.1074/jbc.M205330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185077	hybrid			2022-12-25	WOS:000178791400069
J	Ishida, N; Hayashi, K; Hoshijima, M; Ogawa, T; Koga, S; Miyatake, Y; Kumegawa, M; Kimura, T; Takeya, T				Ishida, N; Hayashi, K; Hoshijima, M; Ogawa, T; Koga, S; Miyatake, Y; Kumegawa, M; Kimura, T; Takeya, T			Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; T-CELL ACTIVATION; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; CYCLOSPORINE-A; KAPPA-B; NF-AT; DEFECTIVE INTERLEUKIN-1; DIFFERENTIATION FACTOR; NUCLEAR-LOCALIZATION	To understand the molecular events coupling between cell proliferation and differentiation by elucidating genes essential for the process, we conducted a large scale gene expression analysis of an in vitro osteoclastogenesis system consisting of recombinant RANKL and mouse RAW264 cells. The entire process leading to the formation of tartrate resistant acid phosphatase-positive multinucleated cells takes 3 days and plates become fully covered with multinucleated cells at 4 days. Microarray probing at eight time points revealed 635 genes that showed greater than 2-fold differential expression for at least one time point and they could be classified into six groups by the "k-means" clustering analysis. Among a group of 106 early inducible genes (within 2-5 h after RANKL stimulation), four genes including NFAT2 were identified as genes whose enhanced expressions were fairly correlated with an efficient induction of matured osteoclasts. Moreover, cyclosporin A significantly suppressed the multinucleated cell formation accompanying the reduction of the nuclear localization of NFAT2. When the expression of NFAT2 was suppressed by introducing antisense NFAT2, multinucleated cell formation was severely hampered. Functional analysis thus combined with gene analysis by microarray technology elucidated a key role of NFAT2 in osteoclastogenesis in vitro.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan; Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 35002, Japan	Nara Institute of Science & Technology; Meikai University	Takeya, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.		Ogawa, Takuya/ABC-9628-2020	Ogawa, Takuya/0000-0001-9194-3079				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Assuma R, 1998, J IMMUNOL, V160, P403; Awumey EM, 1999, BIOCHEM BIOPH RES CO, V254, P248, DOI 10.1006/bbrc.1998.9785; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CHOWDHURY MH, 1991, CALCIFIED TISSUE INT, V49, P275, DOI 10.1007/BF02556217; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hartigan J., 1975, CLUSTERING ALGORITHM; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Itahana K, 1996, ENDOCRINOLOGY, V137, P5036, DOI 10.1210/en.137.11.5036; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; KOHONEN T, 1997, SPRINGER SERIES INFO, V426; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Perry R. L., 2000, FRONT BIOSCI, V5, pD570; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; RALPH P, 1977, J IMMUNOL, V119, P950; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REDDY SV, 1995, J BONE MINER RES, V10, P601; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SAMBROOK J, 2001, MOL CLONING, pCH17; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Spector D. L., 1998, CELLS LAB MANUAL; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	60	325	335	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41147	41156		10.1074/jbc.M205063200	http://dx.doi.org/10.1074/jbc.M205063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171919	hybrid			2022-12-25	WOS:000178791400125
J	Khreiss, T; Jozsef, L; Hossain, S; Chan, JSD; Potempa, LA; Filep, JG				Khreiss, T; Jozsef, L; Hossain, S; Chan, JSD; Potempa, LA; Filep, JG			Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROGRAMMED CELL-DEATH; NEOANTIGEN NEO-CRP; FC-GAMMA-RIII; HUMAN MONOCYTES; AGING NEUTROPHILS; ENDOTHELIAL-CELLS; NITRIC-OXIDE; DNA-SEQUENCE; ANNEXIN-V	Human neutrophil granulocytes die rapidly, and their survival is contingent upon rescue from programmed cell death by signals from the environment. Here we report that a novel signal for delaying neutrophil apoptosis is the classic acute phase reactant, C-reactive protein (CRP). However, this anti-apoptotic activity is expressed only when the cyclic pentameric structure of CRP is lost, resulting in formation of modified or monomeric CRP (mCRP), which may be formed in inflamed tissues. By contrast, native pentameric CRP and CRP peptides 77-82, 174-185, and 201-206 failed to affect neutrophil apoptosis. The apoptosis delaying action of mCRP was markedly attenuated by an antibody against the low affinity IgG immune complex receptor (CD16) but not by an anti-CD32 antibody. mCRP evoked a transient concurrent activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase/A-kt signaling pathways, leading to inhibition of caspase-3 and consequently to delaying apoptosis. Consistently, pharmacological inhibition of either ERK or Akt reversed the anti-apoptotic action of mCRP; however, they did not produce additive inhibition. Thus, mCRP, but not pentameric CRP or peptides derived from CRP, promotes neutrophil survival and may therefore contribute to amplification of the inflammatory response.	Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Ctr Hosp Univ Montreal Hotel Dieu, Ctr Rech, Quebec City, PQ H2W 1T8, Canada; NextEra Therapeut, Vernon Hills, IL 60061 USA	Universite de Montreal; Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Maisonneuve Rosemont Hosp, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	janos.g.filep@umontreal.ca						BALLOU SP, 1992, CYTOKINE, V4, P361, DOI 10.1016/1043-4666(92)90079-7; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; COLOTTA F, 1992, BLOOD, V80, P2012; Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002; DONG AC, 1994, J BIOL CHEM, V269, P6424; Dong Q, 1996, J IMMUNOL, V156, P4815; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fehsel K, 1997, NITRIC OXIDE-BIOL CH, V1, P254, DOI 10.1006/niox.1997.0124; FILEP J, 1989, LIFE SCI, V44, P517, DOI 10.1016/0024-3205(89)90613-9; Filep JG, 1996, BLOOD, V87, P5136, DOI 10.1182/blood.V87.12.5136.bloodjournal87125136; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gould JM, 2001, INFECT IMMUN, V69, P1747, DOI 10.1128/IAI.69.3.1747-1754.2001; Heuertz RM, 1997, MOL MED TODAY, V3, P539, DOI 10.1016/S1357-4310(97)01145-3; HOMBURG CHE, 1995, BLOOD, V85, P532; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KOLBBACHOFEN V, 1995, GLYCOCONJUGATE J, V12, P122, DOI 10.1007/BF00731355; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LILES WC, 1995, BLOOD, V86, P3181; MARNELL LL, 1995, J IMMUNOL, V155, P2185; MOLD C, 1981, J EXP MED, V154, P1703, DOI 10.1084/jem.154.5.1703; Motie M, 1996, J IMMUNOL, V156, P4435; MURPHY TM, 1991, J EXP MED, V173, P495, DOI 10.1084/jem.173.2.495; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PARK JR, 1994, BLOOD, V84, P440; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Potempa LA, 1999, US Patent, Patent No. 5874238; REES RF, 1988, CLIN IMMUNOL IMMUNOP, V48, P95, DOI 10.1016/0090-1229(88)90160-2; ROBEY FA, 1987, J BIOL CHEM, V262, P7053; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHEPHARD EG, 1990, J IMMUNOL, V145, P1469; SHIELDS MJ, 1991, J IMMUNOL METHODS, V141, P253, DOI 10.1016/0022-1759(91)90152-6; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stein MP, 2000, J CLIN INVEST, V105, P369, DOI 10.1172/JCI7817; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tudan C, 2000, J IMMUNOL, V165, P5798, DOI 10.4049/jimmunol.165.10.5798; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; WOO P, 1985, J BIOL CHEM, V260, P3384; Xia DY, 1997, P NATL ACAD SCI USA, V94, P2575, DOI 10.1073/pnas.94.6.2575; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YING SC, 1989, J IMMUNOL, V143, P221; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561; Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355; Zouki C, 2001, FASEB J, V15, P25	58	133	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40775	40781		10.1074/jbc.M205378200	http://dx.doi.org/10.1074/jbc.M205378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12198121	hybrid			2022-12-25	WOS:000178791400080
J	Rosen, GM; Tsai, P; Weaver, J; Porasuphatana, S; Roman, LJ; Starkov, AA; Fiskum, G; Pou, S				Rosen, GM; Tsai, P; Weaver, J; Porasuphatana, S; Roman, LJ; Starkov, AA; Fiskum, G; Pou, S			The role of tetrahydrobiopterin in the regulation of neuronal nitric-oxide synthase-generated superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; ELECTRON-TRANSFER; SPIN TRAP; KINETICS; ACTIVATION; REDUCTION; MECHANISM; CATALYSIS; RADICALS; NITRONE	Tetrahydrobiopterin (H4B) is a critical element in the nitric-oxide synthase (NOS) metabolism Of L-arginine to L-citrulline and NO.. It has been hypothesized that in the absence of or under nonsaturating levels Of L-arginine where O-2 reduction is the primary outcome of NOS activation, H4B promotes the generation of H2O2 at the expense of O-2(.-). The experiments were designed to test this hypothesis. To test this theory, two different enzyme preparations, H4B-bound NOS I and H4B-free NOS I, were used. Initial rates of NADPH turnover and O-2 utilization were found to be considerably greater in the H4B-bound NOS I preparation than in the H4B-free NOS I preparation. In contrast, the initial generation of O-2(.-) from the H4B-free NOS I preparation was found to be substantially greater than that measured using the H4B-bound NOS I preparation. Finally, by spin trapping nearly all of the NOS I produced O-2(.-) we found that the initial rate of H2O2 production by H4B-bound NOS I was considerably greater than that for H4B-free NOS I.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Khon Kaen Univ, Fac Pharmaceut Sci, Dept Toxicol, Khon Kaen 40002, Thailand; Univ Maryland Baltimore Cty, Dept Chem, Baltimore, MD 21250 USA; Univ Maryland, Sch Pharm, Ctr Low Frequency EPR In Vivo Physiol, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; Khon Kaen University; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rosen, GM (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 725 W Lombard St, Baltimore, MD 21201 USA.	grosen@umaryland.edu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; Weaver, John/0000-0003-3304-001X	NCRR NIH HHS [RR 12257] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07263] Funding Source: Medline; NIGMS NIH HHS [R25 GM 55036, GM 52419] Funding Source: Medline; NINDS NIH HHS [NS 34152] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036, R01GM052419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034152] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FREJAVILLE C, 1994, J CHEM SOC CHEM COMM, P1793, DOI 10.1039/c39940001793; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; TRUESDALE GA, 1954, NATURE, V173, P1236, DOI 10.1038/1731236a0; Tsai P, 1999, J CHEM SOC PERK T 2, P1759, DOI 10.1039/a901566c; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Weaver J, 2002, J PHARMACOL EXP THER, V302, P781, DOI 10.1124/jpet.102.035337; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247; Zhao HT, 2001, FREE RADICAL BIO MED, V31, P599, DOI 10.1016/S0891-5849(01)00619-0; Zhou MJ, 1997, ANAL BIOCHEM, V253, P169, DOI 10.1006/abio.1997.2392; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	48	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40275	40280		10.1074/jbc.M200853200	http://dx.doi.org/10.1074/jbc.M200853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183447	hybrid			2022-12-25	WOS:000178791400017
J	Ma, LL; Rudert, WA; Harnaha, J; Wright, M; Machen, J; Lakomy, R; Qian, SG; Lu, LN; Robbins, PD; Trucco, M; Giannoukakis, N				Ma, LL; Rudert, WA; Harnaha, J; Wright, M; Machen, J; Lakomy, R; Qian, SG; Lu, LN; Robbins, PD; Trucco, M; Giannoukakis, N			Immunosuppressive effects of glucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINE; HEXOSAMINE BIOSYNTHESIS PATHWAY; INDUCED INSULIN-RESISTANCE; PROTEIN-KINASE-C; MHC CLASS-II+; GENE-EXPRESSION; DENDRITIC CELLS; O-GLCNAC; TYROSINE PHOSPHORYLATION; N-ACETYLGLUCOSAMINE	Glucosamine is a naturally occurring derivative of glucose and is an essential component of glycoproteins and proteoglycans, important constituents of many eukaryotic proteins. In cells, glucosamine is produced enzymatically by the amidation of glucose 6-phosphate and can then be further modified by acetylation to result in N-acetylglucosamine. Commercially, glucosamine is sold over-the-counter to relieve arthritis. Although there is evidence in favor of the beneficial effects of glucosamine, the mechanism is unknown. Our data demonstrate that glucosamine suppresses the activation of T-lymphoblasts and dendritic cells in vitro as well as allogeneic mixed leukocyte reactivity in a dose-dependent manner. There was no inherent cellular toxicity involved in the inhibition, and the activity was not reproducible with other amine sugars. More importantly, glucosamine administration prolonged allogeneic cardiac allograft survival in vivo. We conclude that, despite its documented effects on insulin sensitivity, glucosamine possesses immunosuppressive activity and could be beneficial as an immunosuppressive agent.	Univ Pittsburgh, Sch Med, Dept Pathol, Inst Diabet,Rangos Res Ctr 5102, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, TE Starzl Transplantat Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Inst Diabet, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Giannoukakis, N (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Inst Diabet,Rangos Res Ctr 5102, 3460 5th Ave, Pittsburgh, PA 15213 USA.							AUSSEL C, 1990, IMMUNOPHARMACOLOGY, V20, P97, DOI 10.1016/0162-3109(90)90012-4; BEKESI JG, 1970, CANCER RES, V30, P2905; BERTRAM J, 1981, THROMB RES, V23, P301, DOI 10.1016/0049-3848(81)90019-0; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSMANN HB, 1971, BIOCHIM BIOPHYS ACTA, V240, P74, DOI 10.1016/0005-2787(71)90515-6; BOSMANN HB, 1972, BIOCHEM PHARMACOL, V21, P1977; CASSEL DL, 1983, CANCER RES, V43, P4582; Cavallo R, 1991, G Batteriol Virol Immunol, V84, P11; CHANG DM, 1995, IMMUNOPHARM IMMUNOT, V17, P437, DOI 10.3109/08923979509016380; Chen MG, 1997, MOL CELL ENDOCRINOL, V135, P67, DOI 10.1016/S0303-7207(97)00191-3; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; FARE G, 1967, NATURE, V213, P308, DOI 10.1038/213308a0; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; FJELDE A, 1956, EXP CELL RES, V10, P88, DOI 10.1016/0014-4827(56)90075-1; FRIEDMAN S J, 1977, Cancer Research, V37, P1141; FRIEDMAN SJ, 1977, CANCER RES, V37, P1068; FRIEDMAN SJ, 1980, P NATL ACAD SCI-BIOL, V77, P1172, DOI 10.1073/pnas.77.2.1172; Fu FM, 1996, TRANSPLANTATION, V62, P659, DOI 10.1097/00007890-199609150-00021; Gouze JN, 2002, FEBS LETT, V510, P166, DOI 10.1016/S0014-5793(01)03255-0; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; IRAHARA M, 1987, IMMUNOBIOLOGY, V174, P190, DOI 10.1016/S0171-2985(87)80038-4; JIN YJ, 1990, J IMMUNOL, V144, P647; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; LEVINE BL, 1991, J IMMUNOL, V147, P3474; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; Lippiello L, 2000, CLIN ORTHOP RELAT R, P229, DOI 10.1097/00003086-200012000-00027; Lu L, 1995, TRANSPLANTATION, V60, P1539, DOI 10.1097/00007890-199560120-00028; Lu LN, 1996, J IMMUNOL, V157, P3577; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; McClain DA, 2000, ENDOCRINOLOGY, V141, P1999, DOI 10.1210/en.141.6.1999; MOLNAR Z, 1972, CANCER RES, V32, P380; MOLNAR Z, 1972, CANCER RES, V32, P756; Monauni T, 2000, DIABETES, V49, P926, DOI 10.2337/diabetes.49.6.926; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; NORDMANN R, 1989, BIOCHEMISTRY-US, V28, P1791, DOI 10.1021/bi00430a055; ONEILL HC, 1988, IMMUNOLOGY, V64, P181; PAPADOGIANNAKIS N, 1989, EUR J IMMUNOL, V19, P1953, DOI 10.1002/eji.1830191029; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; PLAGEMANN PG, 1971, J CELL PHYSIOL, V77, P213, DOI 10.1002/jcp.1040770212; PLAGEMANN PG, 1971, J CELL PHYSIOL, V77, P241, DOI 10.1002/jcp.1040770213; PLAGEMANN PG, 1973, CANCER RES, V33, P482; QUASTEL JH, 1953, NATURE, V171, P252, DOI 10.1038/171252a0; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; Rescigno M, 2001, CELL, V106, P267, DOI 10.1016/S0092-8674(01)00454-8; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rovati LC, 1999, LANCET, V354, P1640, DOI 10.1016/S0140-6736(99)90195-2; RUBIN A, 1954, CANCER RES, V14, P456; SCHOLTISSEK C, 1972, BIOCHIM BIOPHYS ACTA, V277, P459, DOI 10.1016/0005-2787(72)90088-3; Shikhman AR, 2001, J IMMUNOL, V166, P5155, DOI 10.4049/jimmunol.166.8.5155; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TRAXINGER RR, 1992, J BIOL CHEM, V267, P9718; Uldry M, 2002, FEBS LETT, V524, P199, DOI 10.1016/S0014-5793(02)03058-2; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; WILLIAMS TM, 1992, J IMMUNOL, V148, P2609; YAGITA M, 1989, CELL IMMUNOL, V122, P83, DOI 10.1016/0008-8749(89)90150-0; YAGITA M, 1993, CANCER RES, V53, P5600; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	75	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39343	39349		10.1074/jbc.M204924200	http://dx.doi.org/10.1074/jbc.M204924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176986	hybrid			2022-12-25	WOS:000178662500038
J	van der Luit, AH; Budde, M; Ruurs, P; Verheij, M; van Blitterswijk, WJ				van der Luit, AH; Budde, M; Ruurs, P; Verheij, M; van Blitterswijk, WJ			Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RADIATION-INDUCED APOPTOSIS; CANINE KIDNEY-CELLS; MEMBRANE FLUIDITY; PLASMA-MEMBRANE; CHOLERA-TOXIN; ETHER LIPIDS; A549 CELLS; INTERNALIZATION; TRANSPORT	The synthetic alkyl-lysophospholipid (ALP), 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, is an antitumor agent that acts on cell membranes and can induce apoptosis. We investigated how ALP is taken up by cells, how it affects de novo biosynthesis of phosphatidylcholine (PC), and how critical this is to initiate apoptosis. We compared an ALP-sensitive mouse lymphoma cell line, S49, with an ALP-resistant variant, S49(AR). ALP inhibited PC synthesis at the CTP:phosphocholine cytidylyltransferase (CT) step in S49 cells, but not in S49AR cells. Exogenous lysophosphatidylcholine, providing cells with an alternative way (acylation) to generate PC, rescued cells from ALP-induced apoptosis, indicating that continuous rapid PC turnover is essential for cell survival. Apoptosis induced by other stimuli that do not target PC synthesis remained unaffected by lysophosphatidylcholine. Using monensin, low temperature and albumin back-extraction, we demonstrated that ALP is internalized by endocytosis, a process defective in S49 AR cells. This defect neither involved clathrin-coated pitnor fluid-phase endocytosis, but depended on lipid rafts, because disruption of these microdomains with methyl-beta-cyclodextrin or filipin (sequestering cholesterol) or bacterial sphingomyelinase reduced uptake of ALP. Furthermore, ALP was found accumulated in isolated rafts and disruption of rafts also prevented the inhibition of PC synthesis and apoptosis induction in S49 cells. In summary, ALP is internalized by raft-dependent endocytosis to inhibit PC synthesis, which triggers apoptosis.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	van Blitterswijk, WJ (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Verheij, Marcel/O-9652-2018					Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BAZILL GW, 1990, CANCER RES, V50, P7505; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KELLEY EE, 1993, BIOCHEM PHARMACOL, V45, P2435, DOI 10.1016/0006-2952(93)90224-K; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Mattjus P, 1996, LANGMUIR, V12, P1284, DOI 10.1021/la950861z; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mollinedo F, 1997, CANCER RES, V57, P1320; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; POWIS G, 1992, CANCER RES, V52, P2835; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0; Ruiter GA, 1999, CANCER RES, V59, P2457; RUITER GA, 2002, IN PRESS INT J CANC; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Small GW, 1997, LIPIDS, V32, P715, DOI 10.1007/s11745-997-0091-3; Smets LA, 1999, APOPTOSIS, V4, P419, DOI 10.1023/A:1009644208512; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Torgersen ML, 2001, J CELL SCI, V114, P3737; van Blitterswijk WJ, 2001, BIOCHEM SOC T, V29, P819; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P820, DOI 10.1007/BF02535537; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VANBLITTERSWIJK WJ, 1994, CURR TOP MEMBR, V40, P413, DOI 10.1016/S0070-2161(08)60990-9; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZHOU X, 1995, EUR J BIOCHEM, V232, P881, DOI 10.1111/j.1432-1033.1995.881zz.x; ZOELLER RA, 1995, J LIPID RES, V36, P1866	54	145	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39541	39547		10.1074/jbc.M203176200	http://dx.doi.org/10.1074/jbc.M203176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183451	hybrid			2022-12-25	WOS:000178662500063
J	Zaremberg, V; McMaster, CR				Zaremberg, V; McMaster, CR			Differential partitioning of lipids metabolized by separate yeast glycerol-3-phosphate acyltransferases reveals that phospholipase D generation of phosphatidic acid mediates sensitivity to choline-containing lysolipids and drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; DIHYDROXYACETONE PHOSPHATE; HORMONAL-REGULATION; GENE; SYNTHASE; ENZYMES; CLONING; CHOLINEPHOSPHOTRANSFERASE; PATHWAY	In this study we demonstrate that the GAT1 and GAT2 genes encode the major glycerol-3-phosphate acyltransferase activities in Saccharomyces cerevisiae. Genetic inactivation of either GAT1 or GAT2 did not alter cell growth but inactivation of both resulted in growth cessation. Metabolic analyses of gat1 and gat2 yeast detected that the major differences were: (i) a 50% increase in the rate of triacylglycerol synthesis in gat1 yeast and a corresponding 50% decrease in gat2 yeast, and (ii) a 5-fold increase in glycerophosphocholine production through deacylation of phosphatidylcholine synthesized through the CDP-choline pathway in gat1 yeast, whereas gat2 yeast displayed a 10-fold decrease. To address why we observed alterations in phospholipid turnover specific to phosphatidylcholine produced through the CDP-choline pathway in gat1 and gat2 yeast we tested their sensitivity to various cytotoxic lysolipids and observed that gat2 cells were more sensitive to lysophosphatidylcholine, but not other lysolipids. To pursue the mechanism we analyzed their sensitivity to choline-containing lysolipids or drugs that could not be deacylated and/or reacylated. Our data showed that gat1 and gat2 yeast were resistant and sensitive to lysoplatelet activating factor, platelet activating factor, and the anti-tumor lipid edelfosine, respectively, indicating that their sensitivity to these compounds was not because of differences in rates of phosphatidylcholine deacylation. As growth of gat2 cells was impaired in the presence of ethanol, a phospholipase D (Spo14p) inhibitor, we inferred that phospholipase D may play important biologic and metabolic roles in phenotypes observed in gat yeast. Genetic inactivation of the SPO14 gene resulted in increased susceptibility, whereas expression of Escherichia coli diacylglycerol kinase relieved growth inhibition, to choline-containing lysolipids and drugs. Our results are consistent with a model whereby phosphatidic acid generated from phosphatidylcholine hydrolysis by Spo14p regulates susceptibility to choline-containing lysolipid analogs and drugs.	Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Hlth Ctr, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.	cmcmaste@is.dal.ca		McMaster, Christopher/0000-0003-0822-5776				AMES BN, 1960, J BIOL CHEM, V235, P769; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; BAELEE MS, 1984, J BIOL CHEM, V259, P857; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; de Vet ECJM, 2000, J BIOL CHEM, V275, P6276, DOI 10.1074/jbc.275.9.6276; Dircks LK, 1999, J BIOL CHEM, V274, P34728, DOI 10.1074/jbc.274.49.34728; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Henneberry AL, 2001, MOL BIOL CELL, V12, P511, DOI 10.1091/mbc.12.3.511; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Kaiser C., 1994, METHODS YEAST GENETI; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; LEE KS, 1994, J BIOL CHEM, V269, P19725; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUSHITA M, 1995, J BIOCHEM-TOKYO, V117, P447, DOI 10.1093/jb/117.2.447; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Mishra S, 2001, BIOCHEM J, V355, P315, DOI 10.1042/0264-6021:3550315; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PREISS J, 1986, J BIOL CHEM, V261, P8597; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Sambrook J, 2001, MOL CLONING LAB MANU; Shen HF, 1997, J BIOL CHEM, V272, P11215; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	42	61	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39035	39044		10.1074/jbc.M207753200	http://dx.doi.org/10.1074/jbc.M207753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167660	hybrid			2022-12-25	WOS:000178529600128
J	Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K				Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K			Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma	ONCOGENE			English	Article						human telomerase reverse transcriptase; auto-antigen; hepatocellular carcinoma	CHRONIC LIVER-DISEASE; CELLS; CANCER; AUTOANTIBODIES; MALIGNANCIES; BREAST	Human telomerase reverse transcriptase, hTERT, is the catalytic component of human telomerase. Expression of hTERT confers telomerase activity, indicating that hTERT is the rate-limiting component of human telomerase. Here we report the detection of anti-hTERT auto-antibodies in the sera derived patients with hepatocellular carcinoma using recombinant, purified hTERT as an antigen in an enzyme linked immunosorbent assay (ELISA). The levels of anti-hTERT antibodies in serum correlated with progression to hepatocellular carcinoma. In contrast, we detected only low levels of anti-hTERT auto-antibodies in the sera derived from 18 normal volunteers. The observation of hTERT auto-antibodies in the sera derived from cancer patients suggests that such auto-antibodies constitute novel and specific tumor marker.	Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Grad Sch Med, Dept Biol Mol, Div Mol Oncol,Canc Res Inst, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Kanazawa University	Kaneko, S (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.							Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Covini G, 1997, HEPATOLOGY, V25, P75; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; IMAI H, 1992, AM J PATHOL, V140, P859; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; IMAI H, 1993, CANCER-AM CANCER SOC, V71, P26, DOI 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamoto M, 1999, CANCER, V85, P245, DOI 10.1002/(SICI)1097-0142(19990101)85:1<245::AID-CNCR37>3.0.CO;2-9; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NELSON DS, 1977, PATHOLOGY, V9, P155, DOI 10.3109/00313027709085253; Nouso K, 1996, CANCER, V78, P232, DOI 10.1002/(SICI)1097-0142(19960715)78:2<232::AID-CNCR7>3.0.CO;2-N; Saeboe-Larssen S, 2002, J IMMUNOL METHODS, V259, P191, DOI 10.1016/S0022-1759(01)00506-3; SCHATTNER A, 1983, CANCER-AM CANCER SOC, V52, P2156, DOI 10.1002/1097-0142(19831201)52:11<2156::AID-CNCR2820521130>3.0.CO;2-2; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; Treon SP, 2000, SEMIN ONCOL, V27, P598; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Vonderheide RH, 2001, CANCER RES, V61, P8366; WASSERMAN J, 1975, CLIN EXP IMMUNOL, V19, P417; WINTER SF, 1992, CANCER RES, V52, P4168	26	24	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5946	5950		10.1038/sj.onc.1205788	http://dx.doi.org/10.1038/sj.onc.1205788			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185596				2022-12-25	WOS:000177520900016
J	Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM				Murata, H; Khattar, NH; Kang, Y; Gu, LY; Li, GM			Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hypermethylation; breast cancer	NONPOLYPOSIS COLORECTAL-CANCER; IN-SITU; PROMOTER HYPERMETHYLATION; ENDOMETRIAL CARCINOMAS; CELL-LINES; GASTRIC CARCINOMAS; HIGH-FREQUENCY; COLON-CANCER; TUMOR-CELLS; DNA	Breast cancer is the most common cancer in women, but its pathogenesis is still unclear. Microsatellite instability (MSI) has been identified in breast cancer cells, suggesting an association with mismatch repair defects. To test this hypothesis, we investigated MSI, protein expression of hMSH2 and hMLH1, as well as genetic and epigenetic modifications of these two genes in 32 sporadic breast tumors. MSI was identified in 15 cases. Immunohistochemistry analysis revealed that all MSI cases but one had lower than normal expression of hMSH2 (nine cases), hMLH1 (12 cases), or both (seven cases). In tumors with MSI, both genetic and epigenetic modifications of these mismatch repair genes were also identified. Eight cases harbored mutations or polymorphisms in hMSH2 and hMLH1, and 10 exhibited hypermethylation in the promoter region of hMLH1. These results suggest that both genetic and epigenetic alterations of hMSH2 and especially of h-MLH1 contribute to genomic instability and tumorigenesis in sporadic breast cancer.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Markey Canc Ctr, Suite MS 117,800 Rose St, Lexington, KY 40536 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALDAZ CM, 1995, CANCER RES, V55, P3976; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I; Boland CR, 1998, CANCER RES, V58, P5248; CONTEGIACOMO A, 1995, INT J CANCER, V64, P264, DOI 10.1002/ijc.2910640409; CUI J, 1998, CHUNG HUA I HSUEH I, V15, P348; Cunningham JM, 1998, CANCER RES, V58, P3455; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; Friedrich M, 1999, HISTOCHEM J, V31, P717, DOI 10.1023/A:1003996431044; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89; Grady WM, 2001, CANCER RES, V61, P900; Gurin CC, 1999, CANCER RES, V59, P462; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hosoya N, 1998, JPN J CANCER RES, V89, P33, DOI 10.1111/j.1349-7006.1998.tb00476.x; Jonsson M, 1995, EUR J CANCER, V31A, P2330, DOI 10.1016/0959-8049(95)00447-5; Kane MF, 1997, CANCER RES, V57, P808; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1999, CANCER RES, V59, P159; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1999, J MED GENET, V36, P801; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Paulson TG, 1996, CANCER RES, V56, P4021; Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X; Rush EB, 1997, ANN SURG ONCOL, V4, P310, DOI 10.1007/BF02303580; Salvesen HB, 2000, CLIN CANCER RES, V6, P3607; Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Shen KL, 2000, J SURG ONCOL, V74, P100, DOI 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O; Siah SP, 2000, BREAST CANCER RES TR, V60, P135, DOI 10.1023/A:1006315315060; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Toyama T, 1996, CANCER LETT, V108, P205, DOI 10.1016/S0304-3835(96)04414-X; Toyama T, 1996, INT J CANCER, V68, P447, DOI 10.1002/(SICI)1097-0215(19961115)68:4<447::AID-IJC8>3.0.CO;2-0; Vasen HFA, 2001, AM J HUM GENET, V68, P1533, DOI 10.1086/320610; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Weber TK, 1997, CANCER RES, V57, P3798; YEE CJ, 1994, CANCER RES, V54, P1641; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	57	72	84	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5696	5703		10.1038/sj.onc.1205683	http://dx.doi.org/10.1038/sj.onc.1205683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173039				2022-12-25	WOS:000177463400004
J	Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O				Xie, YT; Skytting, B; Nilsson, G; Grimer, RJ; Mangham, CD; Fisher, C; Shipley, J; Bjerkehagen, B; Myklebost, O; Larsson, O			The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11. 2; q11.2) and the cell cycle machinery	ONCOGENE			English	Article						cyclin A; cyclin D1; SYT-SSX; synovial sarcoma	SYT; SSX; CANCER; OVEREXPRESSION; PROLIFERATION; TRANSLOCATION; PROGNOSIS; PROTEINS; GENES	A recent large multi-centre study convincingly confirmed previous observations that the SYT-SSX1 fusion type, compared to SYT-SSX2, of synovial sarcoma is associated with a worse clinical outcome. Apart from the clinical impact, this fact also suggests (1) that the SYT-SSX fusion gene may influence molecular mechanisms involved in tumour growth and progression; and (2) that the SYT-SSX1 fusion type has a stronger influence on these mechanisms than SYT-SSX2. The nature of the underlying mechanisms is, however, still unknown. In this study we made use of the SYT-SSX1 vs SYT-SSX2 concept to investigate whether major, tumour relevant, and growth regulatory proteins (e.g. cyclins and cyclin-dependent kinases) may be involved. Using Western blotting analysis on 74 fresh, fusion variant-typed, tumour samples from localized synovial sarcoma, we found a significant correlation between SYT-SSX1 and high expression of cyclin A (P=0.003) and D1 (P=0.025). Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.	Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430072, Peoples R China; Karolinska Hosp, Dept Orthoped, Stockholm, Sweden; Stockholm Soder Hosp, Dept Orthoped, Stockholm, Sweden; Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England; Royal Marsden NHS Trust, Dept Pathol, London, England; Canc Res Inst, Mol Cytogenet Team, Sutton, Surrey, England; Norwegian Radium Hosp, Dept Pathol, Canc Res Inst, Oslo, Norway; Norwegian Radium Hosp, Dept Tumor Biol, Canc Res Inst, Oslo, Norway	Karolinska Institutet; Karolinska University Hospital; Wuhan University; Karolinska Institutet; Karolinska University Hospital; Royal Orthopaedic Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oslo; University of Oslo	Larsson, O (corresponding author), Karolinska Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Shipley, Janet/0000-0001-6748-8678				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SH, 1998, CLIN CANCER RES, V4, P2377; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; Mishina T, 2000, CLIN CANCER RES, V6, P11; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nilsson G, 1999, CANCER RES, V59, P3180; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shamma A, 1998, INT J ONCOL, V13, P455; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; XIE Y, 2002, IN PRESS CANC RES, V62	27	34	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5791	5796		10.1038/sj.onc.1205700	http://dx.doi.org/10.1038/sj.onc.1205700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173050				2022-12-25	WOS:000177463400015
J	Cabezon, E; Butler, PJG; Runswick, MJ; Carbajo, RJ; Walker, JE				Cabezon, E; Butler, PJG; Runswick, MJ; Carbajo, RJ; Walker, JE			Homologous and heterologous inhibitory effects of ATPase inhibitor proteins on F-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; BINDING; IF1; PURIFICATION; F1F0-ATPASE; F-1-ATPASE; PH	In Saccharomyces cerevisiae, at least three proteins (IF1, STF1, and STF2) appear to be involved in the regulation of ATP synthase. Both IF1 and STF1 inhibit F-1, whereas the proposed function for STF2 is to facilitate the binding of IF1 and STF1 to F-1. The oligomerization properties of yeast IF1 and STF1 have been investigated by sedimentation equilibrium analytical ultracentrifugation and by covalent cross-linking. Both techniques confirm that IF1 and STF1 oligomerize in opposite directions in relation to pH, suggesting that both proteins might regulate yeast F1F0-ATPase under different conditions. Their effects on bovine F-ATPases are also described. Whereas bovine IF1 inhibits yeast F-1-ATPase even better than yeast IF1 or STF1, the capability of yeast IF1 to inhibit the bovine enzyme is very low and decreases with time. Such an effect is also observed in the study of the homologous inhibition of yeast F-1-ATPase. Yeast inhibitors are not as effective as their bovine counterpart, and the complex seems to dissociate gradually.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Cabezon, Elena/K-5874-2014	Walker, John/0000-0001-7929-2162; Cabezon, Elena/0000-0002-6177-5016				Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; Eisenberg H, 1976, BIOL MACROMOLECULES; Gordon-Smith DJ, 2001, J MOL BIOL, V308, P325, DOI 10.1006/jmbi.2001.4570; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1987, J BIOCHEM-TOKYO, V102, P685, DOI 10.1093/oxfordjournals.jbchem.a122106; HASHIMOTO T, 1990, J BIOCHEM-TOKYO, V108, P17, DOI 10.1093/oxfordjournals.jbchem.a123154; HASHIMOTO T, 1981, J BIOCHEM-TOKYO, V90, P1151, DOI 10.1093/oxfordjournals.jbchem.a133567; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Kratky O, 1973, Methods Enzymol, V27, P98; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; NORLING B, 1990, EUR J BIOCHEM, V188, P247, DOI 10.1111/j.1432-1033.1990.tb15396.x; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; vanRaaij MJ, 1996, BIOCHEMISTRY-US, V35, P15618, DOI 10.1021/bi960628f; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	23	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41334	41341		10.1074/jbc.M207169200	http://dx.doi.org/10.1074/jbc.M207169200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186878	hybrid			2022-12-25	WOS:000178985300008
J	Fischer, M; Romisch, W; Schiffmann, S; Kelly, M; Oschkinat, H; Steinbacher, S; Huber, R; Eisenreich, W; Richter, G; Bacher, A				Fischer, M; Romisch, W; Schiffmann, S; Kelly, M; Oschkinat, H; Steinbacher, S; Huber, R; Eisenreich, W; Richter, G; Bacher, A			Biosynthesis of riboflavin in archaea studies on the mechanism of 3,4-dihydroxy-2-butanone-4-phosphate synthase of Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL BIOLUMINESCENCE; 4-PHOSPHATE SYNTHASE; BACILLUS-SUBTILIS; METHANOBACTERIUM-THERMOAUTOTROPHICUM; 4-CARBON PRECURSOR; CYCLOHYDROLASE-II; DEAMINASE; PROTEIN; 6,7-DIMETHYL-8-RIBITYLLUMAZINE	The hypothetical protein predicted by the open reading frame MJ0055 of Methanococcus jannaschii was expressed in a recombinant Escherichia coli strain under the control of a synthetic gene optimized for translation in an eubacterial host. The recombinant protein catalyzes the formation of the riboflavin precursor 3,4-dihydroxy-2-butanone 4-phosphate from ribulose 5-phosphate at a rate of 174 nmol mg(-1) min(-1) at 37 degreesC. The homodimeric 51.6-kDa protein requires divalent metal ions, preferentially magnesium, for activity. The reaction involves an intramolecular skeletal rearrangement as shown by C-13 NMR spectroscopy using [U-C-13(5)]ribulose 5-phosphate as substrate. A cluster of charged amino acid residues comprising arginine 25, glutamates 26 and 28, and aspartates 21 and 30 is essential for catalytic activity. Histidine 164 and glutamate 185 were also shown to be essential for catalytic activity.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Biochem, Dept Prot Crystallog, D-82512 Martinsried, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Technical University of Munich; Max Planck Society	Fischer, M (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Fischer, Markus/AFT-1856-2022; Fischer, Markus J./G-9477-2012; Eisenreich, Wolfgang/A-1258-2013; Richter, Gerald/F-3642-2011	Fischer, Markus/0000-0001-7243-4199; Eisenreich, Wolfgang/0000-0002-9832-8279; Oschkinat, Hartmut/0000-0002-4384-9544; Schiffmann, Susanne/0000-0001-5035-2504				BACHER A, 1986, METHOD ENZYMOL, V122, P192; Bacher A, 2001, VITAM HORM, V61, P1; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; BACHER A, 1996, ESCHERICHIA COLI SAL, V2, P657; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURROWS RB, 1978, J BACTERIOL, V136, P657, DOI 10.1128/JB.136.2.657-667.1978; Eberhardt S, 1997, J BACTERIOL, V179, P2938, DOI 10.1128/jb.179.9.2938-2943.1997; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; FOOR F, 1975, J BIOL CHEM, V250, P3545; HARZER G, 1978, BIOCHIM BIOPHYS ACTA, V540, P48, DOI 10.1016/0304-4165(78)90433-6; HOLLANDER I, 1979, BIOCHEM BIOPH RES CO, V89, P759, DOI 10.1016/0006-291X(79)90694-6; Kelly MJS, 2001, P NATL ACAD SCI USA, V98, P13025, DOI 10.1073/pnas.231323598; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; Lee J., 1985, CHEM BIOLUMINESCENCE, P401; Liao DI, 2002, BIOCHEMISTRY-US, V41, P1795, DOI 10.1021/bi015652u; Liao DI, 2001, STRUCTURE, V9, P11, DOI 10.1016/S0969-2126(00)00550-5; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MEIGHEN EA, 1993, FASEB J, V7, P1016, DOI 10.1096/fasebj.7.11.8370470; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; MULLER F, 1992, CHEM BIOCH FLAVOENZY, V3; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; NIELSEN P, 1981, BIOCHIM BIOPHYS ACTA, V662, P312, DOI 10.1016/0005-2744(81)90044-9; OKANE DJ, 1992, MOL MICROBIOL, V6, P443, DOI 10.1111/j.1365-2958.1992.tb01488.x; Plaut G.W, 1960, J BIOL CHEM, V235, P41; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REUKE B, 1992, J BACTERIOL, V174, P4042, DOI 10.1128/jb.174.12.4042-4049.1992; Richter G, 1999, EUR J BIOCHEM, V261, P57, DOI 10.1046/j.1432-1327.1999.00211.x; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Richter G, 1997, METHOD ENZYMOL, V280, P374; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; VOLK R, 1991, J BIOL CHEM, V266, P20610; WACKER H, 1964, J BIOL CHEM, V239, P3493; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395	47	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41410	41416		10.1074/jbc.M206863200	http://dx.doi.org/10.1074/jbc.M206863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200440	hybrid			2022-12-25	WOS:000178985300016
J	Greene, NDE; Leung, KY; Wait, R; Begum, S; Dunn, MJ; Copp, AJ				Greene, NDE; Leung, KY; Wait, R; Begum, S; Dunn, MJ; Copp, AJ			Differential protein expression at the stage of neural tube closure in the mouse embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; KINASE-C; 2-DIMENSIONAL ELECTROPHORESIS; HEAT-SHOCK; PROTEOMICS; INDUCTION; FILAMENTS; ELEMENTS; NUCLEAR; GENOMES	Analysis of the protein complement of a biological system through proteomics provides the opportunity to directly monitor the functional readout of gene expression. In this study, proteomics was applied to the mouse embryo to investigate the molecular events underlying the processes occurring at the stage of neural tube closure. Protein profiles of embryos between embryonic days 8.5 and 10.5 exhibited a number of stage-specific changes. Identification of developmentally regulated proteins by mass spectrometry revealed several groups of functionally related proteins including circulatory, cytoskeletal, and stress proteins. Additional proteins of unknown function were identified, such as Copine 1 and PICOT, whose developmental regulation was previously unsuspected.	UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England; Harefield Hosp, Imperial Coll Sch Med, Heart Sci Ctr, Natl Heart & Lung Inst, Harefield VB9 6JH, Middx, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	University of London; University College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; University of Oxford	Greene, NDE (corresponding author), UCL, Inst Child Hlth, Neural Dev Unit, Guilford St, London WC1N 1EH, England.	n.greene@ich.ucl.ac.uk	Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Greene, Nicholas D.E./0000-0002-4170-5248				Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Barnes JA, 2000, ANAT EMBRYOL, V202, P67, DOI 10.1007/s004290000090; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Cockroft DL, 1990, POSTIMPLANTATION MAM, P15; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; COPP AJ, 1992, DEV BIOL, V153, P312, DOI 10.1016/0012-1606(92)90116-X; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; DZIADEK M, 1978, J EMBRYOL EXP MORPH, V46, P135; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Hatayama T, 1997, CELL STRUCT FUNCT, V22, P517, DOI 10.1247/csf.22.517; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HOULE J, 1983, DEV BRAIN RES, V9, P189, DOI 10.1016/0165-3806(83)90051-2; JACKSON BW, 1981, DIFFERENTIATION, V20, P203, DOI 10.1111/j.1432-0436.1981.tb01177.x; Jones EA, 2001, J ANAT, V198, P555, DOI 10.1046/j.1469-7580.2001.19850555.x; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; LATHAM KE, 1993, MOL REPROD DEV, V35, P140, DOI 10.1002/mrd.1080350207; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Leung KY, 2001, PROTEOMICS, V1, P787; Loones MT, 1997, CELL MOL LIFE SCI, V53, P179, DOI 10.1007/PL00000590; Lopez MF, 2002, CIRC RES, V90, P380, DOI 10.1161/hh0402.105757; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MURACH KF, 1990, J CELL BIOCHEM, V44, P19, DOI 10.1002/jcb.240440103; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rendon-Huerta E, 1999, BIOCHEM J, V344, P469, DOI 10.1042/0264-6021:3440469; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; Vizzard MA, 2000, DEV BRAIN RES, V119, P217, DOI 10.1016/S0165-3806(99)00174-1; Walsh D, 1997, CELL MOL LIFE SCI, V53, P198, DOI 10.1007/PL00000592; Wilda M, 2001, MECH DEVELOP, V103, P197, DOI 10.1016/S0925-4773(01)00357-4; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902	38	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41645	41651		10.1074/jbc.M203607200	http://dx.doi.org/10.1074/jbc.M203607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200422	hybrid			2022-12-25	WOS:000178985300045
J	Sato, S; Tatebayashi, Y; Akagi, T; Chui, DH; Murayama, M; Miyasaka, T; Planel, E; Tanemura, K; Sun, XY; Hashikawa, T; Yoshioka, K; Ishiguro, K; Takashima, A				Sato, S; Tatebayashi, Y; Akagi, T; Chui, DH; Murayama, M; Miyasaka, T; Planel, E; Tanemura, K; Sun, XY; Hashikawa, T; Yoshioka, K; Ishiguro, K; Takashima, A			Aberrant tau phosphorylation by glycogen synthase kinase-3 beta and JNK3 induces oligomeric tau fibrils in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASES; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; IN-VITRO; ABNORMAL PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; NERVOUS-SYSTEM	Neurofibrillary tangles (NFTs) are found in a wide range of neurodegenerative disorders, including Alzheimer's disease. The major component of NFTs is aberrantly hyperphosphorylated microtubule-associated protein tau. Because appropriate in vivo models have been lacking, the role of tau phosphorylation in NFTs formation has remained elusive. Here, we describe a new model in which adenovirus-mediated gene expression of tau, DeltaMEKK, JNK3, and GSK-3beta in COS-7 cells produces most of the pathological phosphorylation epitopes of tau including AT100. Furthermore, this co-expression resulted in the formation of tau aggregates having short fibrils that were detergent-insoluble and Thioflavin-S-reactive. These results suggest that aberrant tau phosphorylation by the combination of these kinases may be involved in "pretangle," oligomeric tau fibril formation in vivo.	RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan; Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Mitsubishi Kasei Corp, Inst Life Sci, Tokyo 1948511, Japan	RIKEN; RIKEN; Kanazawa University	Takashima, A (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan.			Planel, Emmanuel/0000-0001-5128-0565				Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Chui DH, 1998, J NEUROSCI RES, V53, P99; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nunomura A, 1999, J NEUROSCI, V19, P1959; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Perez M, 1996, J NEUROCHEM, V67, P1183; Perez M, 2000, FEBS LETT, V486, P270, DOI 10.1016/S0014-5793(00)02323-1; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Perry G, 2000, FREE RADICAL BIO MED, V28, P831, DOI 10.1016/S0891-5849(00)00158-1; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TAKASHIMA A, 1995, NEUROSCI LETT, V198, P83, DOI 10.1016/0304-3940(95)11964-X; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; Wilson DM, 1997, AM J PATHOL, V150, P2181; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; YAN MH, 1994, NATURE, V372, P798; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	52	111	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42060	42065		10.1074/jbc.M202241200	http://dx.doi.org/10.1074/jbc.M202241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12191990	hybrid			2022-12-25	WOS:000178985300095
J	Gohler, T; Reimann, M; Cherny, D; Walter, K; Warnecke, G; Kim, E; Deppert, W				Gohler, T; Reimann, M; Cherny, D; Walter, K; Warnecke, G; Kim, E; Deppert, W			Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; HUMAN ENKEPHALIN ENHANCER; CRUCIFORM DNA; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; PROTEIN; GENE; PROMOTER; APOPTOSIS; TRANSACTIVATION	Transcriptional activation of p53-regulated genes is initiated by sequence-specific DNA binding of p53 to target binding sites. Regulation of sequence-specific DNA binding is complex and occurs at various levels. We demonstrate that DNA topology is an important parameter for regulating the selective and highly specific interaction of p53 with its target binding sites. Specific binding of wild-type p53 is greatly enhanced when cognate binding sites are present in a non-linear stem-loop conformation. The C-terminal domain plays a key role in regulating the specific interactions of p53 with target binding sites in a DNA conformation-dependent manner. The C-terminal domain is required for binding to target sites in a non-linear DNA conformation in contrast to the strong inhibitory effects of the C terminus on p53 interaction with linear DNA. We propose that selective binding of p53 to various promoters may be determined by the DNA conformation within p53 cognate sites.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Heinrich Pette Institute; University of Hamburg; Max Planck Society; Russian Academy of Sciences	Kim, E (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BELL D, 1991, BIOCHIM BIOPHYS ACTA, V1089, P299, DOI 10.1016/0167-4781(91)90169-M; Bessard ACH, 1998, ONCOGENE, V16, P883, DOI 10.1038/sj.onc.1201598; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DEB SP, 1994, ONCOGENE, V9, P1341; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hecker D, 1996, ONCOGENE, V12, P953; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Komiya T, 1999, ANTICANCER RES, V19, P4315; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Urano T, 1997, CANCER RES, V57, P3281; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Waga S., 1990, NUCL ACIDS S SER, V22, P81; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	70	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41192	41203		10.1074/jbc.M202344200	http://dx.doi.org/10.1074/jbc.M202344200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171916	Green Published, hybrid			2022-12-25	WOS:000178791400130
J	Kim, OS; Park, EJ; Joe, EH; Jou, I				Kim, OS; Park, EJ; Joe, EH; Jou, I			JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GAMMA-ACTIVATED SITE; IFN-GAMMA; INTERFERON-GAMMA; CEREBROSPINAL-FLUID; GENE-EXPRESSION; KINASE; ALPHA; BETA; PHOSPHORYLATION	Neuronal cell membranes are particularly rich in gangliosides, which play important roles in brain physiology and pathology. Previously, we reported that gangliosides could act as microglial activators and are thus likely to participate in many neuronal diseases. In the present study we provide evidence that JAK-STAT inflammatory signaling mediates gangliosides-stimulated microglial activation. Both in rat primary microglia and murine BV2 microglial cells, gangliosides stimulated nuclear factor binding to GAS/ISRE elements, which are known to be STAT-binding sites. Consistent with this, gangliosides rapidly activated JAK1 and JAK2 and induced phosphoryIation of STAT1 and STAT3. In addition, gangliosides increased transcription of the inflammation-associated genes inducible nitric-oxide synthase, ICAM-1, and MCP-1, which are reported to contain STAT-binding elements in their promoter regions. AG490, a JAK inhibitor, reduced induction of these genes, nuclear factor binding activity, and activation of STAT1 and -3 in gangliosides-treated microglia. AG490 also inhibited gangliosides-induced release of nitric oxide, an inflammation hallmark. Furthermore, AG490 markedly reduced activation of ERK1/2 MAPK, indicating that ERKs act downstream of JAK-STAT signaling during microglial activation. However, AG490 did not affect activation of p38 MAPK. We also report that the sialic acid residues present on gangliosides may be one of the essential components in activation of JAK-STAT signaling. The present study indicates that JAK-STAT signaling is an early event in gangliosides-induced brain inflammatory responses.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea	Ajou University	Jou, I (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea.	jouilo@madang.ajou.ac.kr						BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Bhat NR, 1998, J NEUROSCI, V18, P1633; BLENNOW K, 1991, ARCH NEUROL-CHICAGO, V48, P1032, DOI 10.1001/archneur.1991.00530220048018; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERRY DM, 1967, SCIENCE, V158, P1450, DOI 10.1126/science.158.3807.1450; Dreyfus H, 1997, ANAL BIOCHEM, V249, P67, DOI 10.1006/abio.1997.2143; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Ganster RW, 2000, NITRIC OXIDE BIOL PA, P129; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Garofalo T, 1998, J BIOL CHEM, V273, P35153, DOI 10.1074/jbc.273.52.35153; Gisslen M, 1997, J NEUROVIROL, V3, P148, DOI 10.3109/13550289709015804; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; GOUY H, 1994, J IMMUNOL, V152, P3271; HADER T, 1999, EUR J IMMUNOL, V29, P556; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Igaz P, 2001, INFLAMM RES, V50, P435, DOI 10.1007/PL00000267; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kanda N, 2001, J IMMUNOL, V166, P72, DOI 10.4049/jimmunol.166.1.72; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Ledesma MD, 2000, EMBO REP, V1, P530; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Pyo H, 1999, J BIOL CHEM, V274, P34584, DOI 10.1074/jbc.274.49.34584; RODDEN FA, 1991, J NEUROSURG, V74, P606, DOI 10.3171/jns.1991.74.4.0606; SAITO M, 1979, J BIOL CHEM, V254, P7845; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Tessitore A, 1998, EUR J BIOCHEM, V258, P968, DOI 10.1046/j.1432-1327.1998.2580968.x; Wang SSS, 2001, J BIOL CHEM, V276, P42027, DOI 10.1074/jbc.M102834200; WANG XY, 1995, J BIOL CHEM, V270, P27999; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	61	145	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40594	40601		10.1074/jbc.M203885200	http://dx.doi.org/10.1074/jbc.M203885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12191995	Green Published, hybrid			2022-12-25	WOS:000178791400057
J	Miranda, FF; Teigen, K; Thorolfsson, M; Svebak, RM; Knappskog, PM; Flatmark, T; Martinez, A				Miranda, FF; Teigen, K; Thorolfsson, M; Svebak, RM; Knappskog, PM; Flatmark, T; Martinez, A			Phosphorylation and mutations of Ser(16) in human phenylalanine hydroxylase - Kinetic and structural effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-DEPENDENT PHOSPHORYLATION; AMINO-ACID HYDROXYLASES; INFRARED-SPECTROSCOPY; FUSION PROTEIN; STABILITY; PHENYLKETONURIA; ACTIVATION; EXPRESSION; ENZYME; SEQUENCE	Phosphorylation of phenylalanine hydroxylase (PAH) at Ser(16) by cyclic AMP-dependent protein kinase is a post-translational modification that increases its basal activity and facilitates its activation by the substrate L-Phe. So far there is no structural information on the flexible N-terminal tail (residues 1-18), including the phosphorylation site. To get further insight into the molecular basis for the effects of phosphorylation on the catalytic efficiency and enzyme stability, molecular modeling was performed using the crystal structure of the recombinant rat enzyme. The most probable conformation and orientation of the N-terminal tail thus obtained indicates that phosphorylation of Ser(16) induces a local conformational change as a result of an electrostatic interaction between the phosphate group and Arg(13) as well as a repulsion by Glu(280) in the loop at the entrance of the active site crevice structure. The modeled reorientation of the N-terminal tail residues (Met(1)-Leu(15)) on phosphorylation is in agreement with the observed conformational change and increased accessibility of the substrate to the active site, as indicated by circular dichroism spectroscopy and the enzyme kinetic data for the full-length phosphorylated and nonphosphorylated human PAH. To further validate the model we have prepared and characterized mutants substituting Ser(16) with a negatively charged residue and found that S16E largely mimics the effects of phosphorylation of human PAH. Both the phosphorylated enzyme and the mutants with acidic side chains instead of Ser(16) revealed an increased resistance toward limited tryptic proteolysis and, as indicated by circular dichroism spectroscopy, an increased content of alpha-helical structure. In agreement with the modeled structure, the formation of an Arg(13) to Ser(16) phosphate salt bridge and the conformational change of the N-terminal tail also explain the higher stability toward limited tryptic proteolysis of the phosphorylated enzyme. The results obtained with the mutant R13A and E381A further support the model proposed for the molecular mechanism for the activation of the enzyme by phosphorylation.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Haukleland Hosp, Dept Med Genet, N-5009 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Martinez, A (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Arstadveien 19, N-5009 Bergen, Norway.	aurora.martinez@ibmb.uib.no	Teigen, Knut/K-3934-2012; Martinez, Aurora/M-3088-2019; Miranda, Frederico/A-8946-2015	Teigen, Knut/0000-0002-7031-9215; Martinez, Aurora/0000-0003-1643-6506; 				ABITA JP, 1976, J BIOL CHEM, V251, P5310; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brushia Robert J., 1999, Frontiers in Bioscience, V4, pd618, DOI 10.2741/Brushia; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; CITRON BA, 1994, BIOCHEM BIOPH RES CO, V198, P174, DOI 10.1006/bbrc.1994.1025; DICKSON PW, 1994, J BIOL CHEM, V269, P20369; Doskeland AP, 1996, BIOCHEM J, V313, P409, DOI 10.1042/bj3130409; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; DOSKELAND AP, 1992, EUR J BIOCHEM, V206, P161, DOI 10.1111/j.1432-1033.1992.tb16913.x; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Erlandsen H, 1999, MOL GENET METAB, V68, P103, DOI 10.1006/mgme.1999.2922; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; Gjetting T, 2001, MOL GENET METAB, V72, P132, DOI 10.1006/mgme.2000.3118; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; IWAKI M, 1986, J BIOL CHEM, V261, P2051; Jennings IG, 2001, FEBS LETT, V488, P196, DOI 10.1016/S0014-5793(00)02426-1; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KAUFMAN S, 1986, ADV ENZYME REGUL, V25, P37, DOI 10.1016/0065-2571(86)90007-5; KNAPPSKOG PM, 1993, ADV EXP MED BIOL, V338, P59; Knappskog PM, 1996, HUM MUTAT, V8, P236, DOI 10.1002/(SICI)1098-1004(1996)8:3<236::AID-HUMU7>3.0.CO;2-7; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KOWLESSUR D, 1995, P NATL ACAD SCI USA, V92, P4743, DOI 10.1073/pnas.92.11.4743; LEACH AR, 1992, J COMPUT CHEM, V13, P730, DOI 10.1002/jcc.540130608; Li M, 1998, BIOCHEMISTRY-US, V37, P7869, DOI 10.1021/bi9801053; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; SCRIVER CR, 1996, ANNU REV GENET, V28, P141; Smart JL, 1999, BIOPOLYMERS, V49, P225, DOI 10.1002/(SICI)1097-0282(199903)49:3<225::AID-BIP4>3.0.CO;2-B; SMITH SC, 1984, J BIOL CHEM, V259, P1284; Solstad T, 2000, EUR J BIOCHEM, V267, P6302, DOI 10.1046/j.1432-1327.2000.01715.x; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; TANI K, 1988, P NATL ACAD SCI USA, V85, P1792, DOI 10.1073/pnas.85.6.1792; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; TIPPER J, 1992, J BIOL CHEM, V267, P889; Wang GA, 2001, P NATL ACAD SCI USA, V98, P1537, DOI 10.1073/pnas.031561698; WRETBORN M, 1980, BIOCHEM BIOPH RES CO, V93, P403, DOI 10.1016/0006-291X(80)91091-8	50	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40937	40943		10.1074/jbc.M112197200	http://dx.doi.org/10.1074/jbc.M112197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185072	Green Submitted, hybrid			2022-12-25	WOS:000178791400100
J	Taneja, P; Gu, JM; Peng, R; Carrick, R; Uchiumi, F; Ott, RD; Gustafson, E; Podust, VN; Fanning, E				Taneja, P; Gu, JM; Peng, R; Carrick, R; Uchiumi, F; Ott, RD; Gustafson, E; Podust, VN; Fanning, E			A dominant-negative mutant of human DNA helicase B blocks the onset of chromosomal DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA-PRIMASE; SV40 T-ANTIGEN; LARGE TUMOR-ANTIGEN; MOUSE FM3A CELLS; DEPENDENT ADENOSINETRIPHOSPHATASE-B; SINGLE-STRANDED-DNA; PROTEIN-A; BINDING-SITE; RECOMBINATION; SUBUNIT	A cDNA encoding a human ortholog of mouse DNA helicase B, which may play a role in DNA replication, has been cloned and expressed as a recombinant protein. The predicted human DNA helicase B (HDHB) protein contains conserved helicase motifs (superfamily 1) that are strikingly similar to those of bacterial recD and T4 dda proteins. The HDHB gene is expressed at low levels in liver, spleen, kidney, and brain and at higher levels in testis and thymus. Purified recombinant HDHB hydrolyzed ATP and dATP in the presence of single-stranded DNA, displayed robust 5'-3' DNA helicase activity, and interacted physically and functionally with DNA polymerase alpha-primase. HDHB proteins with mutations in the Walker A or B motif lacked ATPase and helicase activity but retained the ability to interact with DNA polymerase alpha-primase, suggesting that the mutants might be dominant over endogenous HDHB in human cells. When purified HDHB protein was microinjected into the nucleus of cells in early G(1), the mutant proteins inhibited DNA synthesis, whereas the wild type protein had no effect. Injection of wild type or mutant protein into cells at G(1)/S did not prevent DNA synthesis. The results suggest that HDHB function is required for S phase entry.	Vanderbilt Univ, Dept Sci Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Fanning, E (corresponding author), Vanderbilt Univ, Dept Sci Biol, VU Stn B 351634, Nashville, TN 37235 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485] Funding Source: Medline; NIGMS NIH HHS [GM 52948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundsen SK, 2000, P NATL ACAD SCI USA, V97, P7399, DOI 10.1073/pnas.130192397; BARRY J, 1994, J BIOL CHEM, V269, P33063; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; Chedin F, 2002, MOL MICROBIOL, V43, P823, DOI 10.1046/j.1365-2958.2002.02785.x; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; EKI T, 1990, J BIOL CHEM, V265, P26; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15345, DOI 10.1021/bi9810959; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Marintcheva B, 2001, PROG NUCLEIC ACID RE, V70, P77, DOI 10.1016/S0079-6603(01)70014-1; MATSUMOTO K, 1995, BIOCHEMISTRY-US, V34, P7913, DOI 10.1021/bi00024a016; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Ott RD, 2002, J VIROL, V76, P5121, DOI 10.1128/JVI.76.10.5121-5130.2002; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; Qi HY, 2000, GENE DEV, V14, P1777; SAITOH A, 1995, NUCLEIC ACIDS RES, V23, P2014, DOI 10.1093/nar/23.11.2014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Tada S, 2001, NUCLEIC ACIDS RES, V29, P3835, DOI 10.1093/nar/29.18.3835; TAWARAGI Y, 1984, BIOCHEMISTRY-US, V23, P529, DOI 10.1021/bi00298a020; THOEMMES P, 1992, J BIOL CHEM, V267, P6063; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE Y, 1982, FEBS LETT, V149, P44, DOI 10.1016/0014-5793(82)81067-3; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713	61	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40853	40861		10.1074/jbc.M208067200	http://dx.doi.org/10.1074/jbc.M208067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181327	hybrid			2022-12-25	WOS:000178791400090
J	Chen, YR; Han, J; Kori, R; Kong, ANT; Tan, TH				Chen, YR; Han, J; Kori, R; Kong, ANT; Tan, TH			Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PHENETHYL ISOTHIOCYANATE; GAMMA-RADIATION; CELL-DEATH; JNK; INHIBITION; PATHWAY; TRANSDUCTION; M3/6; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	Dietary isothiocyanates induce apoptosis in various cancer cell lines through a c-Jun N-terminal kinase (JNK)dependent mechanism. We found that phenylethyl isothiocyanate (PEITC) was capable of inducing JNK activation and apoptosis in prostate cancer cell lines with distinct p53 statuses. PEITC induced JNK-mediated apoptotic signaling via a different pathway than that used by DNA-damaging agents, because genotoxic-resistant LNCaP prostate cancer cells were equally sensitive to PEITC as parental LNCaP cells. PEITC did not induce significant MKK4 or MKK7 activation and did not activate JNK directly, suggesting that JNK and JNK upstream kinases are not primary targets of PEITC. The JNK dephosphorylation and inactivation rates were decreased in cells exposed to PEITC. Expression levels of M3/6, a JNK-specific phosphatase, were down-regulated by PEITC via a proteasome-dependent mechanism. Taken together, our data suggest that PEITC activates JNK through suppression of JNK dephosphorylation and that PEITC may be an alternative therapeutic agent for cancers that are resistant to genotoxic agents. This study also reveals that JNK phosphatases are potential targets for the development of novel cancer therapeutic agents.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Baylor College of Medicine; Rutgers State University New Brunswick	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Chen, Yi-Rong/CAF-2186-2022; Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Kong, Ah-Ng Tony/AAX-2828-2020; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAH-7991-2022	Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Han, Jin/0000-0003-0662-006X				Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dlugosz JA, 2000, AM J PHYSIOL-RENAL, V279, pF688, DOI 10.1152/ajprenal.2000.279.4.F688; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; GUO Z, 1993, CARCINOGENESIS, V14, P1167, DOI 10.1093/carcin/14.6.1167; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HECHT SS, 1995, J CELL BIOCHEM, P195; Hecht SS, 1999, J NUTR, V129, p768S, DOI 10.1093/jn/129.3.768S; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Huang CS, 1998, CANCER RES, V58, P4102; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISAACS WB, 1991, CANCER RES, V51, P4716; Ito M, 1999, MOL CELL BIOL, V19, P7539; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mikalsen SO, 1998, J BIOL CHEM, V273, P10036, DOI 10.1074/jbc.273.16.10036; MORSE MA, 1993, CANCER LETT, V72, P103, DOI 10.1016/0304-3835(93)90018-5; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SMITH TJ, 1990, CANCER RES, V50, P6817; STONER GD, 1991, CANCER RES, V51, P2063; TALALAY P, 1993, ADV ENZYME REGUL, V28, P273; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATTENBERG LW, 1987, CARCINOGENESIS, V8, P1971, DOI 10.1093/carcin/8.12.1971; WATTENBERG LW, 1981, CANCER RES, V41, P2991; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu K, 2000, BIOCHEM PHARMACOL, V60, P221, DOI 10.1016/S0006-2952(00)00319-1; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547; Yu R, 1996, CANCER RES, V56, P2954; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	63	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39334	39342		10.1074/jbc.M202070200	http://dx.doi.org/10.1074/jbc.M202070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171915	hybrid			2022-12-25	WOS:000178662500037
J	Tran, N; Proenza, C; Macri, V; Petigara, F; Sloan, E; Samler, S; Accili, EA				Tran, N; Proenza, C; Macri, V; Petigara, F; Sloan, E; Samler, S; Accili, EA			A conserved domain in the NH2 terminus important for assembly and functional expression of pacemaker channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE; TETRAMERIZATION DOMAIN; COILED-COILS; HCN1; MODULATION; VOLTAGE; FAMILY; T1	Pacemaker channels are formed by co-assembly of hyperpolarization-activated cyclic nucleotide-gated (HCN) subunits. Previously, we suggested that the NH2 termini of the mouse HCN2 isoform were important for subunit co-assembly and functional channel expression. Using an alignment strategy together with yeast two-hybrid assays, patch clamp electrophysiology, and confocal imaging, we have now identified a domain within the NH2 terminus of the HCN2 subunit that is responsible for interactions between NH2 termini and promoting the trafficking of functional channels to the plasma membrane. This domain is composed of 52 amino acids, is located adjacent to the putative first transmembrane segment, and is highly conserved among the mammalian HCN isoforms. This conserved domain, but not the remaining unconserved NH2-terminal regions of HCN2, specifically interacted with itself in yeast two-hybrid assays. Moreover, the conserved domain was important for expression of currents. Whereas relatively normal whole cell HCN2 currents were produced by channels containing only the conserved domain, further deletion of this region, leaving only a more polar and putative coiled-coil segment, eliminated HCN2 currents and resulted in proteins that localized predominantly in perinuclear compartments. Thus, we suggest that this conserved domain is the critical NH2-terminal determinant of subunit co-assembly and trafficking of pacemaker channels.	Simon Fraser Univ, Sch Kinesiol, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Accili, EA (corresponding author), Simon Fraser Univ, Sch Kinesiol, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada.			Macri, Vincenzo/0000-0003-3463-2877; Proenza, Catherine/0000-0003-4324-6206				Accili EA, 2002, NEWS PHYSIOL SCI, V17, P32, DOI 10.1152/physiologyonline.2002.17.1.32; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Monteggia LM, 2000, MOL BRAIN RES, V81, P129, DOI 10.1016/S0169-328X(00)00155-8; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Moroni A, 2001, J BIOL CHEM, V276, P29233, DOI 10.1074/jbc.M100830200; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; Proenza C, 2000, J BIOL CHEM, V275, P23169, DOI 10.1074/jbc.M003389200; Proenza C, 2002, J BIOL CHEM, V277, P29634, DOI 10.1074/jbc.M200504200; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Viscomi C, 2001, J BIOL CHEM, V276, P29930, DOI 10.1074/jbc.M103971200; Wang J, 2001, J GEN PHYSIOL, V118, P237, DOI 10.1085/jgp.118.3.237; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	25	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43588	43592		10.1074/jbc.M208477200	http://dx.doi.org/10.1074/jbc.M208477200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12193608	hybrid			2022-12-25	WOS:000179272000008
J	Panzenboeck, U; Balazs, Z; Sovic, A; Hrzenjak, A; Levak-Frank, S; Wintersperger, A; Malle, E; Sattler, W				Panzenboeck, U; Balazs, Z; Sovic, A; Hrzenjak, A; Levak-Frank, S; Wintersperger, A; Malle, E; Sattler, W			ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in Vitro blood-brain barrier constituted of porcine brain capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DENSITY-LIPOPROTEIN RECEPTOR; CHOLESTEROL HOMEOSTASIS; ALPHA-TOCOPHEROL; 24S-HYDROXYCHOLESTEROL CEREBROSTEROL; POLARIZED CHOLESTEROL; ALZHEIMERS-DISEASE; APOA-I; SR-BI; EXPRESSION	The objective of the present study was to investigate the involvement of key players in reverse cholesterol/24(S)OH-cholesterol transport in primary porcine brain capillary endothelial cells (pBCEC) that constitute the BBB. We identified that, in addition to scavenger receptor class B, type I (SR-BI), pBCEC express ABCA1 and apolipoprotein A-I (apoA-I) mRNA and protein. Studies on the regulation of ABCA1 by the liver X receptor agonist 24(S)OH-cholesterol revealed increased ABCA1 expression and apoA-I-dependent [H-3]cholesterol efflux from pBCEC. In unpolarized pBCEC, high density lipoprotein, subclass 3 (HDL3)-dependent [H-3]cholesterol efflux, was unaffected by 24(S)OH-cholesterol treatment but was enhanced 5-fold in SR-BI overexpressing pBCEC. Efflux of cellular 24(S)-[H-3]OH-cholesterol was highly efficient, independent of ABCA1, and correlated with SR-BI expression. Polarized pBCEC were cultured on porous membrane filters that allow separate access to the apical and the basolateral compartment. Addition of cholesterol acceptors to the apical compartment resulted in preferential [H-3]cholesterol efflux to the basolateral compartment. HDL3 was a better promoter of basolateral [H-3]cholesterol efflux than lipid-free apoA-I. Basolateral pretreatment with 24(S)OH-cholesterol enhanced apoA-I-dependent basolateral cholesterol efflux up to 2-fold along with the induction of ABCA1 at the basolateral membrane. Secretion of apoA-I also occurred preferentially to the basolateral compartment, where the majority of apoA-I was recovered in an HDL-like density range. In contrast, 24(S)-[H-3]OH-cholesterol was mobilized efficiently to the apical compartment of the in vitro BBB by HDL3, low density lipoprotein, and serum. These results suggest the existence of an autoregulatory mechanism for removal of potentially neurotoxic 24(S)OH-cholesterol. In conclusion, the apoA-I/ABCA1- and HDL/SR-BI-dependent pathways modulate polarized sterol mobilization at the BBB.	Graz Univ, Inst Med Biochem & Med Mol Biol, A-8010 Graz, Austria	University of Graz	Sattler, W (corresponding author), Graz Univ, Inst Med Biochem & Med Mol Biol, Harrachgasse 21, A-8010 Graz, Austria.	wolfgang.sattler@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Panzenbock, Ute/0000-0002-0545-6758				Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Chisholm JW, 2002, J LIPID RES, V43, P36; Costet P, 2000, J BIOL CHEM, V275, P28240; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; FIELDING CJ, 1995, J LIPID RES, V36, P211; Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x; Goti D, 2002, J BIOL CHEM, V277, P28537, DOI 10.1074/jbc.M203989200; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Harris IR, 1998, J LIPID RES, V39, P412; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kolsch H, 2001, J NEURAL TRANSM, V108, P475, DOI 10.1007/s007020170068; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee J, 2002, BIOCHEM J, V364, P475, DOI 10.1042/BJ20011493; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lutjohann D, 2000, J LIPID RES, V41, P195; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Marmorstein AD, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P341; Merched A, 2000, NEUROBIOL AGING, V21, P27, DOI 10.1016/S0197-4580(99)00103-7; MOCKEL B, 1994, J NEUROCHEM, V62, P788; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ritter M, 2002, GENOMICS, V79, P693, DOI 10.1006/geno.2002.6761; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Sparks DL, 2000, MICROSC RES TECHNIQ, V50, P287, DOI 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L; Sun Y, 1999, J LIPID RES, V40, P1799; Tewes B, 1997, DRUG TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER, P91; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Tsuruoka H, 2002, J BIOL CHEM, V277, P2916, DOI 10.1074/jbc.M106445200; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	56	149	156	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42781	42789		10.1074/jbc.M207601200	http://dx.doi.org/10.1074/jbc.M207601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202492	hybrid			2022-12-25	WOS:000179081200048
J	Blagoev, B; Kratchmarova, I; Nielsen, MM; Fernandez, MM; Voldby, J; Andersen, JS; Kristiansen, K; Pandey, A; Mann, M				Blagoev, B; Kratchmarova, I; Nielsen, MM; Fernandez, MM; Voldby, J; Andersen, JS; Kristiansen, K; Pandey, A; Mann, M			Inhibition of adipocyte differentiation by resistin-like molecule alpha - Biochemical characterization of its oligomeric nature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; ACTIVIN-A; PROTEIN; EXPRESSION; RECEPTORS; AFFINITY; OBESITY; FAMILY; LIGAND	A novel family of cysteine-rich secreted proteins with unique tissue distribution has recently been identified. One of the members, resistin (for "resistance to insulin"), also called FIZZ3, was identified in a screen for molecules that are down-regulated in mature adipocytes upon administration of thiazolidinediones. The prototypical member of this family was originally identified from bronchoalveolar lavage fluid of inflamed lungs and designated FIZZ1 ("found in inflammatory zone"). This molecule was also found to be highly expressed in adipose tissue and was named resistin-like molecule a (RELMalpha). Here we demonstrate that RELMalpha inhibits the differentiation of 3T3-L1 preadipocytes into adipocytes. RELMalpha has no effect on proliferation of 3T3-L1 preadipocytes. Pretreatment of 3T3-L1 preadipocytes with RELMalpha does not affect insulin- or platelet-derived growth factor-induced mitogenesis. IRS-1 phosphorylation and glucose transport stimulated by insulin in mature adipocytes were also unaffected by RELMalpha. We show that RELMalpha forms disulfide-linked homooligomers based on results from electrophoresis under reducing and nonreducing conditions, coimmunoprecipitation experiments as well as by mass spectrometry. In addition, RELMalpha is able to form heterooligomers with resistin but not RELMbeta. Since RELMa is expressed by adipose tissue and it is a secreted factor, our findings suggest that RELMalpha may be involved in the control of the adipogenesis as well as in the process of muscle differentiation.	Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark	University of Southern Denmark	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark.		Mann, Matthias/A-3454-2013; Andersen, Jens S/L-2100-2015; Pandey, Akhilesh/B-4127-2009; Kristiansen, Karsten/J-5148-2014	Mann, Matthias/0000-0003-1292-4799; Andersen, Jens S/0000-0002-6091-140X; Pandey, Akhilesh/0000-0001-9943-6127; Kristiansen, Karsten/0000-0002-6024-0917; Blagoev, Blagoy/0000-0002-3596-0066; Kratchmarova, Irina/0000-0001-6613-7315	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Halvorsen Y D, 2000, Pharmacogenomics, V1, P179, DOI 10.1517/14622416.1.2.179; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	29	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42011	42016		10.1074/jbc.M206975200	http://dx.doi.org/10.1074/jbc.M206975200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12189153	hybrid			2022-12-25	WOS:000178985300090
J	Geiben-Lynn, R; Brown, N; Walker, BD; Luster, AD				Geiben-Lynn, R; Brown, N; Walker, BD; Luster, AD			Purification of a modified form of bovine antithrombin III as an HIV-1CD8(+) T-cell antiviral factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MACROPHAGE-DERIVED CHEMOKINE; REVERSE TRANSCRIPTION; HEPARIN-BINDING; HIV-1 INFECTION; MEDIATED SUPPRESSION; SERPIN ANTITHROMBIN; BETA-CHEMOKINES; GENE-EXPRESSION; CD8(+) CELLS	CD8(+) T-cells secrete soluble factor(s) capable of inhibiting both R5- and X4-tropic strains of human immunodeficiency virus type 1 (HIV-1). CCR5 chemokine ligands, released from activated CD8(+) T-cells, contribute to the antiviral activity of these cells. These CC-chemokines, however, do not account for all CD8(+) T-cell antiviral factor(s) (CAF) released from these cells, particularly because the elusive CAF can inhibit the replication of X4 HIV-1 strains that use CXCR4 and not CCR5 as a coreceptor. Here we demonstrate that activated CD8(+) T-cells of HIV-1-seropositive individuals modify serum bovine antithrombin III into an HIV-1 inhibitory factor capable of suppressing the replication of X4 HIV-1. These data indicate that antithrombin III may play a role in the progression of HIV-1 disease.	Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02129 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Partners AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Luster, AD (corresponding author), Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030914, R01AI028568, R01AI046999, R37AI028568] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46999, AI30914, AI28568] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHEN CH, 1993, AIDS RES HUM RETROV, V9, P1079, DOI 10.1089/aid.1993.9.1079; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dunzendorfer S, 2001, BLOOD, V97, P1079, DOI 10.1182/blood.V97.4.1079; EUHUS DM, 1990, INT J CANCER, V45, P1065, DOI 10.1002/ijc.2910450615; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; Garzino-Demo A, 1999, P NATL ACAD SCI USA, V96, P11986, DOI 10.1073/pnas.96.21.11986; Geiben-Lynn R, 2001, J VIROL, V75, P8306, DOI 10.1128/JVI.75.17.8306-8316.2001; Hocini H, 2000, CLIN DIAGN LAB IMMUN, V7, P515, DOI 10.1128/CDLI.7.3.515-518.2000; Horuk R, 1998, NATURE, V393, P524, DOI 10.1038/31116; Kaneider NC, 2001, BIOCHEM BIOPH RES CO, V287, P42, DOI 10.1006/bbrc.2001.5534; Konopka K, 1999, J DENT RES, V78, P1773, DOI 10.1177/00220345990780120201; Larsson H, 2001, J BIOL CHEM, V276, P11996, DOI 10.1074/jbc.M010170200; Le Borgne S, 2000, J VIROL, V74, P4456, DOI 10.1128/JVI.74.10.4456-4464.2000; Leith JG, 1997, AIDS, V11, P575, DOI 10.1097/00002030-199705000-00004; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LIU CS, 1987, EUR J BIOCHEM, V167, P247, DOI 10.1111/j.1432-1033.1987.tb13330.x; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mackewicz CE, 2000, J GEN VIROL, V81, P1261, DOI 10.1099/0022-1317-81-5-1261; MACKEWICZ CE, 1995, P NATL ACAD SCI USA, V92, P2308, DOI 10.1073/pnas.92.6.2308; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Oelschlager C, 2002, BLOOD, V99, P4015, DOI 10.1182/blood.V99.11.4015; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Saif MW, 2001, AIDS PATIENT CARE ST, V15, P15, DOI 10.1089/108729101460065; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48; Shapiro L, 2001, FASEB J, V15, P115, DOI 10.1096/fj.00-0311com; Shugars D C, 1997, Oral Dis, V3 Suppl 1, pS70; Souter PJ, 2001, CRIT CARE MED, V29, P134, DOI 10.1097/00003246-200101000-00027; Struyf S, 1998, J IMMUNOL, V161, P2672; Tomaras GD, 2000, P NATL ACAD SCI USA, V97, P3503, DOI 10.1073/pnas.070521097; Tseng CC, 2000, FEBS LETT, V475, P232, DOI 10.1016/S0014-5793(00)01700-2; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Van Patten SM, 1999, J BIOL CHEM, V274, P10268, DOI 10.1074/jbc.274.15.10268; Wahl SM, 1997, ORAL DIS S1, V3, pS64; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997	44	31	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42352	42357		10.1074/jbc.M207079200	http://dx.doi.org/10.1074/jbc.M207079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12192009	hybrid			2022-12-25	WOS:000178985300131
J	Gong, DM; Zhang, CQ; Chen, XY; Gong, ZZ; Zhu, JK				Gong, DM; Zhang, CQ; Chen, XY; Gong, ZZ; Zhu, JK			Constitutive activation and transgenic evaluation of the function of an Arabidopsis PKS protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT TOLERANCE; SIGNAL-TRANSDUCTION; GENE; TRANSCRIPTION; REDUCTASE; HOMOLOG; ENCODES; TOBACCO; BINDING; SOS1	A novel family of SOS2 (salt overly sensitive 2)-like protein kinase genes (designated PKSes) have been recently identified in Arabidopsis. The biochemical characteristics as well as in vivo roles of most of the PKSes are unclear at present. In this work, we isolated and characterized one of the PKSes, PKS18. PKS18 was expressed in leaves of mature Arabidopsis plants. The glutathione S-transferase (GST)-PKS18 fusion protein was inactive by itself in substrate phosphorylation. An activation loop Thr(169) to Asp mutation, however, highly activated this kinase in vitro (designated PKS18T/D). Kinase activity of the PKS18T/D preferred Mn2+ to Mg2+. The activated kinase showed a substrate specificity, and high catalytic efficiency for a peptide substrate p3 and for ATP. Interestingly, PYKS18T/D transgenic plants were hypersensitive to the phytohormone abscisic acid (ABA) in seed germination and seedling growth, whereas silencing the kinase gene by RNA interference (RNAi) conferred ABA-insensitivity, indicating the involvement of PKS18 in plant ABA signaling.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.	jkzhu@ag.arizona.edu	Zhang, Changqing/C-7872-2012; Gong, Zhizhong/AAS-4796-2021; Zhu, Jian-Kang/F-7658-2011	Zhang, Changqing/0000-0002-0130-4378; Zhu, Jian-Kang/0000-0001-5134-731X; chen, xiuyin/0000-0002-1734-3267	NIGMS NIH HHS [R01GM59138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Ball KL, 1995, FEBS LETT, V377, P189, DOI 10.1016/0014-5793(95)01343-1; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; Gomez-Cadenas A, 1999, P NATL ACAD SCI USA, V96, P1767, DOI 10.1073/pnas.96.4.1767; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; Kang JY, 2002, PLANT CELL, V14, P343, DOI 10.1105/tpc.010362; KEMP RG, 1967, BIOCHEMISTRY-US, V6, P423, DOI 10.1021/bi00854a009; Koornneef M, 1998, PLANT PHYSIOL BIOCH, V36, P83, DOI 10.1016/S0981-9428(98)80093-4; KREIS M, 2000, PLANT PROTEIN KINASE, P1; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Lopez-Molina L, 2001, P NATL ACAD SCI USA, V98, P4782, DOI 10.1073/pnas.081594298; MacRobbie EAC, 2000, P NATL ACAD SCI USA, V97, P12361, DOI 10.1073/pnas.220417197; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; McCourt P, 1999, ANNU REV PLANT PHYS, V50, P219, DOI 10.1146/annurev.arplant.50.1.219; MURANAKA T, 1994, MOL CELL BIOL, V14, P2958, DOI 10.1128/MCB.14.5.2958; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; Qiu QS, 2002, P NATL ACAD SCI USA, V99, P8436, DOI 10.1073/pnas.122224699; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; Shen W, 2001, PLANT PHYSIOL, V125, P1429, DOI 10.1104/pp.125.3.1429; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Sugden C, 1999, PLANT PHYSIOL, V120, P257, DOI 10.1104/pp.120.1.257; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Toroser D, 2000, PLANT PHYSIOL, V123, P403, DOI 10.1104/pp.123.1.403; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; ZHENG RL, 1992, J BIOL CHEM, V267, P23640; Zhu JK, 1998, PLANT CELL, V10, P1181, DOI 10.1105/tpc.10.7.1181	44	58	79	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42088	42096		10.1074/jbc.M205504200	http://dx.doi.org/10.1074/jbc.M205504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198122	hybrid			2022-12-25	WOS:000178985300099
J	Rosado, JA; Brownlow, SL; Sage, SO				Rosado, JA; Brownlow, SL; Sage, SO			Endogenously expressed Trp1 is involved in store-mediated Ca2+ entry by conformational coupling in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; FURA-2-LOADED HUMAN-PLATELETS; OPERATED HTRP3 CHANNELS; ACTIN CYTOSKELETON; HUMAN HOMOLOG; FUNCTIONAL EXPRESSION; IP3 RECEPTOR; MECHANISM; DEPLETION	Physical interaction between transient receptor potential (Trp) channels and inositol 1,4,5-trisphosphate receptors (IP(3)Rs) has been presented as a candidate mechanism for the activation of store-mediated Ca2+ entry. The role of a human homologue of Drosophila transient receptor potential channel, hTrp1, in the conduction of store-mediated Ca2+ entry was examined in human platelets. Incubation of platelets with a specific antibody, which recognizes the extracellular amino acid sequence 557-571 of hTrp1, inhibited both store depletion-induced Ca2+ and Mn2+ entry in a concentration-dependent manner. Stimulation of platelets with the physiological agonist thrombin activated coupling between the IP3 receptor type II and endogenously expressed hTrp1. This event was reversed by refilling of the internal Ca2+ stores but maintained after removal of the agonist if the stores were not allowed to refill. Inhibition of IP3 recycling using Li+ or inhibition of IP(3)Rs with xestospongin C or treatment with jasplakinolide, to stabilize the cortical actin filament network, abolished thrombin-induced coupling between hTrp1 and IP3R type II. Incubation with the anti-hTrp1 antibody inhibited thrombin-evoked Ca2+ entry without affecting Ca2+ release from intracellular stores. These results provide evidence for the involvement of hTrp1 in the activation of store-mediated Ca2+ entry by coupling to IP3R type II in normal human cells.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P9; den Dekker E, 2001, BBA-MOL CELL RES, V1539, P243, DOI 10.1016/S0167-4889(01)00112-4; GRAF E, 1982, BIOCHEMISTRY-US, V21, P4511, DOI 10.1021/bi00261a049; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KIMURA M, 1993, J PHYSIOL-LONDON, V464, P1; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; Sage SO, 1997, EXP PHYSIOL, V82, P807, DOI 10.1113/expphysiol.1997.sp004066; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; SWEENEY M, AM J PHYSL, V283, pL144; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	38	127	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42157	42163		10.1074/jbc.M207320200	http://dx.doi.org/10.1074/jbc.M207320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196544	hybrid			2022-12-25	WOS:000178985300108
J	Wong, GW; Foster, PS; Yasuda, S; Qi, JC; Mahalingam, S; Mellor, EA; Katsoulotos, G; Li, LX; Boyce, JA; Krilis, SA; Stevens, RL				Wong, GW; Foster, PS; Yasuda, S; Qi, JC; Mahalingam, S; Mellor, EA; Katsoulotos, G; Li, LX; Boyce, JA; Krilis, SA; Stevens, RL			Biochemical and functional characterization of human transmembrane tryptase (TMT)/tryptase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; RECEPTOR-ALPHA CHAIN; IL-13 MESSENGER-RNA; AIRWAYS HYPERREACTIVITY; INTERLEUKIN-13 RECEPTOR; COMPLEMENTARY-DNA; SERINE PROTEASES; BINDING SUBUNIT; ALLERGIC-ASTHMA; DEFICIENT MICE	Transmembrane tryptase (TMT)/tryptase gamma is a membrane-bound serine protease stored in the secretory granules of human and mouse lung mast cells (MCs). We now show that TMT reaches the external face of the plasma membrane when MCs are induced to degranulate. Analysis of purified recombinant TMT revealed that it is a two-chain neutral protease. Thus, TMT is the only MC protease identified so far which retains its 18-residue propeptide when proteolytically activated. The genes that encode TMT and tryptase 131 reside on human chromosome 16p13.3. However, substrate specificity studies revealed that TMT and tryptase 61 are functionally distinct even though they are similar to50% identical. Although TMT is rapidly inactivated by the human plasma serpin alpha(1)-antitrypsin in vitro, administration of recombinant TMT (but not recombinant tryptase PI) into the trachea of mice leads to airway hyperresponsiveness (AHR) and increased expression of interleukin (IL) 13. T cells also increase their expression of IL-13 mRNA when exposed to TMT in vitro. TMT is therefore a novel exocytosed surface mediator that can stimulate those cell types that are in close proximity. TMT induces AHR in normal mice but not in transgenic mice that lack signal transducer and activator of transcription (STAT) 6 or the alpha-chain of the cytokine receptor that recognizes both IL-4 and IL-13. Based on these data, we conclude that TMT is an exocytosed MC neutral protease that induces AHR in lungs primarily by activating an IL-13/IL-4Ralpha/STAT6-dependent pathway.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Univ New S Wales, Dept Med, Kogarah, NSW 2217, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; St George Hospital; University of New South Wales Sydney; Australian National University; John Curtin School of Medical Research	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu	Yasuda, Shinsuke/A-4369-2012; Foster, Paul/G-5057-2013	Wong, G. William/0000-0002-5286-6506	NHLBI NIH HHS [HL-36110, HL-63284] Funding Source: Medline; NIAID NIH HHS [AI-31599, AI-48802, AI-23483, AI-52353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL063284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052353, U01AI031599, U19AI031599, R56AI052353, R01AI048802, R01AI023483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Castells MC, 2001, NAT IMMUNOL, V2, P436, DOI 10.1038/87749; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Chan H, 1999, PROTEIN EXPRES PURIF, V15, P251, DOI 10.1006/prep.1998.1025; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; Fang KC, 1999, J IMMUNOL, V162, P5528; Fath MA, 1998, J BIOL CHEM, V273, P13563, DOI 10.1074/jbc.273.22.13563; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hooper JD, 1999, CANCER RES, V59, P3199; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Jaffe JS, 1996, AM J RESP CELL MOL, V15, P473, DOI 10.1165/ajrcmb.15.4.8879181; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kotsimbos TC, 1998, J ALLERGY CLIN IMMUN, V102, P859, DOI 10.1016/S0091-6749(98)70029-6; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; Li HM, 1996, J IMMUNOL, V156, P4833; Li L, 1999, J IMMUNOL, V162, P2477; Li LX, 1998, J IMMUNOL, V161, P5079; LI LX, 1995, J BIOL CHEM, V270, P2258, DOI 10.1074/jbc.270.5.2258; Mahalingam S, 1999, J VIROL, V73, P1479, DOI 10.1128/JVI.73.2.1479-1491.1999; Mahalingam S, 2001, J BIOL CHEM, V276, P7568, DOI 10.1074/jbc.M005773200; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; Marsh DG, 1997, NAT GENET, V15, P389; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; Mattes J, 2001, J IMMUNOL, V167, P1683, DOI 10.4049/jimmunol.167.3.1683; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Murata T, 1996, J IMMUNOL, V156, P2972; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skokos D, 2001, J IMMUNOL, V166, P868, DOI 10.4049/jimmunol.166.2.868; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2000, FASEB J, V14, pA1239; Wang ZM, 1998, BIOL CHEM, V379, P167, DOI 10.1515/bchm.1998.379.2.167; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wong GW, 2001, J BIOL CHEM, V276, P49169, DOI 10.1074/jbc.M108677200; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	82	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41906	41915		10.1074/jbc.M205868200	http://dx.doi.org/10.1074/jbc.M205868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194977	hybrid			2022-12-25	WOS:000178985300078
J	Baggerman, G; Cerstiaens, A; De Loof, A; Schoofs, L				Baggerman, G; Cerstiaens, A; De Loof, A; Schoofs, L			Peptidomics of the larval Drosophila melanogaster central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUSTA-MIGRATORIA; MOLECULAR-CLONING; ALLATOSTATIN PREPROHORMONE; CARDIOACTIVE PEPTIDE; GENOMIC ORGANIZATION; IDENTIFICATION; NEUROPEPTIDE; HORMONE; EXPRESSION; GENE	Neuropeptides regulate most, if not all, biological processes in the animal kingdom, but only seven have been isolated and sequenced from Drosophila melanogaster. In analogy with the proteomics technology, where all proteins expressed in a cell or tissue are analyzed, the peptidomics approach aims at the simultaneous identification of the whole peptidome of a cell or tissue, ie. all expressed peptides with their posttranslational modifications. Using nanoscale liquid chromatography combined with tandem mass spectrometry and data base mining, we analyzed the peptidome of the larval Drosophila central nervous system at the amino acid sequence level. We were able to provide biochemical evidence for the presence of 28 neuropeptides using an extract of only 50 larval Drosophila central nervous systems. Eighteen of these peptides are encoded in previously cloned or annotated precursor genes, although not all of them were predicted correctly. Eleven of these peptides were never purified before. Eight other peptides are entirely novel and are encoded in five different, not yet annotated genes. This neuropeptide expression profiling study also opens perspectives for other eukaryotic model systems, for which genome projects are completed or in progress.	Katholieke Univ Leuven, Lab Dev Physiol & Mol Biol, B-3000 Louvain, Belgium	KU Leuven	Schoofs, L (corresponding author), Katholieke Univ Leuven, Lab Dev Physiol & Mol Biol, Naamsestr 59, B-3000 Louvain, Belgium.	liliane.schoofs@bio.kuleuven.ac.be	schoofs, liliane/ABD-2943-2020; Schoofs, Liliane/F-2815-2010	Schoofs, Liliane/0000-0002-1673-432X; Baggerman, Geert/0000-0002-0661-931X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baggerman G, 2002, PEPTIDES, V23, P635, DOI 10.1016/S0196-9781(01)00657-X; BOGERD J, 1995, J BIOL CHEM, V270, P23038, DOI 10.1074/jbc.270.39.23038; BROECK JV, 2002, PEPTIDES, P635; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Davies SA, 1997, AM J PHYSIOL-REG I, V273, pR823, DOI 10.1152/ajpregu.1997.273.2.R823; De Loof A, 2001, ARCH INSECT BIOCHEM, V47, P129, DOI 10.1002/arch.1044; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; HORODYSKI FM, 1993, EUR J BIOCHEM, V215, P221, DOI 10.1111/j.1432-1033.1993.tb18026.x; HUESMANN GR, 1995, FEBS LETT, V371, P311, DOI 10.1016/0014-5793(95)00929-4; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OUDEJANS RCHM, 1993, PEPTIDES, V14, P877, DOI 10.1016/0196-9781(93)90062-L; Perone MJ, 1997, HISTOL HISTOPATHOL, V12, P1179; Phlippen MK, 2000, J EXP BIOL, V203, P521; SCHAFFER MH, 1990, BIOCHEM J, V269, P315, DOI 10.1042/bj2690315; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1991, GEN COMP ENDOCR, V81, P97, DOI 10.1016/0016-6480(91)90129-T; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; Schoofs L, 1997, PEPTIDES, V18, P145, DOI 10.1016/S0196-9781(96)00236-7; SCHOOFS L, 1993, PEPTIDES, V14, P409, DOI 10.1016/0196-9781(93)90126-2; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; Terhzaz S, 1999, J EXP BIOL, V202, P3667; Torfs P, 2001, EUR J BIOCHEM, V268, P149, DOI 10.1046/j.1432-1327.2001.01858.x; Uttenweiler-Joseph S, 1998, P NATL ACAD SCI USA, V95, P11342, DOI 10.1073/pnas.95.19.11342; Veelaert D, 1997, ENDOCRINOLOGY, V138, P138, DOI 10.1210/en.138.1.138; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V204, P292, DOI 10.1006/bbrc.1994.2458; VEENSTRA JA, 1989, FEBS LETT, V250, P231, DOI 10.1016/0014-5793(89)80727-6; Wei Z, 2000, J INSECT PHYSIOL, V46, P1259, DOI 10.1016/S0022-1910(00)00046-9; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88	38	218	244	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40368	40374		10.1074/jbc.M206257200	http://dx.doi.org/10.1074/jbc.M206257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171930	hybrid			2022-12-25	WOS:000178791400028
J	Gobin, SJP; Biesta, P; de Steenwinkel, JEM; Datema, G; Van den Elsen, PJ				Gobin, SJP; Biesta, P; de Steenwinkel, JEM; Datema, G; Van den Elsen, PJ			HLA-G transactivation by cAMP-response element-binding protein (CREB) - An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G PROMOTER; TRANSCRIPTIONAL REGULATION; GENE; EXPRESSION; SITE; TROPHOBLASTS; SUPPRESSES; PREGNANCY; REGION; CELLS	The expression of HLA-G in extravillous cytotrophoblast cells coincides with a general lack of classical major histocompatibility complex (MHC) class I expression in this tissue. This differential expression of HLA-G and classical HLA class I molecules in trophoblasts suggests a tight transcriptional control of MHC class I genes. Transactivation of the classical MHC class I genes is mediated by two groups of juxtaposed cis-acting elements that can be viewed as regulatory modules. Both modules are divergent in HLA-G, rendering this gene unresponsive to NF-kappaB, IRFI, and class II transactivator (CIITA)-mediated induction pathways. In this study, we searched for alternative regulatory elements in the 1438-bp HLA-G promoter region. HLA-G was not responsive to interferon-a (IFNalpha), IFNbeta, or IFNgamma, despite the presence of an upstream ISRE binding IRF1 in vitro. However, the HLA-G promoter contains three CRE/TRE elements with binding affinity for CREB/ATF and Fos/Jun proteins both in vitro and in vivo. In transient transfection assays, it was shown that HLA-G transactivation is regulated by CREB, CREB-binding protein (CBP), and p300. Moreover, immunohistochemical analysis demonstrated that HLA-G is co-expressed with CREB and CBP in extravillous cytotrophoblasts, revealing the in vivo relevance of this transactivation pathway. This implies a unique regulation of HLA-G transcription among the MHC class I genes.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Gobin, SJP (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands.	gobin@LUMC.nl		Van den Elsen, Peter/0000-0002-5196-0082				Bainbridge DRJ, 2000, J REPROD IMMUNOL, V48, P17, DOI 10.1016/S0165-0378(00)00070-X; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; Carosella ED, 1996, IMMUNOL TODAY, V17, P407, DOI 10.1016/0167-5699(96)30055-8; Chu WJ, 1999, HUM IMMUNOL, V60, P1113, DOI 10.1016/S0198-8859(99)00091-9; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Gobin SJP, 1998, J IMMUNOL, V161, P2276; Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1; Gobin SJP, 1998, IMMUNITY, V9, P531, DOI 10.1016/S1074-7613(00)80636-6; Gobin SJP, 2001, J IMMUNOL, V167, P5175, DOI 10.4049/jimmunol.167.9.5175; Gobin SJP, 1999, J IMMUNOL, V163, P1428; GUILLAUDEUX T, 1993, AM J REPROD IMMUNOL, V30, P228, DOI 10.1111/j.1600-0897.1993.tb00624.x; Heckert LL, 1996, J BIOL CHEM, V271, P31650, DOI 10.1074/jbc.271.49.31650; Knofler M, 2000, ENDOCRINOLOGY, V141, P3737, DOI 10.1210/en.141.10.3737; Le Bouteiller P, 1999, HUM REPROD UPDATE, V5, P223, DOI 10.1093/humupd/5.3.223; Le Bouteiller P, 1999, IMMUNOL REV, V167, P233; Le Bouteiller P, 2001, MICROBES INFECT, V3, P323, DOI 10.1016/S1286-4579(01)01386-7; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; Lefebvre S, 2001, J BIOL CHEM, V276, P6133, DOI 10.1074/jbc.M008496200; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; LOKE YW, 1991, CURR OPIN IMMUNOL, V3, P762, DOI 10.1016/0952-7915(91)90110-M; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Moreau P, 1997, HUM IMMUNOL, V52, P41, DOI 10.1016/S0198-8859(96)00242-X; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; O'Callaghan CA, 1998, IMMUNOL REV, V163, P129, DOI 10.1111/j.1600-065X.1998.tb01192.x; Ober C, 1998, AM J HUM GENET, V62, P1, DOI 10.1086/301692; Riteau B, 1999, J REPROD IMMUNOL, V43, P203, DOI 10.1016/S0165-0378(99)00034-0; Rousseau P, 2000, HUM IMMUNOL, V61, P1132, DOI 10.1016/S0198-8859(00)00199-3; SCHMIDT CM, 1993, J IMMUNOL, V151, P2633; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Wainwright SD, 2000, J IMMUNOL, V164, P319, DOI 10.4049/jimmunol.164.1.319; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	34	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39525	39531		10.1074/jbc.M112273200	http://dx.doi.org/10.1074/jbc.M112273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183445	hybrid			2022-12-25	WOS:000178662500061
J	Louie, TM; Yang, H; Karnchanaphanurach, P; Xie, XS; Xun, LY				Louie, TM; Yang, H; Karnchanaphanurach, P; Xie, XS; Xun, LY			FAD is a preferred substrate and an inhibitor of Escherichia coli general NAD(P)H : flavin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-FLAVIN OXIDOREDUCTASE; RIBONUCLEOTIDE REDUCTASE; FERREDOXIN-NADP(+) REDUCTASE; FLAVOPROTEIN; PURIFICATION; RESOLUTION; BINDING; FAMILY; IRON	Escherichia coli general NAD(P)H:flavin oxidoreductase (Fre) does not have a bound flavin cofactor; its flavin substrates (riboflavin, FMN, and FAD) are believed to bind to it mainly through the isoalloxazine ring. This interaction was real for riboflavin and FMN, but not for FAD, which bound to Fre much tighter than FMN or riboflavin. Computer simulations of Fre-FAD and Fre-FMN complexes showed that FAD adopted an unusual bent conformation, allowing its ribityl side chain and ADP moiety to form an additional 3.28 H-bonds on average with amino acid residues located in the loop connecting Fbeta5 and Falpha1 of the flavin-binding domain and at the proposed NAD(P)H-binding site. Experimental data supported the overlapping binding sites of FAD and NAD(P)H. AMP, a known competitive inhibitor with respect to NAD(P)H, decreased the affinity of Fre for FAD. FAD behaved as a mixed-type inhibitor with respect to NADPH. The overlapped binding offers a plausible explanation for the large K. values of Fre for NADH and NADPH when FAD is the electron acceptor. Although Fre reduces FMN faster than it reduces FAD, it preferentially reduces FAD when both FAIN and FAD are present. Our data suggest that FAD is a preferred substrate and an inhibitor, suppressing the activities of Fre at low NADH concentrations.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Washington State University; Harvard University	Xun, LY (corresponding author), Washington State Univ, Sch Mol Biosci, Sci Hall 301, Pullman, WA 99164 USA.		Yang, Haw/AHD-0857-2022; Pakawatpanurut, Pasit/E-5419-2010	Yang, Haw/0000-0003-0268-6352; Pakawatpanurut, Pasit/0000-0002-7657-4161	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-R01-GM61577-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher A., 1996, ESCHERICHIA COLI SAL, P657; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; INOUYE S, 1994, FEBS LETT, V347, P163, DOI 10.1016/0014-5793(94)00528-1; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; Niviere V, 1999, J BIOL CHEM, V274, P18252, DOI 10.1074/jbc.274.26.18252; Niviere V, 1996, J BIOL CHEM, V271, P16656, DOI 10.1074/jbc.271.28.16656; Niviere V, 1998, BIOCHEMISTRY-US, V37, P11879, DOI 10.1021/bi980396f; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PENFOUND T, 1996, ESCHERICHIA COLI SAL, P721; Puzon GJ, 2002, BIOCHEM BIOPH RES CO, V294, P76, DOI 10.1016/S0006-291X(02)00438-2; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; VOET D, 1995, BIOCHEMISTRY-US, P176; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	27	25	29	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39450	39455		10.1074/jbc.M206339200	http://dx.doi.org/10.1074/jbc.M206339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177066	hybrid			2022-12-25	WOS:000178662500051
J	Nellist, M; Goedbloed, MA; de Winter, C; Verhaaf, B; Jankie, A; Reuser, AJJ; van den Ouweland, AMW; van der Sluijs, P; Halley, DJJ				Nellist, M; Goedbloed, MA; de Winter, C; Verhaaf, B; Jankie, A; Reuser, AJJ; van den Ouweland, AMW; van der Sluijs, P; Halley, DJJ			Identification and characterization of the interaction between tuberin and 14-3-3 zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-GROWTH; TSC2 GENE; HAMARTIN; PHOSPHORYLATION; PROTEINS; PRODUCT; COMPLEX; ACTIVATION	Tuberous sclerosis is caused by mutations to either the TSC1 or TSC2 tumor suppressor gene. The disease is characterized by a broad phenotypic spectrum that includes seizures, mental retardation, renal dysfunction, and dermatological abnormalities. TSC1 encodes a 130-kDa protein called hamartin, and TSC2 encodes a 200-kDa protein called tuberin. Although it has been shown that hamartin and tuberin form a complex and mediate phosphoinositide 3-kinase/Akt-dependent phosphorylation of the ribosomal protein S6, it is not yet clear how inactivation of either protein leads to tuberous sclerosis. Therefore, to obtain additional insight into tuberin and hamartin function, yeast two-hybrid screening experiments were performed to identify proteins that interact with tuberin. One of the proteins identified was 14-3-3zeta, a member of the 14-3-3zeta protein family. The interaction between tuberin and 14-3-3zeta was confirmed in vitro and by co-immunoprecipitation; multiple sites within tuberin for 14-3-3zeta binding were identified; and it was determined that 14-3-3zeta associated with the tuberin-hamartin complex. Finally, it was shown that the tuberin/14-3-3zeta interaction is regulated by Akt-mediated phosphorylation of tuberin, providing insight into how tuberin may regulate phosphorylation of S6.	Erasmus MC, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Utrecht University	Nellist, M (corresponding author), Erasmus MC, Dept Clin Genet, POB 1738,Dr Molewaterpl 50, NL-3000 DR Rotterdam, Netherlands.	nellist@kgen.fgg.eur.nl						Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200	29	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39417	39424		10.1074/jbc.M204802200	http://dx.doi.org/10.1074/jbc.M204802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176984	hybrid			2022-12-25	WOS:000178662500047
J	Gueydan, C; Wauquier, C; De Mees, C; Huez, G; Kruys, W				Gueydan, C; Wauquier, C; De Mees, C; Huez, G; Kruys, W			Identification of ribosomal proteins specific to higher eukaryotic organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; ANGSTROM-RESOLUTION; SUBUNIT; RNA; BINDING; PURIFICATION; SEQUENCES; EXPRESSION; GENES	This report describes the identification of a novel protein named PS1D (Genbank(TM) accession number AJ272345), which is composed of an S1-like RNA-binding domain, a (cysteine)x3-(histidine) CCCH-zinc finger, and a very basic carboxyl domain. PS1D is expressed as two isoforms, probably resulting from the alternative splicing of mRNA. The long PS1D isoform differs from the short one by the presence of 48 additional amino acids at its amino-terminal extremity. Analysis of PS1D subcellular distribution by cell fractionation reveals that this protein belongs to the core of the eukaryotic 60S ribosomal subunit. Interestingly, PS1D protein is a highly conserved protein among mammalians as murine, human, and simian PS1D homologues share more than 95% identity. In contrast, no homologous protein is found in lower eukaryotes such as yeast and Caenorhabditis elegans. These observations indicate that PS1D is the first eukaryotic ribosomal protein that is specific to higher eukaryotes.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; Free Univ Brussels, Inst Biol & Med Mol, Lab Biol Dev, B-6041 Gosselies, Belgium		Gueydan, C (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, 12 Rue Profs Jeener & Brachet, B-6041 Gosselies, Belgium.		Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403; Gueydan, Cyril/0000-0003-3097-7667				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Bottger EC, 2001, EMBO REP, V2, P318, DOI 10.1093/embo-reports/kve062; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CELIS JE, 1994, CELL BIOL LAB HDB, P657; Christophe-Hobertus C, 1999, EUR J BIOCHEM, V265, P491, DOI 10.1046/j.1432-1327.1999.00796.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; Lafontaine DLJ, 2001, NAT REV MOL CELL BIO, V2, P514, DOI 10.1038/35080045; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Nadano D, 2000, JPN J CANCER RES, V91, P802, DOI 10.1111/j.1349-7006.2000.tb01017.x; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SHERTON CC, 1972, J BIOL CHEM, V247, P4460; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; TSURUGI K, 1977, J BIOL CHEM, V252, P3961; TSURUGI K, 1976, J BIOL CHEM, V251, P7940; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485	30	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45034	45040		10.1074/jbc.M208551200	http://dx.doi.org/10.1074/jbc.M208551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12202495	hybrid			2022-12-25	WOS:000179404800058
J	Howe, AG; Zaremberg, V; McMaster, CR				Howe, AG; Zaremberg, V; McMaster, CR			Cessation of growth to prevent cell death due to inhibition of phosphatidylcholine synthesis is impaired at 37 degrees C in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CDP-CHOLINE PATHWAY; ENCODING CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; YEAST GOLGI-COMPLEX; ESCHERICHIA-COLI; CKI GENE; BIOSYNTHESIS; EXPRESSION; CLONING	Phosphatidylcholine is the most abundant phospholipid in eukaryotic cells, comprising 50% of total cellular phospholipid, and thus plays a major role in cellular and organellar biogenesis. In this study, we have used both nutritional deprivation as well as a conditional temperature sensitive allele of PCT1 (CTP:phosphocholine cytidylyltransferase) coupled with an inactivated phosphatidylethanolamine methylation pathway to determine how cells respond to inactivation of phosphatidylcholine synthesis. Metabolic studies determined that phosphatidylcholine biosynthesis decreased to negligible levels within 1 h upon shift to the nonpermissive temperature for the temperature-sensitive PCT1 allele. Phosphatidylcholine mass decreased to negligible levels upon removal of choline from the medium or growth at the nonpermissive temperature, with the levels of the other major phospholipids increasing slightly. Cell growth rate visibly slowed upon cessation of phosphatidylcholine synthesis. Cells remained viable for 7-8 h after phosphatidylcholine synthesis was prevented; however, at time points beyond 8 h, viability was significantly reduced but only if the cells had been previously grown at 37 degreesC and not 25 degreesC. The inhibition of phosphatidylcholine synthesis at 37 degreesC did not alter Golgi-derived vesicle transport to the vacuole as monitored by carboxypeptidase Y processing or to the plasma membrane as determined by invertase secretion. Immunofluorescence microscopy localized Pct1p to the nucleus and nuclear membrane. Pct1p activity is regulated by Sec14p, a cytoplasm/Golgi localized phosphatidylcholine/phosphatidylinositol binding protein that regulates Golgi-derived vesicle transport partially through its ligand-dependent regulation of PCT1 derived enzyme activity. Our nuclear localization of Pct1p indicates that the regulation of Pct1p by Sec14p is indirect.	Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Biochem, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776				AMES BN, 1960, J BIOL CHEM, V235, P769; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CHRISTIANSON TW, 1992, GENE, V110, P112; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CUI Z, 1993, J BIOL CHEM, V268, P16655; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Goldstein A, 1975, Methods Enzymol, V42, P504; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; Henneberry AL, 2001, MOL BIOL CELL, V12, P511, DOI 10.1091/mbc.12.3.511; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; Kaiser C., 1994, METHODS YEAST GENETI; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; KODAKI T, 1987, J BIOL CHEM, V262, P15428; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; PREISS J, 1986, J BIOL CHEM, V261, P8597; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117	35	30	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44100	44107		10.1074/jbc.M206643200	http://dx.doi.org/10.1074/jbc.M206643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200438	hybrid			2022-12-25	WOS:000179272000074
J	Nauze, M; Gonin, L; Chaminade, B; Peres, C; Hullin-Matsuda, F; Perret, B; Chap, H; Gassama-Diagne, A				Nauze, M; Gonin, L; Chaminade, B; Peres, C; Hullin-Matsuda, F; Perret, B; Chap, H; Gassama-Diagne, A			Guinea pig phospholipase B, identification of the catalytic serine and the proregion involved in its processing and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; SUCRASE-ISOMALTASE; PRO REGION; PROTEIN; INTESTINE; B/LIPASE; A(2); PURIFICATION; EXPRESSION; PROPEPTIDE	Guinea pig phospholipase B (GPPLB) is a glycosylated ectoenzyme of intestinal brush border membrane. It displays a broad substrate specificity and is activated by trypsin cleavage. The primary sequence contains four tandem repeat domains (I to IV) and several serines in lipase consensus sequences. We used site-directed mutagenesis to demonstrate that only the serine 399 present in repeat II is responsible for the various enzymatic activities of GPPLB. Furthermore, we characterized for the first time the retinyl esterase activity of the enzyme. We also constructed and expressed in COS-7 cells, an NH2-terminal repeat I deletion mutant which was detected at a very low level by immunoblot. However, confocal microscopy study showed a strong intracellular accumulation with a weak membrane expression of the mutated protein, indicating a role of the NH2-terminal repeat I in the processing of GPPLB. Nevertheless, the Western blot-detected protein presented a glycosylation and trypsin sensitivity patterns similar to wild type PLB. The mutant is also fully active without trypsin treatment, in contrast to native enzyme. Thus, we propose a structural model for GPPLB, in which the repeat I constitutes a lid covering the active site and impairing enzymatic activity, its removal by trypsin leading to an active protein.	Hop Purpan, Inst Federatif Rech Immunol Cellulaire & Mol, INSERM,Dept Lipoprot & Mediateurs Lipid, Unite 563,Ctr Physiopathol Toulouse Purpan, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gassama-Diagne, A (corresponding author), Hop Purpan, Inst Federatif Rech Immunol Cellulaire & Mol, INSERM,Dept Lipoprot & Mediateurs Lipid, Unite 563,Ctr Physiopathol Toulouse Purpan, F-31059 Toulouse, France.		Peres, Carlos Augusto/N-8275-2019; Peres, Carlos A./ABE-8361-2020; Peres, Carlos A./B-1276-2013; Hullin-Matsuda, Françoise/N-3880-2017	Peres, Carlos A./0000-0002-1588-8765; Peres, Carlos A./0000-0002-1588-8765; Hullin-Matsuda, Françoise/0000-0002-6042-2841; Bertrand, PERRET/0000-0001-7568-445X				ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; Beer HD, 1996, BIOCHEM J, V319, P351, DOI 10.1042/bj3190351; BOLL W, 1993, J BIOL CHEM, V268, P12901; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chaminade B, 1999, LIPIDS, V34, pS49, DOI 10.1007/BF02562228; Delagebeaudeuf C, 1998, J BIOL CHEM, V273, P13407, DOI 10.1074/jbc.273.22.13407; Delagebeaudeuf C, 1996, BBA-LIPID LIPID MET, V1303, P119, DOI 10.1016/0005-2760(96)00090-2; DELEENHEER AP, 1979, J CHROMATOGR, V162, P408, DOI 10.1016/S0378-4347(00)81528-5; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; DUGI KA, 1992, J BIOL CHEM, V267, P25086; Fairlie WD, 2001, J BIOL CHEM, V276, P16911, DOI 10.1074/jbc.M010000200; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Ghannoum MA, 2000, CLIN MICROBIOL REV, V13, P122, DOI 10.1128/CMR.13.1.122-143.2000; Harrison EH, 2001, J NUTR, V131, P1405, DOI 10.1093/jn/131.5.1405; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hidaka Y, 2000, J BIOL CHEM, V275, P25155, DOI 10.1074/jbc.M000543200; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jacob R, 2002, J BIOL CHEM, V277, P8217, DOI 10.1074/jbc.M111500200; KIM DK, 1994, FEBS LETT, V343, P213, DOI 10.1016/0014-5793(94)80566-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu T, 2001, BIOCHEMISTRY-US, V40, P7133, DOI 10.1021/bi010237n; MATSUDA H, 1979, BIOCHIM BIOPHYS ACTA, V573, P155, DOI 10.1016/0005-2760(79)90182-6; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1994, J BIOL CHEM, V269, P26933; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; RIGTRUP KM, 1994, BIOCHEMISTRY-US, V33, P2661, DOI 10.1021/bi00175a039; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; Shen H, 2001, ADV DRUG DELIVER REV, V50, pS103, DOI 10.1016/S0169-409X(01)00181-8; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tchoua U, 2000, BBA-MOL CELL BIOL L, V1487, P255, DOI 10.1016/S1388-1981(00)00101-3; Tojo H, 1998, J BIOL CHEM, V273, P2214, DOI 10.1074/jbc.273.4.2214; UPTON C, 1995, TRENDS BIOCHEM SCI, V20, P178, DOI 10.1016/S0968-0004(00)89002-7; Wacker H, 1997, BIOCHEMISTRY-US, V36, P3336, DOI 10.1021/bi962398a; Waite M, 1987, HDB LIPID RES, V5, P155; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200; ZHANG ZZ, 2000, BIOCHEM J, V350, P71	44	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44093	44099		10.1074/jbc.M205761200	http://dx.doi.org/10.1074/jbc.M205761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12194976	hybrid			2022-12-25	WOS:000179272000073
J	Kobayashi, M; Taniura, H; Yoshikawa, K				Kobayashi, M; Taniura, H; Yoshikawa, K			Ectopic expression of necdin induces differentiation of mouse neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; NEURONAL GROWTH SUPPRESSOR; TRANSCRIPTION FACTOR E2F1; POSTMITOTIC NEURONS; NUCLEAR-PROTEIN; FAMILY PROTEINS; MESSENGER-RNA; GENE; APOPTOSIS; DNA	Needin is expressed predominantly in postmitotic neurons, and ectopic expression of this protein strongly suppresses cell growth. Necdin has been implicated in the pathogenesis of Prader-Willi syndrome, a human neurodevelopmental disorder associated with genomic imprinting. Here we demonstrate that ectopic expression of needin induces a neuronal phenotype in neuroblastoma cells. Necdin was undetectable in mouse neuroblastoma N1E-115 cells under undifferentiated and differentiated conditions. N1E-115 cells transfected with necdin cDNA showed morphological differentiation such as neurite outgrowth and expression of the synaptic marker proteins synaptotagmin and synaptophysin. In addition, Western blot analysis of the retinoblastoma protein (Rb) family members Rb, p130, and p107 revealed that necdin cDNA transfectants contained an increased level of p130 and a reduced level of p107, a pattern seen in differentiated G(O) cells. The transcription factors E2F1 and E2F4 physically interacted with necdin via their carboxyl-terminal transactivation domains, but only E2F1 abrogated necdin-induced growth arrest and neurite outgrowth of neuroblastoma cells. Overexpression of E2F1 in differentiated N1E-115 cells induced apoptosis, which was antagonized by co-expression of needin. These results suggest that needin promotes the differentiation and survival of neurons through its antagonistic interactions with E2F1.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 5650871, Japan	Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.							AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LeCouter JE, 1996, ONCOGENE, V12, P1433; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Niinobe M, 2000, DEV NEUROSCI-BASEL, V22, P310, DOI 10.1159/000017455; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Takazaki R, 2002, EXP CELL RES, V277, P220, DOI 10.1006/excr.2002.5558; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Taniura H, 2002, J CELL BIOCHEM, V84, P545, DOI 10.1002/jcb.10047.abs; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2	37	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42128	42135		10.1074/jbc.M205024200	http://dx.doi.org/10.1074/jbc.M205024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198120	hybrid			2022-12-25	WOS:000178985300104
J	Parikh, BA; Coetzer, C; Tumer, NE				Parikh, BA; Coetzer, C; Tumer, NE			Pokeweed antiviral protein regulates the stability of its own mRNA by a mechanism that requires depurination but can be separated from depurination of the alpha-sarcin/ricin loop of rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DELETION MUTANT; RICIN-A-CHAIN; SACCHAROMYCES-CEREVISIAE; INACTIVATING PROTEINS; GLYCOSIDASE ACTIVITY; INHIBITION; INFECTION; VIRUS; RETROTRANSPOSITION; LOCALIZATION	Pokeweed antiviral protein (PAP), a single chain ribosome-inactivating protein (RIP) isolated from pokeweed plants (Phytolacca americana), removes specific adenine and guanine residues from the highly conserved, alpha-sarcin/ ricin loop in the large rRNA, resulting in inhibition of protein synthesis. We recently demonstrated that PAP could also inhibit translation of mRNAs and viral RNAs that are capped by binding to the cap structure and depurinating the RNAs downstream of the cap. Cell growth is inhibited when PAP cDNA is expressed in the yeast Saccharomyces cerevisiae under the control of the galactose-inducible GAL1 promoter. Here, we show that overexpression of wild type PAP in yeast leads to a decrease in PAP mRNA abundance. The decrease in mRNA levels is not observed with an active site mutant, indicating that it is due to the N-glycosidase activity of the protein. PAP expression had no effect on steady state levels of mRNA from four different endogenous yeast genes examined, indicating specificity. We demonstrate that PAP can depurinate the rRNA in trans in a translation-independent manner. When rRNA is depurinated and translation is inhibited, the steady state levels of PAP mRNA increase dramatically relative to the U3 snoRNA. Using a PAP variant which depurinates rRNA, inhibits translation but does not destabilize its mRNA, we demonstrate that PAP mRNA is destabilized after its levels are up-regulated by a mechanism that occurs independently of rRNA depurination and translation. We quantify the extent of rRNA depurination in vivo using a novel primer extension assay and show that the temporal pattern of rRNA depurination is similar to the pattern of PAP mRNA destabilization, suggesting that they may occur by a common mechanism. These results provide the first in vivo evidence that a single chain RIP targets not only the large rRNA but also its own mRNA. These findings have implications for understanding the biological function of RIPs.	Rutgers State Univ, Cook Coll, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA; Rutgers State Univ, Cook Coll, Dept Plant Biol & Pathol, New Brunswick, NJ 08901 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Tumer, NE (corresponding author), Rutgers State Univ, Cook Coll, Ctr Biotechnol, 59 Dudley Rd, New Brunswick, NJ 08901 USA.	tumer@aesop.rutgers.edu	Parikh, Bijal/AAA-5839-2019	Parikh, Bijal/0000-0003-2490-8294				ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; BONNESS MS, 1994, PLANT J, V5, P173, DOI 10.1046/j.1365-313X.1994.05020173.x; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; CARRASCO L, 1975, EUR J BIOCHEM, V54, P499, DOI 10.1111/j.1432-1033.1975.tb04162.x; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 1999, J BIOL CHEM, V274, P3859, DOI 10.1074/jbc.274.6.3859; Hudak KA, 2002, RNA, V8, P1148, DOI 10.1017/S1355838202026638; Hudak KA, 2001, VIROLOGY, V279, P292, DOI 10.1006/viro.2000.0647; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Ogasawara T, 1999, EMBO J, V18, P6522, DOI 10.1093/emboj/18.22.6522; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; READY MP, 1986, P NATL ACAD SCI USA, V83, P5053, DOI 10.1073/pnas.83.14.5053; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; Schwartz DC, 2000, COLD SPRING HARBOR M, V39, P807; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Waurzyniak B, 1997, CLIN CANCER RES, V3, P881; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864; Zoubenko O, 1997, NAT BIOTECHNOL, V15, P992, DOI 10.1038/nbt1097-992	34	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41428	41437		10.1074/jbc.M205463200	http://dx.doi.org/10.1074/jbc.M205463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12171922	hybrid			2022-12-25	WOS:000178985300019
J	Schauvliege, R; Vanrobaeys, J; Schotte, P; Beyaert, R				Schauvliege, R; Vanrobaeys, J; Schotte, P; Beyaert, R			Caspase-11 gene expression in response to lipopolysaccharide and interferon-gamma requires nuclear factor-kappa B and signal transducer and activator of transcription (STAT) 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE DEFICIENT; PROTEASE; IDENTIFICATION; APOPTOSIS; IMMUNITY; CLONING; FAMILY; ENZYME	Murine caspase-11, together with caspase-1, is essential for the production of IL-1beta in response to lipopolysaccharide (LPS). In most cells, caspase-11 is only expressed upon induction with pro-inflammatory stimuli. To understand how caspase-11 expression is transcriptionally regulated, we isolated the caspase-11 gene promoter by genome walking and investigated the mechanisms regulating caspase-11 gene expression in macrophages that are treated with LPS and interferon-gamma. Transient transfections with caspase-11 promoter-luciferase reporter constructs and deletion/mutation analysis revealed an essential role for NF-KB binding in the up-regulation of caspase-11 in response to LPS. In the case of interferon-gamma stimulation, signal transducer and activator of transcription 1 binding to the caspase-11 promoter could be shown to be required for caspase-11 expression.	State Univ Ghent VIB, Unit Mol Signal Transduct Inflammat, Dept Mol Biomed Res, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Unit Mol Signal Transduct Inflammat, Dept Mol Biomed Res, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	rudi.beyaert@dmb.rug.ac.be	Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Desmedt M, 1998, J IMMUNOL, V160, P5300; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111; Hur J, 2001, FEBS LETT, V507, P157, DOI 10.1016/S0014-5793(01)02975-1; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Mackman N, 2000, IMMUNOL RES, V21, P247, DOI 10.1385/IR:21:2-3:247; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schotte P, 2001, J BIOL CHEM, V276, P21153, DOI 10.1074/jbc.M102239200; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Shibata M, 2000, J CLIN INVEST, V106, P643, DOI 10.1172/JCI10203; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243, DOI 10.1111/j.1749-6632.1998.tb08331.x; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	37	117	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41624	41630		10.1074/jbc.M207852200	http://dx.doi.org/10.1074/jbc.M207852200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198138	hybrid			2022-12-25	WOS:000178985300042
J	Uchiumi, T; Honma, S; Endo, Y; Hachimori, A				Uchiumi, T; Honma, S; Endo, Y; Hachimori, A			Ribosomal proteins at the stalk region modulate functional rRNA structures in the GTPase center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; ALPHA-SARCIN CLEAVAGE; ELONGATION-FACTOR-G; COLI 70S RIBOSOME; RICIN A-CHAIN; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BINDING-SITES; CRYSTAL-STRUCTURE; EF-G	Replacement of the L10.L7/L12 protein complex and L11 in Escherichia coli ribosomes with the respective rat counterparts P0-P1/P2 and eukaryotic L12 causes conversion of ribosomal specificity for elongation factors from prokaryotic elongation factor (EF)-Tu/EF-G to eukaryotic EF (eEF)-1alpha/eEF-2. Here we have investigated the effects of protein replacement on the structure and function of two rRNA domains around positions 1070 and 2660 (sarcin/ricin loop) of 23 S rRNA. Protein replacement at the 1070 region in E. coli 50 S subunits was demonstrated by chemical probing analysis. Binding of rat proteins to the 1070 region caused increased accessibility of the 2660 and 1070 regions to ligands for eukaryotic ribosomes: the ribotoxin pepocin for the 2660 region (E. coli numbering), anti-28 S autoantibody for the 1070 region, and eEF-2 for both regions. Moreover, binding of the E. coli L10-L7/L12 complex and L11 to the 1070 region was shown to be responsible for E. coli ribosomal accessibility to another ribotoxin, gypsophilin. Ribosomal proteins at the 1070 region appear to modulate the structures and functions of the 2660 and 1070 RNA regions in slightly different modes in prokaryotes and eukaryotes.	Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan; Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan	Shinshu University; Ehime University	Uchiumi, T (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan.							Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P283, DOI 10.1093/oxfordjournals.jbchem.a130570; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; CHU JL, 1991, J EXP MED, V174, P507, DOI 10.1084/jem.174.3.507; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DABBS ER, 1979, J BACTERIOL, V140, P734, DOI 10.1128/JB.140.2.734-737.1979; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; Draper DE, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P105; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GUDKOV AT, 1978, FEBS LETT, V93, P215, DOI 10.1016/0014-5793(78)81106-5; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; HAMEL E, 1972, J BIOL CHEM, V247, P805; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Holmberg L, 1999, J MOL BIOL, V289, P223, DOI 10.1006/jmbi.1999.2706; Iwasaki K, 1979, Methods Enzymol, V60, P657; KAZIRO Y, 1972, J BIOCHEM, V72, P853, DOI 10.1093/oxfordjournals.jbchem.a129980; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; MILLER SP, 1991, NUCLEIC ACIDS RES, V19, P1657, DOI 10.1093/nar/19.7.1657; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1974, RIBOSOMES, P711; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NATHANS D, 1961, P NATL ACAD SCI USA, V47, P497, DOI 10.1073/pnas.47.4.497; PETTERSSON I, 1979, NUCLEIC ACIDS RES, V6, P2637, DOI 10.1093/nar/6.7.2637; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; RANDI R, 1962, J BIOL CHEM, V237, P3707; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; REMACHA M, 1988, J BIOL CHEM, V263, P9094; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Seggerson K, 1998, RNA, V4, P1203, DOI 10.1017/S1355838298980773; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; Uchiumi T, 1999, J BIOL CHEM, V274, P27578, DOI 10.1074/jbc.274.39.27578; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Uchiumi T, 2002, J BIOL CHEM, V277, P3857, DOI 10.1074/jbc.M107730200; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o; Yoshinari S, 1996, EUR J BIOCHEM, V242, P585, DOI 10.1111/j.1432-1033.1996.0585r.x; Yoshinari S, 1997, BIOSCI BIOTECH BIOCH, V61, P324, DOI 10.1271/bbb.61.324; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	62	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41401	41409		10.1074/jbc.M207424200	http://dx.doi.org/10.1074/jbc.M207424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198134	hybrid			2022-12-25	WOS:000178985300015
J	Avdi, NJ; Malcolm, KC; Nick, JA; Worthen, GS				Avdi, NJ; Malcolm, KC; Nick, JA; Worthen, GS			A role for protein phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH2-terminal kinase pathway in human Neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE; SIGNAL-TRANSDUCTION; MEK KINASE-1; CROSS-TALK; IN-VITRO; SYNERGISTIC ACTIVATION; TYROSINE PHOSPHATASES; CELLULAR STRESSES	Human neutrophil accumulation in inflammatory foci is essential for the effective control of microbial infections. Although exposure of neutrophils to cytokines such as tumor necrosis factor-alpha (TNFalpha), generated at sites of inflammation, leads to activation of MAPK pathways, mechanisms responsible for the fine regulation of specific MAPK modules remain unknown. We have previously demonstrated activation of a TNFalpha-mediated JNK pathway module, leading to apoptosis in adherent human neutrophils (Avdi, N. J., Nick, J. A., Whitlock, B. B., Billstrom, M. A., Henson, P. M., Johnson, G. L., and Worthen, G. S. (2001) J. Biol. Chem. 276, 2189-2199). Herein, evidence is presented linking regulation of the JNK pathway to p38 MAPK and the Ser/Thr protein phosphatase-2A (PP2A). Inhibition of p38 MAPK by SB 203580 and M 39 resulted in significant augmentation of TNFalpha-induced JNK and MKK4 (but not MKK7 or MEKK1) activation, whereas prior exposure to a p38-activating agent (platelet-activating factor) diminished the TNFalpha-induced JNK response. TNFa-induced apoptosis was also greatly enhanced upon p38 inhibition. Studies with a reconstituted cell-free system indicated the absence of a direct inhibitory effect of p38 MAPK on the JNK module. Neutrophil exposure to the Ser/Thr phosphatase inhibitors okadaic acid and calyculin A induced JNK activation. Increased phosphatase activity following TNFa stimulation was shown to be PP2A-associated and p38-dependent. Furthermore, PP2A-induced dephosphorylation of MKK4 resulted in its inactivation. Thus, in neutrophils, p38 MAPK, through a PP2A-mediated mechanism, regulates the JNK pathway, thus determining the extent and nature of subsequent responses such as apoptosis.	Natl Jewish & Med Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish & Med Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Avdi, NJ (corresponding author), Natl Jewish & Med Res Ctr, Dept Med, 1400 Jackson St,D403, Denver, CO 80206 USA.			BRIONES, NATALIE/0000-0002-8342-9552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61407-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; BUSCHER M, 1988, ONCOGENE, V3, P301; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dumont JE, 2001, CELL SIGNAL, V13, P457, DOI 10.1016/S0898-6568(01)00168-1; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; King AG, 1995, ONCOGENE, V11, P2553; Kinoshita K, 1996, GENES CELLS, V1, P29, DOI 10.1046/j.1365-2443.1996.02002.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Liverton NJ, 1999, J MED CHEM, V42, P2180, DOI 10.1021/jm9805236; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Robinson CJM, 2001, CELL SIGNAL, V13, P29, DOI 10.1016/S0898-6568(00)00121-2; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Uh ST, 2000, J BIOL CHEM, V275, P793, DOI 10.1074/jbc.275.2.793; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200	67	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40687	40696		10.1074/jbc.M204455200	http://dx.doi.org/10.1074/jbc.M204455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186863	hybrid			2022-12-25	WOS:000178791400068
J	Edberg, JC; Qin, HW; Gibson, AW; Yee, AMF; Redecha, PB; Indik, ZK; Schreiber, AD; Kimberly, RP				Edberg, JC; Qin, HW; Gibson, AW; Yee, AMF; Redecha, PB; Indik, ZK; Schreiber, AD; Kimberly, RP			The CY domain of the Fc gamma RIa alpha-chain (CD64) alters gamma-chain tyrosine-based signaling and phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; IMMUNOGLOBULIN-G; PROTEIN-KINASE; BETA-SUBUNIT; EPSILON-RI; PSEUDOPOD EXTENSION; BISPECIFIC ANTIBODY; CYTOPLASMIC DOMAIN; MAST-CELLS; IGG-FC	Although the cytoplasmic domain of the human FcgammaRIa alpha-chain lacks tyrosine-based phosphorylation motifs, it modulates receptor cycling and receptor-specific cytokine production. The cytoplasmic domain of FcgammaRIa is constitutively phosphorylated, and the inhibition of dephosphorylation with okadaic acid, an inhibitor of type 1 and type 2A protein serine/threonine phosphatase, inhibits both receptor-induced activation of the early tyrosine phosphorylation cascade and receptor-specific phagocytosis. To explore the basis for these effects of the cytoplasmic domain of FcgammaRIa, we developed a series of human FcgammaRIa molecular variants, expressed in the murine macrophage cell line P388D1, and demonstrate that serine phosphorylation of the cytoplasmic domain is an important regulatory mechanism. Truncation of the cytoplasmic domain and mutation of the cytoplasmic domain serine residues to alanine abolish the okadaic acid inhibition of phagocytic function. In contrast, the serine mutants did not recapitulate the selective effects of cytoplasmic domain truncation on cytokine production. These results demonstrate for the first time a direct functional role for serine phosphorylation in the a-chain of FcgammaRIa and suggest that the cytoplasmic domain of FcgammaRI regulates the different functional capacities of the FcgammaRIa-receptor complex.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Cornell Univ, Hosp Special Surg, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cornell University; Cornell University; University of Pennsylvania	Edberg, JC (corresponding author), Univ Alabama, Dept Med, 1530 3rd Ave S,THT433A, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042476, R01AR033062, P60AR020614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22193] Funding Source: Medline; NIAMS NIH HHS [R01 AR 33062, R01 AR 42476, P60 AR 20614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Edberg JC, 1997, EXP CLIN IMMUNOGENET, V14, P183; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1994, J IMMUNOL, V152, P5826; GIBSON AW, 1999, LUPUS MOL CELLULAR P, P557; Graziano RF, 1997, CANCER IMMUNOL IMMUN, V45, P124, DOI 10.1007/s002620050413; GUYRE PM, 1989, J IMMUNOL, V143, P1650; Hiraoka S, 1999, INT IMMUNOL, V11, P199, DOI 10.1093/intimm/11.2.199; INDIK Z, 1992, IMMUNOBIOLOGY, V185, P183, DOI 10.1016/S0171-2985(11)80640-6; INDIK ZK, 1994, EXP HEMATOL, V22, P599; Karimi K, 1999, J LEUKOCYTE BIOL, V65, P854, DOI 10.1002/jlb.65.6.854; Keler T, 1997, CANCER RES, V57, P4008; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; Larsen EC, 2000, J IMMUNOL, V165, P2809, DOI 10.4049/jimmunol.165.5.2809; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Liu CL, 1996, J CLIN INVEST, V98, P2001, DOI 10.1172/JCI119004; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003; Melendez AJ, 1998, P NATL ACAD SCI USA, V95, P2169, DOI 10.1073/pnas.95.5.2169; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; Posey JA, 1999, J IMMUNOTHER, V22, P371, DOI 10.1097/00002371-199907000-00011; Pullarkat V, 1999, CANCER IMMUNOL IMMUN, V48, P9, DOI 10.1007/s002620050543; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Repp R, 1995, J Hematother, V4, P415, DOI 10.1089/scd.1.1995.4.415; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; Salmon JE, 1996, J CLIN INVEST, V97, P1348, DOI 10.1172/JCI118552; Somasundaram Chezian, 1999, Human Antibodies, V9, P47; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tridandapani S, 2000, J BIOL CHEM, V275, P20480, DOI 10.1074/jbc.M909462199; van der Pol WL, 1998, IMMUNOGENETICS, V48, P222, DOI 10.1007/s002510050426; van Vugt MJ, 1999, BLOOD, V94, P808, DOI 10.1182/blood.V94.2.808.414k31_808_817; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Wang J, 1999, J BIOL CHEM, V274, P24349, DOI 10.1074/jbc.274.34.24349; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616	55	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41287	41293		10.1074/jbc.M207835200	http://dx.doi.org/10.1074/jbc.M207835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12200451	hybrid			2022-12-25	WOS:000178791400142
J	Kannan-Thulasiraman, P; Shapiro, DJ				Kannan-Thulasiraman, P; Shapiro, DJ			Modulators of inflammation use nuclear factor-B-K and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; ESTROGEN-RECEPTOR; DENDRITIC CELLS; GENE; INTERLEUKIN-1-BETA; MECHANISM; PROTEASE; SUPERFAMILY	Proteinase inhibitor 9 (PI-9) inhibits caspase-1 (interleukin (IL)-1beta-converting enzyme) and granzyme B, thereby regulating production of the pro-inflammatory cytokine IL-1beta and susceptibility to granzyme B-induced apoptosis. We show that cellular PI-9 mRNA and protein are induced by IL-1beta, lipopolysaccharide, and 12-O-tetradecanoylphorbol-13-acetate. We identified functional imperfect nuclear factor-B-K (NF-B-K) sites at -135 and -88 and a consensus activator protein-1 (AP-1) site at -308 in the PI-9 promoter region. Using transient transfections in HepG2 cells to assay PI-9 promoter mutations, we find that mutational ablation of the AP-1 site or of either NF-B-K site reduces IL-1beta-induced expression of PI-9 by similar to60%. Mutational ablation of the two NF-KB sites and of the AP-1 site nearly abolishes both basal and IL-1beta-induced expression of PI-9. Nuclear extracts from IL-1beta-treated HepG2 cells exhibited strong, IL-1beta-inducible binding to the NF-KB sites and to the AP-1 site. Electrophoretic mobility shift assays show that after IL-1beta treatment c-Jun/c-Fos and JunD bind to the AP-1 site, whereas the p50/p65 heterodimer binds to the two NF-KB sites. Estrogens induce PI-9, but induction of PI-9 by estrogens and IL-1beta is not synergistic. In transiently transfected, estrogen receptor-positive HepG2ER7 cells, estrogens do not interfere with IL-1beta induction, whereas IL-1beta exhibits dose-dependent repression of estrogen-inducible PI-9 expression. Our surprising finding that the pro-inflammatory cytokine IL-1beta strongly induces PI-9 suggests a novel mechanism for regulating inflammation and apoptosis through a negative feedback loop controlling expression of the anti-inflammatory and anti-apoptotic protein, PI-9.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu			NICHD NIH HHS [HD 16720] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; BIRD PI, 2002, MOD ASP IMMUNOBIOL, V2, P136; Bladergroen BA, 2001, J IMMUNOL, V166, P3218, DOI 10.4049/jimmunol.166.5.3218; BURGER D, 2001, CYTOKINE REFERENCE C, V1, P319; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kordula T, 2000, J NEUROSCI, V20, P7510; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Kumar V, 1997, BASIC PATHOLOGY; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Suzuki T, 1996, J BIOL CHEM, V271, P1626, DOI 10.1074/jbc.271.3.1626; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808	43	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41230	41239		10.1074/jbc.M200379200	http://dx.doi.org/10.1074/jbc.M200379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177049	hybrid			2022-12-25	WOS:000178791400134
J	Nobrega, MP; Bandeira, SCB; Beers, J; Tzagoloff, A				Nobrega, MP; Bandeira, SCB; Beers, J; Tzagoloff, A			Characterization of COX19, a widely distributed gene required for expression of mitochondrial cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C-OXIDASE; MEMBRANE SYSTEM; MESSENGER-RNA; PROTEIN; MUTANTS; VECTORS; IMPORT; ATPASE	COX19, a nuclear gene of Saccharomyces cerevisiae, was cloned by transformation of a respiratory-deficient mutant from complementation group G188 of a pet mutant collection. The gene codes for an 11-kDa protein (Cox19p) required for expression of cytochrome oxidase. Because cox19 mutants are able to synthesize the mitochondrial and nuclear gene products of cytochrome oxidase, Cox19p probably functions post-translationally during assembly of the enzyme. Cox19p is present in the cytoplasm and mitochondria, where it exists as a soluble intermembrane protein. This dual location is similar to what was previously reported for Cox17p, a low molecular weight copper protein thought to be required for maturation of the CuA center of subunit 2 of cytochrome oxidase. The similarity in their subcellular distribution, combined with the presence of four cysteines in Cox19p that align with a subset of the cysteines in Cox19p, suggests that like the latter, Cox19p may function in metal transport to mitochondria.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Vale do Paraiba, Inst Pesquisa & Desenvolvimento, BR-12244000 Sao Jose Dos Campos, Brazil	Columbia University; Universidade do Vale do Paraiba	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM 50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; COSTANZO MC, 1995, CURR GENET, V28, P60, DOI 10.1007/BF00311882; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOGG A, 1991, J MICROBIOL REV, V54, P211; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	39	84	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40206	40211		10.1074/jbc.M207348200	http://dx.doi.org/10.1074/jbc.M207348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171940	hybrid			2022-12-25	WOS:000178791400008
J	Paarmann, I; Spangenberg, O; Lavie, A; Konrad, M				Paarmann, I; Spangenberg, O; Lavie, A; Konrad, M			Formation of complexes between Ca2+center dot calmodulin and the synapse-associated protein SAP97 requires the SH3 domain-guanylate kinase domain-connecting HOOK region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; HUMAN HOMOLOG; PDZ DOMAINS; INTRAMOLECULAR INTERACTION; POSTSYNAPTIC DENSITY; PLASMA-MEMBRANE; CALMODULIN; FAMILY; CALCIUM; CHANNEL	Mammalian synapse-associated protein SAP97, a structural and functional homolog of Drosophila Dlg, is a membrane-associated guanylate kinase (MAGUK) that is present at pre- and postsynaptic sites as well as in epithelial cell-cell contact sites. It is a multidomain scaffolding protein that shares with other members of the MAGUK protein family a characteristic modular organization composed of three sequential protein interaction motifs known as PDZ domains, followed by an Sre homology 3 (SH3) domain, and an enzymatically inactive guanylate kinase (GK)-like domain. Specific binding partners are known for each domain, and different modes of intramolecular interactions have been proposed that particularly involve the SH3 and GK domains and the so-called HOOK region located between these two domains. We identified the HOOK region as a specific site for calmodulin binding and studied the dynamics of complex formation of recombinant calmodulin and SAP97 by surface plasmon resonance spectroscopy. Binding of various SAP97 deletion constructs to immobilized calmodulin was strictly calcium-dependent. From the rate constants of association and dissociation we determined an equilibrium dissociation constant K-d of 122 nM for the association of calcium-saturated calmodulin and a SAP97 fragment, which encompassed the entire SH3-HOOK-GK module. Comparative structure-based sequence analysis of calmodulin binding regions from various target proteins predicts variable affinities for the interaction of calmodulin with members of the MAGUK protein family. Our findings suggest that calmodulin could regulate the intramolecular interaction between the SH3, HOOK, and GK domains of SAP97.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60607 USA	Max Planck Society; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Konrad, M (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.		Lavie, Arnon/H-4927-2012	Lavie, Arnon/0000-0001-5591-8722				Brenman JE, 1998, J NEUROSCI, V18, P8805; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; BURNS NR, 1985, BIOCHEMISTRY-US, V24, P3070, DOI 10.1021/bi00333a040; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Evenas J, 1998, CURR OPIN CHEM BIOL, V2, P293, DOI 10.1016/S1367-5931(98)80072-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hibino H, 2000, EMBO J, V19, P78, DOI 10.1093/emboj/19.1.78; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Li YH, 2002, J BIOL CHEM, V277, P4159, DOI 10.1074/jbc.M110792200; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 1998, J CELL SCI, V111, P2365; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320; 1998, BIATECHNOLOGY HDB VE	50	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40832	40838		10.1074/jbc.M205618200	http://dx.doi.org/10.1074/jbc.M205618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189141	hybrid			2022-12-25	WOS:000178791400087
J	Wadehra, M; Iyer, R; Goodglick, L; Braun, J				Wadehra, M; Iyer, R; Goodglick, L; Braun, J			The tetraspan protein epithelial membrane protein-2 interacts with beta 1 integrins and regulates adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DEPENDENT REGULATION; BINDING-SPECIFICITY; SUPERFAMILY; COMPLEXES; GROWTH; CD151; CD63; CD81; ALPHA-3-BETA-1	The growth arrest-specific-3 (GAS3)/PMP22 proteins are members of the four-transmembrane (tetraspan) superfamily. Although the function of these proteins is poorly understood, GAS3/PMP22 proteins have been implicated in the control of growth and progression of certain cancers. Epithelial membrane protein-2 (EMP2), a GAS3/PMP22 family member, was recently identified as a putative tumor suppressor gene. Here, we addressed the normal function of EMP2 by testing the prediction that it influences integrin-related cell functions. We observed that EMP2 associates with the beta(1) integrin subunit. Co-immunoprecipitation and immunodepletion experiments indicated that similar to60% of beta(1) integrins and EMP2 can be isolated in common protein complexes. Whereas this association between EMP2 and beta(1) integrin may be direct or indirect, it has features of integrin heterodimer selectivity. Thus, by laser confocal microscopy, EMP2 colocalized with alpha(6)beta(1), but not alpha(5)beta(1) integrin. Increased expression of EMP2 also influenced the integrin heterodimer repertoire present on the plasma membrane. EMP2 specifically increased the surface expression of the alpha(6)beta(1) integrin while decreasing that of the alpha(5)beta(1) protein. Reciprocally, reduction in EMP2 expression using a specific ribozyme decreased surface expression of alpha(6)beta(1), integrin. Accordingly, these EMP2-mediated changes resulted in a dramatic alteration in cellular adhesion to extracellular matrix proteins. This study demonstrates for the first time the interaction of a GAS3/PMP22 family member with an integrin protein and suggests that such interactions and their functional consequences are a physiologic role of GAS3/PMP22 proteins.	Univ Calif Los Angeles, David Geffen Sch, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch, Inst Mol Biol, Los Angeles, CA 90095 USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA; Dept Pathol & Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center	Braun, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch, Dept Pathol & Lab Med, CHS 13-222,10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Braun, Jonathan/0000-0003-1646-2974	NCI NIH HHS [5T32 CA 009120-27] Funding Source: Medline; NIAID NIH HHS [AI 28697] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amarzguioui M, 1998, CELL MOL LIFE SCI, V54, P1175, DOI 10.1007/s000180050247; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Attardi LD, 2000, GENE DEV, V14, P704; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; BenPorath I, 1996, GENE, V183, P69, DOI 10.1016/S0378-1119(96)00475-1; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; Brancolini C, 1999, MOL BIOL CELL, V10, P2441, DOI 10.1091/mbc.10.7.2441; CHRISTOPHEHOBER.C, 2001, GENOMICS, V2, P3; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Dackovic J, 2001, EUR J NEUROL, V8, P689, DOI 10.1046/j.1468-1331.2001.00306.x; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; Kikkawa Y, 2000, J CELL SCI, V113, P869; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; Naef R, 1998, MICROSC RES TECHNIQ, V41, P359, DOI 10.1002/(SICI)1097-0029(19980601)41:5<359::AID-JEMT3>3.0.CO;2-L; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shimizu Y, 1996, Hum Cell, V9, P175; SNIPES GJ, 1993, J NEUROCHEM, V61, P1961, DOI 10.1111/j.1471-4159.1993.tb09840.x; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Taylor V, 1996, GENE, V175, P115, DOI 10.1016/0378-1119(96)00134-5; Testa JE, 1999, CANCER RES, V59, P3812; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Wang CX, 2001, BLOOD, V97, P3890, DOI 10.1182/blood.V97.12.3890; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Won WJ, 2002, J IMMUNOL, V168, P5605, DOI 10.4049/jimmunol.168.11.5605; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	43	56	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41094	41100		10.1074/jbc.M206868200	http://dx.doi.org/10.1074/jbc.M206868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189152	hybrid			2022-12-25	WOS:000178791400119
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Ganglioside modulation regulates epithelial cell adhesion and spreading via ganglioside-specific effects on signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; FIBRONECTIN; EXPRESSION; KERATINOCYTES; BINDING; DIFFERENTIATION; TRANSDUCTION	Gangliosides are implicated in regulating cell adhesion and migration on fibronectin by binding with the a, subunit of alpha(5)beta(1) integrin. However, the effects of gangliosides on cell spreading and related signaling pathways are unknown. Increases in gangliosides GT1b and GD3 inhibited spreading on fibronectin, concurrent with inhibition of Src and focal adhesion kinase. Although antibody blockade of GT1b or GD3 function and gene-modulated ganglioside depletion stimulated spreading and activated Src and focal adhesion kinase, the augmented spreading by disruption of GT1b function, but not by disruption of GD3 function, was inhibited by blockade of Src and focal adhesion kinase activation. In contrast, inhibitors of protein kinase C prevented the stimulation of spreading by GD3 functional inhibition, but not by GT1b functional blockade. Modulation of either GT1b or GD3 content affected phosphoinositol 3-kinase activation, and inhibition of this activation reversed the stimulation of cell spreading by anti-GD3 antibody, anti-GT1b antibody, and ganglioside depletion, suggesting that phosphoinositol 3-kinase is an intermediate in both the FAK/Src and protein kinase C pathways that lead to cell spreading. These studies demonstrate that epithelial cell ganglioside GT1b modulates cell spreading through alpha(5)beta(1)/FAK and phosphoinositol 3-kinase signaling, whereas GD3-modulated spreading appears to involve phosphoinositol 3-kinase-dependent protein kinase C signaling.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.			Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR 44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balciunaite E, 2001, BIOCHEM J, V358, P281, DOI 10.1042/0264-6021:3580281; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Disatnik MH, 2002, J CELL SCI, V115, P2151; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MassonGadais B, 1997, EXP CELL RES, V236, P238, DOI 10.1006/excr.1997.3721; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; OKEEFE EJ, 1985, J INVEST DERMATOL, V85, P125, DOI 10.1111/1523-1747.ep12276531; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; Sung Ching-Ching, 1997, Journal of Investigative Dermatology, V108, P662; VUORI K, 1993, J BIOL CHEM, V268, P21459; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wang YL, 1999, METHOD ENZYMOL, V306, P281; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	33	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40410	40419		10.1074/jbc.M207117200	http://dx.doi.org/10.1074/jbc.M207117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183467	hybrid			2022-12-25	WOS:000178791400034
J	Uchida, C; Oda, T; Sugiyama, T; Otani, S; Kitagawa, M; Ichiyama, A				Uchida, C; Oda, T; Sugiyama, T; Otani, S; Kitagawa, M; Ichiyama, A			The role of Sp1 and AP-2 in basal and protein kinase A-induced expression of mitochondrial serine : pyruvate aminotransferase in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; ALANINE-GLYOXYLATE AMINOTRANSFERASE; BOVINE CYP11A GENE; RAT-LIVER; SUBCELLULAR-DISTRIBUTION; PEROXISOMAL SERINE; BINDING PROTEIN; CELL-GROWTH; MOLECULAR EVOLUTION; ACTIVATION DOMAINS	Transcription of mitochondrial serine:pyruvate aminotransferase (SPT) mRNA (SPTm-mRNA) in rat liver is unique in that it occurs from the upstream site of the two transcription start sites within the first exon of the SPT gene and is selectively enhanced by cAMP via the protein kinase A (PKA) signaling pathway. In this study, we identified the DNA elements and nuclear factors responsible for the basal and PKA-induced activities of the upstream promoter. By using a luciferase reporter assay with HepG2 cells, DNase I footprinting analysis, and gel shift experiments, we identified the binding sites for Sp1 and AP-2 within the regions -125 to -89 and -14 to +10, respectively. Mutational analyses indicated that these regions are essential for the transcription factor binding and the SPT promoter activity. Expression of AP-2 caused a marked increase in the basal promoter activity to about the same level as that achieved by PKA. On the other hand, both the basal and PKA-induced activities were elevated by overexpression of Sp1, its effect on PKA-induced activity being more pronounced with coexpression of CBP and repressed by E1A oncoprotein. These results suggest that AP-2 and Sp1 regulate basal promoter activity, and Sp1 is also involved in PKA-mediated expression of the rat SPT gene in concert with the transcriptional coactivator CBP.	Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 3, Shizuoka, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Uchida, C (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, 1-20-1 Hamamatsu, Shizuoka, Japan.	cuchida@hama-med.ac.jp						ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANPURE CJ, 1990, J CELL SCI, V97, P669; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DYAN WS, 1983, CELL, V35, P79; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Goodman RH, 2000, GENE DEV, V14, P1553; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Ichiyama A, 2000, MOL UROL, V4, P333; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MONTLEY A, 1995, J CELL BIOL, V131, P65; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NELSON M, 1992, METHOD ENZYMOL, V216, P279; NISHIYAMA K, 1990, EUR J BIOCHEM, V194, P9, DOI 10.1111/j.1432-1033.1990.tb19420.x; NOGUCHI T, 1978, BIOCHEM J, V170, P173, DOI 10.1042/bj1700173; Oda T, 1997, FEBS LETT, V418, P265, DOI 10.1016/S0014-5793(97)01396-3; ODA T, 1993, GENOMICS, V17, P59, DOI 10.1006/geno.1993.1283; ODA T, 1990, J BIOL CHEM, V265, P7513; Oda T, 1996, BIOCHEM BIOPH RES CO, V228, P341, DOI 10.1006/bbrc.1996.1663; Oda T, 2000, CELL BIOCHEM BIOPHYS, V32, P277, DOI 10.1385/CBB:32:1-3:277; ODA T, 1987, Biomedical Research (Tokyo), V8, P5; OHBAYASHI K, 1995, BIOMED RES-TOKYO, V16, P141, DOI 10.2220/biomedres.16.141; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARK K, 1993, J BIOL CHEM, V268, P17811; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sugiyama T, 2001, FEBS LETT, V508, P16, DOI 10.1016/S0014-5793(01)03010-1; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; Takeuchi S, 1999, MOL BRAIN RES, V74, P208, DOI 10.1016/S0169-328X(99)00298-3; UCHIDA C, 1994, J BIOL CHEM, V26, P8849; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Xue HH, 1999, J BIOL CHEM, V274, P16028, DOI 10.1074/jbc.274.23.16028; Xue HH, 1999, J BIOL CHEM, V274, P16020, DOI 10.1074/jbc.274.23.16020; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; YOKOTA S, 1991, BIOMED RES-TOKYO, V12, P53, DOI 10.2220/biomedres.12.53; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	64	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39082	39092		10.1074/jbc.M201380200	http://dx.doi.org/10.1074/jbc.M201380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169688	hybrid			2022-12-25	WOS:000178662500006
J	Zambrano, A; Villarreal, LP				Zambrano, A; Villarreal, LP			A monoclonal antibody specific for BK virus large T-antigen (clone BK.T-1) also binds the human Ku autoantigen	ONCOGENE			English	Article						BK virus; large T antigen; Ku proteins; antibodies	DNA; INFECTION; GROWTH; P70	A monoclonal antibody directed against the BK virus large T-antigen (clone BK.T-1) has previously been used to evaluate BKV-T antigen (BKV-TAg) expression. However, our experience showed a consistent reactivity to uninfected human, but not rodent cells and tissues. Using immunoprecipitation, Western analysis, amino acid sequencing and end-point dilution analysis, we analysed the BK.T-1 antibody reactivity and identified the bound cellular protein. The results clearly show that the antibody recognizes the large subunit (Ku86) of the Ku autoantigen, the regulatory component of the DNA-PKcs. We also demonstrated that the antibody retained its original reactivity in BKV-TAg transformed hamster kidney cells. The cross-reaction of the BK.T-1 antibody suggests a possible similarity between BKV-TAg and Ku86, but makes the antibody unsuitable for studies of BKV large T-antigen in the human cells.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Villarreal, LP (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Room 3232, Irvine, CA 92697 USA.	lpvillar@uci.edu	Zambrano, Alberto/A-1580-2013; Zambrano, Alberto/Q-6188-2019	Zambrano, Alberto/0000-0001-5677-2999; Zambrano, Alberto/0000-0001-5677-2999				CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Flaegstad T, 1999, CANCER RES, V59, P1160; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MARSHALL J, 1991, ONCOGENE, V6, P1673; MENEGUZZI G, 1981, VIROLOGY, V111, P139, DOI 10.1016/0042-6822(81)90660-7; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1978, VIROLOGY, V85, P137, DOI 10.1016/0042-6822(78)90418-X; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	16	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5725	5732		10.1038/sj.onc.1205692	http://dx.doi.org/10.1038/sj.onc.1205692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173042				2022-12-25	WOS:000177463400007
J	Hua, QX; Chu, YC; Jia, WH; Phillips, NFB; Wang, RY; Katsoyannis, PG; Weiss, MA				Hua, QX; Chu, YC; Jia, WH; Phillips, NFB; Wang, RY; Katsoyannis, PG; Weiss, MA			Mechanism of insulin chain combination - Asymmetric roles of A-chain alpha-helices in disulfide pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; RECEPTOR-BINDING; BIOLOGICAL-ACTIVITY; FOLDING PATHWAY; PHOTO-CIDNP; IGF-I; PROTEIN; PEPTIDE; ASSIGNMENT; DYNAMICS	The A and B chains of insulin combine to form native disulfide bridges without detectable isomers. The fidelity of chain combination thus recapitulates the folding of proinsulin, a precursor protein in which the two chains are tethered by a disordered connecting peptide. We have recently shown that chain combination is blocked by seemingly conservative substitutions in the C-terminal alpha-helix of the A chain. Such analogs, once formed, nevertheless retain high biological activity. By contrast, we demonstrate here that chain combination is robust to non-conservative substitutions in the N-terminal alpha-helix. Introduction of multiple glycine substitutions into the N-terminal segment of the A chain (residues A1-A5) yields analogs that are less stable than native insulin and essentially without biological activity. H-1 NMR studies of a representative analog lacking invariant side chains Ile(A2) and Val(A3) (A chain sequence GGGEQCCTSICSLYQLENYCN. substitutions are italicized and cysteines are underlined) demonstrate local unfolding of the A1-A5 segment in an otherwise native-like structure. That this and related partial folds retain efficient disulfide pairing suggests that the native N-terminal alpha-helix does not participate in the transition state of the reaction. Implications for the hierarchical folding mechanisms of proinsulin and insulin-like growth factors are discussed.	NYU, Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Icahn School of Medicine at Mount Sinai; New York University; Case Western Reserve University	Katsoyannis, PG (corresponding author), NYU, Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA.							BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; BREMS DN, 1992, PROTEIN ENG, V5, P519, DOI 10.1093/protein/5.6.519; CARA JF, 1990, J BIOL CHEM, V265, P17820; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; CHANCE RE, 1993, DIABETES CARE, V16, P133, DOI 10.2337/diacare.16.3.133; CHU YC, 1987, BIOCHEMISTRY-US, V26, P6975, DOI 10.1021/bi00396a018; CHU YC, 1994, BIOCHEMISTRY-US, V33, P11278, DOI 10.1021/bi00203a025; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Grantcharova VP, 1998, NAT STRUCT BIOL, V5, P714, DOI 10.1038/1412; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HU SQ, 1993, BIOCHEMISTRY-US, V32, P2631, DOI 10.1021/bi00061a022; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 1990, BIOCHEMISTRY-US, V29, P10545, DOI 10.1021/bi00498a018; Jacoby E, 1996, J MOL BIOL, V258, P136, DOI 10.1006/jmbi.1996.0239; KATSOYAN.PG, 1966, P NATL ACAD SCI USA, V55, P1554, DOI 10.1073/pnas.55.6.1554; KLINE AD, 1990, BIOCHEMISTRY-US, V29, P2906, DOI 10.1021/bi00464a003; KOBAYASHI M, 1986, BIOCHEM BIOPH RES CO, V137, P250, DOI 10.1016/0006-291X(86)91203-9; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Luo YZ, 2001, BIOCHEMISTRY-US, V40, P5283, DOI 10.1021/bi010122j; MARSHALL RN, 1974, J CLIN ENDOCR METAB, V39, P283, DOI 10.1210/jcem-39-2-283; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; Olsen HB, 1998, J MOL BIOL, V284, P477, DOI 10.1006/jmbi.1998.2175; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; POCKER Y, 1980, BIOCHEMISTRY-US, V19, P5043, DOI 10.1021/bi00563a017; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Shakhnovich EI, 1999, NAT STRUCT BIOL, V6, P99, DOI 10.1038/5785; Shakhnovich EI, 1998, FOLD DES, V3, pR108, DOI 10.1016/S1359-0278(98)00056-X; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; Slieker LJ, 1997, DIABETOLOGIA, V40, pS54, DOI 10.1007/s001250051402; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; STEINER DF, 1988, HORM METAB RES, V20, P443, DOI 10.1055/s-2007-1010855; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; Xu B, 2002, PROTEIN SCI, V11, P104, DOI 10.1110/ps.ps.32102; Zhang JX, 1997, PROTEIN SCI, V6, P1563, DOI 10.1002/pro.5560060720	60	61	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43443	43453		10.1074/jbc.M206107200	http://dx.doi.org/10.1074/jbc.M206107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196530	hybrid			2022-12-25	WOS:000179081200129
J	Young, NM; Brisson, JR; Kelly, J; Watson, DC; Tessier, L; Lanthier, PH; Jarrell, HC; Cadotte, N; Michael, FS; Aberg, E; Szymanski, CM				Young, NM; Brisson, JR; Kelly, J; Watson, DC; Tessier, L; Lanthier, PH; Jarrell, HC; Cadotte, N; Michael, FS; Aberg, E; Szymanski, CM			Structure of the N-linked glycan present on multiple glycoproteins in the gram-negative bacterium, Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; NEISSERIA-MENINGITIDIS; PILIN GLYCOSYLATION; MYCOBACTERIUM-TUBERCULOSIS; IDENTIFICATION; FLAGELLIN; PROTEINS; POLYSACCHARIDES; SPECTROSCOPY; PURIFICATION	Mass spectrometry investigations of partially purified Campylobacter jejuni protein PEB3 showed it to be partially modified with an Asn-linked glycan with a mass of 1406 Da and composed of one hexose, five N-acetylhexosamines and a species of mass 228 Da, consistent with a trideoxydiacetamidohexose. By means of soybean lectin affinity chromatography, a mixture of glycoproteins was obtained from a glycine extract, and two-dimensional gel proteomics analysis led to the identification of at least 22 glycoproteins, predominantly annotated as periplasmic proteins. Glycopeptides were prepared from the glycoprotein mixture by Pronase digestion and gel filtration. The structure of the glycan was determined by using nano-NMR techniques to beGaINAc-alpha1,4-GaINAc-alpha1,4-[Glcbeta1,3-]GaINAc-alpha1,4-GaINAc-alpha1,4-GaINAc-alpha1,3-Bac- beta1,N-Asn-Xaa, where Bac is bacillosamine, 2,4-diacetamido-2,4,6-trideoxyglucopyranose. Protein glycosylation was abolished when the pglB gene was mutated, providing further evidence that the enzyme encoded by this gene is responsible for formation of the glycopeptide N-linkage. Comparison of the pgl locus with that of Neisseria meningitidis suggested that most of the homologous genes are probably involved in the biosynthesis of bacillosamine.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Young, NM (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.							Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; Bedouet L, 1998, MICROBIOS, V94, P183; Benz I, 2001, MOL MICROBIOL, V40, P1403, DOI 10.1046/j.1365-2958.2001.02487.x; Brimer CD, 1998, J BACTERIOL, V180, P3209, DOI 10.1128/JB.180.12.3209-3217.1998; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Gallego RG, 2001, J BIOL CHEM, V276, P30834, DOI 10.1074/jbc.M101013200; Ge YG, 1998, J BACTERIOL, V180, P2418, DOI 10.1128/JB.180.9.2418-2425.1998; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; GUERRY P, 1994, METHOD ENZYMOL, V235, P474; Herrmann JL, 2000, FEBS LETT, V473, P358, DOI 10.1016/S0014-5793(00)01553-2; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; Jennings MP, 1998, MOL MICROBIOL, V29, P975, DOI 10.1046/j.1365-2958.1998.00962.x; Kahler CM, 2001, INFECT IMMUN, V69, P3597, DOI 10.1128/IAI.69.6.3597-3604.2001; Kupce E, 2001, J MAGN RESON, V148, P115, DOI 10.1006/jmre.2000.2224; Kupce E, 1998, J MAGN RESON, V135, P361, DOI 10.1006/jmre.1998.1607; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; Linton D, 2002, MOL MICROBIOL, V43, P497, DOI 10.1046/j.1365-2958.2002.02762.x; LOGAN SM, 1983, INFECT IMMUN, V42, P675, DOI 10.1128/IAI.42.2.675-682.1983; Lu JY, 1996, CARBOHYD RES, V296, P1, DOI 10.1016/S0008-6215(96)00240-6; Marceau M, 1999, J BACTERIOL, V181, P656, DOI 10.1128/JB.181.2.656-661.1999; Moens S, 1997, ARCH MICROBIOL, V168, P169, DOI 10.1007/s002030050484; Molinaro A, 2002, CARBOHYD RES, V337, P467, DOI 10.1016/S0008-6215(02)00004-6; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PEI ZH, 1991, J BIOL CHEM, V266, P16363; Piotto M, 2001, J MAGN RESON, V149, P114, DOI 10.1006/jmre.2001.2287; Power PM, 2000, MICROBIOL-UK, V146, P967, DOI 10.1099/00221287-146-4-967; Rademaker GJ, 1998, ANAL BIOCHEM, V257, P149, DOI 10.1006/abio.1997.2548; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Schaffer C, 2001, EUR J BIOCHEM, V268, P857, DOI 10.1046/j.1432-1327.2001.01961.x; Schaffer C, 2001, PROTEOMICS, V1, P248; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; UHRIN D, 1997, J MAGN RESON, V126, P148; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; Wacker M., 2001, IJMM International Journal of Medical Microbiology, V291, P81; Wyss C, 1998, INFECT IMMUN, V66, P5751, DOI 10.1128/IAI.66.12.5751-5754.1998; YAO RJ, 1994, MOL MICROBIOL, V14, P883, DOI 10.1111/j.1365-2958.1994.tb01324.x; YOUNG NM, 1990, MOL IMMUNOL, V27, P1083, DOI 10.1016/0161-5890(90)90096-I	48	352	380	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42530	42539		10.1074/jbc.M206114200	http://dx.doi.org/10.1074/jbc.M206114200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12186869	hybrid			2022-12-25	WOS:000179081200015
J	Balboa, MA; Balsinde, J				Balboa, MA; Balsinde, J			Involvement of calcium-independent phospholipase A(2) in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE P388D(1) MACROPHAGES; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; PYRROLIDINE INHIBITORS; MEDIATED ACTIVATION; DISTINCT ROLES; CONCANAVALIN-A; PROTEIN-KINASE; RELEASE; ENZYMES	Previous studies have demonstrated that U937 cells are able to mobilize arachidonic acid (AA) and synthesize prostaglandins in response to receptor-directed and soluble stimuli by a mechanism that involves the activation of Group IV cytosolic phospholipase A(2)alpha. In this paper we show that these cells also mobilize AA in response to an oxidative stress induced by H2O2 through a mechanism that appears not to be mediated by cytosolic phospholipase A(2)alpha but by the calcium-independent Group VI phospholipase A(2) (iPLA,). This is supported by the following lines of evidence: (i) the response is essentially calcium-independent, (ii) it is inhibited by bromoenol lactone, and (iii) it is inhibited by an iPLA(2) antisense oligonucleotide. Enzyme assays conducted under a variety of conditions reveal that the specific activity of the iPLA(2) does not change as a result of H2O2 exposure, which argues against the activation of a specific signaling cascade ending in the iPLA(2). Rather, the oxidant acts to perturb membrane homeostasis in a way that the enzyme susceptibility/accessibility to its substrate increases, and this results in altered fatty acid release. In support of this view, not only AA, but also other fatty acids, were found to be liberated in an iPLA(2)-dependent manner in the H2O2-treated cells. Collectively, these studies underscore the importance of the iPLA(2) in modulating homeostatic fatty acid deacylation reactions and document a potentially important route under pathophysiological conditions for increasing free fatty acid levels during oxidative stress.	Univ Valladolid, Sch Med, Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Balsinde, J (corresponding author), Univ Valladolid, Fac Med, CSIC, Inst Biol & Genet Mol,IBGM, Ave Ramon & Cajal 7, E-47005 Valladolid, Spain.		Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BALSINDE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P90, DOI 10.1016/0167-4889(90)90061-H; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V151, P802, DOI 10.1016/S0006-291X(88)80352-8; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BALSINDE J, 2002, IN PRESS FEBS LETT; Birbes H, 2000, BIOCHEM BIOPH RES CO, V276, P613, DOI 10.1006/bbrc.2000.3479; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; CHAKRABORTI S, 1995, CELL SIGNAL, V7, P75, DOI 10.1016/0898-6568(94)00061-F; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; LISTER MD, 1989, J BIOL CHEM, V264, P8520; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Ma ZM, 2002, AM J PHYSIOL-ENDOC M, V282, pE820, DOI 10.1152/ajpendo.00165.2001; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Samanta S, 1998, J NEUROCHEM, V70, P2082; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song JH, 2001, BRAIN RES, V895, P66, DOI 10.1016/S0006-8993(01)02029-7; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4	41	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40384	40389		10.1074/jbc.M206155200	http://dx.doi.org/10.1074/jbc.M206155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181317	hybrid, Green Submitted			2022-12-25	WOS:000178791400030
J	De Antoni, A; Schmitzova, J; Trepte, HH; Gallwitz, D; Albert, S				De Antoni, A; Schmitzova, J; Trepte, HH; Gallwitz, D; Albert, S			Significance of GTP hydrolysis in Ypt1p-regulated endoplasmic reticulum to Golgi transport revealed by the analysis of two novel Ypt1-GAPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; BIOCHEMICAL-CHARACTERIZATION; VESICULAR TRANSPORT; YEAST SUGGESTS; RAB GTPASE; GAP; FUSION; YPT1; IDENTIFICATION; EXPRESSION	We here report on the identification and detailed biochemical characterization of two novel GTPase-activating proteins, Gyp5p and Gyp8p, whose efficient substrate is Ypt1p, a Ypt/Rab-GTPase essential for endoplasmic reticulum-to-Golgi trafficking in yeast. Gyp5p, accelerated the intrinsic GTPase activity of Ypt1p 4.2 X 10(4)-fold and, surprisingly, the 40-fold reduced GTP hydrolysis rate of Ypt1 (Q67L)p 1.5 x 10(4)-fold. At steady state, the two newly discovered GTPase-activating proteins (GAPs) as well as the previously described Gyp1p, which also uses Ypt1p as the preferred substrate, display different sulicellular localization. To add to an understanding of the significance of Ypt1p-bound GTP hydrolysis in vivo, yeast strains expressing the GTPase-deficient Ypt1(Q67L)p and having different Ypt1-GAP genes deleted were created. Depending on the genetic background, different mutants exhibited growth defects at low temperature and, already at permissive temperature, various morphological alterations resembling autophagy. Transport of proteins was not significantly impaired. Growth defects of Ypt1(Q67L)expressing cells could be suppressed on high expression of all three Ypt1-GAPs. We propose that permanently active Ypt1p leads to increased vesicle fusion, which might induce previously unnoticed autophagic degradation of exaggerated membrane-enclosed structures. The data indicate that hydrolysis of Ypt1p-bound GTP is a prerequisite for a balanced vesicle flow between endoplasmic reticulum and Golgi compartments.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Gallwitz, D (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.	dgallwi1@gwdg.de		De Antoni, Anna/0000-0003-4908-1684				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; Albert S, 2000, BIOL CHEM, V381, P453, DOI 10.1515/BC.2000.059; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Du LL, 2001, MOL BIOL CELL, V12, P1215, DOI 10.1091/mbc.12.5.1215; DUGGLEBY RG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P231, DOI 10.1016/0167-4838(91)90007-M; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Li BJ, 1998, YEAST, V14, P915, DOI 10.1002/(SICI)1097-0061(199807)14:10<915::AID-YEA291>3.3.CO;2-P; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Richardson CJ, 1998, MOL CELL BIOL, V18, P827, DOI 10.1128/MCB.18.2.827; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; VOLLMER P, 1995, METHOD ENZYMOL, V257, P118; Vollmer P, 1999, EUR J BIOCHEM, V260, P284, DOI 10.1046/j.1432-1327.1999.00192.x; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Will E, 2001, METHOD ENZYMOL, V329, P50; Will E, 2001, J BIOL CHEM, V276, P12135, DOI 10.1074/jbc.M011451200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	51	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41023	41031		10.1074/jbc.M205783200	http://dx.doi.org/10.1074/jbc.M205783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189143	Green Published, hybrid			2022-12-25	WOS:000178791400111
J	Feng, W; Fan, JS; Jiang, M; Shi, YW; Zhang, M				Feng, W; Fan, JS; Jiang, M; Shi, YW; Zhang, M			PDZ7 of glutamate receptor interacting protein binds to its target via a novel hydrophobic surface area	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTORS; DOMAIN; NMR; RECOGNITION; MEMBRANE; COMPLEX; PROGRAM; ASSOCIATION; LIGANDS; PEPTIDE	Glutamate receptor interacting protein 1 (GRIP1) is a scaffold protein composed of seven PDZ (Postsynaptic synaptic density-95/Discs large Zona occludens-1) domains. The protein plays important roles in the synaptic targeting of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. The interaction between GRIP1 PDZ7 and a Ras guanine nucleotide exchange factor, GRASP-1, regulates synaptic distribution of AMPA receptors. Here, we describe the three-dimensional structure of GRIP1 PDZ7 determined by NMR spectroscopy. GRIP1 PDZ7 contains a closed carboxyl group-binding pocket and a narrow alphaB/betaB-groove that is not likely to bind to classical PDZ ligands. Unexpectedly, GRIP1 PDZ7 contains a large solvent-exposed hydrophobic surface at a site distinct from the conventional ligand-binding alphaB/betaB-groove. NMR titration experiments show that GRIP1 PDZ7 binds to GRASP-1 via this hydrophobic surface. Our data uncover a novel PDZ domain-mediated protein interaction mode that may be responsible for multimerization of other PDZ domain-containing scaffold proteins.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhang, M (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	mzhang@ust.hk	FENG, WEI/C-8966-2012	Zhang, Mingjie/0000-0001-9404-0190; Feng, Wei/0000-0001-9738-9398				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bladt F, 2002, P NATL ACAD SCI USA, V99, P6816, DOI 10.1073/pnas.092130099; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Harris BZ, 2001, J CELL SCI, V114, P3219; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Tochio H, 2000, J MOL BIOL, V303, P359, DOI 10.1006/jmbi.2000.4148; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zhang Q, 2001, J BIOL CHEM, V276, P43216, DOI 10.1074/jbc.M105996200	39	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41140	41146		10.1074/jbc.M207206200	http://dx.doi.org/10.1074/jbc.M207206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12196542	hybrid			2022-12-25	WOS:000178791400124
J	Zolezzi, F; Fuss, J; Uzawa, S; Linn, S				Zolezzi, F; Fuss, J; Uzawa, S; Linn, S			Characterization of a Schizosaccharomyces pombe strain deleted for a sequence homologue of the human damaged DNA binding 1 (DDB1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; FISSION YEAST; CELL-CYCLE; UV DAMAGE; CHROMOSOME SEGREGATION; EXCISION-REPAIR; PROTEIN DDB; CULLIN 4A	Human damaged DNA-binding protein (DDB) is a heterodimer of p48/DDB2 and p127/DDB1 subunits. Mutations in DDB2 are responsible for Xeroderma Pigmentosum group E, but no mutants of mammalian DDB1 have been described. To study DDB1, the Schizosaccharomyces pombe DDB1 sequence homologue (ddb1(+)) was cloned, and a ddb1 deletion strain was constructed. The gene is not essential; however, mutant cells showed a 37% impairment in colony-forming ability, an elongated phenotype, and abnormal nuclei. The ddb1Delta strain was sensitive to UV irradiation, X-rays, methylmethane sulfonate, and thiabendazole, and these sensitivities were compared with those of the well characterized rad13Delta, rhp51Delta, and cds1Delta mutant strains. Ddb1p showed nuclear and nucleolar localization, and the aberrant nuclear structures observed in the ddb1Delta strain suggest a role for Ddb1p in chromosome segregation.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	slinn@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059424] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 08196] Funding Source: Medline; NIGMS NIH HHS [1R01 GM 59424] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1987, CELL, V50, P391, DOI 10.1016/0092-8674(87)90493-4; Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARNITZ JT, 1982, FEBS LETT, V143, P129, DOI 10.1016/0014-5793(82)80288-3; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Butel J S, 1995, Princess Takamatsu Symp, V25, P185; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Edwards RJ, 1997, METHOD ENZYMOL, V283, P471; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; Freeman-Cook LL, 1999, MOL BIOL CELL, V10, P3171, DOI 10.1091/mbc.10.10.3171; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Grewal SIS, 1998, GENETICS, V150, P563; HAGAN IM, 1988, J CELL SCI, V89, P343; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; Humphrey T, 2000, MUTAT RES-FUND MOL M, V451, P211, DOI 10.1016/S0027-5107(00)00051-8; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; Itoh T, 2001, ONCOGENE, V20, P7041, DOI 10.1038/sj.onc.1204909; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; MALESZKA R, 1993, YEAST, V9, P53, DOI 10.1002/yea.320090107; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McCready SJ, 2000, MUTAT RES-FUND MOL M, V451, P197, DOI 10.1016/S0027-5107(00)00050-6; Memisoglu A, 2000, J BACTERIOL, V182, P2104, DOI 10.1128/JB.182.8.2104-2112.2000; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Neuwald AF, 2000, NUCLEIC ACIDS RES, V28, P3570, DOI 10.1093/nar/28.18.3570; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Rhind N, 1998, GENETICS, V149, P1729; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; UZAWA S, 1992, J CELL SCI, V101, P267; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yasuhira S, 1999, J BIOL CHEM, V274, P26822, DOI 10.1074/jbc.274.38.26822; ZHAO YQ, 1995, DNA CELL BIOL, V14, P359, DOI 10.1089/dna.1995.14.359; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	63	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41183	41191		10.1074/jbc.M207890200	http://dx.doi.org/10.1074/jbc.M207890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181326	hybrid			2022-12-25	WOS:000178791400129
J	Mambula, SS; Sau, K; Henneke, P; Golenbock, DT; Levitz, SM				Mambula, SS; Sau, K; Henneke, P; Golenbock, DT; Levitz, SM			Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; TNF-ALPHA; CELL ACTIVATION; CRYPTOCOCCUS-NEOFORMANS; HOST-DEFENSE; LIPOPOLYSACCHARIDE LPS; BACTERIAL LIPOPROTEINS; MYD88-DEFICIENT MICE; BEARING PARTICLES; BINDING-PROTEIN	Aspergillus fumigatus causes life-threatening infections in patients with qualitative and quantitative defects in phagocytic function. Here, we examined the contribution of Toll-like receptor (TLR)-2, TLR4, the adapter protein MyD88, and CD14 to signaling in response to the three forms of A. fumigatus encountered during human disease: resting conidia (RC), swollen conidia (SC), and hyphae (H). Compared with elicited peritoneal macrophages obtained from wild-type and heterozygous mice, TLR2(-/-) and MyD88(-/-) macrophages produced significantly less tumor necrosis factor-alpha (TNFalpha) following A. fumigatus stimulation. In contrast, following stimulation with RC, SC, and H, TLR4(-/-) and CD14(-/-) macrophages exhibited no defects in tumor necrosis factor-alpha release. TLR2(-/-), TLR4(-/-), MyD88(-/-), and CD14(-/-) macrophages bound similar numbers of RC and SC compared with wild-type macrophages. RC, SC, and H stimulated greater activation of a nuclear factor kappaB (NFkappaB)-dependent reporter gene and greater release of tumor necrosis factor-alpha from the human monocytic THP-1 cell line stably transfected with CD14 compared with control cells stably transfected with empty vector. A. fumigatus stimulated NFkappaB-dependent reporter gene activity in the human embryonic kidney cell line, HEK293, only if the cells were transfected with TLR2. Moreover, activity increased when TLR2 and CD14 were co-transfected. Taken together, these data suggest that optimal signaling responses to A. fumigatus require TLR2 in both mouse and human cells. In contrast, a role for CD14 was found only in the human cells. MyD88 acts as a central adapter protein mediating signaling responses following stimulation with RC, SC, and H.	Boston Univ, Sch Med, Evans Mem Dept Clin Res, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Levitz, SM (corresponding author), Boston Med Ctr, Rm X626,650 Albany St, Boston, MA 02118 USA.	slevitz@bu.edu			NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL07501] Funding Source: Medline; NIAID NIH HHS [R01 AI37532, AI-25780, AI-37532] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025780, R01AI037532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Bernheiden M, 2001, J ENDOTOXIN RES, V7, P447, DOI 10.1179/096805101101533061; Brieland JK, 2001, INFECT IMMUN, V69, P1554, DOI 10.1128/IAI.69.3.1554-1560.2001; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Harrison TS, 1997, J INFECT DIS, V176, P485, DOI 10.1086/514068; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; KAN VL, 1988, J INFECT DIS, V158, P407, DOI 10.1093/infdis/158.2.407; KAN VL, 1991, J INFECT DIS, V163, P1154, DOI 10.1093/infdis/163.5.1154; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KOZEL TR, 1989, INFECT IMMUN, V57, P3412, DOI 10.1128/IAI.57.11.3412-3417.1989; Latge JP, 2001, TRENDS MICROBIOL, V9, P382, DOI 10.1016/S0966-842X(01)02104-7; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Levitz S M, 1989, Infect Dis Clin North Am, V3, P1; LEVITZ SM, 1994, INFECT IMMUN, V62, P1975, DOI 10.1128/IAI.62.5.1975-1981.1994; LEVITZ SM, 1991, J CLIN INVEST, V87, P528, DOI 10.1172/JCI115027; LEVITZ SM, 1985, J INFECT DIS, V152, P33, DOI 10.1093/infdis/152.1.33; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Mehrad B, 1999, J IMMUNOL, V162, P1633; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Muzio M, 2000, MICROBES INFECT, V2, P251, DOI 10.1016/S1286-4579(00)00303-8; NEWMAN SL, 1995, J IMMUNOL, V154, P753; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Schelenz S, 1999, MED MYCOL, V37, P183, DOI 10.1046/j.1365-280X.1999.00219.x; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Stevens DA, 2000, CLIN INFECT DIS, V30, P696, DOI 10.1086/313756; Sugawara S, 2001, INFECT IMMUN, V69, P4951, DOI 10.1128/IAI.69.8.4951-4957.2001; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Warris A, 2001, NEW ENGL J MED, V344, P1099, DOI 10.1056/NEJM200104053441415; Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang ZG, 1996, J LEUKOCYTE BIOL, V59, P241, DOI 10.1002/jlb.59.2.241; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	63	244	264	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39320	39326		10.1074/jbc.M201683200	http://dx.doi.org/10.1074/jbc.M201683200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171914	hybrid			2022-12-25	WOS:000178662500035
J	Moore, AL; Roe, MW; Melnick, RF; Lidofsky, SD				Moore, AL; Roe, MW; Melnick, RF; Lidofsky, SD			Calcium mobilization evoked by hepatocellular swelling is linked to activation of phospholipase C gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASES INOSITOL 1,4,5-TRISPHOSPHATE; REGULATORY VOLUME DECREASE; GROWTH-FACTOR RECEPTOR; CELL-VOLUME; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LIVER; TRANSLOCATION; MEMBRANE; RELEASE	Recovery from swelling of hepatocytes and selected other epithelia is triggered by intracellular Ca2+ release from the endoplasmic reticulum, which leads to fluid and electrolyte efflux through volume-sensitive K+ and Cl- channels. The aim of this study was to determine the mechanisms responsible for swelling-mediated hepatocellular Ca2+ mobilization. Swelling of HTC rat hepatoma cells, evoked by exposure to hypotonic medium, elicited transient increases in intracellular levels of inositol 1,4,5-trisphosphate (IP3) and cytosolic [Ca2+]. The latter was attenuated by inhibition of phospholipase C (PLC) with U73122 and by IP3 receptor blockade with 2-aminoethoxydiphenyl borate, but it was unaffected by ryanodine, an inhibitor of intracellular Ca2+-induced Ca2+ release channels. Hypotonic swelling was associated with a transient increase in tyrosine phosphorylation of PLCgamma, with kinetics that paralleled the increases in intracellular IP3 levels and cytosolic [Ca2+]. Confocal imaging of HTC cells exposed to hypotonic medium revealed a swelling-induced association of tyrosine-phosphorylated PLCgamma with the plasma membrane. These findings suggest that activation of PLCgamma by hepatocellular swelling leads to the generation of IP3 and stimulates discharge of Ca2+ from the endoplasmic reticulum via activation of IP3 receptors. By extension, these data support the concept that tyrosine phosphorylation of PLCgamma represents a critical step in adaptive responses to hepatocellular swelling.	Univ Vermont, Coll Med, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05401 USA	University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Coll Med, Dept Med, Burgess 414 MFU, Burlington, VT 05401 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056644, R56DK056644, R29DK047849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK056644, DK047849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1991, FEBS LETT, V278, P103, DOI 10.1016/0014-5793(91)80094-J; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; BERVEN LA, 1995, BIOCHEM PHARMACOL, V49, P1373, DOI 10.1016/0006-2952(95)00050-A; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hirata K, 2002, GASTROENTEROLOGY, V122, P1088, DOI 10.1053/gast.2002.32363; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Leoni S, 2000, MOL CELL BIOCHEM, V204, P41, DOI 10.1023/A:1007053504960; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Missiaen L, 1996, J BIOL CHEM, V271, P4601; MURTHY KS, 1992, J PHARMACOL EXP THER, V260, P90; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; SCHEUER PJ, 1994, LIVER BIOPSY INTERPR, P303; SCHREIBER R, 1995, BIOCHEM J, V309, P19, DOI 10.1042/bj3090019; Shinozuka K, 2001, CLIN EXP PHARMACOL P, V28, P799, DOI 10.1046/j.1440-1681.2001.03525.x; Strassheim D, 2000, J BIOL CHEM, V275, P39767, DOI 10.1074/jbc.M007775200; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241; WILLS EJ, 1976, J CLIN PATHOL, V29, P1, DOI 10.1136/jcp.29.1.1; WONDERGEM R, 1994, ALCOHOL CLIN EXP RES, V18, P1230, DOI 10.1111/j.1530-0277.1994.tb00110.x; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Zhang BH, 1999, BIOCHEM BIOPH RES CO, V257, P89, DOI 10.1006/bbrc.1999.0403; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	38	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34030	34035		10.1074/jbc.M205945200	http://dx.doi.org/10.1074/jbc.M205945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167665	hybrid			2022-12-25	WOS:000177959100068
J	Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E				Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E			Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis	ONCOGENE			English	Article						cathepsin-D; cancer; proliferation; angiogenesis; apoptosis	BREAST-CANCER CELLS; CARCINOMA; GROWTH; METASTASIS; PROTEASE; MATRIX	Cathepsin-D is an independent marker of poor prognosis in human breast cancer. We previously showed that human wild-type cathepsin-D, as well as its mutated form devoid of proteolytic activity stably transfected in 3Y1-Ad12 cancer cells, stimulated tumor growth. To investigate the mechanisms by which human cathepsin-D and its catalytically-inactive counterpart promoted tumor growth in vivo, we quantified the expression of proliferating cell nuclear antigen, the number of blood vessels and of apoptotic cells in M-AM tumor xenografts. We first verified that both human wild-type and mutated cathepsin-D were expressed at a high level in cathepsin-D xenografts, whereas no human cathepsin-D was detected in control xenografts. Our immunohistochemical studies then revealed that both wild-type cathepsin-D and catalytically-inactive cathepsin-D, increased proliferating cell nuclear antigen expression and tumor angiogenesis. Interestingly, wild-type cathepsin-D significantly inhibited tumor apoptosis, whereas catalytically-inactive cathepsin-D did not. We therefore propose that human. cathepsin-D stimulates tumor growth by acting-directly or indirectly-as a mitogenic factor on both cancer and endothelial cells independently of its catalytic activity. Our overall results provide the first mechanistic evidences on the essential role of cathepsin-D at multiple tumor progression steps, affecting cell proliferation, angiogenesis and apoptosis.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France; CHU A Villeneuve, Biol Cellulaire Lab, F-34295 Montpellier 5, France; Ctr Hosp Luxembourg 4, Lab Hemato Cancerol, L-1210 Luxembourg, Luxembourg	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Luxembourg Hospital Center	Liaudet-Coopman, E (corresponding author), Univ Montpellier 1, INSERM, U540, 60 rue Navacelles, F-34090 Montpellier, France.		Berchem, Guy/C-9364-2014; Liaudet-Coopman, Emmanuelle/N-4744-2017	Berchem, Guy/0000-0003-0157-2257; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BARRETT AJ, 1970, BIOCHEM J, V117, P601, DOI 10.1042/bj1170601; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Gonzalez-Vela MC, 1999, HISTOPATHOLOGY, V34, P35; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; Morikawa W, 2000, J BIOL CHEM, V275, P38912, DOI 10.1074/jbc.M005402200; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Tsukuba T, 2000, MOL CELLS, V10, P601, DOI 10.1007/s100590000019; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	24	181	195	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5951	5955		10.1038/sj.onc.1205745	http://dx.doi.org/10.1038/sj.onc.1205745			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185597				2022-12-25	WOS:000177520900017
J	Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA				Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA			A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions	ONCOGENE			English	Article						p53 gene; yeast functional assay; p53 expression; mutational hotspots; enhanced transactivation; Xpc mice	NUCLEOTIDE EXCISION-REPAIR; WILD-TYPE P53; IN-VIVO; HUMAN CANCER; CELL-LINES; IONIZING-RADIATION; GENE-EXPRESSION; TERMINAL DOMAIN; DEFICIENT MICE; BAX PROMOTER	A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122-->L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc-/-) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122-->L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122-->L allele in p53-/- mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122-->L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122-->L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122-->L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122-->L mutant allele in the Xpc-/- background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Dept Pathol, Lab Mol Pathol, SW Med Ctr, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233,Mail Drop D3-01,TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Resnick@NIEHS.NIH.GOV	Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brash DE, 1998, CANCER SURV, V32, P69; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Cheo DL, 2000, CANCER RES, V60, P1580; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCallum DE, 1996, ONCOGENE, V13, P2575; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Rodin SN, 1998, INT J MOL MED, V1, P191; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Takeuchi S, 1998, CANCER RES, V58, P641; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhao RB, 2000, GENE DEV, V14, P981	66	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5704	5715		10.1038/sj.onc.1205779	http://dx.doi.org/10.1038/sj.onc.1205779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173040				2022-12-25	WOS:000177463400005
J	Rush, JS; Cho, SK; Jiang, SM; Hofmann, SL; Waechter, CJ				Rush, JS; Cho, SK; Jiang, SM; Hofmann, SL; Waechter, CJ			Identification and characterization of a cDNA encoding a dolichyl pyrophosphate phosphatase located in the endoplasmic reticulum of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ISOPRENYLTRANSFERASE ACTIVITY; PALMITOYL-PROTEIN THIOESTERASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RAT-LIVER; PIG BRAIN; DIPHOSPHATE PHOSPHATASE; LINKED OLIGOSACCHARIDES; DEVELOPMENTAL-CHANGE; N-GLYCOSYLATION	The CWH8 gene in Saccharomyces cerevisiae has been shown recently (Fernandez, F., Rush, J. S., Toke, D. A., Han, G., Quinn, J. E., Carman, G. M., Choi, J.-Y., Voelker, D. R., Aebi, M., and Waechter, C. J. (2001) J. Biol. Chem. 276, 41455-41464) to encode a dolichyl pyrophosphate (Dol-P-P) phosphatase associated with crude microsomal fractions. Mutations in CWH8 result in the accumulation of Dol-P-P, deficiency in lipid intermediate synthesis, defective protein N-glycosylation, and a reduced growth rate. A cDNA (DOLPP1, GenBank(TM) accession number AB030189) from mouse brain encoding a homologue of the yeast CWH8 gene is now shown to complement the defects in growth and protein N-glycosylation, and to correct the accumulation of Dol-P-P in the cwh8Delta yeast mutant. Northern blot analyses demonstrate a wide distribution of the DOLPP1 mRNA in mouse tissues. Overexpression of Dolpp1p in yeast, COS, and Sf9 cells produces substantial increases in Dol-P-P phosphatase activity but not in dolichyl monophosphate or phosphatidic acid phosphatase activities in microsomal fractions. Subcellular fractionation and immunofluorescence studies localize the enzyme encoded by DOLPP1 to the endoplasmic reticulum of COS cells. The results of protease sensitivity studies with microsomal vesicles from the lpp1Delta/dpp1Delta yeast mutant expressing DOLPP1 are consistent with Dolpp1p having a luminally oriented active site. The sequence of the DOLPP1 cDNA predicts a polypeptide with 238 amino acids, and a new polypeptide corresponding to 27 kDa is observed when DOLPP1 is expressed in yeast, COS, and Sf9 cells. This study is the first identification and characterization of a cDNA clone encoding an essential component of a mammalian lipid pyrophosphate phosphatase that is highly specific for Dol-P-P. The specificity, subcellular location, and topological orientation of the active site described in the current study strongly support a role for Dolpp1p in the recycling of Dol-P-P discharged during protein N-glycosylation reactions on the luminal leaflet of the endoplasmic reticulum in mammalian cells.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Waechter, CJ (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.			Cho, Steve Kyungrae/0000-0001-8547-8430	NIGMS NIH HHS [GM36035] Funding Source: Medline; NINDS NIH HHS [NS35323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAIR WL, 1989, CHEM PHYS LIPIDS, V51, P279, DOI 10.1016/0009-3084(89)90015-7; Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; ALLEN CM, 1978, BIOCHEMISTRY-US, V17, P5020, DOI 10.1021/bi00616a025; APPELKVIST EL, 1981, J BIOCHEM BIOPH METH, V5, P203, DOI 10.1016/0165-022X(81)90045-2; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; BURTON WA, 1979, J BIOL CHEM, V254, P7129; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARSON DD, 1981, J BIOL CHEM, V256, P1552; Cha JH, 2000, J BIOL CHEM, V275, P6901, DOI 10.1074/jbc.275.10.6901; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Frank DW, 1998, J BIOL CHEM, V273, P11791, DOI 10.1074/jbc.273.19.11791; Freeze HH, 2001, BIOCHIMIE, V83, P791, DOI 10.1016/S0300-9084(01)01292-5; Freeze HH, 2001, SEMIN LIVER DIS, V21, P501, DOI 10.1055/s-2001-19031; FREEZE HH, 2001, GLYCOBIOLOGY, V11, pR1; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; HARFORD JB, 1980, BIOCHEM J, V188, P481, DOI 10.1042/bj1880481; HARFORD JB, 1977, BIOCHEM BIOPH RES CO, V76, P1036, DOI 10.1016/0006-291X(77)90960-3; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P102; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; IDOYAGAVARGAS V, 1980, FEBS LETT, V112, P63, DOI 10.1016/0014-5793(80)80128-1; Inoue S, 2000, BIOCHEM BIOPH RES CO, V268, P553, DOI 10.1006/bbrc.2000.2170; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; RIP JW, 1981, J BIOL CHEM, V256, P1929; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; Rush JS, 1998, GLYCOBIOLOGY, V8, P1207, DOI 10.1093/glycob/8.12.1207; RUSH JS, 2000, GLYCOBIOLOGY, V94, P1067; Sambrook J., 2002, MOL CLONING LAB MANU; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SCHER MG, 1984, ARCH BIOCHEM BIOPHYS, V231, P293, DOI 10.1016/0003-9861(84)90391-6; SCHER MG, 1984, J BIOL CHEM, V259, P4580; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; Stukey J, 1997, PROTEIN SCI, V6, P469; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; van Berkel MAA, 1999, GLYCOBIOLOGY, V9, P243, DOI 10.1093/glycob/9.3.243; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; WEDGWOOD JF, 1980, J BIOL CHEM, V255, P1120; WOLF M J, 1991, Glycobiology, V1, P405, DOI 10.1093/glycob/1.4.405; [No title captured]	56	38	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45226	45234		10.1074/jbc.M207076200	http://dx.doi.org/10.1074/jbc.M207076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12198133	hybrid			2022-12-25	WOS:000179404800082
J	Grun, F; Venkatesan, RN; Tabb, MM; Zhou, CC; Cao, JR; Hemmati, D; Blumberg, B				Grun, F; Venkatesan, RN; Tabb, MM; Zhou, CC; Cao, JR; Hemmati, D; Blumberg, B			Benzoate X receptors alpha and beta are pharmacologically distinct and do not function as xenobiotic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; SIGNALING PATHWAY; XENOPUS; SXR; PHYSIOLOGY; INHIBITOR; DEFINES; LIGANDS; BXR	The Xenopus benzoate nuclear hormone receptors, BXRalpha and BXRbeta, share 82% identity within their ligand-binding domains and are classified as members of the NR1I2 subfamily that includes the mammalian steroid and xenobiotic receptor, SXP/PXR. Although alkyl benzoates have been identified as endogenous ligands, the exact role of the benzoate receptors in amphibian physiology has not been established. In this report, we show that BXRalpha and BXRbeta are pharmacologically distinct from each other: BXRa is more promiscuous than BXRbeta with respect to both ligand specificity and co-activator recruitment. BXRalpha can be transactivated by a number of benzoate derivatives including 4-amino-butylbenzoate (4-ABB), 4-hydroxy-butylbenzoate (4-HBB), 3-hydroxy ethyl benzoate (3-HEB), and benzyl benzoate, but only 4-HBB acts as an agonist for both receptors. Furthermore, BXRalpha-specific agonists such as 4-ABB, chlorpyrifos, and trifluralin act as antagonists on BXRbeta. BXRs are widely distributed in adult tissues but do not show any enrichment in liver and intestine, major sites of SXR/PXR expression that are critical in xenobiotic metabolism. Neither BXR shows the broad specificity toward steroids or xenobiotics exhibited by SXR/PXR. Therefore, we conclude that the BXRs are pharmacologically distinct from each other and unlikely to serve as xenobiotic sensors.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Blumberg, B (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5205 McGaugh Hall,Rm 5205, Irvine, CA 92697 USA.		Grun, Felix/C-8271-2011; Cao, Junran/E-7354-2013	Zhou, Changcheng/0000-0001-7649-0710	NIGMS NIH HHS [GM60572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060572] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P1269, DOI 10.1101/gad.12.9.1269; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; HUGHES MK, 1993, MOL BIOL EVOL, V10, P1360; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Koide T, 2001, GENE DEV, V15, P2111, DOI 10.1101/gad.908801; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Nishikawa J, 2000, BIOCHEM BIOPH RES CO, V277, P209, DOI 10.1006/bbrc.2000.3649; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; 1999, NUCL RECEPTOR NOMENC, V97, P161	25	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43691	43697		10.1074/jbc.M206553200	http://dx.doi.org/10.1074/jbc.M206553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12198127	hybrid			2022-12-25	WOS:000179272000021
J	Du, J; Stankiewicz, MJ; Liu, Y; Xi, Q; Schmitz, JE; Lekstrom-Himes, JA; Ackerman, SJ				Du, J; Stankiewicz, MJ; Liu, Y; Xi, Q; Schmitz, JE; Lekstrom-Himes, JA; Ackerman, SJ			Novel combinatorial interactions of GATA-1, PU.1, and C/EBP epsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ENHANCER-BINDING-PROTEIN; DNA-BINDING; LINEAGE COMMITMENT; GRANULOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; RESTRICTED EXPRESSION; TARGETED DISRUPTION; MYELOID DEVELOPMENT; INHIBITOR DOMAIN; CELL-LINES	GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; NIH, Host Def Lab, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA	Ackerman, SJ (corresponding author), Univ Illinois, Coll Med W, Dept Biochem & Mol Biol, MC536,A-312,1819 W Polk St, Chicago, IL 60612 USA.	sackerma@uic.edu			NIAID NIH HHS [AI33043] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033043] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackerman SJ, 2000, RESP MED, V94, P1135, DOI 10.1053/rmed.2000.0913; ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Baltus B, 1999, J LEUKOCYTE BIOL, V66, P683, DOI 10.1002/jlb.66.4.683; Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; GRUART V, 1992, BLOOD, V79, P2592; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2413, DOI 10.1101/gad.12.15.2413; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Onodera K, 1997, J BIOCHEM, V121, P251; ORKIN SH, 1992, BLOOD, V80, P575; Osada S, 1996, J BIOL CHEM, V271, P3891; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Paul CC, 1997, AM J HEMATOL, V56, P79, DOI 10.1002/(SICI)1096-8652(199710)56:2<79::AID-AJH2>3.0.CO;2-Y; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Sun Z, 1996, CURR TOP MICROBIOL, V211, P173; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang JG, 2001, J BIOL CHEM, V276, P17739, DOI 10.1074/jbc.M011546200; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; van Dijk TB, 1998, BLOOD, V91, P2126, DOI 10.1182/blood.V91.6.2126.2126_2126_2132; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; Vyas P, 1999, BLOOD, V93, P2867; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WASMOEN TL, 1989, J EXP MED, V170, P2051, DOI 10.1084/jem.170.6.2051; WASMOEN TL, 1987, P NATL ACAD SCI USA, V84, P3029, DOI 10.1073/pnas.84.9.3029; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamaguchi Y, 1998, BLOOD, V91, P3447, DOI 10.1182/blood.V91.9.3447.3447_3447_3458; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang D, 2000, J BIOL CHEM, V275, P9425, DOI 10.1074/jbc.275.13.9425; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zimmermann N, 2000, J IMMUNOL, V164, P1055, DOI 10.4049/jimmunol.164.2.1055; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1993, BLOOD, V81, P3234	106	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43481	43494		10.1074/jbc.M204777200	http://dx.doi.org/10.1074/jbc.M204777200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202480	hybrid			2022-12-25	WOS:000179081200133
J	Bian, X; Opipari, AW; Ratanaproeksa, AB; Boitano, AE; Lucas, PC; Castle, VP				Bian, X; Opipari, AW; Ratanaproeksa, AB; Boitano, AE; Lucas, PC; Castle, VP			Constitutively active NF kappa B is required for the survival of S-type neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ACTIVATION; ALPHA; GROWTH; TUMOR; PROTEIN; DEATH; IKK	The NFkappaB transcription factors can both promote cell survival and induce apoptosis depending on cell type and context. Neuroblastoma (NB) cells display two predominant culture phenotypes identified as N- and S-types. Malignant S-type cells express neither high levels of MYCN nor Bcl-2, suggesting that other survival mechanisms are important. We characterized NFkappaB activity in S-type cells and determined its role in their survival. S-type lines (SH-EP1 and SK-N-AS) were treated with pyrrolidine dithiocarbamate (PDTC), a NFkappaB inhibitor, or L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK), a serine protease inhibitor that blocks IkappaBalpha degradation. Both agents induced cell death, suggesting that constitutive NFkappaB activity is required for survival. The transient expression of a super-repressor IkappaBalpha mutant killed S-type cells. The inhibition of NFkappaB produced an apoptotic response characterized by the collapse of the mitochondrial transmembrane electrochemical gradient, caspase-9 activation, and apoptotic DNA changes. Constitutive NFkappaB DNA binding activity specifically involving p65 and p50 was demonstrated in S- but not N-type cells by electromobility supershift and gene reporter assays. This study demonstrates a role for NFkappaB in the survival of S-type NB tumor cells and suggests that NFkappaB activity and function differ according to NB tumor cell phenotype.	Univ Michigan, Ctr Comprehens Canc, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Castle, VP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Pediat, Rm 4302,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	vcastle@umich.edu		Lucas, Peter/0000-0003-4880-7172	NCI NIH HHS [CA697276-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOLIVAR R, 1980, CANCER, V46, P1555, DOI 10.1002/1097-0142(19801001)46:7<1555::AID-CNCR2820460710>3.0.CO;2-4; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen SH, 2000, AM J PATHOL, V156, P1085, DOI 10.1016/S0002-9440(10)64976-0; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Devalaraja MN, 1999, CANCER RES, V59, P1372; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DOLE MG, 1995, CANCER RES, V55, P2576; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Gasparian AV, 2002, J CELL SCI, V115, P141; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mora J, 2001, CANCER RES, V61, P6892; OGITA S, 1988, ONCOLOGY, V45, P117, DOI 10.1159/000226544; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Piacentini M, 1996, J PATHOL, V180, P415, DOI 10.1002/(SICI)1096-9896(199612)180:4<415::AID-PATH684>3.0.CO;2-A; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REDDY UR, 1991, J NEUROCHEM, V56, P67, DOI 10.1111/j.1471-4159.1991.tb02563.x; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAXEN L, 1960, CANCER, V13, P899, DOI 10.1002/1097-0142(196009/10)13:5<899::AID-CNCR2820130506>3.0.CO;2-U; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shimada H, 2000, NEUROBLASTOMA, P341; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42144	42150		10.1074/jbc.M203891200	http://dx.doi.org/10.1074/jbc.M203891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198114	hybrid			2022-12-25	WOS:000178985300106
J	Gajate, C; An, FY; Mollinedo, F				Gajate, C; An, FY; Mollinedo, F			Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells - Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN LEUKEMIC-CELLS; ANTITUMOR-ACTIVITY; MINOR-GROOVE; SELECTIVE INDUCTION; ANTICANCER DRUG; TOPOISOMERASE-I; HUMAN PLASMA; DNA	We have found that ecteinascidin-743 (ET-743) inhibited cell proliferation at 1-10 ng/ml, leading to S and G(2)/M arrest and subsequent apoptosis, and induced early apoptosis without previous cell cycle arrest at 10-100 ng/ml in cancer cells. ET-743-mediated apoptosis, did not involve Fas/CD95. ET-743 induced c-Jun NH2-terminal kinase (JNK) and caspase-3 activation, and JNK and caspase inhibition prevented ET-743-induced apoptosis. ET-743 failed to promote apoptosis in caspase-3-deficient MCF-7 cells, further implicating caspase-3 in its proapoptotic action. Overexpression of bcl-2 by gene transfer abrogated ET-743-induced apoptosis, but cells underwent cell cycle arrest. ET-743 triggered cytochrome c release from mitochondria that was inhibited by Bcl-2 overexpression. Inhibition of transcription or protein synthesis did not prevent ET-743-induced apoptosis, but abrogated ET-743-induced cell cycle arrest. Microarray analyses revealed changes in the expression of a small number of cell cycle-related genes (p21, GADD45A, cyclin G2, MCM5, and histones) that suggested their putative involvement in ET-743-induced cell cycle arrest. These data indicate that ET-743 is a very potent anticancer drug showing dose-dependent cytostatic and proapoptotic effects through activation of two different signaling pathways, namely a transcription-dependent pathway leading to cell cycle arrest and a transcription-independent route leading to rapid apoptosis that involves mitochondria, JNK, and caspase-3.	Univ Salamanca, Consejo Super Invest, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Consejo Super Invest, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.			Gajate, Consuelo/0000-0003-0604-6459				Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Erba E, 2001, EUR J CANCER, V37, P97, DOI 10.1016/S0959-8049(00)00357-9; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; GarciaRocha M, 1996, BRIT J CANCER, V73, P875, DOI 10.1038/bjc.1996.176; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hendriks HR, 1999, ANN ONCOL, V10, P1233, DOI 10.1023/A:1008364727071; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Ishikawa Y, 2000, KIDNEY INT, V58, P1078, DOI 10.1046/j.1523-1755.2000.00265.x; Izbicka E, 1998, ANN ONCOL, V9, P981, DOI 10.1023/A:1008224322396; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jimeno Jose M., 1996, Drugs of the Future, V21, P1155; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li WW, 2001, CLIN CANCER RES, V7, P2908; Liang DT, 1999, J CELL SCI, V112, P559; Martinez EJ, 2001, CHEM BIOL, V8, P1151, DOI 10.1016/S1074-5521(01)00082-5; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 1998, ANIMAL CELL CULTURE TECHNIQUES, P264; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; Moore BM, 1997, J AM CHEM SOC, V119, P5475, DOI 10.1021/ja9704500; Moragoda L, 2001, ANTICANCER RES, V21, P873; Morin D, 2001, FEBS LETT, V495, P131, DOI 10.1016/S0014-5793(01)02376-6; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Piwocka K, 2001, FREE RADICAL BIO MED, V31, P670, DOI 10.1016/S0891-5849(01)00629-3; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; RINEHART KL, 1990, J ORG CHEM, V55, P4512, DOI 10.1021/jo00302a007; Rosing H, 1998, J CHROMATOGR B, V710, P183, DOI 10.1016/S0378-4347(98)00143-1; Rosing H, 1998, J MASS SPECTROM, V33, P1134, DOI 10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S; Takahashi N, 2001, CLIN CANCER RES, V7, P3251; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takebayashi Y, 2001, CLIN CANCER RES, V7, P185; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l	55	74	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41580	41589		10.1074/jbc.M204644200	http://dx.doi.org/10.1074/jbc.M204644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198119	hybrid, Green Published			2022-12-25	WOS:000178985300037
J	Hibino, T; Waditee, R; Araki, E; Ishikawa, H; Aoki, K; Tanaka, Y; Takabe, T				Hibino, T; Waditee, R; Araki, E; Ishikawa, H; Aoki, K; Tanaka, Y; Takabe, T			Functional characterization of choline monooxygenase, an enzyme for betaine synthesis in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE BETAINE; ALDEHYDE DEHYDROGENASE; ENHANCED TOLERANCE; ESCHERICHIA-COLI; STRESS TOLERANCE; SALT STRESS; GENE; IDENTIFICATION; OXIDASE; OVEREXPRESSION	In plants, the first step in betaine synthesis was shown to be catalyzed by a novel Rieske-type iron-sulfur enzyme, choline monooxygenase (CMO). Although CMO so far has been found only in Chenopodiaceae and Amaranthaceae, the recent genome sequence suggests the presence of a CMO-Iike gene in Arabidopsis, a betaine non-accumulating plant. Here, we examined the functional properties of CMO expressed in Escherichia coli, cyanobacterium, and Arabidopsis thaliana. We found that E. coli cells in which choline dehydrogenase (CDH) was replaced with spinach CMO accumulate betaine and complement the salt-sensitive phenotype of the CDH-deleted E. coli mutant. Changes of Cys-181 in spinach CMO to Ser, Thr, and Ala and His-287 to Gly, Val, and Ala abolished the accumulation of betaine. The Arabidopsis CMO-like gene was transcribed in Arabidopsis, but its protein was not detected. When the Arabidopsis CMO-like gene was expressed in E. coli, the protein was detected but was found not to promote betaine sysnthesis. Overexpression of spinach CMO in E. coli, Synechococcus sp. PCC7942, and Arabidopsis conferred resistance to abiotic stress. These facts clearly indicate that CMO, but not the CMO-Iike protein, could oxidize choline and that Cys-181 and His-287 are involved in the binding of Fe-S cluster and Fe, respectively.	Meijo Univ, Inst Res, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Grad Sch Environm & Human Sci, Nagoya, Aichi 4688502, Japan	Meijo University; Meijo University	Takabe, T (corresponding author), Meijo Univ, Inst Res, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@ccmfs.meijo-u.ac.jp						Boch J, 1996, J BACTERIOL, V178, P5121, DOI 10.1128/jb.178.17.5121-5129.1996; BURNET M, 1995, PLANT PHYSIOL, V108, P581, DOI 10.1104/pp.108.2.581; Butler CS, 1997, ADV MICROB PHYSIOL, V38, P47; Carredano E, 2000, J MOL BIOL, V296, P701, DOI 10.1006/jmbi.1999.3462; CHERN MK, 1995, BIOCHEM BIOPH RES CO, V213, P561, DOI 10.1006/bbrc.1995.2168; Deshnium P, 1995, PLANT MOL BIOL, V29, P897, DOI 10.1007/BF00014964; FALKENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1034, P253, DOI 10.1016/0304-4165(90)90046-Y; Hayashi H, 1997, PLANT J, V12, P133, DOI 10.1046/j.1365-313X.1997.12010133.x; Hibino T, 2001, PLANT MOL BIOL, V45, P353, DOI 10.1023/A:1006497113323; Holmstrom KO, 2000, J EXP BOT, V51, P177, DOI 10.1093/jexbot/51.343.177; Hoshida H, 2000, PLANT MOL BIOL, V43, P103, DOI 10.1023/A:1006408712416; Huang J, 2000, PLANT PHYSIOL, V122, P747, DOI 10.1104/pp.122.3.747; Incharoensakdi A, 2000, EUR J BIOCHEM, V267, P7015, DOI 10.1046/j.1432-1327.2000.01797.x; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; Lee BH, 1997, PLANT MOL BIOL, V35, P763, DOI 10.1023/A:1005867420619; Lilius G, 1996, BIO-TECHNOL, V14, P177, DOI 10.1038/nbt0296-177; McNeil SD, 2000, PLANT PHYSIOL, V124, P153, DOI 10.1104/pp.124.1.153; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; Nakamura T, 1997, PLANT J, V11, P1115, DOI 10.1046/j.1365-313X.1997.11051115.x; NOMURA M, 1995, PLANT PHYSIOL, V107, P703, DOI 10.1104/pp.107.3.703; Nuccio ML, 2000, METAB ENG, V2, P300, DOI 10.1006/mben.2000.0158; Nuccio ML, 1998, PLANT J, V16, P487, DOI 10.1046/j.1365-313x.1998.00316.x; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; RHODES D, 1987, PLANT PHYSIOL, V84, P781, DOI 10.1104/pp.84.3.781; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Russell BL, 1998, PLANT PHYSIOL, V116, P859, DOI 10.1104/pp.116.2.859; TA DT, 1992, J BIOL CHEM, V267, P11120; Takabe T, 1998, STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, P115; Waditee R, 2002, P NATL ACAD SCI USA, V99, P4109, DOI 10.1073/pnas.052576899; Wang YM, 1999, PLANT CELL PHYSIOL, V40, P668, DOI 10.1093/oxfordjournals.pcp.a029591; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; Wolfe MD, 2001, J BIOL CHEM, V276, P1945, DOI 10.1074/jbc.M007795200; YAMADA H, 1979, AGR BIOL CHEM TOKYO, V43, P2173, DOI 10.1080/00021369.1979.10863769; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	36	58	61	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41352	41360		10.1074/jbc.M205965200	http://dx.doi.org/10.1074/jbc.M205965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12192001	hybrid			2022-12-25	WOS:000178985300010
J	Johnston, AJ; Hoogenraad, J; Dougan, DA; Truscott, KN; Yano, M; Mori, M; Hoogenraad, NJ; Ryan, MT				Johnston, AJ; Hoogenraad, J; Dougan, DA; Truscott, KN; Yano, M; Mori, M; Hoogenraad, NJ; Ryan, MT			Insertion and assembly of human Tom7 into the preprotein translocase complex of the outer mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT RECEPTOR; FUNCTIONAL-ANALYSIS; BIOGENESIS; PRECURSOR; CHANNEL; COMPONENT; PATHWAY; PORE; ELECTROPHORESIS; IDENTIFICATION	Tom7 is a component of the translocase of the outer mitochondrial membrane (TOM) and assembles into a general import pore complex that translocates preproteins into mitochondria. We have identified the human Tom7 homolog and characterized its import and assembly into the mammalian TOM complex. Tom7 is imported into mitochondria in a nucleotide-independent manner and is anchored to the outer membrane with its C terminus facing the intermembrane space. Unlike studies in fungi, we found that human Tom7 assembles into an similar to120-kDa import intermediate in HeLa cell mitochondria. To detect subunits within this complex, we employed a novel supershift analysis whereby mitochondria containing newly imported Tom7 were incubated with antibodies specific for individual TOM components prior to separation by blue native electrophoresis. We found that the 120-kDa complex contains Tom40 and lacks receptor components. This intermediate can be chased to the stable similar to380-kDa mammalian TOM complex that additionally contains Tom22. Overexpression of Tom22 in HeLa cells results in the rapid assembly of Tom7 into the 380-kDa complex indicating that Tom22 is rate-limiting for TOM complex formation. These results indicate that the levels of Tom22 within mitochondria dictate the assembly of TOM complexes and hence may regulate its biogenesis.	La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	La Trobe University; Kumamoto University	Ryan, MT (corresponding author), La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia.	M.Ryan@latrobe.edu.au	dougan, david/B-3359-2010; Hoogenraad, Nicholas J/C-7505-2011; Ryan, Michael/X-2152-2019; Ryan, Michael T/C-6673-2011; Truscott, Kaye/D-3362-2012	dougan, david/0000-0001-9313-1904; Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; Johnston, Amelia/0000-0003-4289-3516; Truscott, Kaye/0000-0002-5352-9835				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; ARGAN C, 1983, J BIOL CHEM, V258, P6667; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; GOPING IS, 1995, FEBS LETT, V373, P45; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARLOW E, 1999, USING ANTIBODIES LAB, P286; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Hoogenraad NJ, 2001, IUBMB LIFE, V51, P345; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; KEIL P, 1993, J BIOL CHEM, V268, P19177; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; Kunkele KP, 1998, J BIOL CHEM, V273, P31032, DOI 10.1074/jbc.273.47.31032; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nuttall SD, 1997, DNA CELL BIOL, V16, P1067, DOI 10.1089/dna.1997.16.1067; PERALTA D, 1993, EUR J BIOCHEM, V211, P881, DOI 10.1111/j.1432-1033.1993.tb17621.x; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Ryan MT, 2002, ADV PROTEIN CHEM, V59, P223; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; SIKORSKI RS, 1989, GENETICS, V122, P19; Suzuki H, 2002, J CELL SCI, V115, P1895; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Terada K, 1996, MOL CELL BIOL, V16, P6103; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000	52	101	105	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42197	42204		10.1074/jbc.M205613200	http://dx.doi.org/10.1074/jbc.M205613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12198123	hybrid			2022-12-25	WOS:000178985300113
J	Kloek, C; Haq, AK; Dunn, SL; Lavery, HJ; Banks, AS; Myers, MG				Kloek, C; Haq, AK; Dunn, SL; Lavery, HJ; Banks, AS; Myers, MG			Regulation of Jak kinases by intracellular leptin receptor sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; OB-R; ERYTHROPOIETIN RECEPTOR; CYTOPLASMIC DOMAINS; CYTOKINE RECEPTORS; ALPHA-INTERFERON; ACTIVATION; INTERLEUKIN-6; EXPRESSION; NEURONS	Leptin signals the status of body energy stores via the leptin receptor (LR), a member of the Type I cytokine receptor family. Type I cytokine receptors mediate intracellular signaling via the activation of associated Jak family tyrosine kinases. Although their COOH-terminal sequences vary, alternatively spliced LR isoforms (LRa-LRd) share common NH2-terminal sequences, including the first 29 intracellular amino acids. The so-called long form LR (LRb) activates Jak-dependent signaling and is required for the physiologic actions of leptin. In this study, we have analyzed Jak activation by intracellular LR sequences under the control of the extracellular erythropoeitin (Epo) (Epo receptor/LRb chimeras). We show that Jak2 is the requisite Jak kinase for signaling by the LRb intracellular domain and confirm the requirement for the Box 1 motif for Jak2 activation. A minimal LRb intracellular domain for Jak2 activation includes intracellular amino acids 31-48. Although the sequence requirements for intracellular amino acids 37-48 are flexible, intracellular amino acids 31-36 of LRb play a critical role in Jak2 activation and contain a loose homology motif found in other Jak2-activating cytokine receptors. The failure of short form sequences to function in Jak2 activation reflects the absence of this motif.	Joslin Diabet Ctr, Div Res, Sect Obes, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, Sect Obes, 1 Joslin Pl, Boston, MA 02215 USA.		Banks, Alexander/B-4832-2012	Banks, Alexander/0000-0003-1787-6925	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK056731, R01DK056731] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56731] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahrenberg G, 2002, MOL ENDOCRINOL, V16, P859, DOI 10.1210/me.16.4.859; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Yan H, 1996, MOL CELL BIOL, V16, P2074; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	33	170	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41547	41555		10.1074/jbc.M205148200	http://dx.doi.org/10.1074/jbc.M205148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196522	hybrid			2022-12-25	WOS:000178985300033
J	Warner, JB; Thalhauser, C; Tao, K; Sahagian, GG				Warner, JB; Thalhauser, C; Tao, K; Sahagian, GG			Role of N-linked oligosaccharide flexibility in mannose phosphorylation of lysosomal enzyme cathepsin L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RECOGNITION DETERMINANTS; LYSINE-BASED STRUCTURE; PROCATHEPSIN-D; DNASE-I; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; IDENTIFICATION; CELLS; PROREGION; RESIDUES; SUBUNIT	Mannose phosphorylation of N-linked oligosaccharides by UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase is a key step in the targeting of lysosomal enzymes in mammalian cells and tissues. The selectivity of this process is determined by lysine-based phosphorylation signals shared by lysosomal enzymes of diverse structure and function. By introducing new glycosylation sites at several locations on the surface of mouse procathepsin L and modeling oligosaccharide conformations for sites that are phosphorylated, it was shown that the inherent flexibility of N-linked oligosaccharides can account for the specificity of the transferase for oligosaccharides at different locations on the protein. By using this approach, the physical relationship between the lysine-based signal and the site of phosphorylation of mannose residues was determined. The analysis also revealed the existence of additional independent lysine-based phosphorylation signals on procathepsin L, which account for the low level of phosphorylation observed when the primary Lys-54/Lys-99 signal is ablated. Mutagenesis of residues that surround Lys-54 and Lys-99 and demonstration of mannose phosphorylation of a glycosylated derivative of green fluorescent protein provide strong evidence that the cathepsin L phosphorylation signal is a simple structure composed of as few as two well placed lysine residues.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NCI NIH HHS [CA66575] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066575] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6664, DOI 10.1021/bi00395a016; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DONG JM, 1989, J BIOL CHEM, V264, P7377; Gonzalez L, 2000, ARCH BIOCHEM BIOPHYS, V383, P17, DOI 10.1006/abbi.2000.2031; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; Jimenez-Barbero J, 1999, CURR OPIN STRUC BIOL, V9, P549, DOI 10.1016/S0959-440X(99)00004-4; KANE SE, 1993, J BIOL CHEM, V268, P11456; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; NATOWICZ M, 1982, J BIOL CHEM, V257, P4412; Nishikawa A, 1999, J BIOL CHEM, V274, P19309, DOI 10.1074/jbc.274.27.19309; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; VARKI A, 1980, J BIOL CHEM, V255, P8398; VARKI A, 1980, J BIOL CHEM, V255, P847	29	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41897	41905		10.1074/jbc.M203097200	http://dx.doi.org/10.1074/jbc.M203097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202476	hybrid			2022-12-25	WOS:000178985300077
J	Yin, XM; Luo, YM; Cao, GD; Bai, L; Pei, W; Kuharsky, DK; Chen, J				Yin, XM; Luo, YM; Cao, GD; Bai, L; Pei, W; Kuharsky, DK; Chen, J			Bid-mediated mitochondrial pathway is critical to ischemic neuronal apoptosis and focal cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY PROTEINS; DELAYED CELL-DEATH; DNA FRAGMENTATION; ARTERY OCCLUSION; CEREBROVASCULAR ANATOMY; FOREBRAIN ISCHEMIA; MESSENGER-RNA; BRAIN-DAMAGE; FAS ANTIGEN	We have investigated the role of the BH3-only pro-death Bcl-2 family protein, Bid, in ischemic neuronal death in a murine focal cerebral ischemia model. Wildtype and bid-deficient mice of inbred C57BL/6 background were subjected to 90-min ischemia induced by left middle cerebral artery occlusion followed by 72-h reperfusion. The volume of ischemic infarct was significantly smaller in the bid-deficient brains than in the wild-type brains, suggesting that Bid participated in the ischemic neuronal death. Indeed, following the ischemic treatment there was a significant reduction of apoptosis in the ischemic areas, particularly in the inner infarct border zone (the penumbra), of the bid-deficient brains. In addition, activation of Bid in the wild-type brains could be readily detected at similar to3 h after ischemia, as evidenced by its proteolytic cleavage and translocation to the mitochondria as determined using Western blot analysis and immunofluorescence staining. Correspondingly, mitochondrial release of cytochrome c could be detected around the same time Bid was cleaved in the wild-type brains. However, no significant cytochrome c release was detected in the bid-deficient brains until 24 h later. This suggests that, although the mitochondrial apoptosis pathway might be activated by multiple mechanisms during focal cerebral ischemia, Bid is critical to its early activation. This notion was further supported by the finding that caspase-3 activation was severely impaired in the bid-deficient brains, whereas activation of caspase-8 was much less affected. Taken together, these data suggest that Bid is activated early in neuronal ischemia in a caspase-8-dependent fashion and that Bid is perhaps one of the earliest and most potent activators of the mitochondrial apoptosis pathway. Thus, the role of Bid in the induction of ischemic neuronal death may render this molecule an attractive target for future therapeutic intervention.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.			Chen, Jun/0000-0002-8077-3403	NATIONAL CANCER INSTITUTE [K01CA074885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965, R01NS038560] Funding Source: NIH RePORTER; NCI NIH HHS [CA74885] Funding Source: Medline; NINDS NIH HHS [NS 35965, NS38560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Araki T, 1998, BRAIN RES, V794, P239, DOI 10.1016/S0006-8993(98)00231-5; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Kondo T, 1997, J NEUROSCI, V17, P4180; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; LI Y, 1995, AM J PATHOL, V146, P1045; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Maeda K, 1998, NEUROREPORT, V9, P1317, DOI 10.1097/00001756-199805110-00012; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; Morita-Fujimura Y, 2001, STROKE, V32, P2356, DOI 10.1161/hs1001.097241; Murakami K, 1998, J NEUROSCI, V18, P205; Nakashima K, 1999, J NEUROTRAUM, V16, P143, DOI 10.1089/neu.1999.16.143; Namura S, 1998, J NEUROSCI, V18, P3659; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Van Loo G, 2002, CELL DEATH DIFFER, V9, P301, DOI 10.1038/sj.cdd.4400966; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	61	102	108	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42074	42081		10.1074/jbc.M204991200	http://dx.doi.org/10.1074/jbc.M204991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200426	hybrid			2022-12-25	WOS:000178985300097
J	Erwert, RD; Winn, RK; Harlan, JM; Bannerman, DD				Erwert, RD; Winn, RK; Harlan, JM; Bannerman, DD			Shiga-like toxin inhibition of FLICE-like inhibitory protein expression sensitizes endothelial cells to bacterial lipopolysaccharide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; TUMOR-NECROSIS-FACTOR; ESCHERICHIA-COLI O157-H7; MULTIPLE ORGAN FAILURE; FACTOR-ALPHA; LUNG INJURY; HEMORRHAGIC COLITIS; DEPENDENT PATHWAY; CASPASE INHIBITOR; GENE-EXPRESSION	Shiga-like toxin (SLT) has been implicated in the pathogenesis of hemolytic uremic syndrome and its attendant endothelial cell (EC) injury. Key serotypes of Escherichia coli produce SLT-1 in addition to another highly pro-inflammatory molecule, lipopolysaccharide (LPS). It has previously been established that SLT-1 induces EC apoptosis and that LPS enhances this effect. LPS alone has no affect on human EC viability, and the mechanism for this enhancement remains unknown. In the present report, we demonstrate that SLT-1 sensitizes EC to LPS-induced apoptosis. Pretreatment with SLT-1 sensitized EC to LPS-induced apoptosis, whereas pretreatment with LPS did not influence SLT-1-induced apoptosis. SLT-1 exposure resulted in decreased expression of FLICE-like inhibitory protein (FLIP), an antiapoptotic protein that has previously been shown to block LPS-induced apoptosis. This SLT-1-mediated decrease in FLIP expression preceded the onset of apoptosis elicited by SLT-1 alone or in combination with LPS. SLT-1-mediated decrements in FLIP expression correlated in a dose- and time-dependent manner with sensitization to LPS-induced apoptosis. Finally, transient or stable overexpression of FLIP protected against LPS enhancement of SLT-1-induced apoptosis, and this protection corresponded with sustained expression of FLIP. Together, these data suggest that SLT-1 sensitizes EC to LPS-induced apoptosis by inhibiting FLIP expression.	ARS, Immunol & Dis Resistance Lab, USDA, ANRI,BARC E, Beltsville, MD 20705 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98104 USA	United States Department of Agriculture (USDA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bannerman, DD (corresponding author), ARS, Immunol & Dis Resistance Lab, USDA, ANRI,BARC E, Bldg 1040,Rm 2, Beltsville, MD 20705 USA.	dbanner@anri.barc.usda.gov			NHLBI NIH HHS [HL 03174, HL 18645] Funding Source: Medline; NIGMS NIH HHS [GM 42686, GM 07037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042686] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bannerman DD, 1999, LAB INVEST, V79, P1181; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; BARRETT TJ, 1989, INFECT IMMUN, V57, P3434, DOI 10.1128/IAI.57.11.3434-3437.1989; BARRETT TJ, 1990, MICROB PATHOGENESIS, V9, P95, DOI 10.1016/0882-4010(90)90083-3; Bierhaus A, 2000, SEMIN THROMB HEMOST, V26, P571, DOI 10.1055/s-2000-13214; BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; COOPERSTOCK MS, 1974, ANTIMICROB AGENTS CH, V6, P422, DOI 10.1128/AAC.6.4.422; Eisenhauer PB, 2001, INFECT IMMUN, V69, P1889, DOI 10.1128/IAI.69.3.1889-1894.2001; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frey EA, 1998, MICROB PATHOGENESIS, V24, P101, DOI 10.1006/mpat.1997.0178; Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Fulda S, 2000, CANCER RES, V60, P3947; GYLES CL, 1992, CAN J MICROBIOL, V38, P734, DOI 10.1139/m92-120; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAREL Y, 1993, J CLIN INVEST, V92, P2110, DOI 10.1172/JCI116811; Hoyt DG, 1996, AM J PHYSIOL-LUNG C, V270, pL689, DOI 10.1152/ajplung.1996.270.4.L689; HOYT DG, 1995, AM J PHYSIOL-LUNG C, V269, pL171, DOI 10.1152/ajplung.1995.269.2.L171; Jacewicz MS, 1999, INFECT IMMUN, V67, P1439, DOI 10.1128/IAI.67.3.1439-1444.1999; Jones NL, 2000, AM J PHYSIOL-GASTR L, V278, pG811, DOI 10.1152/ajpgi.2000.278.5.G811; Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1; KAYE SA, 1993, INFECT IMMUN, V61, P3886, DOI 10.1128/IAI.61.9.3886-3891.1993; Keusch GT, 1996, J INFECT DIS, V173, P1164, DOI 10.1093/infdis/173.5.1164; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LOUISE CB, 1992, INFECT IMMUN, V60, P1536, DOI 10.1128/IAI.60.4.1536-1543.1992; LOUISE CB, 1991, INFECT IMMUN, V59, P4173, DOI 10.1128/IAI.59.11.4173-4179.1991; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; O'Loughlin EV, 2001, MICROBES INFECT, V3, P493, DOI 10.1016/S1286-4579(01)01405-8; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; OGASAWARA T, 1988, MICROB PATHOGENESIS, V4, P127, DOI 10.1016/0882-4010(88)90054-X; OLSON NC, 1995, BRIT VET J, V151, P489, DOI 10.1016/S0007-1935(05)80023-5; Pammer J, 1999, BIOCHEM BIOPH RES CO, V264, P139, DOI 10.1006/bbrc.1999.1436; Pijpers AHJM, 2001, J AM SOC NEPHROL, V12, P767, DOI 10.1681/ASN.V124767; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Proulx F, 1999, CLIN DIAGN LAB IMMUN, V6, P773, DOI 10.1128/CDLI.6.5.773-773.1999; Proulx F, 2001, PEDIATR RES, V50, P163, DOI 10.1203/00006450-200108000-00002; Ray PE, 2001, PEDIATR NEPHROL, V16, P823, DOI 10.1007/s004670100660; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Thijs LG, 1996, CURR TOP MICROBIOL, V216, P209; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; ULEVITCH RJ, 1975, J EXP MED, V142, P1570, DOI 10.1084/jem.142.6.1570; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4; Williams JM, 1999, TOXICOL LETT, V105, P47, DOI 10.1016/S0378-4274(98)00383-X; Yoshida T, 1999, J INFECT DIS, V180, P2048, DOI 10.1086/315116; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	72	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40567	40574		10.1074/jbc.M206351200	http://dx.doi.org/10.1074/jbc.M206351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189147	hybrid			2022-12-25	WOS:000178791400054
J	Receveur, V; Czjzek, M; Schulein, M; Panine, P; Henrissat, B				Receveur, V; Czjzek, M; Schulein, M; Panine, P; Henrissat, B			Dimension, shape, and conformational flexibility of a two domain fungal cellulase in solution probed by small angle X-ray scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; BINDING DOMAINS; CELLULOMONAS-FIMI; BIOLOGICAL MACROMOLECULES; CRYSTALLINE CELLULOSE; GLYCOSYL HYDROLASES; LIMITED PROTEOLYSIS; BACTERIAL CELLULASE; FUNCTIONAL DOMAINS	Cellulase Ce145 from Humicola insolens has a modular structure with a catalytic module and a cellulose-binding module (CBM) separated by a 36 amino acid, glycosylated, linker peptide. The solution conformation of the entire two domain Ce145 protein as well as the effect of the length and flexibility of the linker on the spatial arrangement of the constitutive modules were studied by small angle x-ray scattering combined with the known three-dimensional structure of the individual modules. The measured dimensions of the enzyme show that the linker exhibits an extended conformation leading to a maximum extension between the two centers of mass of each module corresponding to about four cellobiose units on a cellulose chain. The glycosylation of the linker is the key factor defining its extended conformation, and a five proline stretch mutation on the linker was found to confer a higher rigidity to the enzyme. Our study shows that the respective positioning of the catalytic module and the CBM onto the insoluble substrate is most likely influenced by the linker structure and flexibility. Our results are consistent with a model where cellulases can move on the surface of cellulose with a caterpillar-like displacement with free energy restrictions.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; Novozymes, DK-2800 Bagsvaerd, Denmark; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Novozymes; European Synchrotron Radiation Facility (ESRF)	Receveur, V (corresponding author), CNRS, UMR 6098, F-13402 Marseille 20, France.	receveur@afmb.cnrs-mrs.fr	Panine, Pierre/AAF-2506-2019; Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Receveur-Brechot, Veronique/0000-0002-7464-6192				ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ABUJA PM, 1988, BIOCHEM BIOPH RES CO, V156, P180, DOI 10.1016/S0006-291X(88)80821-0; BOISSET C, 1995, FEBS LETT, V376, P49, DOI 10.1016/0014-5793(95)01244-0; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 1999, ROY SOC CH, P202; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; CHRISTENSEN T, 1988, BIO-TECHNOL, V6, P1419, DOI 10.1038/nbt1288-1419; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1988, J BIOL CHEM, V263, P10401; Glatter von O., 1982, SMALL ANGLE XRAY SCA, P167; Guinier A, 1955, SMALL ANGLE SCATERIN; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Jervis EJ, 1997, J BIOL CHEM, V272, P24016, DOI 10.1074/jbc.272.38.24016; Kelly MA, 2001, BIOCHEMISTRY-US, V40, P14376, DOI 10.1021/bi011043a; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Linder M, 1997, J BIOTECHNOL, V57, P15, DOI 10.1016/S0168-1656(97)00087-4; MEINKE A, 1992, GLYCOBIOLOGY, V2, P321, DOI 10.1093/glycob/2.4.321; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PILZ I, 1990, BIOCHEM J, V271, P277, DOI 10.1042/bj2710277; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; RASMUSSEN G, 1991, Patent No. 17243; Receveur V, 1998, FEBS LETT, V426, P57, DOI 10.1016/S0014-5793(98)00309-3; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; SCHULEIN M, 1993, TRICHODERMA REESEI C, V8, P109; SHEN H, 1991, J BIOL CHEM, V266, P11335; SRISODSUK M, 1993, J BIOL CHEM, V268, P20756; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; TOMME P, 1995, ENZYMATIC DEGRADATIO, V618, P142; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	40	87	95	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40887	40892		10.1074/jbc.M205404200	http://dx.doi.org/10.1074/jbc.M205404200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186865	hybrid			2022-12-25	WOS:000178791400094
J	Reid, J; Murray, I; Watt, K; Betney, R; McEwan, IJ				Reid, J; Murray, I; Watt, K; Betney, R; McEwan, IJ			The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; LIGAND-BINDING DOMAIN; AR SUPPRESSES TRANSCRIPTION; RAP74 SUBUNIT; FACTOR IIF; ACTIVATION; COACTIVATOR; TRANSACTIVATION; PROTEIN; IDENTIFICATION	The androgen receptor (AR) is a ligand-activated transcription factor that regulates genes important for male development and reproductive function. The main determinants for the transactivation function lie within the structurally distinct amino-terminal domain. Previously we identified an interaction between the AR-transactivation domain (amino acids 142-485) and the general transcription factor TFIIF (McEwan, I. J., and Gustafsson, J.-Angstrom. (1997) Proc. Natl Acad. Sci. U. S. A. 94, 8485-8490). We have now mapped the binding sites for the AR-transactivation domain within the RAP74 subunit of TFIIF. Both the amino-terminal 136 amino acids and the carboxyl-terminal 155 amino acids of RAP74 interacted with the AR-transactivation domain and were able to rescue basal transcription after squelching by the AR polypeptide. Competition experiments demonstrated that the AR could interact with the holo-TFIIF protein and that the carboxyl terminus of RAP74 represented the principal receptor-binding site. Point mutations within AR-transactivation domain distinguished the binding sites for RAP74 and the p160 coactivator SRC-la and identified a single copy of a six amino acid repeat motif as being important for RAP74 binding. These data indicate that the AR-transactivation domain can potentially make multiple protein-protein interactions with coactivators and components of the general transcriptional machinery in order to regulate target gene expression.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	McEwan, IJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland.	iain.mcewan@abdn.ac.uk						Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; Alen P, 1999, MOL CELL BIOL, V19, P6085; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Cato ACB, 1998, TRENDS ENDOCRIN MET, V9, P150, DOI 10.1016/S1043-2760(98)00039-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAY CM, 1993, J BIOL CHEM, V268, P13556; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gietz RD, 1994, MOL GENETICS YEAST P; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hiipakka RA, 1998, TRENDS ENDOCRIN MET, V9, P317, DOI 10.1016/S1043-2760(98)00081-2; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Irvine RA, 2000, HUM MOL GENET, V9, P267, DOI 10.1093/hmg/9.2.267; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1496, DOI 10.1210/me.15.9.1496; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1505, DOI 10.1210/me.15.9.1505; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lei L, 1999, MOL CELL BIOL, V19, P8372; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; Martin ML, 1996, MOL CELL BIOL, V16, P2110; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McEwan IJ, 2000, BIOCHEM SOC T, V28, P369, DOI 10.1042/0300-5127:0280369; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Park JJ, 2000, CANCER RES, V60, P5946; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; REID J, 2001, THESIS U ABERDEEN; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673	65	46	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41247	41253		10.1074/jbc.M205220200	http://dx.doi.org/10.1074/jbc.M205220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181312	hybrid			2022-12-25	WOS:000178791400136
J	Slevin, M; Kumar, S; Gaffney, J				Slevin, M; Kumar, S; Gaffney, J			Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-DERIVED HYALURONIDASE; SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B; GROWTH-FACTOR; PHOSPHOLIPASE-C; BINDING PROTEINS; CARCINOMA-CELLS; RECEPTOR RHAMM; ACID BINDING	Hyaluronan (HA) is a large nonsulfated glycosaminoglycan and an important regulator of angiogenesis, in particular, the growth and migration of vascular endothelial cells. We have identified some of the key intermediates responsible for induction of mitogenesis and wound recovery. Treatment of bovine aortic endothelial cells with oligosaccharides of hyaluronan (o-HA) resulted in rapid tyrosine phosphorylation and plasma membrane translocation of phospholipase Cgammal (PLCgammal). Cytoplasmic loading with inhibitory antibodies to PLCgammal, Gbeta, and Galpha(i/o/t/z) inhibited activation of extracellular-regulated kinase 1/2 (ERK1/2). Treatment with the Galpha(i/o) inhibitor, pertussis toxin, reduced o-HA-induced PLCgammal tyrosine phosphorylation, protein kinase C (PKC) alpha and beta1/2 membrane translocation, ERK1/2 activation, mitogenesis, and wound recovery, suggesting a mechanism for o-HA-induced angiogenesis through G-proteins, PLCgammal, and PKC. In particular, we demonstrated a possible role for PKCalpha in mitogenesis and PKCbeta1/2 in wound recovery. Using antisense oligonucleotides and the Ras farnesylation inhibitor FTI-277, we showed that o-HA-induced bovine aortic endothelial cell proliferation, wound recovery, and ERK1/2 activation were also partially dependent on Ras activation, and that o-HA-stimulated tyrosine phosphorylation of the adapter protein Shc, as well as its association with Sos1. Binding of Src to Shc was required for its activation and for Ras-dependent activation of ERK1/2, cell proliferation, and wound recovery. Neither Src nor Ras activation was inhibited by pertussis toxin, suggesting that their activation was independent of heterotrimeric G-proteins. However, the specific Src kinase inhibitor PP2 inhibited Gbeta subunit co-precipitation with PLCgammal, suggesting a possible role for Src in activation of PLCgammal and interaction between two distinct o-HA-induced signaling pathways.	Manchester Metropolitan Univ, Dept Biol Sci, Manchester M1 5GD, Lancs, England; Manchester Victoria Univ, Dept Pathol Sci, Manchester M1 5GD, Lancs, England	Manchester Metropolitan University; University of Manchester	Slevin, M (corresponding author), Manchester Metropolitan Univ, Dept Biol Sci, Manchester M1 5GD, Lancs, England.	m.a.slevin@mmu.ac.uk	slevin, mark a/A-1593-2008; Slevin, Mark/AFT-1420-2022	slevin, mark/0000-0003-3767-4861				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEED R, 1997, INT J CANCER, V71, P116; DELPECH B, 1990, INT J CANCER, V46, P388, DOI 10.1002/ijc.2910460309; FARESE RV, 1991, LIPID RELATED 2 MESS, P205; Fieber C, 1999, GENE, V226, P41, DOI 10.1016/S0378-1119(98)00566-6; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garbay C, 2000, BIOCHEM PHARMACOL, V60, P1165, DOI 10.1016/S0006-2952(00)00428-7; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hall CL, 1996, ONCOGENE, V13, P2213; Hall CL, 2001, MATRIX BIOL, V20, P183, DOI 10.1016/S0945-053X(01)00133-0; Harrington EO, 2000, BIOCHEM BIOPH RES CO, V271, P499, DOI 10.1006/bbrc.2000.2655; Hodson EAM, 1999, BIOCHEM BIOPH RES CO, V258, P425, DOI 10.1006/bbrc.1999.0657; Jeay S, 2001, ENDOCRINOLOGY, V142, P147, DOI 10.1210/en.142.1.147; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; KNUDSON W, 1984, P NATL ACAD SCI-BIOL, V81, P6767, DOI 10.1073/pnas.81.21.6767; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; KUMAR S, 1994, NATO ADV SCI INST SE, V263, P219; Lauder H, 1997, BRIT J PHARMACOL, V122, P663, DOI 10.1038/sj.bjp.0701443; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lokeshwar VB, 1996, CANCER RES, V56, P651; Lokeshwar VB, 1999, CANCER RES, V59, P4464; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MARTIN JF, 1990, ENDOTHELIUM INTRO CU, P95; MCCAFFERY RE, 1989, ONCOGENE, V4, P1441; Montesano R, 1996, LAB INVEST, V75, P249; MUKAI H, 1992, J BIOL CHEM, V267, P16237; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Ohta S, 1997, INT J ONCOL, V10, P561; PAULI BU, 1988, HUM PATHOL, V19, P628, DOI 10.1016/S0046-8177(88)80168-0; Pham HT, 1997, CANCER RES, V57, P778; PONTING J, 2002, CURRENT PERSPECTIVES; Rao CM, 1996, BIOCHEM MOL BIOL INT, V40, P327; Roden L, 1989, CIBA F SYMP, P76; ROONEY P, 1993, DIFFERENTIATION, V54, P1; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; SCOTT JE, 1995, J ANAT, V187, P259; Serbulea M, 1999, INT J ONCOL, V14, P733; SHEA TB, 1991, J NEUROSCI, V11, P1685; Skubitz KM, 1998, FEBS LETT, V439, P97, DOI 10.1016/S0014-5793(98)01347-7; Slevin M, 1998, LAB INVEST, V78, P987; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; Tsifrina E, 1999, AM J PATHOL, V155, P1625, DOI 10.1016/S0002-9440(10)65478-8; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Volkov Y, 1998, J IMMUNOL, V161, P6487; Watanabe Michifumi, 1993, Nippon Ganka Gakkai Zasshi, V97, P1034; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1991, INT J RADIAT BIOL, V60, P55, DOI 10.1080/09553009114551541; WEST DC, 1989, CIBA F SYMP, V143, P187; WEST DC, 1988, LANCET, V1, P715; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yassin RR, 1998, PEPTIDES, V19, P47, DOI 10.1016/S0196-9781(97)00276-3; Yasunari K, 2000, HYPERTENSION, V35, P1092, DOI 10.1161/01.HYP.35.5.1092; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	78	256	268	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41046	41059		10.1074/jbc.M109443200	http://dx.doi.org/10.1074/jbc.M109443200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12194965	hybrid, Green Published			2022-12-25	WOS:000178791400114
J	Chan, DA; Sutphin, PD; Denko, NC; Giaccia, AJ				Chan, DA; Sutphin, PD; Denko, NC; Giaccia, AJ			Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HIF-ALPHA; INDUCTION; PROTEIN; CELLS; ERYTHROPOIETIN; DESTRUCTION; HIF-1-ALPHA; EXPRESSION; BINDING	Stabilization of the hypoxia-inducible factor-1 (HIF-1) protein is essential for its role as a regulator of gene expression under low oxygen conditions. Here, employing a novel hydroxylation-specific antibody, we directly show that proline 564 of HIF-1alpha and proline 531 of HIF-2alpha are hydroxylated under normoxia. Importantly, HIF-1alpha Pro-564 and HIF-2alpha Pro-531 hydroxylation is diminished with the treatment of hypoxia, cobalt chloride, desferrioxamine, or dimethyloxalyglycine, regardless of the E3 ubiquitin ligase activity of the von Hippel-Lindau (VHL) tumor suppressor gene. Furthermore, in VHL-deficient cells, HIF-1alpha Pro-564 and HIF-2alpha Pro-531 had detectable amounts of hydroxylation following transition to hypoxia, indicating that the post-translational modification is not reversible. The introduction of v-Src or RasV12 oncogenes resulted in the stabilization of normoxic HIF-1alpha and the loss of hydroxylated Pro-564, demonstrating that oncogene-induced stabilization of HIF-1alpha is signaled through the inhibition of prolyl bydroxylation. Conversely, a constitutively active Akt oncogene stabilized HIF-1alpha under normoxia independently of prolyl hydroxylation, suggesting an alternative mechanism for HIF-1alpha stabilization. Thus, these results indicate distinct pathways for HIF-1alpha stabilization by different oncogenes. More importantly, these findings link oncogenesis with normoxic HIF-1alpha expression through prolyl hydroxylation.	Stanford Univ, Ctr Clin Sci Res, Dept Radiat Oncol, Program Canc Biol, Stanford, CA 94305 USA	Stanford University	Giaccia, AJ (corresponding author), Stanford Univ, Ctr Clin Sci Res, Dept Radiat Oncol, Program Canc Biol, 269 Campus Dr, Stanford, CA 94305 USA.		denko, nicholas/F-8444-2010		NCI NIH HHS [CA67166, CA09302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chen EY, 1999, TERATOLOGY, V60, P215; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ryan HE, 2000, CANCER RES, V60, P4010; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zundel W, 2000, GENE DEV, V14, P391	24	212	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40112	40117		10.1074/jbc.M206922200	http://dx.doi.org/10.1074/jbc.M206922200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12186875	hybrid			2022-12-25	WOS:000178662500133
J	Foghsgaard, L; Lademann, U; Wissing, D; Poulsen, B; Jaattela, M				Foghsgaard, L; Lademann, U; Wissing, D; Poulsen, B; Jaattela, M			Cathepsin B mediates tumor necrosis factor-induced arachidonic acid release in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); INDUCED APOPTOSIS; DEATH PATHWAY; FACTOR-ALPHA; ACTIVATION; INHIBITION; CASPASES; TNF; PROTEASE; RECEPTOR	Arachidonic acid (AA) generated by cytosolic phospholipase A(2) (cPLA(2)) has been suggested to function as a second messenger in tumor necrosis factor (TNF)-induced death signaling. Here, we show that cathepsin B-like proteases are required for the TNF-induced AA release in transformed cells. Pharmaceutical inhibitors of cathepsin B blocked TNF-induced AA release in human breast (MCF-7S1) and cervix (ME-180as) carcinoma as well as murine fibrosarcoma (WEHI-S) cells. Furthermore, TNF-induced AA release was significantly reduced in cathepsin B-deficient immortalized murine embryonic fibroblasts. Employing cPIA(2)-deficient MCF-7S1 cells expressing ectopic cPLA2 or cPLA(2)-deficient immortalized murine embryonic fibroblasts, we showed that cPLA(2) is dispensable for TNF-induced AA release and death in these cells. Furthermore, TNF-induced cathepsin B-dependent AA release could be dissociated from the cathepsin B-independent cell death in MCF-7S1 cells, whereas both events required cathepsin B activity in other cell lines tested. These data suggest that cathepsin B inhibitors may prove useful not only in the direct control of cell death but also in limiting the damage-associated inflammation.	Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Jaattela, M (corresponding author), Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.		Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111				Adam-Klages S, 1998, J IMMUNOL, V161, P5687; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Capper EA, 2001, PROG LIPID RES, V40, P167, DOI 10.1016/S0163-7827(01)00002-9; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1993, J IMMUNOL, V151, P4286; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Katz E, 2001, J IMMUNOL, V166, P137, DOI 10.4049/jimmunol.166.1.137; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Mathiasen IS, 1999, CANCER RES, V59, P4848; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nitatori T, 1996, ADV EXP MED BIOL, V389, P177; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; RashbaStep J, 1997, ARCH BIOCHEM BIOPHYS, V343, P44, DOI 10.1006/abbi.1997.0134; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073	42	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39499	39506		10.1074/jbc.M206669200	http://dx.doi.org/10.1074/jbc.M206669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12185082	hybrid			2022-12-25	WOS:000178662500058
J	Kauppi, M; Wohlfahrt, G; Olkkonen, VM				Kauppi, M; Wohlfahrt, G; Olkkonen, VM			Analysis of the Munc18b-syntaxin binding interface - Use of a mutant Munc18b to dissect the functions of syntaxins 2 and 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; APICAL PLASMA-MEMBRANE; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; 3-DIMENSIONAL STRUCTURE; VESICLE TRAFFICKING; 3T3-L1 ADIPOCYTES; INTESTINAL-CELLS; SNARE COMPLEX; PROTEINS	Munc18b is a mammalian Sec1-related protein that is abundant in epithelial cells and regulates vesicle transport to the apical plasma membrane. We constructed a homology model of Munc18b in complex with syntaxin 3 based on the crystal structure of the neuronal Sec1-syntaxin 1A complex. In this model we identified all residues in the interface between the two proteins that contribute directly to the interaction and mutagenized residues in Munc18b to alter its binding to syntaxins 1A, 2, and 3. The syntaxin-binding properties of the mutants were tested using an in vitro assay and by a co-immuno-precipitation approach employing Munc18b expressed in CHO-K1 cells. Three Munc18b variants, W28S, S42K, and E59K, were generated that are defective in binding to all three syntaxins. A fourth mutant protein, S48D, shows abolishment of syntaxin 3 interaction but binds syntaxin 2 at normal and syntaxin 1A at mildly reduced efficiency. Over-expression of Munc18b S48D inhibited transport of influenza hemagglutinin to the apical surface of Madin-Darby canine kidney II cells, which express syntaxin 2 abundantly, but not of Caco-2 cells, in which syntaxin 3 is the major apical target SNARE (soluble NSF (N-ethylmaleimide sensitive factor) attachment protein receptors). This suggests that, although syntaxin 3 is the main target SNARE operating in exocytic transport to the apical plasma membrane in certain epithelial cell types, syntaxin 2 may play an important role in this trafficking route in others.	Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, FIN-00251 Helsinki, Finland; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	Finland National Institute for Health & Welfare; University of Cologne	Olkkonen, VM (corresponding author), Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, POB 104, FIN-00251 Helsinki, Finland.			Wohlfahrt, Gerd/0000-0003-0530-2000; Olkkonen, Vesa/0000-0001-5553-7997				AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; CASE DA, 1997, AMBER 5; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Delgrossi MH, 1997, J CELL SCI, V110, P2207; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Grusovin J, 2000, BIOCHEM J, V350, P741, DOI 10.1042/0264-6021:3500741; Halachmi N, 1996, J NEUROCHEM, V66, P889; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Khan AH, 2001, J BIOL CHEM, V276, P4063, DOI 10.1074/jbc.M007419200; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehtonen S, 1999, KIDNEY INT, V56, P815, DOI 10.1046/j.1523-1755.1999.00625.x; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Quinones B, 1999, J CELL SCI, V112, P4291; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Riento K, 1996, EUR J BIOCHEM, V239, P638, DOI 10.1111/j.1432-1033.1996.0638u.x; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; Riento K, 1998, J CELL SCI, V111, P2681; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe J, 2001, J CELL SCI, V114, P3323; Rowe J, 1999, J CELL SCI, V112, P1865; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SUOMALAINEN M, 1994, J VIROL, V68, P4879, DOI 10.1128/JVI.68.8.4879-4889.1994; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	55	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43973	43979		10.1074/jbc.M208315200	http://dx.doi.org/10.1074/jbc.M208315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12198139	hybrid			2022-12-25	WOS:000179272000058
J	Bebok, Z; Varga, K; Hicks, JK; Venglarik, CJ; Kovacs, T; Chen, L; Hardiman, KM; Collawn, JF; Sorscher, EJ; Matalon, S				Bebok, Z; Varga, K; Hicks, JK; Venglarik, CJ; Kovacs, T; Chen, L; Hardiman, KM; Collawn, JF; Sorscher, EJ; Matalon, S			Reactive oxygen nitrogen species decrease cystic fibrosis transmembrane conductance regulator expression and cAMP-mediated Cl- secretion in airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; RESPIRATORY-DISTRESS SYNDROME; EXHALED NITRIC-OXIDE; ACUTE LUNG INJURY; APICAL MEMBRANE; ALVEOLAR MACROPHAGES; TYROSINE NITRATION; CHLORIDE CHANNELS; SMOOTH-MUSCLE; CYCLIC-GMP	We investigated putative mechanisms by which nitric oxide modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and function in epithelial cells. Immunoprecipitation followed by Western blotting, as well as immunocytochemical and cell surface biotinylation measurements, showed that incubation of both stably transduced (HeLa) and endogenous CFTR expressing (16HBE14o-, Calu-3, and mouse tracheal epithelial) cells with 100 muM diethylenetriamine NONOate (DETA NONOate) for 24-96 h decreased both intracellular and apical CFTR levels. Calu-3 and mouse tracheal epithelial cells, incubated with DETA NONOate but not with 100 lim 8-bromo-cGMP for 96 h, exhibited reduced cAMP-activated short circuit currents when mounted in Ussing chambers. Exposure of Calu-3 cells to nitric oxide donors resulted in the nitration of a number of proteins including CFTR. Nitration was augmented by proteasome inhibition, suggesting a role for the proteasome in the degradation of nitrated proteins. Our studies demonstrate that levels of nitric oxide that are likely to be encountered in the vicinity of airway cells during inflammation may nitrate CFTR resulting in enhanced degradation and decreased function. Decreased levels and function of normal CFTR may account for some of the cystic fibrosis-like symptoms that occur in chronic inflammatory lung diseases associated with increased NO production.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama, Dept Med, Birmingham, AL 35233 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35233 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Matalon, S (corresponding author), Univ Alabama, Dept Anesthesiol, 901 19th St S,BMR 2,Rm 224, Birmingham, AL 35205 USA.			Sorscher, Eric J./0000-0001-9341-3354; Collawn, James/0000-0002-2528-2759	NHLBI NIH HHS [HL31197, HL51173] Funding Source: Medline; NIDDK NIH HHS [P30 DK54781, P50 DK53090] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031197, R01HL031197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054781, P50DK053090] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; BEBOK Z, 2002, AM J RESP CRIT CARE, V163, pA842; BEBOK Z, 1999, PED PULM S, V19; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRUNNER F, 1995, FEBS LETT, V376, P262, DOI 10.1016/0014-5793(95)01297-X; Buchczyk DP, 2000, BIOL CHEM, V381, P121, DOI 10.1515/BC.2000.017; CLARKE LL, 1992, AM J PHYSIOL, V263, pL519, DOI 10.1152/ajplung.1992.263.5.L519; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; De Andrade JA, 2000, AM J RESP CRIT CARE, V161, P2035, DOI 10.1164/ajrccm.161.6.9907001; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; Greis KD, 1996, ARCH BIOCHEM BIOPHYS, V335, P396, DOI 10.1006/abbi.1996.0522; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Guo Y, 1998, AM J PHYSIOL-LUNG C, V274, pL369, DOI 10.1152/ajplung.1998.274.3.L369; GUPTA S, 1995, BRIT J PHARMACOL, V116, P2201, DOI 10.1111/j.1476-5381.1995.tb15054.x; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hickman-Davis JM, 2002, AM J PHYSIOL-LUNG C, V282, pL944, DOI 10.1152/ajplung.00216.2001; HUSAIN M, 1994, CIRCULATION, V89, P2498, DOI 10.1161/01.CIR.89.6.2498; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jain L, 1998, AM J PHYSIOL-LUNG C, V274, pL475, DOI 10.1152/ajplung.1998.274.4.L475; Jilling T, 1999, AM J PHYSIOL-LUNG C, V277, pL89, DOI 10.1152/ajplung.1999.277.1.L89; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KOIVISTO A, 1993, PFLUG ARCH EUR J PHY, V425, P549, DOI 10.1007/BF00374884; Lei DC, 1996, GENE THER, V3, P427; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meng QH, 2000, J PATHOL, V190, P126, DOI 10.1002/(SICI)1096-9896(200002)190:2<126::AID-PATH500>3.0.CO;2-#; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; Nielsen VG, 2000, AM J RESP CRIT CARE, V161, P1154, DOI 10.1164/ajrccm.161.4.9907033; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PUNJABI CJ, 1994, AM J RESP CELL MOL, V11, P165, DOI 10.1165/ajrcmb.11.2.7519435; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STOOS BA, 1994, J AM SOC NEPHROL, V4, P1855; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; Yates DH, 2001, IMMUNOL CELL BIOL, V79, P178, DOI 10.1046/j.1440-1711.2001.00990.x; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068; Zhu S, 1998, AM J PHYSIOL-LUNG C, V275, pL1031, DOI 10.1152/ajplung.1998.275.6.L1031; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025	58	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43041	43049		10.1074/jbc.M203154200	http://dx.doi.org/10.1074/jbc.M203154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12194970	hybrid			2022-12-25	WOS:000179081200081
J	Huang, HC; Nguyen, T; Pickett, CB				Huang, HC; Nguyen, T; Pickett, CB			Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; ARYL-HYDROCARBON RECEPTOR; HUMAN NEUROBLASTOMA-CELLS; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL-CHARACTERIZATION; NF-E2-RELATED FACTOR-2; TERT-BUTYLHYDROQUINONE; PHENOLIC ANTIOXIDANTS	Nrf2, a basic leucine zipper transcription factor, is an essential activator of the coordinated transcription of genes encoding antioxidant enzymes and phase 11 detoxifying enzymes through the regulatory sequence termed antioxidant response element (ARE). Recently we reported evidence for the involvement of protein kinase C (PKC) in phosphorylating Nrf2 and triggering its nuclear translocation in response to oxidative stress. We show here that phosphorylation of purified rat Nrf2 by the catalytic subunit of PKC was blocked by a synthetic peptide mimicking one of the potential PKC sites. Accordingly, Nrf2 bearing a Ser to Ala mutation at amino acid 40 (S40A) could not be phosphorylated by PKC. The S40A mutation did not affect in vitro binding of Nrf2/MafK to the ARE. However, it partially impaired Nrf2 activation of ARE-driven transcription in a reporter gene assay when Keap1 was overexpressed. In vitro transcribed/translated Keap1 could be coimmunoprecipitated with Nrf2. Phosphorylation of wild-type Nrf2 by PKC promoted its dissociation from Keap1, whereas the Nrf2-S40A mutant remained associated. These findings together with our prior studies suggest that the PKC-catalyzed phosphorylation. of Nrf2 at Ser-40 is a critical signaling event leading to ARE-mediated cellular antioxidant response.	Schering Plough Res Inst, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Pickett, CB (corresponding author), Schering Plough Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.							Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Kang KW, 2001, MOL PHARMACOL, V59, P1147, DOI 10.1124/mol.59.5.1147; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; LI Y, 1992, J BIOL CHEM, V267, P15097; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; McMahon M, 2001, CANCER RES, V61, P3299; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830	37	773	797	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42769	42774		10.1074/jbc.M206911200	http://dx.doi.org/10.1074/jbc.M206911200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12198130	hybrid			2022-12-25	WOS:000179081200046
J	McCole, DF; Keely, SJ; Coffey, RJ; Barrett, KE				McCole, DF; Keely, SJ; Coffey, RJ; Barrett, KE			Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEPENDENT CHLORIDE SECRETION; MUSCARINIC ACETYLCHOLINE-RECEPTOR; EGF RECEPTOR; COUPLED RECEPTORS; FACTOR-ALPHA; T-84 CELLS; TGF-ALPHA; INHIBITION; TRANSPORT	We have shown previously that the muscarinic agonist, carbachol (CCh), transactivates the epidermal growth factor receptor (EGFr) via calmodulin, Pyk-2, and Src kinase activation. EGFr phosphorylation causes extracellular signal-regulated kinase (ERK) activation and inhibits CCh-stimulated chloride secretion across intestinal epithelial cells. Here we investigated whether CCh-stimulated EGFr transactivation involves EGFr ligand release. Pre-incubation of T-84 cell monolayers with a neutralizing antibody to the EGFr ligand binding domain decreased CCh-induced phosphorylation of EGFr and ERK. CCh-stimulated efflux of Rb-86(+) from T-84 cell monolayers, which parallels changes in chloride secretion, was potentiated by anti-EGFr pre-incubation. AntiEGFr did not reduce CCh-stimulated Pyk-2 phosphorylation. Co-incubation with the Src kinase inhibitor PP2 and anti-EGFr had an additive inhibitory effect on CCh-induced ERK phosphorylation greater than either inhibitor alone. CCh caused the basolateral release of transforming growth factor a (TGF-alpha) into T-84 cell bathing media. A metalloproteinase inhibitor, WAY171318, reduced CCh-induced phosphorylation of ERK and completely blocked EGFr phosphorylation and TGF-alpha release. We conclude that CCh-stimulated EGFr transactivation and subsequent ERK activation, a pathway that limits CCh-induced chloride secretion, is mediated by metalloproteinase-dependent extracellular release of TGF-a and intracellular Src activation. These findings have important implications for our understanding of the role of growth factors in regulating epithelial ion secretion.	Univ Calif San Diego, Med Ctr, Sch Med, Div Gastroenterol,Dept Med, San Diego, CA 92103 USA; Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	University of California System; University of California San Diego; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Barrett, KE (corresponding author), Univ Calif San Diego, Med Ctr, Sch Med, Div Gastroenterol,Dept Med, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.		McCole, Declan/AAL-2454-2020; Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NCI NIH HHS [CA46413] Funding Source: Medline; NIDDK NIH HHS [DK28305] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; Barrett K.E.., 1999, ELECTROLYTE SECRETIO; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; CARPENTER G, 2000, SCI STKE, V15, pPE1; CARTLIDGE SA, 1989, BRIT J CANCER, V60, P657, DOI 10.1038/bjc.1989.334; Chang N, 2001, AM J PHYSIOL-GASTR L, V281, pG129, DOI 10.1152/ajpgi.2001.281.1.G129; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DEVOR DC, 1992, AM J PHYSIOL, V263, pC780, DOI 10.1152/ajpcell.1992.263.4.C780; Dignass AU, 2001, EUR J GASTROEN HEPAT, V13, P763, DOI 10.1097/00042737-200107000-00002; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MIETTINEN PJ, 1989, PEDIATR RES, V26, P25, DOI 10.1203/00006450-198907000-00009; OLOUGHLIN EV, 1990, J PAEDIATR CHILD H, V26, P126, DOI 10.1111/j.1440-1754.1990.tb02408.x; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; Schlondorff J, 1999, J CELL SCI, V112, P3603; Slack BE, 2000, BIOCHEM J, V348, P381, DOI 10.1042/0264-6021:3480381; STENSON WF, 1999, TXB GASTROENTEROLOGY, P123; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; THOMAS DM, 1992, GUT, V33, P628, DOI 10.1136/gut.33.5.628; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	46	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42603	42612		10.1074/jbc.M206487200	http://dx.doi.org/10.1074/jbc.M206487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202486	hybrid			2022-12-25	WOS:000179081200024
J	Fourel, G; Miyake, T; Defossez, PA; Li, R; Gilson, E				Fourel, G; Miyake, T; Defossez, PA; Li, R; Gilson, E			General Regulatory Factors (GRFs) as genome partitioners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; C-TERMINAL DOMAINS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; SUBTELOMERIC REGIONS; RIBOSOMAL-PROTEIN; BINDING DOMAIN; SIR PROTEINS; YEAST	Insulators are sequences that uncouple adjacent chromosome domains. Here we have shown that Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity. Insulating domains in Rap1p coincide with previously described transcription activation domains, whereas four adjacent subdomains spanning the whole of the Abf1p C terminus (440-731) were found to display autonomous insulating capacity. That both Rap1p and Abf1p silencing domains either contain or largely overlap with an insulating domain suggests that insulation conveys some undefined chromosome organization capacity that also contributes a function in silencing. Together with Reb1p and Tbf1p, previously involved in the activity of Saccharomyces cerevisiae subtelomeric insulators, insulating potential emerges as a supplementary common property of General Regulatory Factors (GRFs). Thus GRFs, which bind to sites scattered throughout the genome within promoters, would not only play a key role in regulating gene expression but also partition the genome in functionally independent domains.	Ecole Normale Super Lyon, CNRS ENSSL 5665, F-69364 Lyon, France; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Ecole Normale Superieure de Lyon (ENS de LYON); University of Virginia	Fourel, G (corresponding author), Ecole Normale Super Lyon, CNRS ENSSL 5665, 46 Allee Italie, F-69364 Lyon, France.			Defossez, Pierre-Antoine/0000-0002-6463-9263				AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Bussemaker HJ, 2001, NAT GENET, V27, P167, DOI 10.1038/84792; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHO GN, 1995, NUCLEIC ACIDS RES, V23, P2980, DOI 10.1093/nar/23.15.2980; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Deminoff SJ, 2001, GENETICS, V158, P133; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; Fourel G, 2001, EMBO REP, V2, P124, DOI 10.1093/embo-reports/kve024; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Goncalves PM, 1996, MOL MICROBIOL, V19, P535, DOI 10.1046/j.1365-2958.1996.404939.x; Graham IR, 1999, MOL CELL BIOL, V19, P7481; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; HOFFMAN JFX, 1989, CELL, V57, P725; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Idrissi FZ, 2001, J BIOL CHEM, V276, P26090, DOI 10.1074/jbc.M101746200; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Kirkpatrick DT, 1999, GENETICS, V152, P101; Koering CE, 2000, NUCLEIC ACIDS RES, V28, P2519, DOI 10.1093/nar/28.13.2519; Lebrun E, 2001, GENETICS, V158, P167; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lutz M, 2000, BIOCHEM SOC T, V28, P386, DOI 10.1042/0300-5127:0280386; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Miyake T, 2002, MOL CELL BIOL, V22, P505, DOI 10.1128/MCB.22.2.505-516.2002; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Reed SH, 1999, GENE DEV, V13, P3052, DOI 10.1101/gad.13.23.3052; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Ryan MP, 2000, MOL CELL BIOL, V20, P5847, DOI 10.1128/MCB.20.16.5847-5857.2000; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; Stenoien DL, 2000, J CELL BIOCHEM, P99; Sun FL, 1999, CELL, V99, P459, DOI 10.1016/S0092-8674(00)81534-2; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Valerius O, 2002, J BIOL CHEM, V277, P21440, DOI 10.1074/jbc.M201841200; Wiltshire S, 1997, NUCLEIC ACIDS RES, V25, P4250, DOI 10.1093/nar/25.21.4250; Yu LN, 1999, MOL CELL BIOL, V19, P5279	54	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41736	41743		10.1074/jbc.M202578200	http://dx.doi.org/10.1074/jbc.M202578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200417	hybrid			2022-12-25	WOS:000178985300056
J	Strack, S				Strack, S			Overexpression of the protein phosphatase 2A regulatory subunit B gamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEURITE OUTGROWTH; OKADAIC ACID; SERINE/THREONINE PHOSPHATASES; SUBCELLULAR-LOCALIZATION; PC12 CELLS; CYCLIN-G; IDENTIFICATION; TYROSINE; FAMILY	Protein serine/threonine phosphatase 2A (PP2A) is a multifunctional regulator of cellular signaling. Variable regulatory subunits associate with a core dimer of scaffolding and catalytic subunits and are postulated to dictate substrate specificity and subcellular location of the heterotrimeric PP2A holoenzyme. The role of brain-specific, regulatory subunits in neuronal differentiation and signaling was investigated in the PC6-3 subline of PC12 cells. Endogenous Bbeta, Bgamma, and B'beta protein expression was induced during nerve growth factor (NGF)-mediated neuronal differentiation. Transient expression of Bgamma, but not other PP2A regulatory subunits, facilitated neurite outgrowth in the absence and presence of NGF. Tetracycline-inducible expression of Bgamma caused growth arrest and neurofilament expression, further evidence that PP2A/Bgamma can promote differentiation. In PC6-3 cells, but not non-neuronal cell lines, Bgamma specifically promoted long lasting activation of the mitogen-activated protein (MAP) kinase cascade, a key mediator of neuronal differentiation. Pharmacological and dominant-negative inhibition and kinase assays indicate that Bgamma promotes neuritogenesis by stimulating the MAP kinase cascade downstream of the TrkA NGF receptor but upstream or at the level of the B-Raf kinase. Mutational analyses demonstrate that the divergent N terminus is critical for Bgamma activity. These studies implicate PP2A/Bgamma as a positive regulator of MAP kinase signaling in neurons.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Strack, S (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Campagne MV, 1999, MOL BRAIN RES, V64, P1; CHIOU JY, 1992, J NEUROCHEM, V59, P1963, DOI 10.1111/j.1471-4159.1992.tb11034.x; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Giasson BI, 1997, J NEUROBIOL, V32, P193, DOI 10.1002/(SICI)1097-4695(199702)32:2<193::AID-NEU4>3.0.CO;2-3; Gill JS, 1998, MOL BRAIN RES, V57, P123, DOI 10.1016/S0169-328X(98)00080-1; Green S. H., 1995, Methods (Orlando), V7, P222, DOI 10.1006/meth.1995.1028; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Merrick SE, 1997, J NEUROSCI, V17, P5726; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Morice C, 1999, EUR J NEUROSCI, V11, P1995, DOI 10.1046/j.1460-9568.1999.00609.x; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; Schipper HM, 1999, NEUROSCIENCE, V93, P585, DOI 10.1016/S0306-4522(99)00120-7; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 1998, J COMP NEUROL, V392, P515; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; TAPLEY P, 1992, ONCOGENE, V7, P371; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Xing HR, 2001, J BIOL CHEM, V276, P9733, DOI 10.1074/jbc.M008096200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	61	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41525	41532		10.1074/jbc.M203767200	http://dx.doi.org/10.1074/jbc.M203767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12191994	hybrid			2022-12-25	WOS:000178985300030
J	Aslani, A; Olsson, M; Elias, P				Aslani, A; Olsson, M; Elias, P			ATP-dependent unwinding of a minimal origin of DNA replication by the origin-binding protein and the single-strand DNA-binding protein ICP8 from Herpes simplex virus type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL ORIGIN; CRYSTAL-STRUCTURES; UL9 PROTEIN; HELICASE; DOMAIN; ORIS; COMPLEX; OLIGONUCLEOTIDE; SEQUENCE; CLONING	The Herpes simplex virus type I origin-binding protein, OBP, is encoded by the UL9 gene. OBP binds the origin of DNA replication, oriS, in a cooperative and sequence-specific manner. OBP is also an ATP-dependent DNA helicase. We have recently shown that single-stranded oriS folds into a unique and evolutionarily conserved conformation, oriS*, which is stably bound by OBP. OriS* contains a stable hairpin formed by complementary base pairing between box I and box III in oriS. Here we show that OBP, in the presence of the single-stranded DNA-binding protein ICP8, can convert an 80-base pair double-stranded minimal oriS fragment to oriS* and form an OBP-oriS* complex. The formation of an OBP-oriS* complex requires hydrolysable ATP. We also demonstrate that OBP in the presence of ICP8 and ATP promotes slow but specific and complete unwinding of duplex minimal oriS. The possibility that the OBP-oriS* complex may serve as an assembly site for the herpes virus replisome is discussed.	Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, SE-40530 Gothenburg, Sweden.							ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; Aslani A, 2001, P NATL ACAD SCI USA, V98, P7194, DOI 10.1073/pnas.121177198; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Chen YM, 1996, VIROLOGY, V221, P281, DOI 10.1006/viro.1996.0377; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; GAO M, 1988, VIROLOGY, V163, P319, DOI 10.1016/0042-6822(88)90272-3; *GCG, 2000, WISC PACK VERS 10 1; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; Hammarsten O, 1997, NUCLEIC ACIDS RES, V25, P1753, DOI 10.1093/nar/25.9.1753; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kornberg A., 1992, DNA REPLICATION; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOCKSHON D, 1986, J VIROL, V58, P513, DOI 10.1128/JVI.58.2.513-521.1986; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Simonsson S, 1998, J BIOL CHEM, V273, P24633, DOI 10.1074/jbc.273.38.24633; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41204	41212		10.1074/jbc.M208270200	http://dx.doi.org/10.1074/jbc.M208270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183471	hybrid			2022-12-25	WOS:000178791400131
J	Brengues, M; Pintard, L; Lapeyre, B				Brengues, M; Pintard, L; Lapeyre, B			mRNA decay is rapidly induced after spore germination of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; BUDDING YEAST; CELL-CYCLE; BINDING-PROTEIN; MAMMALIAN-CELLS; GENE; TURNOVER; IDENTIFICATION; DEADENYLATION; SPORULATION	Spores from the yeast Saccharomyces cerevisiae can germinate and resume their vegetative growth when placed in favorable conditions. Biochemical studies on germination have been limited by the difficulty of obtaining a pure population of spores germinating synchronously. Here, we report that spores can be purified and sorted according to their size by centrifugal elutriation and that these spores are able to germinate synchronously. Synchronizing their development has allowed reevaluating certain parameters of germination, and we demonstrate that both transcription and translation are induced very rapidly after germination induction. Spores contain mRNAs that are stable for several months in spores kept at 4 degreesC. Germination induction leads to very rapid degradation of these mRNAs, thus providing a simple model to study induction of mRNA decay in eukaryotes. mRNAs from the spore are polyadenylated, capped, and cosediment on sucrose gradients with ribosomes and polysomes and with components of the mRNA degradation machinery. The presence of polysomes in the spores led us to evaluate the activity of the translation apparatus in these cells. We present evidence that there is ongoing transcription and translation in nongerminating yeast spores incubated in water at 30 degreesC, suggesting that these activities could play a role in spore long term survival.	CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lapeyre, B (corresponding author), CRBM, 1919 Route Mende, F-34293 Montpellier 5, France.		pintard, lionel/AAD-8356-2020; PINTARD, Lionel/AAP-7361-2020; PINTARD, Lionel/H-3756-2018	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; Bonnerot C, 2000, MOL CELL BIOL, V20, P5939, DOI 10.1128/MCB.20.16.5939-5946.2000; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; CHOIH SJ, 1977, J BACTERIOL, V131, P63, DOI 10.1128/JB.131.1.63-68.1977; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; ESPOSITO RE, 1981, MOL BIOL YEAST SACCH, V2, P211; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Guthrie C, 1991, METHODS ENZYMOL, V194; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARPER JF, 1980, J BACTERIOL, V143, P958, DOI 10.1128/JB.143.2.958-965.1980; HARTWELL LH, 1970, MOL GEN GENET, V106, P347, DOI 10.1007/BF00324052; HASHIMOTO T, 1958, J BACTERIOL, V76, P406, DOI 10.1128/JB.76.4.406-416.1958; Herman PK, 1997, EMBO J, V16, P6171, DOI 10.1093/emboj/16.20.6171; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; HUTCHISON HT, 1969, J BACTERIOL, V99, P807, DOI 10.1128/JB.99.3.807-814.1969; Johnston LH, 1997, METHOD ENZYMOL, V283, P342; KREGERVANRIJ NJW, 1978, ARCH MICROBIOL, V117, P73, DOI 10.1007/BF00689354; KUPIEC M, 1997, MOL CELLULAR BIOL YE, V2, P889; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NAGASHIMA TERUYA, 1959, ECOL REV, V15, P75; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; ROUSSEAU P, 1972, J BACTERIOL, V109, P1232, DOI 10.1128/JB.109.3.1232-1238.1972; ROUSSEAU P, 1973, CAN J MICROBIOL, V19, P1311, DOI 10.1139/m73-210; ROUSSEAU P, 1973, CAN J MICROBIOL, V19, P547, DOI 10.1139/m73-091; ROUSSEAU P, 1973, J BACTERIOL, V113, P1289, DOI 10.1128/JB.113.3.1289-1295.1973; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STEELE SD, 1974, CAN J MICROBIOL, V20, P929, DOI 10.1139/m74-142; SURDEJ P, 1994, ANNU REV GENET, V28, P263; SUROSKY RT, 1992, MOL CELL BIOL, V12, P3948, DOI 10.1128/MCB.12.9.3948; TRON T, 1995, J BIOL CHEM, V270, P9961, DOI 10.1074/jbc.270.17.9961; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; XU G, 1992, EXPERIENTIA, V48, P786, DOI 10.1007/BF02124304	53	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40505	40512		10.1074/jbc.M206700200	http://dx.doi.org/10.1074/jbc.M206700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181322	hybrid			2022-12-25	WOS:000178791400046
J	Poirier, MA; Li, HL; Macosko, J; Cai, SW; Amzel, M; Ross, CA				Poirier, MA; Li, HL; Macosko, J; Cai, SW; Amzel, M; Ross, CA			Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; IN-VITRO; PALLIDOLUYSIAN ATROPHY; DISEASE; AGGREGATION; OLIGOMERS; INHIBITION; ANTIBODIES; MECHANISM; REPEATS	The pathology of Huntington's disease is characterized by neuronal degeneration and inclusions containing N-terminal fragments of mutant huntingtin (htt). To study htt aggregation, we examined purified htt fragments in vitro, finding globular and protofibrillar intermediates participating in the genesis of mature fibrils. These intermediates were high in beta-structure. Furthermore, Congo Red, a dye that stains amyloid fibrils, prevented the assembly of mutant htt into mature fibrils, but not the formation of protofibrils. Other proteins capable of forming ordered aggregates, such as amyloid beta and alpha-synuclein, form similar intermediates, suggesting that the mechanisms of mutant htt aggregation and possibly htt toxicity may overlap with other neurodegenerative disorders.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biochem & Biophys, Baltimore, MD 21205 USA; Lawrence Berkeley Natl Lab, Donner Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Massachusetts, Dept Chem, N Dartmouth, MA 02747 USA	Johns Hopkins University; Johns Hopkins University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Massachusetts System; University Massachusetts Dartmouth	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, 615 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	caross@jhu.edu	Ross, Christopher A/H-8395-2013	Li, Huilin/0000-0001-8085-8928; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM 40633] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler EL, 1997, J PEPT RES, V50, P73; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Fu FN, 1998, BIOCHEMISTRY-US, V37, P5267, DOI 10.1021/bi9723966; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HARIS P, 2000, INFRARED ANAL PEPTID; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Paulson HL, 2000, BRAIN PATHOL, V10, P293, DOI 10.1111/j.1750-3639.2000.tb00263.x; Peters MF, 2001, J BIOL CHEM, V276, P3188, DOI 10.1074/jbc.M008099200; Peters MF, 1999, NEUROSCI LETT, V275, P129, DOI 10.1016/S0304-3940(99)00758-2; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	35	294	302	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41032	41037		10.1074/jbc.M205809200	http://dx.doi.org/10.1074/jbc.M205809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171927	hybrid			2022-12-25	WOS:000178791400112
J	Robinson, P; Mirza, M; Knott, A; Abdulrazzak, H; Willott, R; Marston, S; Watkins, H; Redwood, C				Robinson, P; Mirza, M; Knott, A; Abdulrazzak, H; Willott, R; Marston, S; Watkins, H; Redwood, C			Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CONTRACTION; HEART-FAILURE; DISEASE PATHOGENESIS; ALTERED REGULATION; TRANSGENIC MICE; MOTILITY ASSAY; MUTATIONS; PROTEIN; CALCIUM; GENETICS	We have compared the in vitro regulatory properties of recombinant human cardiac troponin reconstituted using wild type troponin T with troponin containing the DeltaLys-210 troponin T mutant that causes dilated cardiomyopathy (DCM) and the R92Q troponin T known to cause hypertrophic cardiomyopathy (HCM). Troponin containing DeltaLys-210 troponin T inhibited actin-tropomyosin-activated myosin subfragment-1 ATPase activity to the same extent as wild type at pCa8.5 (>80%) but produced substantially less enhancement of ATPase at pCa4.5. The Ca2+ sensitivity of ATPase activation was increased (DeltapCa(50) = +0.2 pCa units) and cooperativity of Ca2+ activation was virtually abolished. Equimolar mixtures of wild type and DeltaLys-210 troponin T gave a lower Ca2+ sensitivity than with wild type, while maintaining the diminished ATPase activation at pCa4.5 observed with 100% mutant. In contrast, R92Q troponin gave reduced inhibition at pCa8.5 but greater activation than wild type at pCa4.5; Ca2+ sensitivity was increased but there was no change in cooperativity. In vitro motility assay of reconstituted thin filaments confirmed the ATPase results and moreover indicated that the predominant effect of the DeltaLys-210 mutation was a reduced sliding speed. The functional consequences of this DCM mutation are qualitatively different from the R92Q or any other studied HCM troponin T mutation, suggesting that DCM and HCM may be triggered by distinct primary stimuli.	Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England; Univ Oxford, Physiol Lab, Oxford OX3 7BN, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Imperial College London	Redwood, C (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England.	credwood@molbiol.ox.ac.uk		Abdulrazzak, Hassan/0000-0002-0654-7221; Watkins, Hugh/0000-0002-5287-9016				Bing W, 1997, BIOCHEM J, V327, P335, DOI 10.1042/bj3270335; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Hajjar RJ, 2000, CIRCULATION, V101, P1679; HAJJAR RJ, 1992, BASIC RES CARDIOL, V87, P143; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; KEELING PJ, 1995, BRIT HEART J, V73, P417; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Knott A, 2002, J MOL CELL CARDIOL, V34, P469, DOI 10.1006/jmcc.2002.1528; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285; Marston SB, 1996, J MUSCLE RES CELL M, V17, P497, DOI 10.1007/BF00123365; Marston SB, 2001, J MUSCLE RES CELL M, V22, P1, DOI 10.1023/A:1010355716511; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; Montgomery DE, 2001, J PHYSIOL-LONDON, V536, P583, DOI 10.1111/j.1469-7793.2001.0583c.xd; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Perez NG, 1999, CIRCULATION, V99, P1077, DOI 10.1161/01.CIR.99.8.1077; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Purcell IF, 1999, CARDIOVASC RES, V43, P884, DOI 10.1016/S0008-6363(99)00123-6; Redwood C, 2000, CIRC RES, V86, P1146; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; Ruf T, 1998, CARDIOVASC RES, V40, P580, DOI 10.1016/S0008-6363(98)00164-3; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2002, BIOPHYS J, V82, p170A; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; van der Velden J, 2001, CIRCULATION, V104, P1140, DOI 10.1161/hc3501.095485; Watkins H, 2001, EUR HEART J SUPPL, V3, pL43, DOI 10.1016/S1520-765X(01)90064-1; Wolff MR, 1996, J CLIN INVEST, V98, P167, DOI 10.1172/JCI118762	46	107	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40710	40716		10.1074/jbc.M203446200	http://dx.doi.org/10.1074/jbc.M203446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186860	hybrid			2022-12-25	WOS:000178791400071
J	Wong, MD; Lin, YF; Rosen, BP				Wong, MD; Lin, YF; Rosen, BP			The soft metal ion binding sites in the Staphylococcus aureus pI258 CadC Cd(II)/Pb(II)/Zn(II)-responsive repressor are formed between subunits of the homdimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADMIUM RESISTANCE; PLASMID PI258; METALLOREGULATORY PROTEINS; SMTB; IDENTIFICATION; DNA; COMPLEX; QUANTITIES; SEQUENCE; ATPASE	The Staphylococcus aureus plasmid pI258 CadC is a homodimeric repressor that binds Cd(II), Pb(II), and Zn(II) and regulates expression of the cadAC operon. CadC binds two Cd(II) ions per dimer, with a tetrathiolate binding site composed of residues Cys(7), Cys(11), Cys(58), and Cys(60). It is not known whether each site consists of residues from a single monomer or from residues contributed by both subunits. To examine whether Cys(7) and Cys(11) are spatially proximate to Cys(58) and Cys(60) of the same subunit or of the other subunit, homodimers with the same cysteine mutation in each subunit and heterodimers containing different cysteine mutations in the two subunits were reacted with 4,6-bis(bromomethyl)-3,7-dimethyl-1,5-diazabicyclo[3.3.0]octa-3,6- diene-2,8-dione, which cross-links thiol groups that are within 3-6 Angstrom of each other. Cys(7) or Cys(11) cross-linked only with Cys(58) or Cys(60) on the other subunit. The data demonstrate that Cys(7) and Cys" from one monomer are within 3-6 A of either Cys(51) or Cys(60) in the other monomer. The results of this study strongly indicate that each of the two Cd(II) binding sites in the CadC homodimer is composed of Cys(7) and Cys(11) from one monomer and Cys(58) and Cys(60) from the other monomer.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Lin, Yung-Feng/H-3289-2019	Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI 45428] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Archer M, 1999, PROTEIN SCI, V8, P1536, DOI 10.1110/ps.8.7.1536; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Busenlehner LS, 2002, J BIOL INORG CHEM, V7, P551, DOI 10.1007/s00775-001-0336-9; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; Kar SR, 2001, BIOCHEMISTRY-US, V40, P13378, DOI 10.1021/bi011289f; KOSOWER NS, 1980, BIOCHIM BIOPHYS ACTA, V622, P201, DOI 10.1016/0005-2795(80)90031-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li S, 2002, J BIOL CHEM, V277, P25992, DOI 10.1074/jbc.M201619200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; MORNET D, 1985, P NATL ACAD SCI USA, V82, P1658, DOI 10.1073/pnas.82.6.1658; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/ic00224a011; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SHI WP, 1994, J BIOL CHEM, V269, P19826; Sun Y, 2002, MOL MICROBIOL, V44, P1323, DOI 10.1046/j.1365-2958.2002.02961.x; Sun Y, 2001, J BIOL CHEM, V276, P14955, DOI 10.1074/jbc.M010595200; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; Xu C, 1999, METALS AND GENETICS, P5	37	19	22	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40930	40936		10.1074/jbc.M206536200	http://dx.doi.org/10.1074/jbc.M206536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176999	hybrid			2022-12-25	WOS:000178791400099
J	Zeng, ZZ; Yellaturu, CR; Neeli, I; Rao, GN				Zeng, ZZ; Yellaturu, CR; Neeli, I; Rao, GN			5(S)-hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); GROWTH-FACTOR-I; ARACHIDONIC-ACID; 4E-BINDING PROTEIN-1; INITIATION; KINASE; METABOLITES; PHOSPHORYLATION; ANGIOGENESIS; 3-KINASE	To understand the role of eicosanoids in angiogenesis, we have studied the effect of lipoxygenase metabolites of arachidonic acid on human microvascular endothelial cell (HMVEC) DNA synthesis. Among the various lipoxygenase metabolites of arachidonic acid tested, 5(S)-hydroxyeicosatetraenoic acid (5(S)-HETE) induced DNA synthesis in HMVEC. 5(S)-HETE also stimulated Jak-2, STAT-1, and STAT-3 tyrosine phosphorylation and STAT-3-DNA binding activity. Tyrphostin AG490, a specific inhibitor of Jak-2, significantly reduced tyrosine phosphorylation and DNA binding activity of STAT-3 and DNA synthesis induced by 5(S)-HETE. In addition, 5(S)-HETE stimulated phosphatidylinositol 3-kinase (PI3-kinase) activity and phosphorylation of its downstream targets Akt, p70S6K, and 4E-BP1 and their effector molecules ribosomal. protein S6 and eIF4E. LY294002 and rapamycin, potent inhibitors of PI3-kinase and mTOR, respectively, also blocked the DNA synthesis induced by 5(S)-HETE. Interestingly, AG490 attenuated 5(S)-HETE-induced PI3-kinase activity and phosphorylation of Akt, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E. 5(S)-HETE induced the expression of basic fibroblast growth factor 2 (bFGF-2) in a Jak-2- and PI3-kinase-dependent manner. In addition, a neutralizing anti-bFGF-2 antibody completely blocked 5(S)HETE-induced DNA synthesis in HMVEC. Together these results suggest that 5(S)-HETE stimulates HMVEC growth via Jak-2- and PI3-kinase-dependent induction of expression of bFGF-2. These findings also reveal a cross-talk between Jak-2 and PI3-kinase in response to 5(S)-HETE in HMVEC.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [HL 64165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEL PL, 1997, SCIENCE, V278, P687; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OBRIEN ER, 1994, AM J PATHOL, V145, P883; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; PALMBERG L, 1987, J CELL SCI, V88, P151; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHIMAKURA S, 1992, CANCER RES, V52, P1744; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	50	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41213	41219		10.1074/jbc.M204508200	http://dx.doi.org/10.1074/jbc.M204508200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193593	hybrid			2022-12-25	WOS:000178791400132
J	Kawar, ZS; Van Die, I; Cummings, RD				Kawar, ZS; Van Die, I; Cummings, RD			Molecular cloning and enzymatic characterization of a UDP-GalNAc : GlcNAc beta-R beta 1,4-N-acetylgalactosaminyltransferase from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; N-ACETYLGALACTOSAMINE-TRANSFERASE; SNAIL LYMNAEA-STAGNALIS; GOLGI VESICLE MEMBRANES; CIRCULATORY HALF-LIFE; SCHISTOSOMA-MANSONI; ALPHA-LACTALBUMIN; LUTROPIN OLIGOSACCHARIDES	A common terminal structure in glycans from animal glycoproteins and glycolipids is the lactosamine sequence Galbeta4GlcNAc-R (LacNAc or LN). An alternative sequence that occurs in vertebrate as well as in invertebrate glycoconjugates is GalNAcbeta4GlcNAc-R (LacdiNAc or LDN). Whereas genes encoding beta4GalTs responsible for LN synthesis have been reported, the beta4GalNAcT(s) responsible for LDN synthesis has not been identified. Here we report the identification of a gene from Caenorhabditis elegans encoding a UDP-GalNAc:GlcNAcbeta-R beta1,4-N-acetylgalactosaminyltransferase (Cebeta4GalNAcT) that synthesizes the LDN structure. Cebeta4GalNAcT is a member of the beta4GalT family, and its cDNA is predicted to encode a 383-amino acid type 2 membrane glycoprotein. A soluble, epitope-tagged recombinant form of Cebeta4GalNAcT expressed in CHO-Lec8 cells was active using UDP-GalNAc, but not UDPGal, as a donor toward a variety of acceptor substrates containing terminal beta-linked GlcNAc in both N- and O-glycan type structures. The LDN structure of the product was verified by co-chromatography with authentic standards and H-1 NMR spectroscopy. Moreover, Chinese hamster ovary CHO-Lec8 and CHO-Lec2 cells expressing Cebeta4GalNAcT acquired LDN determinants on endogenous glycoprotein N-glycans, demonstrating that the enzyme is active in mammalian cells as an authentic beta4GalNAcT. The identification and availability of this novel enzyme should enhance our understanding of the structure and function of LDN-containing glycoconjugates.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Vrije Univ Amsterdam Med Ctr, NL-1081 BT Amsterdam, Netherlands; Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands	University of Oklahoma System; University of Oklahoma Health Sciences Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 975 NE 10th St,BRC Rm 417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu			NICHD NIH HHS [R01 CH/HD54832-01] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; DO SI, 1992, J BIOCHEM BIOPH METH, V24, P153, DOI 10.1016/0165-022X(94)90068-X; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; EASTON EW, 1992, FEBS LETT, V308, P46, DOI 10.1016/0014-5793(92)81047-P; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; KANG S, 1993, J PARASITOL, V79, P815, DOI 10.2307/3283717; Kotani N, 2001, BIOCHEM J, V357, P827, DOI 10.1042/0264-6021:3570827; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Leffler H, 2001, Results Probl Cell Differ, V33, P57; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; MULDER H, 1995, EUR J BIOCHEM, V227, P175, DOI 10.1111/j.1432-1033.1995.tb20374.x; Nagayama Y, 1998, J BIOL CHEM, V273, P33423, DOI 10.1074/jbc.273.50.33423; Nakamura N, 2001, J NEUROCHEM, V76, P29, DOI 10.1046/j.1471-4159.2001.00004.x; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Neeleman AP, 1996, P NATL ACAD SCI USA, V93, P10111, DOI 10.1073/pnas.93.19.10111; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; Nyame AK, 2000, EXP PARASITOL, V96, P202, DOI 10.1006/expr.2000.4573; NYAME K, 1989, J BIOL CHEM, V264, P3235; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POWELL JT, 1976, J BIOL CHEM, V251, P3645; POWELL JT, 1976, J BIOL CHEM, V251, P3653; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Van den Nieuwenhof IM, 1999, GLYCOBIOLOGY, V9, P115, DOI 10.1093/glycob/9.2.115; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; van Die I, 1999, FEBS LETT, V450, P52, DOI 10.1016/S0014-5793(99)00462-7; van Remoortere A, 2001, INFECT IMMUN, V69, P2396, DOI 10.1128/IAI.69.4.2396-2401.2001; VandenEijnden DH, 1997, BIOCHEM SOC T, V25, P887, DOI 10.1042/bst0250887; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	87	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34924	34932		10.1074/jbc.M206112200	http://dx.doi.org/10.1074/jbc.M206112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167666	hybrid			2022-12-25	WOS:000178117000036
J	Murata, T; Sato, K; Hori, M; Ozaki, H; Karaki, H				Murata, T; Sato, K; Hori, M; Ozaki, H; Karaki, H			Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DEPENDENT RELAXATION; VASCULAR ENDOTHELIUM; ARTERY; EXPRESSION; DISEASE; LUNGS; RAT; PROLIFERATION; CALMODULIN	In the pulmonary artery isolated from 1-week hypoxia-induced pulmonary hypertensive rats, endothelial NO production stimulated by carbachol was decreased significantly in in situ visualization using diaminofluorescein-2 diacetate and also in cGMP content. This change was followed by the decrease in carbachol-induced endothelium-dependent relaxation. Protein expression of endothelial NO synthase (eNOS) and its regulatory proteins, caveolin-1 and heat shock protein 90, did not change in the hypoxic pulmonary artery, indicating that chronic hypoxia impairs eNOS activity at posttranslational level. In the hypoxic pulmonary artery, the increase in intracellular Ca2+ level stimulated by carbachol but not by ionomycin was reduced. We next focused on changes in Ca2+ sensitivity of the eNOS activation system. A morphological study revealed atrophy of endothelial cells and a peripheral condensation of eNOS in hypoxic endothelial cells preserving co-localization between eNOS and Golgi or plasma membranes. However, eNOS was tightly coupled with caveolin-1, and was dissociated from heat shock protein 90 or calmodulin in the hypoxic pulmonary artery in either the presence or absence of carbachol. Furthermore, eNOS Ser(1177) phosphorylation in both conditions significantly decreased without affecting Akt phosphorylation in the hypoxic artery. In conclusion, chronic hypoxia impairs endothelial Ca2+ metabolism and normal coupling between eNOS and caveolin-1 resulted in eNOS inactivity.	Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Dept Vet Pharmacol, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Radio Isotope Ctr, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Murata, T (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Dept Vet Pharmacol, Tokyo 1138657, Japan.			Murata, Takahisa/0000-0002-3328-0796				Barbera J A, 2000, Monaldi Arch Chest Dis, V55, P445; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Chen YF, 2000, AM J MED SCI, V320, P223, DOI 10.1097/00000441-200010000-00001; EDDAHIBI S, 1992, AM J PHYSIOL, V263, P194; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gaine S, 2000, JAMA-J AM MED ASSOC, V284, P3160, DOI 10.1001/jama.284.24.3160; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Hampl V, 2000, PHYSIOL REV, V80, P1337, DOI 10.1152/physrev.2000.80.4.1337; Jiang Z, 2001, J Extra Corpor Technol, V33, P23; Komai H, 2001, CARDIOVASC PATHOL, V10, P29, DOI 10.1016/S1054-8807(00)00063-6; LeCras TD, 1996, AM J PHYSIOL-LUNG C, V270, pL164, DOI 10.1152/ajplung.1996.270.1.L164; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; Maeda Y, 2000, J PHARMACOL EXP THER, V292, P387; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; Mason NA, 1998, J PATHOL, V185, P313, DOI 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Murata T, 2001, LIFE SCI, V69, P2685, DOI 10.1016/S0024-3205(01)01352-2; Murata T, 2001, EUR J PHARMACOL, V421, P45, DOI 10.1016/S0014-2999(01)01015-9; Nakazawa H, 1999, BRIT J PHARMACOL, V128, P1098, DOI 10.1038/sj.bjp.0702878; Rabinovitch M, 2001, J CLIN INVEST, V108, P1109; RABINOVITCH M, 1986, LAB INVEST, V55, P632; Resta TC, 1997, AM J PHYSIOL-HEART C, V272, pH806, DOI 10.1152/ajpheart.1997.272.2.H806; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; SATO K, 1990, J PHARMACOL EXP THER, V255, P114; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHAUL PW, 1993, J CARDIOVASC PHARM, V22, P819, DOI 10.1097/00005344-199312000-00007; Sugimoto K, 2000, HISTOCHEM CELL BIOL, V113, P341; Tyler RC, 1999, AM J PHYSIOL-LUNG C, V276, pL297, DOI 10.1152/ajplung.1999.276.2.L297; Veyssier-Belot C, 1999, CARDIOVASC RES, V44, P274, DOI 10.1016/S0008-6363(99)00230-8; Voelkel NF, 2000, J CLIN INVEST, V106, P733, DOI 10.1172/JCI11144; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; WANSTALL JC, 1992, BRIT J PHARMACOL, V107, P407, DOI 10.1111/j.1476-5381.1992.tb12759.x; XUE C, 1995, NEW ENGL J MED, V333, P1642; Xue C, 1996, HYPERTENSION, V28, P743, DOI 10.1161/01.HYP.28.5.743; XUE C, 1994, AM J PHYSIOL-LUNG C, V267, pL667, DOI 10.1152/ajplung.1994.267.6.L667	40	121	132	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44085	44092		10.1074/jbc.M205934200	http://dx.doi.org/10.1074/jbc.M205934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12185080	hybrid			2022-12-25	WOS:000179272000072
J	Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D				Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D			Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MITOCHONDRIAL DYSFUNCTION; BCL-2; CISPLATIN; CLEAVAGE; SURVIVAL; CALPAIN; CONFORMATION; DOMAIN; CELLS	The anthracyclin doxorubicin (DXR) is a major antitumor agent known to cause cellular damage via a number of mechanisms including free radical formation and inhibition of topoisomerase II. It is not clear, however, how the subsequent lesions may lead to the apoptotic death of the cell. We have here examined the effects of DXR on activation of pro-apoptotic members of the Bcl-2 family, all of which are connected to the mitochondrial events of apoptosis. In two human cell lines (lymphoma and myeloma), clinically relevant concentrations of DXR were found to induce apoptosis, first observed after 24 It of treatment. Apoptosis correlated with modulation of Bak and Bax to their active conformations. bax-as well as bak-deficient mouse embryo fibroblasts were resistant to DXR compared with wild-type mouse embryo fibroblasts further supporting a role for these proteins as main DXR-induced apoptosis regulators. Furthermore, using immunocytochemistry as well as chemical blocking of putative apical pathways we could demonstrate that Bak is activated prior to Bax. In the human cell lines, DXR was furthermore found to induce high protein levels of Bik, another BH3-only protein. DXR-induced apoptosis was completely blocked in Bcl-2-overexpressing U266 cells. Interestingly, in Bcl-2-transfected cells Bak activation was also blocked, while Bax was still partially active in agreement with differential regulation of these two proteins. Furthermore, co-incubation of the phosphatidylinositol 3-kinase (PI3K)-inhibitor LY294002 potentiated the apoptotic response to DXR. This enhanced apoptosis was preceded by enhanced Bak and Bax activation, and both responses as well as apoptosis were blocked in transfectants overexpressing Bcl-2. In summary, several pieces of evidence suggest that DXR induces apoptosis through a sequential and differential activation of Bak and Bax.	Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.	Dan.Grander@cck.ki.se		Panaretakis, Theocharis/0000-0001-5754-6950; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Decaudin D, 1997, CANCER RES, V57, P62; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Finnegan NM, 2001, BRIT J CANCER, V85, P115, DOI 10.1054/bjoc.2001.1850; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	126	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44317	44326		10.1074/jbc.M205273200	http://dx.doi.org/10.1074/jbc.M205273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12193597	hybrid			2022-12-25	WOS:000179272000102
J	Haapasalo, A; Sipola, L; Larsson, K; Akerman, KEO; Stoilov, P; Stamm, S; Wong, G; Castren, E				Haapasalo, A; Sipola, L; Larsson, K; Akerman, KEO; Stoilov, P; Stamm, S; Wong, G; Castren, E			Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRIM Isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTORS; AFFINITY NGF RECEPTOR; FULL-LENGTH; SYNAPTIC TRANSMISSION; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; DOWN-REGULATION; DIFFERENTIAL REGULATION	Brain-derived neurotrophic factor (BDNF) signaling through its receptor TRKB modulates survival, differentiation, and activity of neurons. BDNF activates TRKB on the cell surface, which leads to the initiation of intracellular signaling cascades and different biological responses in neurons. Neuronal activity has been shown to regulate TRKB levels on the plasma membrane of neurons, but little is known about other factors affecting TRKB surface expression levels. We report here that BDNF regulates the cell surface levels of transfected or endogenously expressed full-length TRKB, depending on the exposure time in neuroblastoma cells and primary hippocampal neurons. BDNF rapidly increases TRKB surface expression levels in seconds, whereas treatment of cells with BDNF for a longer time (minutes to hours) leads to decreased TRKB surface levels. Coexpression of the full-length TRKB together with the truncated TRKB.T1 isoform. results in decreased levels of full-length TRKB on the cell surface. This effect is specific to the T1 isoform, because coexpression of a kinase-dead TRKB mutant or another kinase domain-lacking TRKB form, truncated T-Shc, leads to increased TRKB surface levels. Our results suggest that regulation of TRKB surface expression levels by different factors is tightly controlled by complex mechanisms in active neurons.	Univ Kuopio, Dept Neurobiol, AI Virtanen Inst, Kuopio 70211, Finland; Univ Kuopio, Dept Psychiat, Kuopio 70211, Finland; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	University of Eastern Finland; University of Eastern Finland; University of Erlangen Nuremberg	Castren, E (corresponding author), Univ Kuopio, Dept Neurobiol, AI Virtanen Inst, POB 1627, Kuopio 70211, Finland.		Castrén, Eero/A-4618-2010	Castren, Eero/0000-0002-1402-2791; Haapasalo, Annakaisa/0000-0003-0959-2957				ARMANINI MP, 1995, EUR J NEUROSCI, V7, P1403, DOI 10.1111/j.1460-9568.1995.tb01132.x; Balkowiec A, 2000, J NEUROSCI, V20, P7417, DOI 10.1523/jneurosci.20-19-07417.2000; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BECK KD, 1993, J NEUROSCI, V13, P4001; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; Drake CT, 1999, J NEUROSCI, V19, P8009; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Eide FF, 1996, J NEUROSCI, V16, P3123; Frank L, 1997, EXP NEUROL, V145, P62, DOI 10.1006/exnr.1997.6440; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; HAAPASALO A, 1999, BIOCHEMICA, V3, P20; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; Kojima M, 2001, J NEUROSCI RES, V64, P1, DOI 10.1002/jnr.1080; Kostyuk PG, 1999, NEUROSCIENCE, V92, P1157, DOI 10.1016/S0306-4522(99)00221-3; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; Kryl D, 1999, J NEUROSCI, V19, P5823, DOI 10.1523/JNEUROSCI.19-14-05823.1999; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Rubio N, 1997, EUR J NEUROSCI, V9, P1847, DOI 10.1111/j.1460-9568.1997.tb00751.x; Saarelainen T, 2001, CELL MOL NEUROBIOL, V21, P429, DOI 10.1023/A:1012775808253; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Takei N, 1997, J NEUROCHEM, V68, P370; Weible MW, 2001, CYTOMETRY, V43, P182, DOI 10.1002/1097-0320(20010301)43:3<182::AID-CYTO1047>3.0.CO;2-J; WIDMER HR, 1993, BRAIN RES, V614, P325, DOI 10.1016/0006-8993(93)91051-S; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911	61	118	125	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43160	43167		10.1074/jbc.M205202200	http://dx.doi.org/10.1074/jbc.M205202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202482	hybrid			2022-12-25	WOS:000179081200097
J	Madhankumar, AB; Mintz, A; Debinski, W				Madhankumar, AB; Mintz, A; Debinski, W			Alanine-scanning mutagenesis of alpha-helix D segment of interleukin 13 reveals new functionally important residues of the cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; BINDING; CELLS; IL-13; EXPRESSION; COMPONENT; CLONING; SITES; IL4	We documented that a-helices A, C, and D in human interleukin-13 (IL13) participate in interaction with its respective receptors. We hypothesized that a-helix D is the site II of the cytokine that binds IL13Ralpha1, a component of the normal tissue heterodimeric signaling IL13/4 receptor (IL13/4R), and that a-helix D independently binds a monomeric IL13Ralpha2 receptor, which is a nonsignaling glioma-restricted receptor for IL13. Therefore, we alanine-scanned mutagenized helix D of IL13 to identify the residues involved in the respective receptors interaction. Recombinant muteins of IL13 were produced in Escherichia coli, and their structural integrity and identity were verified. The alanine mutants were tested in functional cellular assays, in which IL13 interaction with IL13Ralpha2 (glioma cells) or an ability to functionally stimulate IL13/4R (TF-1 cells) were examined, and also in binding assays. We found that residues 105, 106, and 109 of the D-helix of IL13 are responsible for interacting with the glioma-associated receptor. Moreover, glutamic acids at positions 92 and 110, and leucine at position 104 was found to be important for IL13/4R stimulation. Thus, alpha-helix D of IL13 is the primary site responsible for interaction with the IL13 binding proteins. We propose a model that illustrates the binding mode of IL13 with cancer-related IL13Ralpha2 and physiological IL13/4R.	Penn State Univ, Coll Med, Dept Surg, Neurosurg Sect, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Debinski, W (corresponding author), Penn State Univ, Coll Med, Dept Surg, Neurosurg Sect, 500 Univ Dr, Hershey, PA 17033 USA.	wdebinski@psu.edu			NCI NIH HHS [2R01-CA74145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Debinski W, 1998, CRIT REV ONCOGENESIS, V9, P255; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Debinski W, 1999, CLIN CANCER RES, V5, p3143S; Debinski W, 2000, MOL MED, V6, P440, DOI 10.1007/BF03401786; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Eisenmesser EZ, 2001, J MOL BIOL, V310, P231, DOI 10.1006/jmbi.2001.4765; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HUANG SK, 1995, J IMMUNOL, V155, P2688; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12273, DOI 10.1021/bi00097a001; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mintz A, 2002, NEOPLASIA, V4, P388, DOI 10.1038/sj.neo.7900234; Moy FJ, 2001, J MOL BIOL, V310, P219, DOI 10.1006/jmbi.2001.4764; Nash KT, 2001, CRIT REV ONCOL HEMAT, V39, P87, DOI 10.1016/S1040-8428(01)00124-X; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P1; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Thompson JP, 1999, J BIOL CHEM, V274, P29944, DOI 10.1074/jbc.274.42.29944; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; WILLIAMS SC, 2000, RRD MOLEC CELL BIOL, V1, P19; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	34	41	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43194	43205		10.1074/jbc.M205047200	http://dx.doi.org/10.1074/jbc.M205047200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12189139	hybrid			2022-12-25	WOS:000179081200101
J	Sakane, F; Imai, S; Yamada, K; Murakami, T; Tsushima, S; Kanoh, H				Sakane, F; Imai, S; Yamada, K; Murakami, T; Tsushima, S; Kanoh, H			Alternative splicing of the human diacylglycerol kinase 8 gene generates two isoforms differing in their expression patterns and in regulatory functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; ZETA; ALPHA; ACTIVATION; MECHANISM; RECEPTOR; ISOZYME; FAMILY; CELLS	Diacylglycerol kinase (DGK) plays an important role in signal transduction through modulating the balance between two signaling lipids, diacylglycerol and phosphatidic acid. DGKdelta (type II isozyme) contains a pleckstrin homology domain at the N terminus and a sterile a motif domain at the C terminus. We identified another DGKdelta isoform (DGKdelta2, 135 kDa) that shared the same sequence with DGKdelta previously cloned (DGKdelta1, 130 kDa) except for the 52 residues N-terminally extended. Analysis of panels of human normal and tumor tissue cDNAs revealed that DGKdelta2 was ubiquitously expressed in all normal and tumor tissues examined, whereas the transcript of DGKdelta1 was detected only in ovary and spleen, and in a limited set of tumor-derived cells. The expression of DGKdelta2 was induced by treating cells with epidermal growth factor and tumor-promoting phorbol ester. In contrast, the levels of mRNA and protein of DGKdelta1 were suppressed by phorbol ester treatment. It thus becomes clear that the two DGKdelta isoforms are expressed under distinct regulatory mechanisms. DGKdelta1 was translocated through its pleckstrin homology domain from the cytoplasm to the plasma membrane in response to phorbol ester stimulation, whereas DGKdelta2 remained in the cytoplasm even after stimulation. Further experiments showed that the delta2-specific N-terminal sequence blocks the phorbol ester-dependent translocation of this isoform. Co-immunoprecipitation analysis of differently tagged DGKdelta1 and DGKdelta2 proteins showed that they were able to form homo- as well as hetero-oligomers. Taken together, alternative splicing of the human DGKdelta gene generates at least two isoforms, differing in their expressions and regulatory functions.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Liberal Arts & Sci, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Houssa B, 1997, J BIOL CHEM, V272, P10422; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Raddatz D, 1996, HEPATOLOGY, V24, P928; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3	36	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43519	43526		10.1074/jbc.M206895200	http://dx.doi.org/10.1074/jbc.M206895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12200442	hybrid			2022-12-25	WOS:000179081200137
J	Badaut, C; Williams, R; Arluison, V; Bouffartigues, E; Robert, B; Buc, H; Rimsky, S				Badaut, C; Williams, R; Arluison, V; Bouffartigues, E; Robert, B; Buc, H; Rimsky, S			The degree of oligomerization of the H-NS nucleoid structuring protein is related to specific binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI BGL PROMOTER; ESCHERICHIA-COLI; CURVED DNA; PROU OPERON; IN-VITRO; GENE-EXPRESSION; FUNCTIONAL-SIGNIFICANCE; STATIONARY-PHASE; RNA-POLYMERASE; TRANSCRIPTION	At several E. coli promoters, initiation of transcription is repressed by a tight nucleoprotein complex formed by the assembly of the H-NS protein. In order to characterize the relationship between the structure of H-NS oligomers in solution and on relevant DNA fragments, we have compared wild-type H-NS and several transdominant H-NS mutants using gel shift assays, DNase I footprinting, analytical ultracentrifugation, and reactivity toward a cross-linking reagent. In solution, oligomerization occurs through two protein interfaces, one necessary to construct a dimeric core (and involving residues 1-64) and the other required for subsequent assembly of these dimers. We show that, as well as region 64-95, residues present in the NH2-terminal coiled coil domain also participate in this second interface. Our results support the view that the same interacting interfaces are also involved on the DNA. We propose that the dimeric core recognizes specific motifs, with the second interface being critical for their correct head to tail assembly. The COOH-terminal domain of the protein contains the DNA binding motif essential for the discrimination of this specific functional assembly over competitive nonspecific H-NS polymers.	Inst Pasteur, CNRS, URA 1773, F-75724 Paris 15, France; Inst Gustave Roussy, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Ecole Normale Super Cachan, UMR 8532, F-94805 Villejuif, France; Commissariat Energie Atom Saclay, CNRS, Sect Biophys Fonct Membranaires, DBJC CEA, F-91191 Gif Sur Yvette, France; Commissariat Energie Atom Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Rimsky, S (corresponding author), Inst Gustave Roussy, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Bouffartigues, Emeline/CAG-9939-2022; Robert, Bruno/D-1264-2012; Arluison, Veronique S/F-2714-2019	Bouffartigues, Emeline/0000-0003-2569-4961; Robert, Bruno/0000-0001-5999-4538; Arluison, Veronique S/0000-0003-4056-7282; Badaut, Cyril/0000-0002-0064-6384; Rimsky, Sylvie/0000-0003-2654-3014; Williams, Roy/0000-0002-5442-9166				Afflerbach H, 1998, MOL MICROBIOL, V28, P641, DOI 10.1046/j.1365-2958.1998.00829.x; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BARTH M, 1995, J BACTERIOL, V177, P3455, DOI 10.1128/jb.177.12.3455-3464.1995; Caramel A, 2000, MOL MICROBIOL, V36, P85, DOI 10.1046/j.1365-2958.2000.01827.x; Ceschini S, 2000, J BIOL CHEM, V275, P729, DOI 10.1074/jbc.275.2.729; Dame RT, 2000, NUCLEIC ACIDS RES, V28, P3504, DOI 10.1093/nar/28.18.3504; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; DESANTIS P, 1988, BIOPHYS CHEM, V32, P305, DOI 10.1016/0301-4622(88)87016-9; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; Francetic O, 2000, MOL MICROBIOL, V35, P1506, DOI 10.1046/j.1365-2958.2000.01817.x; Free A, 2001, MOL MICROBIOL, V42, P903, DOI 10.1046/j.1365-2958.2001.02678.x; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HIROTA Y, 1992, NUCL ACIDS S SER, V25, P151; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; Jordi JAM, 2000, J BIOL CHEM, V275, P12123, DOI 10.1074/jbc.275.16.12123; Levinthal M, 1996, RES MICROBIOL, V147, P333, DOI 10.1016/0923-2508(96)84708-5; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Mukerji M, 1997, MOL MICROBIOL, V24, P617, DOI 10.1046/j.1365-2958.1997.3621725.x; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; Rajkumari K, 2001, J BACTERIOL, V183, P6543, DOI 10.1128/JB.183.22.6543-6550.2001; Rajkumari K, 1996, J BACTERIOL, V178, P4176, DOI 10.1128/jb.178.14.4176-4181.1996; Rimsky S, 2001, MOL MICROBIOL, V42, P1311, DOI 10.1046/j.1365-2958.2001.02706.x; Schneider R, 2001, NUCLEIC ACIDS RES, V29, P5107, DOI 10.1093/nar/29.24.5107; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; Schroder O, 2000, J MOL BIOL, V298, P737, DOI 10.1006/jmbi.2000.3708; Shindo H, 1999, FEBS LETT, V455, P63, DOI 10.1016/S0014-5793(99)00862-5; Smyth CP, 2000, MOL MICROBIOL, V36, P962, DOI 10.1046/j.1365-2958.2000.01917.x; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; TANAKA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1097, DOI 10.1271/bbb.58.1097; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; Timchenko T, 1996, EMBO J, V15, P3986, DOI 10.1002/j.1460-2075.1996.tb00772.x; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; Williams RM, 1996, J BACTERIOL, V178, P4335, DOI 10.1128/jb.178.15.4335-4343.1996; Yarmolinsky M, 2000, CURR OPIN MICROBIOL, V3, P138, DOI 10.1016/S1369-5274(00)00065-5; Zhang AX, 1996, EMBO J, V15, P1340, DOI 10.1002/j.1460-2075.1996.tb00476.x	43	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41657	41666		10.1074/jbc.M206037200	http://dx.doi.org/10.1074/jbc.M206037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200432	hybrid			2022-12-25	WOS:000178985300047
J	Guo, CY; Brautigan, DL; Larner, JM				Guo, CY; Brautigan, DL; Larner, JM			Ionizing radiation activates nuclear protein phosphatase-1 by ATM-dependent dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; SIGNAL-TRANSDUCTION; HISTONE H1; PHOSPHORYLATION; TYPE-1; ASSOCIATION; MUTATION; DAMAGE; IDENTIFICATION	Ionizing radiation (IR) is known to activate multiple signaling pathways, resulting in diverse stress responses including apoptosis, cell cycle arrest, and gene induction. IR-activated cell cycle checkpoints are regulated by Ser/Thr phosphorylation, so we tested to see if protein phosphatases were targets of an IR-activated damage-sensing pathway. Jurkat cells were subjected to IR or sham radiation followed by brief P-32 metabolic labeling. Nuclear extracts were subjected to microcystin affinity chromatography to recover phosphatases, and the proteins were analyzed by two-dimensional gel electrophoresis. Protein sequencing revealed that the microcystin-bound proteins with the greatest reduction in P-32 intensity following IR were the alpha and delta isoforms of protein phosphatase 1 (PP1). Both of these PP1 isoforms contain an Arg-Pro-Ile/Val-Thr-Pro-Pro-Arg sequence near the C terminus, a known site of phosphorylation by Cdc/Cdk kinases, and phosphorylation attenuates phosphatase activity. In wild-type Jurkat cells or ataxia telangiectasia (AT) cells that are stably transfected with full-length ATM kinase, IR resulted in net dephosphorylation of this site in PP1 and produced activation of PP1. However, in AT cells that are deficient in ATM, IR failed to induce dephosphorylation or activation of PP1. IR-induced PP1 activation in the nucleus may be a critical component in an ATM-mediated pathway controlling checkpoint activation.	Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Dept Radiat Oncol, Box 800383, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA 72622, CA 40042] Funding Source: Medline; NIGMS NIH HHS [GM 56362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Cohen PTW, 2002, J CELL SCI, V115, P241; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1991, J BIOL CHEM, V266, P18889; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Guo CY, 2000, CANCER RES, V60, P5667; Guo CY, 2002, J BIOL CHEM, V277, P4839, DOI 10.1074/jbc.M110092200; Hughes M, 1996, EMBO J, V15, P4574, DOI 10.1002/j.1460-2075.1996.tb00835.x; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Larner JM, 1997, CANCER SURV, V29, P25; Lavin MF, 1996, CURR OPIN IMMUNOL, V8, P459, DOI 10.1016/S0952-7915(96)80030-6; LIU VF, 1995, STEM CELLS, V13, P117; MARTIN BI, 1994, PROTEIN EXPRES PURIF, V5, P211, DOI 10.1006/prep.1994.1033; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Paulson JR, 1996, J CELL SCI, V109, P1437; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Thompson LJ, 1997, J BIOL CHEM, V272, P29693, DOI 10.1074/jbc.272.47.29693; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	37	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41756	41761		10.1074/jbc.M207519200	http://dx.doi.org/10.1074/jbc.M207519200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202491	hybrid			2022-12-25	WOS:000178985300059
J	Jeyaretnam, B; Glushka, J; Kolli, VSK; Carlson, RW				Jeyaretnam, B; Glushka, J; Kolli, VSK; Carlson, RW			Characterization of a novel lipid-A from Rhizobium species Sin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							27-HYDROXYOCTACOSANOIC ACID; LIPOPOLYSACCHARIDE LPS; INFECTION THREAD; LETHAL TOXICITY; LEGUMINOSARUM; BIOSYNTHESIS; COMPONENT; PHASEOLI; MUTANT; REGION	The structure of the lipid-A from Rhizobium species Sin-1, a nitrogen-fixing Gram-negative bacterial symbiont of Sesbania, was determined by composition, nuclear magnetic resonance spectroscopic, and mass spectrometric analyses. The lipid-A preparation consisted of a mixture of structures due to differences in fatty acylation and in the glycosyl backbone. There were two different disaccharide backbones. One disaccharide consisted of a distal glucosaminosyl residue beta-linked to position 6 of a proximal 2-aminoglucono-1,5-lactonosyl residue, and in the second disaccharide, the proximal residue was 2-amino-2,3-dideoxy-D-erythro-hex-2-enono-1,5-lactone. For both disaccharides, the distal glucosamine was acylated at C-2' primarily with beta-hydroxy-palmitate (beta-OHC16:0) which, in turn, was O-acylated with 27-hydroxyoctacosanoic acid. For some of the lipid-A molecules, the distal glucosaminosyl residue was also acylated at C-3' with beta-hydroxymyristate (beta-OHC14: 0), whereas other molecules were devoid of this acyl substituent. Both the 2-aminoglucono-1,5-lactonosyl and 2-amino-2,3-dideoxy-D-erythro-hex-2-enono-1,5-lactonosyl residues were acylated at C-2, primarily with beta-OHC16:0. Minor amounts of lipid-A molecules contained beta-OHC14:0 at C-3 and/or beta-hydroxystearate (beta-OHC18:0) or beta-hydroxyoctadecenoate (beta-OHC18:1) as the C-2 and C-2' N-acyl substituents.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.				NIGMS NIH HHS [GM61761, GM89583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1993, Patent No. 536969; DEMAAGD RA, 1989, J BACTERIOL, V171, P1143, DOI 10.1128/jb.171.2.1143-1150.1989; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; Jarvis BW, 1997, INFECT IMMUN, V65, P3011, DOI 10.1128/IAI.65.8.3011-3016.1997; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; Kawata T, 1999, BRIT J PHARMACOL, V127, P853, DOI 10.1038/sj.bjp.0702596; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V9, P237, DOI 10.1111/j.1574-695X.1994.tb00499.x; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; Leaf TA, 1996, MICROBIOL-SGM, V142, P1169, DOI 10.1099/13500872-142-5-1169; Literacka E, 1999, FEBS LETT, V456, P227, DOI 10.1016/S0014-5793(99)00952-7; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; LOPPNOW H, 1990, ADV EXP MED BIOL, V256, P561; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MAYER H, 1989, ARCH MICROBIOL, V151, P111, DOI 10.1007/BF00414423; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Pedron T, 2000, IMMUNOLOGY, V101, P262, DOI 10.1046/j.1365-2567.2000.00107.x; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RANA D, 1995, FEMS MICROBIOL LETT, V134, P19, DOI 10.1111/j.1574-6968.1995.tb07908.x; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Russa R, 1996, ARCH MICROBIOL, V165, P26, DOI 10.1007/s002030050292; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; Suda Y, 1997, J BIOCHEM-TOKYO, V121, P1129; TAKADA H, 1992, BACTERIAL ENDOTOXIC, V1, P107; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; Urbanik-Sypniewska T, 2000, IMMUNOBIOLOGY, V202, P408, DOI 10.1016/S0171-2985(00)80043-1; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; Vandenplas ML, 2002, J BIOL CHEM, V277, P41811, DOI 10.1074/jbc.M205252200; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	48	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41802	41810		10.1074/jbc.M112140200	http://dx.doi.org/10.1074/jbc.M112140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12193590	hybrid			2022-12-25	WOS:000178985300065
J	Nishida, T; Yasuda, H				Nishida, T; Yasuda, H			PIAS1 and PIASx alpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; COVALENT MODIFICATION; GENE ACTIVATION; CONJUGATION; INHIBITOR; ENZYME; PML; P53; IDENTIFICATION; COREGULATOR	The androgen receptor (AR) has been shown to be modified by SUMO-1, a ubiquitin-like protein. Recently we showed that PIAS family proteins function as SUMO-E3 ligases. Here we provide evidence that PIAS1 and PIASxalpha act as specific SUMO-E3 ligases for the AR. PIAS1 and PIASxalpha but not PIAS3 or PIASxbeta enhanced the sumoylation of AR in intact cells and in vitro. PIAS1 and PIASxalpha bound Ubc9, the E2 enzyme for SUMO-1, in a RING finger-like domain-dependent manner. Consistent with previous studies (Kahyo, T., Nishida, T., and Yasuda, H. (2001) Mol. Cell 8, 713-718), the RING finger-like domain of the SUMO-E3 was required for ligase activity. The binding of a ligand, e.g. testosterone, to the AR was required for the sumoylation of AR in intact cells. Although AR-dependent transcription was enhanced by PIAS proteins without sumoylation of the receptor, PIAS1 and PIASxalpha repressed AR-dependent transcription in a manner dependent on the ectopic expression of SUMO-1 and their RING finger-like domain. Furthermore, the sumoylation sites of the AR were necessary for the full repressive effect on AR-dependent transactivation, indicating that the sumoylation of AR was crucial for the repression of transactivation of the AR. Thus, PIAS1 and PIASxalpha modulate the AR-dependent transactivation, which, at least in part, can be attributed to their SUMO-E3 activity toward AR.	Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Biol, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Yasuda, H (corresponding author), Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200	39	173	176	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41311	41317		10.1074/jbc.M206741200	http://dx.doi.org/10.1074/jbc.M206741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177000	hybrid			2022-12-25	WOS:000178985300005
J	Noda, M; Yamashita, S; Takahashi, N; Eto, K; Shen, LM; Izumi, K; Daniel, S; Tsubamoto, Y; Nemoto, T; Iino, M; Kasai, H; Sharp, GWG; Kadowaki, T				Noda, M; Yamashita, S; Takahashi, N; Eto, K; Shen, LM; Izumi, K; Daniel, S; Tsubamoto, Y; Nemoto, T; Iino, M; Kasai, H; Sharp, GWG; Kadowaki, T			Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; LACTATE-DEHYDROGENASE; PANCREATIC-ISLETS; DNA; MELLITUS; LINE; PREVALENCE; DEAFNESS; RELEASE; GENE	To elucidate the mechanism underlying diabetes caused by mitochondrial gene mutations, we created a model by applying 0.4 mug/ml ethidium bromide (EtBr) to the murine pancreatic beta cell line betaHC9; in this model, transcription of mitochondrial DNA, but not that of nuclear DNA, was suppressed in association with impairment of glucose-stimulated insulin release (Hayakawa, T., Noda, M., Yasuda, K., Yorifuji, H., Taniguchi, S., Miwa, I., Sakura, H., Terauchi, Y., Hayashi, J.-L, Sharp, G. W. G., Kanazawa, Y., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1998) J. Biol Chem. 273,20300-20307). To elucidate fully the metabolism-secretion coupling in these cells, we measured glucose oxidation, utilization, and lactate production. We also evaluated NADH autofluorescence in betaHC9 cells using two-photon excitation laser microscopy. In addition, we recorded the membrane potential and determined the ATP and ADP contents of the cells. The results indicated 22.2 mm glucose oxidation to be severely decreased by EtBr treatment compared with control cells (by 63% on day 4 and by 78% on day 6; both p < 0.01). By contrast, glucose utilization was only marginally decreased. Lactate production under 22.2 mm glucose was increased by 2.9- and 3.5-fold by EtBr treatment on days 4 and 6, respectively (both p < 0.01). Cellular NADH at 2.8 mm glucose was increased by 35 and 43% by EtBr on days 4 and 6 (both p < 0.01). These data suggest that reduced expression of the mitochondrial electron transport system causes NADH accumulation in 13 cells, thereby halting the tricarboxylic acid cycle on one hand, and on the other hand facilitating anaerobic glucose metabolism. Glucose-induced insulin secretion was lost rapidly along with the EtBr treatment with concomitant losses of membrane potential depolarization and the [Ca2+](i) increase, whereas glibenclamide-induced changes persisted. This is the first report to demonstrate the connection between metabolic alteration of electron transport system and that of tricarboxylic acid cycle and its impact on insulin secretion.	Univ Tokyo, Grad Sch Med Sci, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Cornell University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med Sci, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Noda, Mitsuhiko/W-3905-2019; Nemoto, Tomomi/B-4412-2012	Noda, Mitsuhiko/0000-0003-0413-4631; Nemoto, Tomomi/0000-0001-6102-1495; Kasai, Haruo/0000-0003-2327-9027				AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; AKAZAWA H, 1994, DIABETES RES CLIN PR, V24, pS23; Alcazar O, 2000, BIOCHEM J, V352, P373, DOI 10.1042/0264-6021:3520373; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; DEITEMARY P, 1996, J BIOL CHEM, V271, P20559; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; EIZIRIK DL, 1989, DIABETOLOGIA, V32, P769; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; HAYAKAWA T, 1979, J GEN APPL MICROBIOL, V25, P255, DOI 10.2323/jgam.25.255; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; KIKUCHI M, 1974, DIABETES, V23, P550, DOI 10.2337/diab.23.6.550; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; Maassen JA, 1996, DIABETOLOGIA, V39, P375; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; MIWA I, 1991, BIOCHEM BIOPH RES CO, V180, P709, DOI 10.1016/S0006-291X(05)81123-4; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VIONNET N, 1993, LANCET, V342, P1429, DOI 10.1016/0140-6736(93)92792-R; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8	32	59	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41817	41826		10.1074/jbc.M207690200	http://dx.doi.org/10.1074/jbc.M207690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12169697	hybrid			2022-12-25	WOS:000178985300067
J	Pinkoski, MJ; Droin, NM; Green, DR				Pinkoski, MJ; Droin, NM; Green, DR			Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERSUS-HOST-DISEASE; INFLAMMATORY BOWEL-DISEASE; CD4(+) T-CELLS; ULCERATIVE-COLITIS; SCID MICE; TNF-ALPHA; INDUCED APOPTOSIS; EPITHELIAL-CELLS; FACTOR RECEPTOR; CROHNS-DISEASE	Members of the tumor necrosis factor (TNF) and TNF receptor families play important roles in inducing apoptosis and mediating the inflammatory response. Activated T lymphocytes can trigger the expression of Fas-ligand on non-lymphoid tissue, such as intestinal epithelial cells (IEC), and this, in turn, can induce apoptosis in the T cells. Here, we examine the role of TNFalpha in this feedback regulation. Injection of TNFalpha into mice caused a rapid up-regulation of Fas-ligand mRNA in IEC. TNFalpha-induced activation of the Fas-ligand promoter in IEC requires NF-kappaB as this was blocked by an I-kappaBalphaM super-repressor and by mutation of an NF-kappaB site in the Fas-ligand promoter. Activation of T cells by antigen induced Fas-ligand expression in IEC in vivo in wild type, but not in TNFalpha-/- or TNFR1-/- mice. These results define a novel pathway wherein TNFa, produced by activated T cells in the intestine, induce Fas-ligand expression in IEC. This is the first observation that one member of the TNF superfamily mediates the regulation of another family member and represents a potential feedback mechanism controlling lymphocyte infiltration and inflammation in the small intestine.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Pinkoski, MJ (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Droin, Nathalie M/Y-5506-2018; Green, Douglas R/N-8083-2018	Droin, Nathalie M/0000-0002-6099-5324; Green, Douglas R/0000-0002-7332-1417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044828] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44828-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; Bregenholt S, 2001, IMMUNOL LETT, V78, P7, DOI 10.1016/S0165-2478(01)00240-1; Bregenholt S, 1998, EUR J IMMUNOL, V28, P379, DOI 10.1002/(SICI)1521-4141(199801)28:01<379::AID-IMMU379>3.0.CO;2-X; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; EIGENBRODT ML, 1990, AM J PATHOL, V137, P1065; Elzey BD, 2001, J IMMUNOL, V167, P3049, DOI 10.4049/jimmunol.167.6.3049; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Inagaki-Ohara K, 2001, ONCOGENE, V20, P812, DOI 10.1038/sj.onc.1204172; Iwamoto M, 1996, J PATHOL, V180, P152; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KRAMER B, 1995, J INFLAMM, V45, P183; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; Masuda H, 1995, J Clin Lab Immunol, V46, P111; MURATA Y, 1995, J GASTROENTEROL, V30, P56; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Pinkoski MJ, 2000, NAT IMMUNOL, V1, P461, DOI 10.1038/82701; Plevy SE, 1997, J IMMUNOL, V159, P6276; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Rooney I, 2000, METHOD ENZYMOL, V322, P345; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Speiser DE, 1996, EUR J IMMUNOL, V26, P3055, DOI 10.1002/eji.1830261235; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Takeuchi T, 1999, J IMMUNOL, V162, P518; Trobonjaca Z, 2001, J IMMUNOL, V166, P3804, DOI 10.4049/jimmunol.166.6.3804; Ueyama H, 1998, GUT, V43, P48, DOI 10.1136/gut.43.1.48; VAN AD, 1996, SCIENCE, V274, P787; van den Brink MRM, 2000, TRANSPLANTATION, V70, P184; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Williams AM, 1999, CLIN EXP IMMUNOL, V116, P415; Zhang HG, 2000, J CLIN INVEST, V105, P813, DOI 10.1172/JCI8236; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	44	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42380	42385		10.1074/jbc.M208167200	http://dx.doi.org/10.1074/jbc.M208167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196549	hybrid			2022-12-25	WOS:000178985300135
J	Riley, AM; Morris, SA; Nerou, EP; Correa, V; Potter, BVL; Taylor, CW				Riley, AM; Morris, SA; Nerou, EP; Correa, V; Potter, BVL; Taylor, CW			Interactions of inositol 1,4,5-trisphosphate (IP3) receptors with synthetic poly(ethylene glycol)-linked dimers of IP3 suggest close spacing of the IP3-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; TRISPHOSPHATE RECEPTORS; CA2+; DETERMINANTS; RECOGNITION; INHIBITION; EXPRESSION; MOLECULES; PROTEIN; CELLS	The distances between the inositol 1,4,5-trisphosphate (IP3)-binding sites of tetrameric IP3 receptors were probed using dimers of IP3 linked by poly(ethylene glycol) (PEG) molecules of differing lengths (1-8 nm). Each of the dimers potently stimulated Ca-45(2+) release from permeabilized cells expressing predominantly type 1 (SH-SY5Y cells) or type 2 (hepatocytes) IP3 receptors. The shortest dimers, with PEG linkers of an effective length of 1.5 nm or less, were the most potent, being 3-4-fold more potent than IP3. In radioligand binding experiments using cerebellar membranes, the shortest dimers bound with highest affinity, although the longest dimer (8 nm) also bound with almost 4-fold greater affinity than IP3. The affinity of monomeric IP3 with only the PEG attached was 2-fold weaker than IP3, confirming that the increased affinity of the dimers requires the presence of both IP3 motifs. The increased affinity of the long dimer probably results from the linked IP3 molecules binding to sites on different receptors, because the dimer bound with greater affinity than IP3 to cerebellar membranes, where receptors are densely packed, but with the same affinity as IP3 to purified receptors. IP3 and the IP3 dimers, irrespective of their length, bound with similar affinity to a monomeric IP3-binding domain of the type 1 IP3 receptor expressed in bacteria. Short dimers therefore bind with increased affinity only when the receptor is tetrameric. We conclude that the four IP3-binding sites of an IP3 receptor may be separated by as little as 1.5 nm and are therefore likely to be placed centrally in this large (25 x 25 nm) structure, consistent with previous work indicating a close association between the central pore and the IP3-binding sites of the IP3 receptor.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Cambridge; University of Bath	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	Riley, Andrew M/F-3526-2013; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012; Taylor, Colin/G-2447-2010	Riley, Andrew M/0000-0001-9003-3540; Morris, Stephen/0000-0002-7640-8657; Taylor, Colin/0000-0001-7771-1044				Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; Correa V, 2001, MOL PHARMACOL, V59, P1206, DOI 10.1124/mol.59.5.1206; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; HIRATA M, 1990, J BIOL CHEM, V265, P8404; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Katayama E, 1996, EMBO J, V15, P4844, DOI 10.1002/j.1460-2075.1996.tb00865.x; KNOLL D, 1983, J BIOL CHEM, V258, P5710; Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227; Loidl G, 1999, P NATL ACAD SCI USA, V96, P5418, DOI 10.1073/pnas.96.10.5418; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Morris SA, 2002, BIOCHEM J, V367, P113, DOI 10.1042/BJ20020675; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Portoghese PS, 2001, J MED CHEM, V44, P2259, DOI 10.1021/jm010158+; Rajeswaran WG, 2001, J MED CHEM, V44, P4563, DOI 10.1021/jm0102405; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; Riley AM, 2000, CHEM COMMUN, P983, DOI 10.1039/b002312o; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaschke N, 2001, CHEM BIOL, V8, P313, DOI 10.1016/S1074-5521(01)00011-4; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; YAMASHITA K, 1995, J AM CHEM SOC, V117, P6249, DOI 10.1021/ja00128a011; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	34	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40290	40295		10.1074/jbc.M206925200	http://dx.doi.org/10.1074/jbc.M206925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183463	hybrid			2022-12-25	WOS:000178791400019
J	Zaborowska, Z; Furste, JP; Erdmann, VA; Kurreck, J				Zaborowska, Z; Furste, JP; Erdmann, VA; Kurreck, J			Sequence requirements in the catalytic core of the "10-23" DNA enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME; MESSENGER-RNA; CRYSTAL-STRUCTURE; CLEAVAGE; MECHANISM	A systematic mutagenesis study of the "10-23" DNA enzyme was performed to analyze the sequence requirements of its catalytic domain. Therefore, each of the 15 core nucleotides was substituted separately by the remaining three naturally occurring nucleotides. Changes at the borders of the catalytic domain led to a dramatic loss of enzymatic activity, whereas several nucleotides in between could be exchanged without severe effects. Thymidine at position 8 had the lowest degree of conservation and its substitution by any of the other three nucleotides caused only a minor loss of activity. In addition to the standard nucleotides (adenosine, guanosine, thymidine, or cytidine) modified nucleotides were used to gain further information about the role of individual functional groups. Again, thymidine at position 8 as well as some other nucleotides could be substituted by inosine without severe effects on the catalytic activity. For two positions, additional experiments with 2-aminopurine and deoxypurine, respectively, were performed to obtain information about the specific role of functional groups. In addition to sequence-function relationships of the DNA enzyme, this study provides information about suitable sites to introduce modified nucleotides for further functional studies or for internal stabilization of the DNA enzyme against endonucleolytic attack.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Free University of Berlin	Kurreck, J (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.		Kurreck, Jens/B-7785-2008	Kurreck, Jens/0000-0002-1469-0052				BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Iversen PO, 2001, AM J PHYSIOL-HEART C, V281, pH2211, DOI 10.1152/ajpheart.2001.281.5.H2211; Jen KY, 2000, STEM CELLS, V18, P307, DOI 10.1634/stemcells.18-5-307; Joyce GF, 2001, METHOD ENZYMOL, V341, P503, DOI 10.1016/S0076-6879(01)41173-6; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; KUIMELIS RG, 1996, CATALYTIC RNA, P197; Kurreck J, 2002, J BIOL CHEM, V277, P7099, DOI 10.1074/jbc.M107206200; NG MMP, 1994, BIOCHEMISTRY-US, V33, P12119, DOI 10.1021/bi00206a015; Nowakowski J, 1999, ACTA CRYSTALLOGR D, V55, P1885, DOI 10.1107/S0907444999010550; Nowakowski J, 2000, J MOL BIOL, V300, P93, DOI 10.1006/jmbi.2000.3826; Nowakowski J, 1999, NAT STRUCT BIOL, V6, P151; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SLIM G, 1992, BIOCHEM BIOPH RES CO, V183, P605, DOI 10.1016/0006-291X(92)90525-P; Sun LQ, 2000, PHARMACOL REV, V52, P325; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631	23	80	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40617	40622		10.1074/jbc.M207094200	http://dx.doi.org/10.1074/jbc.M207094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192010	hybrid			2022-12-25	WOS:000178791400060
J	Fukuda, M				Fukuda, M			Synaptotagmin-like protein (Slp) homology domain 1 of Slac2-a/melanophilin is a critical determinant of GTP-dependent specific binding to Rab27A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-VA; MELANOSOME TRANSPORT; PHOSPHOLIPID-BINDING; C2 DOMAINS; ASHEN MICE; FAMILY; EFFECTOR; GTPASES; MELANOCYTES; MOTIF	The N-terminal synaptotagmin-like protein (Slp) homology domain (SHD) of the Slp and Slac2 families has recently been identified as a specific Rab27A-binding domain (Kuroda, T. S., Fukuda, M., Ariga, H., and Mikoshiba, K. (2002) J. Biol. Chem. 277, 9212-9218; Fukuda, M., Kuroda, T. S., and Mikoshiba, K. (2002) J. BioL Chem. 277, 12432-12436). The SHD consists of two conserved a-helical regions (SHD1 and SHD2) that are often separated by two zinc finger motifs. However, the structural basis of Rab27A recognition by the SHD (i.e. involvement of each region (SHD1, zinc finger motifs, and SHD2) in Rab27A recognition and critical residue(s) for Rab27A/SHD interaction) had never been elucidated. In this study, systematic deletion analysis and Ala-based site-directed mutagenesis showed that SHD1 of Slac2-a/melanophilin alone is both necessary and sufficient for high affinity specific recognition of the GTP-bound form of Rab27A. By contrast, the zinc finger motifs and SHD2 are not an autonomous Rab27A-binding site and seem to be important for stabilization of the structure of the SHD or higher affinity Rab27A binding. In addition, chimeric analysis of Rab3A and Rab27A showed that the specific sequence of the switch 11 region of Rab27 isoforms (especially Leu-84, Phe-88, and Asp-91 of Rab27A), which is not conserved in the Rab3 or RabS isoforms, is essential for recognition by the Slac2-a SHD. Based on these findings, I propose that SHD1 of the Slp and Slac2 families be referred to as RBD27 (Rab-binding domain specific for Rab27 isoforms).	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Sun L, 2001, J BIOL CHEM, V276, P12911, DOI 10.1074/jbc.M011110200; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	48	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40118	40124		10.1074/jbc.M205765200	http://dx.doi.org/10.1074/jbc.M205765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12189142	hybrid			2022-12-25	WOS:000178662500134
J	Ouanounou, G; Malo, M; Stinnakre, J; Kreger, AS; Molgo, J				Ouanounou, G; Malo, M; Stinnakre, J; Kreger, AS; Molgo, J			Trachynilysin, a neurosecretory protein isolated from stonefish (Synanceia trachynis) venom, forms nonselective pores in the membrane of NG108-15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTAL ACETYLCHOLINE-RELEASE; ALPHA-LATROTOXIN CHANNELS; WIDOW SPIDER VENOM; NEUROBLASTOMA-CELLS; SYNAPTIC VESICLES; HORRIDA VENOM; PHARMACOLOGICAL PROPERTIES; NEUROMUSCULAR-JUNCTION; COUPLED RECEPTOR; LETHAL FACTOR	Trachynilysin, a protein toxin isolated from the venom of the stonefish Synanceia trachynis, has been reported to elicit massive acetylcholine release from motor nerve endings of isolated neuromuscular preparations and to increase both cytosolic Ca2+ and catecholamine release from chromaffin cells. In the present study, we used the patch clamp technique to investigate the effect of trachynilysin on the cytoplasmic membrane of differentiated NG108-15 cells in culture. Trachynilysin increased membrane conductance the most when the negativity of the cell holding membrane potential was reduced. The trachynilysin-induced current was carried by cations and reversed at about -3 mV in standard physiological solutions, which led to strong membrane depolarization and Ca2+ influx. La3+ blocked the trachynilysin current in a dose-, voltage-, and time-dependent manner, and antibodies raised against the toxin antagonized its effect on the cell membrane. The inside-out configuration of the patch clamp technique allowed the recording of single channel activity from which various multiples of 22 pS elementary conductance were resolved. These results indicate that trachynilysin forms pores in the NG108-15 cell membrane, and they advance our understanding of the toxin's mode of action on motor nerve endings and neurosecretory cells.	CNRS, UPR 9040, Lab Neurobiol Cellulaire & Mol, F-91198 Gif Sur Yvette, France; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University System of Maryland; University of Maryland Baltimore	Molgo, J (corresponding author), CNRS, UPR 9040, Lab Neurobiol Cellulaire & Mol, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.			Ouanounou, Gilles/0000-0001-5658-7005	NIGMS NIH HHS [GM-43728] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Bittner MA, 1998, J NEUROSCI, V18, P2914; CHAMEAU P, 1997, TOXICON, V35, P1662; CHANG DC, 1983, BIOPHYS J, V43, P149, DOI 10.1016/S0006-3495(83)84335-5; Chen DS, 1997, BIOCHEM J, V325, P685, DOI 10.1042/bj3250685; Colasante C, 1996, EUR J NEUROSCI, V8, P2149, DOI 10.1111/j.1460-9568.1996.tb00736.x; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EISENBERG RS, 1984, MEMBRANES CHANNELS N; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; GARNIER P, 1995, TOXICON, V33, P143, DOI 10.1016/0041-0101(94)00151-W; Ghadessy FJ, 1996, J BIOL CHEM, V271, P25575, DOI 10.1074/jbc.271.41.25575; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; Khvotchev M, 2000, NEUROSCIENCE, V101, P793, DOI 10.1016/S0306-4522(00)00378-X; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; KREGER AS, 1991, TOXICON, V29, P733, DOI 10.1016/0041-0101(91)90065-Y; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; Meunier FA, 2000, J CELL SCI, V113, P1119; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Ouanounou G, 2000, CYBIUM, V24, P149; OUANOUNOU G, 1999, TOXICON, V37, P1234; POH CH, 1991, COMP BIOCHEM PHYS B, V99, P793, DOI 10.1016/0305-0491(91)90143-2; ROBBINS J, 1990, PFLUG ARCH EUR J PHY, V416, P130, DOI 10.1007/BF00370234; ROBELLO M, 1989, BIOCHIM BIOPHYS ACTA, V978, P179, DOI 10.1016/0005-2736(89)90112-0; ROBELLO M, 1987, J MEMBRANE BIOL, V95, P55, DOI 10.1007/BF01869630; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROUZAIREDUBOIS B, 1990, CELL SIGNAL, V2, P387, DOI 10.1016/0898-6568(90)90069-M; ROUZAIREDUBOIS B, 1990, PFLUG ARCH EUR J PHY, V416, P393, DOI 10.1007/BF00370745; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Ushkaryov Y, 2002, TOXICON, V40, P1, DOI 10.1016/S0041-0101(01)00204-5; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VANDERKLOOT W, 1994, PHYSIOL REV, V74, P899, DOI 10.1152/physrev.1994.74.4.899; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6	50	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39119	39127		10.1074/jbc.M203433200	http://dx.doi.org/10.1074/jbc.M203433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177053	hybrid			2022-12-25	WOS:000178662500010
J	Ramachander, R; Kim, CA; Phillips, ML; Mackereth, CD; Thanos, CD; McIntosh, LP; Bowie, JU				Ramachander, R; Kim, CA; Phillips, ML; Mackereth, CD; Thanos, CD; McIntosh, LP; Bowie, JU			Oligomerization-dependent association of the SAM domains from Schizosaccharomyces pombe Byr2 and Ste4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE PHOSPHORYLATION; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TYROSINE KINASE; POINTED DOMAIN; PROTEIN; RECEPTOR; TEL; IDENTIFICATION; GENE	SAM (sterile alpha motif) domains are protein-protein interaction modules found in a large number of regulatory proteins. Byr2 and Ste4 are two SAM domain-containing proteins in the mating pheromone response pathway of the fission yeast, Schizosaccharomyces pombe. Byr2 is a mitogen-activated protein kinase kinase kinase that is regulated by Ste4. Tu et al (Tu, H., Barr, M., Dong, D. L., and Wigler, M. (1997) Mol. Cell. Biol. 17, 5876-5887) showed that the isolated SAM domain of Byr2 binds a fragment of Ste4 that contains both a leucine zipper (Ste4-LZ) domain as well as a SAM domain, suggesting that Byr2-SAM and Ste4-SAM may form a hetero-oligomer. Here, we show that the individual SAM domains of Ste4 and Byr2 are monomeric at low concentrations and bind to each other in a 1:1 stoichiometry with a relatively weak dissociation constant of 56 +/- 3 mum. Inclusion of the Ste4-LZ domain, which determines the oligomeric state of Ste4, has a dramatic effect on binding affinity, however. We find that the Ste4-LZ domain is trimeric and, when included with the Ste4-SAM domain, yields a 3:1 Ste4-LZ-SAM:Byr2-SAM complex with a tight dissociation constant of 19 +/- 4 nm. These results suggest that the Ste4-LZ-SAM protein may recognize multiple binding sites on Byr2-SAM, indicating a new mode of oligomeric organization for SAM domains. The fact that high affinity binding occurs only with the addition of an oligomerization domain suggests that it may be necessary to include ancillary oligomerization modules when searching for binding partners of SAM domains.	Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Sunesis Pharmaceut, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of British Columbia; University of British Columbia; University of British Columbia	Bowie, JU (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu	Mackereth, Cameron D./F-7946-2013	Mackereth, Cameron D./0000-0002-0776-7947	NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Bauman P, 1998, BIOCHIMIE, V80, P621, DOI 10.1016/S0300-9084(98)80015-1; Bauman P, 1998, BIOCHEM BIOPH RES CO, V244, P468, DOI 10.1006/bbrc.1998.8292; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HUGHES D, 1993, SIGNAL TRANSDUCTION; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kasten M, 2001, ONCOGENE, V20, P1832, DOI 10.1038/sj.onc.1204295; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MACKERETH CD, 2002, IN PRESS J BIOMOL NM; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; Myszka DG, 1998, ANAL BIOCHEM, V265, P326, DOI 10.1006/abio.1998.2937; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OKAZAKI N, 1991, NUCLEIC ACIDS RES, V19, P7043, DOI 10.1093/nar/19.25.7043; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schultz J, 1997, PROTEIN SCI, V6, P249; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slupsky CM, 1998, BIOCHEM CELL BIOL, V76, P379, DOI 10.1139/bcb-76-2-3-379; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	46	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39585	39593		10.1074/jbc.M207273200	http://dx.doi.org/10.1074/jbc.M207273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171939	hybrid			2022-12-25	WOS:000178662500069
J	Senthilkumar, R; Chaerkady, R; Sharma, KK				Senthilkumar, R; Chaerkady, R; Sharma, KK			Identification and properties of anti-chaperone-like peptides derived from oxidized bovine lens beta(L)-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPEPTIDASE-III; BETA-CRYSTALLIN; CALPAIN-II; RAT LENS; PROTEINS; POLYPEPTIDES; PURIFICATION; ENDOPEPTIDASE; PROTEOLYSIS; HYDROLYSIS	Thermal aggregation of beta(L)-crystallin was higher in the presence of peptide fragments generated from oxidized and trypsin-digested beta(L)-crystallin compared with thermal aggregation of the control proteins without oxidized beta(L)-crystallin fragments. Increased aggregation of beta(L)-crystallin was also observed despite the presence of alpha-crystallin (which has anti-aggregating properties) in the system. Self-aggregation of the oxidized beta(L)-crystallin fragments per se was not observed under the experimental conditions. Reverse-phase HPLC analysis of the precipitate obtained after heating a mixture of beta(L)-crystallin and oxidized beta(L)-crystallin fragments revealed that more than one peptide co-precipitates with beta(L)-crystallin. Electrospray mass spectrometry analysis of the peptides revealed that the molecular weight(s) of the peptides ranged from 1400-1800. Tandem mass spectrometry and a data base search revealed that two of the peptides originated from betaA4-crystallin (LTIFEQENFLGR, residues 121-132) and betaB3-crystallin (AINGTWVGYEFPGYR, residues 153-167) respectively. Oxidized synthetic peptides representing the same sequence were also found to enhance the aggregation of beta(L)-crystallin in a manner similar to oxidized lens beta(L)-crystallin peptides. These data suggest that the polypeptides generated after oxidation and proteolysis of beta(L)-crystallins interact with denaturing proteins and facilitate their aggregation and light scattering, thus behaving like anti-chaperones.	Univ Missouri, Mason Eye Inst, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Mason Eye Inst, 1 Hosp Dr, Columbia, MO 65212 USA.	sharmak@health.missouri.edu	Chaerkady, Raghothama/D-5718-2011		NEI NIH HHS [EY 09855, EY 11981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011981, R01EY009855, R29EY009855] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUGESTEYN RC, 1981, MECHANISMS CATARACT, P71; BARBER GW, 1973, EXP EYE RES, V16, P85, DOI 10.1016/0014-4835(73)90303-5; BARBER GW, 1979, EXP EYE RES, V29, P663; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bhattacharyya J, 2001, J PEPT RES, V57, P428, DOI 10.1034/j.1399-3011.2001.00871.x; BUCKINGHAM RH, 1972, EXP EYE RES, V14, P297, DOI 10.1016/0014-4835(72)90020-6; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; David L L, 1989, Lens Eye Toxic Res, V6, P725; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, V1139, P210, DOI 10.1016/0925-4439(92)90136-B; DILLEY KJ, 1974, EXP EYE RES, V19, P59, DOI 10.1016/0014-4835(74)90073-6; FLESHMAN KR, 1984, EXP EYE RES, V39, P543, DOI 10.1016/0014-4835(84)90054-X; Fujino T, 2000, BBA-PROTEIN STRUCT M, V1478, P102, DOI 10.1016/S0167-4838(00)00004-2; GARNER WH, 1979, DOC OPHTHALMOL P, V18, P91; GEHRKE CW, 1987, J ASSOC OFF ANA CHEM, V70, P171; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1983, BIOCHEM BIOPH RES CO, V113, P65, DOI 10.1016/0006-291X(83)90432-1; KATO Y, 1992, J BIOL CHEM, V267, P23646; Mitton KP, 1996, J BIOL CHEM, V271, P31803, DOI 10.1074/jbc.271.50.31803; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; ROY D, 1982, EXP EYE RES, V34, P909, DOI 10.1016/0014-4835(82)90070-7; ROY D, 1978, EXP EYE RES, V26, P445, DOI 10.1016/0014-4835(78)90131-8; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Sharma KK, 1996, CURR EYE RES, V15, P363, DOI 10.3109/02713689608995826; SHARMA KK, 1986, CURR EYE RES, V5, P373, DOI 10.3109/02713688609025176; SHARMA KK, 1993, EUR J BIOCHEM, V216, P631, DOI 10.1111/j.1432-1033.1993.tb18183.x; SHARMA KK, 1995, EXP EYE RES, V61, P413; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; SIEW EL, 1981, EXP EYE RES, V33, P603, DOI 10.1016/S0014-4835(81)80100-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SPECTOR A, 1963, J BIOL CHEM, V238, P1353; SPIES JR, 1948, ANAL CHEM, V20, P30, DOI 10.1021/ac60013a006; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; SRIVASTAVA OP, 1994, INVEST OPHTH VIS SCI, V35, P207; Srivastava OP, 1996, CURR EYE RES, V15, P511, DOI 10.3109/02713689609000762; SRIVASTAVA OP, 1983, EXP EYE RES, V37, P597, DOI 10.1016/0014-4835(83)90135-5; TAKEMOTO L, 1994, CURR EYE RES, V13, P35, DOI 10.3109/02713689409042396; TAKEMOTO L, 1994, ARCH BIOCHEM BIOPHYS, V315, P133, DOI 10.1006/abbi.1994.1481; TAKEMOTO LJ, 1983, CURR EYE RES, V2, P849; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; WANG KY, 1994, J BIOL CHEM, V269, P13601; Yates Jr, 1999, METH MOL B, V112, P553; YOSHIDA H, 1985, INVEST OPHTH VIS SCI, V26, P653	49	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39136	39143		10.1074/jbc.M204684200	http://dx.doi.org/10.1074/jbc.M204684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176982	hybrid			2022-12-25	WOS:000178662500012
J	Shigi, N; Suzuki, T; Tamakoshi, M; Oshima, T; Watanabe, K				Shigi, N; Suzuki, T; Tamakoshi, M; Oshima, T; Watanabe, K			Conserved bases in the T Psi C loop of tRNA are determinants for thermophile-specific 2-thiouridylation at position 54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; THERMUS-THERMOPHILUS; EXTREME THERMOPHILE; MODIFIED NUCLEOSIDES; SEQUENCE; 5-METHYLAMINOMETHYL-2-THIOURIDINE; RIBOTHYMIDINE; TRANSCRIPTION; BIOSYNTHESIS; REPLACEMENT	2-Thioribothymidine (s(2)T) is a post-transcriptionally modified nucleoside of U54 specifically found in thermophilic bacterial tRNAs. The 2-thiocarbonyl group of s(2)T54 is known to be responsible for the thermostability of tRNA. The s(2)T54 content in tRNA varies depending on the cultivation temperature, a feature that confers thermal adaptation of protein synthesis in Thermus thermophilus. Little is known about the biosynthesis Of s(2)T, including the sulfur donor, modification enzyme, and the tRNA structural requirements. To characterize 2-thiolation at position 54 in tRNA, we constructed an in vivo expression system using tRNA(Asp) with an altered sequence and a host-vector for T. thermophilus. We were able to detect in vivo activity of s(2)T54 thiolase using phenyl mercuric gel electrophoresis followed by Northern hybridization. 2-Thiolation at position 54 was identified in the precursor form of the tRNA, indicating that 2-thiolation precedes tRNA processing. To ascertain the elements that determine 2-thiolation in tRNA, systematic site-directed mutagenesis was carried out using the tRNA(Asp) gene. Conserved residues C56 and A58 were identified as major determinants of 2-thiolation, whereas tertiary interaction between the T and D loops and non-conserved nucleosides in the T loop were revealed not to be important for the reaction.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Biosci Bldg 301,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.		Shigi, Naoki/L-7135-2018; Suzuki, Tsutomu/J-1776-2015	Shigi, Naoki/0000-0003-4452-8264; Suzuki, Tsutomu/0000-0002-9731-1731				Altman Sidney, 1995, P67; Bjork Glenn R., 1995, P165; BJORK GR, 1975, J BACTERIOL, V124, P92; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curran J. F., 1998, MODIFICATION EDITING, P493; DAVANLOO P, 1979, NUCLEIC ACIDS RES, V6, P1571, DOI 10.1093/nar/6.4.1571; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; EMILSSON V, 1992, NUCLEIC ACIDS RES, V20, P4499, DOI 10.1093/nar/20.17.4499; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; HISHINUMA F, 1978, J GEN MICROBIOL, V104, P193, DOI 10.1099/00221287-104-2-193; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Inokuchi Hachiro, 1995, P17; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; KEITH G, 1993, NUCLEIC ACIDS RES, V21, P4399, DOI 10.1093/nar/21.18.4399; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; Nordlund ME, 2000, RNA, V6, P844, DOI 10.1017/S1355838200992422; Qiu FH, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e20; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SCHAEFER KP, 1973, P NATL ACAD SCI USA, V70, P3626, DOI 10.1073/pnas.70.12.3626; Sengupta R, 2000, NUCLEIC ACIDS RES, V28, P1374, DOI 10.1093/nar/28.6.1374; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1983, BIOCHEMISTRY-US, V22, P98, DOI 10.1021/bi00270a014; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; WATANABE K, 1980, J BIOCHEM-TOKYO, V87, P1; WATANABE K, 1979, BIOCHEM BIOPH RES CO, V91, P671, DOI 10.1016/0006-291X(79)91574-2; WATANABE K, 1976, NUCLEIC ACIDS RES, V3, P1703, DOI 10.1093/nar/3.7.1703; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	44	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39128	39135		10.1074/jbc.M207323200	http://dx.doi.org/10.1074/jbc.M207323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177072	hybrid			2022-12-25	WOS:000178662500011
J	Zhou, J; Gupta, K; Yao, J; Ye, KQ; Panda, D; Giannakakou, P; Joshi, HC				Zhou, J; Gupta, K; Yao, J; Ye, KQ; Panda, D; Giannakakou, P; Joshi, HC			Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MITOTIC BLOCK; MULTIDRUG-RESISTANCE; DYNAMIC INSTABILITY; SIGNAL-TRANSDUCTION; GAMMA-TUBULIN; BETA-TUBULIN; TAXOL; ACTIVATION; PHARMACOKINETICS	We have previously discovered the opium alkaloid noscapine as a microtubule interacting agent that binds to tubulin, alters the dynamics of microtubule assembly, and arrests mammalian cells at mitosis (Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J. A., Tekmal, R. R., Petros, J., and Joshi, H. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1601-1606; Ye, K., Zhou, J., Landen, J. W., Bradbury, E. M., and Joshi, H. C. (2001) J. BioL Chem. 276, 46697-46700; Zhou, J., Panda, D., Landen, J. W., Wilson, L., and Joshi, H. C. (2002) J. Biol. Chem. 277, 17200-17208). Here we show that noscapine does not compete with paclitaxel for tubulin binding and can efficiently inhibit the proliferation of both paclitaxel-sensitive and paclitaxel-resistant human ovarian carcinoma cells (i.e. the parental cell line 1A9 and two derivative cell lines, 1A9PTX10 and 1A9PTX22, which harbor beta-tubulin mutations that impair paclitaxel-tubulin interaction (Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T., and Poruchynsky, M. S. (1997) J. Biol. Chem. 272,17118-17125). Strikingly, these cells undergo apoptotic death upon noscapine treatment, accompanied by activation of the c-Jun NH2-terminal kinases (JNK). Furthermore, inhibition of JNK activity by treatment with antisense oligonucleotide or transfection with dominant-negative JNK blocks noscapine-induced apoptosis. These findings thus indicate a great potential for noscapine in the treatment of paclitaxel-resistant human cancers. In addition, our results suggest that the JNK pathway plays an essential role in microtubule inhibitor-induced apoptosis.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cel & Dev Biol, Atlanta, GA 30322 USA; Indian Inst Technol, Bhupat & Jyoti Mehta Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India	Emory University; Emory University; Emory University; Emory University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Joshi, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 615 Michael St, Atlanta, GA 30322 USA.	joshi@cellbio.emory.edu						ADLER V, 1992, J BIOL CHEM, V267, P17001; BHALLA K, 1993, LEUKEMIA, V7, P563; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Burkhart CA, 2001, BBA-REV CANCER, V1471, pO1, DOI 10.1016/S0304-419X(00)00022-6; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; DAHLSTROM B, 1982, EUR J CLIN PHARMACOL, V22, P535, DOI 10.1007/BF00609627; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; Fan MY, 2001, CANCER RES, V61, P4450; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAIKALA V, 1986, EUR J CLIN PHARMACOL, V31, P367, DOI 10.1007/BF00981140; Haskell CM., 1995, CANC TREATMENT, P78; Heatwole V M, 1999, Methods Mol Biol, V115, P141; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Joshi HC, 2001, METHOD CELL BIOL, V67, P179; KARLSSON MO, 1990, EUR J CLIN PHARMACOL, V39, P275, DOI 10.1007/BF00315110; Kawamura KI, 1996, BRIT J CANCER, V73, P183, DOI 10.1038/bjc.1996.33; Ke Y, 2000, CANCER IMMUNOL IMMUN, V49, P217, DOI 10.1007/s002620000109; McIntosh J. Richard, 1994, V13, P413; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Panda D, 2000, BIOCHEMISTRY-US, V39, P5075, DOI 10.1021/bi992217f; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shiah SG, 1999, CANCER RES, V59, P391; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VANTELLINGEN O, 1992, ANTICANCER RES, V12, P1699; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Ye KQ, 2001, J BIOL CHEM, V276, P46697, DOI 10.1074/jbc.C100550200; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029; Zhou J, 2002, J CELL BIOCHEM, V84, P472, DOI 10.1002/jcb.10033	51	56	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39777	39785		10.1074/jbc.M203927200	http://dx.doi.org/10.1074/jbc.M203927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183452	hybrid			2022-12-25	WOS:000178662500092
J	Tsai, AL; Palmer, G; Wu, G; Peng, S; Okeley, NM; van der Donk, WA; Kulmacz, RJ				Tsai, AL; Palmer, G; Wu, G; Peng, S; Okeley, NM; van der Donk, WA; Kulmacz, RJ			Structural characterization of arachidonyl radicals formed by aspirin-treated prostaglandin H synthase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE ACTIVE-SITE; HIGHER OXIDATION-STATES; TYROSYL RADICALS; RIBONUCLEOTIDE REDUCTASE; ENDOPEROXIDE SYNTHASE; HYDROGEN ABSTRACTION; ROTATIONAL BARRIERS; PEROXIDASE REACTION	Peroxide-generated tyrosyl radicals in both prostaglandin H synthase (PGHS) isozymes have been demonstrated to couple the peroxidase and cyclooxygenase activities by serving as the immediate oxidant for arachidonic acid (AA) in cyclooxygenase catalysis. Acetylation of Ser-530 of PGHS-1 by aspirin abolishes all oxygenase activity and transforms the peroxide-induced tyrosyl radical from a functional 33-35-gauss (G) wide doublet/wide singlet to a 26-G narrow singlet unable to oxidize AA. In contrast, aspirin-treated PGHS-2 (ASA-PGHS-2) no longer forms prostaglandins but retains oxygenase activity forming 11(R)- and 15(R)-hydroperoxyeicosatetraenoic acid and also retains the EPR line-shape of the native peroxide-induced 29-30-G wide singlet radical. To evaluate the functional role of the wide singlet radical in ASA-PGHS-2, we have examined the ability of this radical to oxidize AA in single-turnover EPR studies. Anaerobic addition of AA to ASA-PGHS-2 immediately after formation of the wide singlet radical generated either a 7-line EPR signal similar to the pentadienyl AA radical obtained in native PGHS-2 or a 26-28-G singlet radical. These EPR signals could be accounted for by a pentadienyl radical and a strained allyl radical, respectively. Experiments using 11d-AA, 13(R)d-AA, 15d-AA, 13,15d(2)-AA, and octadeuterated AA (d(8)-AA) confirmed that the unpaired electron in the pentadienyl radical is delocalized over C11, C13, and C15. A 6-line EPR radical was observed when 16d(2)-AA was used, indicating only one strongly interacting C16 hydrogen. These results support a functional role for peroxide-generated tyrosyl radicals in lipoxygenase catalysis by ASA-PGHS-2 and also indicate that the AA radical in ASA-PGHS-2 is more constrained than the corresponding radical in native PGHS-2.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.		van der Donk, Wilfred/K-2961-2015	van der Donk, Wilfred/0000-0002-5467-7071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44911, GM52170, GM55807] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bally T, 1999, REV COMP CH, V13, P1, DOI 10.1002/9780470125908.ch1; BASCETTA E, 1982, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39820000110; BOLTON JR, 1965, J CHEM PHYS, V43, P309, DOI 10.1063/1.1696475; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; DAVIES AG, 1981, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29810000633; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FORT RC, 1993, J ORG CHEM, V58, P211, DOI 10.1021/jo00053a038; Gerfen GJ, 1998, J AM CHEM SOC, V120, P3823, DOI 10.1021/ja972166e; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; HELLER C, 1962, J CHEM PHYS, V37, P243, DOI 10.1063/1.1701312; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACINNES I, 1985, J CHEM SOC PERK T 2, P1073; MAIER G, 1983, CHEM BER-RECL, V116, P732, DOI 10.1002/cber.19831160230; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MEADE EA, 1993, J BIOL CHEM, V268, P6610; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Peng S, 2001, J AM CHEM SOC, V123, P3609, DOI 10.1021/ja015599x; Peng S, 2002, J AM CHEM SOC, V124, P10785, DOI 10.1021/ja026880u; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROGERS AS, 1973, J AM CHEM SOC, V95, P6913; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEPHEN MJ, 1960, J CHEM PHYS, V32, P1435, DOI 10.1063/1.1730936; SUSTMANN R, 1979, CHEM BER-RECL, V112, P1440, DOI 10.1002/cber.19791120437; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; TSAI AL, 1994, J BIOL CHEM, V269, P5085; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; Wade D, 1999, CHEM-BIOL INTERACT, V117, P191, DOI 10.1016/S0009-2797(98)00097-0; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	53	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38311	38321		10.1074/jbc.M206961200	http://dx.doi.org/10.1074/jbc.M206961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167656	hybrid			2022-12-25	WOS:000178529600042
J	Zhou, YQ; Chen, YQ; Fisher, JH; Wang, MH				Zhou, YQ; Chen, YQ; Fisher, JH; Wang, MH			Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE; PHOSPHATIDYLINOSITOL-3 KINASE; GENE-PRODUCT; LIPOPOLYSACCHARIDE; MSP; IDENTIFICATION; REQUIREMENT; INVOLVEMENT; INDUCTION	The RON receptor tyrosine kinase is activated by macrophage-stimulating protein, which regulates macrophage migration, phagocytosis, and nitric oxide production. We report here the inhibitory effect of RON on lipopolysaccharide (LPS)-induced cyclooxygenase (Cox)2 expression in mouse macrophages. In RON-expressing macrophages treated with macrophage stimulating protein, LPS-induced prostaglandin E-2 (PGE(2)) production was significantly reduced. The inhibition was accompanied by reduction of Cox-2 protein and mRNA expression. Transcriptional studies indicated that RON activation inhibits LPS-induced luciferase activity driven by the Cox-2 gene promoter. To determine whether RON activation affects LPS-induced NF-kappaB pathway, which is important for Cox-2 expression. Western blot analyses were performed showing that RON activation inhibits LPS-induced IkappaBalpha degradation. The decreased IkappaBalpha degradation was due to reduced IkappaBalpha phosphorylation at Ser-32 as determined by IkappaBalpha (Ser-32) phosphor-antibody. Moreover, we found that LPS-induced IKKbeta activity, an enzyme responsible for phosphorylation of IkappaBalpha, was inhibited upon RON activation. Interestingly, these inhibitory effects were not regulated by RON-mediated phosphatidylinositol-3 kinase. These results suggest that RON activation inhibits LPS-induced macrophage Cox-2 expression. The inhibitory effect is mediated by impairing LPS-activated cascade enzymes that activate NF-kappaB. The inhibition of Cox-2 expression might represent a novel mechanism for the inhibitory functions of RON in vivo against LPS-induced inflammation and septic shock.	Zhejiang Univ, Sch Med, Affiliated Teaching Hosp 1, Div Neurosurg, Hangzhou 310003, Peoples R China; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Immunol, Denver, CO 80204 USA	Zhejiang University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), UCHSC Denver Hlth Med Ctr, Dept Med, Mail A008-4000,777 Bannock St, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; Chen YQ, 1998, J IMMUNOL, V161, P4950; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; CORRELL PH, 1997, GENES FUNCTION, V1, P1; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; Leonard EJ, 1997, CIBA F SYMP, V212, P183; Liu QP, 1999, J IMMUNOL, V163, P6606; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Patel R, 1999, J IMMUNOL, V162, P4191; Pistritto G, 1999, BIOCHEM BIOPH RES CO, V263, P570, DOI 10.1006/bbrc.1999.1413; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Simon, 1999, AM J MED, V106, p37S, DOI [DOI 10.1016/S0002-9343(99)00115-1, 10.1016/S0002-9343(99)00115-1]; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Wang MH, 2000, J IMMUNOL, V164, P3815, DOI 10.4049/jimmunol.164.7.3815; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; Zhang YK, 1999, J BIOL CHEM, V274, P34657, DOI 10.1074/jbc.274.49.34657	50	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38104	38110		10.1074/jbc.M206167200	http://dx.doi.org/10.1074/jbc.M206167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12177064	hybrid			2022-12-25	WOS:000178529600018
J	Valjakka, J; Hemminki, A; Niemi, S; Soderlund, H; Takkinen, K; Rouvinen, J				Valjakka, J; Hemminki, A; Niemi, S; Soderlund, H; Takkinen, K; Rouvinen, J			Crystal structure of an in Vitro affinity- and specificity-matured anti-testosterone Fab in Comiplex with testosterone - Improved affinity results from small structural changes within the variable domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; RANDOM MUTAGENESIS; PHAGE DISPLAY; X-RAY; ANTIBODY; SELECTION; MATURATION; BINDING; EVOLUTION; FRAGMENT	A highly selective, high affinity recombinant anti-testosterone Fab fragment has been generated by stepwise optimization of the complementarity-determining regions (CDRs) by random mutagenesis and phage display selection of a monoclonal antibody (3-C4F5). The best mutant (77 Fab) was obtained by evaluating the additivity effects of different independently selected CDR mutations. The 77 Fab contains 20 mutations and has about 40-fold increased affinity (K-d = 3 x 10(-10) m) when compared with the wild-type (3-C4F5) Fab. To obtain structural insight into factors, which are needed to improve binding properties, we have determined the crystal structures of the mutant 77 Fab fragment with (2.15 Angstrom) and without testosterone (2.10 Angstrom) and compared these with previously determined wild-type structures. The overall testosterone binding of the 77 Fab is similar to that of the wild-type. The improved affinity and specificity of the 77 Fab fragment are due to more comprehensive packing of the testosterone with the protein, which is the result of small structural changes within the variable domains. Only one important binding site residue Glu-95 of the heavy chain CDR3 is mutated to alanine in the 77 Fab fragment. This mutation, originally selected from the phage library based on improved specificity, provides more free space for the testosterone D-ring. The light chain CDR1 of 77 Fab containing eight mutations has the most significant effect on the improved affinity, although it has no direct contact with the testosterone. The mutations of CDR-L1 cause a rearrangement in its conformation, leading to an overall fine reshaping of the binding site.	Univ Joensuu, Dept Chem, FIN-80101 Joensuu, Finland; Finnish Red Cross, Helsinki 00310, Finland; Orion Diagnost, Oulunsalo 90460, Finland; VTT Biotechnol, Espoo 02044, Finland	University of Eastern Finland; VTT Technical Research Center Finland	Valjakka, J (corresponding author), Univ Joensuu, Dept Chem, POB 111, FIN-80101 Joensuu, Finland.	jarkko.valjakka@joensuu.fi						AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chames P, 1998, J IMMUNOL, V161, P5421; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; Daugherty PS, 2000, P NATL ACAD SCI USA, V97, P2029, DOI 10.1073/pnas.030527597; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hemminki A, 1998, IMMUNOTECHNOLOGY, V4, P59, DOI 10.1016/S1380-2933(98)00002-5; Hemminki A, 1998, PROTEIN ENG, V11, P311, DOI 10.1093/protein/11.4.311; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; Hoogenboom HR, 1997, TRENDS BIOTECHNOL, V15, P62, DOI 10.1016/S0167-7799(97)84205-9; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KABAT EA, 1991, SEQUENCES PROTEIN IM; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamminmaki U, 1999, J MOL BIOL, V291, P589, DOI 10.1006/jmbi.1999.2981; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCREE DE, 1999, XTALVIEW 4 0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Saviranta P, 1998, PROTEIN ENG, V11, P143, DOI 10.1093/protein/11.2.143; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Short MK, 2002, J BIOL CHEM, V277, P16365, DOI 10.1074/jbc.M110444200; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; Valjakka J, 2000, ACTA CRYSTALLOGR D, V56, P218, DOI 10.1107/S0907444999016224; Valjakka J, 2002, J BIOL CHEM, V277, P4183, DOI 10.1074/jbc.M105579200; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	41	39	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44021	44027		10.1074/jbc.M208392200	http://dx.doi.org/10.1074/jbc.M208392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12196551	hybrid			2022-12-25	WOS:000179272000064
J	Mu, ZM; Yin, XY; Prochownik, EV				Mu, ZM; Yin, XY; Prochownik, EV			Pag, a putative tumor suppressor, interacts with the Myc Box II domain of C-myc and selectively alters its biological function and target gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PHYSIOLOGICAL INHIBITOR; ESSENTIAL COFACTOR; ZIPPER PROTEIN; GROWTH-FACTORS; CELL-GROWTH; DNA-BINDING; MAX; TRANSFORMATION; APOPTOSIS	The highly conserved Myc Box II (MBII) domain of c-Myc is critically important for transformation and transcriptional regulation. A yeast two-hybrid screen identified Pag as a MBII-interacting protein. Pag, a member of the peroxiredoxin family, has been reported previously to bind to and inhibit the cytostatic properties of the c-Abl oncoprotein. We now show that Pag promotes increased cell size and confers a proapoptotic phenotype, two hallmark features of ectopic c-Myc overexpression. Pag and c-Myc also confer resistance to oxidative stress, a previously unrecognized property of the latter protein. In contrast, Pag inhibits tumorigenesis by c-Myc-overexpressing fibroblasts and causes a broad but selective loss of c-Myc target gene regulation. Pag is therefore an MBII-interacting protein that can either mimic or enhance some of the c-Myc properties while at the same inhibiting others. These features, along with the previously identified interaction with c-Abl, provide support for the idea that Pag functions as a tumor suppressor.	Childrens Hosp Pittsburgh, Sect Hematol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Program Mol Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Sect Hematol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu			NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; ISHII T, 1993, J BIOL CHEM, V268, P18633; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MITTELMAN F, 1994, CATALOG CHROMOSOMAL; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; NEMOTO Y, 1990, GENE, V91, P261, DOI 10.1016/0378-1119(90)90097-B; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; PROSPERI MT, 1994, GENOMICS, V19, P236, DOI 10.1006/geno.1994.1053; Prosperi MT, 1998, FEBS LETT, V423, P39, DOI 10.1016/S0014-5793(98)00057-X; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THANNICKAL VJ, 2000, AM J PHYSIOL, V279, pC1005; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagawa T, 2000, CANCER LETT, V156, P27, DOI 10.1016/S0304-3835(00)00434-1; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	59	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43175	43184		10.1074/jbc.M206066200	http://dx.doi.org/10.1074/jbc.M206066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196529	hybrid			2022-12-25	WOS:000179081200099
J	Orozco, IJ; Kim, SJ; Martinson, HG				Orozco, IJ; Kim, SJ; Martinson, HG			The Poly(A) signal, without the assistance of any downstream element, directs RNA polymerase II to pause in vivo and then to release stochastically from the template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT GENES; ZINC-FINGER PROTEIN; ALPHA-2 GLOBIN GENE; MAJOR LATE PROMOTER; CCAAT BOX SEQUENCE; HEAT-SHOCK GENES; C-MYC GENE; TRANSCRIPTION TERMINATION; MESSENGER-RNA; IN-VITRO	Genes encoding polyadenylated mRNAs depend on their poly(A) signals for termination of transcription. Typically, transcription downstream of the poly(A) signal gradually declines to zero, but often there is a transient increase in polymerase density immediately preceding the decline. Special elements called pause sites are traditionally invoked to account for this increase. Using run-on transcription from the nuclei of transfected cells, we show that both the pause and the gradual decline that follow a poly(A) site are generated entirely by the poly(A) signal itself in a series of model constructs. We found no other elements to be involved and argue that the elements called pause sites do not function through pausing. Both the poly(A)-dependent pause and the subsequent decline occurred earlier for a stronger poly(A) signal than for a weaker one. Because the gradual decline resembles the abortive elongation that occurs downstream of many promoters, one model has proposed that the poly(A) signal flips the polymerase from the elongation mode to the abortive mode like a binary switch. We compared abortive elongators with poly(A) terminators and found a 4-fold difference in processivity. We conclude that poly(A) terminating polymerases do not merely revert to their prior state of low processivity but rather convert to a new termination-prone condition.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Martinson, HG (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM50863] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050863] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1986, J BIOL CHEM, V261, P1496; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; BAKER CC, 1989, J VIROL, V63, P3529, DOI 10.1128/JVI.63.8.3529-3534.1989; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Brackenridge S, 1997, NUCLEIC ACIDS RES, V25, P2326, DOI 10.1093/nar/25.12.2326; Burns CM, 1999, J BIOL CHEM, V274, P5245, DOI 10.1074/jbc.274.8.5245; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; Chao LC, 1999, MOL CELL BIOL, V19, P5588; CONNELLY S, 1989, CELL, V57, P561, DOI 10.1016/0092-8674(89)90126-8; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DREYER C, 1978, EUR J BIOCHEM, V86, P241, DOI 10.1111/j.1432-1033.1978.tb12305.x; Dye MJ, 2001, CELL, V105, P669, DOI 10.1016/S0092-8674(01)00372-5; EGGERMONT J, 1993, EMBO J, V12, P2539, DOI 10.1002/j.1460-2075.1993.tb05909.x; EICK D, 1994, ANAL BIOCHEM, V218, P347, DOI 10.1006/abio.1994.1190; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; HAGENBUCHLE O, 1984, CELL, V38, P737, DOI 10.1016/0092-8674(84)90269-1; Hans H, 2000, MOL CELL BIOL, V20, P2926, DOI 10.1128/MCB.20.8.2926-2932.2000; Hansen K, 1998, EMBO J, V17, P3066, DOI 10.1093/emboj/17.11.3066; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; IWAMOTO S, 1986, J VIROL, V59, P112, DOI 10.1128/JVI.59.1.112-119.1986; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MAA MC, 1990, J BIOL CHEM, V265, P12513; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; OWCZAREK CM, 1992, NUCLEIC ACIDS RES, V20, P851, DOI 10.1093/nar/20.4.851; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; Peterson ML, 2002, MOL CELL BIOL, V22, P5606, DOI 10.1128/MCB.22.15.5606-5615.2002; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; PRIBYL TM, 1988, MOL CELL BIOL, V8, P5369, DOI 10.1128/MCB.8.12.5369; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; SPENCER CA, 1993, MOL CELL BIOL, V13, P1296, DOI 10.1128/MCB.13.2.1296; TANTRAVAHI J, 1993, MOL CELL BIOL, V13, P578, DOI 10.1128/MCB.13.1.578; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Valerius O, 2002, J BIOL CHEM, V277, P21440, DOI 10.1074/jbc.M201841200; VANDENBERGH DJ, 1991, J MOL BIOL, V220, P255, DOI 10.1016/0022-2836(91)90011-T; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; XU M, 1986, J BIOL CHEM, V261, P3838; Yeung G, 1998, MOL CELL BIOL, V18, P276, DOI 10.1128/MCB.18.1.276; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhu AQ, 1998, BIOCHEMISTRY-US, V37, P11202, DOI 10.1021/bi9729110	69	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42899	42911		10.1074/jbc.M207415200	http://dx.doi.org/10.1074/jbc.M207415200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196547	hybrid			2022-12-25	WOS:000179081200063
J	Perrot, V; Vazquez-Prado, J; Gutkind, JS				Perrot, V; Vazquez-Prado, J; Gutkind, JS			Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated rho GEF (LARG) and PDZ-RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; AXON GUIDANCE; ACTIVE RAC; SEMAPHORIN RECEPTORS; MOLECULAR-BASIS; P115 RHOGEF; BINDING; CYTOSKELETON; GTPASES; FAMILY	Plexins represent a novel family of transmembrane receptors that transduce attractive and repulsive signals mediated by the axon-guiding molecules semaphorins. Emerging evidence implicates Rho GTPases in these biological events. However, Plexins lack any known catalytic activity in their conserved cytoplasmic tails, and how they transduce signals from semaphorins to Rho is still unknown. Here we show that Plexin B2 associates directly with two members of a recently identified family of Dbl homology/pleckstrin homology containing guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and Leukemia-associated Rho GEF (LARG). This physical interaction is mediated by their PDZ domains and a PDZ-binding motif found only in Plexins of the B family. In addition, we show that ligand-induced dimerization of Plexin B is sufficient to stimulate endogenous RhoA potently and to induce the reorganization of the cytoskeleton. Moreover, overexpression of the PDZ domain of PDZ-RhoGEF but not its regulator of G protein signaling domain prevents cell rounding and neurite retraction of differentiated PC12 cells induced by activation of endogenous Plexin 131 by semaphorin 4D. The association of Plexins with LARG and PDZ-RhoGEF thus provides a direct molecular mechanism by which semaphorins acting on Plexin B can control Rho, thereby regulating the actin-cytoskeleton during axonal guidance and cell migration.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		VAZQUEZ-PRADO, JOSE/C-1630-2017; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aoki J, 1999, BIOCHEM J, V340, P365, DOI 10.1042/0264-6021:3400365; BISMUTH G, 2002, SCI STKE, pRE4; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Christensen CRL, 1998, CANCER RES, V58, P1238; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Whitford KL, 2001, NEURON, V32, P1, DOI 10.1016/S0896-6273(01)00459-7; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	29	182	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43115	43120		10.1074/jbc.M206005200	http://dx.doi.org/10.1074/jbc.M206005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183458	hybrid			2022-12-25	WOS:000179081200091
J	Deval, J; Selmi, B; Boretto, J; Egloff, MP; Guerreiro, C; Sarfati, S; Canard, B				Deval, J; Selmi, B; Boretto, J; Egloff, MP; Guerreiro, C; Sarfati, S; Canard, B			The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POL GENE-MUTATIONS; COMBINATION THERAPY; DRUG-SENSITIVITY; ZIDOVUDINE AZT; HIV-1; KINETICS; STRAINS; FITNESS; PROGRAM; MUTANTS	Nucleoside analogues are currently used to treat human immunodeficiency virus infections. The appearance of up to five substitutions (A62V, V751, F77L, F116Y, and Q151M) in the viral reverse transcriptase promotes resistance to these drugs, and reduces efficiency of the antiretroviral chemotherapy. Using pre-steady state kinetics, we show that Q151M and A62V/V751I/F77L/F116Y/ Q151M substitutions confer to reverse transcriptase (RT) the ability to discriminate an analogue relative to its natural counterpart, and have no effect on repair of the analogue-terminated DNA primer. Discrimination results from a selective decrease of the catalytic rate constant k(pol): 18-fold (from 7 to 0.3 s(-1)), 13-fold (from 1.9 to 0.14 s(-1)), and 12-fold (from 13 to 1 s(-1)) in the case of ddATP, ddCTP, and 3'-azido-3'-deoxythymidine 5'- triphosphate (AZTTP), respectively. The binding affinities of the triphosphate analogues for RT remain unchanged. Molecular modeling explains drug resistance by a selective loss of electrostatic interactions between the analogue and RT. Resistance was overcome using a-boranophosphate nucleotide analogues. Using A62V/V75I/ F77L/F116Y/Q151M RT, k(pol) increases up to 70- and 13-fold using a-boranophosphate-ddATP and a-boranophosphate AZTTP, respectively. These results highlight the general capacity of such analogues to circumvent multidrug resistance when RT-mediated nucleotide resistance originates from the selective decrease of the catalytic rate constant k(pol).	CNRS, F-13288 Marseille 9, France; Univ Aix Marseille 1, UMR Architecture & Fonct Macromol Biol 6098, F-13288 Marseille, France; Univ Aix Marseille 2, UMR Architecture & Fonct Macromol Biol 6098, F-13288 Marseille 9, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, ESIL Case 925,163 Ave Luminy, F-13288 Marseille 9, France.			Canard, Bruno/0000-0003-4924-1991				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Garcia-Lerma JG, 2000, J VIROL, V74, P9339, DOI 10.1128/JVI.74.20.9339-9346.2000; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHAFER RW, 1995, J INFECT DIS, V172, P70, DOI 10.1093/infdis/172.1.70; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; Wainberg MA, 1999, ANTIVIR THER, V4, P87	30	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42097	42104		10.1074/jbc.M206725200	http://dx.doi.org/10.1074/jbc.M206725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194983	hybrid			2022-12-25	WOS:000178985300100
J	Duchene, J; Schanstra, JP; Pecher, C; Pizard, A; Susini, C; Esteve, JP; Bascands, JL; Girolami, JP				Duchene, J; Schanstra, JP; Pecher, C; Pizard, A; Susini, C; Esteve, JP; Bascands, JL; Girolami, JP			A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; MESANGIAL CELLS; KINASE CASCADES; DNA-SYNTHESIS; GROWTH-FACTOR; B-2 RECEPTOR; B2 RECEPTOR; ACTIVATION; BINDING; PHOSPHORYLATION	Mitogenic G protein-coupled receptor (GPCR) signaling has been extensively studied. In contrast, little is known about anti-mitogenic GPCR signaling. We show here that anti-mitogenic signaling of a GPCR, the bradykinin B2 receptor, involves a novel direct protein-protein interaction. The antiproliferative effect of bradykinin was accompanied by a transient increase in protein-tyrosine phosphatase activity. Using surface plasmon resonance analysis, we observed that an immunoreceptor tyrosine-based inhibitory motif (ITIM) located in the C-terminal part of the B2 receptor interacted specifically with the protein-tyrosine phosphatase SHP-2. The interaction was confirmed in primary culture renal mesangial cells by co-immunoprecipitation of a B2 receptor-SHP-2 complex. The extent of the interaction was transiently. increased by stimulation with bradykinin, which was accompanied by an increase in specific SHP-2 phosphatase activity. Mutational analysis of the key ITIM residue confirmed that the B2 receptor ITIM sequence is required for interaction with SHP-2, SHP-2 activation, and the anti-mitogenic effect of bradykinin. Finally, in mesangial cells transfected with a dominant-negative form of SHP-2, bradykinin lost the ability to inhibit cell proliferation. These observations demonstrate that bradykinin inhibits cell proliferation by a novel mechanism involving a direct protein-protein interaction between a GPCR (the B2 receptor) and SHP-2.	CHU Rangueil, INSERM, U388, Inst Louis Bugnard,IFR 31, F-31403 Toulouse, France; CHU Rangueil, INSERM, U531, Inst Louis Bugnard,IFR 31, F-31403 Toulouse, France; INSERM, U367, Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Schanstra, JP (corresponding author), CHU Rangueil, INSERM, U388, Inst Louis Bugnard,IFR 31, 1 Av J Poulhes, F-31403 Toulouse, France.	schans@toulouse.inserm.fr	Pizard, Anne CM/P-4754-2016; Schanstra, Joost P/X-7724-2018; Bascands, Jean-loup/G-3260-2013; Duchene, Johan/Q-9472-2019	Pizard, Anne CM/0000-0003-2705-6365; Schanstra, Joost P/0000-0002-7471-372X; Duchene, Johan/0000-0002-3973-0022; Bascands, Jean-loup/0000-0002-1667-5913				Alric C, 2000, INT J MOL MED, V5, P85; Alric C, 1999, IMMUNOPHARMACOLOGY, V45, P57, DOI 10.1016/S0162-3109(99)00151-4; Bascands JL, 1996, J AM SOC NEPHROL, V7, P81; Bruhns P, 1999, J IMMUNOL, V162, P3168; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dixon BS, 1997, AM J PHYSIOL-CELL PH, V273, pC7, DOI 10.1152/ajpcell.1997.273.1.C7; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; EMOND C, 1990, EUR J PHARMACOL, V190, P381, DOI 10.1016/0014-2999(90)94203-A; Famiglietti SJ, 1999, IMMUNOL LETT, V68, P35, DOI 10.1016/S0165-2478(99)00027-9; Fathy DB, 1999, J BIOL CHEM, V274, P29603, DOI 10.1074/jbc.274.42.29603; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; GODIN C, 1991, BIOCHEM PHARMACOL, V42, P117, DOI 10.1016/0006-2952(91)90689-3; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; Golser R, 2000, J BIOL CHEM, V275, P5291, DOI 10.1074/jbc.275.8.5291; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Olcese L, 1996, J IMMUNOL, V156, P4531; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PATEL KV, 1992, CANCER RES, V52, P334; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	47	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40375	40383		10.1074/jbc.M202744200	http://dx.doi.org/10.1074/jbc.M202744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177051	hybrid			2022-12-25	WOS:000178791400029
J	Hsi, LC; Wilson, LC; Eling, TE				Hsi, LC; Wilson, LC; Eling, TE			Opposing effects of 15-lipoxygenase-1 and-2 metabolites on MAPK signaling in prostate - Alteration in peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; GROWTH-FACTOR-I; KINASE-MEDIATED PHOSPHORYLATION; HUMAN COLORECTAL-CANCER; CELL-CYCLE ARREST; PPAR-GAMMA; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBIT GROWTH; MAMMALIAN LIPOXYGENASES	Human prostate tumors have elevated levels of 15-lipoxygenase-1 (15-LOX-1) and data suggest that 15-LOX-1 may play a role in the development of prostate cancer. In contrast, 15-LOX-2 expression is higher in normal rather than in tumor prostate tissue and appears to suppress cancer development. We recently reported that 13-(S)-HODE, the 15-LOX-1 metabolite, up-regulates the MA-P kinase signaling pathway and subsequently down-regulates PPARgamma in human colorectal carcinoma cells. To determine whether this mechanism is applicable to prostate cancer and what the effects of 15-LOX-2 are, we investigated the effect of 15-LOX-1, 15-LOX-2, and their metabolites on epidermal growth factor (EGF)- and insulin-like growth factor (IGF)-1 signaling in prostate carcinoma cells. In PC3 cells, 13-(S)-HODE, a 15-LOX-1 metabolite, upregulated MAP kinase while in contrast 15-(S)-HETE, a 15-LOX-2 metabolite, down-regulated MAP kinase. As a result, 13-(S)-HODE increased PPARgamma phosphorylation while a subsequent decrease in PPARgamma phosphorylation was observed with 15-(S)-HETE. Thus, 15-LOX metabolites have opposing effects on the regulation of the MAP kinase signaling pathway and a downstream target of MAP kinase signaling like PPARgamma. In addition to the EGF signaling pathway, the IGF signaling pathway appears to be linked to prostate cancer. 13-(S)-HODE and 15-(S)-HETE up-regulate or down-regulate, respectively, both the MAPK and Akt pathways after activation with IGF-1. Thus, the effect of these lipid metabolites is not solely restricted to EGF signaling and not solely restricted to MAPK signaling. These results provide a plausible mechanism to explain the apparent opposing effects 15-LOX-1 and 15-LOX-2 play in prostate cancer.	NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050144, Z01ES050144, Z01ES050143] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chang TH, 2000, CANCER RES, V60, P1129; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiGiovanni J, 2000, CANCER RES, V60, P1561; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; HENKE DC, 1984, ANAL BIOCHEM, V162, P156; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ikawa H, 1999, CANCER RES, V59, P360; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, CANCER RES, V61, P497; SIGAL E, 1990, J BIOL CHEM, V265, P5113; Takashima T, 2001, INT J ONCOL, V19, P465; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; TOTONEZ P, 1994, NUCLEIC ACIDS RES, V22, P5623; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	42	131	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40549	40556		10.1074/jbc.M203522200	http://dx.doi.org/10.1074/jbc.M203522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189136	hybrid			2022-12-25	WOS:000178791400052
J	Kluck, CJ; Patzelt, H; Genevaux, P; Brehmer, D; Rist, W; Schneider-Mergener, J; Bukau, B; Mayer, MP				Kluck, CJ; Patzelt, H; Genevaux, P; Brehmer, D; Rist, W; Schneider-Mergener, J; Bukau, B; Mayer, MP			Structure-function analysis of HscC, the Escherichia coli member of a novel subfamily of specialized Hsp70 chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAJ MOLECULAR CHAPERONE; SUBSTRATE-SPECIFICITY; NUCLEOTIDE EXCHANGE; GENE-EXPRESSION; NASCENT CHAIN; ATPASE DOMAIN; SWISS-MODEL; BINDING; SEQUENCE; MODULATION	Hsp70 chaperones assist protein folding processes through nucleotide-controlled cycles of substrate binding and release. In our effort to understand the structure-function relationship within the Hsp70 family of proteins, we characterized the Escherichia coli member of a novel Hsp70 subfamily, HscC, and identified considerable differences to the well studied E. coli homologue, DnaK, which together suggest that HscC is a specialized chaperone. The basal ATPase cycle of HscC had k(cat) and K-m values that were 8- and 10,000-fold higher than for DnaK. The HscC ATPase was not affected by the nucleotide exchange factor of DnaK GrpE and stimulated 8-fold by Dj1C, a DnaJ protein with a putative transmembrane domain, but not by other DnaJ proteins tested. Substrate binding dynamics and substrate specificity differed significantly between HscC and DnaK. These differences are explicable by distinct structural variations. HscC does not have general chaperone activity because it did not assist refolding of a denatured model substrate. In vivo, HscC failed to complement temperature sensitivity of DeltadnaK cells. Deletion of hscC caused a slow growth phenotype that was suppressed after several generations. Triple knock-outs of all E. coli genes encoding Hsp70 proteins (DeltadnaK DeltahscA DeltahscC) were viable, indicating that Hsp70 proteins are not strictly essential for viability. An extensive search for DeltahscC phenotypes revealed a hypersensitivity to Cd2+ ions and UV irradiation, suggesting roles of HscC in the cellular response to these stress treatments. Together our data show that the Hsp70 structure exhibits an astonishing degree of adaptive variations to accommodate requirements of a specialized function.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Geneva, Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Univ Klinikum Berlin, Charite, Inst Med Immunol, D-10098 Berlin, Germany; Jerini AG, D-10115 Berlin, Germany	Ruprecht Karls University Heidelberg; University of Freiburg; University of Geneva; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Shire Pharmaceuticals Limited	Mayer, MP (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	M.Mayer@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013; Genevaux, Pierre/A-4851-2015	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199; Patzelt, Holger/0000-0001-9886-8374; Rist, Wolfgang/0000-0002-0626-3544; GENEVAUX, Pierre/0000-0001-7539-3126				Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Courcelle J, 2001, GENETICS, V158, P41; CRAIG E, 1999, MOL CHAPERONES FOLDI, P139; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; Genevaux P, 2001, J BACTERIOL, V183, P5747, DOI 10.1128/JB.183.19.5747-5750.2001; Gisler SM, 1998, J MOL BIOL, V279, P833, DOI 10.1006/jmbi.1998.1815; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUPTA RS, 1993, J MOL EVOL, V37, P573; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; HA JH, 1999, MOL CHAPERONES FOLDI, P573; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Itoh T, 1999, DNA Res, V6, P299, DOI 10.1093/dnares/6.5.299; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Laufen T., 1998, MOL CHAPERONES PROTE, P241; Lopez-Buesa P, 1998, P NATL ACAD SCI USA, V95, P15253, DOI 10.1073/pnas.95.26.15253; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; PRENTKI P, 1991, GENE, V103, P17, DOI 10.1016/0378-1119(91)90385-O; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Rudiger S, 2000, J MOL BIOL, V304, P245, DOI 10.1006/jmbi.2000.4193; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	55	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41060	41069		10.1074/jbc.M206520200	http://dx.doi.org/10.1074/jbc.M206520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183460	hybrid			2022-12-25	WOS:000178791400115
J	Lange, U; Loffler-Walz, C; Englert, HC; Hambrock, A; Russ, U; Quast, U				Lange, U; Loffler-Walz, C; Englert, HC; Hambrock, A; Russ, U; Quast, U			The stereoenantiomers of a pinacidil analog open or close cloned ATP-sensitive K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR SUR2B; PANCREATIC BETA-CELLS; POTASSIUM CHANNELS; HIGH-AFFINITY; BINDING; GLIBENCLAMIDE; MUSCLE; CYANOGUANIDINES; ENANTIOMERS; NUCLEOTIDES	ATP-dependent K+ channels (K-ATP channels) are composed of pore-forming subunits Kir6.x and sulfonylurea receptors (SURs). Cyanoguanidines such as pinacidil and P1075 bind to SUR and enhance MgATP binding to and hydrolysis by SUR, thereby opening K-ATP channels. In the vasculature, openers of K-ATP channels produce vasorelaxation. Some novel eyanoguanidines, however, selectively reverse opener-induced vasorelaxation, suggesting that they might be K-ATP channel blockers. Here we have analyzed the interaction of the enantiomers of a racemic cyanoguanidine blocker, PNU-94750, with Kir6.2/SUR channels. In patch clamp experiments, the R-enantiomer (PNU-96293) inhibited Kir6.2/SUR2 channels (IC50 similar to50 nm in the whole cell configuration), whereas the S-enantiomer (PNU-96179) was a weak opener. Radioligand binding studies showed that the R-enantiomer was more potent and that it was negatively allosterically coupled to MgATP binding, whereas the S-enantiomer was weaker and positively coupled. Binding experiments also suggested that both enantiomers bound to the P1075 site of SUR. This is the first report to show that the enantiomers of a K-ATP channel modulator affect channel activity and coupling to MgATP binding in opposite directions and that these opposite effects are apparently mediated by binding to the same (opener) site of SUR.	Univ Tubingen, Dept Pharmacol & Toxicol, D-72074 Tubingen, Germany; Aventis Pharma Deutschland GMBH, D-65926 Frankfurt, Germany	Eberhard Karls University of Tubingen; Sanofi-Aventis	Quast, U (corresponding author), Univ Tubingen, Dept Pharmacol & Toxicol, Wilhelmstr 56, D-72074 Tubingen, Germany.							Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BARLOW R, 1990, TRENDS PHARMACOL SCI, V11, P148, DOI 10.1016/0165-6147(90)90065-G; BECHEM M, 1988, TRENDS PHARMACOL SCI, V9, P257, DOI 10.1016/0165-6147(88)90156-3; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; BRAY KM, 1992, J BIOL CHEM, V267, P11689; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Christopoulos A, 1998, TRENDS PHARMACOL SCI, V19, P351, DOI 10.1016/S0165-6147(98)01240-1; Coghlan MJ, 2001, J MED CHEM, V44, P1627, DOI 10.1021/jm000484+; Dabrowski M, 2001, DIABETOLOGIA, V44, P747, DOI 10.1007/s001250051684; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; Draper NR., 1981, APPLIED REGRESSION A, P458; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; GARRINO MG, 1988, BRIT J PHARMACOL, V93, P61, DOI 10.1111/j.1476-5381.1988.tb11405.x; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 2002, BIOCHEM SOC T, V30, P333, DOI 10.1042/bst0300333; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Hambrock A, 2002, BRIT J PHARMACOL, V136, P995, DOI 10.1038/sj.bjp.0704801; Hambrock A, 2001, MOL PHARMACOL, V60, P190, DOI 10.1124/mol.60.1.190; Hambrock A, 1998, BRIT J PHARMACOL, V125, P577, DOI 10.1038/sj.bjp.0702109; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUMPHREY SJ, 1996, Patent No. 5567722; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Khan SA, 1997, J PHARMACOL EXP THER, V283, P1207; Lawson K, 2000, KIDNEY INT, V57, P838, DOI 10.1046/j.1523-1755.2000.00923.x; Loffler-Walz C, 2002, MOL PHARMACOL, V61, P407, DOI 10.1124/mol.61.2.407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manley PW, 2001, BRIT J PHARMACOL, V133, P275, DOI 10.1038/sj.bjp.0704071; MANLEY PW, 1992, J MED CHEM, V35, P2327, DOI 10.1021/jm00090a025; QUAST U, 1993, MOL PHARMACOL, V43, P474; QUAST U, 1993, EUR J PHARM-MOLEC PH, V245, P165, DOI 10.1016/0922-4106(93)90124-R; Quast U, 2001, N-S ARCH PHARMACOL, V363, pR72; QUAST U, 1996, POTASSIUM CHANNELS T, P173; Russ U, 2001, J PHARMACOL EXP THER, V299, P1049; Russ U, 1999, MOL PHARMACOL, V56, P955, DOI 10.1124/mol.56.5.955; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; SCHWANSTECHER M, 1992, BRIT J PHARMACOL, V106, P295, DOI 10.1111/j.1476-5381.1992.tb14331.x; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	52	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40196	40205		10.1074/jbc.M206685200	http://dx.doi.org/10.1074/jbc.M206685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171936	hybrid			2022-12-25	WOS:000178791400007
J	Lim, R; Winteringham, LN; Williams, JH; McCulloch, RK; Ingley, E; Tiao, JYH; Lalonde, JP; Tsai, SW; Tilbrook, PA; Sun, Y; Wu, XH; Morris, SW; Klinken, SP				Lim, R; Winteringham, LN; Williams, JH; McCulloch, RK; Ingley, E; Tiao, JYH; Lalonde, JP; Tsai, SW; Tilbrook, PA; Sun, Y; Wu, XH; Morris, SW; Klinken, SP			MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							J2E ERYTHROID-CELLS; MYELODYSPLASTIC SYNDROME; NUCLEAR-LOCALIZATION; SERINE PHOSPHORYLATION; KINASE RAF; GENE; ASSOCIATION; CLONING; MLF1; ERYTHROPOIETIN	A yeast two-hybrid screen was conducted to identify binding partners of Mlf1, an oncoprotein recently identified in a translocation with nucleophosmin that causes acute myeloid leukemia. Two proteins isolated in this screen were 14-3-3zeta and a novel adaptor, Madm. Mlf1 contains a classic RSXSXP sequence for 14-3-3 binding and is associated with 14-3-3 via this phosphorylated motif. Madm co-immunoprecipitated with Mlf1 and co-localized in the cytoplasm. In addition, Madm recruited a serine kinase, which phosphorylated both Madm and Mlf1 including the RSXSXP motif. In contrast to wildtype Mlf1, the oncogenic fusion protein nucleophosmin (NPM)-MLF1 did not bind 14-3-3zeta, had altered Madm binding, and localized exclusively in the nucleus. Ectopic expression of Madm in M1 myeloid cells suppressed cytokine-induced differentiation unlike Mlf1, which promotes maturation. Because the Mlf1 binding region of Madm and its own dimerization domain overlapped, the levels of Madm and Mlf1 may affect complex formation and regulate differentiation. In summary, this study has identified two partner proteins of Mlf1 that may influence its subcellular localization and biological function.	Royal Perth Hosp, Western Australian Inst Med Res, Med Res Fdn, Lab Canc Med, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Bentley, WA 6102, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6009, Australia; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10029 USA	Royal Perth Hospital; University of Western Australia; Curtin University; University of Western Australia; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Icahn School of Medicine at Mount Sinai	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, Level 6 MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@cyllene.uwa.edu.au	Winteringham, Louise/H-6105-2014; Endersby, Raelene/A-2969-2013; Ingley, Evan/C-2401-2013	Endersby, Raelene/0000-0003-3554-2769; Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Tiao, Jim/0000-0001-6692-9697; Winteringham, Louise/0000-0002-8117-5069	NATIONAL CANCER INSTITUTE [R01CA076301, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765, CA 76301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P198; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardin SC, 1998, BIOTECHNIQUES, V24, P344, DOI 10.2144/98243bm01; HAWLEY RG, 1994, GENE THER, V1, P136; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Hooper JD, 2000, GENOMICS, V66, P113, DOI 10.1006/geno.2000.6167; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoneda-Kato N, 1999, ONCOGENE, V18, P3716, DOI 10.1038/sj.onc.1202711; YonedaKato N, 1996, ONCOGENE, V12, P265; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	36	38	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40997	41008		10.1074/jbc.M206041200	http://dx.doi.org/10.1074/jbc.M206041200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176995	hybrid, Green Published			2022-12-25	WOS:000178791400108
J	Kikawa, KD; Vidale, DR; Van Etten, RL; Kinch, MS				Kikawa, KD; Vidale, DR; Van Etten, RL; Kinch, MS			Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL KINASE; PHOSPHOTYROSYL PHOSPHATASE; E-CADHERIN; PROTEIN; OVEREXPRESSION; PHOSPHORYLATION; EXPRESSION; GROWTH; ECK; ACTIVATION	Intracellular signaling by protein tyrosine phosphorylation is generally understood to govern many aspects of cellular behavior. The biological consequences of this signaling pathway are important because the levels of protein tyrosine phosphorylation are frequently elevated in cancer cells. In the classic paradigm, tyrosine kinases promote tumor cell growth, survival, and invasiveness, whereas tyrosine phosphatases negatively regulate these same behaviors. Here, we identify one particular tyrosine phosphatase, low molecular weight tyrosine phosphatase (LAW-PTP), which is frequently overexpressed in transformed cells. We also show that overexpression of LMW-PTP is sufficient to confer transformation upon non-transformed epithelial cells. Notably, we show that the EphA2 receptor tyrosine kinase is a prominent substrate for LMW-PTP and that the oncogenic activities of LMW-PTP result from altered EphA2 expression and function. These results suggest a role for LMW-PTP in transformation progression and link its oncogenic potential to EphA2.	Medimmune Inc, Gaithersburg, MD 20878 USA; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	AstraZeneca; Medimmune; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kinch, MS (corresponding author), Medimmune Inc, 35 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	kinchm@medimmune.com		Kinch, Michael/0000-0003-3939-3756	NATIONAL CANCER INSTITUTE [U01CA091318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER; NCI NIH HHS [1 U01 CA91318] Funding Source: Medline; NIGMS NIH HHS [GM27003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; BRYSON GLM, 1995, GENOMICS, V30, P133; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Clark GJ, 1996, ONCOGENE, V12, P169; COBB BS, 1993, ONCOGENE, V8, P2897; EASTY DJ, 1995, CANCER RES, V55, P2528; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Hess AR, 2001, CANCER RES, V61, P3250; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; SHEVRIN DH, 1989, PROSTATE, V15, P187, DOI 10.1002/pros.2990150212; Shimizu H, 2001, BIOCHEM BIOPH RES CO, V289, P602, DOI 10.1006/bbrc.2001.6007; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947	33	116	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39274	39279		10.1074/jbc.M207127200	http://dx.doi.org/10.1074/jbc.M207127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167657	hybrid			2022-12-25	WOS:000178662500029
J	Sansom, OJ; Clarke, AR				Sansom, OJ; Clarke, AR			The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice	ONCOGENE			English	Article						mismatch repair; apoptosis; P53; clonogenic survival; cisplatin	DNA MISMATCH REPAIR; MURINE SMALL-INTESTINE; DRUG-RESISTANCE; MUTATION FREQUENCY; ANTICANCER AGENTS; GAMMA-IRRADIATION; HMLH1 EXPRESSION; TUMOR-CELLS; DAMAGE; CISPLATIN	Apoptosis and long term enterocyte survival were examined in vivo after exposure to three cytotoxic agents (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU)) within mice either singly or doubly mutant for p53 and Msh2. P53 deficiency caused abrogation of the immediate apoptotic response to each agent, but only led to increased survival after cisplatin treatment. Msh2 deficiency reduced the apoptotic response to each agent, but only led to increased crypt survival after NMNU treatment. Following cisplatin treatment, the response of (Msh2(-/-), p53(-/-)) mice paralleled that of the p53(-/-) mice. A delayed wave of apoptosis was observed in both p53(-/-) and (Msh2(-/-), p53(-/-)) mice demonstrating this phenomenon to be independent of functional Mismatch repair (MMR). We conclude that loss of either p53 or Msh2 dependent apoptosis does not predict long-term crypt survival in vivo, however genetic status clearly can modulate survival for some agents such as cisplatin.	Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BOSARI S, 1995, VIRCHOWS ARCH, V427, P229; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown JM, 1999, CANCER RES, V59, P1391; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fink D, 1998, CLIN CANCER RES, V4, P1; FLEISCHHACKER M, 1994, MODERN PATHOL, V7, P435; Gong JG, 1999, NATURE, V399, P806; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hemminki K., 1994, V125, P313; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Lin XJ, 2001, CANCER RES, V61, P1508; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Ochs K, 2000, CANCER RES, V60, P5815; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1985, CELL CLONES MANUAL M; Pritchard DM, 1998, CANCER RES, V58, P5453; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	37	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5934	5939		10.1038/sj.onc.1205760	http://dx.doi.org/10.1038/sj.onc.1205760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185594				2022-12-25	WOS:000177520900014
J	van Amsterdam, IMC; Ubbink, M; van den Bosch, M; Rotsaert, F; Sanders-Loehr, J; Canters, GW				van Amsterdam, IMC; Ubbink, M; van den Bosch, M; Rotsaert, F; Sanders-Loehr, J; Canters, GW			A new type 2 copper cysteinate azurin - Involvement of an engineered exposed cysteine in copper binding through internal rearrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA AZURIN; RESONANCE RAMAN-SPECTROSCOPY; ZINC SUPEROXIDE-DISMUTASE; MEDIATED PROTEIN OXIDATION; SPERM WHALE MYOGLOBIN; EXOGENOUS LIGANDS; CRYSTAL-STRUCTURES; ELECTRON-TRANSFER; HIS117GLY AZURIN; PROXIMAL LIGAND	The double mutant H117G/N42C azurin exhibits tetragonal type 2 copper site characteristics with Cys(42) as one of the copper ligands as concluded from spectroscopic evidence (UV-visible, EPR, and resonance Raman). Analysis of the kinetics of copper uptake by the apoprotein by means of stopped flow spectroscopy suggests that the solvent-exposed CyS42 assists in binding the metal ion and carrying it over to the active site where it becomes coordinated by, among others, a second cysteine, Cys(112). A structure is proposed in which the loop from residue 36 to 47 has rearranged to form a tetragonal type 2 copper site with Cys(42) as one of the ligands. The process of copper uptake as observed for the double mutant may be relevant for a better understanding of the way copper chaperones accept and transfer metal ions in the living cell.	Leiden Univ, Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA	Leiden University; Leiden University - Excl LUMC	Canters, GW (corresponding author), Leiden Univ, Inst Chem, Gorlaeus Labs, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	canters@chem.leidenuniv.nl	Ubbink, Marcellus/E-2158-2011	Ubbink, Marcellus/0000-0002-2615-6914	NIGMS NIH HHS [GM-18865] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez ML, 2001, J AM CHEM SOC, V123, P576, DOI 10.1021/ja994322i; Andrew CR, 1996, ACCOUNTS CHEM RES, V29, P365, DOI 10.1021/ar950084u; Andrew CR, 1997, J BIOL INORG CHEM, V2, P98, DOI 10.1007/s007750050111; ANDREW CR, 1994, J AM CHEM SOC, V116, P11489, DOI 10.1021/ja00104a032; ANDREW CR, 1995, J AM CHEM SOC, V117, P10759, DOI 10.1021/ja00148a025; Andrew CR, 1996, J AM CHEM SOC, V118, P10436, DOI 10.1021/ja960969g; BARRICK D, 1995, CURR OPIN BIOTECH, V6, P411, DOI 10.1016/0958-1669(95)80070-0; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BLASZAK JA, 1983, J BIOL CHEM, V258, P9886; Cabiscol Elisa, 2000, International Microbiology, V3, P3; CZERNUSZEWICZ RS, 1986, INORG CHEM, V25, P696, DOI 10.1021/ic00225a022; Das TK, 1999, INORG CHEM, V38, P1952, DOI 10.1021/ic990049+; Dean RT, 1997, BIOCHEM J, V324, P1; DENBLAAUWEN T, 1991, J AM CHEM SOC, V113, P5050, DOI 10.1021/ja00013a046; DENBLAAUWEN T, 1993, BIOCHEMISTRY-US, V32, P12455, DOI 10.1021/bi00097a025; DENBLAAUWEN T, 1993, J AM CHEM SOC, V115, P1121, DOI 10.1021/ja00056a042; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; Hammann C, 1997, J MOL BIOL, V266, P357, DOI 10.1006/jmbi.1996.0764; HAN J, 1993, J AM CHEM SOC, V115, P4256, DOI 10.1021/ja00063a048; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; JETER RM, 1984, ARCH MICROBIOL, V138, P124, DOI 10.1007/BF00413012; Jeuken LJC, 2000, J MOL BIOL, V299, P737, DOI 10.1006/jmbi.2000.3754; Jeuken LJC, 2000, J AM CHEM SOC, V122, P12186, DOI 10.1021/ja0006144; JEUKEN LJC, 2001, THESIS U LEIDEN LEID, P129; Konz JO, 1998, BIOTECHNOL PROGR, V14, P393, DOI 10.1021/bp980021l; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroes SJ, 1996, J BIOL INORG CHEM, V1, P551, DOI 10.1007/s007750050091; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Lu Y, 1996, INORG CHEM, V35, P1692, DOI 10.1021/ic9513189; LU Y, 1992, J AM CHEM SOC, V114, P3560, DOI 10.1021/ja00035a064; LU Y, 1993, P NATL ACAD SCI USA, V90, P11456, DOI 10.1073/pnas.90.24.11456; Mandal S, 1997, COORDIN CHEM REV, V160, P191, DOI 10.1016/S0010-8545(96)01342-2; MARET W, 1986, J AM CHEM SOC, V108, P6351, DOI 10.1021/ja00280a036; MARKS RHL, 1979, ARCH BIOCHEM BIOPHYS, V195, P103, DOI 10.1016/0003-9861(79)90331-X; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MCREE DE, 1994, P NATL ACAD SCI USA, V91, P12847, DOI 10.1073/pnas.91.26.12847; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Messerschmidt A, 1998, P NATL ACAD SCI USA, V95, P3443, DOI 10.1073/pnas.95.7.3443; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sandberg A, 2002, BIOCHEMISTRY-US, V41, P1060, DOI 10.1021/bi0157621; Schnepf R, 2001, J AM CHEM SOC, V123, P2186, DOI 10.1021/ja001880k; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; van Amsterdam IMC, 2001, CHEM-EUR J, V7, P2398, DOI 10.1002/1521-3765(20010601)7:11<2398::AID-CHEM23980>3.0.CO;2-L; VANDERSPOEL D, 1999, GROMACS USER MANUAL; VANGUNSTEREN WF, 1996, GRONINGEN MOL SIMULA; vanPouderoyen G, 1996, BIOCHEMISTRY-US, V35, P1397, DOI 10.1021/bi951604w; Wang XT, 1999, J AM CHEM SOC, V121, P2947, DOI 10.1021/ja982636k; YAMANAKA T, 1963, J BIOCHEM-TOKYO, V53, P256, DOI 10.1093/oxfordjournals.jbchem.a127689	59	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44121	44130		10.1074/jbc.M202977200	http://dx.doi.org/10.1074/jbc.M202977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12186859	hybrid			2022-12-25	WOS:000179272000077
J	Abbey, SE; Potter, LR				Abbey, SE; Potter, LR			Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; STIMULATED CGMP ACCUMULATION; CULTURED MOUSE ASTROCYTES; CYCLIC-GMP ACCUMULATION; HOMOLOGOUS DESENSITIZATION; ENDOTHELIAL-CELLS; DOWN-REGULATION; PHORBOL ESTER; CYCLASE	Natriuretic peptides bind their cognate cell surface guanylyl cyclase receptors and elevate intracellular cGMP concentrations. In vascular smooth muscle cells, this results in the activation of the type I cGMP-dependent protein kinase and vasorelaxation. In contrast, pressor hormones like arginine-vasopressin, angiotensin II, and endothelin bind serpentine receptors that interact with G(q) and activate phospholipase Cbeta The products of this enzyme, diacylglycerol and inositol trisphosphate, activate the conventional and novel forms of protein kinase C (PKC) and elevate intracellular calcium concentrations, respectively. The latter response results in vasoconstriction, which opposes the actions of natriuretic peptides. Previous reports have shown that pressor hormones inhibit natriuretic peptide receptors NPR-A or NPR-B in a variety of different cell types. Although the mechanism for this inhibition remains unknown, it has been universally accepted that PKC is an obligatory component of this pathway primarily because pharmacologic activators of PKC mimic the inhibitory effects of these hormones. Here, we show that in A10 vascular smooth muscle cells, neither chronic PKC down-regulation nor specific PKC inhibitors block the AVP-dependent desensitization of NPR-B even though both processes block PKC-dependent desensitization. In contrast, the cell-permeable calcium chelator, BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-NNN',N'-tetraacetic acid, tetraacetoxymethyl ester), abrogates the AVP-dependent desensitization of NPR-B, and ionomycin, a calcium ionophore, mimics the AVP effect. These data show that the inositol trisphosphate/calcium. arm of the phospholipase C pathway mediates the desensitization of a natriuretic peptide receptor in A10 cells. In addition, we report that CNP attenuates AVP-dependent elevations in intracellular calcium concentrations. Together, these data reveal a dominant role for intracellular calcium in the reciprocal regulation of these two important vasoactive signaling systems.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Potter, LR (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007612] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL66397, R01 HL066397] Funding Source: Medline; NIAMS NIH HHS [AR07612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BELLEMANN P, 1988, J RECEPTOR RES, V8, P407, DOI 10.3109/10799898809049001; Braunewell KH, 2001, J NEUROCHEM, V78, P1277, DOI 10.1046/j.1471-4159.2001.00506.x; Brown J, 1997, AM J PHYSIOL-HEART C, V272, pH2919, DOI 10.1152/ajpheart.1997.272.6.H2919; Bryan PM, 2002, J BIOL CHEM, V277, P16041, DOI 10.1074/jbc.M110626200; Centrella M, 2001, TRENDS ENDOCRIN MET, V12, P235, DOI 10.1016/S1043-2760(01)00431-3; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; Chun TH, 1997, HYPERTENSION, V29, P1296, DOI 10.1161/01.HYP.29.6.1296; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Crook RB, 1997, BIOCHEM J, V324, P49, DOI 10.1042/bj3240049; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; FETHIERE J, 1993, MOL CELL BIOCHEM, V124, P11, DOI 10.1007/BF01096376; FETHIERE J, 1992, FEBS LETT, V305, P77, DOI 10.1016/0014-5793(92)80868-H; Fowkes RC, 2000, J ENDOCRINOL, V166, P195, DOI 10.1677/joe.0.1660195; FURUYA M, 1995, ANN NY ACAD SCI, V748, P517; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; Joubert S, 2001, BIOCHEMISTRY-US, V40, P11096, DOI 10.1021/bi010580s; KAWABE J, 1992, BIOCHIM BIOPHYS ACTA, V1175, P81, DOI 10.1016/0167-4889(92)90012-Z; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; Levin ER, 1998, NEW ENGL J MED, V339, P321; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; MCARDLE CA, 1993, ENDOCRINOLOGY, V132, P2065, DOI 10.1210/en.132.5.2065; MUKHOPADHYAY AK, 1989, ENDOCRINOLOGY, V125, P686, DOI 10.1210/endo-125-2-686; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; OKAHARA K, 1995, FEBS LETT, V373, P108, DOI 10.1016/0014-5793(95)01027-C; Olshevskaya EV, 2002, MOL CELL BIOCHEM, V230, P139, DOI 10.1023/A:1014248208584; Paulding WR, 1996, AM J PHYSIOL-CELL PH, V270, pC740, DOI 10.1152/ajpcell.1996.270.3.C740; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Potter LR, 2000, J BIOL CHEM, V275, P31099, DOI 10.1074/jbc.M005506200; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; REYNOLDS EE, 1986, BIOCHEM BIOPH RES CO, V136, P927, DOI 10.1016/0006-291X(86)90421-3; Richards AM, 1996, HEART, V76, P36, DOI 10.1136/hrt.76.3_Suppl_3.36; Schulz S, 1999, VITAM HORM, V57, P123; SHINOMIYA M, 1994, BIOCHEM BIOPH RES CO, V205, P1051, DOI 10.1006/bbrc.1994.2772; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUMNERS C, 1991, AM J PHYSIOL, V260, pC79, DOI 10.1152/ajpcell.1991.260.1.C79; Thibault G, 1996, LIFE SCI, V58, P2345, DOI 10.1016/0024-3205(96)00235-4; Tsang D, 1997, REGUL PEPTIDES, V70, P91, DOI 10.1016/S0167-0115(97)00013-X; Ueno H, 1997, CIRCULATION, V96, P2272; WEI CM, 1993, AM J PHYSIOL, V264, pH71, DOI 10.1152/ajpheart.1993.264.1.H71; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314; Yeung VTF, 1996, J NEUROSCI RES, V46, P686, DOI 10.1002/(SICI)1097-4547(19961215)46:6<686::AID-JNR6>3.0.CO;2-B; YEUNG VTF, 1992, FEBS LETT, V308, P301, DOI 10.1016/0014-5793(92)81298-Z; Zlock DW, 1997, HYPERTENSION, V29, P83, DOI 10.1161/01.HYP.29.1.83	67	46	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42423	42430		10.1074/jbc.M206686200	http://dx.doi.org/10.1074/jbc.M206686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12196532	hybrid			2022-12-25	WOS:000179081200002
J	Cecconi, I; Scaloni, A; Rastelli, G; Moroni, M; Vilardo, PG; Costantino, L; Cappiello, M; Garland, D; Carper, D; Petrash, JM; Del Corso, A; Mura, U				Cecconi, I; Scaloni, A; Rastelli, G; Moroni, M; Vilardo, PG; Costantino, L; Cappiello, M; Garland, D; Carper, D; Petrash, JM; Del Corso, A; Mura, U			Oxidative modification of aldose reductase induced by copper ion - Definition of the metal-protein interaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYZED OXIDATION; DNA; COMPLEXES; RADICALS; DAMAGE; INTERCONVERSION; INHIBITION; KINETICS; RAT	Aldose reductase (ALR2) is susceptible to oxidative inactivation by copper ion. The mechanism underlying the reversible modification of ALR2 was studied by mass spectrometry, circular dichroism, and molecular modeling approaches on the enzyme purified from bovine lens and on wild type and mutant recombinant forms of the human placental and rat lens ALR2. Two equivalents of copper ion were required to inactivate ALR2: one remained weakly bound to the oxidized protein whereas the other was strongly retained by the inactive enzyme. Cys(303) appeared to be the essential residue for enzyme inactivation, because the human C303S mutant was the only enzyme form tested that was not inactivated by copper treatment. The final products of human and bovine ALR2 oxidation contained the intramolecular disulfide bond Cys(298)-Cys(303). However, a Cys(80)-Cys(303) disulfide could also be formed. Evidence for an intramolecular rearrangement of the Cys(80)-Cys(303) disulfide to the more stable product Cys(111)-Cys(303) is provided. Molecular modeling of the holoenzyme supports the observed copper sequestration as well as the generation of the Cys(80)-Sys(303) disulfide. However, no evidence of conditions favoring the formation of the Cys(298)-Cys(303) disulfide was observed. Our proposal is that the generation of the Cys(298)Cys(303) disulfide, either directly or by rearrangement of the Cys(80)-Cys(303) disulfide, may be induced by the release of the cofactor from ALR2 undergoing oxidation. The occurrence of a less interactive site for the cofactor would also provide the rationale for the lack of activity of the disulfide enzyme forms.	Univ Pisa, Dept Fisiol & Biochim, I-56100 Pisa, Italy; CNR, IABBAM, Proteom & Mass Spectrometry, I-80147 Naples, Italy; Univ Modean & Reggio Emilia, Dipartimento Sci Farmaceut, I-41100 Modena, Italy; NEI, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Universita di Modena e Reggio Emilia; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mura, U (corresponding author), Univ Pisa, Dept Fisiol & Biochim, Via S Maria 55, I-56100 Pisa, Italy.	umura@dfb.unipi.it	Cappiello, Mario/L-3877-2019; Rastelli, Giulio/D-2224-2015; Costantino, Luca/D-7608-2015	Rastelli, Giulio/0000-0002-2474-0607; Costantino, Luca/0000-0001-5334-8084; Mura, Umberto/0000-0001-8280-6275; CAPPIELLO, MARIO/0000-0002-8864-5043; Scaloni, Andrea/0000-0001-9362-8515				AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BOHREN KM, 1993, ENZYMOLOGY MOL BIOL, V4, P267; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1992, MEDICINE, V71, P139, DOI 10.1097/00005792-199205000-00004; CAPPIELLO M, 1994, EXP EYE RES, V58, P491, DOI 10.1006/exer.1994.1042; CAPPIELLO M, 1995, BIOCHEM BIOPH RES CO, V207, P775, DOI 10.1006/bbrc.1995.1254; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; CASE DA, 1999, AMBER6; Cecconi I, 1998, BIOCHEMISTRY-US, V37, P14167, DOI 10.1021/bi981159f; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9; GIANNESSI M, 1993, ARCH BIOCHEM BIOPHYS, V300, P423, DOI 10.1006/abbi.1993.1057; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14366, DOI 10.1021/bi00044a013; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14356, DOI 10.1021/bi00044a012; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUTTERIDGE JMC, 1982, BIOCHEM PHARMACOL, V31, P2801, DOI 10.1016/0006-2952(82)90136-8; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARMAN D, 1965, J GERONTOL, V20, P151, DOI 10.1093/geronj/20.2.151; HAY BP, 1993, COORDIN CHEM REV, V126, P177, DOI 10.1016/0010-8545(93)85036-4; INAGAKI K, 1982, CHEM PHARM BULL, V30, P3244; JORGENSEN WL, 1987, J AM CHEM SOC, V109, P1891, DOI 10.1021/ja00241a001; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KOBAYASHI S, 1988, BIOCHIM BIOPHYS ACTA, V949, P143, DOI 10.1016/0167-4781(88)90065-6; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI YB, 1994, CARCINOGENESIS, V15, P1421, DOI 10.1093/carcin/15.7.1421; LIN J, 1977, JPN J OPHTHALMOL, V41, P130; Linder MC, 1996, AM J CLIN NUTR, V63, P797; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; OGIHARA H, 1995, PEDIATR RES, V37, P219, DOI 10.1203/00006450-199502000-00016; OLD SE, 1990, P NATL ACAD SCI USA, V87, P4942, DOI 10.1073/pnas.87.13.4942; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pierloot K, 1997, J AM CHEM SOC, V119, P218, DOI 10.1021/ja962381f; Ryde U, 1996, J MOL BIOL, V261, P586, DOI 10.1006/jmbi.1996.0484; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TALLIS GA, 1990, CLIN CHEM, V36, P568; TARLE I, 1993, J BIOL CHEM, V268, P25687; Ueda J, 1996, ARCH BIOCHEM BIOPHYS, V325, P65, DOI 10.1006/abbi.1996.0008; Urzhumtsev A, 1997, STRUCTURE, V5, P601, DOI 10.1016/S0969-2126(97)00216-5; Vilardo PG, 2001, BIOCHEMISTRY-US, V40, P11985, DOI 10.1021/bi0104975; Vinci F, 2000, PROTEIN SCI, V9, P525; WEAST RC, 1985, HDB CHEM PHYSICS; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	56	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42017	42027		10.1074/jbc.M206945200	http://dx.doi.org/10.1074/jbc.M206945200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12183464	hybrid			2022-12-25	WOS:000178985300091
J	Cornilescu, G; Lee, BR; Cornilescu, CC; Wang, GS; Peterkofsky, A; Clore, GM				Cornilescu, G; Lee, BR; Cornilescu, CC; Wang, GS; Peterkofsky, A; Clore, GM			Solution structure of the phosphoryl transfer complex between the cytoplasmic A domain of the mannitol transporter IIMannitol and HPr of the Escherichia coli phoshotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; PHOSPHOCARRIER PROTEIN HPR; HISTIDINE-CONTAINING PROTEIN; RESIDUAL DIPOLAR COUPLINGS; C-TERMINAL DOMAIN; ACTIVE-SITE; ENZYME-II; NMR-SPECTROSCOPY; BACTERIAL PHOSPHOENOLPYRUVATE; STAPHYLOCOCCUS-CARNOSUS	The solution structure of the complex between the cytoplasmic A domain (IIA(Mtl)) of the mannitol transporter IIMannitol and the histidine-containing phosphocarrier protein (HPr) of the Escherichia coli phosphotransferase system has been solved by NMR, including the use of conjoined rigid body/torsion angle dynamics, and residual dipolar couplings, coupled with cross-validation, to permit accurate orientation of the two proteins. A convex surface on HPr, formed by helices 1 and 2, interacts with a complementary concave depression on the surface of IIA(Mtl) formed by helix 3, portions of helices 2 and 4, and beta-strands 2 and 3. The majority of intermolecular contacts are hydrophobic, with a small number of electrostatic interactions at the periphery of the interface. The active site histidines, His-15 of HPr and His-65 of IIA(Mtl), are in close spatial proximity, and a pentacoordinate phosphoryl transition state can be readily accommodated with no change in protein-protein orientation and only minimal perturbations of the backbone immediately adjacent to the histidines. Comparison with two previously solved structures of complexes of HPr with partner proteins of the phosphotransferase system, the N-terminal domain of enzyme I (EIN) and enzyme IIA(Glucose) (IIA(Glc)), reveals a number of common features despite the fact that EIN, IIA(Glc), and IIA(Mtl) bear no structural resemblance to one another. Thus, entirely different underlying structural elements can form binding surfaces for HPr that are similar in terms of both shape and residue composition. These structural comparisons illustrate the roles of surface and residue complementarity, redundancy, incremental build-up of specificity and conformational side chain plasticity in the formation of transient specific protein-protein complexes in signal transduction pathways.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-30I, Bethesda, MD 20892 USA.		Cornilescu, Claudia/K-1981-2015; Cornilescu, Gabriel/H-3113-2011; Cornilescu, Claudia/H-1959-2012; Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Cornilescu, Claudia/0000-0002-2401-7806; Cornilescu, Gabriel/0000-0002-1204-8904; Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AB E, 1997, PROTEIN SCI, V6, P304; AB E, 2001, J MOL BIOL, V308, P993, DOI 10.1006/jmbi.2001.4623; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; FISCHER R, 1992, EUR J BIOCHEM, V204, P963, DOI 10.1111/j.1432-1033.1992.tb16717.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; JACOBSON GR, 1979, J BIOL CHEM, V254, P249; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KROON GJA, 1993, PROTEIN SCI, V2, P1331, DOI 10.1002/pro.5560020816; KRUSE R, 1993, PROTEIN ENG, V6, P417, DOI 10.1093/protein/6.4.417; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEE CA, 1983, J BIOL CHEM, V258, P761; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; Napper S, 1996, BIOCHEMISTRY-US, V35, P11260, DOI 10.1021/bi9603480; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; Prestegard JH, 2001, CURR OPIN CHEM BIOL, V5, P584, DOI 10.1016/S1367-5931(00)00247-7; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; SCHWIETERS CD, 2002, IN PRESS J MAGN RESO; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; Sondej M, 2002, BIOCHEMISTRY-US, V41, P5556, DOI 10.1021/bi011990j; STEPHAN MM, 1989, BIOCHEMISTRY-US, V28, P7941, DOI 10.1021/bi00445a058; Tchieu JH, 2001, J MOL MICROB BIOTECH, V3, P329; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; van Montfort RLM, 1998, STRUCTURE, V6, P377, DOI 10.1016/S0969-2126(98)00039-2; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908; Zweckstetter M, 2002, J BIOMOL NMR, V23, P127, DOI 10.1023/A:1016316415261	78	60	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42289	42298		10.1074/jbc.M207314200	http://dx.doi.org/10.1074/jbc.M207314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12202490	hybrid			2022-12-25	WOS:000178985300124
J	Guillet, V; Ohta, N; Cabantous, S; Newton, A; Samama, JP				Guillet, V; Ohta, N; Cabantous, S; Newton, A; Samama, JP			Crystallographic and biochemical studies of DivK reveal novel features of an essential response regulator in Caulobacter crescentus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-DIVISION; SECONDARY STRUCTURE; BACTERIAL CHEMOTAXIS; MAGNESIUM-BINDING; HISTIDINE KINASES; CRYSTAL-STRUCTURE; CHEY; PROTEIN; DIFFERENTIATION	DivK is an essential response regulator in the Gramnegative bacterium Caulobacter crescentus and functions in a complex phosphorelay system that precisely controls the sequence of developmental events during the cell division cycle. Structure determinations of this single domain response regulator at different pH values demonstrated that the five-stranded alpha/beta fold of the DivK protein is fully defined only at acidic pH. The crystal structures of the apoprotein and of metal-bound DivK complexes at higher pH values revealed a synergistic pH- and cation binding-induced flexibility of the beta4-alpha4 loop and of the alpha4 helix. This motion increases the solvent accessibility of the single cysteine residue in the protein. Solution state studies demonstrated a 200-fold pH-dependent increase in the affinity of manganese for the protein between pH 6.0 and 8.5 that seems to involve deprotonation of an acido-basic couple. Taken together, these results suggest that flexibility of critical regions of the protein, ionization of the cysteine 99 residue and improved K-D values for the catalytic metal ion are coupled events. We propose that the molecular events observed in the isolated protein may be required for DivK activation and that they may be achieved in vivo through the specific protein-protein interactions between the response regulator and its cognate kinases.	CNRS, IPBS, Grp Cristallog Biol, F-31077 Toulouse, France; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Centre National de la Recherche Scientifique (CNRS); Princeton University	Samama, JP (corresponding author), CNRS, IPBS, Grp Cristallog Biol, F-31077 Toulouse, France.	Jean-Pierre.Samama@igbmc.u-strasbg.fr	Cabantous, Stephanie/M-3282-2014; Cabantous, Stephanie/AAB-5113-2020; Guillet, Valérie/C-6058-2011	Cabantous, Stephanie/0000-0002-8406-9421; Cabantous, Stephanie/0000-0002-8406-9421; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058794] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabantous S, 2002, ACTA CRYSTALLOGR D, V58, P1249, DOI 10.1107/S0907444902008338; DEGNEN ST, 1972, J MOL BIOL, V64, P671, DOI 10.1016/0022-2836(72)90090-3; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; Foussard M, 2001, MICROBES INFECT, V3, P417, DOI 10.1016/S1286-4579(01)01390-9; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; Hung D, 2000, PROKARYOTIC DEVELOPMENT, P361; Jacobs C, 2001, P NATL ACAD SCI USA, V98, P4095, DOI 10.1073/pnas.051609998; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Madhusudan, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3; MOY FJ, 1994, BIOCHEMISTRY-US, V33, P10731, DOI 10.1021/bi00201a022; NEWTON A, 2002, IN PRESS HISTIDINE K; Ohta N, 2000, PROKARYOTIC DEVELOPMENT, P341; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; SOMMER JM, 1991, GENETICS, V129, P623; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Wheeler RT, 1999, MOL CELL, V4, P683, DOI 10.1016/S1097-2765(00)80379-2; Wu JG, 1998, P NATL ACAD SCI USA, V95, P1443, DOI 10.1073/pnas.95.4.1443; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000; Zundel CJ, 1998, FEBS LETT, V441, P242, DOI 10.1016/S0014-5793(98)01556-7	46	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42003	42010		10.1074/jbc.M204789200	http://dx.doi.org/10.1074/jbc.M204789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176983	hybrid			2022-12-25	WOS:000178985300089
J	Munshi, HG; Wu, YI; Ariztia, EV; Stack, MS				Munshi, HG; Wu, YI; Ariztia, EV; Stack, MS			Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 GELATINASE-A; TISSUE INHIBITOR; IV COLLAGENASE; ENHANCED PRODUCTION; DIFFERENTIAL REGULATION; 72-KDA GELATINASE; COMPLEX-FORMATION; CATALYTIC DOMAIN; EPIDERMAL-CELLS; CONCANAVALIN-A	Activation of matrix metalloproteinase 2 (MMP-2) has been shown to play a significant role in the behavior of cancer cells, affecting both migration and invasion. The activation process requires multimolecular complex formation involving pro-MMP-2, membrane type 1-MMP (MT1-MMP), and tissue inhibitor of metalloproteinases-2 (TIMP-2). Because calcium is an important regulator of keratinocyte function, we evaluated the effect of calcium on AMP regulation in an oral squamous cell carcinoma line (SCC25). Increasing extracellular calcium (0.09-1.2 mm) resulted in a dose-dependent increase in MT1-MMP-dependent pro-MMP-2 activation. Despite the requirement for MT1-MMP in the activation process, no changes in MT1-MMP expression, cell surface localization, or endocytosis were apparent. However, increased generation of the catalytically inactive 43-kDa MT1-MMP autolysis product and decline in the TIMP-2 levels in conditioned media were observed. The decrease in TIMP-2 levels in the conditioned media was prevented by a broad spectrum MMP inhibitor, suggesting that calcium promotes recruitment of TIMP-2 to MT1-MMP on the cell surface. Despite the decline in soluble TIMP-2, no accumulation of TIMP-2 in cell lysates was seen. Blocking TIMP-2 degradation with bafilomycin A1 significantly increased cell-associated TIMP-2 levels in the presence of high calcium. These data suggest that the decline in TIMP-2 is because of increased calcium-mediated MT1-MMP-dependent degradation of TIMP-2. In functional studies, increasing calcium enhanced MMP-dependent cellular migration on laminin-5-rich matrix using an in vitro colony dispersion assay. Taken together, these results suggest that changes in extracellular calcium can regulate post-translational MMP dynamics and thus affect the cellular behavior of oral squamous cell carcinoma.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NIDCR NIH HHS [P01 DE12328] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aznavoorian S, 2001, CANCER RES, V61, P6264; AZZAM HS, 1992, CANCER RES, V52, P4540; Baumann P, 2000, BRIT J CANCER, V83, P1387, DOI 10.1054/bjoc.2000.1454; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Crescimanno C, 1996, EXP CELL RES, V227, P240, DOI 10.1006/excr.1996.0273; Deryugina EI, 1997, J CELL SCI, V110, P2473; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1998, CANCER RES, V58, P5529; Gilles C, 2001, J CELL SCI, V114, P2967; Gospodarowicz D, 1984, METHODS PREPARATION, P275; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; HERNANDEZBARREN.S, 2002, SEMIN CANCER BIOL, V12, P1312; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kawata R, 2002, ACTA OTO-LARYNGOL, V122, P101, DOI 10.1080/00016480252775823; Kobayashi T, 1998, DERMATOLOGY, V197, P1, DOI 10.1159/000017967; Kobayashi T, 2000, IUBMB LIFE, V50, P221; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Liabakk NB, 1996, CANCER RES, V56, P190; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LOHI J, 1995, J BIOL CHEM, V270, P17602, DOI 10.1074/jbc.270.29.17602; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Makela M, 1999, EXP CELL RES, V251, P67, DOI 10.1006/excr.1999.4564; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MENON GK, 1994, J INVEST DERMATOL, V102, P789, DOI 10.1111/1523-1747.ep12377921; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagavarapu U, 2002, J INVEST DERMATOL, V118, P573, DOI 10.1046/j.1523-1747.2002.01713.x; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Raby BN, 2001, INT J CANCER, V93, P644, DOI 10.1002/ijc.1380; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Simon C, 1998, CANCER RES, V58, P1135; Stanton H, 1998, J CELL SCI, V111, P2789; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; YU M, 1995, CANCER RES, V55, P3272; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	76	47	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41480	41488		10.1074/jbc.M207695200	http://dx.doi.org/10.1074/jbc.M207695200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194986	hybrid			2022-12-25	WOS:000178985300025
J	Brackertz, M; Boeke, J; Zhang, R; Renkawitz, R				Brackertz, M; Boeke, J; Zhang, R; Renkawitz, R			Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEIN; DNA METHYLTRANSFERASE GENE; HISTONE DEACETYLASE; METHYLATED DNA; IMMUNODEFICIENCY SYNDROME; FRAGILE-X; COMPLEX; CHROMATIN; MECP2; INSTABILITY	Methyl-CpG-binding domain proteins (MBD) mediate functional responses of methylated DNA. MBD2 and MBD3 are components of the MeCP1 protein complex, which contains the Mi-2/NuRD complex and includes 66 and 68-kDa polypeptides. Here we identified two highly related 66-kDa proteins in a yeast two-hybrid screen with MBD2b. Based on the high degree of sequence conservation to the previously identified Xenopus p66 subunit of the Mi-2/NuRD complex, we termed these proteins hp66alpha and hp66beta. hp66alpha is the human orthologue of Xenopus p66, whereas hp66beta, previously identified as a component of the human MeCP1 complex, is a second member of a p66 gene family. Coprecipitation of hp66alpha and MBD2 demonstrates their in vivo association. Furthermore, confocal microscopy shows a nuclear colocalization of hp66alpha with hp66beta and MBD2 in a speckled pattern. hp66alpha is a potent transcriptional repressor reducing gene activity about 100-fold and is ubiquitously coexpressed with hp66beta in cell lines and in fetal and adult tissues. We demonstrate direct binding of both p66 family members to MBD2 as well as MBD3. Interestingly, hp66alpha, which binds with a higher affinity than hp66beta, interacts via two interaction domains in contrast to a single interaction domain present in hp66beta. These results demonstrate that two highly related mammalian p66 proteins display overlapping functions and are involved in methylation dependent transcriptional repression.	Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Justus Liebig University Giessen	Renkawitz, R (corresponding author), Univ Giessen, Genet Inst, Heinrich Buff Ring 58-62, D-35392 Giessen, Germany.							Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballestar E, 2001, EUR J BIOCHEM, V268, P5397, DOI 10.1046/j.0014-2956.2001.02480.x; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	38	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40958	40966		10.1074/jbc.M207467200	http://dx.doi.org/10.1074/jbc.M207467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183469	hybrid			2022-12-25	WOS:000178791400103
J	Nakhost, A; Kabir, N; Forscher, P; Sossin, WS				Nakhost, A; Kabir, N; Forscher, P; Sossin, WS			Protein kinase C isoforms are translocated to microtubules in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEINS; APLYSIA NEURONS; GROWTH CONES; CELLS; ACTIN; BINDING; PKC; ORGANIZATION; CYTOSKELETON; LOCALIZATION	Activation of protein kinase C (PKC) increases microtubule (MT) growth lifetimes, resulting in extension of a nocodazole-sensitive population of MTs in Aplysia growth cones. We examined whether the two phorbol ester-activated PKCs in Aplysia, the Ca2+-activated PKC Apl I and the Ca2+-independent PKC Apl 11, are associated with these MTs. Phorbol esters translocated PKC to the Triton X-100-insoluble fraction, and a significant portion of this translocated pool was sensitive to low concentrations of nocodazole. Low doses of nocodazole had no effect on the amount of PKC in the Triton X-100-insoluble fraction in the absence of phorbol esters, whereas higher doses of nocodazole reduced basal levels of PKC Apl II. The F-actin cytoskeletal disrupter, latrunculin A, removed both PKCs from the Triton X-100-insoluble fraction in both control and phorbol ester-treated nervous systems. PKC Apl 11 also directly interacted with purified MTs. In detergent-extracted cells, both PKCs immunolocalized predominantly with MTs. PKCs were associated with newly formed MTs invading the actin-rich peripheral growth cone domain after PKC activation. Our results are consistent with a central role for PKCs in regulating MT extension.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Yale Univ, New Haven, CT 06520 USA	McGill University; Yale University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Rm 776,3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.		Kabir, Nurul/I-2240-2014	Kabir, Nurul/0000-0003-4735-4028	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028695] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 28695, R01 NS051786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GarciaRocha M, 1997, EXP CELL RES, V230, P1, DOI 10.1006/excr.1996.3364; Hosotani T, 2001, GENES CELLS, V6, P775, DOI 10.1046/j.1365-2443.2001.00461.x; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kabir N, 2001, J CELL BIOL, V152, P1033, DOI 10.1083/jcb.152.5.1033; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KILEY SC, 1995, J CELL SCI, V108, P1003; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; KRUGER KE, 1991, J NEUROSCI, V11, P2303; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Minamide LS, 1997, J BIOL CHEM, V272, P8303, DOI 10.1074/jbc.272.13.8303; Nakhost A, 1998, J NEUROCHEM, V71, P1221; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Rochlin MW, 1996, J NEUROSCI, V16, P3236; Rosner H, 1996, NEUROSCI LETT, V219, P175, DOI 10.1016/S0304-3940(96)13201-8; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P4329, DOI 10.1073/pnas.78.7.4329; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; SOSSIN WS, 1994, MOL BRAIN RES, V24, P210, DOI 10.1016/0169-328X(94)90134-1; SOSSIN WS, 1993, J BIOL CHEM, V268, P5763; Sossin WS, 1996, J NEUROSCI, V16, P10; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Volkov Y, 1998, J IMMUNOL, V161, P6487; Volkov Y, 2001, NAT IMMUNOL, V2, P508, DOI 10.1038/88700; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417	35	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40633	40639		10.1074/jbc.M205099200	http://dx.doi.org/10.1074/jbc.M205099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183453	hybrid			2022-12-25	WOS:000178791400062
J	Rosmann, S; Hahn, D; Lottaz, D; Kruse, MN; Stocker, W; Sterchi, EE				Rosmann, S; Hahn, D; Lottaz, D; Kruse, MN; Stocker, W; Sterchi, EE			Activation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBENZOIC ACID HYDROLASE; NON-PANCREATIC HYDROLYSIS; PLASMA-MEMBRANE PROTEINS; SINGLE-CHAIN UROKINASE; HUMAN SMALL-INTESTINE; HUMAN COLON-CANCER; EPITHELIAL-CELLS; PABA-PEPTIDE; BETA-SUBUNIT; CACO-2 CELLS	The activation of latent proenzymes is an important mechanism for the regulation of localized proteolytic activity. Human meprin-alpha, an astacin-like zinc metalloprotease expressed in normal colon epithelial cells, is secreted as a zymogen into the intestinal lumen. Here, meprin is activated after propeptide cleavage by trypsin. In contrast, colorectal cancer cells secrete meprin-a in a non-polarized way, leading to accumulation and increased activity of meprin-alpha in the tumor stroma. We have analyzed the activation mechanism of promeprin-alpha in colorectal cancer using a co-culture model of the intestinal mucosa composed of colorectal adenocarcinoma cells (Caco-2) cultivated on filter supports and intestinal fibroblasts grown in the companion dish. We provide evidence that meprin-a is activated by plasmin and show that the presence of plasminogen in the basolateral compartment of the co-cultures is sufficient for promeprin-alpha activation. Analysis of the plasminogen-activating system in the co-cultures revealed that plasminogen activators produced and secreted by fibroblasts converted plasminogen to active plasmin, which in turn generated active meprin-alpha. This activation mechanism offers an explanation for the observed meprin-a activity in the tumor stroma, a prerequisite for a potential role of this protease in colorectal cancer.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Bern, Dept Pediat, CH-3012 Bern, Switzerland; Univ Munster, Inst Zoophysiol, D-48143 Munster, Germany	University of Bern; University of Bern; University of Munster	Sterchi, EE (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	erwin.sterchi@mci.unibe.ch	Stöcker, Walter/AAB-9704-2019	Stöcker, Walter/0000-0002-1515-6994				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BUO L, 1993, APMIS, V101, P235, DOI 10.1111/j.1699-0463.1993.tb00106.x; BURTIN P, 1985, INT J CANCER, V35, P307, DOI 10.1002/ijc.2910350305; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; Choi NS, 2000, ANAL BIOCHEM, V281, P236, DOI 10.1006/abio.2000.4572; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CZERNICHOW B, 1989, INT J CANCER, V44, P238, DOI 10.1002/ijc.2910440209; DAHLQVIST A, 1984, SCAND J CLIN LAB INV, V44, P169, DOI 10.3109/00365518409161400; Darmoul D, 2001, BRIT J CANCER, V85, P772, DOI 10.1054/bjoc.2001.1976; de Both NJ, 1999, BRIT J CANCER, V81, P934, DOI 10.1038/sj.bjc.6690790; Ducroc R, 2002, LIFE SCI, V70, P1359, DOI 10.1016/S0024-3205(01)01519-3; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GRONDAHLHANSEN J, 1991, AM J PATHOL, V138, P111; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; Hansen TP, 1999, APMIS, V107, P689, DOI 10.1111/j.1699-0463.1999.tb01461.x; Harvey SR, 1999, AM J PATHOL, V155, P1115, DOI 10.1016/S0002-9440(10)65214-5; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; Kohler D, 2000, FEBS LETT, V465, P2, DOI 10.1016/S0014-5793(99)01712-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Lottaz D, 1999, CANCER RES, V59, P1127; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MACKAY AR, 1990, CANCER RES, V50, P5997; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Mariadason JM, 2000, J CELL PHYSIOL, V183, P347, DOI 10.1002/(SICI)1097-4652(200006)183:3<347::AID-JCP7>3.0.CO;2-W; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Pandrea IV, 2000, EXP MOL PATHOL, V69, P37, DOI 10.1006/exmp.2000.2309; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PYKE C, 1994, HISTOPATHOLOGY, V24, P131, DOI 10.1111/j.1365-2559.1994.tb01291.x; QUAX PHA, 1990, CANCER RES, V50, P1488; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; REAL FX, 1992, INT J CANCER, V51, P173, DOI 10.1002/ijc.2910510203; Rothen-Rutishauser B, 2000, PHARMACEUT RES, V17, P460, DOI 10.1023/A:1007585105753; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STERCHI EE, 1983, J PEDIATR GASTR NUTR, V2, P539, DOI 10.1097/00005176-198302030-00024; STERCHI EE, 1982, CLIN SCI, V62, P557, DOI 10.1042/cs0620557; STOCKER W, 1995, PROTEIN SCI, V4, P823; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; Walker PD, 1998, KIDNEY INT, V53, P1673, DOI 10.1046/j.1523-1755.1998.00949.x; Williams SJ, 2001, INT J CANCER, V93, P67, DOI 10.1002/ijc.1304; Wilson AJ, 2000, GUT, V47, P105, DOI 10.1136/gut.47.1.105; Yang JL, 2000, INT J CANCER, V89, P431, DOI 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502; ZWEIBAUM A, 1983, INT J CANCER, V32, P407, DOI 10.1002/ijc.2910320403	70	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40650	40658		10.1074/jbc.M206203200	http://dx.doi.org/10.1074/jbc.M206203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189145	hybrid			2022-12-25	WOS:000178791400064
J	Xiong, WF; Tapprich, WE; Cox, GS				Xiong, WF; Tapprich, WE; Cox, GS			Mechanism of gonadotropin gene expression - Identification of a novel negative regulatory element at the transcription start site of the glycoprotein hormone alpha-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; MAJOR LATE PROMOTER; CIS-ACTING ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PITUITARY-SPECIFIC EXPRESSION; CAMP-RESPONSIVE ENHANCER; CELL-SPECIFIC EXPRESSION; TISSUE-SPECIFIC ENHANCER; PROTEIN-BINDING DOMAINS; HUMAN-LUNG-TUMOR	Regulation of the glycoprotein hormone a-subunit (GPHalpha) gene has been studied extensively in pituitary and placental cell lines, but little is known of the transcriptional regulators important for its ectopic expression. To investigate the molecular basis for ectopic expression, it was critical to define cis-regulatory elements and their cognate trans-acting factors that modulate promoter activity in epithelial cell types that do not normally express GPH. DNA-mediated transient expression of promoter-reporter constructs was used to identify a novel negative regulatory element located at the GPHa gene transcription start site. Truncation or site-directed mutagenesis of this element produced up to a 10-fold increase in promoter activity. Electrophoretic mobility shift analysis detected a protein that binds specifically to a DNA motif encompassing the cap site. Based on competitive DNA binding studies with mutated oligonucleotides, it was determined that bases from -5 to -2 and +4 to +11 are critical for protein binding. The DNA sequence flanking the transcription start site from -9 to +11 is an imperfect palindrome; consequently, this motif is referred to as the cap site diad element (CSDE) and the cognate factor as the cap site-binding protein (CSBP). CSBP activity was present at different levels in nuclear extracts prepared from a variety of cell types. Significantly, the ratio of activities exhibited by the GPHa promoter with a mutated CSDE compared with the promoter with a wild-type CSDE was dependent on the transfected cell line and its content of CSBP. These results indicate that a negative regulatory element centered at the GPHa gene cap site and its cognate DNA-binding protein make a significant contribution to the production of a-subunit in a variety of tumor tissues. A detailed understanding of this cis/trans pair may further suggest a mechanism to explain, at least in part, how this gene becomes activated in nonendocrine tumors.	Univ Nebraska, Nebraska Med Ctr 984525, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Dept Biol, Omaha, NE 68182 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	Cox, GS (corresponding author), Univ Nebraska, Nebraska Med Ctr 984525, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Blackman M R, 1978, Adv Intern Med, V23, P85; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNSTEIN GD, 1973, ANN INTERN MED, V78, P39, DOI 10.7326/0003-4819-78-1-39; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CAMPAIN JA, 1994, CELL GROWTH DIFFER, V5, P827; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CLAY CM, 1993, J BIOL CHEM, V268, P13556; COLE LA, 1981, CANCER RES, V41, P1615; COSGROVE DE, 1989, BIOCHIM BIOPHYS ACTA, V1007, P44, DOI 10.1016/0167-4781(89)90128-0; COSGROVE DE, 1990, ARCH BIOCHEM BIOPHYS, V280, P95, DOI 10.1016/0003-9861(90)90523-2; Cox GS, 1998, BBA-GENE STRUCT EXPR, V1396, P67, DOI 10.1016/S0167-4781(97)00175-9; COX GS, 1987, MOL CELL BIOL, V7, P1592, DOI 10.1128/MCB.7.5.1592; Cox GS, 1997, BIOCHEM BIOPH RES CO, V233, P425, DOI 10.1006/bbrc.1997.6474; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FITCH WM, 1976, FED PROC, V35, P2092; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GHOSH NK, 1977, NATURE, V267, P435, DOI 10.1038/267435a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HUSSA RO, 1978, J CLIN ENDOCR METAB, V46, P69, DOI 10.1210/jcem-46-1-69; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KUMAR S, 1992, J NATL CANCER I, V84, P42, DOI 10.1093/jnci/84.1.42; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIEBLICH JM, 1977, NATURE, V265, P746, DOI 10.1038/265746a0; LIEBLICH JM, 1976, NATURE, V260, P530, DOI 10.1038/260530a0; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1989, MOL CLONING LAB MANU; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Patton GA, 2000, CRIT CARE MED, V28, P1231, DOI 10.1097/00003246-200004000-00060; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; RABSON AS, 1973, JNCI-J NATL CANCER I, V50, P669; REES LH, 1975, J ENDOCRINOL, V67, P143, DOI 10.1677/joe.0.0670143; RIVERA RT, 1989, J CELL BIOL, V108, P2423, DOI 10.1083/jcb.108.6.2423; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSEN SW, 1974, NEW ENGL J MED, V290, P1441, DOI 10.1056/NEJM197406272902601; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUDDON RW, 1979, CANCER RES, V39, P3885; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHETH NA, 1997, BRIT J CANCER, V30, P566; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WEINTRAUB BD, 1973, J CLIN INVEST, V52, P335; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	78	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40235	40246		10.1074/jbc.M207177200	http://dx.doi.org/10.1074/jbc.M207177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177069	hybrid			2022-12-25	WOS:000178791400012
J	Grant, GA; Hu, ZQ; Xu, XL				Grant, GA; Hu, ZQ; Xu, XL			Cofactor binding to Escherichia coli D-3-phosphoglycerate dehydrogenase induces multiple conformations which alter effector binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED ALLOSTERIC REGULATION; END PRODUCT INHIBITION; DOMAIN INTERFACE; SERINE BIOSYNTHESIS; SERA GENE; MECHANISM; COOPERATIVITY; PURIFICATION; NUCLEOTIDE; SEQUENCE	The inhibition of Escherichia coli D-3-phosphoglycerate dehydrogenase by L-serine is positively cooperative with a Hill coefficient of similar to2, whereas the binding of the inhibitor, L-serine, to the apoenzyme displays positive cooperativity in the binding of the first two serine molecules and negative cooperativity in the binding of the last two serine molecules. An earlier report demonstrated that the presence of phosphate appeared to lessen the degree of both the positive and negative cooperativity, but the cause of this effect was unknown. This study demonstrates that the presence of intrinsically bound NADH was responsible to a substantial degree for this effect. In addition, this study also provides evidence for negative cooperativity in NADH binding and for at least two NADH-induced conformational forms of the enzyme that bind the inhibitor in the physiological range. Successive binding of NADH to the enzyme resulted in an increase in the affinity for the first inhibitor ligand bound and a lessening of both the positive and negative cooperativity of inhibitor binding as compared with that seen in the absence of NADH. This effect was specific for NADH and was not observed in the presence of NAD(+) or the substrate alpha-ketoglutarate. Conversely, the binding Of L-serine did not have a significant effect on the stoichiometry of NADH binding, consistent with it being a V-type allosteric system. Thus, cofactor-related conditions were found in equilibrium binding experiments that significantly altered the cooperativity of inhibitor binding. Since the result of inhibitor binding is a reduction in the catalytic activity, the binding of inhibitor to these NADH-induced conformers must also induce additional conformations that lead to differential inhibition of catalytic activity.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	ggrant@pcg.wustl.edu			NIGMS NIH HHS [GM 56676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; CONWAY A, 1968, BIOCHEMISTRY-US, V7, P4011, DOI 10.1021/bi00851a031; DUBROW R, 1977, J BIOL CHEM, V252, P1527; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; GRANT GA, BIOCHEMISTRY, V38, P16548; HORECKER BL, 1948, J BIOL CHEM, V175, P385; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P31; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	21	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39548	39553		10.1074/jbc.M208019200	http://dx.doi.org/10.1074/jbc.M208019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183470	hybrid			2022-12-25	WOS:000178662500064
J	Greenstone, HL; Santoro, F; Lusso, P; Berger, EA				Greenstone, HL; Santoro, F; Lusso, P; Berger, EA			Human herpesvirus 6 and measles virus employ distinct CD46 domains for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; DECAY-ACCELERATING FACTOR; RECOMBINANT VACCINIA VIRUS; MONOCLONAL-ANTIBODIES; CELLULAR RECEPTOR; COMPLEMENT ACTIVATION; MULTIPLE ISOFORMS; BINDING DOMAINS; MCP; SITES	We employed a quantitative cell fusion assay to identify structural domains of CD46 required for its function as a receptor for human herpesvirus 6 (HHV-6). We examined the activities of recombinant variants of CD46, including different isoforms as well as engineered truncations and molecular chimeras with decay-accelerating factor, a related protein in the family of regulators of complement activation (RCA). We observed strong receptor activity for all four CD46 isoforms, which differ in the membrane-proximal extracellular and cytoplasmic domains, indicating that the critical determinants for HHV-6 receptor activity reside outside the C-terminal portion of CD46. Analysis of the short consensus repeat (SCR) regions that comprise most of the extracellular portion of CD46 indicated a strong dependence on SCRs 2 and 3 and no requirement for SCRs 1 or 4. Fusion-inhibition studies with SCR-specific monoclonal antibodies supported the essential role of SCRs 2 and 3 in HHV-6 receptor activity. These findings contrast markedly with fusion mediated by measles virus glycoproteins for which we observed a strict dependence on SCRs 1 and 2, consistent with previous reports. These results expand the emerging notion that CD46 and other members of the RCA family are co-opted in distinct manners by different infectious pathogens.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; San Raffaele Sci Inst, Dept Biol & Technol Res, Unit Human Virol, I-20132 Milan, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Berger, EA (corresponding author), NIAID, Viral Dis Lab, NIH, Bldg 4,Rm 237, Bethesda, MD 20892 USA.							ADAMS EM, 1991, J IMMUNOL, V147, P3005; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; Atabani SF, 2001, J INFECT DIS, V184, P1, DOI 10.1086/321009; Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; Christiansen D, 2000, J GEN VIROL, V81, P911, DOI 10.1099/0022-1317-81-4-911; Christiansen D, 2000, MOL IMMUNOL, V37, P687, DOI 10.1016/S0161-5890(01)00002-5; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giannakis E, 2002, J IMMUNOL, V168, P4585, DOI 10.4049/jimmunol.168.9.4585; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; Hsu EC, 1999, VIROLOGY, V258, P314, DOI 10.1006/viro.1999.9712; Hsu EC, 1997, J VIROL, V71, P6144, DOI 10.1128/JVI.71.8.6144-6154.1997; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; Karnauchow TM, 1998, J VIROL, V72, P9380, DOI 10.1128/JVI.72.11.9380-9383.1998; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kondo K, 2002, J MED VIROL, V67, P364, DOI 10.1002/jmv.10082; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; Manchester M, 2000, VIROLOGY, V274, P5, DOI 10.1006/viro.2000.0469; Manchester M, 1997, VIROLOGY, V233, P174, DOI 10.1006/viro.1997.8581; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Martino TA, 1998, VIROLOGY, V244, P302, DOI 10.1006/viro.1998.9122; MOLINA H, 1991, J BIOL CHEM, V266, P12173; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Powell RM, 1999, J GEN VIROL, V80, P3145, DOI 10.1099/0022-1317-80-12-3145; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Seya T, 1999, INT J BIOCHEM CELL B, V31, P1255, DOI 10.1016/S1357-2725(99)00092-8; SEYA T, 1990, J IMMUNOL, V145, P238; SEYA T, 1995, IMMUNOLOGY, V84, P619; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Shafren DR, 1998, J IMMUNOL, V160, P2318; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Yamanishi K, 1996, BAILLIERE CLIN INF D, V3, P507	54	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39112	39118		10.1074/jbc.M206488200	http://dx.doi.org/10.1074/jbc.M206488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171934	hybrid			2022-12-25	WOS:000178662500009
J	Odemis, V; Moepps, B; Gierschik, P; Engele, J				Odemis, V; Moepps, B; Gierschik, P; Engele, J			Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression - Implications for brain inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; CENTRAL-NERVOUS-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; FUNCTIONAL EXPRESSION; CHROMOSOMAL LOCALIZATION; EMBRYONIC EXPRESSION; NEURONAL APOPTOSIS; MOLECULAR-CLONING; HIV-1 CORECEPTOR; HUMAN ASTROCYTES	The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 control the migration of neurons and microglial cells in the central nervous system. Although functional CXCR4 is also expressed by astroglia, recent studies have failed to observe a chemotactic response of these cells to SDF-1. Here, we demonstrate that SDF-1-dependent chemotaxis can be induced by treating cultured cortical astroglia with either dibutyryl cyclic AMP (dbcAMP; 10(-4) M) or interleukin-6 (IL-6; 10 ng/ml). Flow cytometric analysis revealed that both the dbcAMP- and IL-6-induced onset of SDF-1-dependent chemotaxis of astroglia are due to the increased cell surface expression of CXCR4. In addition, dbcAMP and IL-6 also increased CXCR4 transcript levels, further suggesting that both treatments primarily affect CXCR4 surface expression in astroglia by stimulation of gene expression. Moreover, unlike the case with IL-6 and dbcAMP, which allowed for an optimal chemotactic response to SDF-1 only after 48 h, a similar chemotactic response, associated with an increase in CXCR4 cell surface expression, already occurred after 24 h when astroglial cultures were maintained with medium conditioned by IL-6- or dbcAMP-pretreated astrocytes, indicating that the stimulatory effects of IL-6 and cAMP on CXCR4 cell surface expression involve a secondary mechanism. The findings that elevated extracellular levels of IL-6 or factors positively coupled to cAMP result in increased CXCR4 cell surface expression levels and subsequent SDF-1-dependent chemotaxis in central nervous system astrocytes point to a crucial role of this chemokine during reactive gliosis and human immunodeficiency virus-mediated dementia.	Univ Ulm, Abt Pharmakol & Toxikol, D-89069 Ulm, Germany; Univ Ulm, Abt Anat & Zellbiol, D-89069 Ulm, Germany	Ulm University; Ulm University	Engele, J (corresponding author), Univ Leipzig, Inst Anat, Liebigstr 13, D-04103 Leipzig, Germany.							Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Boutet A, 2001, GLIA, V34, P165, DOI 10.1002/glia.1051.abs; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; Cole SW, 1999, J IMMUNOL, V162, P1392; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Engele J, 1996, NEUROSCIENCE, V73, P397, DOI 10.1016/0306-4522(96)00045-0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1998, J IMMUNOL, V160, P1522; Franke B, 1998, HISTOCHEM CELL BIOL, V110, P595, DOI 10.1007/s004180050322; Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Honczarenko M, 1999, BLOOD, V94, P2990, DOI 10.1182/blood.V94.9.2990.421k36_2990_2998; Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Lavi E, 1997, AM J PATHOL, V151, P1035; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Lin CL, 1998, EUR J IMMUNOL, V28, P4114, DOI 10.1002/(SICI)1521-4141(199812)28:12<4114::AID-IMMU4114>3.0.CO;2-C; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Meucci O, 1996, J NEUROSCI, V16, P4080; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Sarau HM, 1997, J PHARMACOL EXP THER, V283, P411; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanabe S, 1997, J IMMUNOL, V159, P905; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Waltenberger J, 1996, J MOL CELL CARDIOL, V28, P1523, DOI 10.1006/jmcc.1996.0142; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	57	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39801	39808		10.1074/jbc.M200472200	http://dx.doi.org/10.1074/jbc.M200472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171912	hybrid			2022-12-25	WOS:000178662500095
J	Jaiswal, AS; Bloom, LB; Narayan, S				Jaiswal, AS; Bloom, LB; Narayan, S			Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1	ONCOGENE			English	Article						DNA damage; cell cycle arrest; p21; long-patch BER	POLYMERASE-BETA; NUCLEAR ANTIGEN; CDK-CYCLIN; LIGASE I; P21; PCNA; REPLICATION; EXPRESSION; BINDING; DAMAGE	Molecular interactions among cell cycle and DNA repair proteins have been described, but the impact of many of these interactions on cell cycle control and DNA repair remains unclear. The cyclin-dependent kinase inhibitor, p21, is known to be involved in DNA damage-induced cell cycle arrest and blocking DNA replication and repair. Participation of p21 has been implicated in nucleotide excision repair. However, the role of p21 in the base excision repair (BER) pathway has not been thoroughly studied. In the present investigation, we treated isogenic mouse embryonic fibroblast (MEF) cell lines containing wild-type (MEF-polbeta) or DNA polymerase beta (polbeta) gene-knockout (MEFpolbetaKO) with oxidative DNA-damaging agent, plumbagin, and examined its effect on p21 levels and BER activity. Plumbagin treatment caused a S-G(2)/M phase arrest and cell death of both MEF cell tines, induced p21 levels, and decreased p21-mediated long-patch (LP) BER by blocking DNA ligase activity in the polbeta-dependent pathway and by blocking both FEN1 and DNA ligase activity in polbeta-independent pathway. These findings suggest that plumbagin induced p21 levels play a regulatory role in cell cycle arrest, apoptosis, and polbeta-dependent and -independent LP-BER pathways in MEF cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Coll Med, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Bloom, Linda B/F-3684-2014		NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NCI NIH HHS [CA77721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ames B N, 1991, Jpn J Cancer Res, V82, P1460; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEDFORD P, 1988, CANCER RES, V48, P3019; Bennett SE, 2001, J BIOL CHEM, V276, P42588, DOI 10.1074/jbc.M106212200; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brozmanova J, 2001, NEOPLASMA, V48, P85; Cadet J, 2000, MUTAT RES-REV MUTAT, V462, P121, DOI 10.1016/S1383-5742(00)00022-3; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Esposito F, 1998, CELL DEATH DIFFER, V5, P940, DOI 10.1038/sj.cdd.4400427; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Fotedar R, 1996, ONCOGENE, V12, P2155; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HILL BT, 1994, EUR J CANCER, V30A, P832, DOI 10.1016/0959-8049(94)90301-8; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Jaiswal AS, 2002, MUTAT RES-FUND MOL M, V500, P17, DOI 10.1016/S0027-5107(01)00296-2; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KATO T, 1994, MUTAGENESIS, V9, P245, DOI 10.1093/mutage/9.3.245; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Krokan HE, 1997, BIOCHEM J, V325, P1; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LI Y, 1994, ONCOGENE, V9, P2261; McDonald E, 1996, CANCER RES, V56, P2250; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Sugie S, 1998, CANCER LETT, V127, P177, DOI 10.1016/S0304-3835(98)00035-4; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WANG LM, 1992, CANCER RES, V52, P4824; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	68	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5912	5922		10.1038/sj.onc.1205789	http://dx.doi.org/10.1038/sj.onc.1205789			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185591				2022-12-25	WOS:000177520900011
J	Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y				Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y			Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers	ONCOGENE			English	Article						beta-catenin; Wnt/wingless signaling pathway; MT1-MMP; colon cancer	MESSENGER-RNA EXPRESSION; COLON-CARCINOMA CELLS; BETA-CATENIN; GELATINASE-A; HEPATOCELLULAR CARCINOMAS; CLINICAL-SIGNIFICANCE; INTERGLOBULAR DOMAIN; PROMOTES ACTIVATION; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY	Genetic alterations of APC and CTNNB1 (beta-catenin) have been identified in a number of human cancers including tumors arising in the colon and liver. Mutations in these genes lead to abnormal accumulation of beta-catenin and constitutive activation of target genes in the Wnt signaling pathway. To clarify the precise role of accumulated beta-catenin in colorectal carcinogenesis, we searched for genes involved in the beta-catenin/Tcf signaling pathway by cDNA microarray. MT1 - MMP (membrane-type matrix metalloproteinase) was among 84 genes that were down-regulated after beta-catenin had been depleted by transduction of wild-type APC in SW480 cells. Expression of MT1 - MMP was elevated in 22 of 24 colon carcinomas we examined. Reporter assays and an electromobility-shift assay revealed a DNA fragment between - 1169 bp and - 1163 bp in the 5' flanking region of this gene to be a target of the beta-catenin/Tcf4 complex. Our results indicate that MT1 - MMP is a direct down-stream target in the Wnt signaling pathway, and that one of the ways accumulated beta-catenin contributes to colorectal carcinogenesis is by transactivating this gene.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Med Informat, SNP Res Ctr,Minato Ku, Tokyo, Japan; Univ Tokyo, Dept Canc Cell Res, Inst Med Sci, Minato Ku, Tokyo, Japan	University of Tokyo; RIKEN; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Takahashi, Meiko/0000-0002-8344-5472				Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; Fujita M, 2001, CANCER RES, V61, P7722; Ha HY, 2001, CANCER RES, V61, P984; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hlubek F, 2001, CANCER RES, V61, P8089; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imanishi Y, 2000, HUM PATHOL, V31, P895, DOI 10.1053/hupa.2000.9756; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kikuchi A, 2001, BRIT J CANCER, V85, P741, DOI 10.1054/bjoc.2001.1973; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lin YM, 2001, CANCER RES, V61, P6345; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maekawa R, 2000, CLIN EXP METASTAS, V18, P61, DOI 10.1023/A:1026553414492; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mimori K, 2001, ONCOL REP, V8, P401; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsunezuka Y, 1996, CANCER RES, V56, P5678; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415	52	213	230	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5861	5867		10.1038/sj.onc.1205755	http://dx.doi.org/10.1038/sj.onc.1205755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185585				2022-12-25	WOS:000177520900005
J	Kayyali, US; Pennella, CM; Trujillo, C; Villa, O; Gaestel, M; Hassoun, PM				Kayyali, US; Pennella, CM; Trujillo, C; Villa, O; Gaestel, M; Hassoun, PM			Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ACTIN POLYMERIZATION; MOLECULAR MECHANISMS; MESSENGER-RNA; STRESS; PHOSPHORYLATION; EXPRESSION; PATHWAY; PROTEIN-KINASE-2; PERMEABILITY	Exposure to hypoxia causes structural changes in the endothelial cell layer that alter its permeability and its interaction with leukocytes and platelets. One of the well characterized cytoskeletal changes in response to stress involves the reorganization of the actin cytoskeleton and the formation of stress fibers. This report describes cytoskeletal changes in pulmonary microvascular endothelial cells in response to hypoxia and potential mechanisms involved in this process. The hypoxia-induced actin redistribution appears to be mediated by components downstream of MAPK p38, which is activated in pulmonary endothelial cells in response to hypoxia. Our results indicate that kinase MM, which is a substrate of p38, becomes activated by hypoxia, leading to the phosphorylation of one of its substrates, HSP27. Because HSP27 phosphorylation is known to alter actin distribution in response to other stimuli, we postulate that it also causes the actin redistribution observed in hypoxia. This notion is supported by the observations that similar actin redistribution occurs in cells overexpressing constitutively active MK2 or phosphomimicking HSP27 mutant. Overexpressing dominant negative MK2 blocks the effects of hypoxia on the actin cytoskeleton. Taken together these results indicate that hypoxia stimulates the p38-MK2-HSP27 pathway leading to significant alteration in the actin cytoskeleton.	Tufts New England Med Ctr, Div Pulm & Crit Care, Tupper Res Inst, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Tufts Medical Center; Tufts University; Hannover Medical School	Kayyali, US (corresponding author), Tufts New England Med Ctr, Div Pulm & Crit Care, Tupper Res Inst, Dept Med, 750 Washington St,257, Boston, MA 02111 USA.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652	NHLBI NIH HHS [HL49441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049441, R29HL049441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF215, DOI 10.1152/ajprenal.1998.274.1.F215; BADESCH DB, 1989, AM J RESP CELL MOL, V1, P489, DOI 10.1165/ajrcmb/1.6.489; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Carini R, 2001, HEPATOLOGY, V33, P131, DOI 10.1053/jhep.2001.21050; Conrad PW, 2000, CELL SIGNAL, V12, P463, DOI 10.1016/S0898-6568(00)00091-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Erukhimov JA, 2000, AM J RESP CRIT CARE, V162, P288, DOI 10.1164/ajrccm.162.1.9806088; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ichikawa H, 1997, CIRC RES, V81, P922; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kacimi R, 2000, CARDIOVASC RES, V46, P139, DOI 10.1016/S0008-6363(00)00007-9; Kayyali US, 2001, J BIOL CHEM, V276, P14359, DOI 10.1074/jbc.M010100200; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; Marais E, 2001, J MOL CELL CARDIOL, V33, P769, DOI 10.1006/jmcc.2001.1347; O'Rourke JF, 1997, ONCOL RES, V9, P327; OGAWA S, 1990, ADV EXP MED BIOL, V281, P303; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PARTRIDGE CA, 1995, AM J PHYSIOL-LUNG C, V269, pL52, DOI 10.1152/ajplung.1995.269.1.L52; Pinsky DJ, 1996, J CLIN INVEST, V97, P493, DOI 10.1172/JCI118440; Pitt BR, 2002, AM J RESP CELL MOL, V26, P6, DOI 10.1165/ajrcmb.26.1.f224; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSSEAU EPM, 1983, J BIOMECH, V16, P339, DOI 10.1016/0021-9290(83)90017-9; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Seko Y, 1997, BIOCHEM BIOPH RES CO, V239, P840, DOI 10.1006/bbrc.1997.7570; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STELZNER TJ, 1988, J CLIN INVEST, V82, P1840, DOI 10.1172/JCI113800; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; Wakayama T, 1998, CELL BIOL INT, V22, P295, DOI 10.1006/cbir.1998.0252; WANG GL, 1993, J BIOL CHEM, V268, P21513; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Zulueta JJ, 2002, AM J RESP CELL MOL, V26, P22, DOI 10.1165/ajrcmb.26.1.4510	44	95	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42596	42602		10.1074/jbc.M205863200	http://dx.doi.org/10.1074/jbc.M205863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12202485	hybrid			2022-12-25	WOS:000179081200023
J	Deka, RK; Machius, M; Norgard, MV; Tomchick, DR				Deka, RK; Machius, M; Norgard, MV; Tomchick, DR			Crystal structure of the 47-kDa lipoprotein of Treponema pallidum reveals a novel penicillin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ELECTROSPRAY MASS-SPECTROMETRY; SITE-DIRECTED MUTAGENESIS; A BETA-LACTAMASES; ESCHERICHIA-COLI; ACTIVE-SITE; CARBOXYPEPTIDASE ACTIVITY; MEMBRANE-PROTEINS; OUTER-MEMBRANE; SUBSP PALLIDUM	Syphilis is a complex sexually transmitted disease caused by the spirochetal bacterium Treponema pallidum. T. pallidum has remained exquisitely sensitive to penicillin, but the mode of action and lethal targets for beta-lactams are still unknown. We previously identified the T. pallidum 47-kDa lipoprotein (Tp47) as a penicillin-binding protein (PBP). Tp47 contains three hypothetical consensus motifs (SVTK, TEN, and KTG) that typically form the active center of other PBPs. Yet, in this study, mutations of key amino acids within these motifs failed to abolish the penicillin binding activity of Tp47. The crystal structure of Tp47 at a resolution of 1.95 A revealed a fold different from any other known PBP; Tp47 is predominantly beta-sheet, in contrast to the alpha/beta-fold common to other PBPs. It comprises four distinct domains: two complex beta-sheet-containing N-terminal domains and two C-terminal domains that adopt immunoglobulin-like folds. The three hypothetical PBP signature motifs do not come together to form a typical PBP active site. Furthermore, Tp47 is unusual in that it displays beta-lactamase activity (k(cat) for penicillin = 271 +/- 6 s(-1)), a feature that hindered attempts to identify the active site in Tp47 by co-crystallization and mass spectrometric techniques. Taken together, Tp47 does not fit the classical structural and mechanistic paradigms for PBPs, and thus Tp47 appears to represent a new class of PBP.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.		Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016692] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16692] Funding Source: Medline; PHS HHS [I-0940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; CUNNINGHAM TM, 1987, J BACTERIOL, V169, P5298, DOI 10.1128/jb.169.11.5298-5300.1987; Davies C, 2001, J BIOL CHEM, V276, P616, DOI 10.1074/jbc.M004471200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gardina PJ, 1997, MOL MICROBIOL, V23, P1181, DOI 10.1046/j.1365-2958.1997.3001661.x; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1988, REV INFECT DIS, V10, P726; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; HADONOU AM, 1992, EUR J BIOCHEM, V207, P97, DOI 10.1111/j.1432-1033.1992.tb17025.x; Hagedorn HJ, 2002, J CLIN MICROBIOL, V40, P973, DOI 10.1128/JCM.40.3.973-978.2002; HAYASHI S, 1988, J BACTERIOL, V170, P5392, DOI 10.1128/jb.170.11.5392-5395.1988; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HAYES NS, 1977, INFECT IMMUN, V17, P174, DOI 10.1128/IAI.17.1.174-186.1977; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JONES SA, 1984, J EXP MED, V160, P1404, DOI 10.1084/jem.160.5.1404; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; Kelly JA, 1998, CELL MOL LIFE SCI, V54, P353, DOI 10.1007/s000180050163; Kerfeld CA, 1998, BIOCHEMISTRY-US, V37, P13911, DOI 10.1021/bi9810252; Lu WP, 1999, BIOCHEMISTRY-US, V38, P6537, DOI 10.1021/bi990025e; Luthy L, 2002, J BIOL CHEM, V277, P10187, DOI 10.1074/jbc.M108993200; MALHOTRA KT, 1992, J BIOL CHEM, V267, P11386; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Nelson DE, 2001, J BACTERIOL, V183, P3055, DOI 10.1128/JB.183.10.3055-3064.2001; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORGARD MV, 1983, INFECT IMMUN, V42, P435, DOI 10.1128/IAI.42.2.435-445.1983; NORGARD MV, 1986, INFECT IMMUN, V54, P500, DOI 10.1128/IAI.54.2.500-506.1986; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ponstingl H, 2000, PROTEINS, V41, P47; RADOLF JD, 1989, INFECT IMMUN, V57, P1248, DOI 10.1128/IAI.57.4.1248-1254.1989; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; SPRATT BG, 1988, REV INFECT DIS, V10, P699; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; Sun YP, 1998, J MASS SPECTROM, V33, P1009, DOI 10.1002/(SICI)1096-9888(1998100)33:10<1009::AID-JMS717>3.0.CO;2-4; Turk B, 1997, BIOL CHEM, V378, P141; van Oers NSC, 2000, NAT IMMUNOL, V1, P322, DOI 10.1038/79774; VANDERLINDEN MPG, 1994, BIOCHEM J, V303, P357, DOI 10.1042/bj3030357; WEIGEL LM, 1994, P NATL ACAD SCI USA, V91, P11611, DOI 10.1073/pnas.91.24.11611; WEIGEL LM, 1994, ANTIMICROB AGENTS CH, V38, P330, DOI 10.1128/AAC.38.2.330; WEIGEL LM, 1992, INFECT IMMUN, V60, P1568, DOI 10.1128/IAI.60.4.1568-1576.1992; WEIGEL LM, 1994, THESIS U TEXAS; Yang Y, 2000, J BIOL CHEM, V275, P26674; ZREIN M, 1995, J CLIN MICROBIOL, V33, P525, DOI 10.1128/JCM.33.3.525-527.1995	52	41	52	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41857	41864		10.1074/jbc.M207402200	http://dx.doi.org/10.1074/jbc.M207402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196546	hybrid			2022-12-25	WOS:000178985300072
J	Digits, JA; Pyun, HJ; Coates, RM; Casey, PJ				Digits, JA; Pyun, HJ; Coates, RM; Casey, PJ			Stereospecificity and kinetic mechanism of human prenylcysteine lyase, an unusual thioether oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; REDUCTIVE HALF-REACTION; FARNESYLCYSTEINE ANALOGS; SUBSTRATE-SPECIFICITY; MONOAMINE-OXIDASE; INHIBITION; CELLS; PURIFICATION; ENDOPROTEASE	Prenylated proteins contain either a 15-carbon farnesyl or a 20-carbon geranylgeranyl isoprenoid covalently attached to cysteine residues at or near their C terminus. The cellular abundance of prenylated proteins, as well as the stability of the thioether bond, poses a metabolic challenge to cells. A lysosomal enzyme termed prenylcysteine lyase has been identified that degrades a variety of prenylcysteines. Prenylcysteine lyase is a FAD-dependent thioether oxidase that produces free cysteine, an isoprenoid aldehyde, and hydrogen peroxide as products of the reaction. Here we report initial studies of the kinetic mechanism and stereospecificity of this unusual enzyme. We utilized product and dead end inhibitors of prenylcysteine lyase to probe the kinetic mechanism of the multistep reaction. The results with these inhibitors, together with those of other experiments, suggest that the reaction catalyzed by prenylcysteine lyase proceeds through a sequential mechanism. The reaction catalyzed by the enzyme is stereospecific, in that the pro-S hydride of the farnesylcysteine is transferred to FAD to initiate the reaction. With (2R,1'S)-[1'-H-2(1)]farnesylcysteine as a substrate, a primary deuterium isotope effect of 2 was observed on the steady state rate. However, the absence of an isotope effect on an observed pre-steady-state burst of hydrogen peroxide formation implicates a partially rate-determining proton transfer after a relatively fast C-H (C-D) bond cleavage step. Furthermore, no pre-steady-state burst of cysteine was observed. The finding that the rate of cysteine formation was within 2-fold of the steady-state k(cat) value indicates that cysteine production is one of the primary rate-limiting steps in the reaction. These results provide substantial new information on the catalytic mechanism of prenylcysteine lyase.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	Duke University; Duke University; University of Illinois System; University of Illinois Urbana-Champaign	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Casey, Patrick/0000-0002-7366-9309	NCRR NIH HHS [RR 04648] Funding Source: Medline; NIGMS NIH HHS [GM 13956, GM 46372] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON TE, 1993, BIOCHEMISTRY-US, V32, P2024, DOI 10.1021/bi00059a019; Bright H.B., 1975, ENZYMES, V12B, P421; BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8232; CASHMAN JR, 1990, CHEM RES TOXICOL, V3, P344, DOI 10.1021/tx00016a012; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COOK P, 1991, ENZYME MECH ISOTOPE, P204; COREY EJ, 1972, TETRAHEDRON LETT, P4339; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; DENU JM, 1994, BIOCHEMISTRY-US, V33, P4001, DOI 10.1021/bi00179a029; DERENZO EC, 1956, ADV ENZYMOL REL S BI, V17, P293; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P368, DOI 10.1016/0005-2787(65)90557-5; Edelstein RL, 1998, J ORG CHEM, V63, P5298, DOI 10.1021/jo980304s; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; GERLACH H, 1973, CHEM COMMUN, V48, P274; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Heasley CJ, 1996, BIOCHEM BIOPH RES CO, V225, P6, DOI 10.1006/bbrc.1996.1122; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; Kahn K, 1997, BIOCHEMISTRY-US, V36, P4731, DOI 10.1021/bi963184w; KOSTER JF, 1968, BIOCHIM BIOPHYS ACTA, V151, P11, DOI 10.1016/0005-2744(68)90156-3; Lambert J., 1987, INTRO ORGANIC SPECTR, P351; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; Marcinkeviciene J, 2000, ARCH BIOCHEM BIOPHYS, V377, P178, DOI 10.1006/abbi.2000.1769; MASSEY V, 1967, J BIOL CHEM, V242, P1259; MASSEY V, 1964, FED PROC, V23, P18; MIDLAND MM, 1979, J AM CHEM SOC, V101, P2352, DOI 10.1021/ja00503a019; MILLER JR, 1995, J AM CHEM SOC, V117, P7830, DOI 10.1021/ja00134a038; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; OI S, 1971, ARCH BIOCHEM BIOPHYS, V145, P557, DOI 10.1016/S0003-9861(71)80015-2; Palmer G, 1968, BIOL OXIDATIONS, P263; Parish CA, 1997, BIOCHEMISTRY-US, V36, P2686, DOI 10.1021/bi961844r; PARK SB, 1994, CHEM RES TOXICOL, V7, P191, DOI 10.1021/tx00038a012; Perez-Sala D, 1998, FEBS LETT, V426, P319, DOI 10.1016/S0014-5793(98)00365-2; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; Ravn MM, 2000, ORG LETT, V2, P573, DOI 10.1021/ol991230p; RAYN MM, 2000, EUR J ORG CHEM, P1401; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SEGEL IH, 1975, ENZYME KINETICS, P506; SILVERMAN RB, 1995, ACCOUNTS CHEM RES, V28, P335, DOI 10.1021/ar00056a003; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; TIPTON KF, 1968, EUR J BIOCHEM, V5, P316, DOI 10.1111/j.1432-1033.1968.tb00372.x; Tschantz WR, 2001, J BIOL CHEM, V276, P2321, DOI 10.1074/jbc.C000616200; Tschantz WR, 1999, J BIOL CHEM, V274, P35802, DOI 10.1074/jbc.274.50.35802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; WATSON JL, 1996, BIOCHEMISTRY-US, V35, P1342; Xu YJ, 1996, MOL PHARMACOL, V50, P1495; Yamashita M, 1998, PROTEIN ENG, V11, P1075, DOI 10.1093/protein/11.11.1075; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG L, 1994, J BIOL CHEM, V269, P15973; Zhang LL, 1997, J BIOL CHEM, V272, P23354, DOI 10.1074/jbc.272.37.23354; [No title captured]	59	16	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41086	41093		10.1074/jbc.M208069200	http://dx.doi.org/10.1074/jbc.M208069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12186880	hybrid			2022-12-25	WOS:000178791400118
J	Kontani, K; Tada, M; Ogawa, T; Okai, T; Saito, K; Araki, Y; Katada, T				Kontani, K; Tada, M; Ogawa, T; Okai, T; Saito, K; Araki, Y; Katada, T			Di-Ras, a distinct subgroup of Ras family GTPases with unique biochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; PC12 CELLS; PROTEIN; RAP1; GENE; IDENTIFICATION; ACTIVATION; EFFECTORS; OVARIAN; R-RAS3	The small GTPase Ras family regulates a variety of cell functions including proliferation and differentiation. Here we have identified novel Ras members, human Di-Ras1 and Di-Ras2, belonging to a distinct branch of the GTPase family. Di-Ras1 and Di-Ras2 specifically expressed in heart and brain share 30 - 40% overall identity with other members of Ras family, however, they have the following characteristic substitutions at highly conserved regions among the Ras family. 1) Thr-63 and Ser-65 in Di-Ras are substituted for Ala-59 and Gln-61 positions in Ha-Ras, respectively, that are known to be critical for GTP hydrolysis. 2) Within the effector domains, Di-Ras has Ile at a position corresponding to Asp-33 in Ha-Ras, which is important for its interaction with the downstream effector Raf. As predicted by these substitutions, Di-Ras has only a quite low level of GTPase activity and exists predominantly as a GTP-bound form upon its expression in living cells. Moreover, Di-Ras fails to interact with the Ras-binding domain of Raf, resulting in no stimulation of mitogen-activated protein kinase. Interestingly, introduction of Di-Ras into HEK293T cells induces large cellular vacuolation. These findings raise the possibility that Di-Ras might regulate cell morphogenesis in a manner distinct from other members of Ras family.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan	University of Tokyo	Katada, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan.		Tada, Minoru/AHB-5933-2022	Tada, Minoru/0000-0003-4739-1259; Saito, Kota/0000-0003-2478-2687				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Foster R, 1996, MOL CELL BIOL, V16, P2689; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; HAN LM, 1995, MOL CELL BIOL, V15, P1318; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; JOHN J, 1988, J BIOL CHEM, V263, P11792; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; PIZON V, 1988, ONCOGENE, V3, P201; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214	29	49	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41070	41078		10.1074/jbc.M202150200	http://dx.doi.org/10.1074/jbc.M202150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12194967	hybrid			2022-12-25	WOS:000178791400116
J	McAlinden, A; Crouch, EC; Bann, JG; Zhang, PN; Sandell, LJ				McAlinden, A; Crouch, EC; Bann, JG; Zhang, PN; Sandell, LJ			Trimerization of the amino propeptide of type IIA procollagen using a 14-amino acid sequence derived from the coiled-coil neck domain of surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; GCN4 LEUCINE-ZIPPER; OLIGOMERIZATION-STATE; TRIPLE-HELIX; I COLLAGEN; OSTEOGENESIS IMPERFECTA; PRO-ALPHA-1(I) CHAIN; EXPRESSION; STABILITY; POSITION	The folding of a collagen triple helix usually requires the presence of additional sequences that contribute to the association and correct alignment of the collagen chains. We recently reported that the C-terminal neck and lectin domains of a collagenous C-type lectin, rat pulmonary surfactant protein D (SP-D), are sufficient to drive the trimerization of a heterologous type IIA procollagen amino propeptide sequence. However, the conformation of the resulting trimeric IIA propeptide and the specific contributions of the SP-D sequence to trimerization were not elucidated. In the present study, we show that trimerization of the fusion protein is associated with correct folding of the collagen helix within the IIA propeptide domain (as assessed by circular dichroism) and that the constituent chains are hydroxylated. Chemical cross-linking and analytical ultracentrifugation showed that the IIA amino-propeptide retains its trimeric configuration even after proteolytic removal of the SP-D domains. By contrast, IIA amino-propeptides synthesized without fusion to the neck or lectin domains are assembled exclusively as monomers. To localize the trimerization sequence, mutant chimeric cDNA constructs were designed containing premature termination codons within the coiled-coil neck domain. A short, 14-amino acid sequence corresponding to the first two heptad repeats of the neck domain was sufficient to drive the trimeric association of the IIA amino-propeptide a-chains. However, deletion of the collagen domain resulted in the secretion of monomers. These studies demonstrate that two heptad repeats are sufficient for trimeric association of the propeptide but indicate that cooperative interactions between the coiled-coil and collagen domains are required for the formation of a stable helix.	Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Sandell, LJ (corresponding author), Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Orthopaed Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.			McAlinden, Audrey/0000-0001-8433-4224	NHLBI NIH HHS [HL 44015, HL 29594] Funding Source: Medline; NIAMS NIH HHS [AR 36994] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Brown JH, 1996, PROTEINS, V26, P134; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; FISHER LW, 1987, J BIOL CHEM, V262, P13457; FLEISCHMAJER R, 1986, J INVEST DERMATOL, V87, P553; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Goodman M, 1998, BIOPOLYMERS, V47, P127, DOI 10.1002/(SICI)1097-0282(1998)47:2<127::AID-BIP2>3.0.CO;2-W; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; Kishore U, 1996, BIOCHEM J, V318, P505, DOI 10.1042/bj3180505; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; Larrain J, 2000, DEVELOPMENT, V127, P821; Mazzorana M, 1996, J BIOL CHEM, V271, P29003, DOI 10.1074/jbc.271.46.29003; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Wagschal K, 1999, PROTEIN SCI, V8, P2312; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; WU CH, 1986, J BIOL CHEM, V261, P482; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	43	13	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41274	41281		10.1074/jbc.M202257200	http://dx.doi.org/10.1074/jbc.M202257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12194968	hybrid			2022-12-25	WOS:000178791400140
J	Suzuki, T; Yamakuni, T; Hagiwara, M; Ichinose, H				Suzuki, T; Yamakuni, T; Hagiwara, M; Ichinose, H			Identification of ATF-2 as a transcriptional regulator for the tyrosine hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-RESPONSE ELEMENT; CYCLOHYDROLASE-I GENE; C-FOS TRANSCRIPTION; CYCLIC-AMP; BINDING PROTEIN; DNA-BINDING; ADRENAL-MEDULLA; FACTOR CREB; CELL-LINES; PHOSPHORYLATION	Transcriptional regulation of catecholamine-synthesizing genes is important for the determination of neurotransmitters during brain development. We found that three catecholamine-synthesizing genes were transcriptionally up-regulated in cloned PC12D cells over-expressing V-1, a protein that is highly expressed during postnatal brain development (1). To reveal the molecular mechanism to regulate the expression of tyrosine hydroxylase (TH), which is the rate-limiting enzyme for catecholamine biosynthesis, we analyzed the transcription factors responsible for TH induction in the V-1 clonal cells. First, by using reporter constructs, we found that the transcription mediated by cAMP-responsive element (CRE) was selectively enhanced in the V-1 cells, and TH promoter activity was totally dependent on the CRE in the promoter region of the TH gene. Next, immunoblot analyses and a transactivation assay using a GAL4 reporter system revealed that ATF-2, but not cAMP-responsive element-binding protein (CREB), was highly phosphorylated and activated in the V-1 cells, while both CREB and ATF-2 were bound to the TH-CRE. Finally, the enhanced TH promoter activity was competitively attenuated by expression of a plasmid containing the ATF-2 transactivation domain. These data demonstrated that activation of ATF-2 resulted in the increased transcription of the TH gene and suggest that ATF-2 may be deeply involved in the transcriptional regulation of catecholamine-synthesizing genes during neural development.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, Toyoake, Aichi 4701192, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut Mol Biol, Aoba Ku, Sendai, Miyagi 9808578, Japan; Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; Tokyo Med & Dent Univ, Inst Med Res, Dept Functional Genom, Tokyo 1138510, Japan	Fujita Health University; Tohoku University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Tokyo Medical & Dental University (TMDU)	Ichinose, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, Toyoake, Aichi 4701192, Japan.		Yamakuni, Tohru/AAE-3541-2019; Ichinose, Hiroshi/D-8986-2015	Ichinose, Hiroshi/0000-0001-6008-6860; Yamakuni, Tohru/0000-0003-3968-7949				Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cazorla P, 2000, J NEUROCHEM, V74, P1829, DOI 10.1046/j.1471-4159.2000.0741829.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ghee M, 1998, MOL BRAIN RES, V55, P101, DOI 10.1016/S0169-328X(97)00370-7; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guo Z, 1998, J NEUROSCI, V18, P8163; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hirayama K, 2001, J NEUROCHEM, V79, P576, DOI 10.1046/j.1471-4159.2001.00583.x; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; Kapatos G, 2000, J BIOL CHEM, V275, P5947, DOI 10.1074/jbc.275.8.5947; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KIM KS, 1993, J BIOL CHEM, V268, P15689; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; Lebel M, 2001, J NEUROCHEM, V77, P558, DOI 10.1046/j.1471-4159.2001.00257.x; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; Nankova B, 1996, MOL BRAIN RES, V35, P164, DOI 10.1016/0169-328X(95)00201-3; Nankova BB, 2000, J NEUROSCI, V20, P5647, DOI 10.1523/JNEUROSCI.20-15-05647.2000; Parker D, 1999, MOL CELL BIOL, V19, P5601; Piech-Dumas KM, 1999, MOL BRAIN RES, V70, P219, DOI 10.1016/S0169-328X(99)00149-7; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1998, J NEUROCHEM, V70, P1029; Sumi-Ichinose C, 2001, J BIOL CHEM, V276, P41150, DOI 10.1074/jbc.M102237200; Sun BY, 2002, J NEUROCHEM, V80, P295, DOI 10.1046/j.0022-3042.2001.00692.x; Suzuki T, 2002, BIOCHEM BIOPH RES CO, V293, P962, DOI 10.1016/S0006-291X(02)00343-1; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; Tinti C, 1997, J BIOL CHEM, V272, P19158, DOI 10.1074/jbc.272.31.19158; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Trocme C, 1997, J NEUROSCI RES, V48, P489, DOI 10.1002/(SICI)1097-4547(19970615)48:6<489::AID-JNR1>3.0.CO;2-6; Usukura J, 2000, GENES CELLS, V5, P515, DOI 10.1046/j.1365-2443.2000.00345.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yamakuni T, 1998, J BIOL CHEM, V273, P27051, DOI 10.1074/jbc.273.42.27051; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	54	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40768	40774		10.1074/jbc.M206043200	http://dx.doi.org/10.1074/jbc.M206043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12196528	hybrid			2022-12-25	WOS:000178791400079
J	Ikeda, M; Beitz, E; Kozono, D; Guggino, WB; Agre, P; Yasui, M				Ikeda, M; Beitz, E; Kozono, D; Guggino, WB; Agre, P; Yasui, M			Characterization of aquaporin-6 as a nitrate channel in mammalian cells - Requirement of pore-lining residue threonine 63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; WATER PERMEATION; PROTON PUMP; PROTEIN; ACID; PERMEABILITY; CONDUCTANCE; SELECTIVITY; MECHANISM; MEMBRANES	Aquaporins (AQP) were originally regarded as plasma membrane channels that are freely permeated by water or small uncharged solutes but not by ions. Unlike other aquaporins, AQP6 overexpressed in Xenopus laevis oocytes was previously found to exhibit Hg2+ or pH-activated ion conductance. AQP6 could not be analyzed electrophysiologically in mammalian cells, however, because the protein is restricted to intracellular vesicles. Here we report that addition of a green fluorescence protein (GFP) tag to the N terminus of rat AQP6 (GFP-AQP6) redirects the protein to the plasma membranes of transfected mammalian cells. This permitted measurement of rapid, reversible, pH-induced anion currents by GFP-AQP6 in human embryonic kidney 293 cells. Surprisingly, anion selectivity relative to Cl- revealed high nitrate permeability even at pH 7.4; P-NO3/P-CI > 9.8. Site-directed mutation of a pore-lining threonine to isoleucine at position 63 at the midpoint of the channel reduced NO3-/Cl- selectivity. Moreover, no anomalous mole-fraction behavior was observed with NO3-/Cl- mixtures, suggesting a single ion-binding pore in each subunit. Our studies indicate that AQP6 exhibits a new form of anion permeation with marked specificity for nitrate conferred by a specific pore-lining residue, observations that imply that the primary role of AQP6 may be in cellular regulation rather than simple fluid transport.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Yasui, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat & Biol Chem, 420 Physiol Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	myasui@jhmi.edu	Yasui, Masato/L-3312-2013	Ikeda, Masahiro/0000-0003-2539-8812	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; Hazama A, 2002, J BIOL CHEM, V277, P29224, DOI 10.1074/jbc.M204258200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IKEDA M, 1993, J MEMBRANE BIOL, V136, P231; Jentsch TJ, 2002, NATURE, V415, P276, DOI 10.1038/415276a; Klemm AR, 1998, BBA-BIOMEMBRANES, V1373, P17, DOI 10.1016/S0005-2736(98)00082-0; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF1014, DOI 10.1152/ajprenal.2000.279.6.F1014; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; STOFFEKOVA K, 1998, AM J PHYSIOL, V275, pC1113; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; Tewari KP, 2000, AM J PHYSIOL-CELL PH, V279, pC40, DOI 10.1152/ajpcell.2000.279.1.C40; TOJO A, 1994, AM J PHYSIOL-RENAL, V267, pF509, DOI 10.1152/ajprenal.1994.267.4.F509; Valles PG, 2000, KIDNEY INT, V58, P1641, DOI 10.1046/j.1523-1755.2000.00325.x; Walsh MA, 1998, ACTA CRYSTALLOGR D, V54, P522, DOI 10.1107/S0907444997013656; Yanochko GM, 2002, J NEUROSCI, V22, P2530, DOI 10.1523/JNEUROSCI.22-07-02530.2002; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808	33	149	154	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39873	39879		10.1074/jbc.M207008200	http://dx.doi.org/10.1074/jbc.M207008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177001	hybrid			2022-12-25	WOS:000178662500104
J	Zhou, MI; Wang, HM; Ross, JJ; Kuzmin, I; Xu, CG; Cohen, HT				Zhou, MI; Wang, HM; Ross, JJ; Kuzmin, I; Xu, CG; Cohen, HT			The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; FACTOR MESSENGER-RNA; GENE-PRODUCT; KINASE-C; GROWTH; VHL; MUTATIONS; DISEASE; BINDING; FINGER	The von Hippel-Lindau disease gene (VHL) is the causative gene for most adult renal cancers. However, the mechanism by which VHL protein functions as a renal tumor suppressor remains largely unknown. To identify low occupancy VHL protein partners with potential relevance to renal cancer, we screened a human kidney library against human VHL p30 using a yeast two-hybrid approach. Jade-1 (gene for Apoptosis and Differentiation in Epithelia) encodes a previously uncharacterized 64-kDa protein that interacts strongly with VHL protein and is most highly expressed in kidney. Jade-1 protein is short-lived and contains a candidate destabilizing (PEST) motif and plant homeodomains that are not required for the VHL interaction. Jade-1 is abundant in proximal tubule cells, which are clear-cell renal cancer precursors, and expression increases with differentiation. Jade-1 is expressed in cytoplasm and the nucleus diffusely and in speckles, where it partly colocalizes with VHL. VHL reintroduction into renal cancer cells increases endogenous Jade-1 protein abundance up to 10-fold. Furthermore, VHL increases Jade-1 protein half-life up to 3-fold. Thus, direct protein stabilization is identified as a new VHL function. Moreover, Jade-1 protein represents a novel candidate regulatory factor in VHL-mediated renal tumor suppression.	Boston Univ, Med Ctr, Evans Biomed Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Nephrol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Hematol Oncol Sect, Boston, MA 02118 USA; NCI, Frederick Canc Res Ctr, NIH, Frederick, MD 21702 USA	Boston University; Boston University; Boston University; Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cohen, HT (corresponding author), Boston Univ, Med Ctr, Evans Biomed Res Ctr, X-535,650 Albany St, Boston, MA 02118 USA.	htcohen@bu.edu		Cohen, Herbert/0000-0003-1900-8718	NATIONAL CANCER INSTITUTE [F32CA079133, R01CA079830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007053] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079830, R01-CA79830, F32-CA79133] Funding Source: Medline; NIDDK NIH HHS [T32-DK07053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Devarajan P, 2001, J BIOL CHEM, V276, P40599, DOI 10.1074/jbc.M103424200; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GABIG TG, 1994, J BIOL CHEM, V269, P29515; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Helbing CC, 1997, CANCER RES, V57, P1255; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Kamada M, 2001, CANCER RES, V61, P4184; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LoghmanAdham M, 1997, KIDNEY INT, V52, P229, DOI 10.1038/ki.1997.325; Los M, 1996, LAB INVEST, V75, P231; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shiao YH, 2000, CANCER RES, V60, P2816; Szelci J, 2000, J STEROID BIOCHEM, V72, P89, DOI 10.1016/S0960-0760(00)00025-X; Tsuchiya H, 1996, CANCER RES, V56, P2881; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	68	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39887	39898		10.1074/jbc.M205040200	http://dx.doi.org/10.1074/jbc.M205040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169691	hybrid			2022-12-25	WOS:000178662500106
J	Cordero, JB; Cozzolino, M; Lu, Y; Vidal, M; Slatopolsky, E; Stahl, PD; Barbieri, MA; Dusso, A				Cordero, JB; Cozzolino, M; Lu, Y; Vidal, M; Slatopolsky, E; Stahl, PD; Barbieri, MA; Dusso, A			1,25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN KERATINOCYTES; VITAMIN-D ANALOGS; FACTOR-ALPHA; EGF RECEPTOR; TYROSINE KINASES; EXPRESSION; ACTIVATION; ENDOCYTOSIS; CARCINOMA; PRECURSOR	1,25(OH)(2)D-3 antiproliferative properties are widely known. However, the molecular bases of these properties are only partially elucidated. Since 1,25(OH)(2)D-3 effectively arrests growth in many tumors and hyperplastic tissues whose growth is driven by co-expression of EGFR and its ligand TGF-alpha, it was hypothesized that 1,25(OH)(2)D-3 could affect the TGF-alpha/EGFR-autocrine growth loop. This study examined 1,25(OH)(2)D-3 regulation of EGFR-growth signals, using human epidermoid A431 cells, in which the overexpression of EGFR and TGF-a constitute the major autocrine mitogenic signal. 1,25(OH)(2)D-3 inhibited autocrine and EGF-induced A431 cell proliferation. Furthermore, 1,25(OH)(2)D-3 changed the cellular localization of both TGF-alpha and EGFR and inhibited ligand-dependent phosphorylation of EGFR and ERK1/2. In addition, 1,25(OH)(2)D-3 impaired autocrine and EGF-induced nuclear translocation of activated EGFR and, consequently, its binding to AT-rich DNA sequences and transcriptional activation of the cyclin D1 promoter. These results demonstrate that 1,25(OH)(2)D-3 alters EGFR membrane trafficking and down-regulates EGFR growth signaling.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Barbieri, MA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	Alejandro.Barbieri@cellbiology.wustl.edu; adusso@im.wustl.edu	Cozzolino, Mario/AAB-9965-2022; Dusso, Adriana S/E-8617-2011; Stahl, Philip/D-6315-2012	Cozzolino, Mario/0000-0002-8494-6252; Cordero, Julia/0000-0003-1701-9480	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015, R01AI035884, R37AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35884, AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanell J, 2001, CANCER RES, V61, P6500; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Busse D, 2001, SEMIN ONCOL, V28, P47, DOI 10.1053/sonc.2001.28550; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Cozzolino M, 2001, KIDNEY INT, V60, P2109, DOI 10.1046/j.1523-1755.2001.00042.x; DERYNCK R, 1987, CANCER RES, V47, P707; DRIMAN DK, 1992, HUM PATHOL, V23, P1360, DOI 10.1016/0046-8177(92)90055-8; Dusso AS, 2001, KIDNEY INT, V59, P855; El-Obeid A, 2002, BIOCHEM BIOPH RES CO, V290, P349, DOI 10.1006/bbrc.2001.6210; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GUSTERSON B, 1985, INT J CANCER, V36, P689; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Segaert S, 1998, J INVEST DERMATOL, V111, P551, DOI 10.1046/j.1523-1747.1998.00367.x; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P234, DOI 10.1097/00004347-199407000-00007; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Verstuyf A, 2000, EXPERT OPIN INV DRUG, V9, P443, DOI 10.1517/13543784.9.3.443; Wang QM, 1996, CANCER RES, V56, P264; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Yabushita H, 1996, J Obstet Gynaecol Res, V22, P529; Zhao XY, 2001, STEROIDS, V66, P293, DOI 10.1016/S0039-128X(00)00164-1; Zugmaier G, 1996, BRIT J CANCER, V73, P1341, DOI 10.1038/bjc.1996.256	46	90	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38965	38971		10.1074/jbc.M203736200	http://dx.doi.org/10.1074/jbc.M203736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12181310	hybrid			2022-12-25	WOS:000178529600120
J	Paul-Pletzer, K; Yamamoto, T; Bhat, MB; Ma, JJ; Ikemoto, N; Jimenez, LS; Morimoto, H; Williams, PG; Parness, J				Paul-Pletzer, K; Yamamoto, T; Bhat, MB; Ma, JJ; Ikemoto, N; Jimenez, LS; Morimoto, H; Williams, PG; Parness, J			Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MALIGNANT HYPERTHERMIA; SARCOPLASMIC-RETICULUM; POSTULATED ROLE; FUNCTIONAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTOR; DOMAIN-III; CONTRACTION; EXPRESSION; PROTEINS	Dantrolene is a drug that suppresses intracellular Ca2+ release from sarcoplasmic reticulum (SR) in skeletal muscle and is used as a therapeutic agent in individuals susceptible to malignant hyperthermia. Although its precise mechanism of action has not been elucidated, we have identified the N-terminal region (amino acids 1-1400) of the skeletal muscle isoform of the ryanodine receptor (RyR1), the primary Ca2+ release channel in SR, as a molecular target for dantrolene using the photoaffinity analog [H-3]azidodantrolene. Here, we demonstrate that heterologously expressed RyR1 retains its capacity to be specifically labeled wit [H-3]azidodantrolene, indicating that muscle specific factors are not required for this ligand-receptor interaction. Synthetic domain peptides of RyR1 previously shown to affect RyR1 function in vitro and in vivo were exploited as potential drug binding site mimics and used in photoaffinity labeling experiments. Only DP1 and DP1-2s, peptides containing the amino acid sequence corresponding to RyR1 residues 590-609, were specifically labeled by [H-3]azidodantrolene. A monoclonal anti-RyR1 antibody that recognizes RyR1 and its 1400-amino acid N-terminal fragment recognizes DP1 and DP1-2s in both Western blots and immunoprecipitation assays and specifically inhibits [H-3]azidodantrolene photolabeling of RyR1 and its N-terminal fragment in SR. Our results indicate that synthetic domain peptides can mimic a native, ligand-binding conformation in vitro and that the dantrolene-binding site and the epitope for the monoclonal antibody on RyR1 are equivalent and composed of amino acids 590-609.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA; EO Lawrence Berkeley Lab, Natl Tritum Labelling Fac, Berkeley, CA 94720 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Cleveland Clinic Foundation; Rutgers State University New Brunswick; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco	Parness, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Staged res Annex 2,Rm 117,661 Hoes Ln, Piscataway, NJ 08854 USA.				NCRR NIH HHS [P41 RR01237] Funding Source: Medline; NIAMS NIH HHS [AR-16922, 5 R01 AR45593] Funding Source: Medline; NIA NIH HHS [R01 AG-15556] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922, R01AR045593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Bhat MB, 1999, BIOPHYS J, V77, P808, DOI 10.1016/S0006-3495(99)76933-X; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; De Ferrari GV, 2001, BIOCHEMISTRY-US, V40, P10447, DOI 10.1021/bi0101392; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; El-Hayek R, 1999, J BIOL CHEM, V274, P33341, DOI 10.1074/jbc.274.47.33341; Froemming GR, 2001, FRONT BIOSCI-LANDMRK, V6, pD65, DOI 10.2741/froemmin; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Hosoi E, 2001, J IMMUNOL, V167, P4887, DOI 10.4049/jimmunol.167.9.4887; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Ikemoto N, 2000, TRENDS CARDIOVAS MED, V10, P310, DOI 10.1016/S1050-1738(01)00067-6; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Lokuta AJ, 2002, FEBS LETT, V511, P90, DOI 10.1016/S0014-5793(01)03312-9; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Nasu T, 1996, GEN PHARMACOL, V27, P513, DOI 10.1016/0306-3623(95)00102-6; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; Palnitkar SS, 1999, J MED CHEM, V42, P1872, DOI 10.1021/jm9805079; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Protasi F, 2002, FRONT BIOSCI, V7, pD650, DOI 10.2741/protasi; Sambuughin N, 2001, NEUROMUSCULAR DISORD, V11, P530, DOI 10.1016/S0960-8966(01)00202-4; Sambuughin N, 2001, AM J HUM GENET, V69, P204, DOI 10.1086/321270; SENGUPTA C, 1980, FEBS LETT, V117, P37, DOI 10.1016/0014-5793(80)80908-2; Shevchenko S, 1998, J MEMBRANE BIOL, V161, P33, DOI 10.1007/s002329900312; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; Szentesi P, 2001, J GEN PHYSIOL, V118, P355, DOI 10.1085/jgp.118.4.355; TAKESHIMA H, 1993, ANN NY ACAD SCI, V707, P165, DOI 10.1111/j.1749-6632.1993.tb38051.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Villen J, 2002, CHEMBIOCHEM, V3, P175, DOI 10.1002/1439-7633(20020301)3:2/3<175::AID-CBIC175>3.0.CO;2-W; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Yamamoto T, 2000, J BIOL CHEM, V275, P11618, DOI 10.1074/jbc.275.16.11618; Yamamoto T, 2002, J BIOL CHEM, V277, P993, DOI 10.1074/jbc.M105837200; Yamamoto T, 2002, J BIOL CHEM, V277, P984, DOI 10.1074/jbc.M102347200; Yamamoto T, 2002, BIOCHEMISTRY-US, V41, P1492, DOI 10.1021/bi015581z; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	45	104	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34918	34923		10.1074/jbc.M205487200	http://dx.doi.org/10.1074/jbc.M205487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167662	hybrid			2022-12-25	WOS:000178117000035
J	Xu, CW; Luo, ZJ				Xu, CW; Luo, ZJ			Inactivation of Ras function by allele-specific peptide aptamers	ONCOGENE			English	Article						allele-specific; Ras; functional genomics; peptide aptamer	SIGNAL-TRANSDUCTION; GENETIC SELECTION; PLASMA-MEMBRANE; ACTIVATION; PROTEINS; CONNECTIONS; DROSOPHILA; SEQUENCE; C-RAF-1; SWITCH	One challenge facing biology is the elucidation of the function of the estimated 30000 human genes and their polymorphic variants. Reagents that affect the activity of specific genes will be useful in the dissection of cellular regulatory networks. Here, as a test case, we used a two-bait two-hybrid system to identify peptide aptamers that distinguish allelic forms of H-Ras. Some of these anti-Ras aptamters inhibit the interaction of oncogenic Ras with c-Raf1 in vitro, and abolish EGF-stimulated activation of c-Raf1 in vivo. These experiments show that the inactivation of protein function by peptide aptamers represents a viable approach to the understanding and control of signaling pathways and oncogenic missense alleles.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Boston Univ, Sch Med, Dept Med, Diabet & Metab Unit, Boston, MA 02118 USA	Memorial Sloan Kettering Cancer Center; Boston University	Xu, CW (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA.	w-xu@ski.mskcc.org	Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289	NIGMS NIH HHS [GM57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	21	23	25	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5753	5757		10.1038/sj.onc.1205680	http://dx.doi.org/10.1038/sj.onc.1205680			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173045	Bronze			2022-12-25	WOS:000177463400010
J	de Bruyn, KMT; Rangarajan, S; Reedquist, KA; Figdor, CG; Bos, JL				de Bruyn, KMT; Rangarajan, S; Reedquist, KA; Figdor, CG; Bos, JL			The small GTPase Rap1 is required for Mn2+- and antibody-induced LFA-1-and VIA-4-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN-KINASE-II; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; INDUCED ACTIVATION; MOLECULE-1 ICAM-1; CYTOPLASMIC TAIL; INTEGRIN LFA-1; LYMPHOCYTES-T; BINDING	In T-lymphocytes the Ras-like small GTPase Rap1 plays an essential role in stimulus-induced inside-out activation of integrin LFA-1 (alpha(L)beta(2)) and VLA-4 (alpha(4)beta(1)). Here we show that Rap1 is also involved in the direct activation of these integrins by divalent cations or activating antibodies. Inhibition of Rap1 either by Rap GTPase-activating protein (RapGAP) or the Rap1 binding domain of RalGDS abolished both Mn2+- and KIM185 (anti-LFA-1)-induced LFA-1-mediated cell adhesion to intercellular adhesion molecule 1. Mn2+- and TS2/16 (anti-VLA-4)-induced VLA-4-mediated adhesion were inhibited as well. Interestingly, both Mn2+, KIM185 and TS2/16 failed to induce elevated levels of Rap1GTP. These findings indicate that available levels of GTP-bound Rap1 are required for the direct activation of LFA-1 and VLA-4. Pharmacological inhibition studies demonstrated that both Mn2+- and KIM185-induced adhesion as well as Rap1-induced adhesion require intracellular calcium but not signaling activity of the MEK-ERK pathway. Moreover, functional calmodulin signaling was shown to be a prerequisite for Rap1-induced adhesion. From these results we conclude that in addition to stimulus-induced inside-out activation of integrins, active Rap1 is required for cell adhesion induced by direct activation of integrins LFA-1 and VLA-4. We suggest that Rap1 determines the functional availability of integrins for productive binding to integrin ligands.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 AB Utrecht, Netherlands; Univ Nijmegen, Med Ctr, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands	Utrecht University; Utrecht University; Radboud University Nijmegen	Bos, JL (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Univ Weg 100,POB 85060, NL-3508 AB Utrecht, Netherlands.	j.l.bos@med.uu.nl	Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bouvard D, 1998, J CELL SCI, V111, P657; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1990, BIOESSAYS, V12, P421, DOI 10.1002/bies.950120905; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Fagerholm SC, 2001, FEBS LETT, V491, P131, DOI 10.1016/S0014-5793(01)02182-2; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lacabaratz-Porret C, 1998, BIOCHEM J, V332, P173, DOI 10.1042/bj3320173; Liu SC, 2000, J CELL SCI, V113, P3563; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Tominaga Y, 1998, J IMMUNOL, V161, P4016; Tsuchida J, 1997, FEBS LETT, V416, P212, DOI 10.1016/S0014-5793(97)01206-4; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	50	94	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29468	29476		10.1074/jbc.M204990200	http://dx.doi.org/10.1074/jbc.M204990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12171996	hybrid, Green Published			2022-12-25	WOS:000177509300017
J	Schling, P; Schafer, T				Schling, P; Schafer, T			Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; LEUCINE AMINOPEPTIDASE; HUMAN PREADIPOCYTES; SYSTEM; ADIPOCYTES; CONVERSION; PROTEIN; EXPRESSION; VESICLES; BINDING	Human adipose tissue expresses all components necessary for the local production of angiotensin II, which has multiple functions in adipose tissue, ranging from regulation of local blood flow to complex influences on tissue homeostasis. Still the mechanisms controlling human adipose tissue angiotensin II concentrations are not yet known. We investigated whether angiotensin II is degraded by human primary cultured preadipocytes and adipocytes and which enzymes are responsible for its metabolism. Distinct but transient angiotensin II production was limited by degradation due to consecutive proteolytic cleavage by endopeptidase and aminopeptidase activities. The endopeptidase could be identified as neprilysin expressed on the surface of both preadipocytes and adipocytes. Degradation of angiotensin II was preceded by a lag phase that was considerably longer in preadipocytes. This time span could not be explained by an induction of neprilysin nor by an increase in its surface localization. Following the lag phase, adipocytes showed a higher degradation activity than preadipocytes as mirrored by increased neprilysin levels and activity measured in their membrane fractions. Our findings demonstrate that human preadipocytes and adipocytes differentially express functional neprilysin and aminopeptidase activity involved in the regulation of angiotensin II concentrations in human adipose tissue.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	University of Regensburg; Ruprecht Karls University Heidelberg	Schling, P (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	petra.schling@klinik.uni-regens-burg.de		Schaefer, Thorsten/0000-0003-4867-8374				Ailhaud G, 1999, ANN NY ACAD SCI, V892, P127, DOI 10.1111/j.1749-6632.1999.tb07791.x; Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRANDALL DL, 1994, DRUG DEVELOP RES, V32, P117, DOI 10.1002/ddr.430320208; Engeli S, 1999, J HYPERTENS, V17, P555, DOI 10.1097/00004872-199917040-00014; Engeli S, 2000, HYPERTENSION, V35, P1270, DOI 10.1161/01.HYP.35.6.1270; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; Fontenele-Neto JD, 2001, J COMP NEUROL, V438, P399, DOI 10.1002/cne.1323; Ganju RK, 1996, BLOOD, V88, P4159; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; HERSHEY JC, 1995, J BIOL CHEM, V270, P25096, DOI 10.1074/jbc.270.42.25096; INDIG FE, 1989, FEBS LETT, V255, P237, DOI 10.1016/0014-5793(89)81098-1; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; Jonsson J R, 1994, Blood Press, V3, P72; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; Karlsson C, 1998, J CLIN ENDOCR METAB, V83, P3925, DOI 10.1210/jc.83.11.3925; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kobayashi H., 1996, Zoophysiology, V35, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLOW H, 1997, INT J OBES S2, V21, P92; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Massiera F, 2001, FASEB J, V15, P2727, DOI 10.1096/fj.01-0457fje; Mentlein R, 1996, PEPTIDES, V17, P709, DOI 10.1016/0196-9781(96)00066-6; MORTON JJ, 1985, CLIN SCI, V68, P483, DOI 10.1042/cs0680483; Mulholland F, 1986, Adv Exp Med Biol, V198 Pt A, P41; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Pinterova L, 2000, GEN PHYSIOL BIOPHYS, V19, P329; Riemann D, 2001, BIOCHEM J, V354, P47, DOI 10.1042/0264-6021:3540047; ROSELL S, 1979, PHYSIOL REV, V59, P1078, DOI 10.1152/physrev.1979.59.4.1078; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SAYE JA, 1993, AM J PHYSIOL, V264, pC1570, DOI 10.1152/ajpcell.1993.264.6.C1570; Schling P, 2002, NEWS PHYSIOL SCI, V17, P99, DOI 10.1152/nips.01349.2001; Schling P, 2001, HORM METAB RES, V33, P189, DOI 10.1055/s-2001-14951; Schling P, 1999, INT J OBESITY, V23, P336, DOI 10.1038/sj.ijo.0800821; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SPENCERDENE B, 1994, DEVELOPMENT, V120, P3213; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; WANG J, 1976, J NUTR, V106, P1687, DOI 10.1093/jn/106.12.1687; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325	44	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48066	48075		10.1074/jbc.M204058200	http://dx.doi.org/10.1074/jbc.M204058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12196514	hybrid			2022-12-25	WOS:000179789600014
J	Borggrefe, T; Davis, R; Erdjument-Bromage, H; Tempst, P; Kornberg, RD				Borggrefe, T; Davis, R; Erdjument-Bromage, H; Tempst, P; Kornberg, RD			A complex of the Srb8,-9,-10, and-11 transcriptional regulatory proteins from yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; MEDIATOR COMPLEXES; KINASES; CTD; HOLOENZYME; PHOSPHORYLATION; REVEALS; SRB10; FORMS	The Srb8, -9, -10, and -11 proteins of yeast have been isolated as a discrete, stoichiometric complex. The isolated complex phosphorylates the C-terminal domain (CTD) of the largest subunit of RNA polymerase 11 at serines 2 and 5. In addition to the previously reported human homologs of Srb10 and 11, we have identified TRAP230/ARC240 and TRAP240/ARC250 as the human homologs of Srb8 and Srb9, showing the entire Srb8/9/10/11 complex is conserved from yeast to humans.	Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Stanford University; Memorial Sloan Kettering Cancer Center	Borggrefe, T (corresponding author), Univ Ulm, Dept Immunol, D-89081 Ulm, Germany.			Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Bienkiewicz EA, 2000, J MOL BIOL, V297, P119, DOI 10.1006/jmbi.2000.3545; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu HY, 2001, J BIOL CHEM, V276, P7541, DOI 10.1074/jbc.M009112200; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Treisman JE, 2001, DEVELOPMENT, V128, P603; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yuryev A, 1996, GENETICS, V143, P661; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	38	126	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44202	44207		10.1074/jbc.M207195200	http://dx.doi.org/10.1074/jbc.M207195200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12200444	hybrid			2022-12-25	WOS:000179272000087
J	Tussie-Luna, MI; Michel, B; Hakre, S; Roy, AL				Tussie-Luna, MI; Michel, B; Hakre, S; Roy, AL			The SUMO ubiquitin-protein isopeptide ligase family member Miz1/PIASx beta/Siz2 is a transcriptional cofactor for TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; RETINOBLASTOMA-PROTEIN; SYNDROME DELETION; BINDING PROTEIN; YEAST SEPTINS; GENE; IDENTIFICATION; CONJUGATION; ENCODES; MOTIF	We have shown previously that a TFII-I-related protein, hMusTRD1/BEN, represses transcriptional activity of TFII-I. The repression by hMusTRD1/BEN was hypothesized to occur via a two-step competition mechanism involving a cytoplasmic shuttling factor and a nuclear cofactor required for transcriptional activation of TFII-I. Employing a two-hybrid approach with both yeast genomic and mouse cDNA libraries in parallel, we have identified the RING-like zinc finger containing Miz1/PIASxbeta/Siz2, which is a ubiquitin-protein isopeptide ligase in the SUMO pathway, as the potential nuclear cofactor that interacts with both TFII-I and hMus-TRD1/BEN. Our conclusion is based on the following observations. First, the interactions are biochemically confirmed in mammalian cells where Miz1/mPIASxbeta interacts with both TFII-I and hMusTRD1/BEN when these proteins are ectopically co-expressed. Second, coexpression of a nuclear localization signal-deficient mutant of Miz1/mPIASxbeta with wild type TFII-I fails to alter the subcellular localization of the former. Finally, ectopically expressed Miz1/mPIASxbeta augments the transcriptional activity of TFII-I and relieves the repression exerted by a mutant hMusTRD1/BEN that co-localized with TFII-I in the nucleus.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045150, R01AI045150] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45150] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Franke Y, 1999, CYTOGENET CELL GENET, V86, P296, DOI 10.1159/000015322; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tassabehji M, 1999, EUR J HUM GENET, V7, P737, DOI 10.1038/sj.ejhg.5200396; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749	38	28	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43185	43193		10.1074/jbc.M207635200	http://dx.doi.org/10.1074/jbc.M207635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12193603	hybrid			2022-12-25	WOS:000179081200100
J	Gutierrez, O; Pipaon, C; Inohara, N; Fontalba, A; Ogura, Y; Prosper, F; Nunez, G; Fernandez-Luna, JL				Gutierrez, O; Pipaon, C; Inohara, N; Fontalba, A; Ogura, Y; Prosper, F; Nunez, G; Fernandez-Luna, JL			Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; INNATE; EXPRESSION; MUTATIONS; DIFFERENTIATION; SUSCEPTIBILITY; INHIBITION; INFLIXIMAB; APOPTOSIS; LINES	Nod2, a member of the Apaf1/Nod protein family, confers responsiveness to bacterial products and activates NF-kappaB, a transcription factor that plays a central role in innate immunity. Recently, genetic variation in Nod2 has been associated with susceptibility to Crohn's disease. Here, we report that expression of Nod2 is induced upon differentiation of CD34(+) hematopoietic progenitor cells into granulocyte or monocyte/macrophages. In peripheral blood cells, the highest levels of Nod2 were observed in CD14(+) (monocytes), CD15(+) (granulocytes), and CD40(+)/CD86(+) (dendritic cells) cell populations. Notably, stimulation of myeloblastic and epithelial cells with bacterial lipopolysaccharide or TNFalpha resulted in up-regulation of Nod2. A search for consensus sites within the Nod2 promoter revealed a NF-kappaB binding element that was required for transcriptional activity in response to TNFalpha. Moreover, ectopic expression of p65 induced transactivation, whereas that of dominant-negative IkappaBalpha blocked the transcriptional activity of the Nod2 promoter. Upon stimulation with TNFalpha or lipopolysaccharide, both p50 and p65 subunits of NF-kappaB were bound to the Nod2 promoter. Thus, Nod2 expression is enhanced by proinflammatory cytokines and bacterial components via NF-kappaB, a mechanism that may contribute to the amplification of the innate immune response and susceptibility to inflammatory disease.	Hosp Univ Marques Valdecilla, Unidad Genet Mol, Santander 39008, Spain; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Navarra Clin, Hematol Serv, Pamplona, Spain	Hospital Universitario Marques de Valdecilla (HUMV); University of Michigan System; University of Michigan; University of Navarra	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques Valdecilla, Unidad Genet Mol, Santander 39008, Spain.	fluna@humv.es	Prosper, Felipe/H-6859-2017; Nuñez, Gabriel/A-7160-2014; Pipaon, Carlos/L-4922-2014	Prosper, Felipe/0000-0001-6115-8790; Pipaon, Carlos/0000-0002-3851-6710	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060421] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-61707] Funding Source: Medline; NIGMS NIH HHS [GM-60421] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415; Elson CO, 2002, NEW ENGL J MED, V346, P614, DOI 10.1056/NEJM200202213460812; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keller SA, 2000, BLOOD, V96, P2537; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lau R, 2001, J IMMUNOTHER, V24, P66, DOI 10.1097/00002371-200101000-00008; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; PRICE JE, 1990, CANCER RES, V50, P717; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	31	364	374	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41701	41705		10.1074/jbc.M206473200	http://dx.doi.org/10.1074/jbc.M206473200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12194982	hybrid, Green Published			2022-12-25	WOS:000178985300052
J	Hourton-Cabassa, C; Mesneau, A; Miroux, B; Roussaux, J; Ricquier, D; Zachowski, A; Moreau, F				Hourton-Cabassa, C; Mesneau, A; Miroux, B; Roussaux, J; Ricquier, D; Zachowski, A; Moreau, F			Alteration of plant mitochondrial proton conductance by free fatty acids - Uncoupling protein involvement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; FUNCTIONAL RECONSTITUTION; POTATO MITOCHONDRIA; ELECTRON-TRANSPORT; GENE; NUCLEOTIDES; EXPRESSION; UCP1; YEAST; MICE	We characterized the uncoupling activity of the plant uncoupling protein from Solanum tuberosum (StUCP) using mitochondria from intact potato tubers or from yeast (Saccharomyces cerevisiae) expressing the StUCP gene. Compared with mitochondria from transfected yeast, StUCP is present at very low levels in intact potato mitochondrial membranes (at least thirty times lower) as shown by immunodetection with anti-UCP1 antibodies. Under conditions that ruled out undesirable effects of nucleotides and free fatty acids on uncoupling activity measurement in plant mitochondria, the linoleic acid-induced depolarization in potato mitochondria was insensitive to the nucleotides ATP, GTP, or GDP. In addition, sensitivity to linoleic acid was similar in potato and in control yeast mitochondria, suggesting that uncoupling occurring in potato mitochondria was because of a UCP-independent proton diffusion process. By contrast, yeast mitochondria expressing StUCP exhibited a higher sensitivity to free fatty acids than those from the control yeast and especially a marked proton conductance in the presence of low amounts of linoleic acid. However, this fatty acid-induced uncoupling was also insensitive to nucleotides. Altogether, these results suggest that uncoupling of oxidative phosphorylation and heat production cannot be the dominant feature of StUCP expressed in native potato tissues. However, it could play a role in preventing reactive oxygen species production as proposed for mammalian UCP2 and UCP3.	Univ Paris 06, CNRS, UMR 7632, Lab Physiol Cellulaire & Mol Plantes, F-75252 Paris 05, France; UPMC, Lab Biol Cellulaire Vegetale, F-75005 Paris, France; CNRS, UPR 9078, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France; IRNEM, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Moreau, F (corresponding author), Univ Paris 06, CNRS, UMR 7632, Lab Physiol Cellulaire & Mol Plantes, 154,4 Pl Jussieu, F-75252 Paris 05, France.	fmoreau@ccr.jussieu.fr	Miroux, Bruno/E-9267-2017; ZACHOWSKI, Alain/A-9029-2011	Miroux, Bruno/0000-0002-3066-4700; Cabassa, Cecile/0000-0001-5643-4551				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Borecky J, 2001, FEBS LETT, V505, P240, DOI 10.1016/S0014-5793(01)02835-6; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; Caiveau O, 2001, J BIOL CHEM, V276, P5788, DOI 10.1074/jbc.M006231200; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Considine MJ, 2001, PLANT PHYSIOL, V126, P1619, DOI 10.1104/pp.126.4.1619; Costa ADT, 1999, J BIOENERG BIOMEMBR, V31, P527, DOI 10.1023/A:1005408809619; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GUTMAN, 1971, BIOCHEMISTRY-US, V10, P4763, DOI 10.1021/bi00801a025; Ito K, 1999, PLANT SCI, V149, P167, DOI 10.1016/S0168-9452(99)00159-4; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P34882, DOI 10.1074/jbc.273.52.34882; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; MIROUX B, 1992, J BIOL CHEM, V267, P13603; MOORE AL, 1991, PLANT PHYSIOL, V95, P34, DOI 10.1104/pp.95.1.34; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; Nantes IL, 1999, FEBS LETT, V457, P103, DOI 10.1016/S0014-5793(99)01017-0; Pastore D, 2000, FEBS LETT, V470, P88, DOI 10.1016/S0014-5793(00)01292-8; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RUSTIN P, 1980, PLANT PHYSIOL, V66, P457, DOI 10.1104/pp.66.3.457; Silva MAPE, 1999, PLANT SCI, V143, P27; VALERIO M, 1993, EUR J BIOCHEM, V216, P565, DOI 10.1111/j.1432-1033.1993.tb18175.x; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Watanabe A, 1999, PLANT CELL PHYSIOL, V40, P1160, DOI 10.1093/oxfordjournals.pcp.a029501	38	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41533	41538		10.1074/jbc.M202805200	http://dx.doi.org/10.1074/jbc.M202805200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196511	hybrid			2022-12-25	WOS:000178985300031
J	Hu, KA; Carroll, J; Rickman, C; Davletov, B				Hu, KA; Carroll, J; Rickman, C; Davletov, B			Action of complexin on SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; PROTEIN; SYNTAXIN; EXOCYTOSIS; SNAP-25; PALMITOYLATION; NEUROTOXINS; MACHINERY	Calcium-dependent synaptic vesicle exocytosis requires three SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) proteins: synaptobrevin/vesicle-associated membrane protein in the vesicular membrane and syntaxin and SNAP-25 in the presynaptic membrane. The SNAREs form a thermodynamically stable complex that is believed to drive fusion of vesicular and presynaptic membranes. Complexin, also known as synaphin, is a neuronal cytosolic protein that acts as a positive regulator of synaptic vesicle exocytosis. Complexin binds selectively to the neuronal SNARE complex, but how this promotes exocytosis remains unknown. Here we used purified full-length and truncated SNARE proteins and a gel shift assay to show that the action of complexin on SNARE complex depends strictly on the transmembrane regions of syntaxin and synaptobrevin. By means of a preparative immunoaffinity procedure to achieve total extraction of SNARE complex from brain, we demonstrated that complexin is the only neuronal protein that tightly associates with it. Our data indicated that, in the presence of complexin, the neuronal SNARE proteins assemble directly into a complex in which the transmembrane regions interact. We propose that complexin facilitates neuronal exocytosis by promoting interaction between the complementary syntaxin and synaptobrevin transmembrane regions that reside in opposing membranes prior to fusion.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275; Rickman, Colin/0000-0001-8938-524X				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Eastwood SL, 2000, MOL PSYCHIATR, V5, P425, DOI 10.1038/sj.mp.4000741; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lawrence GW, 2002, J CELL SCI, V115, P667; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; MONCK JR, 1994, NEURON, V12, P707, DOI 10.1016/0896-6273(94)90325-5; Morton AJ, 2001, BRAIN RES BULL, V56, P111, DOI 10.1016/S0361-9230(01)00611-6; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; RuizMontasell B, 1996, EUR J NEUROSCI, V8, P2544, DOI 10.1111/j.1460-9568.1996.tb01548.x; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71	34	62	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41652	41656		10.1074/jbc.M205044200	http://dx.doi.org/10.1074/jbc.M205044200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200427	hybrid			2022-12-25	WOS:000178985300046
J	Levy, L; Neuveut, C; Renard, CA; Charneau, P; Branchereau, S; Gauthier, F; Van Nhieu, JT; Cherqui, D; Petit-Bertron, AF; Mathieu, D; Buendia, MA				Levy, L; Neuveut, C; Renard, CA; Charneau, P; Branchereau, S; Gauthier, F; Van Nhieu, JT; Cherqui, D; Petit-Bertron, AF; Mathieu, D; Buendia, MA			Transcriptional activation of interleukin-8 by beta-catenin-Tcf4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; BETA-CATENIN; COLON-CARCINOMA; COLORECTAL CARCINOMAS; TRANSGENIC MICE; CYCLIN D1; EXPRESSION; TARGET; CELLS	Nuclear translocation of beta-catenin and its association with Tcf/Lef factors are key steps in transduction of the Wnt signal, which is aberrantly activated in a variety of human cancers. In a search for new beta-catenin-Tcf target genes, we analyzed beta-catenin-induced alterations of gene expression in primary human hepatocytes, after transduction of either dominant stable beta-catenin or its truncated, transactivation-deficient counterpart by means of a lentiviral vector. cDNA microarray analysis revealed a limited set of up-regulated genes, including known Writ targets such as matrilysin and keratin-1. In this screen, we identified the CXC chemokine interleukin 8 (IL-8) as a direct target of beta-catenin-Tcf4. IL-8 is constitutively expressed in various cancers, and it has been implicated in tumor progression through its mitogenic, motogenic, and angiogenic activities. The IL-8 promoter contains a unique consensus Tcf/Lef site that is critical for IL-8 activation by beta-catenin. We show here that the p300 coactivator was required for efficient transactivation of beta-catenin on this promoter. Ectopic expression of beta-catenin in hepatoma cells promoted IL-8 secretion, which stimulated endothelial cell migration. These data define IL-8 as a Wnt target and suggest that IL-8 induction by beta-catenin might be implicated in developmental and tumorigenic processes.	Inst Pasteur, Inserm U163, Unite Recombinaison & Express Genet, F-75015 Paris, France; Inst Pasteur, Grp Virol Mol & Vectorol, F-75015 Paris, France; Inst Pasteur, Unite Cytokines & Inflammat, Dept Mol Med, F-75015 Paris, France; Hop Bicetre, Serv Chirurg Pediat, F-94270 Le Kremlin Bicetre, France; Hop Henri Mondor, AP HP, Dept Pathol, F-94010 Creteil, France; Hop Henri Mondor, AP HP, Serv Chirurg Digest, F-94010 Creteil, France; Univ Paris 12, F-94010 Creteil, France; Inst Genet Mol, UMR 5535, IFR 24, F-34293 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Buendia, MA (corresponding author), Inst Pasteur, Inserm U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75015 Paris, France.	rnbuendia@pasteur.fr	LEVY, Laurence/AAF-5672-2021; CHARNEAU, Pierre/M-1565-2017	CHARNEAU, Pierre/0000-0003-1184-5773; Neuveut, Christine/0000-0001-6520-271X				Akiba J, 2001, INT J ONCOL, V18, P257; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadoret A, 2001, CANCER RES, V61, P3245; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dong G, 2001, CANCER RES, V61, P5911; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hlubek F, 2001, CANCER RES, V61, P8089; Inoue K, 2000, CANCER RES, V60, P2290; Kitadai Y, 1998, AM J PATHOL, V152, P93; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Luca M, 1997, AM J PATHOL, V151, P1105; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MARTY C, 1994, CRIT CARE MED, V22, P673, DOI 10.1097/00003246-199404000-00025; Monga SPS, 2002, CANCER RES, V62, P2064; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Ougolkov AV, 2002, GASTROENTEROLOGY, V122, P60, DOI 10.1053/gast.2002.30306; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Satyamoorthy K, 2002, CELL GROWTH DIFFER, V13, P87; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Shimoda K, 1998, HEPATOLOGY, V28, P108, DOI 10.1002/hep.510280116; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tordjman R, 2001, BLOOD, V97, P1968, DOI 10.1182/blood.V97.7.1968; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yoong KF, 1999, HEPATOLOGY, V30, P100, DOI 10.1002/hep.510300147; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang XB, 2001, CANCER RES, V61, P6050	56	113	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42386	42393		10.1074/jbc.M207418200	http://dx.doi.org/10.1074/jbc.M207418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200448	hybrid, Green Published			2022-12-25	WOS:000178985300136
J	Yaman, I; Fernandez, J; Sarkar, B; Schneider, RJ; Snider, MD; Nagy, LE; Hatzoglou, M				Yaman, I; Fernandez, J; Sarkar, B; Schneider, RJ; Snider, MD; Nagy, LE; Hatzoglou, M			Nutritional control of mRNA stability is mediated by a conserved AU-rich element that binds the cytoplasmic shuttling protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AVAILABILITY; MESSENGER-RNA STABILITY; 3'-UNTRANSLATED REGION; REGULATORY DOMAIN; HEAT-SHOCK; GENE; STABILIZATION; TRANSLATION; EXPRESSION; CAT-1	The cationic amino acid transporter, Cat-1, is a high affinity transporter of the essential amino acids, arginine and lysine. Expression of the cat-1 gene increases during nutritional stress as part of the adaptive response to starvation. Amino acid limitation induces coordinate increases in stability and translation of the cat-1 mRNA, at a time when global protein synthesis decreases. It is shown here that increased cat-1 mRNA stability requires an. 11 nucleotide AU-rich element within the distal 217 bases of the 3'-untranslated region. When this 217-nucleotide nutrient sensor AU-rich element (NS-ARE) is present in a chimeric mRNA it confers mRNA stabilization during amino acid starvation. HuR is a member of the EIAV family of RNA-binding proteins that has been implicated in regulating the stability of ARE-containing mRNAs. We show here that the cytoplasmic concentration of HuR increases during amino acid starvation, at a time when total cellular HuR levels decrease. In addition, RNA gel shift experiments in vitro demonstrated that HuR binds to the NS-ARE and binding was dependent on the 11 residue AU-rich element. Moreover, HuR binding to the NS-ARE in extracts from amino acid-starved cells increased in parallel with the accumulation of cytoplasmic HuR. It is proposed that an adaptive response of cells to nutritional stress results in increased mRNA stability mediated by HuR binding to the NS-ARE.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	Case Western Reserve University; Case Western Reserve University; New York University	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.		yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319, R01DK053307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011975] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA011975, R01 AA011975-10] Funding Source: Medline; NIDDK NIH HHS [R01 DK053307, 5T32 DK07319, T32 DK007319, R01 DK53307-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Bruhat A, 2001, CURR OPIN CLIN NUTR, V4, P439, DOI 10.1097/00075197-200109000-00016; Closs EI, 2002, CURR OPIN NEPHROL HY, V11, P99, DOI 10.1097/00041552-200201000-00015; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; FERNANDEZ JM, 2002, J BIOL CHEM, V4, P4; FERNANDEZ JM, 2001, J BIOL CHEM, V29, P29; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lee WY, 2000, J BIOL CHEM, V275, P33998, DOI 10.1074/jbc.M005040200; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Loflin P, 2001, FEBS LETT, V492, P233, DOI 10.1016/S0014-5793(01)02260-8; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X	30	100	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41539	41546		10.1074/jbc.M204850200	http://dx.doi.org/10.1074/jbc.M204850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12196519	hybrid, Green Accepted			2022-12-25	WOS:000178985300032
J	Fan, GB; Siebert, F; Sheves, M; Vogel, R				Fan, GB; Siebert, F; Sheves, M; Vogel, R			Rhodopsin with 11-cis-locked chromophore is capable of forming an active state photoproduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; LIGHT-STABLE RHODOPSIN; SCHIFF-BASE COUNTERION; METARHODOPSIN-II; BOVINE RHODOPSIN; CRYSTAL-STRUCTURE; MOLECULAR-ORIGIN; ALPHA-SUBUNIT; ISOMERIZATION; ACTIVATION	The visual pigment rhodopsin is characterized by an 11-cis retinal chromophore bound to Lys-296 via a protonated Schiff base. Following light absorption the C-11=C-12 double bond isomerizes to trans configuration and triggers protein conformational alterations. These alterations lead to the formation of an active intermediate (Meta II), which binds and activates the visual G protein, transducin. We have examined by UV-visible and Fourier transform IR spectroscopy the photochemistry of a rhodopsin analogue with an 11-cis-locked chromophore, where cis to trans isomerization around the C-11=C-12 double bond is prevented by a 6-member ring structure (Rh-6.10). Despite this lock, the pigment was found capable of forming an active photoproduct with a characteristic protein conformation similar to that of native Meta II. This intermediate is further characterized by a protonated Schiff base and protonated Glu-113, as well as by its ability to bind a transducin-derived peptide previously shown to interact efficiently with native Meta II. The yield of this active photointermediate is pH-dependent and decreases with increasing pH. This study shows that with the C-11=C-12 double bond being locked, isomerization around the C-9=C-10 or the C-13=C-14 double bonds may well lead to an activation of the receptor. Additionally, prolonged illumination at pH 7.5 produces a new photoproduct absorbing at 385 nm, which, however, does not exhibit the characteristic active protein conformation.	Univ Freiburg, Inst Mol Med & Zellforsch, Biophys Grp, D-79104 Freiburg, Germany; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	University of Freiburg; Weizmann Institute of Science	Sheves, M (corresponding author), Inst Mol Med & Zellforsch, Arbeitsgrp Biophys, Hermann Herder Str 9, D-79104 Freiburg, Germany.							AKITA H, 1980, J AM CHEM SOC, V102, P6372; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BOUNDS D, 1967, NATURE, V216, P1178; CHANG CH, 1985, BIOPHYS J, V47, P509, DOI 10.1016/S0006-3495(85)83944-8; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; FANG JM, 1983, J AM CHEM SOC, V105, P5162, DOI 10.1021/ja00353a068; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FOSTER KW, 1989, BIOCHEMISTRY-US, V28, P819, DOI 10.1021/bi00428a061; FUKADA Y, 1984, BIOCHEMISTRY-US, V23, P5826, DOI 10.1021/bi00319a023; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KANDORI H, 1989, BIOCHEMISTRY-US, V28, P6460, DOI 10.1021/bi00441a045; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS J, 1995, J AM CHEM SOC, V917, P918; LEWIS JW, 1995, J AM CHEM SOC, V35, P289; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MIZUKAMI T, 1993, P NATL ACAD SCI USA, V90, P4072, DOI 10.1073/pnas.90.9.4072; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; Nishimura S, 1998, BIOCHEMISTRY-US, V37, P15816, DOI 10.1021/bi981451n; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SHEIKH SP, 1996, NATURE, V383, P747; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; TAKAHASHI T, 1991, BIOCHEM BIOPH RES CO, V178, P1273, DOI 10.1016/0006-291X(91)91031-7; VANDERSTEEN R, 1989, RECL TRAV CHIM PAY B, V108, P20; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Vogel R, 2002, J BIOL CHEM, V277, P40222, DOI 10.1074/jbc.M205032200; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; Vogel R, 2001, BIOCHEMISTRY-US, V40, P13342, DOI 10.1021/bi0113667; ZHANG Q, 1996, J AM CHEM SOC, V118, P12828; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	48	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40229	40234		10.1074/jbc.M205033200	http://dx.doi.org/10.1074/jbc.M205033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177057	hybrid			2022-12-25	WOS:000178791400011
J	Yik, JHN; Saxena, A; Weigel, JA; Weigel, PH				Yik, JHN; Saxena, A; Weigel, JA; Weigel, PH			Nonpalmitoylated human asialoglycoprotein receptors recycle constitutively but are defective in coated pit-mediated endocytosis, dissociation, and delivery of ligand to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; INTRACELLULAR SIGNALING PATHWAYS; ACYL-COENZYME-A; GALACTOSYL RECEPTORS; FATTY ACYLATION; TRANSFERRIN RECEPTORS; ATP DEPLETION; PROTEINS; INACTIVATION; PALMITOYLATION	The hepatic asialoglycoprotein receptor (ASGP-R) internalizes desialylated glycoproteins via the clathrin-coated pit pathway and mediates their delivery to lysosomes for degradation. The human ASGP-R contains two subunits, H1 and H2. Cytoplasmic residues Cys(36) in H1, as well as Cys(54) and Cys(58) in H2 are palmitoylated (Zeng, F.-Y., and Weigel, P. H. (1996) J. BioL Chem. 271, 32454). In order to study the function(s) of ASGP-R palmitoylation, we mutated these Cys residues to Ser and generated stably transfected SK-Hep-1 cell lines expressing either wild-type or nonpalmitoylated ASGP-Rs. Compared with wild-type ASGP-Rs, palmitoylation-defective ASGP-Rs showed normal ligand binding, intracellular distribution and trafficking patterns, and pH-induced dissociation profiles in vitro. However, continuous ASOR uptake, and the uptake of prebound cell surface ASOR were slower in cells expressing palmitoylation-defective ASGP-Rs than in cells expressing wild-type ASGP-Rs. Unlike native ASGP-Rs in hepatocytes or hepatoma cells, which mediate endocytosis via the clathrin-coated pit pathway and are almost completely inhibited by hypertonic medium, only similar to40% of the ASOR uptake in SK-Hep-1 cells expressing wild-type ASGP-Rs was inhibited by hyperosmolarity. This result suggests the existence of an alternate nonclathrin-mediated internalization pathway, such as transcytosis, for the entry of ASGP-R-ASOR complexes into these cells. In contrast, ASOR uptake mediated by cells expressing palmitoylation-defective ASGP-Rs showed only a marginal difference under hypertonic conditions, indicating that most of the nonpalmitoylated ASGP-Rs were not internalized and processed normally through the clathrin-coated pit pathway. Furthermore, cells expressing wild-type ASGP-Rs were able to degrade the internalized ASOR, whereas ASOR dissociation was impaired and degradation was barely detectable in cells expressing nonpalmitoylated ASGP-Rs. We conclude that palmitoylation of the ASGP-R is required for its efficient endocytosis of ligand by the clathrin-dependent endocytic pathway and, in particular, for the proper dissociation and delivery of ligand to lysosomes.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu	Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIGMS NIH HHS [GM 49695] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; Joseph M, 1996, INDIAN J BIOCHEM BIO, V33, P343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MEDH JD, 1991, J BIOL CHEM, V266, P8771; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; OKA JA, 1989, J BIOL CHEM, V264, P12016; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Sanderson M, 2000, ALBION, V32, P365, DOI 10.2307/4053835; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Saxena A, 2001, MOL BIOL CELL, V12, p215A; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; Stockert R J, 1991, Targeted Diagn Ther, V4, P41; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDEURS B, 1989, INT REV CYTOL, V117, P131; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEIGEL PH, 1983, J BIOL CHEM, V258, P5095; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; WU GY, 1987, J BIOL CHEM, V262, P4429; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388; Zeng FY, 1996, BIOCHEM BIOPH RES CO, V218, P325, DOI 10.1006/bbrc.1996.0057; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	58	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40844	40852		10.1074/jbc.M204780200	http://dx.doi.org/10.1074/jbc.M204780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171918	hybrid			2022-12-25	WOS:000178791400089
J	Goffredo, D; Rigamonti, D; Tartari, M; De Micheli, A; Verderio, C; Matteoli, M; Zuccato, C; Cattaneo, E				Goffredo, D; Rigamonti, D; Tartari, M; De Micheli, A; Verderio, C; Matteoli, M; Zuccato, C; Cattaneo, E			Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; MOUSE MODEL; CELLULAR TOXICITY; CASPASE CLEAVAGE; DISEASE; CALPAIN; EXPRESSION; FRAGMENTS; BRAIN; PROTEOLYSIS	Huntington's disease (HD) is caused by a polyglutamine expansion in the amino-terminal region of huntingtin. Mutant huntingtin is proteolytically cleaved by caspases, generating amino-terminal aggregates that are toxic for cells. The addition of calpains to total brain homogenates also leads to cleavage of wild-type huntingtin, indicating that proteolysis of mutant and wildtype huntingtin may play a role in HD. Here we report that endogenous wild-type huntingtin is promptly cleaved by calpains in primary neurons. Exposure of primary neurons to glutamate or 3-nitropropionic acid increases intracellular calcium concentration, leading to loss of intact full-length wild-type huntingtin. This cleavage could be prevented by calcium chelators and calpain inhibitors. Degradation of wild-type huntingtin by calcium-dependent proteases thus occurs in HD neurons, leading to loss of wild-type huntingtin neuroprotective activity.	Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Dept Med Pharmacol, Inst Neurosci, Natl Res Council, I-20133 Milan, Italy	University of Milan; University of Milan; University of Milan	Cattaneo, E (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Via Balzaretti 9, I-20133 Milan, Italy.	elena.cattaneo@unimi.it	Matteoli, Michela/K-4526-2018; verderio, claudia/K-4415-2016	Matteoli, Michela/0000-0002-3569-7843; CATTANEO, ELENA/0000-0002-0755-4917; verderio, claudia/0000-0001-7216-5873; ZUCCATO, CHIARA/0000-0003-1771-3392	Telethon [E.0840] Funding Source: Medline	Telethon(Fondazione Telethon)		ALHO H, 1988, DEV BRAIN RES, V39, P193, DOI 10.1016/0165-3806(88)90023-5; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Grunewald T, 1999, ANN NY ACAD SCI, V893, P203, DOI 10.1111/j.1749-6632.1999.tb07827.x; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hansson O, 2001, EUR J NEUROSCI, V14, P1492, DOI 10.1046/j.0953-816x.2001.01767.x; Ho LW, 2001, J MED GENET, V38, P450, DOI 10.1136/jmg.38.7.450; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Kim M, 1999, J NEUROSCI, V19, P964; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Kumar U, 1997, EXP NEUROL, V145, P412, DOI 10.1006/exnr.1997.6473; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	31	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39594	39598		10.1074/jbc.C200353200	http://dx.doi.org/10.1074/jbc.C200353200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12200414	hybrid			2022-12-25	WOS:000178662500070
J	Palmby, TR; Abe, K; Der, CJ				Palmby, TR; Abe, K; Der, CJ			Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY PROTEINS; RAS TRANSFORMATION; STRUCTURAL BASIS; EXCHANGE FACTOR; DBL FAMILY; ACTIVATION; BINDING; PROTOONCOGENE; MOLECULES; RAC1	Vav family proteins are members of the Dbl family of guanine nucleotide exchange factors and activators of Rho family small GTPases. In addition to the Dbl homology (DH) domain important for guanine nucleotide exchange factor catalytic function, all Dbl family proteins contain an adjacent pleckstrin homology (PH) domain that serves to regulate DH domain activity. Although the role of the PH domain in Vav function has been evaluated extensively, its precise role and whether it serves a distinct role in different Vav proteins remain unresolved. Additionally, the precise role of an adjacent cysteine-rich domain (CRD) in regulating DH domain function is also unclear. In this study, we evaluated the contribution of these putative protein-protein or protein-lipid interaction domains to Vav signaling and transforming activity. In contrast to previous observations, we found that the PH domain is critical for Vav transforming activity. Similarly, the CRD was also essential and served a function distinct from that of the PH domain. Although mutation of either domain reduced Vav membrane association, addition of plasma membrane targeting sequences to either the CRD or PH domain mutant proteins did not restore Vav transforming activity. This result contrasts with other Dbl family proteins, where a membrane targeting sequence alone was sufficient to restore the loss of function caused by mutation of the PH domain. Furthermore, green fluorescent protein fusion proteins containing the PH domain or CRD, or both, failed to target to the plasma membrane, suggesting that these two domains also serve regulatory functions independent of promoting membrane localization. Finally, we found that phosphatidylinositol 3-kinase activation may promote Vav membrane association via phosphatidylinositol 3,4,5-triphosphate binding to the PH domain.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA063071, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA42978, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COX AD, 1995, METHOD ENZYMOL, V255, P195; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; SOLSKI PA, 1995, METHOD ENZYMOL, V250, P435; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; VAN AL, 1997, GENE DEV, V11, P2295; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39350	39359		10.1074/jbc.M202641200	http://dx.doi.org/10.1074/jbc.M202641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177050	hybrid, Green Published			2022-12-25	WOS:000178662500039
J	Rani, MRS; Hibbert, L; Sizemore, N; Stark, GR; Ransohoff, RM				Rani, MRS; Hibbert, L; Sizemore, N; Stark, GR; Ransohoff, RM			Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VAV PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR-SUPPRESSOR; PROTEIN-KINASE; CELL-SURVIVAL; 1-PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT	We previously reported (Rani, M. R., Asthagiri, A. R., Singh, A., Sizemore, N., Sathe, S. S., Li, X., DiDonato, J. D., Stark, G. R., and Ransohoff, R. M. (2001) J. Biol. Chem. 276, 44365-44368) that IFN-beta induction of beta-R1 in fibrosarcoma cells required transcription factors ISGF-3 and NF-kappaB. IFN-beta treatment did not augment the abundance of NF-kappaB, but led to phosphorylation of the NF-kappaB subunit p65 and induced a nuclear activity capable of phosphorylating a p65-GST fusion construct in the carboxy-terminal transactivation domain (TAD), residues 354-551. We now present evidence for the involvement of phosphoinositide 3-kinase (PI3K) in this pat way. Pretreatment of HT1080-derived fibrosarcoma cells with pharmacological inhibitors of PI3K (wortmannin or LY294002) selectively inhibited IFN-beta-induced beta-R1 mRNA accumulation in a dose-dependent manner. In stably transfected cell lines, bovine p85, the regulatory subunit of PI3K, functioned as a dominant-negative inhibitor of interferon (IFN) signaling via PI3K and selectively suppressed IFN-beta-mediated induction of beta-R1. Overexpression of PTEN (phosphatase and tensin homologue mutated on chromosome ten), an antagonist of PI3K, blocked induction of a beta-R1 promoter-reporter construct. Studies with PTEN mutants suggested that the lipid kinase activity of PI3K was essential for IFN-beta-induced transcription of beta-R1. Consistent with this finding, a dominant-negative mutant of the serine-threonine kinase Akt, a downstream effector of PI3K, selectively blocked IFN-beta-mediated induction of the beta-R1 promoter reporter. Furthermore, IFN-beta-mediated phosphorylation of GST-p65 was blocked by pretreatment with LY294002. These data suggest that IFN-beta acts through PI3K to enhance the transactivation competence of NF-kappaB complexes through phosphorylation of p65 within the TAD. The results provide novel insight into the role of PI3K in the transcriptional response to IFN-beta.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.				NCI NIH HHS [2PO1 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Holland KA, 1997, J BIOL CHEM, V272, P21045, DOI 10.1074/jbc.272.34.21045; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ozes ON, 1999, NATURE, V401, P82; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Rani MRS, 2001, J BIOL CHEM, V276, P44365, DOI 10.1074/jbc.C100417200; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200	43	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38456	38461		10.1074/jbc.M203204200	http://dx.doi.org/10.1074/jbc.M203204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12169689	hybrid			2022-12-25	WOS:000178529600060
J	Hakimi, MA; Speicher, DW; Shiekhattar, R				Hakimi, MA; Speicher, DW; Shiekhattar, R			The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 GENE-PRODUCT; DYNEIN SUPERFAMILY PROTEINS; GAP-RELATED DOMAIN; TUMOR-SUPPRESSOR; ORGANELLE TRANSPORT; AXONAL-TRANSPORT; NF1; MICROTUBULES; IDENTIFICATION; CYTOSKELETON	Mutations in either of the two tumor suppressor genes NF1 (neurofibromin) and NF2 (merlin) result in Neurofibromatosis, a condition predisposing individuals to developing a variety of benign and malignant tumors of the central and peripheral nervous systems. Here we report the identification of two distinct NF1-containing complexes, one in the soluble and the other in the particulate fraction of HeLa extract. We show that the soluble NF1 complex delineates a large holo-NF1 complex (2 MDa) encompassing the components of a smaller particulate core-NF1 complex (400 kDa). Purification of the core-NF1 complex followed by mass spectrometric analysis revealed the motor protein, kinesin-1 heavy chain (HsuKHC/KIF5B), as a catalytic subunit of both NF-1-containing complexes. Importantly, although NF1 and NF2 are not in a stable association, NF2 is also a component of a distinct kinesin-1-containing complex. These results point to kinesin-1 as a common denominator between NF1 and NF2.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.upenn.edu	HAKIMI, Mohamed-ali/Q-6475-2019; HAKIMI, Mohamed-ali/GYJ-0879-2022; HAKIMI, Mohamed-Ali/F-9806-2014	HAKIMI, Mohamed-ali/0000-0002-2547-8233; HAKIMI, Mohamed-Ali/0000-0002-2547-8233	NATIONAL CANCER INSTITUTE [R01CA090758] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90758-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mautner VF, 1996, NEUROSURGERY, V38, P880, DOI 10.1097/00006123-199605000-00004; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Upadhyaya M, 1998, NEUROFIBROMATOSIS TY, P65; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	33	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36909	36912		10.1074/jbc.C200434200	http://dx.doi.org/10.1074/jbc.C200434200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12191989	hybrid			2022-12-25	WOS:000178447100002
J	Kinsella, TM; Ohashi, CT; Harder, AG; Yam, GC; Li, WQ; Peelle, B; Pali, ES; Bennett, MK; Molineaux, SM; Anderson, DA; Masuda, ES; Payan, DG				Kinsella, TM; Ohashi, CT; Harder, AG; Yam, GC; Li, WQ; Peelle, B; Pali, ES; Bennett, MK; Molineaux, SM; Anderson, DA; Masuda, ES; Payan, DG			Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IGE	Inteins are polypeptide sequences found in a small set of primarily bacterial proteins that promote the splicing of Ranking pre-protein sequences to generate mature protein products. Inteins can be engineered in a "split and inverted" configuration such that the protein splicing product is a cyclic polypeptide consisting of the sequence linking two intein subdomains. We have engineered a split intein into a retroviral expression system to enable the intracellular delivery of a library of random cyclic peptides in human cells. Cyclization of peptides could be detected in cell lysates using mass spectrometry. A functional genetic screen to identify 5-amino acid-long cyclic peptides that block interleukin-4 mediated IgE class switching in B cells yielded 13 peptides that selectively inhibited germ line epsilon transcription. These results demonstrate the generation of cyclic peptide libraries in human cells and the power of functional screening to rapidly identify biologically active peptides.	Rigel Inc, San Francisco, CA 94080 USA		Payan, DG (corresponding author), Rigel Inc, 240 E Grand Ave, San Francisco, CA 94080 USA.	dgpayan@rigel.com		Masuda, Esteban/0000-0002-3175-2868				Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Lorens JB, 2001, CURR OPIN BIOTECH, V12, P613, DOI 10.1016/S0958-1669(01)00269-5; Losman JA, 1999, J IMMUNOL, V162, P3770; Monticelli S, 2001, ALLERGY, V56, P270, DOI 10.1034/j.1398-9995.2001.00129.x; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Peelle B, 2001, J PROTEIN CHEM, V20, P507, DOI 10.1023/A:1012514715338; Peelle B, 2001, CHEM BIOL, V8, P521, DOI 10.1016/S1074-5521(01)00031-X; Perler FB, 2000, CURR OPIN BIOTECH, V11, P377, DOI 10.1016/S0958-1669(00)00113-0; RYAN MD, 1991, J GEN VIROL, V72, P2727, DOI 10.1099/0022-1317-72-11-2727; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Scott CP, 2001, CHEM BIOL, V8, P801, DOI 10.1016/S1074-5521(01)00052-7; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; SWOFT SE, 1999, CURRENT PROTOCOLS IM, P1; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Vera MD, 2002, MED RES REV, V22, P102, DOI 10.1002/med.10003	19	76	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37512	37518		10.1074/jbc.M206162200	http://dx.doi.org/10.1074/jbc.M206162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167667	hybrid			2022-12-25	WOS:000178447100077
J	Johnson, EF; Hinz, W; Atreya, CE; Maley, F; Anderson, KS				Johnson, EF; Hinz, W; Atreya, CE; Maley, F; Anderson, KS			Mechanistic characterization of Toxoplasma gondii thymidylate synthase (TS-DHFR)-dihydrofolate reductase - Evidence for a TS intermediate and TS half-sites reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; LACTOBACILLUS-CASEI; LEISHMANIA-TROPICA; INACTIVE MUTANTS; ACTIVITY ENZYME; BINDING; GENE; RESTORATION; SIMULATION	This study describes the use of rapid transient kinetic methods to characterize the bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme from Toxoplasma gondii. In addition to elucidating the detailed kinetic scheme for this enzyme, this work provides the first direct kinetic evidence for the formation of a TS intermediate and for half-sites TS reactivity in human and Escherichia coli monofunctional TS and in T. gondii and Leishmania major bifunctional TS-DHFR. Comparison of the T. gondii TS-DHFR catalytic mechanism to that of the L. major enzyme reveals the mechanistic differences to be predominantly in DHFR activity. Specifically, TS ligand induced domain-domain communication involving DHFR activation is observed only in the L. major enzyme and, whereas both DHFR activities involve a rate-limiting conformational change, the change occurs at different positions along the kinetic pathway.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; New York State Dept Hlth, Albany, NY 12201 USA	Yale University; State University of New York (SUNY) System	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline; NIAID NIH HHS [AI44630] Funding Source: Medline; NIGMS NIH HHS [GMO7205] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Berlett BS, 2000, ANAL BIOCHEM, V287, P329, DOI 10.1006/abio.2000.4876; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CURTHOYS NP, 1972, J BIOL CHEM, V247, P1959; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Elcock AH, 1997, BIOCHEMISTRY-US, V36, P16049, DOI 10.1021/bi971709u; Elcock AH, 1996, J MOL BIOL, V262, P370, DOI 10.1006/jmbi.1996.0520; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; GALIVAN JH, 1976, BIOCHEMISTRY-US, V15, P356, DOI 10.1021/bi00647a018; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KALLEN RG, 1966, J BIOL CHEM, V241, P5845; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; MALEY F, 1995, BIOCHEMISTRY-US, V34, P1469, DOI 10.1021/bi00005a001; MATHEWS CK, 1960, J BIOL CHEM, V130, P134; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; ROLAND AR, 1996, OPPORTUNISTIC COMPLI, V5, P81; ROOS DS, 1993, J BIOL CHEM, V268, P6269; SANTI DV, 1984, FOLATES PTERIDINES, V1, P343; Saxl RL, 2001, BIOCHEMISTRY-US, V40, P5275, DOI 10.1021/bi002925x; Spencer HT, 1997, BIOCHEMISTRY-US, V36, P4212, DOI 10.1021/bi961794q; STROUD RM, 1994, NAT STRUCT BIOL, V1, P131, DOI 10.1038/nsb0394-131; Vasquez JR, 1996, MOL BIOCHEM PARASIT, V79, P153, DOI 10.1016/0166-6851(96)02647-3	32	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43126	43136		10.1074/jbc.M206523200	http://dx.doi.org/10.1074/jbc.M206523200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12192007	hybrid			2022-12-25	WOS:000179081200093
J	Poelarends, GJ; Konings, WN				Poelarends, GJ; Konings, WN			The transmembrane domains of the ABC multidrug transporter LmrA form a cytoplasmic exposed, aqueous chamber within the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; CYSTEINE-SCANNING MUTAGENESIS; LACTOCOCCUS-LACTIS; BINDING; GENE; ACCESSIBILITY; SPECTROSCOPY; EXPRESSION; REVEALS; SYSTEMS	The ABC multidrug transporter LmrA of Lactococcus lactis consists of six putative transmembrane segments (TMS) and a nucleotide binding domain. LmrA functions as a homodimer in which the two membrane domains form the solute translocation path across the membrane. To obtain structural information of LmrA a cysteine scanning accessibility approach was used. Cysteines were introduced in the cysteine-less wild-type LmrA in each hydrophilic loop and in TMS 6, and each membrane-embedded aromatic residue was mutated to cysteine. Of the 41 constructed single cysteine mutants, only one mutant, L301C, was not expressed. Most single-cysteine mutants were capable of drug transport and only three mutants, F37C, M299C, and N300C, were inactive, indicating that none of the aromatic residues in the transmembrane regions of LmrA are crucial for substrate binding or transport. Modification of the active mutants with N-ethylmaleimide blocked the transport activity in five mutants (S132C, L174C, S206C, S234C, and L292C). All cysteine residues in external and internal loops were accessible to fluorescein maleimide. The labeling experiments also showed that this thiol reagent cannot cross the membrane under the conditions used and confirmed the presence of six TMSs in each monomeric half of the transporter. Surprisingly, several single cysteines in the predicted TMSs could also be labeled by the bulky fluorescein maleimide molecule, suggesting unrestricted accessibility via an aqueous pathway. The periodicity of fluorescein maleimide accessibility of residues 291 to 308 in TMS 6 showed that this membrane-spanning a-helix has one face of the helix exposed to an aqueous cavity along its full-length. This finding, together with the solvent accessibility of 11 of 15 membrane-embedded aromatic residues, indicates that the transmembrane domains of the LmrA transporter form, under nonenergized conditions, an aqueous chamber within the membrane, which is open to the intracellular milieu.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Konings, WN (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	w.n.konings@biol.rug.nl	Konings, Wilhelmus N./C-7063-2013	Poelarends, Gerrit/0000-0002-6917-6368				Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; Poelarends GJ, 2000, DRUG RESIST UPDATE, V3, P330, DOI 10.1054/drup.2000.0173; POELARENDS GJ, 2002, ABC PROTEINS BACTERI, P243; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Vigano C, 2000, J BIOL CHEM, V275, P10962, DOI 10.1074/jbc.275.15.10962; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42891	42898		10.1074/jbc.M206508200	http://dx.doi.org/10.1074/jbc.M206508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183459	hybrid			2022-12-25	WOS:000179081200062
J	Swevers, L; Ito, K; Iatrou, K				Swevers, L; Ito, K; Iatrou, K			The BmE75 nuclear receptors function as dominant repressors of the nuclear receptor BmHR3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECDYSONE-INDUCIBLE GENE; DNA-BINDING PROPERTIES; DROSOPHILA METAMORPHOSIS; BOMBYX-MORI; DEVELOPMENTAL EXPRESSION; ORPHAN RECEPTOR; CHORISTONEURA HORMONE-RECEPTOR-3; HORMONAL-CONTROL; LIGAND-BINDING; MANDUCA-SEXTA	The orphan nuclear receptors BmE75 and BmHR3 are induced by 20-hydroxyecdysone in the ovary of the silk moth Bombyx mori at the beginning of pupation and show stage-specific expression in ovarian follicles during pharate adult development. To analyze the function of these receptors, we have developed a transactivation assay based on the transcriptional stimulation of a retinoic acid receptor-related receptor response element (RORE)-linked promoter-reporter construct. Co-transfection of a Bombyx cell line with a BmHR3A expression construct results in constitutive activation of the reporter, whereas expression of BmE75 has no measurable effects on reporter expression. However, when the BmE75 receptors are co-introduced with BmHR3A into the cells, the BmHR3A-mediated transactivation is repressed. Repression of BmHR3A by BmE75 occurs by two distinct mechanisms. Increasing doses of BmE75 efficiently displace BmHR3A bound to the RORE target site in gel retardation assays, indicating that both receptors compete for common DNA target sites. However, analysis of the function of deletion mutants of BmE75 in the transactivation assay indicates that repression can also occur in the absence of the DNA-binding domain and that the C-terminal F domain is sufficient for repression. In gel retardation assays, the two receptor types form a ternary complex on a single RORE, suggesting that repression is also mediated by protein interactions on the DNA target site. Yeast two-hybrid assays show that BmHR3A interacts with BmE75 and that this interaction is dependent on the C terminus of BmHR3A and the F domain of BmE75. Because the C terminus of BmHR3A contains a strong activation domain, we predict that BmE75 blocks activation by BmHR3A through competition for co-activator binding sites located at the C terminus of BmHR3A. Our data also indicate that the transcriptional activities of BmHR3A and BmE75 are integrated in such a way that activation of RORE-linked target genes depends on the relative expression levels of the two receptor types.	Natl Ctr Sci Res Demokritos, Inst Biol, Athens 15310, Greece; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	National Centre of Scientific Research "Demokritos"; University of Calgary	Iatrou, K (corresponding author), Natl Ctr Sci Res Demokritos, Inst Biol, POB 60228, Athens 15310, Greece.							Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Eystathioy T, 2001, MECH DEVELOP, V103, P107, DOI 10.1016/S0925-4773(01)00335-5; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Glass CK, 2000, GENE DEV, V14, P121; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HENRICH VC, 1995, INSECT BIOCHEM MOLEC, V25, P881, DOI 10.1016/0965-1748(95)00030-Y; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HUET F, 1995, DEVELOPMENT, V121, P1195; JINDRA M, 1994, EUR J BIOCHEM, V221, P665, DOI 10.1111/j.1432-1033.1994.tb18779.x; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; JOHNSON R, 1992, VIROLOGY, V190, P815, DOI 10.1016/0042-6822(92)90919-G; Kageyama Y, 1997, GENES CELLS, V2, P559, DOI 10.1046/j.1365-2443.1997.1460344.x; Lam G, 1999, DEV BIOL, V212, P204, DOI 10.1006/dbio.1999.9343; Lam GT, 1997, DEVELOPMENT, V124, P1757; Lu M, 1997, J BIOL CHEM, V272, P30724, DOI 10.1074/jbc.272.49.30724; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OGAJ S, 2000, GENBANK TM; PALLI SR, 1992, DEV BIOL, V150, P306, DOI 10.1016/0012-1606(92)90244-B; Palli SR, 1996, INSECT BIOCHEM MOLEC, V26, P485, DOI 10.1016/0965-1748(96)00004-5; Palli SR, 1997, ARCH INSECT BIOCHEM, V35, P33, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<33::AID-ARCH4>3.3.CO;2-5; Palli SR, 1997, DEV GENET, V20, P36, DOI 10.1002/(SICI)1520-6408(1997)20:1&lt;36::AID-DVG5&gt;3.0.CO;2-A; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1993, INSECT BIOCHEM MOLEC, V23, P91, DOI 10.1016/0965-1748(93)90086-8; Swevers L, 1999, INSECT BIOCHEM MOLEC, V29, P955, DOI 10.1016/S0965-1748(99)00059-4; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6; Swevers L, 1998, MECH DEVELOP, V72, P3, DOI 10.1016/S0925-4773(97)00180-9; SWEVERS L, IN PRESS INSECT BIOC; Thummel CS, 1997, BIOESSAYS, V19, P669, DOI 10.1002/bies.950190806; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSUCHIDA K, 1987, ARCH INSECT BIOCHEM, V5, P167, DOI 10.1002/arch.940050303; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhou BH, 1998, DEV BIOL, V193, P127, DOI 10.1006/dbio.1997.8798	40	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41637	41644		10.1074/jbc.M203581200	http://dx.doi.org/10.1074/jbc.M203581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200421	hybrid			2022-12-25	WOS:000178985300044
J	Xu, QH; Konta, T; Furusu, A; Nakayama, K; Lucio-Cazana, J; Fine, LG; Kitamura, M				Xu, QH; Konta, T; Furusu, A; Nakayama, K; Lucio-Cazana, J; Fine, LG; Kitamura, M			Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids - Selective roles of nuclear receptors and contribution to the antiapoptotic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; DUAL-SPECIFICITY PHOSPHATASE; ACID RECEPTOR; INDUCED APOPTOSIS; X-RECEPTOR; GRANULOCYTIC DIFFERENTIATION; CONDITIONAL EXPRESSION; CELL-PROLIFERATION; GENE-TRANSFER; C-MYC	All-trans-retinoic acid (t-RA) inhibits hydrogen peroxide (H2O2)-induced apoptosis by inhibiting the c-Jun N-terminal kinase (JNK)-activator protein 1 (AP-1) pathway. In this report, we examined the involvement of mitogen-activated protein kinase phosphatase 1 (MKP-1) in suppression of JNK and the antiapoptotic effect of t-RA and the roles of nuclear receptors in the regulation of MKP-1 by t-RA. We found that not only t-RA, but also a selective agonist of retinoic acid receptor (RAR), a selective agonist of retinoid X receptor (RXR), and a pan-agonist of RAR and RXR all induced MKP-1 at the transcriptional level. Activation of RAR was required for all of these triggering effects, but activation of RXR was required only for the RXR agonist-induced MKP-1 expression. Among the three RAR subtypes, RARalpha and RARgamma, but not RARbeta, mediated the t-RA-induced MKP-1 expression. The antiapoptotic effect of t-RA on H2O2-induced apoptosis in several cell types was correlated with the inducibility of MKP-1 by t-RA. Inhibition of MKP-1 by vanadate enhanced JNK phosphorylation and attenuated the antiapoptotic effect of t-RA. Furthermore, overexpression of MKP-1 inhibited H2O2-induced JNK phosphorylation and apoptosis. To our knowledge, this is the first to demonstrate that 1) MKP-1 is inducible by retinoids at the transcriptional level, 2) RXR and individual RAR subtypes have different roles in this process, and 3) the induced MKP-1 plays a significant role in mediating both JNK inhibition and the antiapoptotic effect of t-RA in oxidative stress.	UCL, Royal Free & Univ Coll Med Sch, Dept Med, London W1T 3AA, England; Univ Alcala de Henares, Fac Med, Dept Fisiol, E-28871 Alcala De Henares, Spain; Jikei Univ, Sch Med, Inst Clin Med & Res, Chiba 2778567, Japan; PLA, Gen Hosp Chinese, Dept Nephrol, Beijing 100853, Peoples R China	University of London; University College London; Universidad de Alcala; Jikei University	Xu, QH (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Med, 7th Floor, London W1T 3AA, England.	q.xu@ucl.ac.uk	Konta, Tsuneo/AAO-9286-2021; Lucio-Cazana, Francisco-Javier/B-8149-2009	Lucio-Cazana, Francisco-Javier/0000-0001-9249-8501				Agarwal C, 1996, J BIOL CHEM, V271, P12209, DOI 10.1074/jbc.271.21.12209; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Burrow CR, 2000, EXP NEPHROL, V8, P219; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DE LUCA LM, 1991, FASEB J, V5, P2924; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Ebisawa M, 1999, CHEM PHARM BULL, V47, P1778; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ishikawa Y, 2000, KIDNEY INT, V58, P1078, DOI 10.1046/j.1523-1755.2000.00265.x; Ishikawa Y, 1999, J AM SOC NEPHROL, V10, P2290; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kikuchi K, 2001, BIOORG MED CHEM LETT, V11, P1215, DOI 10.1016/S0960-894X(01)00177-9; Kitamura M, 1996, P NATL ACAD SCI USA, V93, P7387, DOI 10.1073/pnas.93.14.7387; KITAMURA M, 1994, J CLIN INVEST, V94, P497, DOI 10.1172/JCI117361; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Kosaka C, 2001, HYPERTENS RES, V24, P579, DOI 10.1291/hypres.24.579; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li Y, 1999, J BIOL CHEM, V274, P15360, DOI 10.1074/jbc.274.22.15360; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOPEZBARAHONA M, 1993, J BIOL CHEM, V268, P25617; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Peterson VJ, 2002, BIOCHEM J, V362, P173, DOI 10.1042/0264-6021:3620173; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Soprano DR, 2000, J CELL BIOCHEM, V77, P604, DOI 10.1002/(SICI)1097-4644(20000615)77:4<604::AID-JCB8>3.3.CO;2-K; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Szondy Z, 1998, BIOCHEM J, V331, P767, DOI 10.1042/bj3310767; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Umemiya H, 1997, J MED CHEM, V40, P4222, DOI 10.1021/jm9704309; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; Wagner J, 2001, NEPHROL DIAL TRANSPL, V16, P441, DOI 10.1093/ndt/16.3.441; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu QH, 2002, EXP NEPHROL, V10, P171; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864	61	63	67	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41693	41700		10.1074/jbc.M207095200	http://dx.doi.org/10.1074/jbc.M207095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12186877	hybrid			2022-12-25	WOS:000178985300051
J	Gell, D; Kong, Y; Eaton, SA; Weiss, MJ; Mackay, JP				Gell, D; Kong, Y; Eaton, SA; Weiss, MJ; Mackay, JP			Biophysical characterization of the alpha-globin binding protein alpha-hemoglobin stabilizing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBULAR PROTEINS; BETA-TUBULIN; MACROMOLECULES; HYDRATION; VOLUMES; CHAINS; RBL2P	alpha-Hemoglobin stabilizing protein (AHSP) is a small (12 kDa) and abundant erythroid-specific protein that binds specifically to free alpha-(hemo)globin and prevents its precipitation. When present in excess over beta-globin, its normal binding partner, alpha-globin can have severe cytotoxic effects that contribute to important human diseases such as beta-thalassemia. Because AHSP might act as a chaperone to prevent the harmful aggregation of alpha-globin during normal erythroid cell development and in diseases of globin chain imbalance, it is important to characterize the biochemical properties of the AHSP(.)alpha-globin complex. Here we provide the first structural information about AHSP and its interaction with a-globin. We find that AHSP is a predominantly alpha-helical globular protein with a somewhat asymmetric shape. AHSP and alpha-globin are both monomeric in solution as determined by analytical ultracentrifugation and bind each other to form a complex with 1:1 subunit stoichiometry, as judged by gel filtration and amino acid analysis. We have used isothermal titration calorimetry to show that the interaction is of moderate affinity with an association constant of I X 10(7) M-1 and is thus likely to be biologically significant given the concentration of AHSP (similar to0.1 mm) and hemoglobin (similar to4 mm) in the late pro-erythroblast.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA	University of Sydney; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.		Weiss, Mitchell J/W-9814-2018; Weiss, Mitchell J/A-1245-2013	Weiss, Mitchell J/0000-0003-2460-3036; Gell, David/0000-0003-0382-1181; Eaton, Sally/0000-0003-2036-1607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 61692, R01 DK061692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abruzzi KC, 2002, MOL CELL BIOL, V22, P138, DOI 10.1128/MCB.22.1.138-147.2002; Archer JE, 1998, MOL CELL BIOL, V18, P1757, DOI 10.1128/MCB.18.3.1757; ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; Ascoli F, 1981, Methods Enzymol, V76, P72; BEYCHOK S, 1967, J BIOL CHEM, V242, P2460; Bucci E, 1981, Methods Enzymol, V76, P97; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; HUANG SC, 2001, DISORDERS HEMOGLOBIN, P166; Ikeda-Saito M, 1981, Methods Enzymol, V76, P113; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MACDONALD VW, 1994, METHOD ENZYMOL, V231, P480; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; PENA MC, 1988, BIOCHIM BIOPHYS ACTA, V957, P380, DOI 10.1016/0167-4838(88)90229-4; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; Rachmilewitz EA, 2001, DISORDERS HEMOGLOBIN, P233; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TELLER DC, 1976, NATURE, V260, P729, DOI 10.1038/260729a0; Turner B W, 1981, Methods Enzymol, V76, P596; WAKS M, 1973, J BIOL CHEM, V248, P6462; Waxman E, 1994, MODERN ANAL ULTRACEN, P189; WILLIAMS RC, 1976, BIOCHEMISTRY-US, V15, P2207, DOI 10.1021/bi00655a028; YIP YK, 1972, J BIOL CHEM, V247, P7237	33	88	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40602	40609		10.1074/jbc.M206084200	http://dx.doi.org/10.1074/jbc.M206084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12192002	hybrid			2022-12-25	WOS:000178791400058
J	Lobo, S; Greentree, WK; Linder, ME; Deschenes, RJ				Lobo, S; Greentree, WK; Linder, ME; Deschenes, RJ			Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; POLYBASIC DOMAIN; IN-VITRO; H-RAS; PALMITOYLATION; PEPTIDE; MOTIF; AUTOACYLATION; PURIFICATION; ACYLATION	Most Ras proteins are posttranslationally modified by a palmitoyl lipid moiety through a thioester linkage. However, the mechanism by which this occurs is not known. Here, evidence is presented that the Ras2 protein of Saccharomyces cerevisiae is palmitoylated by a Ras protein acyltransferase (Ras PAT) encoded by the ERF2 and ERF4 genes. Erf2p is a 41-kDa protein localized to the membrane of the endoplasmic reticulum and contains a conserved DHHC cysteine-rich domain (DHHC-CRD). Erf2p co-purifies with Erf4p (26 kDa) when it is expressed in yeast or in Escherichia coli. The Erf2p/Erf4p complex is required for Ras PAT activity, and mutations within conserved residues (Cys(189), His(201) and Cys(203)) of the Erf2p DHHC-CRD domain abolish Ras PAT activity. Furthermore, a palmitoyl-Erf2p intermediate is detected suggesting that Erf2p is directly involved in palmitate transfer. ERF2 and ERF4 are the first genes identified that encode a palmitoyltransferase for a Ras GTPase.	Univ Iowa, Dept Biochem, Iowa City, IA 52240 USA; Univ Iowa, Genet Program, Iowa City, IA 52240 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63130 USA	University of Iowa; University of Iowa; Washington University (WUSTL)	Deschenes, RJ (corresponding author), Univ Iowa, Dept Biochem, 3135 MERF, Iowa City, IA 52242 USA.		Deschenes, Robert J/E-4926-2010; Linder, Maurine/AAU-9999-2021	Deschenes, Robert J/0000-0001-8325-4257; Linder, Maurine/0000-0003-2202-9712	NATIONAL CANCER INSTITUTE [R01CA050211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA050211, R01 CA050211-15A2, CA 50211] Funding Source: Medline; NIGMS NIH HHS [GM 51466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; BONDE M, 1992, ANAL BIOCHEM, V200, P195, DOI 10.1016/0003-2697(92)90298-L; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; JUNG V, 1995, MOL CELL BIOL, V15, P1333; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Linder M.E., 2001, ENZYM, V21, P215; Liu L, 1999, J BIOL CHEM, V274, P3252; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MITCHELL DA, 1994, J BIOL CHEM, V269, P21540; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4	26	343	355	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41268	41273		10.1074/JBC.M206573200	http://dx.doi.org/10.1074/JBC.M206573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193598	hybrid			2022-12-25	WOS:000178791400139
J	Mchaourab, HS; Dodson, EK; Koteiche, HA				Mchaourab, HS; Dodson, EK; Koteiche, HA			Mechanism of chaperone function in small heat shock proteins - Two-mode binding of the excited states of T4 lysozyme mutants by alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; LENS EPITHELIAL-CELLS; B-CRYSTALLIN; MOLECULAR CHAPERONE; THERMODYNAMIC CONSEQUENCES; PROTECTIVE ACTIVITY; HYDROGEN-EXCHANGE; MISSENSE MUTATION; CONSERVED DOMAIN; STRESS-PROTEINS	To elucidate the mechanism of alphaA-crystallin chaperone function, a detailed thermodynamic analysis of its binding to destabilized, site-directed mutants of T4 lysozyme was carried out. The selected mutants form a ladder of stabilities spanning the 5-10 kcal/mol range of free energy of unfolding. The crystal structures of the majority of the mutants have been previously determined and found to be similar to that of the wild type with no evidence of static local unfolding. Complex formation between aA-crystallin and T4 lysozyme was observed directly via the changes in the electron paramagnetic resonance lineshape of a nitroxide introduced at a non-destabilizing, solvent exposed site in T4 lysozyme. alphaA-Crystallin differentially interacts with the mutants, binding the more destabilized ones to a larger extent despite the similar structure of their native states. Our results suggest that the states recognized by aA-crystallin are non-native excited states distinct from the unfolded state. Stable complexes are formed when the free energy of binding to alphaA-crystallin is on the order of the free energy associated with the transition from the excited state to the native state. Biphasic binding isotherms reveal two modes of interactions with distinct affinities and stoichiometries. Highly destabilized mutants preferentially bind to the high capacity mode, suggesting conformational preference in the use of each mode. Furthermore, binding can be enhanced by increased temperature and pH, which may be reflecting conformational changes in aA-crystallin oligomeric structure.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NEI NIH HHS [EY R01 12683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Bettelheim FA, 1999, BIOCHEM BIOPH RES CO, V261, P292, DOI 10.1006/bbrc.1999.1031; BLABER M, 1993, BIOCHEMISTRY-US, V32, P11363, DOI 10.1021/bi00093a013; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Clarke J, 1997, TRENDS BIOCHEM SCI, V22, P284, DOI 10.1016/S0968-0004(97)01087-6; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Llinas M, 1999, NAT STRUCT BIOL, V6, P1072; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Neal R, 2001, BIOCHEM BIOPH RES CO, V280, P14, DOI 10.1006/bbrc.2000.4092; Pace CN, 2000, PROTEINS, P1; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Treweek TM, 2000, BBA-PROTEIN STRUCT M, V1481, P175, DOI 10.1016/S0167-4838(00)00109-6; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang KY, 2001, EUR J BIOCHEM, V268, P6335, DOI 10.1046/j.0014-2956.2001.02580.x; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; Zhang XM, 1996, J SCI FOOD AGR, V70, P102, DOI 10.1002/(SICI)1097-0010(199601)70:1&lt;102::AID-JSFA468&gt;3.0.CO;2-C	57	72	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40557	40566		10.1074/jbc.M206250200	http://dx.doi.org/10.1074/jbc.M206250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12189146	hybrid			2022-12-25	WOS:000178791400053
J	Richter, W; Conti, M				Richter, W; Conti, M			Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN-KINASE; CATALYTIC DOMAIN; PHOSPHORYLATION; BINDING; ACTIVATION; INTERACTS; PDE4; IDENTIFICATION; PURIFICATION	The cAMP-specific PDE4 family consists of four genes, each expressed as several splice variants. These variants are termed long and short forms depending on the presence or absence of two unique N-terminal domains called upstream conserved regions 1 and 2 (UCR1 and 2). UCR1 and UCR2 have been shown to form a module necessary for the activation of PDE4 upon phosphorylation by the cAMP-dependent kinase (PKA). Here we have uncovered PDE4 oligomerization as a novel function for the UCR1/UCR2 module. Using several different approaches including gel filtration, sucrose density gradient centrifugation, pull-down of differentially tagged PDE constructs, and yeast two-hybrid assay, we show that the long PDE4 splice variant PDE4D3 behaves as a dimer, whereas the short splice variant PDE4D2 is a monomer. Internal deletions of either the C-terminal portion of UCR1 or the N-terminal portion of UCR2 abolishes dimerization of PDE4D3 indicating that both domains are involved in this intermolecular interaction. The dimerization, however, is structurally distinguishable from a previously described intramolecular interaction involving the same domains. PKA phosphorylation and site-directed mutagenesis shown to ablate the latter do not interfere with dimerization. Therefore, dimerization of the long PDE4 forms may be an additional function of the UCR domains that further explains differences in the regulatory properties between the long and short PDE4 splice variants.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu		Richter, Wito/0000-0001-5588-9060	NICHD NIH HHS [HD 20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1997, BIOCHEM J, V328, P539; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lario PL, 2001, ARCH BIOCHEM BIOPHYS, V394, P54, DOI 10.1006/abbi.2001.2513; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Richter W, 2000, PROTEIN EXPRES PURIF, V19, P375, DOI 10.1006/prep.2000.1260; Rocque WJ, 1997, PROTEIN EXPRES PURIF, V9, P191, DOI 10.1006/prep.1996.0683; Saldou Natalie, 1998, Cell Biochemistry and Biophysics, V28, P187, DOI 10.1007/BF02737811; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, CURR OPIN CELL BIOL, V14, P160, DOI 10.1016/S0955-0674(02)00316-2; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	44	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40212	40221		10.1074/jbc.M203585200	http://dx.doi.org/10.1074/jbc.M203585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177055	hybrid			2022-12-25	WOS:000178791400009
J	Wu, DQ; Terrian, DM				Wu, DQ; Terrian, DM			Regulation of caveolin-1 expression and secretion by a protein kinase C epsilon signaling pathway in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL/CLONAL GROWTH; TUMOR-SUPPRESSOR; MYC EXPRESSION; UP-REGULATION; ANDROGEN; ACTIVATION; ELEMENTS; TRANSCRIPTION; PROLIFERATION; CARCINOMA	Caveolin-1, androgen receptor, c-Myc, and protein kinase Cepsilon (PKCepsilon) proteins are overrepresented in most advanced prostate cancer tumors. Previously, we demonstrated that PKCepsilon has the capacity to enhance the expression of both caveolin-1 and c-Myc in cultured prostate cancer cells and is sufficient to induce the growth of androgen-independent tumors. In this study, we have uncovered further evidence of a functional interplay among these proteins in the CWR22 model of human prostate cancer. The results demonstrated that PKCepsilon expression was naturally up-regulated in recurrent CWR22 tumors and that this oncoprotein was required to sustain the androgen-independent proliferation of CWR-R1 cells in culture. Gene transfer experiments demonstrated that PKCepsilon had the potential to augment the expression and secretion of a biologically active caveolin-1 protein that supports the growth of the CWR-R1 cell line. Antisense and pharmacological experiments provided additional evidence that the sequential activation of PKCepsilon, mitogen-activated protein kinases, c-Myc, and androgen receptor signaling drove the downstream expression of caveolin-1 in CWR-R1 cells. Finally, we demonstrate that mitogen-activated protein kinases were required downstream of PKCepsilon to derepress the transcriptional elongation of the c-myc gene. Our findings support the hypothesis that PKCepsilon may advance the recurrence of human prostate cancer by promoting the expression of several important downstream effectors of disease progression.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Wu, DQ (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 8397] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Balaji KC, 1997, UROLOGY, V50, P1007, DOI 10.1016/S0090-4295(97)00390-7; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; El Gedaily A, 2001, PROSTATE, V46, P184; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Gregory CW, 2001, CANCER RES, V61, P2892; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Li LK, 2001, CANCER RES, V61, P4386; Li YK, 1996, J BIOL CHEM, V271, P27025, DOI 10.1074/jbc.271.43.27025; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MOBERG KH, 1992, ONCOGENE, V7, P411; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sheflin L, 2000, BIOCHEM BIOPH RES CO, V276, P144, DOI 10.1006/bbrc.2000.3424; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Tahir SA, 2001, CANCER RES, V61, P3882; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wu DQ, 2002, CANCER RES, V62, P2423; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873	34	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40449	40455		10.1074/jbc.M206270200	http://dx.doi.org/10.1074/jbc.M206270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12185081	hybrid			2022-12-25	WOS:000178791400039
J	Huang, JH; Zhao, Q; Mooney, SM; Lee, FS				Huang, JH; Zhao, Q; Mooney, SM; Lee, FS			Sequence determinants in hypoxia-inducible factor-1 alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIF-ALPHA; DEGRADATION DOMAIN; FACTOR 1-ALPHA; PROTEIN; VHL; HIF-1-ALPHA; COMPLEX; BINDING; SYSTEM; OXYGEN	Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor induced by hypoxia. Under normoxic conditions, site-specific proline hydroxylation of the alpha subunits of HIF allows recognition by the von Hippel-Lindau tumor suppressor protein (VHL), a component of an E3 ubiquitin ligase complex that targets these subunits for degradation by the ubiquitin-proteasome pathway. Under hypoxic conditions, this hydroxylation is inhibited, allowing the a subunits of HIF to escape VHL-mediated degradation. Three enzymes, prolyl hydroxylase domain-containing proteins 1, 2, and 3 (PHD1, -2, and -3; also known as HIF prolyl hydroxylase 3, 2, and 1, respectively), have recently been identified that catalyze proline hydroxylation of HIF a subunits. These enzymes hydroxylate specific prolines in HIF a subunits in the context of a strongly conserved LXXLAP sequence motif (where X indicates any amino acid and P indicates the hydroxylacceptor proline). We report here that PHD2 has the highest specific activity toward the primary hydroxylation site of HIF-lalpha. Furthermore, and unexpectedly, mutations can be tolerated at the - 5, -2, and - 1 positions (relative to proline) of the LXXLAP motif. Thus, these results provide evidence that the only obligatory residue for proline hydroxylation in HIF-1a is the hydroxylacceptor proline itself.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, 422 Curie Blvd, Philadelphia, PA 19104 USA.	franklee@mail.med.upenn.edu		Lee, Frank/0000-0003-2511-1834	NCI NIH HHS [R01 CA090261, R01-CA090261] Funding Source: Medline; NIDDK NIH HHS [R01-DK55672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marchetti S, 2002, J CELL SCI, V115, P2075; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, ADV EXP MED BIOL, V502, P365; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136	46	247	255	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39792	39800		10.1074/jbc.M206955200	http://dx.doi.org/10.1074/jbc.M206955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181324	Green Accepted, hybrid			2022-12-25	WOS:000178662500094
J	Harndahl, L; Jing, XJ; Ivarsson, R; Degerman, E; Ahren, B; Manganiello, VC; Renstrom, E; Holst, LS				Harndahl, L; Jing, XJ; Ivarsson, R; Degerman, E; Ahren, B; Manganiello, VC; Renstrom, E; Holst, LS			Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PROTEIN-KINASE-A; ISLET HORMONE-SECRETION; GLUCAGON-LIKE PEPTIDE-1; ADENYLATE-CYCLASE; IN-VITRO; RAT; AMP; EXPRESSION; ACTIVATION	Cyclic AMP potentiates glucose-stimulated insulin release and mediates the stimulatory effects of hormones such as glucagon-like peptide 1 (GLP-1) on pancreatic beta-cells. By inhibition of cAMP-degrading phosphodiesterase (PDE) and, in particular, selective inhibition of PDE3 activity, stimulatory effects on insulin secretion have been observed. Molecular and functional information on beta-cell PDE3 is, however, scarce. To provide such information, we have studied the specific effects of the PDE3B isoform by adenovirus-mediated overexpression. In rat islets and rat insulinoma cells, approximate 10-fold overexpression of PDE3B was accompanied by a 6-8-fold increase in membrane-associated PDE3B activity. The cAMP concentration was significantly lowered in transduced cells (INS-1(832/13)), and insulin secretion in response to stimulation with high glucose (11.1 mM) was reduced by 40% (islets) and 50% (INS-1). Further, the ability of GLP-1 (100 nM) to augment glucose-stimulated insulin secretion was inhibited by similar to30% (islets) and 70% (INS-1). Accordingly, when stimulating with cAMP, a substantial decrease (65%) in exocytotic capacity was demonstrated in patch-clamped single beta-cells. In untransduced insulinoma cells, application of the PDE3-selective inhibitor OPC3911 (10 muM) was shown to increase glucose-stimulated insulin release as well as cAMP-enhanced exocytosis. The findings suggest a significant role of PDE3B as an important regulator of insulin secretory processes.	Lund Univ, Dept Cell & Mol Biol, Ctr Biomed, SE-22184 Lund, Sweden; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Lund Univ, Dept Med, Biomed Ctr, SE-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, Biomed Ctr, SE-22184 Lund, Sweden	Lund University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lund University; Lund University	Harndahl, L (corresponding author), Lund Univ, Dept Cell & Mol Biol, Ctr Biomed, C11, SE-22184 Lund, Sweden.		Tuluc, Petronel/C-2527-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad M, 2000, BRIT J PHARMACOL, V129, P1228, DOI 10.1038/sj.bjp.0703165; Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barg S, 1999, P NATL ACAD SCI USA, V96, P5539, DOI 10.1073/pnas.96.10.5539; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON GR, 1972, J CLIN INVEST, V51, P232, DOI 10.1172/JCI106808; CERASI E, 1970, Hormone and Metabolic Research, V2, P246; CHARLES MA, 1973, SCIENCE, V179, P569, DOI 10.1126/science.179.4073.569; Choi YH, 2001, BIOCHEM J, V353, P41, DOI 10.1042/0264-6021:3530041; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; ElMetwally M, 1997, EUR J PHARMACOL, V324, P227, DOI 10.1016/S0014-2999(97)00076-9; Erdogan S, 1997, BIOCHEM J, V321, P165, DOI 10.1042/bj3210165; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRILL V, 1975, DIABETES, V24, P746, DOI 10.2337/diabetes.24.8.746; GRILL V, 1973, FEBS LETT, V33, P311, DOI 10.1016/0014-5793(73)80218-2; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; HELLMAN B, 1974, BIOCHIM BIOPHYS ACTA, V372, P127, DOI 10.1016/0304-4165(74)90079-8; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HOWELL SL, 1994, DIABETOLOGIA, V37, P30; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; MURAD F, 1971, P NATL ACAD SCI USA, V68, P736, DOI 10.1073/pnas.68.4.736; Parker JC, 1997, BIOCHEM BIOPH RES CO, V236, P665, DOI 10.1006/bbrc.1997.7034; Parker JC, 1995, BIOCHEM BIOPH RES CO, V217, P916, DOI 10.1006/bbrc.1995.2858; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; RASCON A, 1994, J BIOL CHEM, V269, P11962; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; SHAFIEENICK R, 1995, BRIT J PHARMACOL, V115, P1486, DOI 10.1111/j.1476-5381.1995.tb16641.x; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHARP GWG, 1979, DIABETOLOGIA, V16, P287, DOI 10.1007/BF01223617; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SNYDER PB, 1999, EMERGING THERAPEUTIC, V3, P587; TAIRA M, 1993, J BIOL CHEM, V268, P18573; THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223	49	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37446	37455		10.1074/jbc.M205401200	http://dx.doi.org/10.1074/jbc.M205401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12169692	hybrid			2022-12-25	WOS:000178447100069
J	Scott, MGH; Le Rouzic, E; Perianin, A; Pierotti, V; Enslen, H; Benichou, S; Marullo, S; Benmerah, A				Scott, MGH; Le Rouzic, E; Perianin, A; Pierotti, V; Enslen, H; Benichou, S; Marullo, S; Benmerah, A			Differential nucleocytoplasmic shuttling of beta-arrestins - Characterization of a leucine-rich nuclear export signal in beta-arrestin2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-COATED VESICLES; BETA(2)-ADRENERGIC RECEPTOR; REGULATED KINASES; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; ENDOCYTOSIS; LOCALIZATION; ACTIVATION; ADAPTER	beta-arrestins (betaarrs) are two highly homologous proteins that uncouple G protein-coupled receptors from their cognate G proteins, serve as adaptor molecules linking G protein-coupled receptors to clathrin-coat components (AP-2 complex and clathrin), and act as scaffolding proteins for ERK1/2 and JNK3 cascades. A striking difference between the two betaarrs (betaarr1 and betaarr2) is that betaarr1 is evenly distributed throughout the cell, whereas betaarr2 shows an apparent cytoplasmic localization at steady state. Here, we investigate the molecular determinants underlying this differential distribution. betaarr2 is constitutively excluded from the nucleus by a leptomycin B-sensitive pathway because of the presence of a classical leucine-rich nuclear export signal in its C terminus (L395/L397) that is absent in betaarr1. In addition, using a nuclear import assay in yeast we showed that betaarr2 is actively imported into the nucleus, suggesting that betaarr2 undergoes constitutive nucleocytoplasmic shuttling. In cells expressing betaarr2, JNK3 is mostly cytosolic. A point mutation of the nuclear export signal (L395A) in betaarr2, which was sufficient to redistribute betaarr2 from the cytosol to the nucleus, also caused the nuclear relocalization of JNK3. These data indicate that the nucleocytoplasmic shuttling of betaarr2 controls the subcellular distribution of JNK3.	Inst Cochin, Dept Cell Biol, F-75679 Paris 14, France; Inst Cochin, Dept Infect Dis, F-75679 Paris, France; Inst Fer A Moulin, INSERM, U536, F-75005 Paris, France; Fac Necker Enfants Malad, INSERM, F-75730 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marullo, S (corresponding author), Inst Cochin, Dept Cell Biol, Pavillon Gustave Roussy, F-75679 Paris 14, France.		benmerah, alexandre/H-3742-2017; Marullo, Stefano/C-6142-2008; Enslen, Hervé/AAH-4492-2021; Scott, Mark/R-3521-2019; Enslen, Hervé/M-3400-2017	benmerah, alexandre/0000-0003-0188-8016; Marullo, Stefano/0000-0001-9604-9973; Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Benichou, Serge/0000-0003-3602-3530; Scott, Mark G.H./0000-0002-1557-1856				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Potter RM, 2002, J BIOL CHEM, V277, P8970, DOI 10.1074/jbc.M111086200; Poupon V, 2002, J BIOL CHEM, V277, P8941, DOI 10.1074/jbc.M108385200; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511	41	159	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37693	37701		10.1074/jbc.M207552200	http://dx.doi.org/10.1074/jbc.M207552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167659	hybrid			2022-12-25	WOS:000178447100101
J	Chu, X; Cheung, JY; Barber, DL; Birnbaumer, L; Rothblum, LI; Conrad, K; Abrasonis, V; Chan, YM; Stahl, R; Carey, DJ; Miller, BA				Chu, X; Cheung, JY; Barber, DL; Birnbaumer, L; Rothblum, LI; Conrad, K; Abrasonis, V; Chan, YM; Stahl, R; Carey, DJ; Miller, BA			Erythropoietin modulates calcium influx through TRPC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN ERYTHROID PRECURSORS; CAPACITATIVE CA2+ ENTRY; CENTRAL-NERVOUS-SYSTEM; MOLECULAR MECHANISMS; HUMAN ERYTHROBLASTS; CATION CHANNEL; RECEPTOR; DIFFERENTIATION	Mammalian isoforms of calcium-permeable Drosophila transient receptor potential channels (TRPC) are involved in the sustained phase of calcium entry in non-excitable cells. Erythropoietin (Epo) stimulates a rise in intracellular calcium ([Ca](i)) via activation of voltage-independent calcium channel(s) in erythroid cells. Here, involvement of murine orthologs of classical TRPC in the Epo-modulated increase in [Ca](i) was examined. RTPCR of TRPC 1-6 revealed high expression of only TRPC2 in Epo-dependent cell lines HCD-57 and Ba/F3 Epo-R, in which Epo stimulates a rise in [Ca](i). Using RT-PCR, Western blotting, and immunolocalization, expression of the longest isoform of mTRPC2, clone 14, was demonstrated in HCD-57 cells, Ba/F3 Epo-R cells, and primary murine erythroblasts. To determine whether erythropoietin is capable of modulating calcium influx through TRPC2, CHO cells were cotransfected with Epo-R subcloned into pTracer-CMV and either murine TRPC2 clone 14 or TRPC6, a negative control, into pQBI50. Successful transfection of Epo-R was verified in single cells by detection of green fluorescent protein from pTracer-CMV using digital video imaging, and successful transfection of TRPC was confirmed by detection of blue fluorescent protein fused through a flexible linker to TRPC. [Ca](i) changes were simultaneously monitored in cells loaded with Rhod-2 or Fura Red. Epo stimulation of CHO cells cotransfected with Epo-R and TRPC2 resulted in a rise in [Ca](i) above base line (372 +/- 71%), which was significantly greater (p less than or equal to 0.0007) than that seen in cells transfected with TRPC6 or empty pQBI50 vector. This rise in [Ca](i) required Epo and extracellular calcium. These results identify a calcium-permeable channel, TRPC2, in erythroid cells and demonstrate modulation of calcium influx through this channel by erythropoietin.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA; Ontario Canc Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M9, Canada; NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA	Geisinger Medical Center; Geisinger Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Miller, BA (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.			Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925, R01NS037716, R01NS041363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline; NIGMS NIH HHS [GM 46991] Funding Source: Medline; NINDS NIH HHS [NS 37716, NS 41363, NS 21925] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Cheung JY, 2001, NEPHRON, V87, P215, DOI 10.1159/000045918; Dame C, 2001, BIOL NEONATE, V79, P228; Damen JE, 1996, EXP HEMATOL, V24, P1455; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLO B, 1993, BLOOD, V81, P783; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HENSOLD JO, 1991, BLOOD, V77, P1362; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MITANI A, 1994, J NEUROCHEM, V62, P626; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Wu Yiming, 1997, American Journal of Physiology, V273, pH2161; YOSHINO M, 1995, BRAIN RES, V695, P179, DOI 10.1016/0006-8993(95)00743-A; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	44	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34375	34382		10.1074/jbc.M205541200	http://dx.doi.org/10.1074/jbc.M205541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167663	hybrid			2022-12-25	WOS:000177959100110
J	Andersen, C; Schiffler, B; Charbit, A; Benz, R				Andersen, C; Schiffler, B; Charbit, A; Benz, R			pH-induced collapse of the extracellular loops closes Escherichia coli maltoporin and allows the study of asymmetric sugar binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; DIFFUSION CHANNELS; CRYSTAL-STRUCTURES; LIPID-MEMBRANES; RATE CONSTANTS; PORIN SCRY; IN-VITRO; LAMB; TRANSPORT	LamB (maltoporin) is essential for the uptake of maltose and malto-oligosaccharides across the outer membrane of Escherichia coli. Purified LamB was reconstituted in artificial lipid bilayer membranes forming channels in the permanently open configuration at neutral pH. Almost complete channel closure was observed when the pH on both sides of the membrane was lowered to pH 4. When LamB was added to only one side of the membrane, the cis-side, and the pH was lowered at either side of the membrane, the cis- or the trans-side, the response to pH was asymmetric, suggesting preferential orientation of maltoporin channels and pH-dependent closure of only one side of the channel. In experiments with LamB mutants in which major external loops L4, L6, and/or L9 were deleted, we identified the surface-exposed loops L4 and L6 as the cause of pH-mediated closure. The pH dependence of the LamB channel is consistent with the assumption that it inserts in a preferential orientation into the lipid bilayer. About 70-80% of the reconstituted channels are oriented with the extracellular entrance toward the side to which the protein was added (the cis-side) and with the periplasmic opening on the opposite side (the trans-side). The possibility of closing the channels, which are oriented in the reverse direction by low pH at the trans-side, allowed the deduction of channel asymmetry with respect to carbohydrate binding kinetics. Whereas maltose binding was found to be almost symmetric with respect to the channel orientation, the sucrose and trehalose binding to LamB was asymmetric. The results are discussed in respect to possible physiological function of the pH-dependent closure of maltoporin.	Univ Wurzburg, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; CHU Necker Enfants Malad, INSERM U411, F-75730 Paris 15, France	University of Wurzburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Andersen, C (corresponding author), Univ Wurzburg, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany.			charbit, alain/0000-0001-5243-4861; Benz, Roland/0000-0002-9510-9265				Andersen C, 1998, EUR J BIOCHEM, V254, P679, DOI 10.1046/j.1432-1327.1998.2540679.x; ANDERSEN C, 1995, J GEN PHYSIOL, V105, P385, DOI 10.1085/jgp.105.3.385; Andersen C, 2002, J MEMBRANE BIOL, V185, P83, DOI 10.1007/s00232-001-0113-2; Andersen C, 1999, MOL MICROBIOL, V32, P851, DOI 10.1046/j.1365-2958.1999.01406.x; Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; Chagneau C, 2001, J BACTERIOL, V183, P5675, DOI 10.1128/JB.183.19.5675-5683.2001; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; DONALDSON DM, 1974, INFECT IMMUN, V10, P657, DOI 10.1128/IAI.10.3.657-666.1974; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; HEYDE M, 1987, MOL GEN GENET, V208, P511, DOI 10.1007/BF00328148; Jordy M, 1996, J MOL BIOL, V259, P666, DOI 10.1006/jmbi.1996.0348; Kullman L, 2002, BIOPHYS J, V82, P803, DOI 10.1016/S0006-3495(02)75442-8; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; Muller DJ, 1999, J MOL BIOL, V285, P1347, DOI 10.1006/jmbi.1998.2359; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; Orlik F, 2002, BIOPHYS J, V82, P2466, DOI 10.1016/S0006-3495(02)75589-6; Orlik F, 2002, BIOPHYS J, V83, P309, DOI 10.1016/S0006-3495(02)75171-0; REST RF, 1977, INFECT IMMUN, V16, P145, DOI 10.1128/IAI.16.1.145-151.1977; Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHMID K, 1991, MOL MICROBIOL, V5, P941, DOI 10.1111/j.1365-2958.1991.tb00769.x; SCHULEIN K, 1995, MOL MICROBIOL, V17, P757, DOI 10.1111/j.1365-2958.1995.mmi_17040757.x; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TODT JC, 1992, BIOCHEM BIOPH RES CO, V189, P1498, DOI 10.1016/0006-291X(92)90244-F; Van Gelder P, 2000, BIOPHYS CHEM, V85, P153, DOI 10.1016/S0301-4622(99)00153-2; Wang YF, 1997, J MOL BIOL, V272, P56, DOI 10.1006/jmbi.1997.1224; XU GZ, 1986, BIOCHIM BIOPHYS ACTA, V862, P57, DOI 10.1016/0005-2736(86)90468-2; Zhang P, 1998, SOLID STATE NUCL MAG, V12, P221, DOI 10.1016/S0926-2040(98)00069-1	35	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41318	41325		10.1074/jbc.M206804200	http://dx.doi.org/10.1074/jbc.M206804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12185084	hybrid			2022-12-25	WOS:000178985300006
J	Jang, SI; Steinert, PM				Jang, SI; Steinert, PM			Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL ENVELOPES; PROLINE-RICH PROTEINS; PROXIMAL PROMOTER; IN-VITRO; C-FOS; MOUSE KERATINOCYTES; NUCLEAR-PROTEIN; GENE-EXPRESSION; BINDING; DIFFERENTIATION	The major protein component of the cornified cell envelope barrier structure of the epidermis is loricrin, and it is expressed late during terminal differentiation in epidermal keratinocytes. We have previously shown that an AP1 site located in the proximal promoter region (position -55) is essential for human loricrin promoter activity (Rossi, A., Jang, S-I., Ceci, R., Steinert, P. M., and Markova, N. G. (1998) J. Invest. Dermatol 110, 34-40). In this study we show that its regulation requires complex cooperative and competitive interactions between multiple transcription factors in keratinocytes located in different compartments of the epidermis. We show that as few as 154 base pairs of 5'-upstream sequences from the cap site can direct the keratinocyte-specific expression in cultured keratinocytes. Mutation and DNA-protein analyses show that Sp1, c-Jun, an unidentified regulator, and the co-activator p300/CREB-binding protein up-regulate whereas Sp3, CREB-1/CREMalpha/ATF-1, Jun B, and an AP2-like protein (termed the keratinocyte-specific repressor-1 (KSR-1)) suppress loricrin promoter activity. We show that CREB protein can compete with c-Jun for the AP1 site and repress loricrin promoter activity. We show here that the protein kinase A pathway can activate loricrin expression by manipulation of the Sp1, Sp3, and KSR-1 levels in the nucleus. Thus, in undifferentiated cells, loricrin expression is suppressed by Jun B, Sp3, and KSR-1 proteins. But in advanced differentiated cells, levels of Sp3, KSR-1, and CREB proteins are lower; the unidentified regulator protein can bind; Sp1 and c-Jun are increased; and then p300/CBP is recruited. Together, these events allow loricrin transcription to proceed. Indeed, the synergistic effects of the Sp1, c-Jun, and p300 factors indicate that p300/CBP might act as bridge to form an active transcription complex.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Jang, SI (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 50,Rm 1529, Bethesda, MD 20892 USA.	jangs@mail.nih.gov						Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHATTON B, 1994, ONCOGENE, V9, P375; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HOHL D, 1993, AM J DERMATOPATH, V15, P20, DOI 10.1097/00000372-199302000-00004; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jessen BA, 2000, GENE, V254, P77, DOI 10.1016/S0378-1119(00)00291-2; KAWACHI Y, 2001, J INVEST DERMATOL 2, V119, P376; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; Rutberg SE, 1999, ONCOGENE, V18, P1569, DOI 10.1038/sj.onc.1202463; RYSECK RP, 1991, ONCOGENE, V6, P533; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Sinha S, 2001, P NATL ACAD SCI USA, V98, P2455, DOI 10.1073/pnas.051633598; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEVEN AC, 1994, J CELL SCI, V107, P693; TAMAI K, 1994, J BIOL CHEM, V269, P493; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WU RL, 1994, J BIOL CHEM, V269, P28450; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YONEDA K, 1992, J BIOL CHEM, V267, P18060	69	76	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42268	42279		10.1074/jbc.M205593200	http://dx.doi.org/10.1074/jbc.M205593200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200429	hybrid			2022-12-25	WOS:000178985300122
J	Liao, VHC; Dong, J; Freedman, JH				Liao, VHC; Dong, J; Freedman, JH			Molecular characterization of a novel, cadmium-inducible gene from the nematode Caenorhabditis elegans - A New gene that contributes to the resistance to cadmium toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE GENE; DEPENDENT PROTEIN-KINASE; CELL-SPECIFIC EXPRESSION; STRUCTURAL ORGANIZATION; METALLOTHIONEIN GENES; REGULATORY ELEMENTS; SEQUENCE ANALYSES; RESPONSIVE GENES; OXIDATIVE STRESS; METAL RESISTANCE	Cadmium is an environmental contaminant that is both a human toxicant and carcinogen. To inhibit cadmium-induced damage, cells respond by increasing the expression of genes that encode stress-response proteins. We previously reported the identification of 48 cadmium-inducible mRNAs in the nematode Caenorhabditis elegans. Here we describe a new cadmium-responsive gene, designated cdr-1, whose rate and level of inducible expression parallel those of the C. elegans metallothioneins. The CDR-1 mRNA contains an open reading frame of 831 bp and encodes a predicted 32-kDa, integral membrane protein. Following cadmium exposure, cdr-1 is transcribed exclusively in intestinal cells of post-embryonic C. elegans. In vivo, the CDR-1 protein is targeted specifically to the intestinal cell lysosomes. cdr-1 transcription is significantly induced by cadmium but not by other tested stressors. These results indicate that cdr-1 expression is regulated by cadmium and in a cell-specific fashion. Inhibition of CDR-1 expression renders C. elegans susceptible to cadmium toxicity. In conclusion, cdr-1 defines a new class of cadmium-inducible genes and encodes an integral membrane, lysosomal protein. This protein functions to protect against cadmium toxicity.	Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Feng Chia Univ, Dept Environm Sci & Engn, Taichung 40724, Taiwan; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University; Feng Chia University; Duke University	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu		Liao, Vivian/0000-0002-4676-9953	NIEHS NIH HHS [ES09949] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009949] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM J, 1989, J BIOL CHEM, V264, P6371; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Aylett B. J., 1979, CHEM BIOCH BIOL CADM, P1, DOI DOI 10.1007/978-1-59259-458-0; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Cioci LK, 2000, ENVIRON TOXICOL CHEM, V19, P2122, DOI [10.1897/1551-5028(2000)019&lt;2122:TSOTNC&gt;2.3.CO;2, 10.1002/etc.5620190823]; CLOKEY GV, 1986, MECH AGEING DEV, V35, P79, DOI 10.1016/0047-6374(86)90068-0; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Endo T, 2002, COMP BIOCHEM PHYS C, V131, P223, DOI 10.1016/S1532-0456(02)00009-1; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Favello A, 1995, METHOD CELL BIOL, V48, P551; Fay RM, 1996, FOOD CHEM TOXICOL, V34, P1175, DOI 10.1016/S0278-6915(97)00094-X; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; Friberg L., 1986, HDB TOXICOLOGY METAL, P130; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 1996, DEV BIOL, V178, P276, DOI 10.1006/dbio.1996.0218; GEORGE SG, 1979, BIOCHIM BIOPHYS ACTA, V580, P234, DOI 10.1016/0005-2795(79)90136-3; GIGLIO AM, 1994, BIOCHEM MOL BIOL INT, V33, P41; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HATCHER EL, 1995, FREE RADICAL BIO MED, V19, P805, DOI 10.1016/0891-5849(95)00099-J; Havelaar AC, 1998, FEBS LETT, V436, P223, DOI 10.1016/S0014-5793(98)01133-8; HAWKINS MG, 1995, J BIOL CHEM, V270, P14666, DOI 10.1074/jbc.270.24.14666; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HESCHL MFP, 1990, COMP BIOCHEM PHYS B, V96, P633, DOI 10.1016/0305-0491(90)90206-9; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HILL KK, 1995, GENETICS, V141, P595; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HU ED, 1990, J BIOL CHEM, V265, P5072; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kawasaki M, 1999, EMBO J, V18, P3604, DOI 10.1093/emboj/18.13.3604; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; KOIZUMI T, 1992, J TOXICOL ENV HEALTH, V37, P25, DOI 10.1080/15287399209531654; KOSTIC MM, 1993, EUR J HAEMATOL, V51, P86; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND M, 1994, J BIOL CHEM, V269, P14820; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liao VHC, 1998, J BIOL CHEM, V273, P31962, DOI 10.1074/jbc.273.48.31962; LU XY, 1990, J BIOL CHEM, V265, P3293; MACMORRIS M, 1992, MOL CELL BIOL, V12, P1652, DOI 10.1128/MCB.12.4.1652; MACMORRIS M, 1994, MOL CELL BIOL, V14, P484, DOI 10.1128/MCB.14.1.484; MARIGOMEZ JA, 1990, HISTOCHEMISTRY, V94, P191, DOI 10.1007/BF02440187; MARSHALL AT, 1994, J SUBMICR CYTOL PATH, V26, P59; MCGHEE JD, 1990, GENETICS, V125, P505; Mello C, 1995, METHOD CELL BIOL, V48, P451; Moilanen LH, 1999, J BIOL CHEM, V274, P29655, DOI 10.1074/jbc.274.42.29655; Murata M, 1999, J CELL PHYSIOL, V180, P105, DOI 10.1002/(SICI)1097-4652(199907)180:1<105::AID-JCP12>3.0.CO;2-5; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; SALOVSKY P, 1992, HUM EXP TOXICOL, V11, P217, DOI 10.1177/096032719201100310; SLICE LW, 1990, J BIOL CHEM, V265, P256; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; STRINGHAM EG, 1994, ENVIRON TOXICOL CHEM, V13, P1211, DOI 10.1897/1552-8618(1994)13[1211:THLSOT]2.0.CO;2; STRINGHAM EG, 1992, GENE, V113, P165, DOI 10.1016/0378-1119(92)90392-3; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Tatara CP, 1997, AQUAT TOXICOL, V39, P279, DOI 10.1016/S0166-445X(97)00030-1; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WILLIAMS PL, 1990, ENVIRON TOXICOL CHEM, V9, P1285, DOI [10.1897/1552-8618(1990)9[1285:ATTUTN]2.0.CO;2, 10.1002/etc.5620091007]; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	83	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42049	42059		10.1074/jbc.M206740200	http://dx.doi.org/10.1074/jbc.M206740200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12189149	hybrid			2022-12-25	WOS:000178985300094
J	Noga, AA; Zhao, Y; Vance, DE				Noga, AA; Zhao, Y; Vance, DE			An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; CULTURED RAT HEPATOCYTES; LIVER CELL-CULTURE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MCA-RH7777 CELLS; METHYLATION; CHOLINE; EXPRESSION; MOUSE; GENE	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine (PC). We investigated whether there was diminished secretion of lipoproteins from hepatocytes derived from mice that lacked PEMT (Pemt(-/-)) compared with Pemt(+/+) mice. Hepatocytes were incubated with 0.75 mm oleate, the media were harvested, and triacylglycerol (TG), PC, apolipoprotein (apo) B100, and apoB48 were isolated and quantified. Compared with hepatocytes from Pemt(+/+) mice, hepatocytes from Pemt(-/-) mice secreted 50% less TG, whereas secretion of PC was unaffected. Fractionation of the secreted lipoproteins on density gradients demonstrated that the decrease in TG was in the very low density lipoprotein (VLDL)/low density lipoprotein fractions. The secretion of apoB100 was decreased by similar to70% in VLDLs/low density lipoproteins, whereas there was no significant decrease in apoB48 secretion in any fraction. Transfection of McArdle hepatoma cells (that lack PEMT) with PEMT cDNA enhanced secretion of TG in the VLDLs. Because the levels of PC in the hepatocytes and hepatoma cells were unaffected by the lack of PEMT expression, there appears to be an unexpected requirement for PEMT in the secretion of apoB100-containing VLDLs.	Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CUI Z, 1993, J BIOL CHEM, V268, P16655; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; FAST DG, 1995, BBA-LIPID LIPID MET, V1258, P159, DOI 10.1016/0005-2760(95)00116-T; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P926; KUKSIS A, 1978, NUTR REV, V36, P201; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P11, DOI 10.1016/S0005-2760(96)00101-4; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; PRICHARD PH, 1982, J BIOL CHEM, V257, P6362; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; ROBINSON BS, 1989, BIOCHEM J, V260, P207, DOI 10.1042/bj2600207; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE JE, 1986, FEBS LETT, V204, P243, DOI 10.1016/0014-5793(86)80820-1; VANCE JE, 1986, BIOCHIM BIOPHYS ACTA, V875, P501, DOI 10.1016/0005-2760(86)90070-6; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; Vermeulen PS, 1997, J LIPID RES, V38, P447; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Walkey CJ, 1999, BBA-MOL CELL BIOL L, V1436, P405, DOI 10.1016/S0005-2760(98)00147-7; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Wu XJ, 1996, J LIPID RES, V37, P1198; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; ZHOU X, 1992, J LIPID RES, V33, P1233	39	177	179	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42358	42365		10.1074/jbc.M204542200	http://dx.doi.org/10.1074/jbc.M204542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12193594	hybrid			2022-12-25	WOS:000178985300132
J	Zheng, GL; Dai, J; Woldegiorgis, G				Zheng, GL; Dai, J; Woldegiorgis, G			Identification by mutagenesis of a conserved glutamate (Glu(487)) residue important for catalytic activity in rat liver carnitine palmitoyltransferase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; GENE; EXPRESSION; MUTATION; HEART; DEFICIENCY; MYOGLOBINURIA; HISTIDINE; ISOFORM; BINDING	Mammalian mitochondrial membranes express two active but distinct carnitine palmitoyltransferases: carnitine palmitoyltransferase I (CPTI), which is malonyl coA-sensitive and detergent-labile; and carnitine palmitoyltransferase II (CPTII), which is malonyl coA-insensitive and detergent-stable. To determine the role of the highly conserved C-terminal acidic residues glutamate 487 (Glu(487)) and glutamate 500 (Glu(500)) on catalytic activity in rat liver CPTII, we separately mutated these residues to alanine, aspartate, or lysine, and the effect of the mutations on CPTII activity was determined in the Escherichia coli-expressed mutants. Substitution of Glu(487) with alanine, aspartate, or lysine resulted in almost complete loss in CPTII activity. Because a conservative substitution mutation of this residue, Glu(487) with aspartate (E487D), resulted in a 97% loss in activity, we predicted that Glu(487) would be at the active-site pocket of CPTII The substantial loss in CPTII activity observed with the E487K mutant, along with the previously reported loss in activity observed in a child with a CPTII deficiency disease, establishes that Glu(487) is crucial for maintaining the configuration of the liver isoform of the CPTII active site. Substitution of the conserved Glu(500) in CPTII with alanine or aspartate reduced the V-max for both substrates, suggesting that Glu(500) may be important in stabilization of the enzyme-substrate complex. A conservative substitution of Glu(500) to aspartate resulted in a significant decrease in the V-max for the substrates. Thus, Glu(500) may play a role in substrate binding and catalysis. Our site-directed mutagenesis studies demonstrate that Glu(487) in the liver isoform of CPTII is essential for catalysis.	Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA	Oregon Health & Science University	Woldegiorgis, G (corresponding author), Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.				NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bonnefont JP, 1999, MOL GENET METAB, V68, P424, DOI 10.1006/mgme.1999.2938; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P19157; BROWN NF, 1993, BIOCHEM J, V294, P79, DOI 10.1042/bj2940079; Bruno C, 2000, J CHILD NEUROL, V15, P390, DOI 10.1177/088307380001500607; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; DAY PJ, 1992, J BIOL CHEM, V267, P5122; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; JOHNSON TM, 1995, BIOCHEM J, V309, P689, DOI 10.1042/bj3090689; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; PANDE SV, 1993, J CLIN INVEST, V91, P1247, DOI 10.1172/JCI116288; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Tao Bernard Y., 1994, P69; TARONI F, 1993, NAT GENET, V4, P314, DOI 10.1038/ng0793-314; VERDERIO E, 1995, HUM MOL GENET, V4, P19, DOI 10.1093/hmg/4.1.19; Vladutiu GD, 2000, MOL GENET METAB, V70, P134, DOI 10.1006/mgme.2000.3009; Wataya K, 1998, HUM MUTAT, V11, P377; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	28	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42219	42223		10.1074/jbc.M202914200	http://dx.doi.org/10.1074/jbc.M202914200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12200419	hybrid			2022-12-25	WOS:000178985300116
J	Guo, XL; Kui, S; Wang, F; Lawrence, DS; Zhang, ZY				Guo, XL; Kui, S; Wang, F; Lawrence, DS; Zhang, ZY			Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; INSULIN SENSITIVITY; KINETIC-ANALYSIS; STRUCTURAL BASIS; IN-VIVO; BINDING; IDENTIFICATION; RECEPTOR	Protein-tyrosine phosphatases (PTPs) are important for the control of proper cellular tyrosine phosphorylation. Despite the large number of PTPs encoded in the human genome and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific inhibitors. Such inhibitors could serve as useful tools for determining the physiological functions of PTPs and may constitute valuable therapeutics in the treatment of several human diseases. However, because of the highly conserved nature of the active site, it has been difficult to develop selective PTP inhibitors. By taking an approach to tether together two small ligands that can interact simultaneously with the active site and a unique proximal noncatalytic site, we have recently acquired Compound 2 (see Fig. 1), the most potent and selective PTP1B inhibitor identified to date, which exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPs. We describe an evaluation of the interaction between 2 and its analogs with PTP1B and its site-directed mutants selected based on hydrogen/deuterium exchange of PTP1B backbone amides in the presence and absence of 2. We have established the binding mode of Compound 2 and identified 12 PTP1B residues that are important for the potency and selectivity of Compound 2. Although many of the residues important for Compound 2 binding are not unique to PTP1B, the combinations of all contact residues differ between PTP isozymes, which suggest that the binding surface defined by these residues in individual PTPs determines inhibitor selectivity. Our results provide structural information toward understanding of the molecular basis for potent and selective PTP1B inhibition and further establish the feasibility of acquiring potent, yet highly selective, PTP inhibitory agents.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Albert Einstein Coll Med, Lab Macromol Anal & Proteom, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; Deng H, 2002, BIOCHEMISTRY-US, V41, P5865, DOI 10.1021/bi016097z; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Resing KA, 1999, PROG BIOPHYS MOL BIO, V71, P501, DOI 10.1016/S0079-6107(98)00048-0; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Solas D, 1996, J ORG CHEM, V61, P1537, DOI 10.1021/jo9517508; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; Wang F, 1998, BIOCHEMISTRY-US, V37, P15289, DOI 10.1021/bi981481q; Wang F, 1997, BIOCHEMISTRY-US, V36, P3755, DOI 10.1021/bi963065g; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yokomatsu T, 1997, TETRAHEDRON, V53, P815, DOI 10.1016/S0040-4020(96)01063-0; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484	42	76	77	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41014	41022		10.1074/jbc.M207347200	http://dx.doi.org/10.1074/jbc.M207347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12193602	hybrid			2022-12-25	WOS:000178791400110
J	Werner, AB; de Vries, E; Tait, SWG; Bontjer, J; Borst, J				Werner, AB; de Vries, E; Tait, SWG; Bontjer, J; Borst, J			TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; CYTOCHROME-C RELEASE; NF-KAPPA-B; DEPENDENT APOPTOSIS; KILLER/DR5 GENE; DEATH; ACTIVATION; BCL-2; FAMILY; MEMBER	The death receptor ligand TRAIL arouses much interest for clinical application. We found that TRAIL receptor could induce cytochrome c (Cyt c) release from mitochondria in cells that failed to respond to CD95. Therefore, we examined whether these two closely related death receptors use different intermediates to convey the apoptotic signal to mitochondria. Dominant negative FADD, FLIPL, or a Bid mutant lacking cleavage sites for caspase-8/10 completely inhibited Cyt c release in response to either receptor. Depletion of Bid from TRAIL- or CD95-activated cytosols blocked their capacity to mediate Cyt c release from mitochondria in vitro, whereas Bax depletion reduced it. We conclude that FADD, caspase-8/10, and caspase-cleaved Bid are required for TRAIL receptor and CD95 signaling to mitochondria, whereas Bax is a common accessory. In vitro, caspase-8 treatment of cytosol from CD95-resistant cells permitted generation of truncated Bid and its association with mitochondria. However, this cytosol impaired the ability of truncated Bid to liberate Cyt c from exogenous mitochondria. We conclude that the TRAIL receptor can bypass or neutralize the activity of cytosolic factor that blocks truncated Bid function. This may benefit the capacity of TRAIL to break apoptosis resistance in tumor cells.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl		Borst, Jannie/0000-0002-8043-5009; Tait, Stephen/0000-0001-7697-132X				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2001, CANCER RES, V61, P1645; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheikh MS, 1998, CANCER RES, V58, P1593; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40760	40767		10.1074/jbc.M204351200	http://dx.doi.org/10.1074/jbc.M204351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12196516	hybrid			2022-12-25	WOS:000178791400078
J	Kim, MS; Baek, MJ; Lee, MH; Park, JW; Lee, SY; Soderhall, K; Lee, BL				Kim, MS; Baek, MJ; Lee, MH; Park, JW; Lee, SY; Soderhall, K; Lee, BL			A new easter-type serine protease cleaves a masquerade-like protein during prophenoloxidase activation in Holotrichia diomphalia larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; BETA-1,3-GLUCAN RECOGNITION PROTEIN; FRESH-WATER CRAYFISH; MANDUCA-SEXTA; MOLECULAR-CLONING; COLEOPTERAN INSECT; CDNA CLONING; PURIFICATION; SILKWORM; ENZYME	The prophenoloxidase (proPO) activation pathway, like the vertebrate complement system, consists of a protease cascade and functions as a non-self-recognition system in these animals. Determining the molecular mechanism by which pattern recognition molecules differentiate non-self from self and transduce signals that stimulate defense responses is a key for understanding the ways in which innate immune systems are regulated. However, the proPO system is poorly defined at the molecular level. The proPO-activating system of the insect Holotrichia diomphalia comprises several components, some of which have been cloned and characterized, such as the novel 27-kDa proPO-activating factor-III (PPAF-III) from the plasma of H. diomphalia larvae and two prophenoloxidases. The PPAF-III gene encodes an easter-type serine protease zymogen consisting of 351 amino acid residues with a mass of 40 kDa. The purified 27-kDa PPAF-III specifically cleaved a 55-kDa proPPAF-II to generate a 45-kDa PPAF-II with or without Ca2+ present. Furthermore, two Holotrichia prophenoloxidases (proPO-I and 41) have been characterized, and their structural changes during activation were examined by in vitro reconstitution experiments. When the proPOs were incubated with PPAF-I, the 79-kDa proPOs were converted to 76-kDa proPOs, which did not exhibit any phenoloxidase (PO) activity. However, when the proPOs were incubated simultaneously with PPAF-I, proPPAF-II, and PPAF-III in the presence of Ca2+, a 60-kDa protein (PO-1) with PO activity was detected in addition to the 76-kDa proPO-II protein. These results indicate that the conversion of Holotrichia proPOs to enzymatically active phenoloxidase is accomplished by PPAF-I, PAF-II, and PPAF-III through a two-step limited proteolysis in the presence of Ca2+.	Pusan Natl Univ, Coll Pharm, Kumjeong Ku, Pusan 609735, South Korea; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Kumjeong Ku, Jangjeon Dong, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Baek, Moo-Jun/W-1736-2019	Baek, Moo-Jun/0000-0003-3567-6687; Lee, So Young/0000-0003-3130-785X				Ahmed A, 1999, P NATL ACAD SCI USA, V96, P14795, DOI 10.1073/pnas.96.26.14795; Ashida Masaaki, 1998, P135; ASPAN A, 1991, INSECT BIOCHEM, V21, P363, DOI 10.1016/0020-1790(91)90002-V; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; Cho MY, 1999, EUR J BIOCHEM, V262, P737, DOI 10.1046/j.1432-1327.1999.00416.x; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; Hyuk T, 1997, MOL CELLS, V7, P90; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; MURUGASUOEI B, 1995, GENE DEV, V9, P139, DOI 10.1101/gad.9.2.139; MUTA T, 1990, J BIOL CHEM, V265, P22426; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200	30	118	138	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39999	40004		10.1074/jbc.M205508200	http://dx.doi.org/10.1074/jbc.M205508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12185078	hybrid			2022-12-25	WOS:000178662500119
J	Rasanen, TL; Alhonen, L; Sinervirta, R; Keinanen, T; Herzig, KH; Suppola, S; Khomutov, AR; Vepsalainen, J; Janne, J				Rasanen, TL; Alhonen, L; Sinervirta, R; Keinanen, T; Herzig, KH; Suppola, S; Khomutov, AR; Vepsalainen, J; Janne, J			A polyamine analogue prevents acute pancreatitis and restores early liver regeneration in transgenic rats with activated polyamine catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; MICE; EXPRESSION; HYPUSINE; CELLS; OVEREXPRESSION; INHIBITION; METABOLISM; GROWTH	We recently generated a transgenic rat model for acute pancreatitis, which was apparently caused by a massive depletion of pancreatic polyamines spermidine and spermine due to inducible activation of their catabolism (Alhonen, L., Parkkinen, J. J., Keinanen, T., Sinervirta, R., Herzig, K. H., and Janne, J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8290-8295). When subjected to partial hepatectomy, these animals showed striking activation of polyamine catabolism at 24 h postoperatively with a profound decrease in hepatic spermidine and spermine pools and failure to initiate liver regeneration. Here we show that pancreatitis in this model could be totally prevented, as judged by histopathology and plasma a-amylase activity, by administration of 1-methylspermidine, a metabolically stable analogue of spermidine. Similarly, the analogue, given prior to partial hepatectomy, restored early liver regeneration in the transgenic rats, as indicated by a dramatic increase in the number of proliferating cell nuclear antigen-positive hepatocytes from about 1% to more than 40% in response to the drug. The present results suggest that the extremely high concentration of spermidine in the pancreas, in fact the highest in the mammalian body, may have a critical role in maintaining organ integrity. The failure to initiate liver regeneration in the absence of sufficient hepatic polyamine pools similarly indicates that polyamines are required for proper commencement of the regenerative process.	Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	University of Eastern Finland; University of Eastern Finland; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Janne, J (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland.		Khomutov, Alex/G-2128-2015; Keinänen, Tuomo/AAC-5630-2019	Khomutov, Alex/0000-0001-6833-7855				Alhonen L, 2000, P NATL ACAD SCI USA, V97, P8290, DOI 10.1073/pnas.140122097; Alhonen L, 2002, BIOCHEM J, V362, P149, DOI 10.1042/0264-6021:3620149; Bergeron RJ, 1998, J MED CHEM, V41, P3901, DOI 10.1021/jm980390o; BERNACKI RJ, 1992, CANCER RES, V52, P2424; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; HALMEKYTO M, 1993, BIOCHEM J, V291, P505, DOI 10.1042/bj2910505; HALMEKYTO M, 1991, J BIOL CHEM, V266, P19746; Higgins GM, 1931, ARCH PATHOL, V12, P186; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Khomutov AR, 1996, TETRAHEDRON, V52, P13751, DOI 10.1016/0040-4020(96)00836-8; LAKANEN JR, 1992, J MED CHEM, V35, P724, DOI 10.1021/jm00082a013; Lukkarinen J, 1997, STROKE, V28, P639, DOI 10.1161/01.STR.28.3.639; NIEDERAU C, 1986, J CLIN INVEST, V78, P1056, DOI 10.1172/JCI112661; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Suppola S, 1999, BIOCHEM J, V338, P311, DOI 10.1042/0264-6021:3380311; Suppola S, 2001, BIOCHEM J, V358, P343, DOI 10.1042/0264-6021:3580343; THEOCHARIS SE, 1994, DIGEST DIS SCI, V39, P245, DOI 10.1007/BF02090193; Varnado BL, 2000, BIOORG CHEM, V28, P395, DOI 10.1006/bioo.2000.1195	22	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39867	39872		10.1074/jbc.M205967200	http://dx.doi.org/10.1074/jbc.M205967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181316	hybrid			2022-12-25	WOS:000178662500103
J	Szymkiewicz, I; Kowanetz, K; Soubeyran, P; Dinarina, A; Lipkowitz, S; Dikic, I				Szymkiewicz, I; Kowanetz, K; Soubeyran, P; Dinarina, A; Lipkowitz, S; Dikic, I			CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; PROTEIN C-CBL; ADAPTER PROTEIN; NEGATIVE REGULATION; EGF RECEPTOR; PLASMA-MEMBRANE; CELL-ADHESION; SH3 DOMAINS; A431 CELLS; UBIQUITINATION	The Cbl family of ubiquitin ligases in mammals contains three members, Cbl, Cbl-b, and Chl-3, that are involved in down-regulation of receptor tyrosine kinases (RTKs) by mediating receptor ubiquitination and degradation. More recently, a novel pathway has been identified whereby Cbl promotes internalization of EGF receptor via a CIN85/endophilin pathway that is functionally separable from the ubiquitin ligase activity of Cbl (1). Here we show that Cbl-b, but not Chl-3, utilize the same mechanism to down-regulate multiple RTKs. CIN85 was shown to bind to the minimal binding domain identified in the carboxyl terminus of Cbl-b. Ligand-induced phosphorylation of Cbl-b further increased their interactions and led to a rapid and sustained recruitment of CIN85 in the complex with EGF or PDGF receptors. Inhibition of binding between CIN85 and Cbl-b was sufficient to impair Cbl-b-mediated internalization of EGF receptors, while being dispensable for Cbl-b-directed polyubiquitination of EGF receptors. Moreover, CIN85 and Cbl/Cbl-b were constitutively associated with activated PDGF, EGF, or c-Kit receptors in several tumor cell lines. Our data reveal a common pathway utilized by Cbl and Cbl-b that may have an important and redundant function in negative regulation of ligand-activated as well as oncogenically activated RTKs in vivo.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; NCI, Canc Genet Branch, Ctr Canc Res, Gaithersburg, MD 20899 USA	Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.		Dikic, Ivan/O-4650-2015; Pilecka, Iwona/AAT-9114-2021; Soubeyran, Philippe/P-1758-2018	Dikic, Ivan/0000-0001-8156-9511; Pilecka, Iwona/0000-0002-5057-346X; Soubeyran, Philippe/0000-0002-5876-3217				Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; de Melker AA, 2001, J CELL SCI, V114, P2167; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Klapper LN, 2000, CANCER RES, V60, P3384; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; REISS M, 1991, CANCER RES, V51, P6254; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sjoblom T, 2001, CANCER RES, V61, P5778; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; THOMPSON DM, 1985, CANCER SURV, V4, P767; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	46	97	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39666	39672		10.1074/jbc.M205535200	http://dx.doi.org/10.1074/jbc.M205535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177062	hybrid			2022-12-25	WOS:000178662500079
J	Dhe-Paganon, S; Duda, K; Iwamoto, M; Chi, YI; Shoelson, SE				Dhe-Paganon, S; Duda, K; Iwamoto, M; Chi, YI; Shoelson, SE			Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; MUTATIONS; GENE; DIFFRACTION; YOUNG; RAR	HNF4alpha is an orphan member of the nuclear receptor family with prominent functions in liver, gut, kidney and pancreatic beta cells. We have solved the x-ray crystal structure of the HNF4alpha ligand binding domain, which adopts a canonical fold. Two conformational states are present within each homodimer: an open form with a helix 12 (alpha12) extended and collinear with alpha10 and a closed form with alpha12 folded against the body of the domain. Although the protein was crystallized without added ligands, the ligand binding pockets of both closed and open forms contain fatty acids. The carboxylic acid headgroup of the fatty acid ion pairs with the guanidinium group of Arg(226) at one end of the ligand binding pocket, while the aliphatic chain fills a long, narrow channel that is lined with hydrophobic residues. These findings suggest that fatty acids are endogenous ligands for HNF4alpha and establish a framework for understanding how HNF4alpha activity is enhanced by ligand binding and diminished by MODY1 mutations.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.	Steven.Shoelson@joslin.harvard.edu			NIDDK NIH HHS [T32 DK07260, R01 DK43123] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043123, T32DK007260] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2001, NUCL RECEPTORS GENET; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Lehto M, 1999, DIABETOLOGIA, V42, P1131, DOI 10.1007/s001250051281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	24	218	225	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37973	37976		10.1074/jbc.C200420200	http://dx.doi.org/10.1074/jbc.C200420200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12193589	hybrid			2022-12-25	WOS:000178529600002
J	Tu, C; Qian, MZ; An, HQ; Wadhwa, NR; Duda, D; Yoshioka, C; Pathak, Y; McKenna, R; Laipis, PJ; Silverman, DN				Tu, C; Qian, MZ; An, HQ; Wadhwa, NR; Duda, D; Yoshioka, C; Pathak, Y; McKenna, R; Laipis, PJ; Silverman, DN			Kinetic analysis of multiple proton shuttles in the active site of human carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; CATALYTIC PROPERTIES; STRUCTURAL-CHANGES; REFINED STRUCTURE; CHEMICAL RESCUE; SKELETAL-MUSCLE; MUTANTS; RESOLUTION; MECHANISM; RESIDUES	We have prepared a site-specific mutant of human carbonic anhydrase (HCA) II with histidine residues at positions 7 and 64 in the active site cavity. Using a different isozyme, we have placed histidine residues in HCA III at positions 64 and 67 and in another mutant at positions 64 and 7. Each of these histidine residues can act as a proton transfer group in catalysis when it is the only nonliganding histidine in the active site cavity, except His(7) in HCA III. Using an O-18 exchange method to measure rate constants for intramolecular proton transfer, we have found that inserting two histidine residues into the active site cavity of either isozyme II or III of carbonic anhydrase results in rates of proton transfer to the zinc-bound hydroxide that are antagonistic or suppressive with respect to the corresponding single mutants. The crystal structure of Y7H HCA II, which contains both His(7) and His(64) within the active site cavity, shows the conformation of the side chain of His(64) moved from its position in the wild type and hydrogen-bonded through an intervening water molecule with the side chain of His(7). This suggests a cause of decreased proton transfer in catalysis.	Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Silverman, DN (corresponding author), Univ Florida, Coll Med, Ctr Hlth, Box 100267, Gainesville, FL 32601 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHEN X, 1993, BIOCHEMISTRY-US, V32, P7861, DOI 10.1021/bi00082a004; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; Duda D, 2001, BIOCHEMISTRY-US, V40, P1741, DOI 10.1021/bi002295z; Duda DM, 2002, ACTA CRYSTALLOGR D, V58, P849, DOI 10.1107/S0907444902003700; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; HECK RW, 1994, J BIOL CHEM, V269, P24742; Jackman JE, 1996, BIOCHEMISTRY-US, V35, P16421, DOI 10.1021/bi961786+; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jude KM, 2002, BIOCHEMISTRY-US, V41, P2485, DOI 10.1021/bi015808q; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; Kresge AJ, 1999, METHODS ENZYMOL, V308, P276; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; LOGRASSO PV, 1991, BIOCHEMISTRY-US, V30, P8463, DOI 10.1021/bi00098a025; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; Lu DS, 1998, J AM CHEM SOC, V120, P4006, DOI 10.1021/ja973397o; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Mallis RJ, 2000, FEBS LETT, V482, P237, DOI 10.1016/S0014-5793(00)02022-6; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P13089, DOI 10.1021/bi961416l; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; Otwinowski Z., 2000, INT TABLES CRYSTALLO, VF, P226; Qian MZ, 1997, BIOCHEMISTRY-US, V36, P15758, DOI 10.1021/bi972081q; REN XL, 1995, BIOCHEMISTRY-US, V34, P8492, DOI 10.1021/bi00026a033; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TU CK, 1986, J BIOL CHEM, V261, P100; TU CK, 1994, J BIOL CHEM, V269, P23002; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TU CK, 1983, J BIOL CHEM, V258, P8867; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715	44	14	17	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38870	38876		10.1074/jbc.M205791200	http://dx.doi.org/10.1074/jbc.M205791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12171926	hybrid			2022-12-25	WOS:000178529600109
J	Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H				Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H			Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells	ONCOGENE			English	Article						myosin II regulatory light chain; diphosphorylation; Rho-kinase; reorganization of actin filaments; nonmuscle cells	SMOOTH-MUSCLE MYOSIN; GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; FOCAL ADHESIONS; SERINE/THREONINE KINASE; PLATELET MYOSIN; CLEAVAGE FURROW; TUMOR-CELLS; HELA-CELLS; 2ND SITE	Phosphorylation of myosin 11 regulatory light chain (MRLC) is important for cell motility and cytokinesis in nonmuscle cells. Although the regulation of monophosphorylated MRLC at serine 19 throughout the cell cycle was examined in detail, MRLC diphosphorylation at both threonine 18 and serine 19 is still unclear. Here we found that Rho-kinase has an activity for MRLC diphosphorylation in nonmuscle cells using sequential column chromatographies. Transfection of Rho-kinase-EGFP induced the excess diphosphorylated MRLC and the bundling of the actin filaments. Conversely, the treatment of cells with a specific inhibitor of Rho-kinase, Y-27632, resulted in the decrease of endogenous diphosphorylated MRLC and actin stress fibers. Immunolocatization studies showed that both diphosphorylated MRLC and Rho-kinase accumulated and colocalized at the contractile ring and the midbody in dividing cells. Taken together, it is suggested that Rho-kinase contributes to MRLC diphosphorylation and reorganization of actin filaments in nonmuscle cells.	Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan; Hiroshima Univ, Dept Mol Radiobiol, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University	Hosoya, H (corresponding author), Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan.			Hamao, Kozue/0000-0002-9594-1940				Ai S, 2001, ATHEROSCLEROSIS, V155, P321, DOI 10.1016/S0021-9150(00)00585-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; APPLEGATE D, 1992, J CELL BIOL, V117, P1223, DOI 10.1083/jcb.117.6.1223; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Helige C, 1997, INVAS METAST, V17, P26; Hino M, 2000, BIOCHEM BIOPH RES CO, V271, P164, DOI 10.1006/bbrc.2000.2553; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kolega J, 1999, CELL MOTIL CYTOSKEL, V43, P255, DOI 10.1002/(SICI)1097-0169(1999)43:3<255::AID-CM8>3.0.CO;2-T; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Murata-Hori M, 1998, BIOMED RES-TOKYO, V19, P111, DOI 10.2220/biomedres.19.111; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suizu F, 2000, J BIOCHEM-TOKYO, V128, P435, DOI 10.1093/oxfordjournals.jbchem.a022771; TAKAISHI K, 1994, ONCOGENE, V9, P273; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	42	70	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5852	5860		10.1038/sj.onc.1205747	http://dx.doi.org/10.1038/sj.onc.1205747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185584				2022-12-25	WOS:000177520900004
